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Most	   individuals	   are	   infected	   with	   EBV,	   which	   establishes	   latent	   infection	   in	   B	   cells.	  
Although	   usually	   asymptomatic,	   EBV	   persistence	   is	   associated	   with	   several	   types	   of	  
lymphoma.	  TGFβ	  signals	  via	  TGFβ	  receptors	  (TGFβR)	  1	  and	  2	  and	  is	  generally	  pro-­‐apoptotic	  
and	  anti-­‐proliferative,	  but	  EBV	  infection	  renders	  cells	  resistant	  to	  these	  effects.	  The	  aim	  of	  
this	  thesis	  was	  to	  investigate	  further	  the	  mechanism	  by	  which	  this	  occurs.	  
	  
Using	   the	   EBV-­‐negative	   Burkitt	   lymphoma	   cell	   line	   BL31	   infected	   with	   a	   panel	   of	   BAC-­‐
derived	   wild-­‐type	   and	   recombinant	   EBVs,	   this	   study	   has	   confirmed	   by	   qRT-­‐PCR	   that	   EBV	  
down-­‐regulates	  TGFβR2	  transcription,	  leading	  to	  suppression	  of	  TGFβ	  signalling	  as	  detected	  
by	  western	  blot	   for	  phosphorylated	  SMAD2.	  Use	  of	   recombinant	  viruses	  with	  deletions	  of	  
individual	  latent	  proteins	  has	  shown	  that	  LMP1,	  LMP2A,	  EBNA3B	  and	  EBNA3C	  cooperate	  in	  
this	   repression	   of	   TGFβR2	   and	   suppression	   of	   signalling.	   Chromatin	   immunoprecipitation	  
analysis	   has	   shown	   that	   the	   repression	   of	   TGFβR2	   is	   accompanied	   by	   deposition	   of	   the	  
repressive	  epigenetic	  mark	  histone	  H3	  lysine	  27	  trimethylation	  and	  concomitant	  binding	  of	  
SUZ12,	  a	  subunit	  of	  polycomb-­‐repressive	  complex	  2,	  to	  the	  TGFβR2	  promoter.	   Infection	  of	  
primary	   B	   cells	   with	   EBV	   also	   leads	   to	   repression	   of	   TGFβR2	   and	   suppression	   of	   TGFβ	  
signalling.	  
	  
Additionally,	  EBV	  up-­‐regulates	  TGFβR3,	  a	  co-­‐receptor	  for	  signalling	  by	  both	  TGFβ	  and	  bone	  
morphogenetic	  proteins	  (BMPs),	  a	  related	  group	  of	  ligands	  which	  signal	  via	  SMADs	  1,	  5	  and	  
8.	   This	   led	   to	   an	   investigation	   into	   the	   effects	   of	   EBV	   on	   BMP	   signalling.	   Although	   EBV	  
increases	  signalling	  in	  response	  to	  BMP2,	  BMP4	  and	  BMP6	  in	  BL31	  cells,	  this	   is	  not	  via	  the	  
up-­‐regulation	  of	  TGFβR3.	  BMP2	  and	  BMP4	  induce	  G1	  arrest	  in	  BL31	  cells,	  but	  EBV	  does	  not	  
alter	  this.	  EBV	  also	  up-­‐regulates	  SMAD1	  and	  down-­‐regulates	  SMAD5.	  	  
	  
The	  polycomb-­‐mediated	  repression	  of	  TGFβR2	  is	  a	  mechanism	  by	  which	  EBV	  might	  promote	  
lymphomagenesis.	   In	   addition,	   the	   finding	   that	   EBV	   alters	   several	   components	   of	   BMP	  
signalling	  suggests	  that	  BMP	  signalling	  may	  be	  important	  in	  B-­‐cell	  biology.	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BAC	  	   Bacterial	  artificial	  chromosome	  
BART	   BamHI	  A	  rightward	  transcript	  
BCL	  (2	  or	  6	  or	  -­‐XL)	  	   B	  cell	  lymphoma	  
BCR	  	   B	  cell	  receptor	  
BFL1	   BCL2	  family	  protein	  A1	  
BH	  	   BCL2	  homology	  
BIC	   B	  cell	  integration	  cluster	  
BIM	  	   BCL2	  Interacting	  Mediator	  of	  cell	  death	  
BL	  	   Burkitt	  lymphoma	  
BLIMP1	   B	  lymphocyte-­‐induced	  maturation	  protein	  1	  
BM	   Bone	  marrow	  
BMP	  	   Bone	  morphogenetic	  protein	  
BMPR	  	   BMP	  receptor	  
bp	   Base	  pairs	  
BSA	  	   Bovine	  serum	  albumin	  
CBP	   CREB-­‐binding	  protein	  
CBF1	   C-­‐promoter	  binding	  factor	  1	  
CD	  	   Cluster	  of	  differentiation	  
CDK	   Cyclin-­‐dependent	  kinase	  
CDKI	   Cyclin-­‐dependent	  kinase	  inhibitor	  
cDNA	   Complementary	  DNA	  
C/EBP	   CCAAT	  enhancer	  binding	  protein	  
c-­‐FLIP	   Cellular	  homologue	  of	  FLICE-­‐inhibitory	  protein	  
ChIP	  	   Chromatin	  immunoprecipitation	  
ChIP-­‐seq	   ChIP-­‐sequencing	  
CLL	   B-­‐cell	  chronic	  lymphocytic	  leukaemia	  
CLP	   Common	  lymphoid	  progenitor	  
Co-­‐Smad	  	   Common	  mediator	  Smad	  
Cp	  	  	   C	  promoter	  
CpG	  	  	   Cytosine-­‐phosphate-­‐guanine	  
CR2	   Complement	  receptor	  2	  
CSR	   Class	  switch	  recombination	  
Ct	   Threshold	  cycle	  
CTAR	   C-­‐terminal	  activation	  region	  
CtBP	   C-­‐terminal	  binding	  protein	  
DISC	   Death-­‐inducing	  signalling	  complex	  
DLBCL	  	   Diffuse	  large	  B-­‐cell	  lymphoma	  
DMSO	   Dimethyl	  sulfoxide	  






DNMT	  	   DNA	  methyltransferase	  
DSB	   Double	  strand	  break	  
DZ	   Dark	  zone	  
EA	   Early	  antigen	  
EBER	  	   EBV-­‐encoded	  small	  RNA	  
EBNA	  	   EBV	  nuclear	  antigen	  
EBNA-­‐LP	  	  	   EBV	  nuclear	  antigen-­‐leader	  protein	  
EBNA2-­‐ER	   EBNA2-­‐oestrogen	  receptor	  fusion	  protein	  
EBV	  	   Epstein-­‐Barr	  virus	  
EDTA	  	   Ethylene	  diamine	  tetra-­‐acetic	  acid	  
EED	  	   Embryonic	  ectoderm	  development	  
ELISA	   Enzyme-­‐linked	  immunosorbent	  assay	  
ERK	  	  	   Extracellular	  signal-­‐regulated	  kinase	  
EtOH	   Ethanol	  
EZH2	  	   Enhancer	  of	  zeste	  homologue	  2	  
FC	   Flow	  cytometry	  
FCS	  	   Foetal	  calf	  serum	  
FDC	   Follicular	  dendritic	  cell	  
FL	  	   Follicular	  lymphoma	  
FLICE	   FADD-­‐like	  interleukin-­‐1	  beta-­‐converting	  enzyme	  
GAPDH	   Glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  
GC	  	   Germinal	  centre	  
GDF	  	   Growth	  and	  differentiation	  factor	  
GFP	   Green	  fluorescent	  protein	  
GIPC	  	   GAIP	  (G-­‐alpha	  interacting	  protein)-­‐interacting	  protein,	  c-­‐terminus	  	  
GNB2L1	  	   Guanine	  nucleotide-­‐binding	  protein	  subunit	  beta-­‐2-­‐like	  1	  
GRU	   Green	  Raji	  units	  
HDAC	   Histone	  deacetylase	  
HGF	   Hepatocyte	  growth	  factor	  
HHV	   Human	  herpesvirus	  
HIV	   Human	  immunodeficiency	  virus	  
HL	  	   Hodgkin	  lymphoma	  
HLA	   Human	  leucocyte	  antigen	  
HRP	   Horseradish	  peroxidase	  
HRS	   Hodgkin	  and	  Reed-­‐Sternberg	  
H3K4Me3	  	   Trimethylation	  of	  lysine	  4	  of	  histone	  H3	  
H3K9Ac	  	   Acetylation	  of	  lysine	  9	  of	  histone	  H3	  
H3K27Me3	   Trimethylation	  of	  lysine	  27	  of	  histone	  H3	  
HSC	   Haematopoietic	  stem	  cell	  
HT	  (4HT)	   4-­‐hydroxytamoxifen	  
HTLV1	   Human	  T-­‐lymphotropic	  virus	  1	  
IAP	   Inhibitor	  of	  apoptosis	  
ICAM-­‐1	  	   Intracellular	  adhesion	  molecule	  -­‐1	  
Id	  or	  ID	   Inhibitor	  of	  DNA	  binding,	  or	  inhibitor	  of	  differentiation	  	  
IE	   Immediate	  early	  
IFN	  	   Interferon	  






IL	   Interleukin	  	  
IM	   Infectious	  mononucleosis	  
IP	   Immunoprecipitation	  
IR	   Internal	  repeat	  
I-­‐Smad	  	   Inhibitory	  Smad	  
ITAM	   Immune-­‐receptor	  tyrosine-­‐based	  activation	  motif	  
JAK	  	   Janus	  kinase	  
JNK	   c-­‐Jun	  N-­‐terminal	  kinase	  
kb	   Kilobases	  
kbp	   Kilobase	  pairs	  
kDa	  	   KiloDalton	  
KO	   Knockout	  
KSHV	  	   Kaposi	  sarcoma	  herpesvirus	  
LANA	  	   Latency-­‐associated	  nuclear	  antigen	  
LB	   Luria	  Bertani	  
LCL	  	   Lymphoblastoid	  cell	  line	  
LFA	   Leucocyte	  function-­‐associated	  antigen	  
LMP	   Latent	  membrane	  protein	  
LZ	   Light	  zone	  
MALT	   Mucosa-­‐associated	  lymphoid	  tissue	  
MAPK	  	   Mitogen	  activated	  protein	  kinase	  
MCL1	   Myeloid	  cell	  leukaemia	  sequence	  1	  
MDM2	   Murine	  double	  minute	  2	  
MHC	   Major	  histocompatibility	  complex	  
MH1,	  MH2	   MAD	  homology	  1,	  2	  
MIRA	  	   Methylated	  CpG	  island	  recovery	  assay	  	  	  
miRNA	  or	  miR	   MicroRNA	  
MIS	   Müllerian	  inhibiting	  substance	  
mRNA	   Messenger	  ribonucleic	  acid	  
NCoR	   Nuclear	  receptor	  co-­‐repressor	  
NFκB	   Nuclear	  factor	  kappa	  B	  
NK	   Natural	  killer	  
NPC	   Nasopharyngeal	  carcinoma	  
OriLyt	   Origin	  of	  lytic	  replication	  
OriP	  	   Origin	  of	  plasmid	  replication	  
PARP	  	   Poly	  ADP	  ribose	  polymerase	  
PB	  	   Peripheral	  blood	  
PBL	  	   Peripheral	  blood	  lymphocyte	  
PBMC	  	   Peripheral	  blood	  mononuclear	  cell	  
PBS	   Phosphate-­‐buffered	  saline	  
PcG	  	   Polycomb	  group	  
PCR	  	   Polymerase	  chain	  reaction	  
PEL	  	   Primary	  effusion	  lymphoma	  
PI3-­‐K	  	   Phosphatidylinositol-­‐3-­‐kinase	  
PI	  	   Propidium	  iodide	  
PMA	   Phorbol	  myristate	  acetate	  






PRC	   Polycomb	  repressive	  complex	  
pSMAD	   Phosphorylated	  SMAD	  
PTLD	   Post-­‐transplant	  lymphoproliferative	  disorder	  
PUMA	  	   p53-­‐upregulated	  modulator	  of	  apoptosis	  
Qp	  	   Q	  promoter	  
qPCR	   Quantitative	  polymerase	  chain	  reaction	  
qRT-­‐PCR	  	   Quantitative	  reverse-­‐transcriptase	  polymerase	  chain	  reaction	  
RAG	   Recombination	  activating	  genes	  
Rb	   Retinoblastoma	  
RBP-­‐Jκ	  	   Recombinant	  binding	  protein	  J	  kappa	  
Rev	   Revertant	  to	  wild-­‐type	  
RNA	  	   Ribonucleic	  acid	  
RPMI	   Roswell	  Park	  Memorial	  Institute	  medium	  
R-­‐Smad	  	   Receptor-­‐regulated	  Smad	  
SBE	   Smad-­‐binding	  element	  
SD	   Standard	  deviation	  
SDS	   Sodium	  dodecyl	  sulphate	  
SDS-­‐PAGE	  	   SDS	  polyacrylamide	  gel	  electrophoresis	  
SHM	   Somatic	  hypermutation	  
shRNA	  	   	   Short	  hairpin	  RNA	  
siRNA	   Small	  interfering	  RNA	  
Smurf	   Smad	  ubiquitin	  regulatory	  factor	  
STAT	   Signal	  transducer	  and	  activator	  of	  transcription	  
sTGFβR3	  	   Soluble	  TGFβR3	  
SUZ12	  	  	   Suppressor	  of	  zeste	  12	  homologue	  
TAK1	   TGFβ-­‐associated	  kinase	  1	  
TBE	   Tris-­‐Borate-­‐EDTA	  buffer	  
TBS	   Tris-­‐buffered	  saline	  
TEMED	   Tetramethylethylenediamine	  
TGFβ	   Transforming	  growth	  factor	  beta	  (TGFβ1	  if	  not	  otherwise	  specified)	  
TGFβR1	  	   Transforming	  growth	  factor	  beta	  receptor	  1	  
TGFβR2	  	   Transforming	  growth	  factor	  beta	  receptor	  2	  
TGFβR3	  	   Transforming	  growth	  factor	  beta	  receptor	  3	  
TNF	   Tumour	  necrosis	  factor	  
TPA	   12-­‐O-­‐tetradecanoylphorbol-­‐13-­‐acetate	  
TR	   Tandem	  repeat	  
TRADD	   TNF-­‐receptor-­‐associated	  death	  domain	  
TRAF	   TNF-­‐receptor	  activating	  factor	  or	  TNF-­‐receptor	  associated	  factor	  
TRAIL	   TNF-­‐related	  apoptosis	  inducing	  ligand	  
TSA	   Trichostatin	  A	  
TSG	   Tumour	  suppressor	  gene	  
TSS	   Transcription	  start	  site	  
UTR	   Untranslated	  region	  
VCA	   Viral	  capsid	  antigen	  
Wp	  	   W	  promoter	  
WT	   Wild-­‐type	  




 	  	  	  Introduction	  Chapter	  1
	  
1.1	  Epstein-­‐Barr	  virus	  
1.1.1	  Overview	  
Epstein-­‐Barr	   virus	   (EBV)	   is	   a	   gamma-­‐herpes	   virus	   that	   persistently	   infects	   over	   90%	  of	   the	  
human	  population	  worldwide.	  In	  less	  developed	  countries,	  EBV	  infection	  is	  mostly	  acquired	  
in	   childhood,	   whereas	   in	   more	   developed	   countries	   acquisition	   may	   be	   delayed	   until	   the	  
teenage	  years	  (Crawford	  2001).	  Primary	  infection	  is	  usually	  asymptomatic	  in	  children,	  but	  if	  
acquired	  at	  an	  older	  age	  it	  can	  cause	  the	  syndrome	  of	  infectious	  mononucleosis	  (IM).	  Once	  
infection	   is	  acquired,	   it	  persists	   for	   the	   life	  of	   the	  host	  within	  B	   lymphocytes	   (B	  cells),	  kept	  
under	   control	   by	   the	   cellular	   immune	   response.	   Persistent	   infection	   is	   generally	  
asymptomatic	   to	   the	   immunocompetent	  host,	  but	   in	   the	   setting	  of	   immune	   suppression	   it	  
can	  be	  associated	  with	  development	  of	  B	  cell	  lymphoproliferative	  diseases	  thought	  to	  be	  due	  
to	  defective	  immune	  responses.	  Even	  in	  apparently	  immunocompetent	  hosts,	  however,	  EBV	  
is	  causally	  associated	  with	  several	  types	  of	  lymphoid	  malignancy,	  including	  Burkitt	  lymphoma	  
(BL),	  Hodgkin	  lymphoma	  (HL)	  and	  certain	  T	  cell	  lymphomas	  (Crawford	  2001),	  as	  well	  as	  with	  
epithelial	  cell	  malignancies	  including	  nasopharyngeal	  carcinoma	  (NPC)	  and	  gastric	  carcinoma	  
(Shibata	  and	  Weiss	  1992,	  Young	  and	  Rickinson	  2004).	  	  
	  
1.1.2	  The	  discovery	  of	  EBV	  as	  the	  first	  human	  tumour	  virus	  
In	  1957,	  Denis	  Burkitt,	  a	  British	  surgeon	  working	  in	  Uganda,	  observed	  two	  cases	  of	  a	  tumour	  
presenting	   in	   the	   jaw	   of	   children.	   He	   searched	   the	   records	   of	  Mulago	   Hospital	   for	   similar	  
cases	  and	  thus	  described	  a	  novel	  tumour,	  composed	  of	  small	  round	  cells	  and	  subsequently	  
known	   as	   BL,	   in	   1958	   (Burkitt	   1958).	   Burkitt	   went	   on	   to	   show	   epidemiologically	   that	   this	  
tumour	   was	   mostly	   confined	   to	   a	   particular	   region	   of	   Africa,	   subsequently	   known	   as	   the	  
‘Lymphoma	  belt’	  (Smith	  2012).	  He	  presented	  these	  findings	  at	  the	  Middlesex	  Hospital	  during	  
a	   visit	   to	   England	   in	   1961,	   describing	   the	   tumour’s	   association	   with	   climatic	   conditions	  
including	   temperature	   and	   rainfall.	   A	   medical	   virologist,	   Anthony	   Epstein,	   was	   in	   the	  
audience,	   and	   became	   fascinated	   by	   this	   tumour,	   postulating	   that	   the	   climatic	   variation	  
suggested	  an	  infectious	  cause	  for	  the	  tumours.	  A	  collaboration	  was	  established,	  and	  samples	  




of	   the	   tumour	   were	   transported	   to	   England	   to	   be	   investigated	   by	   Epstein.	   After	   multiple	  
failed	  attempts	  to	  identify	  virus	  in	  the	  samples,	  Epstein	  and	  colleagues	  managed	  to	  establish	  
the	   first	   cell	   line	   from	   one	   of	   the	   BL	   tumours,	   designated	   EB1,	   in	   1964	   (Epstein	   and	   Barr	  
1964).	  Examination	  of	  a	  fixed	  embedded	  section	  of	  EB1	  cells	  by	  electron	  microscopy	  revealed	  
virus	  particles,	  reported	  with	  his	  laboratory	  colleagues	  Bert	  Achong	  and	  Yvonne	  Barr	  (Epstein	  
et	   al.	   1964).	   Thus	   the	   Epstein-­‐Barr	   virus,	   as	   it	   later	   became	   known,	   was	   the	   first	   human	  
tumour	  virus	  identified	  (Pattle	  and	  Farrell	  2006).	  Four	  years	  later,	  EBV	  was	  shown	  to	  be	  the	  
causative	  agent	  of	  IM	  (Evans	  et	  al.	  1968,	  Henle	  et	  al.	  1968),	  although	  IM	  had	  been	  described	  
long	  before	  this.	  	  
	  
1.1.3	  Infectious	  mononucleosis	  and	  the	  immune	  response	  to	  EBV	  
The	  life	  cycle	  of	  EBV	  has	  two	  distinct	  phases:	  the	  lytic	  cycle	  (for	  viral	  replication	  and	  spread	  to	  
other	   hosts)	   and	   the	   latent	   cycle	   (for	   viral	   persistence).	   When	   symptomatic,	   acute	   EBV	  
infection	   results	   in	   IM,	   typically	   comprising	   fever,	   malaise,	   pharyngitis,	   headaches,	  
generalised	   lymphadenopathy,	   hepatomegaly	   and	   splenomegaly	   (Crawford	   2001).	   There	   is	  
an	   associated	   marked	   lymphocytosis,	   with	   the	   blood	   film	   showing	   atypical	   lymphocytes,	  
which	   consist	  mainly	   of	   CD8	   positive	   T	   cells	   reactive	   predominantly	   against	   lytic,	   but	   also	  
against	  latent	  EBV	  antigens;	  NK	  cells	  are	  also	  increased	  during	  IM	  (Callan	  et	  al.	  1998,	  Hislop	  
et	  al.	  2007,	  Balfour	  et	  al.	  2013).	  EBV	  infection	  of	  B	  cells	  initially	  drives	  them	  to	  proliferate	  as	  
B	   lymphoblasts	   (described	   in	   further	   detail	   below),	   with	   up	   to	   18%	   of	   B	   cells	   being	   EBV-­‐
positive	  early	  after	  infection	  (Robinson	  et	  al.	  1980,	  Hislop	  et	  al.	  2007).	  The	  symptoms	  of	  IM	  
are	  largely	  due	  to	  the	  massive	  T	  cell	  response	  to	  the	  infection	  (Crawford	  2001).	  In	  IM,	  there	  is	  
prolonged	   high	   level	   shedding	   of	   virus	   in	   the	   oropharynx	   for	   several	  months.	   EBV-­‐specific	  
CD8+	  T	  cells	  are	   found	   in	  significantly	  reduced	  numbers	   in	  the	  tonsil	  compared	  to	  blood	   in	  
IM,	  suggesting	  that	  immune	  control	  is	  less	  efficient	  in	  the	  tonsil	  than	  in	  the	  blood	  (Hislop	  et	  
al.	  2005).	  	  
	  
T	   cell	   immune	   surveillance	   is	   thus	   highly	   important	   in	   controlling	   persistent	   EBV	   infection,	  
but	   is	   unable	   to	   completely	   clear	   the	   virus.	   Normally	   the	   infected	   B	   cells	   are	   targeted	  
promptly	  by	  cytotoxic	  T	  cells	  to	   limit	  their	  proliferation.	   In	   immunocompetent	  EBV	  carriers,	  
an	  equilibrium	  develops	  between	  proliferation	  of	  infected	  B	  cells	  and	  the	  immune	  response.	  




Even	   in	  asymptomatic,	   immunocompetent	  carriers	  up	  to	  5%	  of	  the	  total	  circulating	  pool	  of	  
CD8	  positive	  T	  cells	  are	  reactive	  against	  EBV	  antigens	  (Tan	  et	  al.	  1999,	  Hislop	  et	  al.	  2007),	  and	  
there	  is	  continued	  low	  level	  shedding	  of	  virus,	  with	  low	  numbers	  of	  latently	  infected	  B	  cells	  in	  
the	  blood	  (approximately	  1-­‐50	  per	  million	  B	  cells)	  (Khan	  et	  al.	  1996).	  	  
	  
Defective	   T	   cell	   immunity	   predisposes	   to	   EBV-­‐associated	   lymphoid	   proliferation.	   EBV-­‐
associated	   B	   cell	   lymphomas	   occur	   with	   increased	   frequency	   following	   iatrogenic	  
immunosuppression,	   particularly	   following	   solid	   organ	   transplantation,	   but	   also	   less	  
commonly	   after	   treatment	   of	   inflammatory	   disorders	  with	   immunosuppressive	   agents.	   An	  
increased	  incidence	  of	  EBV-­‐driven	  lymphoid	  proliferations	  is	  also	  seen	  in	  HIV	  infection	  as	  well	  
as	   in	  several	  congenital	   immune	  deficiency	  syndromes	  (Swerdlow	  et	  al.	  2008).	   	  Even	   in	  the	  
absence	  of	  clinically	  symptomatic	  disease,	  immunosuppressed	  individuals	  have	  an	  expansion	  
of	  latently	  infected	  B	  cells	  in	  the	  peripheral	  blood,	  as	  well	  as	  a	  higher	  EBV	  DNA	  viral	  load,	  as	  a	  
result	  of	  viral	  replication,	  compared	  to	  immunocompetent	  carriers	  (Babcock	  et	  al.	  1999).	  	  
	  
There	   is	   increasing	   evidence	   that	   NK	   cells	   are	   important	   in	   the	   immune	   response	   to	   EBV	  
[reviewed	  in	  (Chijioke	  et	  al.	  2013)].	  In	  vitro,	  NK	  cells	  can	  limit	  the	  transformation	  of	  B	  cells	  by	  
EBV	  in	  the	  first	  few	  days	  after	  infection,	  due	  to	  production	  of	  interferon-­‐gamma	  (IFNγ),	  with	  
tonsillar	  NK	  cells	  producing	  significant	  amounts	  of	  IFN	  (Strowig	  et	  al.	  2008).	  	  
	  
1.1.4	  Establishment	  of	  latent	  infection:	  in	  vivo	  and	  in	  vitro	  
As	  well	   as	   B	   cells,	   EBV	   can	   infect	   epithelial	   cells	   and	   rarely	   other	   cell	   types,	   although	   the	  
efficiency	  of	  infection	  is	  greatest	  for	  B	  cells.	  The	  virus	  initially	  enters	  B	  cells	  by	  binding	  of	  its	  
envelope	  protein	  gp350	  to	  complement	  receptor	  2	  (CR2),	  also	  known	  as	  CD21,	  on	  the	  B	  cell	  
surface.	   In	   vivo,	   EBV	   persists	   long-­‐term	   within	   the	   population	   of	   resting	   memory	   B	   cells	  
(Thorley-­‐Lawson	  2001).	   In	  this	   latent	  phase	  a	  limited	  set	  of	  nine	  viral	  proteins	  is	  expressed,	  
including	  six	  EBV	  nuclear	  antigens	  (EBNA1,	  EBNA2,	  EBNA3A,	  EBNA3B,	  EBNA3C	  and	  EBNA-­‐LP)	  
and	   three	   latent	  membrane	  proteins	   (LMP1,	   LMP2A	  and	  LMP2B).	  Expression	  of	   these	  nine	  
viral	  genes	  is	  known	  as	  latency	  III	  expression	  or	  the	  growth	  programme.	  	  
	  




EBV	  is	  spread	  between	  human	  hosts	  by	  oral	  transmission	  through	  saliva.	  Most	  new	  cases	  of	  
EBV	  infection	  are	  acquired	  from	  an	  individual	  with	  an	  established	  persistent	  infection	  rather	  
than	   during	   acute	   infection	   (Longnecker	   et	   al.	   2013).	   Although	   the	  mechanism	   is	   not	   fully	  
understood,	   it	   is	   thought	   that	   transmitted	   virus	   initially	   infects	   epithelial	   cells	   in	   the	  
oropharynx,	  replicating	  within	  them	  and	  releasing	  virus	  particles	   locally.	  Although	  epithelial	  
cells	  in	  the	  tonsil,	  but	  not	  in	  other	  parts	  of	  the	  body,	  express	  CD21	  mRNA	  (Jiang	  et	  al.	  2008),	  
they	  are	  not	  thought	  to	  express	  CD21	  protein	  and	  thus	  it	  is	  not	  clear	  how	  epithelial	  infection	  
occurs	  (Shannon-­‐Lowe	  and	  Rowe	  2011).	  Local	  epithelial	  replicative	  infection	  can	  then	  infect	  
naïve	   resting	   B	   cells	   as	   they	   circulate	   through	   the	   oropharynx,	   within	   tonsillar	   mucosa-­‐
associated	  lymphoid	  tissue	  (MALT).	  	  
	  
To	  establish	  persistent	   infection	   in	  vivo,	  David	  Thorley-­‐Lawson	  has	  proposed	   the	   ‘Germinal	  
Centre	  model’	  in	  which	  EBV	  utilises	  the	  normal	  B	  cell	  differentiation	  pathway	  in	  order	  to	  gain	  
access	   to	   the	   population	   of	   memory	   B	   cells	   (Thorley-­‐Lawson	   2001,	   Hawkins	   et	   al.	   2013,	  
Thorley-­‐Lawson	   et	   al.	   2013)	   (see	   section	   1.2	   for	   further	   details	   of	   B	   cell	   differentiation	  
pathways	  including	  the	  germinal	  centre).	  In	  this	  model,	  EBV	  initially	  infects	  naïve	  B	  cells	  and	  
drives	   these	   to	   proliferate	   as	   activated	   B	   cell	   blasts,	   with	   differentiation	   within	   germinal	  
centres	  to	  become	  centroblasts,	  centrocytes	  and	  finally	  resting	  memory	  B	  cells.	  This	  series	  of	  
events	  involves	  silencing	  of	  EBV	  gene	  expression	  from	  latency	  III	  (in	  which	  the	  full	  set	  of	  nine	  
latent	  proteins	  is	  expressed),	  via	  latency	  II	  and	  latency	  I	  to	  latency	  0	  in	  which	  no	  EBV	  proteins	  
can	  be	  detected	  (fig.	  1.1)	  (Thorley-­‐Lawson	  and	  Gross	  2004).	  The	  proteins	  expressed	  in	  each	  









Figure	  1.1:	  EBV	  persistence	  	  
Thorley-­‐Lawson	   has	   proposed	   a	   model	   in	   which	   EBV	   initially	   infects	   naïve	   B	   cells	   and	   drives	   them	   to	  
differentiate	  into	  B	  cell	  blasts,	  which	  are	  rapidly	  proliferating.	  At	  this	  stage	  the	  full	  set	  of	  nine	  latency	  proteins	  
is	   expressed	   (latency	   III	   or	   the	   growth	   programme).	   The	   infected	   cell	   then	   goes	   to	   a	   germinal	   centre	   (GC)	  
where	  it	  differentiates	  into	  a	  GC	  B	  cell.	  By	  the	  time	  it	  leaves	  the	  GC	  as	  a	  post-­‐GC	  B	  cell,	  it	  has	  down-­‐regulated	  
expression	  of	  EBNA2,	  the	  EBNA3	  proteins	  and	  EBNA-­‐LP,	  expressing	  a	  more	  limited	  set	  of	  proteins	  (latency	  II).	  It	  
then	  differentiates	  further	  into	  a	  memory	  B	  cell,	  at	  which	  stage	  no	  viral	  proteins	  are	  expressed,	  except	  when	  
the	   cell	   divides,	  when	   EBNA1	   is	   expressed	   to	   ensure	   viral	   replication.	   The	  memory	   B	   cell	   can	   subsequently	  
differentiate	  into	  a	  plasma	  cell,	  becoming	  lytic	  in	  the	  process,	  releasing	  new	  EBV	  virions	  which	  can	  then	  infect	  
further	  B	  cells	  or	  be	  secreted	  in	  saliva	  and	  infect	  a	  new	  host.	  Adapted	  from	  (Thorley-­‐Lawson	  and	  Gross	  2004).	  	  
	  
	  
Once	  the	  EBV-­‐infected	  cells	  differentiate	   into	  memory	  B	  cells	  and	   leave	  the	  GC,	  some	  cells	  
differentiate	   further	   to	  become	  plasma	   cells.	   This	  differentiation	   leads	   to	   activation	  of	   the	  
BZLF1	   promoter	   (see	   section	   1.1.8	   on	   lytic	   replication	   for	   details),	   resulting	   in	   lytic	   EBV	  
replication	   (Laichalk	  and	  Thorley-­‐Lawson	  2005),	  hence	   free	  virus	  particles	  are	  released	   into	  
the	  blood.	  It	  is	  also	  thought	  that	  infected	  memory	  B	  cells,	  which	  circulate	  through	  blood	  and	  
lymphoid	   organs,	   can	   differentiate	   into	   plasma	   cells	   in	   the	   oropharynx,	   undergoing	   lytic	  
replication	  there.	  The	  released	  virus	  particles	  can	  then	  infect	  oropharyngeal	  epithelial	  cells	  or	  
be	  shed	  as	  virus	  directly	  into	  the	  saliva,	  thus	  transmitting	  the	  virus	  to	  a	  new	  host	  (Longnecker	  




et	  al.	  2013).	  In	  asymptomatic	  carriers,	  virus	  is	  shed	  in	  saliva	  continuously,	  although	  the	  level	  
of	  virus	  shedding	  varies	  over	  time	  within	  an	  individual.	  However,	  as	  the	  level	  of	  shedding	  is	  
too	   great	   to	   be	   explained	   merely	   by	   tonsillar	   B	   cell	   infection,	   it	   has	   been	   proposed	   that	  
repeated,	   short-­‐lived	   exponential	   infection	   of	   tonsillar	   epithelial	   cells,	   initiated	   by	   lytic	  
replication	  in	  an	  infected	  plasma	  cell,	  leads	  to	  continuous	  salivary	  viral	  shedding	  (Hadinoto	  et	  
al.	   2009).	   In	   addition,	   concurrent	   oropharyngeal	   infection,	   for	   instance	   with	   group	   A	  
streptococcus,	   a	   common	   cause	   of	   pharyngitis,	   can	   lead	   to	   increased	   viral	   lytic	   replication	  
and	  hence	  increased	  salivary	  viral	  shedding	  (Ueda	  et	  al.	  2014).	  	  
	  
In	  vitro,	  EBV	  can	  transform	  B	  cells	  to	  produce	  lymphoblastoid	  cell	  lines	  (LCLs),	  which	  express	  
latency	   III	   EBV	   gene	   products.	   It	   is	   thought	   that	   EBV	   drives	   B	   cells	   to	   proliferate	   as	  
lymphoblasts	  but	   they	  are	  unable	   to	  differentiate	   further	   in	   vitro	   and	  hence	   full	   latency	   III	  
expression	  remains.	  More	  recently	  it	  has	  been	  shown	  that	  EBV	  infection	  in	  vitro	  leads	  to	  an	  
initial	   hyper-­‐proliferative	   phase	   in	   the	   first	   few	  days	   after	   infection,	   possibly	   equivalent	   to	  
the	  hyper-­‐proliferation	  seen	  within	  germinal	  centres	  (see	  section	  1.2	  on	  B	  cell	  development),	  
with	   induction	   of	   cellular	   genes	   involved	   in	   proliferation,	   such	   as	   MYC.	   Cellular	   genes	  
responsible	   for	   limiting	   DNA	   damage	   are	   also	   activated.	   This	   phase	   is	   then	   followed	   by	   a	  
phase	  of	  slower	  proliferation	  resulting	  in	  establishment	  of	  LCLs	  (Nikitin	  et	  al.	  2010).	  	  	  
	  
Infection	   of	   epithelial	   cells	   by	   EBV	   in	   vitro	   is	  more	   difficult	   to	   achieve,	   although	   has	   been	  
successfully	   demonstrated	   by	   Shannon-­‐Lowe	   et	   al	   using	   direct	   transfer	   of	   virus	   from	   the	  
surface	  of	  recently	  infected	  B	  cells	  (Shannon-­‐Lowe	  et	  al.	  2009).	  Although	  the	  epithelial	  cells	  
were	  infected	  by	  this	  method,	  infection	  was	  not	  maintained,	  and	  in	  fact	  the	  EBV	  genome	  was	  
gradually	   lost	   from	   the	   initially	   infected	   cells	   during	   successive	   cellular	   replications,	  
suggesting	   that	   EBV	   infection	   does	   not	   provide	   a	   growth	   advantage	   in	   epithelial	   cells	  
(Shannon-­‐Lowe	  et	  al.	  2009).	  	  
	  
There	  is	  also	  recent	  evidence	  that	  one	  of	  the	  earliest	  viral	  products	  of	  lytic	   infection,	  BZLF1	  
(see	   section	  1.1.8	  on	   lytic	   replication),	   is	   also	   transiently	   expressed	  early	   after	   infection	  of	  
naïve	  B	  cells	  and	  helps	  to	  drive	  the	  initial	  proliferation	  of	  B	  cells,	  without	  inducing	  lytic	  viral	  
replication	   at	   this	   stage;	   in	   addition	   other	   lytic	   genes	   are	   transiently	   expressed	   early	   after	  
infection	  (Kalla	  et	  al.	  2010,	  Kalla	  and	  Hammerschmidt	  2012).	  




1.1.5	  Classification	  and	  structure	  of	  EBV	  
EBV	   is	  a	  member	  of	   the	  Herpesviridae,	  of	  which	   there	  are	  eight	  viruses	   infecting	  humans,	  
designated	   Human	   herpesviruses	   (HHV)	   1-­‐8;	   EBV	   is	   also	   known	   as	   human	   herpesvirus	   4	  
(HHV-­‐4).	   Herpesviruses	   are	   generally	   found	   ubiquitously,	   with	   a	   high	   seroprevalence	   in	  
adults.	   They	   are	   mostly	   acquired	   in	   childhood	   and	   result	   in	   persistent	   infection	   for	   the	  
lifetime	  of	  the	  host.	  These	  infections	  are	  usually	  asymptomatic	  in	  immunocompetent	  hosts	  
but	  can	  cause	  severe	  disease	  in	  immune-­‐compromised	  hosts.	  	  
	  
The	   Herpesviridae	   are	   subdivided	   into	   three	   subfamilies,	   the	   alpha,	   beta	   and	   gamma	  
herpesvirinae,	  based	  on	  their	  biological	  properties.	  EBV	   is	  a	  gamma-­‐herpesvirus;	   these	  are	  
characterised	   by	   latency	   in	   lymphocytes	   and	   the	   ability	   to	   induce	   lympho-­‐proliferation.	  
There	  are	  four	  genera	  within	  the	  gamma-­‐herpesvirinae,	  of	  which	  only	  two	  contain	  members	  
that	  infect	  humans:	  the	  gamma-­‐1	  or	  Lymphocryptovirus	  genus,	  which	  includes	  EBV,	  and	  the	  
gamma-­‐2	  or	  Rhadinovirus	  genus,	  which	  includes	  KSHV	  (HHV-­‐8)	  (Pellett	  and	  Roizman	  2013).	  	  
	  
Like	  other	  herpesviruses,	   the	  EBV	  particle	   consists	  of	   a	   linear,	  double-­‐stranded	  DNA	  core,	  
enclosed	   within	   a	   nucleocapsid	   (containing	   viral	   capsid	   antigen,	   VCA),	   which	   is	   in	   turn	  
surrounded	  by	  a	  protein	  tegument	  and	  then	  an	  outer	  envelope	  studded	  with	  glycoproteins	  
(Longnecker	  et	  al.	  2013).	  These	  glycoproteins	  are	  important	  for	  binding	  to	  and	  fusion	  with	  
host	  cellular	  membranes,	  for	  example	  gp350	  which	  binds	  to	  CR2	  on	  B	  cells	  and	  gp42	  which	  
is	  needed	  for	  fusion	  between	  the	  virus	  envelope	  and	  the	  host	  cell	  membrane.	  	  
	  
1.1.6	  The	  EBV	  genome	  
The	  EBV	  genome	  is	  approximately	  172	  kilobase	  pairs	  (kbp)	  in	  size	  (see	  fig.	  1.2).	  The	  genome	  
is	   linear	   within	   the	   virus	   particle	   but	   becomes	   circularised	   within	   the	   host	   cell	   as	   an	  
extrachromosomal	   episome.	   There	   is	   a	   single	   repeated	   sequence	   found	   at	   both	   terminal	  
regions	  of	  the	  linear	  genome,	  the	  terminal	  repeat	  (TR),	  and	  also	  a	  3	  kbp	  tandemly	  repeated	  
sequence	  within	   the	   genome,	   the	   internal	   repeat	   (IR1).	   There	   are	   usually	   6-­‐12	   repeats	   of	  
IR1;	  this	  is	  of	  significance	  as	  it	  contains	  the	  W	  promoter	  (Wp).	  	  
	  
By	   16-­‐20	   hours	   post-­‐infection	   in	   B	   cells,	   the	   viral	   genome	   becomes	   circularised	   and	   then	  
transcription	  of	  viral	  genes	  commences.	  The	  first	  transcripts,	  initiated	  at	  Wp,	  are	  EBNA2	  and	  




EBNA-­‐LP;	  these	  are	  followed	  by	  EBNA1.	  Transcription	  then	  switches	  to	  the	  C	  promoter	  (Cp)	  
and	  gives	  rise	  to	  transcripts	  coding	  for	  EBNA-­‐LP,	  2,	  3A,	  3B,	  3C	  and	  1	  (see	  fig.	  1.2).	  LMP1	  and	  
LMP2	  are	  subsequently	  transcribed	  from	  a	  promoter	  responding	  to	  EBNA2	  (Bornkamm	  and	  
Hammerschmidt	  2001).	  The	  Cp	  and	  Wp	  promoters	  drive	  transcription	  of	  the	  six	  EBNA	  genes,	  
and	   their	   function	   is	  mutually	   exclusive	   (Woisetschlaeger	  et	   al.	   1989);	   after	   infection	  of	  B	  
cells	  by	  EBV,	  Wp	  is	  used	  initially	  and	  then	  Cp	  is	  up-­‐regulated.	  	  
	  
	  
Figure	  1.2:	  Schematic	  diagram	  of	  the	  circularised	  EBV	  episome	  	  
The	  location	  of	  the	  latent	  genes	  and	  their	  promoters,	  as	  well	  as	  immediate	  early	  lytic	  genes,	  are	  shown.	  OriP	  =	  
origin	  of	  plasmid	  replication,	  oriLyt	  =	  origin	  of	  lytic	  replication.	  IR1	  =	  internal	  repeat	  region.	  Wp,	  Cp	  and	  Qp	  are	  
alternative	  promoters.	  The	  immediate	  early	  genes,	  BZLF1	  and	  BHRF1,	  are	  shown	  in	  yellow.	  Adapted	  from	  (Kalla	  
and	  Hammerschmidt	  2012).	  
	  
1.1.7	  EBV	  latent	  gene	  products	  
The	   latency-­‐associated	   viral	   gene	   products	   and	   their	   functions	   will	   now	   be	   described	   in	  




























1.1.7.1	  EBV	  nuclear	  antigens	  
EBNA1	  	  
EBNA1	   is	   expressed	   in	   all	   forms	   of	   latency,	   as	   well	   as	   all	   EBV-­‐associated	   tumours,	   and	  
maintains	   the	   viral	   genome	   in	   its	   episomal	   state	   through	   sequence-­‐specific	   binding	   to	   the	  
plasmid	  origin	  of	  viral	  replication	  (OriP).	   It	  enhances	  transcription	  from	  Cp	  and	  also	   inhibits	  
transcription	   from	   Qp,	   hence	   contributing	   to	   transcriptional	   regulation	   of	   the	   EBNAs	  
(including	   EBNA1	   itself)	   and	   LMP1	   (Young	   and	   Rickinson	   2004).	   It	   also	   tethers	   the	   EBV	  
genome	  to	  host	  cell	   chromosomes	   in	  metaphase,	  ensuring	  partitioning	  of	   the	  EBV	  genome	  
during	  cell	  division	  (Kanda	  et	  al.	  2001).	  	  
	  
EBNA2	  
EBNA2	   is	  one	  of	   the	   first	  proteins	  expressed	  after	  virus	  entry	   into	  B	  cells	  and	   is	  absolutely	  
required	   for	  B	  cell	   transformation	  to	  LCLs	   (Cohen	  et	  al.	  1989,	  Hammerschmidt	  and	  Sugden	  
1989).	   It	   binds	   to	   the	   host	   DNA-­‐binding	   protein	   recombination	   signal	   binding	   protein	   for	  
immunoglobulin	  kappa	  J	  region	  (RBP-­‐Jκ),	  also	  known	  as	  C-­‐promoter	  binding	  factor	  1	  (CBF1),	  a	  
downstream	  component	  of	  the	  Notch	  signalling	  pathway	  (Waltzer	  et	  al.	  1994,	  Zimber-­‐Strobl	  
et	   al.	   1994,	   Zimber-­‐Strobl	   and	   Strobl	   2001).	   It	   transactivates	   both	   viral	   and	   cellular	   genes,	  
including	   the	   viral	   latency	   genes	   LMP1	   and	   LMP2A	   and	   the	   cellular	   genes	  CD21	   and	  CD23	  
(Bornkamm	  and	  Hammerschmidt	  2001).	  It	  also	  activates	  MYC	  (Kaiser	  et	  al.	  1999).	  EBNA2	  also	  
drives	   the	   switch	   from	   Wp	   to	   Cp	   usage	   that	   occurs	   early	   after	   B	   cell	   infection	  
(Woisetschlaeger	  et	  al.	  1991).	  	  
	  
Two	  types	  of	  EBV	  have	  been	  identified,	  types	  1	  and	  2	  (or	  A	  and	  B),	  according	  to	  differences	  
in	   the	   EBNA2	   protein	   (Dambaugh	   et	   al.	   1984).	   There	   are	   also	   sequence	   variations	   in	  
EBNA3A,	  EBNA3B	  and	  EBNA3C	  and	  EBNA-­‐LP	  between	  the	  two	  types	  (Rowe	  et	  al.	  1989).	  Type	  
1	  is	  more	  efficient	  at	  B	  cell	  transformation	  than	  type	  2	  in	  vitro	  (Rickinson	  et	  al.	  1987),	  due	  to	  
a	  stronger	  and	  faster	  induction	  of	  LMP1	  (Cancian	  et	  al.	  2011).	  Type	  1	  is	  thought	  to	  be	  more	  
common	  in	  most	  populations,	  although	  the	  frequency	  of	  type	  2	  is	  increased	  in	  Central	  Africa	  
and	  New	  Guinea	  such	  that	  the	  two	  types	  have	  similar	  frequencies	  in	  these	  regions	  (Young	  et	  
al.	  1987).	  	  
	  




The	  EBNA3	  proteins	  
EBNA3A,	  EBNA3B	  and	  EBNA3C	  are	  each	  composed	  of	  over	  900	  amino	  acids	  and	  are	  encoded	  
by	   a	   short	   5’	   exon	   and	   a	   long	   3’	   exon,	   arranged	   in	   tandem	  within	   the	   EBV	   genome.	   Their	  
transcripts	  are	  alternatively	   spliced	   from	  very	   long	  mRNAs	   initiated	  at	  Cp	  or	  Wp	   (Bodescot	  
and	   Perricaudet	   1986,	   Bornkamm	   and	   Hammerschmidt	   2001).	   Full	   determination	   of	   the	  
secondary	  structure	  of	   the	  EBNA3	  proteins	  has	  proved	  elusive,	  but	   they	  all	  have	  a	  proline-­‐
rich	  domain	  (Yenamandra	  et	  al.	  2009).	  They	  share	  approximately	  40%	  amino	  acid	  sequence	  
homology,	   suggesting	   they	  have	   evolved	   from	  gene	  duplication	   events	   (Yenamandra	   et	   al.	  
2009).	  
	  
The	  EBNA3	  proteins	  cannot	  bind	  to	  DNA	  directly	  but	  interact	  with	  RBP-­‐Jκ,	  which	  itself	  binds	  
to	  DNA.	  Hence	  the	  EBNA3	  proteins	  act	  as	  transcriptional	  regulators,	  modulating	  expression	  
of	   both	   viral	   and	   cellular	   genes.	   They	   compete	   with	   EBNA2	   for	   binding	   to	   RBP-­‐Jκ	   and	  
therefore	  antagonise	  the	  activity	  of	  EBNA2	  in	  transient	  assays	  (Waltzer	  et	  al.	  1996).	  EBNA3A	  
and	   EBNA3C,	   but	   not	   EBNA3B,	   were	   originally	   thought	   to	   be	   essential	   for	   B	   cell	  
transformation/immortalisation	   (Tomkinson	   et	   al.	   1993);	   however,	   it	   has	   recently	   been	  
shown	   that	   EBNA3A	   can	  be	   dispensed	  with	   in	   immortalisation,	   although	   the	   outgrowth	  of	  
cells	   is	   less	   efficient	   and	   requires	   the	   presence	   of	   feeder	   cells	   (Hertle	   et	   al.	   2009).	   EBNA3	  
proteins	   are	   targets	   for	   EBV-­‐specific	   CD8	   T	   cells	   responses	   and	   are	   highly	   immunogenic	  
(Murray	   et	   al.	   1992),	   with	   those	   CD8+	   T	   cells	   reactive	   against	   latent	   antigens	   being	  
predominantly	  directed	  against	  the	  EBNA3	  proteins	  (Hislop	  et	  al.	  2007).	  
	  
EBNA3C	  was	  first	  demonstrated	  to	  be	  a	  transcriptional	  regulator	  in	  the	  early	  1990s,	  when	  it	  
was	  shown	  to	  up-­‐regulate	  CD21	  and	  LMP1	  expression	  (Wang	  et	  al.	  1990a,	  Allday	  et	  al.	  1993).	  
It	  was	  subsequently	  shown	  that	  it	  does	  not	  bind	  directly	  to	  the	  CD21	  promoter	  (Radkov	  et	  al.	  
1997)	  and	  thus	  was	   thought	  not	   to	  bind	  directly	   to	  DNA	  but	   instead	  to	  exert	   its	  effects	  on	  
transcriptional	  activity	  indirectly	  via	  interactions	  with	  DNA	  binding	  proteins	  such	  as	  PU1	  and	  
RBP-­‐Jκ	   (Robertson	   et	   al.	   1995,	   Zhao	   and	   Sample	   2000).	   EBNA3C	   interacts	   with	   several	  
transcriptional	   co-­‐activators	   and	   co-­‐repressors,	   including	   p300	   and	   histone	   deacetylases	  
(HDAC)	   (Radkov	   et	   al.	   1999,	   Subramanian	   et	   al.	   2002),	   and	   to	   bind	   the	   co-­‐repressor	   of	  
transcription	   C-­‐terminal	   binding	   protein	   (CtBP)	   (Touitou	   et	   al.	   2001,	   Skalska	   et	   al.	   2010).	  
EBNA3C	  has	  also	  been	  shown	  to	  have	  oncogenic	  functions	  by	  cooperating	  with	  activated	  Ras	  




to	   immortalise	   rat	   embryonic	   fibroblasts	   (Parker	   et	   al.	   1996).	   Furthermore,	   EBNA3C	  
deregulates	   cell	   cycle	   checkpoints	   (Parker	   et	   al.	   2000,	   Krauer	   et	   al.	   2004).	   EBV	   infection	  
induces	   the	   DNA-­‐damage	   response	   early	   after	   B	   cell	   infection	   in	   vitro,	   and	   EBNA3C	   is	  
important	  in	  limiting	  this	  response	  and	  thus	  allowing	  survival	  of	  the	  infected	  cells	  (Nikitin	  et	  
al.	  2010).	  	  
	  
EBNA3A	  was	  also	  subsequently	  shown	  to	  bind	  to	  CtBP	  and	  cooperate	  with	  Ras	  to	  transform	  
rat	   embryonic	   fibroblasts	   (Hickabottom	   et	   al.	   2002).	   EBNA3A	   and	   EBNA3C	   cooperate	   to	  
down-­‐regulate	   BIM,	   a	   pro-­‐apoptotic	   protein	   important	   in	   the	   pathogenesis	   of	   Burkitt	  
lymphoma	  (Anderton	  et	  al.	  2008,	  Paschos	  et	  al.	  2009),	  and	  they	  also	   interact	  with	  CtBP	  to	  
repress	  p16INK4A,	  hence	  allowing	  the	  proliferation	  of	  LCLs	  (Maruo	  et	  al.	  2006,	  Skalska	  et	  al.	  
2010,	  Maruo	  et	   al.	   2011,	   Skalska	  et	   al.	   2013).	   In	   fact,	   extensive	   cooperation	  between	   the	  
EBNA3	  proteins	  in	  regulation	  of	  cellular	  genes	  has	  been	  shown	  in	  a	  global	  exome	  microarray	  
analysis,	  with	  390	  out	  of	  1201	  differentially	  regulated	  genes	  requiring	  more	  than	  one	  of	  the	  
EBNA3s	  for	  their	  regulation	  [www.epstein-­‐barrvirus.org.uk	  (White	  et	  al.	  2010)].	  	  	  
	  
EBNA3B	   is	   completely	   dispensable	   for	   B	   cell	   transformation,	   yet	   it	   has	   not	   been	   selected	  
against	  during	  the	  course	  of	  evolution,	  suggesting	   it	  has	  a	  role	   in	  vivo.	   It	  has	  recently	  been	  
demonstrated	   to	   act	   as	   a	   tumour	   suppressor	   in	   a	   humanised	  mouse	  model	   (White	   et	   al.	  
2012).	  A	  case	  of	  a	  highly	  aggressive	  PTLD	  in	  vivo	  has	  been	  reported	  in	  which	  the	  virus	  had	  an	  
EBNA3B	  deletion,	  further	  supporting	  the	  tumour	  suppressor	  effect	  of	  EBNA3B	  (Gottschalk	  et	  
al.	   2001).	   Thus	   it	   is	   thought	   to	   counteract	   the	   oncogenic	   properties	   of	   other	   EBV	   latent	  
antigens,	  ensuring	  survival	  of	  the	  host	  in	  order	  to	  transmit	  infection	  to	  others.	  	  
	  
EBNA-­‐LP	  
EBV	  leader	  protein	  (EBNA-­‐LP)	  is	  highly	  expressed,	  along	  with	  EBNA2,	  early	  after	  EBV-­‐induced	  
B	   cell	   transformation.	   It	   is	   transcribed	   from	  multiple	   copies	   of	  Wp,	   since	  Wp	   is	   contained	  
within	   the	   internal	   repeat	   (IR1)	   region	   of	   the	   EBV	   genome	   (see	   fig.	   1.2).	   Hence	   multiple	  
different-­‐sized	  isoforms	  of	  EBNA-­‐LP	  are	  initially	  expressed	  during	  B	  cell	  transformation.	  Then,	  
as	   immortalisation	   becomes	   established,	   transcription	   occurs	   increasingly	   from	   Cp	   rather	  
than	  Wp	  and	  hence	  the	  expression	  of	  EBNA-­‐LP	  decreases	  (Nitsche	  et	  al.	  1997)	  (see	  fig.1.2).	  
EBNA-­‐LP	   is	   a	   potent	   co-­‐activator	   of	   EBNA2,	   activating	   EBNA2-­‐mediated	   transcriptional	  




activation	  of	  viral	  and	  cellular	  genes,	  and	  is	  therefore	  important	  for	  B	  cell	  transformation,	  for	  
instance	   it	   enhances	   the	   transactivation	  of	   LMP1	  by	   EBNA2	   (Nitsche	  et	   al.	   1997).	   EBNA-­‐LP	  
causes	   the	   relocation	   of	   HDAC4	   and	   HDAC5	   from	   EBNA2-­‐responsive	   promoters	   to	   the	  
cytoplasm	  (Portal	  et	  al.	  2006)	  and	  displaces	  the	  transcriptional	  co-­‐repressor	  nuclear	  receptor	  
co-­‐repressor	   (NCoR),	   which	   would	   otherwise	   inhibit	   RBP-­‐Jκ,	   from	   EBNA2-­‐responsive	  
promoters,	  thus	  enhancing	  the	  effect	  of	  EBNA2	  which	  acts	  to	  increase	  transcription	  via	  RBP-­‐
Jκ	  (Portal	  et	  al.	  2011).	  
	  
1.1.7.2	  Latent	  membrane	  proteins	  
LMP1	  
It	  was	  originally	  thought	  that	  LMP1	  was	  absolutely	  required	  for	  B	  cell	  transformation	  (Kaye	  
et	  al.	  1993)	  and	  for	  continued	  growth	  of	  established	  LCLs	  (Kilger	  et	  al.	  1998).	  In	  the	  absence	  
of	   EBNA2,	   LMP1	   was	   not	   able	   to	   maintain	   proliferation	   but	   did	   increase	   B	   cell	   survival	  
(Zimber-­‐Strobl	   et	   al.	   1996).	   Subsequent	   work	   by	   Wolfgang	   Hammerschmidt’s	   group,	  
however,	   has	   shown,	   using	   LCLs	   with	   conditional	   expression	   of	   LMP1,	   that	   when	   LMP1	  
expression	  was	  very	  low,	  the	  cells	  were	  able	  to	  survive	  but	  unable	  to	  proliferate	  (Kilger	  et	  al.	  
1998).	  Members	   of	   this	   group	  have	   successfully	  managed	   to	  produce	   LCLs	  with	   LMP1	  KO	  
virus,	  but	  at	  markedly	  reduced	  frequency	  compared	  to	  wild-­‐type,	  and	  only	  in	  the	  presence	  
of	   irradiated	   fibroblast	   feeder	   cells	   (Dirmeier	   et	   al.	   2003),	   confirming	   that	   LMP1	   is	   not	  
absolutely	   required	   for	   transformation	   but	   the	   efficiency	   of	   this	   is	   extremely	   reduced	  
without	  LMP1	  expression.	  	  	  
	  
LMP1	   is	   a	  membrane	  protein	   of	   386	   amino	   acids,	  with	   six	   transmembrane	  domains	   and	   a	  
200-­‐amino-­‐acid	   cytoplasmic	   domain,	   containing	   two	   C-­‐terminal	   activation	   regions,	   CTAR1	  
and	   CTAR2,	   which	   are	   essential	   for	   its	   signalling	   functions.	   CTAR1	   associates	   with	   tumour	  
necrosis	   factor	   (TNF)-­‐receptor	   activating	   factors	   (TRAFs),	   and	   CTAR2	   associates	   with	   TNF-­‐
receptor-­‐associated	   death	   domain	   proteins	   (TRADD),	   both	   activating	   the	   nuclear	   factor	  
kappa-­‐B	  (NFκB)	  pathway	  (Huen	  et	  al.	  1995).	  The	  TRAFs	  interact	  with	  other	  kinases,	  resulting	  
in	   activation	   of	   other	   signalling	   pathways	   including	   NFκB,	   phosphoinositide-­‐3	   kinase	   (PI3-­‐
K)/Akt,	   extracellular	   signal-­‐regulated	   kinase/mitogen-­‐activated	   protein	   kinase	   (ERK/MAPK)	  




and	   Janus	   kinase/signal	   transducers	   and	   activators	   of	   transcription	   (JAK/STAT)	   (Young	   and	  
Rickinson	  2004).	  
	  
LMP1	   thus	   functions	   as	   a	   constitutively	   active	   member	   of	   the	   TNF-­‐receptor	   superfamily,	  
providing	  growth	  and	  survival	  signals	  to	  B	  cells	  by	  mimicking	  the	  CD40	  interaction	  with	  CD40	  
ligand	  on	  T	  cells	  (Kilger	  et	  al.	  1998,	  Uchida	  et	  al.	  1999).	  LMP1	  expression	  in	  EBV-­‐negative	  B	  
cell	  lines	  results	  in	  expression	  of	  adhesion	  molecules	  (e.g.	  ICAM-­‐1,	  LFA-­‐1	  and	  LFA-­‐3)	  and	  cell	  
clumping,	   as	   well	   as	   up-­‐regulation	   of	   the	   B	   cell	   activation	  markers	   CD23,	   CD40	   and	   CD44	  
(Wang	  et	  al.	  1990a).	  LMP1	  also	  down-­‐regulates	  BLIMP1-­‐α,	  thus	  disrupting	  differentiation	  to	  
plasma	  cells	  (Vrzalikova	  et	  al.	  2011).	  
	  
LMP1	  is	  oncogenic	  both	  in	  vitro,	  transforming	  rodent	  fibroblasts	  (Wang	  et	  al.	  1985),	  and	  in	  
vivo,	  where	   its	  expression	  results	   in	   lymphomas	   in	   transgenic	  mice	   (Kulwichit	  et	  al.	  1998).	  
Furthermore,	  LMP1	  expression	  is	  protective	  against	  apoptosis,	  by	  up-­‐regulation	  of	  the	  anti-­‐
apoptotic	  protein	  BCL2	   in	  B	  cells	   (Henderson	  et	  al.	  1991),	  as	  well	  as	  by	   induction	  of	  other	  
anti-­‐apoptotic	  proteins,	  via	  NFκB	   [reviewed	   in	   (Allday	  2009)]	   (see	  section	  1.5.3	   for	   further	  
explanation	   of	   apoptotic	   pathways).	   By	  mimicking	   CD40,	   leading	   to	   activation	   of	   NFκB,	   it	  
induces	  cFLIP	  expression,	  inhibiting	  extrinsic	  apoptosis	  pathways	  [reviewed	  in	  (Spender	  and	  
Inman	   2011)].	   LMP1	   also	   inhibits	   BAX	   promoter	   activity,	   another	   means	   of	   preventing	  
apoptosis	   (Grimm	   et	   al.	   2005).	   In	   addition,	   it	   prevents	   senescence	   in	   mouse	   embryonic	  
fibroblasts	  by	  inhibiting	  induction	  of	  the	  cdk	  inhibitor	  p16INK4B	  (Yang	  et	  al.	  2000).	  
	  
LMP2A	  and	  LMP2B	  
LMP2A	  and	  LMP2B	  are	  related	   integral	  membrane	  proteins,	  each	  with	  12	   transmembrane	  
domains	  and	  a	  cytoplasmic	  tail,	  which	  are	  not	  required	  for	  in	  vitro	  immortalisation	  of	  B	  cells	  
(Longnecker	  et	  al.	  1993b,	  Speck	  et	  al.	  1999).	  The	  LMP2	  gene	  encodes	  2	  mRNA	  isoforms,	  with	  
exons	  2-­‐9	   common	   to	  both	   LMP2A	  and	   LMP2B,	  but	   a	  unique	  5’	   exon	   for	   each;	   exon	  1	  of	  
LMP2B	  is	  non-­‐coding	  whereas	  that	  of	  LMP2A	  encodes	  the	  cytoplasmic	  N-­‐terminal	  sequence,	  
through	   which	   signalling	   occurs	   (Rechsteiner	   et	   al.	   2008).	   The	   exons	   encoding	   the	   LMP2	  
proteins	  are	  found	  at	  both	  ends	  of	  the	  linear	  EBV	  genome	  and	  the	  promoters	  of	  both	  share	  
a	  bidirectional	  EBNA2	  response	  element	  (Harada	  and	  Kieff	  1997)	  (see	  fig.	  1.2).	  The	  LMP2A	  




promoter	  is	  used	  to	  transcribe	  exon	  1	  of	  LMP2A,	  whereas	  all	  the	  other	  exons	  are	  transcribed	  
from	  the	  LMP2B	  promoter.	  
	  
LMP2A	  can	  act	  as	  a	  constitutively	  active	  B	  cell	  receptor	  (BCR)	  mimic	  and	  hence	  can	  drive	  the	  
proliferation	   and	   survival	   of	   B	   cells	   in	   the	   absence	   of	   BCR	   signalling	   (Mancao	   and	  
Hammerschmidt	  2007).	  Thus	  it	  is	  able	  to	  rescue	  cells	  lacking	  strong	  BCR	  stimulation	  due	  to	  
low	  affinity	  for	  antigen,	  which	  would	  otherwise	  die,	  enabling	  survival	  of	  EBV-­‐infected	  cells.	  
The	  cytoplasmic	  N-­‐terminal	  domain	  of	  LMP2A	  contains	  an	  immune-­‐receptor	  tyrosine-­‐based	  
activation	  motif	  (ITAM).	  In	  B	  cells,	  LMP2A	  recruits	  the	  Src	  family	  kinase	  Lyn	  to	  its	  N-­‐terminal	  
region,	  leading	  to	  constitutive	  phosphorylation	  of	  multiple	  tyrosine	  residues,	  including	  in	  the	  
ITAM	  (Fruehling	  and	  Longnecker	  1997).	  This	   in	   turn	   leads	   to	   recruitment,	  phosphorylation	  
and	   consequent	   activation	   of	   Syk,	   resulting	   in	   constitutive	   activation	   of	   PI3K/Akt,	   which	  
promotes	  B	  cell	  survival	  (Portis	  and	  Longnecker	  2004).	  LMP2A	  also	  activates	  other	  signalling	  
pathways	   including	   NFκB	   and	   MAPK	   (Swanson-­‐Mungerson	   et	   al.	   2005,	   Anderson	   and	  
Longnecker	  2008).	  LMP2A	  protects	  B	  cells	  from	  apoptosis	  by	  several	  mechanisms	  including	  
induction	   of	   anti-­‐apoptotic	   BCL-­‐XL	   and	   survivin	   (Portis	   et	   al.	   2003,	   Portis	   and	   Longnecker	  
2004,	   Bultema	   et	   al.	   2009)	   (see	   section	   1.5.3	   for	   details	   on	   apoptosis).	   In	   a	   murine	  
transgenic	  model,	  LMP2A	  protects	  from	  apoptosis	  by	  induction	  of	  NFκB	  and	  BCL2	  (Swanson-­‐
Mungerson	   et	   al.	   2010).	   Furthermore,	   EBV	   increases	   proteasomal	   degradation	   of	   pro-­‐
apoptotic	  BIM	  via	  activation	  of	  the	  MAPK/ERK	  pathway,	  and	  this	  is	  likely	  to	  occur	  via	  LMP2A	  
[(Clybouw	  et	  al.	  2005),	  reviewed	  in	  (Allday	  2009)].	  	  	  
	  
The	  function	  of	  LMP2B	  in	  B	  cells	   is	  not	  entirely	  understood,	  although	  it	  has	  been	  shown	  to	  
bind	   to	   LMP2A,	   blocking	   its	   phosphorylation	   and	   activation,	   hence	   regulating	   its	   activity	  
(Rovedo	  and	  Longnecker	  2007).	  	  
	  
1.1.7.3	  EBV-­‐encoded	  RNAs	  and	  microRNAs	  
As	  well	   as	   latent	  proteins,	   latent	   EBV	  also	  expresses	   a	  number	  of	  non-­‐coding	  RNAs.	   These	  
include	  the	  EBV-­‐encoded	  small	  RNAs	   (EBERs),	  EBER1	  and	  EBER2,	  which	  are	  of	  167	  and	  172	  
nucleotides	   respectively,	   first	   described	   in	   1981	   [(Lerner	   et	   al.	   1981)	   and	   reviewed	   in	  
(Swaminathan	  2008)]	   (see	   fig.	   1.2).	   They	  are	  produced	  abundantly	   in	   all	   EBV-­‐infected	   cells	  




and	  expressed	  in	  all	  latency	  types,	  suggesting	  that	  they	  have	  an	  important	  function.	  Although	  
they	   are	   not	   essential	   for	   B	   cell	   transformation	   (Swaminathan	   et	   al.	   1991),	   EBERs	   induce	  
oncogenic	  properties	  in	  EBV-­‐negative	  Akata	  cells,	  including	  up-­‐regulation	  of	  BCL2	  leading	  to	  
resistance	  to	  apoptosis	  (Komano	  et	  al.	  1999)	  and	  enhance	  proliferation	  in	  EBV-­‐negative	  BJAB	  
BL	   cells	   (Yamamoto	   et	   al.	   2000).	   However,	   their	   functions	   are	   still	   not	   completely	  
understood.	  	  
	  
EBV	   also	   produces	   microRNAs	   (miRNAs),	   which	   are	   functional	   but	   non-­‐coding	   RNAs	   of	  
around	  21-­‐25	  nucleotides	  in	  length.	  miRNAs	  bind	  to	  specific	  mRNA	  sequences,	  usually	  within	  
their	  3’	  untranslated	  regions	  (UTR),	   leading	  to	  reduced	  translation	  or	  enhanced	  destruction	  
of	  the	  target	  mRNA.	  They	  are	  increasingly	  recognised	  as	  being	  produced	  by	  several	  different	  
viruses	  including	  herpesviruses,	  and	  regulate	  both	  viral	  and	  host	  gene	  expression	  [reviewed	  
in	  (Grundhoff	  and	  Sullivan	  2011)].	  EBV	  expresses	  44	  of	  these	  mature	  miRNAs	  (Grundhoff	  and	  
Sullivan	   2011),	   which	   are	   expressed	   from	   two	   regions	   of	   the	   EBV	   genome,	   the	   	  BamHI	   A	  
region	   and	   the	   BamHI	   H	   region.	   These	   miRNAs	   are	   known	   as	   the	   BamHI	   A	   rightward	  
transcript	   (BART)	   miRNAs	   and	   the	   BHRF1	   miRNAs	   respectively.	   The	   two	   groups	   are	  
differentially	  expressed	   in	  cell	   lines:	  BART	  miRNAs	  are	   strongly	  expressed	   in	  NPC	  cell	   lines,	  
but	  not	  EBV-­‐infected	  primary	  epithelial	   cell	   lines	   (Shannon-­‐Lowe	  et	  al.	  2009),	   and	  are	  only	  
weakly	  expressed	  in	  LCLs	  and	  EBV-­‐infected	  BL	  cell	  lines.	  The	  BHRF1	  miRNAs	  are	  expressed	  in	  
LCLs	  and	  latency	  III-­‐expressing	  BL	  cell	  lines	  but	  undetectable	  in	  NPC	  cell	  lines	  (Cai	  et	  al.	  2006).	  
EBV	  miRNAs	  can	  regulate	  both	  viral	  and	  host	  cellular	  gene	  expression.	  	  
	  
It	   is	   increasingly	   recognised	   that	   miRNAs	   expressed	   by	   oncogenic	   herpesviruses	   can	  
contribute	   to	  oncogenesis	   (Grundhoff	   and	   Sullivan	  2011).	   In	   the	   case	  of	   EBV,	   for	   example,	  
miR-­‐BART5	   has	   been	   shown	   to	   target	   the	   pro-­‐apoptotic	   protein	   PUMA,	   hence	   leading	   to	  
resistance	  to	  apoptosis	  in	  epithelial	  cells	  (Choy	  et	  al.	  2008)	  and	  the	  BART	  miRNAs	  can	  protect	  
BL	  cells	   from	  apoptosis,	  probably	  by	   inhibiting	  caspase	  3	   (Vereide	  et	  al.	  2013).	   In	  addition,	  
the	   BHRF1-­‐3	  miRNAs	   inhibit	   apoptosis	   and	   promote	   cell	   cycle	   progression	   early	   after	   EBV	  
infection	  of	  primary	  B	  cells	  (Seto	  et	  al.	  2010).	   It	   is	   likely	  that	  further	  oncogenic	  functions	  of	  
EBV-­‐associated	  miRNAs	  will	  be	  identified	  in	  future.	  	  




1.1.8	  Lytic	  infection	  
During	  lytic	  viral	  replication,	  multiple	  viral	  genes	  are	  expressed.	  The	  first	  event	  in	  a	  sequence	  
is	  the	  expression	  of	  immediate	  early	  (IE)	  genes	  BZLF1	  (also	  known	  as	  ZEBRA,	  Zta	  or	  EB1)	  and	  
BRLF1	  (also	  known	  as	  Rta)	  (see	  fig.	  1.2).	  These	  in	  turn	  transactivate	  viral	  early	  genes,	  leading	  
to	   expression	   of	   early	   antigens	   including	   early	   antigen	   diffuse	   component	   EA-­‐D,	   which	   is	  
regulated	   by	   the	   BMRF1	   promoter	   (Holley-­‐Guthrie	   et	   al.	   1990).	   Then	   late	   genes	   are	  
expressed,	  resulting	  in	  the	  structural	  components	  of	  the	  virions,	  which	  can	  then	  be	  released	  
from	  the	  host	  cell,	  acquiring	  the	  envelope	  by	  budding	  through	  the	  host	  cell	  membrane,	  and	  
usually	   killing	   the	   host	   cell	   in	   the	   process.	   When	   EBV	   infects	   epithelial	   cells,	   it	   generally	  
causes	   lytic	   replication,	  whereas	   infection	  of	  B	  cells	  eventually	   results	   in	  persistent	   (latent)	  
infection,	   although	   lytic	   replication	   is	   again	   initiated	   when	   differentiation	   to	   plasma	   cells	  
occurs	  (Laichalk	  and	  Thorley-­‐Lawson	  2005,	  Longnecker	  et	  al.	  2013).	  	  
	  
In	   a	   persistently	   infected	   host,	   the	   majority	   of	   infected	   B	   cells	   contain	   latent	   virus,	   but	  
intermittently	  the	  virus	  can	  reactivate	  to	  the	  lytic	  form	  in	  occasional	  cells.	  This	  is	  thought	  to	  
occur	  in	  response	  to	  B	  cell	  stimulation	  by	  other	  antigens,	  due	  to	  stimulation	  of	  the	  BCR.	  	  In	  
vitro,	   lytic	   replication	   can	   be	   induced	   by	   several	   mechanisms	   including	   anti-­‐Ig,	   12-­‐O-­‐
tetradecanoylphorbol-­‐13-­‐acetate	   (TPA),	   transforming	   growth	   factor	   beta	   (TGFβ),	   histone	  
deacetylase	  (HDAC)	   inhibitors	  and	  DNA	  methyl	   transferase	  (DNMT)	   inhibitors,	  although	  the	  
ability	  of	  these	  agents	  to	  induce	  lytic	  replication	  varies	  between	  cell	  lines	  (zur	  Hausen	  et	  al.	  
1978,	  Ben-­‐Sasson	  and	  Klein	  1981,	   Takada	  1984,	  di	  Renzo	  et	   al.	   1994,	  Chang	  and	   Liu	  2000,	  
Fahmi	   et	   al.	   2000,	   Inman	   et	   al.	   2001,	   Countryman	   et	   al.	   2008,	   Ghosh	   et	   al.	   2012).	   These	  
signals	  act	  on	  the	  two	  viral	   IE	  promoters	  Zp	  and	  Rp	  to	  increase	  their	  activity,	  resulting	  in	  IE	  
gene	  expression.	  	  
	  
	   	  




1.2	  Normal	  B	  cell	  development	  and	  function	  
1.2.1	  Antibody	  production	  
B	   cells	   are	   the	   main	   effectors	   of	   the	   humoral	   immune	   response,	   being	   responsible	   for	  
antibody	  production.	  The	  antigen	  specificity	  of	  the	  B	  cell	  is	  provided	  by	  a	  surface	  receptor,	  
the	   B	   cell	   receptor	   (BCR),	   which	   binds	   to	   a	   particular	   epitope	   of	   an	   antigen.	   Every	   B	   cell	  
produced	  has	  a	  unique	  antigen	  specificity,	  although	  all	   the	  BCRs	  on	  one	  cell	  are	   identical.	  
The	  BCR	  can	  subsequently	  be	  secreted	  by	  a	  B	  cell	  as	  antibody.	  There	  are	  five	  main	  classes	  of	  
antibody:	  IgM,	  IgD,	  IgG,	  IgE	  and	  IgA,	  which	  all	  have	  different	  effector	  functions.	  An	  antibody	  
is	   a	   Y-­‐shaped	   immunoglobulin	  molecule	   (fig.	   1.3)	   consisting	   of	   two	   identical	   heavy	   chains	  
and	   two	   identical	   light	   chains,	  bound	   together	  by	  disulphide	  bonds.	   The	   light	   chains	  have	  
two	   domains,	   the	   variable	   domain	   VL	   at	   the	   N-­‐terminal	   end	   and	   the	   C-­‐terminal	   constant	  
domain	  CL.	  The	  heavy	  chains	  each	  have	  a	  variable	  domain	  VH	  at	  the	  N-­‐terminal	  end	  and	  at	  
least	   three	   (depending	   on	   the	   antibody	   class)	   constant	   domains	   (fig.	   1.3).	   The	   variable	  
regions	  of	  both	  heavy	  and	  light	  chains	  are	  therefore	  adjacent	  on	  each	  ‘arm’	  of	  the	  molecule,	  
and	   this	   is	   the	   region	   that	   binds	   to	   an	   epitope	   of	   a	   particular	   antigen.	   The	   stem	   of	   the	  
molecule,	   known	   as	   the	   Fc	   portion,	   consists	   of	   the	   heavy	   chain	   constant	   regions	   and	   its	  
structure	  varies	  according	  to	  the	  antibody	  class.	  This	  region	  performs	  the	  effector	  functions	  
of	  the	  antibody,	  or	  is	  bound	  to	  the	  B	  cell	  surface	  membrane	  in	  the	  form	  of	  the	  BCR.	  There	  
are	   five	  main	   types	  of	  heavy	  chain	  constant	   region,	  γ,	  μ,	  δ,	  α	  and	  ε,	  which	  determine	   the	  
class	   (or	   istoype)	   of	   the	   antibody	   produced,	   which	   are	   IgG,	   IgM,	   IgD,	   IgA	   and	   IgE	  
respectively.	  There	  are	  two	  isotypes	  of	  light	  chain,	  κ	  and	  λ.	  	  
	   	  





Figure	  1.3:	  Schematic	  diagram	  of	  antibody	  structure	  	  
An	  antibody	  or	  immunoglobulin	  (Ig)	  molecule	  consists	  of	  a	  pair	  of	  heavy	  chains	  (blue)	  and	  a	  pair	  of	  light	  chains	  
(red)	   joined	  by	  disulphide	  bonds	   (shown	  as	   fine	  blue	   lines).	   The	   light	   chain	   consists	   of	   a	   variable	   (VL)	   and	   a	  
constant	   (CL)	   light	  chain	  domain.	  The	  heavy	  chain	  consists	  of	  a	  variable	   (VH)	  and	  at	   least	   three	  constant	   (CH)	  
domains,	  CH1,	  CH2	  and	  CH3.	  CH2	  and	  CH3	  comprise	  the	  Fc	  region,	  which	  performs	  the	  effector	  functions	  of	  the	  
antibody	   and	   varies	   according	   to	   the	   class	   (isotype).	   The	   unique	   antigen	   binding	   regions	   are	   made	   by	   VH	  
combined	  with	  VL	  at	  the	  N-­‐termini.	  	  	  
	  	  
The	   diverse	   repertoire	   of	   antigen	   specificities	   is	   enabled	   by	   the	   variable	   regions	   of	   heavy	  
and	   light	   chains.	   The	   human	   heavy	   chain	   gene	   locus,	   on	   chromosome	   14,	   consists	   of	  
multiple	  gene	  segments	  including	  40	  variable	  (V)	  gene	  segments,	  25	  diversity	  (D)	  segments	  
and	  6	  joining	  (J)	  segments	  (see	  fig.	  1.4).	  When	  a	  B	  cell	  makes	  its	  heavy	  chain,	  one	  of	  the	  D	  
segments	   is	   chosen	   at	   random	  and	   joined	   to	   one	  of	   the	   J	   segments,	   in	   the	  process	   of	  DJ	  
rearrangement.	  Then	  the	  DJ	  segment	  is	  joined	  to	  a	  V	  segment,	  i.e.	  VDJ	  rearrangement.	  The	  
resulting	  VDJ	  is	  then	  joined	  to	  the	  appropriate	  constant	  region	  segment	  depending	  on	  which	  
isotype	  of	  antibody	  is	  to	  be	  made.	  The	  light	  chain	  loci	  each	  consist	  of	  multiple	  V	  and	  J	  (but	  
not	  D)	  segments	  and	  thus	  VJ	  rearrangements	  are	  made	  in	  a	  similar	  way	  to	  create	  diversity	  of	  
the	   light	   chains.	   The	   recombination	   of	   the	   gene	   segments	   is	   catalysed	   by	   the	   V(D)J	  
recombinase	   enzyme	   complex,	   which	   includes	   the	   proteins	   RAG1	   and	   RAG2	   encoded	   by	  
recombination	   activating	   genes	   RAG1	   and	   RAG2.	   Each	   gene	   segment	   is	   flanked	   by	   a	  
recombination	   signal	   sequence,	   and	   the	   RAG	   proteins	   introduce	   double	   strand	   breaks	  
(DSBs)	  in	  the	  DNA	  between	  the	  gene	  segments	  to	  be	  joined	  and	  their	  recombination	  signal	  
sequences	  (Murphy	  2011).	  RAG	  then	  recruits	  DNA	  repair	  enzymes	  to	  join	  the	  segments.	   In	  




this	  process,	  a	  small	  number	  of	  nucleotides	  may	  be	   lost	  or	  gained	  between	  the	  segments,	  
and	  this	  adds	  to	  the	  diversity	  generated	  on	  the	  antibody	  variable	  region.	  	  	  
	  
	  
Figure	  1.4:	  The	  human	  heavy	  chain	  locus	  
The	  human	  heavy	  chain	  gene	   locus	  on	  chromosome	  14	  consists	  of	  40	  variable	  (V)	  segments,	  25	  diversity	   (D)	  
segments,	  6	  joining	  (J)	  segments	  and	  then	  the	  constant	  (C)	  segments	  which	  encode	  the	  five	  different	  classes	  of	  
heavy	  chain,	  IgM,	  IgD,	  IgG,	  IgE	  and	  IgA	  respectively.	  Adapted	  from	  (Alberts	  et	  al.	  2008).	  
	  
1.2.2	  B	  cell	  development	  within	  the	  bone	  marrow	  
B	   cells	   develop	   initially	   in	   the	   bone	  marrow	   (BM)	   from	   CD34+	   haematopoietic	   stem	   cells	  
(HSCs),	  which	  give	  rise	  to	  all	  haematopoietic	  cells.	  During	  this	  maturation	  process	  within	  the	  
BM,	  which	  is	  antigen-­‐independent,	  the	  B	  cells	  gradually	  migrate	  towards	  the	  central	  sinus,	  
remaining	  in	  contact	  with	  stromal	  cells.	  HSCs	  differentiate	  first	   into	  the	  common	  lymphoid	  
progenitor	  cell,	  which	  can	  give	  rise	  to	  T	  or	  B	  cells	   (Pieper	  et	  al.	  2013).	  Once	  committed	  to	  
the	  B	  cell	   lineage,	  the	  cell	  develops	  through	  the	  pro-­‐B	  then	  pre-­‐B	  cell	  stages	  (see	  fig.	  1.5).	  
During	  the	  process	  of	  B	  cell	  maturation,	  immunoglobulin	  genes	  are	  rearranged	  in	  turn.	  First	  
the	  IgH	  (Ig	  heavy	  chain)	  locus,	  with	  D-­‐J	  rearrangement	  occurring	  in	  the	  early	  pro-­‐B	  cell,	  and	  
then	   V-­‐DJ	   rearrangement	   in	   the	   late	   pro-­‐B	   stage.	   In	   the	   subsequent	   pre-­‐B	   cell	   stage	   the	  
light-­‐chain	  genes	  are	  rearranged.	  Once	  at	  the	  immature	  B	  cell	  stage,	  IgH	  VDJ	  and	  light	  chain	  
VJ	  having	  been	  rearranged,	  IgM	  is	  now	  expressed	  on	  the	  cell	  surface	  (Murphy	  2011).	  At	  this	  
stage	   the	   cell	   exits	   the	   BM	   into	   peripheral	   blood,	   and	   also	   starts	   to	   express	   surface	   IgD.	  
These	   mature	   naïve,	   non-­‐proliferating,	   B	   cells	   now	   migrate	   via	   the	   blood	   to	   secondary	  
lymphoid	  organs	   (the	   spleen,	   lymph	  nodes,	   or	  mucosa-­‐associated	   lymphoid	   tissue,	  MALT)	  
and	  continue	  to	  circulate	  through	  these	  until	  either	  they	  encounter	  the	  relevant	  antigen	  or	  
die.	  
	   	  


























Figure	  1.5:	  Stages	  of	  development	  of	  B	  cells	  within	  the	  bone	  marrow	  
B	   cells	   are	   originally	   derived	   from	   haematopoietic	   stem	   cells	   (HSCs),	   which	   differentiate	   into	   a	   common	  
lymphoid	   progenitor	   (CLP).	   The	   earliest	   stage	   of	   commitment	   to	   the	   B	   cell	   lineage	   is	   the	   pro-­‐B	   cell.	   In	   this	  
stage,	   RAG	   genes	   are	   expressed	   and	   rearrangements	   of	   the	   D-­‐J	   segments	   of	   the	   heavy	   chain	   locus	   occur,	  
followed	   by	   V-­‐DJ	   rearrangement.	   Once	   this	   has	   successfully	   occurred,	   a	   complete	   Ig	   μ	   heavy	   chain	   is	  
expressed,	  bound	  to	  a	  surrogate	  light	  chain	  as	  the	  pre-­‐BCR	  which	  is	  briefly	  expressed	  on	  the	  cell	  surface.	  The	  
cell	  then	  differentiates	  into	  a	  pre-­‐B	  cell,	  which	  initially	  proliferates	  and	  production	  of	  the	  surrogate	  light	  chain	  
stops.	  The	  cell	   then	  stops	  dividing,	   the	  RAG	  genes	  are	  re-­‐expressed	  and	   light	  chain	  V-­‐J	  gene	  rearrangements	  
occur.	   Once	   a	   light	   chain	   has	   successfully	   been	   produced,	   the	   complete	   IgM	  molecule	   is	   expressed	   at	   the	  
surface	  and	  the	  cell	  is	  released	  from	  the	  bone	  marrow	  as	  an	  immature	  B	  cell.	  	  
	  
	  
1.2.3	  Further	  B	  cell	  development	  within	  secondary	  lymphoid	  tissue	  
B	   cells	   encounter	   antigens	   bound	   to	   follicular	   dendritic	   cells	   (FDCs)	   within	   secondary	  
lymphoid	  tissues.	  If	  an	  antigen	  presented	  by	  FDCs	  is	  recognised	  by	  the	  BCR,	  the	  BCR-­‐antigen	  
complex	  is	  endocytosed,	  processed	  by	  the	  B	  cell	  and	  presented	  on	  the	  surface	  in	  association	  
with	  major	   histocompatibility	   complex	   (MHC)	   class	   II	  molecules,	   allowing	   recognition	   and	  
Gene	  
rearrangement	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help	  by	  antigen-­‐specific	  CD4+	  T-­‐helper	  (TH)	  cells.	  The	  binding	  of	  BCR	  by	  antigen	  stimulates	  
further	   development	   of	   the	   B	   cell,	   which	   becomes	   activated,	   differentiates	   into	   a	  
centroblast	  which	  proliferates	  and	  initiates	  a	  germinal	  centre	  (GC)	  reaction	  within	  the	  lymph	  
node	   (or	   other	   lymphoid	   tissue).	   The	   GC	   reaction	   is	   a	   means	   of	   further	   increasing	   the	  
specificity	  of	  antibody	  and	  producing	  immune	  effector	  cells	  in	  the	  form	  of	  plasma	  cells	  and	  
memory	  B	   cells	   (see	   fig.	   1.6).	   By	   light	  microscopy,	  GCs	  have	   two	   zones,	   a	  dark	   zone	   (DZ),	  
consisting	   of	   rapidly	   proliferating	   B	   cells,	   and	   a	   light	   zone	   (LZ),	   in	   which	   B	   cells	   are	  
interspersed	  with	  T	  cells	  (mainly	  CD4+)	  and	  FDCs	  (Klein	  and	  Dalla-­‐Favera	  2008).	  Within	  the	  
GC,	   the	   centroblast	   undergoes	   rapid	   proliferation	   (dividing	   every	   6-­‐12	   hours),	   and	   the	  
enzyme	   activation-­‐induced	   cytidine	   deaminase	   (AID)	   is	   up-­‐regulated.	   	   This	   enzyme	  
deaminates	   cytosine	   to	   uracil,	   resulting	   in	   a	   G:U	  mismatch,	  which	   is	   recognised	   by	   uracil	  
DNA	   glycosylase	   or	   processed	   by	   one	   of	   several	   DNA	   repair	   pathways,	   leading	   to	   the	  
formation	  of	  single	  nucleotide	  changes	  within	  the	  variable	  regions	  of	  heavy	  and	  light	  chain	  
genes	  (Klein	  and	  Dalla-­‐Favera	  2008).	  This	  process,	  known	  as	  somatic	  hypermutation	  (SHM),	  
combined	   with	   rapid	   proliferation,	   leads	   to	   multiple	   variants	   with	   differing	   affinity	   for	  
antigen	  (Fear	  2013).	  From	  these	  variants,	  any	  with	  enhanced	  affinity	  for	  the	  antigen	  will	  be	  
selected	  but	  the	  remainder	  (the	  majority)	  will	  die.	  Interleukin-­‐4	  (IL-­‐4)	  produced	  by	  TH2	  cells	  
enhances	  proliferation/survival	  of	  B	  cells,	  plus	  promotes	  Ig	  isotype	  switching	  to	  IgG1	  and	  IgE	  
(Snapper	  et	  al.	  1988,	  King	  and	  Mohrs	  2009).	  
	  
The	  proliferating	  centroblasts	  differentiate	  into	  centrocytes	  and	  at	  the	  same	  time	  migrate	  to	  
the	  LZ	  of	   the	  GC.	  Centrocytes	  with	   the	  highest	  affinity	   for	  antigen	  receive	  survival	   signals,	  
leading	  to	  down-­‐regulation	  of	  pro-­‐apoptotic	  genes.	  However,	  in	  the	  absence	  of	  such	  survival	  
signals	   the	  default	  position	  of	   centrocytes	   is	   to	  die	  by	  apoptosis.	  GC	  B	   cells	   are	   therefore	  
generally	   pro-­‐apoptotic:	   BCL6,	   a	   transcriptional	   repressor	   essential	   for	   GC	   formation,	   is	  
selectively	   up-­‐regulated	   in	  GC	  B	   cells	   and	   silences	   anti-­‐apoptotic	   BCL2	   (Saito	   et	   al.	   2009),	  
and	  GC	  B	   cells	   express	  high	   levels	   of	   FAS,	   part	   of	   the	   extrinsic	   pathway	  of	   apoptosis	   (see	  
section	   1.5.3).	   In	   addition,	   BCL6	   represses	   p53	   (Phan	   and	   Dalla-­‐Favera	   2004),	   which	   is	  
normally	  responsible	  for	  DNA	  damage	  responses,	  and	  thus	  allows	  the	  GC	  B	  cells	  to	  tolerate	  
the	  DNA	  damage	  induced	  by	  the	  SHM	  process.	  	  
	  




MYC	  is	  a	  highly	  important	  DNA-­‐binding	  transcription	  factor	  which	  regulates	  multiple	  genes	  
including	   those	   regulating	   cell	   cycle	   progression,	   apoptosis	   and	   senescence.	   Expression	  of	  
MYC	  is	  increased	  in	  LZ	  B	  cells	  but	  then	  repressed	  in	  DZ	  B	  cells	  by	  a	  direct	  action	  of	  BCL6	  on	  
the	  MYC	  promoter.	  In	  addition,	  MYC	  expression	  is	  required	  for	  maintenance	  of	  GCs	   in	  vivo	  
(Dominguez-­‐Sola	   et	   al.	   2012).	   In	   those	   cells	   that	   receive	   survival	   signals,	   heavy	   chain	  
(isotype)	   class	   switching	   occurs,	   in	   order	   to	   produce	   IgG,	   IgA	   or	   IgE.	   This	   process	   is	   also	  
dependent	   upon	   AID,	   and	   involves	   deletion	   of	   all	   coding	   sequences	   between	   the	   VDJ	  
segment	  and	  the	  relevant	  C	  segment	  (for	  example,	  Cα	  if	   IgA	   is	  to	  be	  made;	  see	  fig.	  1.4),	  a	  
process	  known	  as	  class	  switch	  recombination	  (CSR).	  
	  
Victora	  and	  Nussenzweig	  have	  recently	  proposed	  an	  updated	  model	  for	  the	  GC	  reaction,	  in	  
which	  the	  driving	  force	  behind	  B	  cell	  affinity	  maturation	  and	  selection	  is	  competition	  for	  T	  
cell	  help,	  with	  signals	  received	  through	  BCR	  being	  essential	  for	  survival.	   It	  has	  been	  shown	  
that	  the	  functional	  distinction	  between	  the	  DZ	  and	  LZ	  is	  less	  marked	  than	  previously	  thought	  
and	  that	  cells	  migrate	  cyclically	  through	  the	  LZ	  and	  DZ	  compartments,	  rather	  than	  passing	  
through	   sequentially.	   Nevertheless,	   proliferation	   occurs	  mainly	   in	   the	  DZ	   and	   selection	   in	  
the	   LZ,	   but	   these	   authors	   propose	   that	   the	   DZ	   and	   LZ	   cells	   represent	   the	   same	   cell	  
population	   in	   different	   states	   of	   activation	   (Victora	   et	   al.	   2012,	   Victora	   and	   Nussenzweig	  
2012).	  	  
	  
The	  mature	   activated	   B	   cells	  which	   survive	   the	   GC	   reaction	   can	   then	   develop	   into	   either	  
long-­‐term	  memory	  B	  cells	  (which	  comprise	  approximately	  40%	  of	  the	  B	  cell	  population)	  or	  
plasma	  cells,	  which	  stay	  within	  lymph	  nodes	  or	  migrate	  to	  the	  BM	  and	  continue	  to	  produce	  
antibody	   (Murphy	   2011).	   The	   long-­‐term	   memory	   B	   cells,	   with	   high	   affinity	   antibody,	  
continue	  to	  circulate	  around	  the	  body	   for	  many	  years,	  and	   if	   their	  antigen	   is	  encountered	  
again	  they	  are	  primed	  to	  differentiate	  rapidly	  into	  plasma	  cells	  and	  secrete	  large	  amounts	  of	  
high	   affinity	   antibody,	   resulting	   in	   a	   secondary	   immune	   response	  which	   has	   a	   shorter	   lag	  
time	  and	  a	  greater	  amount	  of	  antibody	  production	  than	  seen	  in	  the	  primary	  response.	  	  Such	  
immunological	  memory	  can	  remain	  for	  the	  lifetime	  of	  the	  host,	  even	  if	  the	  original	  antigen	  
was	  encountered	  many	  years	  previously,	  and	  is	  the	  basis	  for	  vaccination.	  Memory	  B	  cells	  re-­‐
join	  the	  pool	  of	  continuously	  circulating	  B	  cells.	  	  





Figure	  1.6:	  Schematic	  diagram	  of	  the	  traditional	  model	  of	  the	  germinal	  centre	  reaction	  
Resting	   naïve	   mature	   B	   cells,	   expressing	   IgM	   and	   IgD,	   continuously	   circulate	   through	   blood	   and	   lymphoid	  
tissue.	  When	  the	  cell	  meets	  its	  antigen	  (Ag),	  it	  differentiates	  into	  a	  centroblast	  and	  starts	  to	  proliferate	  rapidly.	  
During	   this	   proliferation,	   somatic	   hypermutation	   (SHM),	   occurs,	   catalysed	   by	   activation-­‐induced	   cytidine	  
deaminase	  (AID),	  to	  introduce	  single	  base-­‐pair	  changes	  into	  the	  VDJ	  regions	  of	  the	  rearranged	  genes	  encoding	  
the	  heavy	  and	   light	   Ig	  chains.	  This	   takes	  place	  mostly	  within	   the	  dark	  zone	  of	   the	  GC.	  The	  centroblasts	   then	  
differentiate	  into	  centrocytes	  and	  migrate	  to	  the	  light	  zone,	  where	  antigen	  is	  presented	  by	  FDCs	  and	  T	  cell	  help	  
occurs,	  in	  order	  to	  select	  cells	  with	  high	  affinity	  for	  antigen.	  Cells	  with	  high	  affinity	  bind	  to	  antigen	  and	  receive	  
survival	   signals,	  whereas	   the	  default	  position	   is	   for	  cells	   to	  die	  by	  apoptosis	   if	   such	  signals	  are	  not	   received.	  
Those	   cells	  which	   survive	   can	   then	  undergo	   further	  differentiation	   into	  memory	  B	   cells	  or	  plasma	  cells	  with	  
class	  switch	  recombination	  (CSR)	  occurring,	  also	  catalysed	  by	  AID,	  to	  enable	  to	  cell	  to	  produce	  IgG,	  IgA	  or	  IgE	  
antibody.	   The	   resulting	   memory	   B	   cells	   or	   plasma	   cells	   can	   then	   leave	   the	   lymph	   node	   and	   continue	   to	  
circulate	  around	  the	  body.	  Adapted	  from	  (Klein	  and	  Dalla-­‐Favera	  2008).	  	  
	  
1.3	  EBV-­‐associated	  lymphomas	  
EBV	   is	   associated	   with	   several	   different	   types	   of	   lymphoma,	   predominantly	   B	   cell	  
lymphomas	  but	  also	   some	  T	  cell	   lymphomas;	  only	   the	  B	  cell	   lymphomas	  will	  be	  discussed	  
here.	  Each	  type	  of	   lymphoma	  is	  thought	  to	  arise	  from	  a	  particular	  type	  of	  cell	  along	  the	  B	  
cell	  differentiation	  pathway,	  with	  different	  tumours	  expressing	  different	  latent	  proteins	  (see	  
table	  1.1).	  	  
	  




Latency	  type	   Viral	  proteins	  expressed	   Cell/tumour	  type	  
0	  (latency)	   None	   None	  identified	  
I	   EBNA1	   BL	  (group	  I)	  
II	  (default	  programme)	   EBNA1,	  LMP1,	  LMP2	   Hodgkin	  lymphoma,	  NPC	  
III	  (growth	  programme)	   EBNA1,	  EBNA2,	  EBNA-­‐LP,	  
EBNA3A,	  EBNA3B,	  EBNA3C,	  




Table	  1.1:	  Viral	  proteins	  expressed	  in	  the	  different	  EBV	  latency	  types	  and	  their	  corresponding	  tumours	  	  
In	   latent	   infection	   EBV	   expresses	   nine	   latent	   proteins,	   the	   EBV	   nuclear	   antigens	   EBNA1,	   EBNA2,	   EBNA3A,	  
EBNA3B,	  EBNA3C	  and	  EBNA-­‐leader	  protein	  (EBNA-­‐LP)	  as	  well	  as	  three	  latent	  membrane	  proteins	  LMP1,	  LMP2A	  
and	  LMP2B.	  EBV-­‐associated	  tumours	  have	  characteristic	  expression	  of	  these	  latent	  proteins,	  thought	  to	  reflect	  
their	  cell	  of	  origin.	  	  
	  
1.3.1	  Immunodeficiency-­‐associated	  lymphomas	  
EBV-­‐associated	   lympho-­‐proliferative	  disorders	  occur	  with	   increased	   frequency	   in	   immuno-­‐
compromised	   individuals,	   including	   as	   a	   result	   of	   solid	   organ	  or	   haematopoietic	   stem	   cell	  
transplants	   (known	   as	   post-­‐transplant	   lymphoproliferative	   disorders	   or	   PTLD),	   in	   HIV	  
infection	   or	   due	   to	   other	   congenital	   or	   acquired	   immune	   deficiencies.	   Early-­‐onset	   PTLD,	  
occurring	   in	   the	   first	   year	   after	   transplant,	   are	   usually	   EBV-­‐positive	   and	   express	   the	   full	  
complement	   of	   latent	   proteins	   (latency	   III).	   This	   suggests	   that	   they	   are	   virus-­‐transformed	  
cells	  that	  are	  able	  to	  grow	  out	  due	  to	  the	  lack	  of	  effective	  T	  cell	  surveillance;	  the	  EBNA3s	  in	  
particular	  are	  highly	  immunogenic	  such	  that	  these	  cells	  would	  normally	  be	  quickly	  destroyed	  
in	  the	  presence	  of	  functional	  T	  cells	  (Murray	  et	  al.	  1992,	  Hislop	  et	  al.	  2007).	  As	  a	  result,	  such	  
tumours	   respond	  well	   to	   adoptively	   transferred	   cytotoxic	   T	   cell	   therapy	   (Gottschalk	   et	   al.	  
2005).	   PTLD	   encompasses	   a	   spectrum	   of	   disease,	   from	   a	   polyclonal	   lympho-­‐proliferation	  
resembling	  IM,	  through	  polymorphic	  PTLD	  to	  a	  monomorphic	  lymphoma	  resembling	  diffuse	  
large	   B	   cell	   lymphoma	   (DLBCL)	   or	   another	   B	   cell	   lymphoma	   such	   as	   BL	   (Swerdlow	   et	   al.	  
2008).	  	  
	  
EBV-­‐positive	   tumours	   occurring	   in	   the	   setting	   of	   advanced	   HIV	   infection,	   in	   contrast,	   are	  
aggressive	   B	   cell	   lymphomas	   and	   are	   always	   monoclonal.	   These	   tumours	   are	   most	  
commonly	   immunoblastic	   lymphomas,	   a	   morphological	   subtype	   of	   DLBCL,	   and	   include	  




primary	   central	   nervous	   system	   lymphoma	   (Swerdlow	  et	   al.	   2008).	   EBV-­‐positive	  DLBCL	   of	  
the	  elderly	  is	  a	  recently	  defined	  EBV-­‐positive	  clonal	  proliferation	  that	  occurs	  in	  patients	  aged	  
over	  50	  years,	  without	  any	  known	  predisposing	  immunodeficiency,	  with	  increased	  incidence	  
in	   Japan	   compared	   to	   Western	   countries	   (Oyama	   et	   al.	   2003,	   Oyama	   et	   al.	   2007).	   It	   is	  
believed	  to	  develop	  as	  a	  result	  of	  the	  gradual	  decline	  in	  function	  of	  the	  cellular	  branch	  of	  the	  
immune	  system	  occurring	  with	  increasing	  age.	  
	  
1.3.2	  Hodgkin	  Lymphoma	  
Classical	  Hodgkin	  lymphoma	  (HL)	  is	  characterised	  by	  the	  presence	  of	  occasional	  large	  mono-­‐	  
or	  multinucleated	   tumour	   cells,	   called	  Hodgkin	   and	   Reed-­‐Sternberg	   (HRS)	   cells,	  within	   an	  
abundant	   heterogeneous	   mixture	   of	   non-­‐neoplastic	   cells.	   The	   neoplastic	   HRS	   cells	   of	  
Classical	  HL	  are	  EBV-­‐positive	  in	  around	  40%	  of	  cases	  overall,	  with	  variations	  in	  EBV-­‐positivity	  
between	  different	  histological	  subtypes	  and	  depending	  on	  the	  clinical	  setting.	  The	  subtypes	  
include	  lymphocyte-­‐rich,	  nodular	  sclerosis,	  mixed	  cellularity	  and	  lymphocyte-­‐depleted,	  with	  
EBV	  associated	  mainly	  with	   the	   latter	   two	   subtypes.	   In	   tropical	   regions	  up	   to	  100%	  of	  HL	  
cases	  are	  EBV-­‐positive	  (Swerdlow	  et	  al.	  2008).	   	  HL	  also	  occurs	  with	   increased	  frequency	   in	  
HIV-­‐infected	  individuals,	  where	  almost	  all	  cases	  are	  EBV-­‐positive	  (Swerdlow	  et	  al.	  2008).	  In	  
EBV-­‐positive	   cases	   the	  neoplastic	  HRS	   cells	   express	   the	   latency	   II	   set	  of	   viral	   proteins,	   i.e.	  
EBNA1,	   LMP1	   and	   LMP2A.	   Isolated	   HRS	   cells	   have	   been	   shown	   to	   have	   clonal	  
immunoglobulin	  gene	  rearrangements	  with	  a	  high	  degree	  of	  SHM,	  suggesting	  that	  they	  are	  
derived	  from	  GC	  B	  cells	  which	  have	  acquired	  a	  crippling	  mutation	  rendering	  them	  unable	  to	  
exit	   from	   the	   GC	   and	   complete	   differentiation	   to	   memory	   B	   cells	   (Kanzler	   et	   al.	   1996).	  
LMP2A	  is	  able	  to	  rescue	  GC	  B	  cells	  that	  would	  otherwise	  undergo	  apoptosis,	  by	  performing	  
the	   pro-­‐survival	   functions	   of	   the	   BCR	   (Mancao	   et	   al.	   2005,	  Mancao	   and	   Hammerschmidt	  
2007).	  
	  
1.3.3	  Burkitt	  Lymphoma	  
BL	   is	   an	   extremely	   rapidly-­‐growing	   tumour	   of	   B	   cells	   which	   is	   characterised	   by	   a	  
chromosomal	   translocation	   involving	   the	   MYC	   proto-­‐oncogene	   with	   one	   of	   the	   genes	  
encoding	   the	   immunoglobulin	   heavy	   or	   light	   chains.	   This	   leads	   to	   aberrant	   constitutive	  




expression	   of	   MYC,	   resulting	   in	   uncontrolled	   proliferation	   but	   also	   a	   lower	   threshold	   for	  
induction	  of	  apoptosis.	  	  
	  
BL	   can	   be	   divided	   into	   three	   forms:	   endemic,	   which	   is	   always	   EBV-­‐positive	   and	   occurs	   in	  
association	  with	  malaria	   in	   children	   in	   equatorial	   Africa	   and	   Papua	  New	  Guinea;	   sporadic,	  
which	  occurs	  throughout	  the	  world	  in	  adults	  with	  no	  apparent	  underlying	  predisposition	  and	  
is	  EBV-­‐positive	   in	  around	  30%	  of	  cases;	  and	  immunodeficiency	  (usually	  HIV)	  -­‐	  associated,	   in	  
which	  around	  40%	  of	  cases	  are	  EBV-­‐positive.	  HIV-­‐associated	  BL	  usually	  occurs	  with	  a	  higher	  
CD4	   count	   than	   other	   HIV-­‐associated	   malignancies,	   thought	   to	   reflect	   the	   importance	   of	  
chronic	  antigenic	  B	  cell	  stimulation	  rather	  than	  immunosuppression	  in	  its	  pathogenesis	  [(Kirk	  
et	  al.	  2001),	  reviewed	  in	  (Molyneux	  et	  al.	  2012,	  Gloghini	  et	  al.	  2013)].	  	  
	  
It	   is	   thought	   that	   the	   BL	   tumour	   cell	   derives	   from	   a	   post-­‐GC	   cell	   which	   continues	   to	  
proliferate	  due	  to	  deregulation	  of	  MYC.	  Double	  strand	  breaks	  (DSB),	  created	  by	  AID,	  are	  a	  
necessary	  intermediate	  in	  the	  process	  of	  CSR,	  with	  the	  MYC	  promoter	  region	  being	  essential	  
for	  the	  recruitment	  of	  AID	  in	  order	  to	  initiate	  DSB	  [reviewed	  in	  (Fear	  2013)].	  Although	  AID	  
can	  also	  induce	  mutations	  in	  many	  other	  B	  cell	  genes	  (Liu	  et	  al.	  2008),	  these	  are	  repaired	  by	  
different	   mechanisms	   which	   are	   less	   subject	   to	   error,	   for	   example	   the	   p53,	   ataxia	  
telangiectasia	  mutated	   (ATM)	  and	  p14ARF	  pathways	   that	  protect	  against	  DNA	  damage	  and	  
oncogenic	  stress.	  AID	  activity	  is	  therefore	  essential	  for	  the	  DSBs	  that	  allow	  translocation	  of	  
MYC	  to	  IgH	  (Robbiani	  et	  al.	  2008).	  Point	  mutations	  of	  the	  translocated	  MYC	  can	  also	  occur	  in	  
BL,	  resulting	  from	  the	  action	  of	  AID.	  These	  can	  lead	  to	  loss	  of	  the	  ability	  of	  MYC	  to	  induce	  
BIM,	   thus	   the	   mutants	   retain	   ability	   to	   promote	   proliferation,	   but	   lose	   ability	   to	   induce	  
apoptosis	  (Hemann	  et	  al.	  2005).	  
	  
The	   exact	   role	   of	   EBV	   in	   pathogenesis	   is	   still	   unclear,	   but	   it	   has	   been	   proposed	   that	   EBV	  
promotes	  development	  of	  BL	  by	  causing	  other	  changes	  in	  cellular	  genes	  which	  enable	  the	  cell	  
to	   tolerate	   dysregulated	   MYC	   without	   undergoing	   apoptosis	   or	   senescence,	   roughly	  
equivalent	   to	   the	  MYC	  mutants	   described	   above	   (Thorley-­‐Lawson	   and	   Allday	   2008,	   Allday	  
2009).	  EBNA3A	  and	  EBNA3C	  cooperate	  to	  down-­‐regulate	  pro-­‐apoptotic	  BIM,	  thus	  again	  MYC-­‐
induced	   proliferation	   can	   occur	   without	   induction	   of	   apoptosis	   (Anderton	   et	   al.	   2008,	  
Thorley-­‐Lawson	  and	  Allday	  2008,	  Allday	  2009,	  Paschos	  et	  al.	  2009).	  	  




Although	  MYC	   translocations	  are	  the	  hallmark	  of	  BL,	   they	  are	  not	  sufficient	   to	  cause	   it,	  as	  
the	  presence	  of	  the	  translocation	  has	  been	  identified	  in	  normal	  individuals	  (Janz	  et	  al.	  2003)	  
and	  can	  occur,	  at	  lower	  frequency,	  in	  DLBCL	  or	  in	  the	  related	  category	  described	  in	  the	  2008	  
WHO	   Classification	   ‘B	   cell	   lymphoma,	   unclassifiable,	   with	   features	   intermediate	   between	  
diffuse	  large	  B	  cell	  lymphoma	  and	  Burkitt	  lymphoma’	  (Swerdlow	  et	  al.	  2008,	  Lin	  et	  al.	  2012).	  
The	  gene	  expression	  profile	  of	  BL	  has	  been	  identified	  to	  be	  distinct	  from	  that	  of	  DLBCL	  (Dave	  
et	   al.	   2006,	   Hummel	   et	   al.	   2006)	   and	   recently	   several	   groups	   have	   demonstrated	   the	  
involvement	   of	   recurrent	   gene	   mutations	   in	   BL,	   particularly	   ID3	   which	   acts	   as	   a	   tumour	  
suppressor	  (Love	  et	  al.	  2012,	  Richter	  et	  al.	  2012,	  Schmitz	  et	  al.	  2012).	  	  
	  
1.4	  Systems	  for	  studying	  the	  effects	  of	  EBV	  in	  vitro	  and	  in	  vivo	  
Early	   investigations	   of	   the	   effects	   of	   specific	   EBV	   latent	   proteins	   were	   performed	   using	  
naturally	  occurring	  EBV-­‐positive	  BL	   cell	   lines	   in	  which	   the	  virus	   lacks	  expression	  of	  one	  or	  
more	   latent	   proteins,	   such	   as	   P3HR1-­‐BL	  or	  Daudi,	  which	  both	   lack	   full	   EBNA2	  expression.	  
However,	   in	  order	  to	  prove	  that	   the	  phenotypic	  effects	  of	   this	  were	  due	  to	  EBNA2,	   it	  was	  
necessary	   to	   reinsert	   the	   EBNA2	   gene	   into	   these	   cells	   by	   transfection	   in	   order	   to	   show	  
reversal	  of	  the	  phenotype	  [for	  example	  (Cordier	  et	  al.	  1990)].	  Therefore	  it	  was	  necessary	  to	  
develop	  a	  system	  for	   rationally	   investigating	   the	  effects	  of	  other	   latent	  proteins	   for	  which	  
naturally	  occurring	  mutants	  were	  not	  available.	  	  	  
	  
Due	  to	  the	  large	  size	  of	  the	  EBV	  genome,	  it	  was	  not	  possible	  to	  adequately	  study	  the	  effects	  
of	  mutant	  EBV	  using	  conventional	  cloning	  techniques.	  Therefore,	  the	  EBV	  bacterial	  artificial	  
chromosome	  (BAC)	  system	  was	  developed	  by	  Delecluse	  et	  al	  in	  the	  late	  1990s.	  They	  cloned	  
the	  complete	  B95.8	  EBV	  genome,	  along	  with	  a	  green	  fluorescent	  protein	  (GFP)	  reporter	  and	  
a	  hygromycin	  resistance	  cassette,	   into	  an	  F-­‐factor	  based	  replicon	  in	  E.	  coli	  (Delecluse	  et	  al.	  
1998).	  This	  enabled	  creation	  of	  recombinant	  EBV,	  which	  could	  be	   inserted	  by	  homologous	  
recombination.	   A	   shuttle	   vector	   system	   was	   then	   used	   to	   introduce	   the	   BAC	   into	   a	   293	  
eukaryotic	   producer	   cell	   line.	   Recombinant	   BAC-­‐containing	   producer	   cells	   could	   then	   be	  
selected	   for	  by	  addition	  of	  hygromycin,	  which	   is	   toxic	   to	  BAC-­‐negative	   cells.	   The	   cells	   can	  
then	   be	   induced	   to	   lytic	   replication	   so	   that	   recombinant	   infectious	   virions	   are	   produced	  
(Delecluse	  et	  al.	  1998,	  Feederle	  et	  al.	  2010).	  The	  recombinant	  viruses	  obtained	  can	  then	  be	  




used	   to	   infect	   primary	   B	   cells	   or	   EBV-­‐negative	   BL	   cell	   lines	   in	   order	   to	   investigate	   the	  
phenotypic	  effects	  of	  deletion	  of	  individual	  latent	  genes.	  	  
	  
Studies	   investigating	   the	   effects	   of	   EBV	   early	   after	   B	   cell	   infection	   have	   been	   done	   using	  
purified	  B	  cells	  extracted	  from	  peripheral	  blood	  or	  occasionally	  from	  other	  lymphoid	  organs,	  
such	  as	  extracted	  tonsils,	  or	  in	  some	  case	  peripheral	  blood	  mononuclear	  cells	  (PBMCs).	  LCLs	  
are	  established	   in	  vitro	  by	  infecting	  resting	  B	  cells	  or	  PBMCs	  with	  EBV,	  following	  which	  the	  
cells	  develop	  into	  a	  continuously	  proliferating	  immortalised	  cell	  line.	  In	  this	  way,	  the	  effects	  
of	  EBV	   infection	  on	  the	  cellular	  phenotype	  can	  be	   investigated.	  LCLs	  express	  markers	  of	  B	  
cell	  activation,	  such	  as	  CD23	  (Thorley-­‐Lawson	  and	  Mann	  1985).	  	  
	  
BL	  cell	  lines	  have	  generally	  been	  established,	  as	  in	  the	  initial	  case	  by	  Epstein,	  by	  setting	  up	  a	  
suspension	  culture	  using	  free-­‐floating	  cells	  from	  a	  fresh	  human	  biopsy	  sample	  (Epstein	  and	  
Barr	  1964).	   Subsequently,	   cell	   lines	  were	  established	   in	  a	   similar	  manner	   from	  samples	  of	  
EBV-­‐negative	  BL	  (including	  BL2	  and	  BL31	  as	  used	  in	  this	  study)	  and	  it	  was	  shown	  that	  these	  
could	   be	   successfully	   infected	   with	   the	   prototypic	   wild-­‐type	   EBV	   strain	   B95.8	   in	   vitro	   to	  
produce	   a	   continuously	   proliferating	   EBV-­‐positive	   cell	   line	   (Calender	   et	   al.	   1987).	  
Phenotypically,	  BL	  generally	  correspond	  to	  resting	  B	  cells,	  being	  small	  and	  round,	  whereas	  
LCLs	   have	   a	   phenotype	   more	   like	   activated	   B	   blasts,	   with	   increased	   cell	   size,	   more	  
voluminous	  cytoplasm	  and	  ruffling	  of	  the	  cell	  membrane.	  	  
	  
There	   are	   advantages	   and	   disadvantages	   to	   studying	   the	   effects	   of	   EBV	   using	   primary	   B	  
cells/LCLs	   and	   in	   vitro	   infection	   of	   EBV-­‐negative	   BL.	   The	   main	   problem	   with	   LCLs	   is	   that	  
several	  of	  the	  EBV	  latent	  antigens	  are	  needed	  for	  establishment	  and	  continued	  proliferation	  
of	   the	   LCL	   itself,	   and	   therefore	   it	   is	   not	   possible	   to	   directly	   investigate	   the	   effects	   of	  
deletion/mutation	  of	   these	  genes.	  Using	  EBV-­‐negative	  BL	   infected	  with	  recombinant	  virus,	  
on	  the	  other	  hand,	  it	  is	  possible	  to	  investigate	  the	  effects	  of	  deletion	  of	  individual	  EBV	  latent	  
antigens,	   since	   this	   should	   not	   affect	   the	   proliferation	   of	   the	   cell	   lines	   themselves.	   The	  
disadvantage	  of	  BL,	  however,	   is	  that	  they	  are	  already	  highly	  dysregulated,	  having	  acquired	  
multiple	  mutations	  and/or	  epigenetic	  changes	   in	  order	   to	  develop	   into	   tumour	  cells.	  They	  
therefore	  match	  the	  situation	  in	  the	  normal	  EBV	  life	  cycle	  in	  humans	  less	  closely	  than	  LCLs.	  
Furthermore,	   any	   cell	   line	   propagated	   in	   vitro	   is	   subject	   to	   continuous	   selection	   during	  




repeated	   passage;	   for	   instance	   it	   has	   been	   shown	   that	   changes	   in	   expression	   in	  multiple	  
genes	  occur	  between	  early	  and	  late	  passage	  LCLs	  (Lee	  et	  al.	  2010).	  
	  	  	  	  
Since	  EBV	  is	  a	  human-­‐only	  pathogen,	  there	  is	  no	  direct	  animal	  model	  of	  EBV	  with	  which	  to	  
study	   its	   effects	   in	   vivo.	   However,	   immunodeficient	   mice	   have	   had	   components	   of	   the	  
human	  immune	  system	  incorporated,	  in	  order	  to	  create	  a	  humanised	  mouse	  model	  of	  EBV	  
infection	  (Yajima	  et	  al.	  2008).	  A	  similar	  model	  has	  recently	  been	  used	  to	  study	  the	  effects	  of	  
recombinant	  EBV	  in	  vivo,	  for	  example	  in	  (White	  et	  al.	  2012).	  
	  
1.4.1	  Cell	  lines	  established	  from	  EBV-­‐positive	  BL	  
EBV-­‐positive	  BL	  can	  be	  divided	  into	  groups	  I-­‐III	  based	  on	  their	  phenotype,	  according	  to	  their	  
degree	   of	   phenotypic	   change	   towards	   that	   of	   LCLs	   and	   their	   expression	   of	   EBV	   latent	  
proteins,	   with	   group	   I	   expressing	   EBNA1	   only,	   group	   II	   expressing	   EBNA2	   and	   LMP1,	   and	  
group	  III	  expressing	  the	  full	  set	  of	  nine	  latent	  proteins.	  However,	  some	  BL	  have	  been	  shown	  
to	   express	   EBNA2	   without	   LMP1	   (Rowe	   et	   al.	   1987).	   When	   EBV-­‐positive	   BL	   are	   initially	  
cultured	   from	   a	   fresh	   biopsy,	   they	   usually	   express	   CD10,	   but	   are	   negative	   for	   CD23,	   and	  
express	  type	  I	  latency	  EBV	  antigens.	  However,	  in	  continued	  culture	  they	  show	  a	  phenotypic	  
shift	   to	   type	   III	   latency	   expression,	   along	   with	   expression	   of	   B	   cell	   activation	   markers	  
including	  CD23,	   and	   loss	  of	  CD10	  expression,	   accompanied	  by	  a	   change	   in	  morphology	   to	  
more	  closely	  resemble	  LCLs	  as	  well	  as	  cell	  clumping	  (Rowe	  et	  al.	  1987).	  	  
	  
Group	  I	  BL	  use	  the	  Q	  promoter	  (Qp)	  for	  EBNA1	  expression,	  whereas	  in	  latency	  III	  (LCLs)	  the	  
promoters	   Wp	   and	   Cp	   are	   used	   (see	   fig.	   1.2).	   A	   subset	   of	   BL	   has	   more	   recently	   been	  
identified	   in	  which	  the	   latency	   III-­‐associated	  promoter	  Wp,	  rather	  than	   latency-­‐I	  associated	  
Qp,	  is	  active	  but	  in	  which	  a	  deletion	  of	  EBNA2	  results	  in	  lack	  of	  expression	  of	  LMP1,	  LMP2A	  
and	   LMP2B	   and	   lack	   of	   activity	   of	   Cp	   (Kelly	   et	   al.	   2002).	   These	   Wp-­‐restricted	   BL,	   which	  
express	  EBNA1,	  EBNA3A,	  EBNA3B,	  EBNA3C	  and	  a	  truncated	  EBNA-­‐LP,	  but	  no	  EBNA2	  or	  LMPs,	  
are	  relatively	  protected	  from	  apoptosis	  induced	  by	  anti-­‐IgM	  and	  ionomycin	  when	  compared	  
to	   type	   I	   BL	   (which	   express	   only	   EBNA1)	   (Kelly	   et	   al.	   2005).	   The	   naturally	   occurring	   EBV-­‐
positive	   BL	  which	   lack	   full	   EBNA2	   expression,	   including	   Daudi	   and	   P3HR1-­‐BL	   (as	   described	  
above),	  as	  well	  as	  BAC-­‐derived	  recombinant	  EBNA2	  KO-­‐infected	  BL,	  were	  similarly	  resistant	  




to	  apoptosis	  induced	  by	  these	  agents	  (Kelly	  et	  al.	  2005).	  MYC,	  which	  is	  overexpressed	  in	  BL,	  
generally	  makes	  them	  prone	  to	  apoptosis,	  and	  thus	  the	  resistance	  to	  apoptosis	  seen	  in	  Wp-­‐
restricted	   BL	   provides	   a	   survival	   advantage.	   This	   suggests	   that	   the	   addition	   of	   the	   EBNA3	  
proteins	   gives	   the	  Wp-­‐restricted	  BL	   an	   advantage	   in	   terms	  of	   protection	   against	   apoptosis	  
induced	  by	  several	  agents.	  Indeed	  this	  has	  been	  shown,	  as	  for	  instance	  EBNA3A	  and	  EBNA3C	  
cooperate	  to	  down-­‐regulate	  pro-­‐apoptotic	  BIM	  (Anderton	  et	  al.	  2008,	  Paschos	  et	  al.	  2009).	  
The	  EBNA3	  proteins	  are	  normally	  highly	  immunogenic	  (Murray	  et	  al.	  1992);	  however,	  these	  
Wp-­‐restricted	  BL	  were	  not	  recognised	  by	  EBV-­‐specific	  CD8-­‐positive	  T	  cells.	  LMP1	  expression	  
enhances	  antigen-­‐processing	  activity	  and	  expression	  of	  human	  leucocyte	  antigen	  (HLA)	  class	  I	  
molecules	  (Rowe	  et	  al.	  1995,	  Brooks	  et	  al.	  2009),	  and	  thus	  it	  was	  proposed	  that	  the	  lack	  of	  
LMP1	   expression	   in	   Wp-­‐restricted	   BL	   allows	   them	   to	   avoid	   T	   cell	   recognition	   in	   spite	   of	  
expressing	  EBNA3	  proteins	  (Kelly	  et	  al.	  2002).	  	  	  	  
	  
1.5	  Mechanisms	  of	  lymphoma	  development	  
Lymphoma	   is	   a	   form	  of	   cancer,	   i.e.	   a	   clonal	   proliferation	  of	   abnormal	   lymphoid	   cells.	   Cell	  
division	   and	   differentiation	   are	   normally	   tightly	   controlled,	   but	   loss	   of	   control	   over	   such	  
processes	   can	   lead	   to	   cancer	   development.	   Loss	   of	   control	   can	   generally	   be	   acquired	   by	  
either	  abnormal	  over-­‐activation	  of	   regulatory	  genes	  which	  control	  proliferation,	  known	  as	  
oncogenes,	  or	  by	  loss	  of	  expression	  of	  genes	  which	  normally	  control	  processes	  such	  as	  cell	  
division,	  differentiation	  and	  apoptosis.	  Such	  genes	  are	  known	  as	  tumour	  suppressor	  genes	  
(TSGs).	  	  
	  
Haematopoietic	  tumours	  including	  lymphoma	  typically	  develop	  as	  a	  result	  of	  a	  series	  of	  such	  
changes,	  and	  arise	  originally	  within	  a	  single	  cell.	  As	  the	  cell	  proliferates	  abnormally,	  further	  
changes	  can	  be	  acquired	  leading	  to	  a	  more	  abnormal	  phenotype.	  The	  dysregulation	  of	  gene	  
expression	   may	   occur	   in	   a	   number	   of	   ways,	   including	   by	   genetic	   mutation	   (i.e.	   altered	  
genetic	   sequence),	   chromosomal	   abnormalities	   such	   as	   translocations,	   deletions	   or	  
inversions,	   or	   by	   changes	   which	   alter	   the	   expression	   of	   genes	   without	   altering	   the	  
underlying	   DNA	   sequence,	   known	   as	   epigenetic	   changes;	   these	   will	   now	   be	   discussed	  
further.	   TSGs	   include	   genes	   which	   regulate	   progression	   through	   the	   cell	   cycle,	   or	   which	  
control	  apoptosis;	  these	  processes	  will	  be	  discussed	  further	  later	  in	  this	  section.	  




1.5.1	  Epigenetic	  modifications	  
Epigenetic	  modifications	  affect	  the	  expression	  of	  genes	  without	  altering	  the	  underlying	  DNA	  
sequence	  (Berger	  et	  al.	  2009).	  They	  include	  covalent	  histone	  modifications	  and	  methylation	  
of	   CpG	   dinucleotides	   of	   DNA.	   These	   changes	   can	   result	   in	   transcriptional	   silencing	   or	  
activation	  of	  genes,	  can	  be	  heritable	  and	  are	   increasingly	   recognised	  as	  being	   important	   in	  
the	  development	  of	  cancer	  [reviewed	  in	  (Esteller	  2007)].	  
	  
1.5.1.1	  Histone	  modifications	  
In	  eukaryotic	   cells,	  DNA	  within	  chromosomes	   is	  packaged	  by	   interactions	  with	  histone	  and	  
non-­‐histone	   proteins	   to	   form	   chromatin.	   The	   basic	   unit	   of	   chromatin	   packaging	   is	   the	  
nucleosome,	  consisting	  of	  an	  octamer	  of	  histone	  proteins	   (two	  each	  of	  histones	  H2A,	  H2B,	  
H3	  and	  H4)	  forming	  a	  protein	  core	  around	  which	  DNA	  is	  wound	  (Luger	  et	  al.	  1997).	  Histones	  
can	  undergo	  reversible	  covalent	  modifications	  of	  their	  N-­‐terminal	  tails,	  resulting	  in	  changes	  
in	  the	  transcriptional	  activity	  of	  particular	  genes.	  Such	  modifications	  include,	  among	  others,	  
methylation	  and	  acetylation	  of	  lysines.	  Generally,	  acetylation	  of	  histones,	  for	  example	  lysine	  
9	  of	  histone	  H3	  (H3K9Ac),	  is	  associated	  with	  transcriptional	  activation,	  as	  is	  trimethylation	  of	  
lysine	   4	   of	   histone	   H3	   (H3K4Me3),	   whereas	   trimethylation	   of	   lysine	   27	   of	   histone	   H3	  
(H3K27Me3)	  is	  associated	  with	  transcriptional	  repression	  (Kouzarides	  2007).	  	  
	  
The	   polycomb	   group	   (PcG)	   proteins	   are	   a	   group	   of	   proteins	   that	   were	   first	   described	   in	  
Drosophila	   and	   are	   vitally	   important	   for	   embryonic	   development	   and	   cell	   differentiation.	  
They	  have	  also	  been	  shown	  to	  be	  necessary	  for	  maintenance	  of	  identities	  of	  stem,	  progenitor	  
and	   differentiated	   cells	   (Pietersen	   and	   van	   Lohuizen	   2008).	   They	   function	   within	   groups	  
called	   polycomb	   repressive	   complexes	   (PRC)	   and	   are	   involved	   in	   chromatin	   modifications	  
leading	  to	  gene	  repression.	  PRC2	  consists	  of	  the	  histone	  methyltransferase	  enzyme	  enhancer	  
of	   zeste	   homologue	   2	   (EZH2),	   embryonic	   ectoderm	   development	   (EED)	   and	   suppressor	   of	  
zeste	   12	   homologue	   (SUZ12)	   (Kirmizis	   et	   al.	   2004)	   (see	   fig.	   1.7).	   EZH2	   performs	   H3K27	  
trimethylation	   (Cao	  et	  al.	  2002).	  Until	   recently	   this	  was	   thought	   to	   result	   in	   recruitment	  of	  
PRC1;	  however,	   there	   is	   increasing	  evidence	   that	  H3K27Me3	  may	  not	  always	   recruit	  PRC1,	  
since	   some	   PRC1	   complexes	   lack	   the	   site	   necessary	   for	   H3K27Me3	   binding;	   instead,	   PRC1	  
may	   be	   recruited	   by	   other	  means,	   especially	   in	  mammalian	   cells	   (reviewed	   in	   (Simon	   and	  




Kingston	  2013).	  PRC1	  catalyses	  the	  ubiquitylation	  of	  histone	  H2A	  on	  K119	  (Cao	  et	  al.	  2005)	  
which	   contributes	   to	  maintenance	  of	   the	   created	   repressive	   chromatin	   state,	   although	   the	  
mechanism	  of	  this	  is	  not	  currently	  understood	  (Simon	  and	  Kingston	  2013).	  EZH2	  also	  recruits	  
DNA	   methyltransferases	   hence	   marking	   genes	   for	   DNA	   methylation	   (Vire	   et	   al.	   2006,	  










Figure	  1.7:	  Schematic	  diagram	  of	  polycomb	  repressive	  complex	  2	  (PRC2)	  
The	  core	  components	  of	  PRC2	  are	  enhancer	  of	  zeste	  homologue	  2	  (EZH2),	  embryonic	  ectoderm	  development	  
(EED),	  suppressor	  of	  zeste	  12	  homologue	  (SUZ12)	  and	  the	  histone	  binding	  proteins,	  Retinoblastoma	  associated	  
proteins	  46	  and	  48	   (RbAp46/48).	  PRC2	  has	  histone	  methyltransferase	  activity	  specific	   for	   lysine	  27	  of	  histone	  
H3,	  resulting	  in	  transcriptional	  repression	  by	  trimethylation	  (H3K27Me3)	  (Kuzmichev	  et	  al.	  2002,	  Kirmizis	  et	  al.	  
2004).	  	  	  
	  
It	  has	  been	  shown	  that	  some	  genes	  have	  both	  active	  (H3K4Me3)	  and	  repressive	  (H3K27Me3)	  
chromatin	   marks	   simultaneously;	   these	   are	   known	   as	   bivalent	   domains	   (Bernstein	   et	   al.	  
2006).	  It	  is	  thought	  that	  in	  this	  way	  the	  genes	  are	  ‘poised’	  for	  either	  activation	  or	  inactivation	  
in	  preparation	  for	  differential	  expression	  during	  cell	  differentiation,	  suggesting	  that	  bivalency	  
allows	   postponement	   of	   the	   decision	   as	   to	   whether	   the	   gene	   should	   be	   activated	   or	  
repressed	   (Pietersen	   and	   van	   Lohuizen	   2008).	   These	   genes	   tend	   to	   be	   important	   in	  
developmental	  control	  and	  are	  often	  epigenetically	  silenced	  by	  promoter	  DNA	  methylation	  in	  
cancer	  (Ohm	  et	  al.	  2007).	  
	  




1.5.1.2	  DNA	  methylation	  
A	   further	   type	   of	   epigenetic	   modification	   is	   methylation	   of	   cytosine	   bases	   in	   CpG	  
dinucleotides	  within	  genomic	  DNA.	  Within	  the	  genome	  there	  are	   fewer	  CpG	  dinucleotides	  
than	  would	  be	  expected,	   assuming	  an	  equal	  distribution	  of	   all	   nucleotides.	   Those	  present	  
are	  also	  not	  evenly	  distributed	  along	  the	  genome,	  being	  concentrated	  in	  particular	  regions	  
known	   as	   ‘CpG	   islands’,	   which	   are	   often	   around	   1kbp	   in	   length	   and	   found	   within	   the	  
promoter	  regions	  of	  around	  60-­‐70%	  of	  human	  genes.	  Although	  CpGs	  outside	  of	  CpG	  islands	  
are	  generally	  methylated,	  the	  DNA	  within	  CpG	  islands	  is	  normally	  unmethylated,	  and	  genes	  
where	  this	  occurs	  are	  transcriptionally	  active.	  However,	  CpG	  methylation	  within	  CpG	  islands	  
leads	   to	   transcriptional	   silencing	   of	   the	   relevant	   gene.	   When	   CpGs	   are	   methylated,	   this	  
modification	   is	   heritable	   and	   hence	   epigenetic.	   DNA	   methylation	   is	   important	   in	  
malignancies,	   where	   hypermethylation	  within	   gene	   promoters	   often	   leads	   to	   silencing	   of	  
tumour	  suppressor	  genes	  (Esteller	  2007).	  	  
	  
1.5.2	  The	  cell	  cycle	  
The	  cell	   cycle	   is	   a	   regulated	   series	  of	  events	  enabling	   the	  cell	   to	  divide.	   It	   consists	  of	   two	  
active	   phases,	   the	   S	   (or	   DNA	   synthesis)	   phase,	   in	   which	   DNA	   replication	   occurs,	   and	   the	  
mitosis	  (M)	  phase,	  which	  is	  followed	  by	  cytokinesis.	  In	  between	  these	  phases	  are	  two	  resting	  
(Gap)	  phases,	  G1	  and	  G2	  (fig.	  1.8).	  Cells	  can	  also	  exit	  the	  cell	  cycle	  completely	  from	  G1	  for	  a	  
longer	   time,	   entering	   a	   resting	   phase,	   G0.	   Senescence	   is	   a	   permanent	   exit	   from	   the	   cell	  
cycle.	  	  
	  
Progression	  through	  the	  cell	  cycle	  is	  tightly	  controlled	  by	  a	  set	  of	  cyclin-­‐dependent	  kinases	  
(CDK),	  whose	  kinase	  activity	   is	   in	  turn	  dependent	  on	  binding	  by	  cyclins,	  which	  are	  positive	  
regulators	  and	  determine	  the	  specificity	  of	  the	  CDK.	  Cyclins	  are	  classified	  into	  four	  groups,	  
the	  A,	  B,	  D	  and	  E	  cyclins.	  Specific	  cyclins	  are	  expressed	  at	  specific	  times	  during	  the	  cell	  cycle	  
and	   thus	   regulate	   the	   activity	   of	   the	   CDKs,	   with	   the	   levels	   of	   cyclin	   expression	   being	  
controlled	  by	  synthesis	  and	  degradation.	  Expression	  of	  specific	  CDKs	  also	  occurs	  at	  specific	  
times	  within	  the	  cycle,	  with	  CDKs	  2,	  4	  and	  6	  acting	  in	  interphase	  and	  CDK1	  acting	  in	  mitosis.	  
D	   cyclins	   are	   expressed	   early	   in	   G1	   and	   bind	   to	   CDK4	   and	   CDK6,	   allowing	   progression	  




through	  G1;	  cyclin	  E	  expression	  then	  activates	  CDK2	  to	  allow	  progression	   into	  the	  S	  phase	  
(fig.	  1.8).	  	  	  
	  
	  
Figure	  1.8:	  Cell	  cycle	  regulation	  
The	  cell	   cycle	   consists	  of	   the	  S	  phase,	   in	  which	  DNA	  synthesis	  occurs,	   the	  M	  phase	   for	  mitosis	   and	   two	  gap	  
phases,	  G1	   and	  G2.	   Progression	  between	   stages	   is	   controlled	  by	   cyclin-­‐dependent	   kinases	   (CDKs)	  which	   are	  
expressed	  at	  distinct	  stages.	  These	  are	  controlled	  by	  binding	  to	  specific	  cyclins.	  The	  CDKs	  are	  regulated	  by	  two	  
families	   of	   CDK	   inhibitors,	   the	   INK	   and	   the	   CIP/KIP	   families.	   The	   restriction	   point	   R	   controls	   entry	   to	   the	   S	  
phase,	   and	   the	   cell	   is	   committed	   to	   DNA	   replication	   once	   R	   has	   been	   passed.	   Adapted	   from	   (Dehay	   and	  
Kennedy	  2007).	  
	  
There	   are	   also	  CDK	   inhibitors	   (CDKIs)	  which	  modulate	   the	   activity	   of	   CDKs;	   these	   fall	   into	  
two	   groups:	   the	   CIP/KIP	   family	   (p21CIP1/WAF1,	   p27KIP1	   and	   p57KIP2)	   and	   the	   INK4	   family	  
(p15INK4B,	   p16INK4A,	   p18INK4C	   and	   p19INK4D).	   p15INK4B	   is	   encoded	   by	  CDKN2B,	   which	   is	   found	  
close	   to	   the	   genes	   for	   two	   other	   tumour	   suppressors,	   p14ARF	   and	   p16INK4a	   at	   the	  
INK4a/ARF/INK4b	   locus,	  which	   is	   frequently	   deleted	   in	   cancer.	   Both	   p15INK4B	   and	   p16INK4A	  
bind	  to	  and	  inactivate	  CDK4/6,	  which	  promote	  proliferation;	  thus	  expression	  of	  p15INK4B	  or	  
p16INK4A	  result	  in	  cell	  cycle	  arrest.	  p14ARF	  inhibits	  MDM2,	  leading	  to	  the	  stabilisation	  of	  p53	  
(Kim	  and	  Sharpless	  2006).	  	  	  
	  




The	  INK4	  CDKIs	  bind	  specifically	  to	  CDK4/6,	  preventing	  their	  association	  with	  cyclin	  D.	  The	  
CIP/KIP	   CDKIs	   interact	  with	   cyclin	  D-­‐CDK4/6	   and	  with	   cyclin	   E-­‐CDK2	   (fig.	   1.8).	   Progression	  
through	  the	  cell	  cycle	   is	   regulated	  at	  certain	  checkpoints:	   the	  G1	  checkpoint	  or	   restriction	  
point	   R	   (see	   fig.	   1.8),	   which	   controls	   entry	   to	   the	   S	   phase,	   a	   G2/M	   checkpoint,	   and	   a	  
checkpoint	  at	   the	  metaphase-­‐anaphase	   transition.	  These	  checkpoints	  serve	   to	  ensure	   that	  
conditions,	  both	  intracellular	  and	  in	  the	  environment,	  are	  suitable	  for	  the	  cell	  to	  replicate	  its	  
DNA	   and	   divide.	   They	   are	   controlled	   mainly	   by	   the	   CDKIs.	   The	   G1	   restriction	   point	   R	   is	  
particularly	  important	  as,	  once	  this	  is	  passed,	  the	  cell	  is	  committed	  to	  DNA	  replication.	  	  	  
	  
Retinoblastoma	   protein	   (Rb)	   is	   another	   tumour	   suppressor	   gene	  which	   controls	   cell	   cycle	  
progression.	  During	  the	  cell	  cycle	  it	  is	  progressively	  phosphorylated	  and	  dephosphorylated.	  
It	   is	  hypophosphorylated	   in	  non-­‐cycling	  cells,	  and	   in	   this	   state	   it	  binds	  proteins	  of	   the	  E2F	  
family,	  inhibiting	  transcription	  of	  E2F	  target	  genes.	  When	  Rb	  is	  phosphorylated,	  the	  binding	  
to	  E2F	  is	  disrupted,	  allowing	  E2F	  to	  activate	  transcription	  of	  its	  target	  genes,	  which	  generally	  
promote	   cell	   cycle	   progression,	   DNA	   replication	   and	   mitosis	   [reviewed	   in	   (Polager	   and	  
Ginsberg	  2008)].	  	  	  
	  
If	  a	  cell	  detects	  unfavourable	  conditions,	  including	  DNA	  damage	  or	  mutation,	  then	  arresting	  
in	  G1,	   for	   instance,	  allows	  time	  for	  the	  problem	  to	  be	  repaired,	   if	  possible.	  Disturbance	  of	  
these	  checkpoints	  are	  frequently	  found	  in	  cancer,	  often	  due	  to	  mutations	  of	  CDKIs.	  This	  can	  
result	  in	  replication	  of	  damaged	  or	  mutated	  DNA	  and/or	  uncontrolled	  proliferation.	  If	  these	  
checkpoints	  are	  disrupted,	  and	  thus	  replication	  of	  mutated	  or	  damaged	  DNA	  occurs,	  this	  can	  
lead	   to	   secondary	  mutations	   or	   genomic	   instability,	   allowing	   progression	   towards	   tumour	  
development.	  When	  DNA	  damage	  or	  mutation	   is	  detected,	  or	   there	  are	  other	  particularly	  
unfavourable	  conditions	  that	  cannot	  be	  rectified,	  the	  cell	  can	  also	  undergo	  apoptosis,	  which	  
will	  now	  be	  described.	  	  
	  
1.5.3	  Apoptosis	  
Apoptosis	   is	   a	   form	  of	   programmed	   cell	   death,	   leading	   to	   destruction	   of	   the	   cell	  without	  
causing	  any	  inflammatory	  response.	  It	  results	  in	  characteristic	  phenotypic	  changes,	  including	  
nuclear	   and	   cytoplasmic	   condensation	   and	   nuclear	   fragmentation	   (Kerr	   et	   al.	   1972).	   It	   is	  




used	   extensively	   to	   destroy	   cells	   which	   are	   no	   longer	   required,	   for	   example	   during	  
embryonic	   development	   and	   in	   removal	   of	   auto-­‐reactive	   B	   or	   T	   cells	   during	   their	  
development	  in	  the	  immune	  system.	  	  
	  
There	  are	   two	  distinct	   apoptotic	   signalling	  pathways,	   the	  extrinsic	   and	   intrinsic	  pathways,	  
which	   nevertheless	   show	   some	   degree	   of	   overlap	   (see	   fig.	   1.9).	   Both	   pathways	   involve	  
activation	  of	  a	  series	  of	  caspase	  enzymes,	  found	  as	  inactive	  procaspases	  which	  are	  activated	  
by	  proteolytic	  cleavage.	  The	  initial	  members	  activated	  are	  the	  ‘initiator’	  caspases,	  which	  in	  
turn	   activate	   downstream	   caspases	   including	   ‘effector’	   or	   ‘executioner’	   caspases,	   which	  
carry	   out	   the	   specific	   functions	   leading	   to	   cellular	   breakdown.	   The	   extrinsic	   and	   intrinsic	  
pathways	  converge	  at	  the	  level	  of	  effector	  caspases,	  but	  require	  different	  initiator	  caspases:	  
the	  extrinsic	  system	  needs	  caspase	  8	  whereas	  the	  intrinsic	  pathway	  requires	  caspase	  9	  for	  
initiation	  [reviewed	  in	  (Strasser	  2005)].	  The	  effector	  caspases	   include	  caspase	  3,	  caspase	  6	  
and	  caspase	  7.	  
	  
The	  extrinsic	  apoptotic	  pathway	  is	  triggered	  by	  the	  binding	  of	  extracellular	  ligands	  belonging	  
to	  the	  tumour	  necrosis	  factor	  (TNF)	  family	  to	  specific	  cell-­‐surface	  death	  receptors,	  which	  are	  
in	  turn	  members	  of	  the	  TNF	  receptor	  family.	  The	  ligands	  include	  TNFα,	  FAS-­‐ligand	  and	  TNF-­‐
related	  apoptosis	  inducing	  ligand	  (TRAIL),	  among	  others,	  and	  the	  receptors	  include	  FAS.	  The	  
cytoplasmic	   portion	   of	   the	   transmembrane	   death	   receptor,	   known	   as	   the	   death	   domain,	  
recruits	  intracellular	  proteins	  forming	  the	  death-­‐inducing	  signalling	  complex	  (DISC),	  resulting	  
in	  pro-­‐apoptotic	  conditions	  within	  the	  cell.	  Caspase	  8,	  the	  initiator	  caspase	  of	  the	  extrinsic	  
pathway,	   is	   recruited	   into	  DISC.	  Once	   activated	   it	   then	   cleaves	   the	   executioner	   caspase	  3	  
(Danial	  and	  Korsmeyer	  2004).	  
	  
The	  alternative,	  intrinsic,	  apoptotic	  pathway	  is	  initiated	  from	  within	  the	  cell	   in	  response	  to	  
DNA	  damage,	  hypoxia	  or	  a	   lack	  of	  extracellular	  survival	   signals.	  The	   initiation	  of	  apoptosis	  
via	   this	   pathway	   is	   largely	   regulated	   by	   the	   balance	   between	   pro-­‐apoptotic	   and	   anti-­‐
apoptotic	  members	   of	   the	  BCL2	  protein	   family	   [reviewed	   in	   (Danial	   and	   Korsmeyer	   2004,	  
Volkmann	  et	  al.	  2014)].	   	  The	  anti-­‐apoptotic	  members	  contain	   four	  highly	  conserved	  BCL2-­‐
homology	  (BH)	  domains	  1-­‐4	  and	  include	  BCL2	  itself,	  BCL-­‐XL,	  BFL1	  (also	  known	  as	  BCL2A1,	  or	  
simply	  A1)	  and	  MCL-­‐1.	  The	  pro-­‐apoptotic	  members	  are	  divided	  into	  two	  subgroups	  based	  on	  




their	  structure:	  the	  first	  group	  share	  homology	  in	  the	  BH1-­‐3	  domains	  and	  include	  BAX	  and	  
BAK,	  and	  the	  second	  group,	  the	  ‘BH3	  only’	  proteins	  (so	  called	  as	  they	  have	  homology	  with	  
BCL2	  only	  in	  the	  BH3	  domain),	  includes	  BAD,	  BIK,	  BIM,	  BID,	  PUMA	  and	  NOXA.	  	  
	  
BAX	  and/or	  BAK	  are	  required	  for	  intrinsic	  apoptosis	  induced	  by	  the	  BH3-­‐only	  proteins,	  thus	  
functioning	  downstream	  of	   the	  BH3-­‐only	  proteins;	  although	   the	  process	   is	  not	  completely	  
understood,	   BAX	   and	   BAK	   are	   thought	   to	   be	   redundant.	   BAK	   is	   localised	   to	   the	   outer	  
mitochondrial	  membrane,	  whereas	  BAX	   is	   found	  within	   the	  cytosol.	  When	  activated,	   they	  
create	   pores	   in	   the	   outer	   mitochondrial	   membrane,	   allowing	   release	   into	   the	   cytosol	   of	  
proteins	  which	  execute	  apoptosis,	  leading	  to	  activation	  of	  caspase	  9;	  once	  the	  mitochondrial	  
membrane	   is	   permeable	   the	   process	   leading	   to	   cell	   death	   is	   irreversible	   (Volkmann	   et	   al.	  
2014).	   The	   activity	   of	   BAX/BAK	   is	   tightly	   regulated	   by	   the	   balance	   between	   the	   anti-­‐
apoptotic	  BH3-­‐only	  proteins.	  BIM,	  BID	  and	  PUMA	  are	  direct	  activators	  of	  BAX/BAK,	  thought	  
to	   bind	   directly	   to	   BAX/BAK.	   BID,	   BIM	   and	   PUMA	   can	   also	   form	   heterodimers	   with	   anti-­‐
apoptotic	   BCL2	   family	  members,	   inhibiting	   their	   activity.	   The	   anti-­‐apoptotic	   BH3	   proteins	  
such	  as	  BCL2	  and	  BCL-­‐XL	  can	  antagonise	  BAX/BAK	  and	  can	  also	  sequester	  the	  pro-­‐apoptotic	  
members	  (such	  as	  BIM	  and	  PUMA),	  thus	  preventing	  their	  action	  (Volkmann	  et	  al.	  2014).	  	  
	  
The	   intrinsic	  pathway	   involves	  release	  from	  mitochondria	  of	  cytochrome	  c,	  which	  binds	  to	  
the	   cytosolic	   protein	   apoptotic	   protease	   activating	   factor	   1	   (APAF1),	   leading	   to	   a	  
conformational	   change	   and	   activation	   of	   APAF1,	   which	   then	   interacts	   with	   caspase	   9	  
forming	  a	  protein	  complex	  termed	  the	  apoptosome,	  resulting	   in	  activation	  of	  downstream	  
effector	  caspases	  [(Li	  et	  al.	  1997),	  reviewed	  in	  (Wurstle	  et	  al.	  2012)].	  
	  
One	  of	  the	  BH3-­‐only	  proteins,	  BID,	  is	  activated	  by	  caspase	  8,	  being	  cleaved	  into	  a	  pro-­‐death	  
C-­‐terminal	  fragment,	  tBID,	  which,	  along	  with	  BIM	  and	  PUMA,	  can	  in	  turn	  activate	  BAX/BAK	  
or	  inhibit	  the	  anti-­‐apoptotic	  proteins	  such	  as	  BCL-­‐XL.	  BID	  therefore	  provides	  a	  link	  between	  
the	  extrinsic	  and	  intrinsic	  pathways	  (Volkmann	  et	  al.	  2014).	  Other	  proteins	  that	  can	  inhibit	  
activation	  of	  executioner	  caspases	  are	  the	  Inhibitor	  of	  apoptosis	  (IAP)	  family,	  which	  inhibit	  
caspases	  3,	  7	  and	  9	  (Deveraux	  et	  al.	  1997,	  Deveraux	  et	  al.	  1998).	  
	  
	  





Figure	  1.9:	  Schematic	  diagram	  of	  the	  intrinsic	  and	  extrinsic	  pathways	  of	  apoptosis	  
The	   extrinsic	   pathway,	   shown	   on	   the	   right,	   is	   activated	   by	   extracellular	   death	   ligands,	   which	   bind	   to	   the	  
transmembrane	   death	   receptor,	   leading	   to	   activation	   of	   intracellular	   caspase	   8	   which	   in	   turn	   can	   activate	  
effector	  caspases	  leading	  to	  the	  processes	  of	  apoptosis.	  Apoptosis	  can	  also	  be	  initiated	  from	  inside	  the	  cell,	  the	  
intrinsic	   pathway	   (shown	   on	   the	   left),	   in	   response	   to	   hypoxia,	   DNA	   damage	   or	   lack	   of	   survival	   signals.	  
Activation	  of	  this	  pathway	  is	  regulated	  by	  the	  BCL2	  family	  of	  proteins,	   including	  both	  pro-­‐apoptotic	  and	  anti-­‐
apoptotic	  members.	   The	   pro-­‐apoptotic	  members	   such	   as	   BIM	   and	   PUMA	   cause	   activation	   of	   BAX	   and	   BAK	  
which	  interact	  with	  the	  mitochondrion,	  causing	  release	  of	  cytochrome	  c.	  This	  in	  turn	  interacts	  with	  APAF1	  and	  
activated	  caspase	  9	  to	  form	  the	  apoptosome	  complex,	  which	  also	  activates	  effector	  caspases.	  The	  extrinsic	  and	  
intrinsic	  pathways	  share	  cross-­‐talk	  via	  pro-­‐apoptotic	  BID.	  	  See	  main	  text	  for	  further	  details	  of	  these	  pathways.	  	  	  
	  
1.5.3.1	  Apoptosis	  mechanisms	  within	  the	  germinal	  centre	  
Within	   the	   GC,	   when	   a	   BCR	   binds	   to	   an	   antigen	   with	   high	   affinity,	   T	   cell	   help	   leads	   to	  
signalling	  through	  CD40/CD40	  ligand	  (CD40L).	  This	  leads	  to	  induction	  of	  anti-­‐apoptotic	  BCL-­‐
XL	   and	   hence	   promotes	   survival	   of	   cells	   expressing	   a	   high	   affinity	   BCR;	   without	   the	  





























1996).	  CD40	  signalling	  via	  NFκB	  induces	  c-­‐FLIP	  expression,	  thus	  rendering	  cells	  which	  receive	  
CD40	  signals	  resistant	  to	  FAS-­‐induced	  apoptosis	  (van	  Eijk	  et	  al.	  2001).	  
	  
The	   extrinsic	   pathway	   of	   apoptosis	   is	   also	   thought	   to	   be	   important	   in	   apoptosis	   of	   low-­‐
affinity	  B	  cells	   in	  the	  GC,	  which	  do	  not	  receive	  the	  survival	  signal	  CD40	  ligand	  from	  T	  cells.	  
FAS	  is	  required	  for	  apoptosis	  in	  GC	  B	  cells	  lacking	  T	  cell	  help	  (Takahashi	  et	  al.	  2001).	  In	  these	  
cells,	   a	   preformed	   FAS	   DISC	   is	   present,	   which	   does	   not	   require	   ligand	   binding	   for	   its	  
activation.	   The	   cellular	   homologue	   of	   FLICE-­‐inhibitory	   protein,	   c-­‐FLIP,	   normally	   interferes	  
with	   DISC	   formation,	   but	   is	   lost	   from	   GC	   B	   cells	   lacking	   the	   CD40L	   survival	   signal,	   thus	  
allowing	  DISC	  to	  become	  active,	  resulting	  in	  apoptosis	  via	  activation	  of	  caspase	  8	  (Hennino	  
et	  al.	  2001).	  	  
	  
In	  GC	  B	  cells,	  signalling	  via	  the	  BCR,	  in	  the	  absence	  of	  the	  CD40/CD40L	  interaction	  as	  a	  result	  
of	  T	  cell	  help,	  also	  contributes	  to	  the	  default	  apoptotic	  state	  via	   induction	  of	  BIK	  and	  BIM.	  
BIM	   [BCL2-­‐interacting	   mediator	   of	   cell	   death,	   encoded	   by	   the	   gene	   BCL2-­‐like-­‐protein	   11	  
(BCL2L11)]	   binds	  with	  high	   affinity	   to	   all	   the	  pro-­‐survival	   BCL2	   family	  members,	   inhibiting	  
their	   function,	   and	   is	   thus	  an	  extremely	  potent	   inducer	  of	   apoptosis.	  BIM	   is	  expressed	  by	  
most	  lymphoid	  cells	  and	  is	  essential	  for	  deletion	  of	  autoreactive	  T	  and	  B	  cells	  [reviewed	  in	  
(Strasser	  2005)].	  BIM	  is	  an	  important	  tumour	  suppressor	  in	  B	  cells,	  with	  even	  loss	  of	  a	  single	  
allele	  accelerating	  lymphomagenesis	  in	  an	  Eμ	  Myc	  mouse	  model	  (Egle	  et	  al.	  2004).	  	  
	  
In	  GC	  B	  cells	  (centroblasts),	  transforming	  growth	  factor	  β	  (TGFβ)	  also	  induces	  apoptosis	  by	  
autocrine	  signalling,	  leading	  to	  SMAD3/4-­‐dependent	  induction	  of	  BIK	  and	  PUMA	  along	  with	  
down-­‐regulation	  of	  BCL-­‐XL,	  thus	  contributing	  to	  the	  default	  apoptotic	  state,	  along	  with	  FAS	  
(Spender	   et	   al.	   2009,	   Spender	   et	   al.	   2013).	   This	   TGFβ-­‐induced	   apoptotic	   pathway	   occurs	  
independently	  of	  both	  FAS	  and	  TRAIL	  and	  thus	  uses	  the	  intrinsic	  pathway	  (Inman	  and	  Allday	  
2000a).	   Phosphorylation	   of	   SMAD2,	   showing	   that	   TGFβ	   signalling	   is	   active,	   has	   been	  
demonstrated	   by	   immunohistochemistry	   in	   both	   the	   LZ	   and	   DZ	   of	   GCs	   in	   normal	   human	  
tonsil	  tissue	  (Spender	  et	  al.	  2009).	  BAK/BAK	  are	  also	  needed	  for	  TGFβ-­‐induced	  apoptosis	  in	  
GCs,	  as	  BL	  deficient	  in	  these	  resist	  TGFβ-­‐induced	  apoptosis,	  for	  example	  the	  EBV-­‐negative	  BL	  
cell	   line	  CA46	  does	  not	   undergo	   apoptosis	  with	   TGFβ,	   and	   lacks	  BAX	  expression	   (Spender	  
and	  Inman	  2009a).	  




1.6	  Transforming	  growth	  factor	  β	  and	  bone	  morphogenetic	  protein	  signalling	  
1.6.1	  Overview	  of	  TGFβ	  and	  bone	  morphogenetic	  protein	  (BMP)	  signalling	  
TGFβ	  was	  first	  discovered	  in	  the	  early	  1980s,	  when	  it	  was	  initially	  characterised	  by	  its	  ability	  
to	   induce	   a	   transformed	   phenotype	   in	   fibroblasts	   (Anzano	   et	   al.	   1983),	   hence	   its	   name.	  	  
However,	   it	   has	   subsequently	   been	   found	   to	  be	   important	   in	  many	  processes,	   controlling	  
cell	  proliferation,	  differentiation,	  apoptosis,	  developmental	  fate	  and	  immune	  regulation.	  In	  
addition,	   TGFβ	   modulates	   human	   haematopoiesis	   by	   selectively	   regulating	   growth	   of	  
immature	  haematopoietic	  cells,	  but	  not	  more	  differentiated	  cells	  (Sing	  et	  al.	  1988)	  and	  has	  
recently	  been	   shown	   to	   restore	  quiescence	  of	  HSCs	   following	   recovery	  of	  haematopoiesis	  
after	  myelosuppressive	  chemotherapy	  (Brenet	  et	  al.	  2013).	  
	  
Subsequently,	   the	   discovery	   of	   many	   related	   ligands	   and	   their	   receptors	   has	   led	   to	   the	  
definition	   of	   a	   TGFβ	   signalling	   superfamily	   which	   also	   includes	   the	   bone	   morphogenetic	  
proteins	   (BMPs)	   as	   well	   as	   other	   related	   ligands.	   This	   superfamily	   is	   characterised	   by	   a	  
signalling	   pathway	   consisting	   of	   extracellular	   ligand,	   type	   I	   and	   type	   II	   transmembrane	  
receptors	  which	  possess	  serine/threonine	  kinases,	  and	  downstream	  signalling	  by	  a	  group	  of	  
Smad	  proteins.	  	  
	  
Generally	  in	  the	  TGFβ	  superfamily,	  a	  ligand	  homodimer	  binds	  to	  and	  brings	  together	  a	  dimer	  
of	   type	   I	  and	  a	  dimer	  of	   type	   II	   receptors	  on	   the	  cell	   surface,	   resulting	   in	  phosphorylation	  
and	  activation	  of	   the	   type	   I	   receptors	  by	   the	   type	   II	   receptors	   (see	   fig.	   1.10).	   This	   in	   turn	  
leads	   to	   recruitment	   and	   phosphorylation	   of	   a	   receptor-­‐regulated	   Smad	   protein,	   which	  
forms	   a	   complex	   with	   Smad4	   (the	   common	   mediator	   Smad).	   The	   Smad	   complex	   then	  
accumulates	  in	  the	  nucleus,	  where	  the	  Smads	  regulate	  gene	  expression	  by	  interacting	  with	  
transcription	  factors	  and/or	  binding	  directly	  to	  DNA	  (reviewed	  in	  Shi	  and	  Massague	  2003).	  
TGFβ	  superfamily	  signalling	  influences	  a	  large	  number	  of	  genes	  and	  the	  effects	  are	  specific	  
to	  both	  cell	   type	  and	  extracellular	  conditions.	  As	  well	  as	   type	   I	  and	   II	   receptors,	   there	  are	  
also	  co-­‐receptors	   (or	  accessory	   receptors;	   see	   table	  1.5)	  which	  can	  bind	  TGFβ	  superfamily	  
ligands	   and	   regulate	   ligand	   binding	   to	   the	   corresponding	   ligand	   receptors.	   The	   main	  
components	  of	  TGFβ	  superfamily	  signalling	  will	  all	  be	  described	  in	  further	  detail	  below.	  
	  






Figure	  1.10:	  Simple	  overview	  of	  the	  TGFβ	  and	  BMP	  signalling	  pathways	  
A	   TGFβ1	   ligand	   dimer	   binds	   to	   a	   homodimer	   of	   TGFβR2.	   Ligand	   binding	   causes	   association	   of	   TGFβR2	  with	  
TGFβR1	  (also	  as	  a	  homodimer).	  TGFβR2	  then	  phosphorylates	  and	  activates	  TGFβR1,	  leading	  to	  the	  recruitment,	  
phosphorylation	   and	   activation	   of	   the	   receptor-­‐mediated	   or	   R-­‐SMAD,	   SMAD2	   or	   SMAD3.	   Generally	   two	  
phosphorylated	  R-­‐SMADs	   then	   form	  a	   trimeric	  complex	  with	   the	  common	  mediator	  SMAD,	  SMAD4,	  and	   the	  
complex	  accumulates	  in	  the	  nucleus.	  In	  the	  nucleus	  the	  SMAD	  complex	  binds	  directly	  to	  DNA	  or	  interacts	  with	  
transcription	  factors,	  as	  well	  as	  co-­‐activators	  or	  co-­‐repressors,	  to	  regulate	  expression	  of	  multiple	  target	  genes.	  
The	   BMP	   signalling	   pathway	   (shown	   on	   the	   right	   of	   the	   figure)	   is	   similar,	   but	   the	   canonical	   R-­‐SMADs	   are	  
SMAD1,	  SMAD5	  and	  SMAD8.	  The	  co-­‐receptor	  TGFβR3	  facilitates	  ligand	  binding	  to	  TGFβR2.	  	  
	  
1.6.2	  TGFβ	  superfamily	  ligands	  	  
The	   TGFβ	   superfamily	   is	   a	   large	   group	  of	   cytokines	   characterised	  by	  having	   six	   conserved	  
cysteine	   residues.	   The	   family	   is	   divided	   into	   two	   subfamilies,	   according	   to	   both	   sequence	  
similarity	   and	   their	   downstream	   signalling	   pathways.	   These	   are	   the	   TGFβ/activin/nodal	  
subfamily	   and	   the	   bone	   morphogenetic	   protein	   (BMP)/GDF	   (growth	   and	   differentiation	  
factor)/MIS	   (Müllerian	   inhibiting	   substance,	   also	   known	   as	   anti-­‐Müllerian	   hormone	   AMH)	  




subfamily	   (Shi	   and	   Massague	   2003).	   Within	   the	   subfamilies	   there	   are	   several	   different	  
ligands,	   some	   of	   which	   have	   alternative	   names,	   as	   shown	   in	   tables	   1.2A	   and	   B.	   The	   two	  
subfamilies	  of	  ligand	  differ	  in	  their	  receptor-­‐binding	  characteristics:	  the	  TGFβ/activin	  family	  
ligands	   have	   a	   high	   affinity	   for	   type	   II	   receptors	   and	   only	   bind	   to	   type	   I	   receptors	   in	   the	  
presence	  of	  type	  II	  receptors.	  The	  BMP	  subfamily	  members,	  on	  the	  other	  hand,	  have	  a	  high	  
affinity	  for	  the	  type	  I	  receptors	  and	  a	  lower	  affinity	  for	  type	  II	  receptors	  (Shi	  and	  Massague	  
2003).	  	  	  
	  
The	   active	   form	   of	   ligand	   is	   a	   dimer	   stabilised	   by	   hydrophobic	   interactions	   (Shi	   and	  
Massague	   2003).	   TGFβ	   ligands	   are	   secreted	   in	   an	   inactive	   form,	   requiring	   proteolytic	  
cleavage	  before	  they	  are	  available	  for	  binding	  to	  their	  receptors,	  whereas	  other	  ligands	  are	  
secreted	   in	   active	   form	   but	   then	   bound	   by	   locally	   secreted	   antagonists	   (ligand	   binding	  
traps),	  hence	  regulating	  their	  availability	  for	  binding	  to	  receptors	  (de	  Caestecker	  2004).	  	  
	  
1.6.3	  BMP	  Signalling	  
BMPs	  have	  roles	  in	  formation	  of	  bone	  and	  cartilage,	  control	  of	  haematopoiesis	  and	  immune	  
regulation.	   Members	   can	   be	   pro-­‐proliferative	   or	   anti-­‐proliferative,	   depending	   on	   the	   cell	  
type	   and	   general	   context.	   They	   promote	   growth	   and	   differentiation	   in	   osteoblasts,	   and	  
promote	   differentiation	   in	   early	   haematopoietic	   progenitors,	   whereas	   they	   are	   anti-­‐














Table	  1.2:	  Ligands	  of	  the	  TGFβ	  superfamily	  	  
(A):	   TGFβ/activin/nodal	   subfamily	   (B):	   BMP/GDF/MIS	   subfamily.	   Alternative	   names	   are	   shown,	   where	   they	  
exist.	  
	  
1.6.4	  TGFβ	  receptors	  
1.6.4.1	  Type	  I	  and	  type	  II	  receptors	  
There	  are	  two	  main	  types	  of	  receptor	  for	  all	  ligands	  in	  the	  TGFβ	  signalling	  superfamily:	  type	  I	  
(which	  propagate	  signal)	  and	  type	  II	  (which	  activate	  the	  type	  I	  receptors).	  In	  humans	  there	  
A	   TGFβ	   Activins	   Nodal	  
	   Gene	   Other	  name	   Gene	   Other	  names	   Gene	  
	   TGFB1	   TGFβ1	   INHA	   Inhibin	  α	   NODAL	  
	   TGFB2	   TGFβ2	   INHBA	   Inhibin	  β	  A,	  activin	  A	   	  
	   TGFB3	   TGFβ3	   INHBB	   Inhibin	  β	  B,	  activin	  AB	   	  
	   	   	   INHBC	   Inhibin	  β	  C	   	  
	   	   	   INHBE	   Inhibin	  β	  E,	  activin	   	  
	   	  
	  
	  
	   	  
	  
B	   BMPs	   GDFs	   AMH	  
	   Gene	   Other	  name(s)	   Gene	   Other	  name(s)	   Gene	   Other	  name	  
	   BMP2	   	   GDF1	   	   AMH	   MIS	  
	   BMP3	   osteogenin	   GDF2	   BMP9	   	   	  
	   BMP4	   	   GDF3	   	   	   	  
	   BMP5	   	   GDF5	   BMP14	   	   	  
	   BMP6	   	   GDF6	   BMP13	   	   	  
	   BMP7	   OP-­‐1	   GDF7	   BMP12	   	   	  
	   BMP8B	   BMP-­‐8,	  OP-­‐2	   GDF9	   	   	   	  
	   BMP10	   	   GDF10	   BMP3b	   	   	  
	   BMP15	   	   GDF11	   BMP11	   	   	  
	   	   	   GDF15	   	   	   	  
	   	   	   MSTN	   GDF8,	  myostatin	   	   	  




are	  seven	  type	  I	  and	  five	  type	  II	  receptors.	  Type	  I	  receptors	  are	  called	  activin	  receptor-­‐like	  
kinases	  (ALK)	  1-­‐7;	  many	  have	  alternative	  names	  reflecting	  the	  ligand(s)	  they	  bind	  (see	  table	  
1.3).	  Both	  types	  of	  receptor	  consist	  of	  an	  N-­‐terminal	  extracellular	  ligand-­‐binding	  domain,	  a	  
single-­‐pass	  transmembrane	  domain	  and	  a	  cytoplasmic	  C-­‐terminal	  domain	  which	  contains	  a	  
serine/threonine	  kinase	  (Shi	  and	  Massague	  2003).	  Type	  I	  receptors	  also	  have	  a	  characteristic	  
GS	  domain,	  consisting	  of	  the	  specific	  amino	  acid	  sequence	  SGSGSG,	   immediately	  at	  the	  N-­‐
terminal	  side	  of	  the	  kinase	  domain.	  This	  GS	  domain	  is	  phosphorylated	  by	  the	  constitutively	  
active	   type	   II	   receptor,	  hence	  activating	   the	   type	   I	   receptor.	  Phosphorylation	  of	   the	   type	   I	  
receptor	   by	   the	   type	   II	   receptor	   leads	   to	   a	   conformational	   change:	   in	   the	   absence	   of	  
phosphorylation	  by	  the	  type	  II	  receptor,	  the	  type	  I	  receptor	  binds	  the	  protein	  FK506-­‐binding	  
protein	   FKBP12,	   silencing	   the	   type	   I	   receptor’s	   kinase	   activity,	   whereas	   once	   the	   type	   I	  
receptor	  becomes	  phosphorylated	  this	  protein	   is	  released	  and	  the	  receptor	   is	  able	  to	  bind	  
Smads	  (Huse	  et	  al.	  2001).	  
	  
Type	   I	   receptors	   also	   have	   a	   nine	   amino	   acid	   L45	   loop,	   within	   the	   kinase	   domain,	   which	  
determines	   the	   recruitment	   of	   the	   appropriate	   Smads	   and	   the	   signalling	   specificity,	   by	  
binding	   to	   the	  L3	   loop	  of	   the	  R-­‐Smad	   (Feng	  and	  Derynck	  1997);	   for	   instance,	  TGFβR1	  and	  
ALK4	   have	   identical	   L45	   sequences,	   for	   interactions	  with	   Smad2/3,	   whereas	   BMPRIA	   and	  
BMPRIB	  share	  a	  different	  L45	  sequence,	  as	  they	  bind	  to	  Smad1/5/8	  (Chen	  et	  al.	  1998).	  When	  
not	  bound	  to	  ligand,	  both	  type	  I	  and	  type	  II	  receptors	  are	  found	  as	  homodimers	  on	  the	  cell	  
surface.	  On	   binding	   of	   ligand,	   a	   complex	   forms	   between	   a	   ligand	   dimer,	   a	   homodimer	   of	  
type	  I	  receptors	  and	  a	  homodimer	  of	  type	  II	  receptors,	  resulting	   in	  activation	  of	  the	  type	  I	  
receptors	  which	  then	  signal	  to	  the	  cytoplasmic	  Smad	  proteins.	  	  
	  
Type	  I	  receptors	  differ	  in	  their	  specificity	  for	  both	  ligands	  and	  other	  receptors.	  For	  example,	  
TGFβR1	  can	  only	  bind	  to	  TGFβ	  ligands	  (TGFβ1,	  2	  and	  3)	  and	  only	  binds	  to	  TGFβR2,	  whereas	  
others,	  such	  as	  ALK2,	  can	  bind	  several	  different	   ligands	  and/or	  type	  II	  receptors	  (Feng	  and	  
Derynck	  2005).	  Type	  II	  receptors	  also	  differ	  in	  their	  specificity	  for	  both	  type	  I	  receptors	  and	  
ligands	  (see	  table	  1.4).	   In	  addition,	   ligands	  vary	   in	  their	  binding	  capabilities:	  TGFβ1,	  TGFβ3	  
and	  activins	  can	  bind	  to	  their	  type	  II	  receptors	  without	  needing	  a	  type	  I	  receptor,	  whereas	  
BMP2,	   BMP4	   and	   BMP7	   bind	   primarily	   to	   their	   type	   I	   receptors,	   BMPRIA	   or	   BMPRIB	  




(Derynck	   and	   Zhang	   2003).	   TGFβ2,	   on	   the	   other	   hand,	   can	   interact	   only	  with	   pre-­‐formed	  
type	  II-­‐type	  I-­‐receptor	  complexes.	  	  
	  
1.6.4.2	  TGFβR2	  
The	  TGFβR2	  gene	  on	  chromosome	  3	  (Mathew	  et	  al.	  1994)	  encodes	  a	  592-­‐amino	  acid	  protein	  
which,	  like	  other	  type	  II	  receptors,	  consists	  of	  an	  extracellular	  domain	  (including	  the	  ligand	  
binding	  domain),	  a	  transmembrane	  domain	  and	  an	  intracellular	  domain,	  which	  contains	  the	  
serine/threonine	  kinase.	  TGFβR2	  binds	  only	  TGFβ	  ligands,	  but	  can	  bind	  to	  the	  BMP	  receptors	  
ALK1	  and	  ALK2	   in	  addition	  to	  TGFβR1	  (de	  Caestecker	  2004).	  TGFβ	   ligands	  bind	  to	  TGFβR2,	  
resulting	  in	  conformational	  changes	  within	  the	  extracellular	  domain	  (Hart	  et	  al.	  2002).	  This	  
results	   in	   recruitment,	   binding	   and	   phosphorylation	   of	   TGFβR1,	   which	   then	   induces	  
phosphorylation	  of	   Smad2	  and	   Smad3.	   TGFβR2	   can	  bind	   ligand	  without	   requiring	   TGFβR1	  
(Lin	   et	   al.	   1992),	   but	   can	  only	   signal	  when	   it	   forms	   a	   complex	  with	   TGFβR1	   (Wrana	  et	   al.	  
1992).	   TGFβR1	   and	   TGFβR2	   bind	   TGFβ1	   and	   TGFβ3	   with	   higher	   affinity	   than	   TGFβ2,	  
especially	  in	  cells	  lacking	  TGFβR3	  (Cheifetz	  et	  al.	  1990).	  	  
	  
The	  human	  TGFβR2	  promoter	  has	  been	  fairly	  well	  characterised	  (fig.	  1.11),	  and	  lacks	  a	  TATA	  
box	   or	   CAAT	   box	   near	   its	   transcription	   start	   site	   (TSS)	   (Humphries	   et	   al.	   1994,	   Bae	   et	   al.	  
1995).	  It	  has	  several	  Sp1	  binding	  sites,	  at	  positions	  -­‐25,	  -­‐59,	  -­‐102	  and	  -­‐143	  relative	  to	  the	  TSS	  
(Bae	  et	  al.	  1995,	  Jennings	  et	  al.	  2001),	  with	  Sp1	  binding	  being	  necessary	  for	  basal	  activity	  of	  
the	  promoter	  (Jennings	  et	  al.	  2001).	  DNA	  methylation	  at	  Sp1	  binding	  sites,	  resulting	  in	  lack	  
of	  Sp1	  binding,	  has	  been	  shown	  to	  inhibit	  transcription	  of	  TGFβR2	  (Zhao	  et	  al.	  2005,	  Chen	  et	  
al.	  2007).	  HDAC1	  interacts	  with	  Sp1	  leading	  to	  transcriptional	  repression	  (Doetzlhofer	  et	  al.	  
1999)	   and	   this	   mechanism	   has	   been	   shown	   to	   repress	   TGFβR2	   transcription	   in	   human	  















Figure	  1.11:	  Schematic	  diagram	  of	  the	  TGFβR2	  promoter	  region	  
The	  predicted	  transcription	  start	  site	  (TSS)	  for	  transcript	  variant	  1	  is	  shown	  at	  position	  +1.	  The	  5’	  UTR	  is	  shown	  
as	  a	  grey	  box,	  with	   the	  ATG	  start	   codon	   shown	  and	   the	   coding	   region	  of	  exon	  1	   shown	  as	  a	  black	  box.	   The	  
locations	  and	  sizes	  of	  CpG	  islands	  are	  also	  shown.	  	  	  
	  
1.6.4.3	  TGFβR3	  (betaglycan)	  
TGFβR3,	  also	  known	  as	  betaglycan,	  is	  a	  co-­‐receptor	  for	  TGFβ	  signalling.	  It	  is	  found	  in	  higher	  
numbers	  on	  the	  cell	  surface	  than	  TGFβR1	  or	  TGFβR2,	  and	  is	  expressed	  on	  virtually	  every	  cell	  
type	  except	  endothelial	   cells	   (Cheifetz	   et	   al.	   1990)	   and	  haematopoietic	  progenitor	   cells	   in	  
mice	  (Ohta	  et	  al.	  1987).	  TGFβR3	  is	  an	  851	  amino-­‐acid	  proteoglycan	  which	  possesses	  a	  large	  
extracellular	  domain,	  a	  single	  transmembrane	  domain	  and	  a	  short	  cytoplasmic	  domain	  of	  43	  
amino	  acids,	  which	   lacks	  a	  kinase	   (Lopez-­‐Casillas	  et	  al.	  1991,	  Wang	  et	  al.	  1991);	   like	  other	  
TGFβRs	  it	  exists	  as	  a	  homodimer.	  Its	  glycosylation	  by	  the	  addition	  of	  glycosaminoglycans	  is	  
thought	  to	  be	  important	  for	  its	  function.	  The	  cytoplasmic	  domain	  of	  TGFβR3	  is	  necessary	  for	  
promotion	  of	  TGFβ	  signalling	  (Blobe	  et	  al.	  2001b).	  
	  
TGFβR3	   directly	   binds	  multiple	   ligands,	   including	   TGFβ1,	   TGFβ2,	   TGFβ3	   (all	   of	  which	   bind	  
with	  high	  affinity),	   inhibin,	  BMP2,	  BMP4,	  BMP7,	  and	  GDF5,	  and	   facilitates	   their	  binding	   to	  
the	  relevant	  type	  II	  receptors,	  hence	  enhancing	  TGFβ	  and	  BMP	  signalling	  (Gatza	  et	  al.	  2010).	  
TGFβR3	   can	   also	   present	   BMP2	   to	   the	   type	   I	   receptors	   BMPRIA	   or	   BMPRIB,	   increasing	  
signalling	  by	  BMP2	   (Kirkbride	  et	  al.	   2008).	   In	  addition,	   certain	   ligands	   (inhibin	  and	  TGFβ2)	  
require	  TGFβR3	  for	  their	  binding	  to	  type	  II	  receptors	  (Gatza	  et	  al.	  2010).	  By	  facilitating	  the	  
binding	  of	  inhibin	  to	  both	  activin	  receptor	  II	  and	  BMPR2,	  TGFβR3	  can	  mediate	  the	  inhibition	  
of	  both	  activin	  and	  BMP	  signalling	  by	  inhibin	  (Lewis	  et	  al.	  2000,	  Wiater	  and	  Vale	  2003).	  	  
	  
TGFβR3	  undergoes	  shedding	  of	   its	  ectodomain	  by	  proteolytic	  cleavage	  at	  a	  site	  within	  the	  
extracellular	  domain,	  resulting	   in	  the	  presence	  of	  soluble	  TGFβR3	  (sTGFβR3)	  (Andres	  et	  al.	  




1989,	  Lopez-­‐Casillas	  et	  al.	  1991);	  the	  levels	  of	  this	  soluble	  form	  appear	  to	  correlate	  with	  that	  
on	  the	  cell	  surface,	  suggesting	  that	  it	  is	  constitutively	  shed	  (Gatza	  et	  al.	  2010).	  sTGFβR3	  can	  
bind	  to	  TGFβ	  ligands	  in	  extracellular	  fluid,	  sequestering	  them	  and	  preventing	  their	  binding	  to	  
cell	  surface	  TGFβRs,	  hence	  negatively	  regulating	  TGFβ	  and	  BMP	  signalling	  (Lopez-­‐Casillas	  et	  
al.	  1994).	  However,	  at	  low	  TGFβ	  concentrations,	  sTGFβR3	  can	  conversely	  enhance	  binding	  of	  
TGFβ	  ligands	  to	  cell	  surface	  receptors	  (Fukushima	  et	  al.	  1993).	  	  
	  
TGFβR3	  can	  also	  form	  a	  complex	  with	  β-­‐arrestin2	  and	  BMPRIB	  resulting	  in	  internalisation	  of	  
BMPRIB,	  which	  enhances	  BMP	  signalling	   (Lee	  et	  al.	  2009).	  The	  cytoplasmic	  PDZ	  domain	  of	  
TGFβR3	  can	  bind	   to	  GAIP-­‐interacting	  protein,	  C-­‐terminus	   (GIPC),	   stabilising	  TGFβR3	  at	   the	  
cell	  surface	  and	  hence	  enhancing	  TGFβ	  signalling	  (Blobe	  et	  al.	  2001a).	  Phosphorylation	  of	  a	  
cytoplasmic	  domain	  of	  TGFβR3	  by	  TGFβR2	   leads	   to	  binding	  of	  TGFβR3	   to	  β-­‐arrestin2.	  The	  
subsequent	   complex	   formation	   between	   TGFβR3:β-­‐arrestin2	   and	   GIPC	   leads	   to	   ligand-­‐
independent	  endocytosis	  of	  the	  whole	  TGFβ	  signalling	  receptor	  complex	  and	  hence	  down-­‐
regulation	  of	  TGFβ	  signalling	  (Chen	  et	  al.	  2003,	  Finger	  et	  al.	  2008a).	  TGFβR3	  therefore	  has	  
dual	  roles	  in	  modulating	  both	  TGFβ	  signalling	  and	  BMP	  signalling	  depending	  on	  the	  context	  
and,	  in	  addition,	  inhibits	  activin	  signalling.	  
	  
TGFβ1	   binds	   to	   TGFβR3	   with	   much	   lower	   affinity	   than	   to	   TGFβR1	   and	   TGFβR2.	   TGFβR3	  
associates	   with	   TGFβR2	   only	   in	   the	   presence	   of	   ligand,	   without	   binding	   to	   TGFβR1.	   It	  
presents	  TGFβ1	  to	  TGFβR2,	  forming	  a	  stable	  ligand	  transfer	  complex,	  and	  thus	  increases	  the	  
affinity	  of	  TGFβR2	  for	  TGFβ1.	  It	  markedly	  increases	  the	  affinity	  of	  TGFβ2	  ligand	  for	  TGFβR2	  
such	  that	  in	  the	  presence	  of	  TGFβR3,	  TGFβ2	  is	  nearly	  as	  potent	  as	  TGFβ1	  in	  certain	  cell	  types	  
(Lopez-­‐Casillas	  et	   al.	   1993).	  Murine	  hematopoietic	  progenitor	   cells	  which	   lack	  TGFβR3	  are	  
fairly	   resistant	   to	   TGFβ2	   (Ohta	   et	   al.	   1987),	   whereas	   cells	   expressing	   TGFβR3	   are	   more	  
responsive	   to	   TGFβ2.	   TGFβR3	   is	   not	   essential	   for	   TGFβ	   signalling.	   However,	   it	   has	   been	  
shown	   to	   be	   essential	   for	   haematopoiesis,	   as	   TGFβR3	   knockout	   mice	   show	   embryonic	  
lethality	  due	  to	  ineffective	  erythropoiesis	  (Stenvers	  et	  al.	  2003).	  	  
	  
The	  gene	  encoding	  TGFβR3	  is	  on	  chromosome	  1	  and	  includes	  16	  exons	  transcribed	  from	  two	  
promoters,	  proximal	  and	  distal	   (Hempel	  et	  al.	  2008,	  Gatza	  et	  al.	  2010).	  The	  gene	  contains	  
three	  non-­‐coding	  exons	  in	  its	  5’	  region	  (fig.	  1.12).	  Two	  TGFβR3	  mRNA	  transcripts	  have	  been	  




identified	   which	   differ	   in	   their	   5’	   UTR	   regions,	   in	   keeping	   with	   the	   existence	   of	   two	  
promoters	   (Hempel	   et	   al.	   2008).	   The	   proximal	   promoter	   is	   approximately	   25kb	   from	   the	  
translational	  ATG	   start	   codon,	  with	   the	  distal	   promoter	   being	   45kb	   from	   the	   start	   codon.	  
The	  proximal	  promoter	  is	  located	  between	  base	  pairs	  -­‐165	  to	  -­‐75	  from	  the	  proximal	  TSS;	  this	  
region	   contains	   an	   Sp1	   site,	   conserved	   across	   rat,	   mouse	   and	   human	   TGFβR3,	   plus	   an	  
upstream	  GC-­‐rich	  region.	  The	  sequence	  of	  the	  proximal	  promoter	  in	  humans	  is	  identical	  to	  
the	  rat	  and	  mouse	  TGFβR3	  promoters	  (Wang	  et	  al.	  1991,	  Ji	  et	  al.	  1999,	  Lopez-­‐Casillas	  et	  al.	  
2003,	  Hempel	  et	  al.	  2008).	  The	  distal	  promoter	  has	  been	  found	  to	  be	  highly	  methylated	  in	  
several	   cell	   lines,	   suggesting	   that	   the	   proximal	   promoter	   is	   generally	  more	   active	   in	  most	  




Figure	  1.12:	  Schematic	  diagram	  of	  the	  TGFβR3	  promoters	  
The	  TGFβR3	  gene	  has	  two	  alternative	  promoters,	  distal	  and	  proximal,	  with	  the	  transcriptional	  start	  sites	  (TSS)	  
shown	  for	  each.	  Published	  TGFβR3	  mRNA	  transcripts	  differ	  in	  their	  5’	  UTRs	  (untranslated	  exons	  shown	  as	  grey	  
boxes),	  either	  having	  exons	  C	  and	  B,	  or	  alternatively	  exon	  A,	  and	  then	  share	  a	  common	  exon	  in	  which	  the	  ATG	  
start	  codon	  is	  found	  (translated	  region	  shown	  in	  black).	  Also	  shown	  are	  the	  predicted	  CpG	  islands	  around	  the	  
















Gene	   Other	  
name	  
Ligand(s)	   Type	  II	  receptor	  (s)	   Smads	  
ACVRL1	   ALK1	   TGFβ,	  Activin	  A,	  BMP9,	  BMP10	   TGFβR2;	  ActRII,	  ActRIIB	   1/5/8	  
ACVR1	   ALK2,	  	  
ACVR1A	  
BMP	   6/7,	   BMP9,	   Activin	   A,	  
AMH,	  TGFβ	  
ActRII,	   ActRIIB,	   AMHRII,	  
TGFβR2	  
1/5/8	  
BMPR1A	   ALK3	   BMP2,	  BMP4,	  BMP6,	  BMP7	   BMPRII,	   ActRII,	   ActRIIB,	  
AMHRII	  
1/5/8	  
ACVR1B	   ALK4,	  	  
ActRIB	  
Nodal,	  Activin	  A,	  GDF1,	  GDF11	   ActRII,	  ActRIIB	   2/3	  
TGFBR1	   ALK5,	  
TGFβR1	  
TGFβ1,2,3	   TGFβR2	   2/3	  
BMPR1B	   ALK6	   BMP2,	   BMP4,	   BMP6,	   BMP7,	  
GDF-­‐5,6,9b,	  AMH	  
BMPRII,	   ActRII,	   ActRIIB,	  
AMHRII	  
1/5/8	  
ACVR1C	   ALK7	   Nodal,	  activins	   ActRII,	  ActRIIB	   2/3	  
Table	  1.3:	  Type	  I	  receptors	  of	  the	  TGFβ	  superfamily	  
The	  ligands	  and	  Smads	  which	  bind	  to	  the	  receptors	  are	  shown	  (de	  Caestecker	  2004,	  Mueller	  and	  Nickel	  2012).	  
ALK=activin-­‐like	  receptor	  kinase;	  ActR=activin	  receptor.	  
	  
Gene	   Other	  
name	  
Ligands	   Type	  I	  receptors	  
TGFBR2	   TGFβR2	   TGFβ1,2,3	   TGFβR1,	  ALK1,	  ALK2	  
ACVR2A	   ActRII	   Activins/inhibins,	   nodal;	   GDF1,	   5,	  	  
8,	  9b,	  11;	  	  BMPs	  2,	  6,	  7,	  9	  
ALK1,	   ALK2,	   BMPRIA,	   ALK4,	  
BMPRIB,	  ALK7	  
ACVR2B	   ActRIIB	   Activins/inhibins;	  nodal;	  GDF1,	  5,	  8,	  
9b,	  11;	  BMPs	  2,	  6,	  7,	  9	  
ALK1,	   ALK2,	   BMPRIA,	   ALK4,	  
BMPRIB,	  ALK7	  
BMPR2	   BMPRII	   BMPs	  2,4,6,7,9;	  GDF-­‐5,6,	  9b;	  
inhibin	  A	  
BMPR1A,	  BMPR1B	  
AMHR2	   AMHRII,	  
MISRII	  
AMH/MIS	   ALK2,	  BMPRIA,	  BMPRIB	  
Table	  1.4:	  Type	  II	  receptors	  of	  the	  TGFβ	  superfamily	  
The	  ligands	  and	  type	  I	  receptors	  which	  bind	  are	  shown	  (de	  Caestecker	  2004,	  Mueller	  and	  Nickel	  2012).	  
	  
	  




Gene	   Other	  name	   Ligands	  
TGFBR3	   TGFβR3,	  Betaglycan	   TGFβ1,	  2	  and	  3;	  Inhibin,	  BMP2,	  BMP4,	  BMP7,	  GDF5	  
ENG	   Endoglin	   BMP2,	  BMP7,	  BMP9,	  activin;	  TGFβ1,	  TGFβ3	  
TDGF1	   Cripto	   Nodal,	  GDF1,3	  
Table	  1.5:	  Co-­‐receptors	  (accessory	  receptors)	  of	  the	  TGFβ	  superfamily	  
Alternative	  names	  and	  ligands	  are	  shown	  (de	  Caestecker	  2004,	  Mueller	  and	  Nickel	  2012).	  
	  
1.6.5	  Smads	  
The	   downstream	   intracellular	   signals	   from	   TGFβ	   and	   BMP	   receptors	   are	   propagated	   by	  
Smad	   proteins.	   There	   are	   8	   Smad	   proteins	   separated	   into	   three	   families:	   the	   receptor-­‐
activated	  or	  R-­‐Smads	   (Smad1,	   Smad2,	   Smad3,	   Smad5	  and	   Smad8,	   also	   known	  as	   Smad9),	  
the	   common-­‐mediator	   or	   co-­‐Smad	   (Smad4)	   and	   two	   inhibitory	   or	   I-­‐Smads	   (Smad6	   and	  
Smad7).	   	   Only	   the	   R-­‐Smads	   can	   be	   directly	   phosphorylated	   and	   activated	   by	   the	   type	   I	  
receptor	   kinases.	   Canonical	   signalling	   by	   the	   TGFβ	   subfamily	   occurs	   through	   Smad2	   and	  
Smad3,	  whereas	  the	  BMP	  superfamily	  ligands	  signal	  through	  Smad1,	  Smad5	  and	  Smad8	  (see	  
fig.	  1.10).	  The	  I-­‐Smads	  compete	  with	  R-­‐Smads	  for	  receptor	  and	  co-­‐Smad	  binding	  and	  target	  
the	  receptors	  for	  degradation.	  	  
	  
The	   Smad	   proteins	   are	   all	   approximately	   500	   amino	   acids	   in	   length	   and	   consist	   of	   two	  
conserved	  domains,	  the	  N-­‐terminal	  MAD	  homology	  1	  (MH1)	  and	  C-­‐terminal	  MAD	  homology	  
2	  (MH2)	  domains,	  separated	  by	  a	  more	  divergent	  linker	  domain.	  The	  C-­‐terminus	  of	  R-­‐Smads	  
has	   a	   characteristic	   SXS	   motif,	   the	   two	   serines	   of	   which	   are	   phosphorylated	   by	   type	   I	  
receptors	   resulting	   in	   Smad	   activation.	   The	  MH2	   domain	   contains	   the	   L3	   loop	   region	   for	  
interaction	  with	  the	  L45	  loop	  on	  type	  I	  receptors	  and	  a	  region	  for	  oligomerisation	  with	  other	  
Smads,	  whereas	  the	  MH1	  domain	  enables	  the	  Smad	  to	  bind	  to	  DNA	  and	  interact	  with	  other	  
DNA	  binding	  proteins	  (Attisano	  and	  Wrana	  2000).	  Smad2	  and	  Smad3	  share	  an	   identical	  L3	  
loop,	  and	  Smad1/5/8	  share	  an	  alternative	  identical	  L3	  loop,	  thus	  ensuring	  specificity	  of	  the	  
type	  I	  receptors	  for	  R-­‐Smads.	  	  
	  
In	   the	   inactive	   state,	   the	   R-­‐Smads	   are	   located	   primarily	   in	   the	   cytoplasm,	   the	   co-­‐Smad	  
(Smad4)	   in	   the	  cytoplasm	  and	  nucleus,	  and	  the	   I-­‐Smads	  predominantly	   in	   the	  nucleus	   (Shi	  




and	  Massague	  2003).	   	  R-­‐Smads	  undergo	  constant	  nucleo-­‐cytoplasmic	  shuttling	  even	  in	  the	  
absence	  of	  signalling.	  Phosphorylation	  of	  the	  R-­‐Smad	  at	  the	  C-­‐terminal	  SXS	  motif	  by	  type	  I	  
receptors	   results	   in	   a	   conformational	   change	   leading	   to	   its	  dissociation	   from	   the	   receptor	  
and	   allowing	   the	   R-­‐Smad	   to	   form	   a	   complex	  with	   other	   Smads	   including	   Smad4	   (Derynck	  
and	   Zhang	   2003).	   Activated	   R-­‐Smads	   can	   form	   a	   dimer	  with	   Smad4	   or	   a	   trimer	  with	   one	  
Smad4	  molecule	  and	  one	  other	  R-­‐Smad	  (Inman	  and	  Hill	  2002),	  although	  more	  recently	  the	  
existence	   of	   mixed	   R-­‐Smad	   complexes,	   in	   some	   cases	   not	   including	   Smad4,	   have	   been	  
demonstrated	   (Daly	   et	   al.	   2008,	   Gronroos	   et	   al.	   2012).	   Formation	   of	   an	   activated	   Smad	  
complex	  promotes	  its	  accumulation	  in	  the	  nucleus,	  a	  process	  facilitated	  by	  the	  interaction	  of	  
the	   Smad	  MH2	  domain	  with	   nucleoporins.	   R-­‐Smad	   shuttling	   continues	   in	   the	  presence	  of	  
signal,	   by	   continuous	   receptor-­‐mediated	   phosphorylation	   in	   the	   cytoplasm	   and	   de-­‐
phosphorylation	   by	   R-­‐Smad	   phosphatases	   in	   the	   nucleus.	   This	   enables	   the	   R-­‐Smads	   to	  
monitor	   receptor	   activity	   (Inman	   et	   al.	   2002).	   	   Smad4	   accumulates	   in	   the	   nucleus	   once	  
bound	   to	   activated	   R-­‐Smads,	   but	   also	   undergoes	   nucleo-­‐cytoplasmic	   shuttling	  
independently	   of	   signalling.	   It	   is	   thought	   that	   a	   nuclear	   export	   signal	   in	   the	   Smad4	   linker	  
region	   is	   hidden	   when	   Smad4	   is	   bound	   to	   R-­‐Smad	   (Watanabe	   et	   al.	   2000).	   Nucleo-­‐
cytoplasmic	   shuttling	   is	   halted	   by	   blocking	   of	   the	   nucleoporin	   interaction	   by	  
phosphorylation	  of	   the	  Smad1	   linker	   region	  and	  binding	  of	   the	  E3	  ubiquitin	   ligase	  Smurf1	  
(Sapkota	  et	  al.	  2007).	  	  
	  
Stimulation	   of	   a	   cell	   with	   TGFβ	   ligand	   results	   in	   simultaneous	   changes	   in	   expression	   of	  
hundreds	  of	   genes,	   some	  being	  positively	  and	  others	  negatively	   regulated.	  These	  changes	  
depend	  on	  the	  cell	  type	  and	  other	  conditions	  of	  the	  cell	  (Kang	  et	  al.	  2003,	  Massague	  2012).	  
Smads	   cooperate	   both	   with	   each	   other	   and	   with	   other	   DNA	   binding	   proteins;	   the	  
transcription	   factors	   cooperating	   with	   Smads	   include	   those	   from	   multiple	   families,	   e.g.	  
forkhead,	  homeobox,	  Jun/Fos,	  and	  Runx	  [reviewed	  in	  (Attisano	  and	  Wrana	  2000,	  Feng	  and	  
Derynck	   2005)].	   Smad4	   and	   R-­‐Smads,	  with	   the	   exception	   of	   Smad2,	   bind	   to	   specific	   DNA	  
sequences,	   called	   Smad-­‐binding	   elements	   (SBEs),	   within	   the	   promoters	   of	   target	   genes.	  
Smad3	  and	  Smad4	  bind	  to	  SBEs	  consisting	  of	  GTCT	  and	  its	  palindrome	  AGAC	  (Dennler	  et	  al.	  
1998,	  Zawel	  et	  al.	  1998),	  found	  within	  promoters	  of	  certain	  TGFβ	  target	  genes	  such	  as	  JUNB	  
and	   SMAD7	   (Jonk	   et	   al.	   1998,	   Nagarajan	   et	   al.	   1999).	   Smad1,	   on	   the	   other	   hand,	   binds	  
preferentially	  to	  the	  GC-­‐rich	  sequences	  GCCGNC	  or	  GRCGNC,	  found	  within	  the	  promoters	  of	  




BMP-­‐responsive	  genes	  such	  as	  ID1	  and	  SMAD6	  (Ishida	  et	  al.	  2000,	  Lopez-­‐Rovira	  et	  al.	  2002).	  
These	   sequences,	   Smad1-­‐binding	   elements,	   are	   often	   found	   near	   Smad3/Smad4	   binding	  
elements	   GTCT	   or	   AGAC,	   so	   that	   Smad4	   bound	   to	   Smad1	   within	   the	   complex	   can	   also	  
interact	  with	  the	  DNA	  (Ross	  and	  Hill	  2008).	  	  
	  
The	  MH1	  domain	  of	  Smad3	  is	  able	  to	  bind	  to	  SBEs,	  but	  Smad2	  is	  unable	  to	  bind	  directly	  to	  
DNA	   and	   so	   must	   interact	   with	   DNA	   indirectly	   via	   recruitment	   of	   transcription	   factors.	  
Smad2	  and	  Smad3	  share	  91%	  amino	  acid	  homology	  overall,	  but	  Smad2	  has	  an	  additional	  30-­‐
amino-­‐acid	  sequence	  within	   its	  MH1	  domain,	  transcribed	  by	  exon	  3,	  and	  it	   is	  thought	  that	  
this	  sterically	  hinders	  the	  binding	  of	  Smad2	  to	  DNA,	  since	  a	  mutated	  form	  of	  Smad2,	  lacking	  
exon	  3,	  is	  able	  to	  bind	  DNA	  (Yagi	  et	  al.	  1999).	  	  
	  
Although	  canonical	  TGFβ	  signalling	  induces	  phosphorylation	  of	  Smad2	  and	  Smad3,	  these	  can	  
have	  different	   functions	  and	  are	   therefore	  generally	  non-­‐redundant,	  although	   the	   relative	  
importance	   of	   each	   varies	   between	   cell	   types	   (Kretschmer	   et	   al.	   2003,	   Kim	   et	   al.	   2005,	  
Brown	  et	  al.	  2007).	  An	  investigation	  of	  murine	  embryonic	  fibroblasts	  with	  knockout	  (KO)	  of	  
Smad2	   or	   Smad3	   showed	   that	   both	   Smads	   were	   required	   for	   TGFβ-­‐mediated	   growth	  
inhibition,	   whereas	   the	   induction	   of	   Smad7	   and	   auto-­‐induction	   of	   TGFβ1	   only	   required	  
Smad3	   expression.	   Other	   TGFβ	   target	   genes	   required	   one	   or	   other	   Smad	   specifically,	   or	  
neither	   (Piek	   et	   al.	   2001).	   However,	   in	  murine	  mammary	   epithelial	   cells,	   Smad3	  was	   not	  
required	   for	   TGFβ-­‐mediated	   growth	   inhibition	   (Yang	   et	   al.	   2002).	   In	   HaCaT	   (human	  
keratinocyte)	   cells,	   Smad3,	   but	   not	   Smad2,	   was	   needed	   for	   TGFβ-­‐induced	   growth	   arrest,	  
p21CIP1/WAF1	  induction	  and	  c-­‐MYC	  repression	  (Kretschmer	  et	  al.	  2003,	  Kim	  et	  al.	  2005).	  A	  DNA	  
array	  revealed	  several	  distinct	  sets	  of	  TGFβ	  target	  genes:	  (1)	  those	  that	  specifically	  required	  
Smad2	  or	  Smad3,	  (2)	  those	  requiring	  either	  Smad2	  or	  Smad3	  in	  a	  redundant	  fashion,	  or	  (3)	  a	  
set	  that	  were	  entirely	  independent	  of	  Smad2	  and	  Smad3	  (Kretschmer	  et	  al.	  2003).	  	  	  
	  
The	  binding	  of	   Smads	   to	  DNA,	  even	   for	   those	   that	  do	  bind	  directly,	   is	  of	   low	  affinity,	   and	  
thus	   they	   require	   interaction	   with	   specific	   transcription	   factors	   to	   alter	   transcription	   of	  
target	   genes;	   this	   contributes	   to	   the	   diversity	   of	   TGFβ	   responses	   in	   different	   cellular	  
contexts.	   The	   accumulation	   of	   Smad	   complexes	   within	   the	   nucleus	   as	   either	   dimers	   or	  




trimers	  (involving	  two	  R-­‐Smad	  molecules	  with	  one	  Smad4)	  depends	  on	  which	  transcription	  
factor	  is	  involved	  in	  the	  interaction	  (Inman	  and	  Hill	  2002).	  
	  
As	   well	   as	   interacting	   with	   transcription	   factors,	   Smads	   can	   recruit	   co-­‐activators	   such	   as	  
CREB-­‐binding	   protein	   (CBP)	   and	   p300,	   both	   histone	   acetyl	   transferases,	   which	   bring	  
sequence-­‐specific	  transcription	  factors	  into	  close	  proximity	  with	  RNA	  polymerase	  II.	  Smads	  
can	  also	  recruit	  co-­‐repressors,	  such	  as	  Ski/SnoN,	  which	  repress	  Smad-­‐induced	  transcription.	  	  
	  
1.6.6	  Cross-­‐talk	  between	  TGFβ	  and	  BMP	  signalling	  pathways	  
In	  recent	  years	  the	  concept	  of	  distinct	  canonical	  TGFβ	  and	  BMP	  signalling	  via	  Smad2/3	  and	  
Smad1/5/8	   respectively	   has	   been	   increasingly	   challenged.	   First	   it	   was	   demonstrated	   in	  
endothelial	  cells	  that	  TGFβ	  could	  stimulate	  phosphorylation	  of	  both	  Smad2/3	  and	  Smad1/5.	  
This	   occurred	   via	   the	   formation	   of	   heteromeric	   receptor	   complexes	   containing	   TGFβR1	  
(which	   activates	   Smad2/3)	   and	   ALK1	   (which	   stimulates	   Smad1/5/8)	   and	   required	   the	  
endothelial-­‐cell-­‐specific	   co-­‐receptor	   endoglin	   (Goumans	   et	   al.	   2002).	   Initially	   this	   was	  
thought	   to	   be	   specific	   to	   endothelial	   cells,	   as	   ALK1	   is	   not	   expressed	   in	   other	   cell	   types.	  
However,	   it	   was	   subsequently	   demonstrated	   that	   formation	   of	   similar	   mixed	   receptor	  
complexes	   and	   mixed	   R-­‐Smad	   complexes,	   leading	   to	   activation	   of	   both	   Smad2/3	   and	  
Smad1/5/8	   by	   TGFβ,	   occur	   in	   other	   cell	   types	   including	   epithelial	   cells,	   fibroblasts	   and	  
epithelial-­‐derived	  tumour	  cell	   lines	   (Daly	  et	  al.	  2008).	   In	   this	  case,	   the	  receptor	  complexes	  
included	   a	   dimer	   of	   TGFβR2	   complexed	   with	   a	   TGFβR1	   monomer	   and	   a	   BMP	   receptor	  
monomer,	   either	   ALK2	   or	   BMPRIA	   (ALK3).	   They	   demonstrated	   the	   formation	   of	  mixed	   R-­‐
Smad	  complexes	  consisting	  of	  a	  phosphorylated	  Smad2	  or	  3	  with	  a	  phosphorylated	  Smad1	  
or	  5,	  without	  a	  Smad4	  molecule,	  and	  proposed	  that	  these	  mixed	  R-­‐Smad	  complexes	  could	  
themselves	   accumulate	   in	   the	   nucleus	   and	   alter	   transcription	   of	   target	   genes	   (Daly	   et	   al.	  
2008).	  	  
	  
It	  was	  thought	  that	  in	  order	  for	  TGFβ	  to	  stimulate	  phosphorylation	  of	  the	  ‘BMP-­‐type’	  Smads	  
1/5/8,	  one	  of	  the	  BMP	  type	  1	  receptors	  (ALK1,	  ALK2,	  ALK3	  or	  ALK6)	  would	  have	  to	  be	  within	  
the	   receptor	   complex.	   However,	   Wrighton	   et	   al	   showed	   that	   TGFβ	   could	   induce	  
phosphorylation	  of	  Smad1	  independently	  of	  BMP	  type	  I	  receptors	  in	  a	  murine	  mesenchymal	  




cell	  line	  and	  a	  human	  hepatoma	  cell	  line	  (Wrighton	  et	  al.	  2009)	  and	  another	  group	  showed	  
that	   TGFβ	   induced	   phosphorylation	   of	   Smad1	   in	   a	   murine	   mammary	   epithelial	   cell	   line,	  
again	   via	   the	   L45	   loop	   of	   TGFβR1	   (interacting	   with	   non-­‐canonical	   Smads	   1/5)	   and	  
independently	  of	  BMP	  receptors	   (Liu	  et	  al.	  2009).	  Thus	  the	  requirement	   for	  BMP	  receptor	  
involvement	   in	   TGFβ-­‐induced	   phosphorylation	   of	   Smad1/5	   appears	   to	   vary	   between	   cell	  
lines	  or	  cell	  types.	  	  
	  
TGFβ-­‐induced	   phosphorylation	   of	   Smad1/5	   has	   now	   been	   demonstrated	   in	   endothelial,	  
epithelial	  cells,	  fibroblasts	  and	  B	  cells	  (Goumans	  et	  al.	  2002,	  Daly	  et	  al.	  2008,	  Liu	  et	  al.	  2009,	  
Wrighton	  et	  al.	  2009,	  Rai	  et	  al.	  2010,	  Jiang	  and	  Aguiar	  2014).	  In	  B	  cells	  the	  requirement	  for	  
TGFβR2	  and	  TGFβR1	  was	  consistently	  shown,	  whereas	  BMP	  receptors	  ALK2/3	  were	  required	  
only	  in	  one	  of	  the	  DLBCL	  lines	  tested	  (Rai	  et	  al.	  2010).	  Hill	  and	  colleagues	  have	  recently	  gone	  
on	   to	   show,	   in	   a	   breast	   cancer-­‐derived	   epithelial	   cell	   line,	   that	   TGFβ	   acts	   via	   TGFβR1	   to	  
induce	  mixed	  R-­‐Smad	  complexes	  containing	  phosphorylated	  Smad1/5	  and	  phosphorylated	  
Smad3	   (but	   not	   Smad2).	   These	   heteromeric	   complexes	   had	   a	   direct	   inhibitory	   effect	   on	  
BMP-­‐responsive	  elements,	  so	  that	  in	  the	  presence	  of	  both	  TGFβ	  and	  BMP	  ligands,	  the	  TGFβ	  
signals	   antagonised	   BMP	   signals,	   with	   Smad3	   being	   required	   to	   mediate	   TGFβ-­‐induced	  
repression	  of	  BMP-­‐induced	  transcription	  (Gronroos	  et	  al.	  2012).	  	  
	  
1.6.7	  Regulation	  of	  TGFβ	  and	  BMP	  signalling	  pathways	  
TGFβ	  signalling	  is	  regulated	  at	  multiple	  levels:	  by	  controlling	  the	  amount	  of	  ligand	  available,	  
cell	  surface	  expression	  of	  receptors,	  availability	  of	  Smads,	  degradation	  of	  signalling	  pathway	  
components,	   and	   by	   inhibitory	   molecules	   including	   the	   inhibitory	   Smads	   (I-­‐Smads).	   This	  
regulation	  is	  important	  for	  ensuring	  that	  signalling	  is	  terminated	  appropriately.	  	  
	  
Internalisation	  of	  receptors	  is	  used	  either	  to	  enhance	  signalling	  or	  to	  degrade	  the	  receptor,	  
depending	   on	   the	   mechanism	   of	   endocytosis	   used.	   Clathrin-­‐mediated	   endocytosis	   of	  
receptor	   complexes	   to	   early	   endosomes	   results	   in	   enhanced	   signalling,	   and	   receptors	   can	  
return	   from	   there	   to	   the	   cell	   surface.	   Clathrin-­‐independent	   receptor	   endocytosis	   to	  
caveolin-­‐positive	   vesicles,	   on	   the	   other	   hand,	   results	   in	   receptor	   degradation	   and	   thus	  
reduced	  signalling	  (Finger	  et	  al.	  2008a).	  




As	  described	   in	   section	  1.6.5,	   Smads	  are	   continuously	   shuttled	   from	   the	  cytoplasm	   to	   the	  
nucleus	   and	  back	   again,	   although	   in	   the	  presence	  of	   ligand	   they	   remain	   for	   longer	   in	   the	  
nucleus,	   due	   to	   masking	   of	   nuclear	   export	   signals	   (Itoh	   and	   ten	   Dijke	   2007).	   Smad	  
phosphatases,	  found	  in	  the	  nucleus,	  dephosphorylate	  Smads,	  hence	  deactivating	  them	  and	  
allowing	  them	  to	  be	  exported	  from	  the	  nucleus	  back	  into	  the	  cytoplasm.	  Smad	  activity	  can	  
also	  be	  terminated	  via	  ubiquitin-­‐mediated	  proteasomal	  degradation.	  
	  
The	  I-­‐Smads	  6	  and	  7	  inhibit	  signalling	  by	  several	  mechanisms.	  Smad6	  is	  usually	  more	  specific	  
to	   BMP	   signalling,	   whereas	   Smad7	   inhibits	   both	   TGFβ	   and	   BMP	   signalling	   (Attisano	   and	  
Wrana	  2000).	  The	   I-­‐Smads	  compete	  with	  R-­‐Smads	   for	  binding	   to	  Smad4	   (Moustakas	  et	  al.	  
2001).	   They	   also	   recruit	   the	   Smad	   ubiquitin	   regulatory	   factors	   Smurf1	   and	   Smurf2,	  which	  
ubiquitinate	  activated	  R-­‐Smads,	  targeting	  them	  for	  proteasome-­‐mediated	  degradation	  and	  
hence	   down-­‐regulating	   signalling.	   Smurf1	   targets	   Smads	   1	   and	   5	   and	   therefore	  
preferentially	   inhibits	   BMP	   signalling	   (Zhu	   et	   al.	   1999),	   whereas	   Smurf2	   targets	   activated	  
Smad2	   and	   thus	   down-­‐regulates	   TGFβ	   signalling	   (Zhang	   et	   al.	   2001).	   Smad7	   also	   leads	   to	  
dephosphorylation	  and	  inactivation	  of	  TGFβR1	  (Ebisawa	  et	  al.	  2001,	  Shi	  et	  al.	  2004).	  TGFβ,	  
activin	  and	  BMP	  signalling	  up-­‐regulate	  transcription	  of	  the	  I-­‐Smads,	  thus	  providing	  a	  means	  
of	  ensuring	  the	  transience	  of	  signalling	  (Nakao	  et	  al.	  1997)	  via	  a	  negative	  feedback	  loop.	  
	  
Signalling	  can	  also	  be	  terminated	  by	  the	  inhibition	  of	  	  formation	  of	  complexes	  between	  type	  
I	  and	  type	  II	  receptors,	  such	  as	  by	  the	  decoy	  type	  1	  receptor,	  BMP	  and	  activin	  membrane-­‐
bound	  inhibitor	  (BAMBI)	  (Itoh	  and	  ten	  Dijke	  2007).	  Co-­‐repressors	  such	  as	  Ski/SnoN	  are	  also	  
important	   in	   controlling	   Smad	   function,	   as	   they	   inhibit	   Smad-­‐induced	   target	   gene	  
transcription.	   In	   addition,	   SnoN	   can	   sequester	   Smads	   in	   the	   cytoplasm,	   preventing	   their	  
activation	   and	   nuclear	   accumulation.	   Ski	   and	   SnoN	   are	   also	   TGFβ	   target	   genes,	   thus	  
providing	   another	   negative	   feedback	   loop	   mechanism	   to	   ensure	   signalling	   can	   be	  
terminated	  (Itoh	  and	  ten	  Dijke	  2007).	  	  
	  




1.6.8	   Smad-­‐independent	   TGFβ	   signalling	   pathways	   and	   TGFβ	   receptor-­‐independent	  
activation	  of	  Smads	  
It	  is	  increasingly	  recognised	  that	  TGFβ	  can	  also	  activate	  other	  signalling	  pathways,	  via	  both	  
Smad-­‐dependent	  and	  Smad-­‐independent	  mechanisms.	  These	   include	  MAPK,	  ERK,	   JNK	  and	  
PI3K/Akt	   pathways	   [reviewed	   in	   (Massague	   2012,	   Mu	   et	   al.	   2012)].	   It	   has	   recently	   been	  
shown	   that	   TGFβR1	   within	   the	   TGFβR	   complex	   also	   interacts	   with	   and	   activates	   TNF-­‐
receptor-­‐associated	  factor	  6	  (TRAF6),	  causing	  activation	  of	  TGFβ-­‐associated	  kinase	  1	  (TAK1),	  
in	   epithelial	   cells	   [reviewed	   in	   (Landstrom	   2010)].	   This	   process	   is	   Smad-­‐independent	   and	  
leads	   to	   activation	   of	   JNK	   and	   p38	   MAP	   kinases,	   resulting	   in	   promotion	   of	   apoptosis	  
(Sorrentino	  et	  al.	  2008,	  Yamashita	  et	  al.	  2008a).	  
	  
In	  addition,	   it	  has	  been	  shown	  that	  R-­‐Smads	  can	  be	  phosphorylated,	  at	   the	  C-­‐terminal,	  by	  
other	   ligands	   independently	   of	   TGFβRs	   [reviewed	   in	   (Heldin	   and	   Moustakas	   2012)],	   for	  
example	   hepatocyte	   growth	   factor	   (HGF)	   can	   phosphorylate	   Smad2	   independently	   of	  
TGFβRs;	   the	  receptor	  kinase	  responsible	   for	   this	   is	  not	  known	  (de	  Caestecker	  et	  al.	  1998).	  
Furthermore,	  ERK/MAP	  kinases	  can	  phosphorylate	  Smads	   in	   their	   linker	   regions,	   inhibiting	  
them	  by	  preventing	  their	  accumulation	  in	  the	  nucleus;	  p38	  and	  JNK	  MAP	  kinases,	  as	  well	  as	  
TAK1,	  are	  also	  able	  to	  do	  this	  [reviewed	  in	  (Heldin	  and	  Moustakas	  2012)].	  BMPs	  and	  TGFβ	  
can	  also	  lead	  to	  phosphorylation	  of	  the	  linker	  region	  of	  Smad1,	  in	  addition	  to	  activation	  by	  
MAP	  kinases,	  and	  it	   is	  thought	  that	  this	  may	  represent	  a	  means	  of	   integrating	   inputs	  from	  
various	   sources,	   controlling	   the	   accumulation	   of	   Smad1	   in	   the	   nucleus,	   as	   linker	  
phosphorylation	   usually	   prevents	   its	   nuclear	   translocation	   (Sapkota	   et	   al.	   2007).	   It	   can	  
therefore	   be	   seen	   that,	   as	   more	   is	   discovered	   about	   TGFβ	   signalling	   pathways,	   their	  
complexity	  seems	  to	  increase.	  	  
	  
1.6.9	  TGFβ	  responses	  	  
TGFβ	   signalling	   is	   generally	   anti-­‐proliferative	   and/or	   pro-­‐apoptotic	   in	   most	   cell	   types,	  
although	  the	  effect	  varies	  according	  to	  the	  cell	  type	  and	  the	  context	  [reviewed	  in	  (Massague	  
2012)].	  The	  mechanisms	  of	  these	  responses	  in	  different	  cell	  types	  will	  now	  be	  discussed	  in	  
more	  detail.	  




1.6.9.1	  TGFβ	  responses	  in	  epithelial	  cells	  
In	   epithelial	   cells,	   TGFβ	   can	   induce	   cell	   cycle	   arrest	   or	   apoptosis.	   TGFβ	   induces	   the	   CDKIs	  
p15INK4B	  and	  p21CIP1/WAF1	  (hereafter	  referred	  to	  as	  p15	  and	  p21	  respectively),	  leading	  to	  cell	  
cycle	  arrest	  in	  the	  G1	  phase	  (Hannon	  and	  Beach	  1994,	  Datto	  et	  al.	  1995).	  TGFβ	  also	  leads	  to	  
repressed	   transcription	   of	   c-­‐Myc,	   via	   binding	   of	   Smad3	   to	   its	   promoter	   (Frederick	   et	   al.	  
2004).	   Smad3	   therefore	   seems	   to	   be	   particularly	   important	   for	   TGFβ-­‐induced	   cell	   cycle	  
arrest.	  The	  repression	  of	  c-­‐Myc	  is	  required	  for	  induction	  of	  p15,	  as	  c-­‐Myc	  normally	  represses	  
p15	  by	  binding	  to	   its	  promoter	  (Warner	  et	  al.	  1999,	  Seoane	  et	  al.	  2001);	  thus	  TGFβ	  and	  c-­‐
Myc	   functionally	   oppose	   each	   other.	   In	   epithelial	   cells,	   TGFβ	   causes	   repression	   of	   Id	  
proteins,	  resulting	  in	  growth	  arrest	  (Ling	  et	  al.	  2002).	  	  
	  
The	   mechanism	   of	   TGFβ-­‐induced	   apoptosis	   in	   epithelial	   cells	   is	   less	   well	   understood.	  
Overexpression	   of	   Smad3,	   or	   to	   a	   lesser	   extent	   Smad2,	   can	   promote	   apoptosis	   in	   lung	  
epithelial	   cells	   (Yanagisawa	  et	  al.	  1998)	  and	  a	  dominant	  negative	  Smad3,	  or	  expression	  of	  
Smad7,	  can	  inhibit	  TGFβ-­‐mediated	  apoptosis	  in	  a	  hepatoma	  cell	  line	  (Yamamura	  et	  al.	  2000).	  
However,	   Smad7	  can	  either	  promote	  or	   inhibit	   apoptosis	   in	  different	   contexts	   (Patil	   et	  al.	  
2000,	  Yamamura	  et	  al.	  2000).	  Smad3	  is	  required	  for	  TGFβ-­‐induced	  apoptosis,	  but	  not	  TGFβ-­‐
induced	  arrest,	  in	  murine	  mammary	  epithelium	  (Yang	  et	  al.	  2002),	  and	  is	  also	  necessary	  for	  
TGFβ-­‐induced	  apoptosis	  in	  a	  rat	  hepatoma	  cell	  line	  (Kim	  et	  al.	  2002).	  
	  
The	   determinant	   of	   TGFβ	   responses	   in	   epithelial	   cells,	   in	   terms	   of	   apoptosis	   or	   cell	   cycle	  
arrest,	   may	   involve	   cross-­‐talk	   between	   TGFβ	   signalling	   and	   the	   PI3K/Akt	   pathway.	   In	  
hepatocytes,	   activated	   (phosphorylated)	   Akt	   can	   interact	   with	   unphosphorylated	   Smad3,	  
sequestering	   the	   Smad3	   so	   that	   it	   is	   unable	   to	   be	   phosphorylated	   and	   accumulate	   in	   the	  
nucleus.	  Since	  TGFβ-­‐induced	  apoptosis	  in	  epithelial	  cells	  depends	  on	  Smad3	  but	  not	  Smad2,	  
this	  prevents	  TGFβ	  from	  inducing	  apoptosis,	  but	  phosphorylation	  and	  nuclear	  accumulation	  
of	   Smad2	   can	   continue	   in	   response	   to	   TGFβ,	   which	   can	   thus	   cause	   TGFβ-­‐induced	   arrest	  
(Conery	   et	   al.	   2004,	   Remy	   et	   al.	   2004).	   Thus	   it	   has	   been	   proposed	   that	   the	   ratio	   of	  
Smad3:Akt	  expression	  determines	  whether	  the	  response	  to	  TGFβ	  is	  apoptosis	  or	  arrest,	  i.e.	  
a	  ratio	  above	  a	  certain	  threshold	  leads	  to	  apoptosis	  whereas	  below	  this	  threshold	  cell	  cycle	  
arrest	  occurs	  (Conery	  et	  al.	  2004).	  	  	  




1.6.9.2	  TGFβ	  responses	  in	  normal	  B	  cells	  
TGFβ	  can	  also	  induce	  apoptosis	  or	  growth	  arrest	   in	  mature	  B	  cells.	  Primary	  B	  cells	  purified	  
from	   peripheral	   blood	   or	   umbilical	   cord	   blood	   undergo	   spontaneous	   apoptosis,	   which	   is	  
increased	  with	  TGFβ	  treatment	  (Douglas	  et	  al.	  1997,	  Lagneaux	  et	  al.	  1998).	  The	  importance	  
of	   Smad3	   for	   apoptosis	   is	   less	   understood	   in	   B	   cells	   than	   epithelial	   cells,	   although	   TGFβ-­‐
induced	   apoptosis	   occurs	   via	   Smad3	   in	  murine	   B	   cells	   (Wildey	   et	   al.	   2003),	   and	   a	   recent	  
study	  has	  demonstrated	  a	  specific	  role	  for	  SMAD3	  binding	  to	  the	  PUMA	  promoter	  in	  TGFβ-­‐
induced	  apoptosis	   in	  human	  BL	  cells	   (Spender	  et	  al.	  2013).	  However,	   there	   is	  currently	  no	  
evidence	  that	  the	  system	  based	  on	  a	  threshold	  of	  Smad3:Akt	  determining	  TGFβ	  response,	  as	  
found	  in	  epithelial	  cells,	  occurs	  in	  B	  cells.	  	  
	  
GC	  B	  cells	  are	  primed	  for	  apoptosis,	  with	  increased	  expression	  of	  FAS,	  c-­‐Myc	  and	  BAX,	  and	  
decreased	  expression	  of	  BCL2,	  compared	  to	  naïve	  or	  memory	  B	  cells	  (Martinez-­‐Valdez	  et	  al.	  
1996).	  TGFβ-­‐induced	  apoptosis	  is	  also	  important	  in	  GC	  B	  cells,	  leading	  to	  ‘death	  by	  neglect’	  
in	  cells	   lacking	  high	  affinity	  receptors	  for	  antigen	  (Spender	  et	  al.	  2009,	  Spender	  and	  Inman	  
2011).	   Purified	   CD77+	   centroblasts	   undergo	   spontaneous	   apoptosis,	   but	   can	   be	   partly	  
rescued	   from	   this	  by	   the	  mitogen	  phorbol	  myristate	  acetate	   (PMA)	   (Spender	  et	   al.	   2009).	  
Blocking	   autocrine	   TGFβ	   signalling	   with	   the	   TGFβR1	   inhibitor	   SB431542	   also	   led	   to	   a	  
reduction	   in	   spontaneous	   apoptosis,	   confirming	   that	   autocrine/paracrine	   signalling	  
contributes	   to	   the	   default	   apoptotic	   state	   in	   GC	   B	   cells.	   This	   was	   shown	   to	   occur	   via	  
induction	  of	  BIK	  and	  down-­‐regulation	  of	  BCL-­‐XL	  (Spender	  et	  al.	  2009).	  
	  
The	  majority	  of	  studies	  on	  the	  anti-­‐proliferative	  effects	  of	  TGFβ	  in	  normal	  B	  cells	  have	  been	  
done	  using	  B	  cells	  isolated	  and	  purified	  from	  peripheral	  blood	  or	  tonsil	  extracts.	  Since	  these	  
are	   naturally	   quiescent,	   it	   is	   necessary	   to	   artificially	   stimulate	   them	   to	   proliferate	   before	  
treating	  with	  TGFβ,	  generally	  by	  using	  mitogens	  such	  as	  PMA,	  anti-­‐IgM,	  or	  cytokines	  such	  as	  
IL-­‐4.	  In	  these	  artificially	  stimulated	  B	  cells,	  TGFβ	  induces	  cell	  cycle	  arrest	  in	  G1	  (Kehrl	  et	  al.	  
1986,	  Blomhoff	  et	  al.	  1987,	  Smeland	  et	  al.	  1987).	  TGFβ1	  is	  secreted	  by	  resting	  B	  cells,	  with	  
secretion	   increased	   upon	   B	   cell	   activation,	   thus	   autocrine/paracrine	   TGFβ1	   production	  
probably	  limits	  B	  cell	  proliferation	  under	  normal	  circumstances	  (Kehrl	  et	  al.	  1986,	  Kremer	  et	  
al.	  1992).	  




More	   recently	   the	  effects	   of	   TGFβ	  have	  been	   investigated	   in	  human	   centroblasts	   isolated	  
and	  purified	  (by	  CD77	  positive	  selection)	  from	  human	  tonsil	  extracts	  (Spender	  et	  al.	  2009).	  
CD77+	  centroblasts	  are	  naturally	  proliferating,	  and	  TGFβ	  inhibits	  their	  proliferation	  (Spender	  
et	  al.	  2009).	  Autocrine	  TGFβ	  signalling	  via	  TGFβR1	  also	  occurs	  in	  centroblasts.	  	  	  
	  
1.6.10	  Dysregulation	  of	  TGFβ	  signalling	  in	  malignancies	  
1.6.10.1	  Dysregulation	  of	  TGFβ	  signalling	  in	  epithelial	  cell	  malignancies	  
In	  non-­‐haematopoietic	  malignancies,	  TGFβ	  can	  have	  both	  tumour	  suppressive	  and	  tumour	  
promoting	   effects.	   Often,	   its	   effects	   are	   tumour	   suppressive	   initially	   but	   then	   it	   becomes	  
tumour	  promoting	   in	   association	  with	  progression	  of	   the	   tumour,	   generally	   in	   association	  
with	   increased	   production	   of	   TGFβ1	   by	   the	   tumour	   itself	   (Bernabeu	   et	   al.	   2009).	   In	   this	  
tumour	   promoting	   stage	   TGFβ	   can	   promote	   epithelial	   to	   mesenchymal	   transition,	  
invasiveness	   and	  metastasis,	   as	   it	   reduces	   cell-­‐cell	   adhesion	   and	   increases	   cell	  motility	   of	  
epithelial	   cells	   (Elliott	   and	  Blobe	  2005,	  Hannigan	  et	  al.	   2010).	   Increased	  TGFβ1	  expression	  
and/or	   secretion	  correlate	  with	  adverse	  prognosis	   in	  breast,	  ovarian	  and	  prostate	   cancers	  
(Bristow	  et	  al.	  1999,	  Shariat	  et	  al.	  2004,	  Desruisseau	  et	  al.	  2006).	  	  
	  
Many	   non-­‐haematopoietic	   tumours	   show	   resistance	   to	   TGFβ	   signalling,	   often	   associated	  
with	   mutations	   or	   reduced	   expression	   of	   TGFβR2	   or	   TGFβR1,	   or	   abnormalities	   of	   other	  
signalling	   components	   such	   as	   Smad4	   mutations	   (Elliott	   and	   Blobe	   2005).	   For	   instance,	  
TGFβR2	  has	  been	   shown	   to	  be	  mutated	   in	   colorectal	   tumours	   especially	   those	   associated	  
with	   microsatellite	   instability	   (Markowitz	   et	   al.	   1995).	   Loss	   of	   TGFβR2	   expression,	   in	   the	  
absence	  of	  somatic	  mutation,	  occurs	  in	  prostate	  cancer	  (Li	  et	  al.	  2008),	  and	  CpG	  methylation	  
of	  the	  TGFβR2	  promoter	  is	  found	  in	  lung	  and	  prostate	  cancers	  (Zhang	  et	  al.	  2004,	  Zhao	  et	  al.	  
2005).	  Changes	  in	  histone	  acetylation,	  as	  well	  as	  CpG	  methylation,	  of	  the	  TGFβR2	  promoter	  
have	   been	   shown	   in	   lung	   cancer	   cell	   lines,	   correlating	   with	   loss	   of	   growth-­‐inhibitory	  
response	  to	  TGFβ	  (Osada	  et	  al.	  2001).	  TGFβR2	  is	  mutated	  or	  its	  expression	  also	  low	  in	  gastric	  
carcinoma	  cells,	  correlating	  with	  loss	  of	  sensitivity	  to	  TGFβ	  (Park	  et	  al.	  1994).	  
	  
TGFβR3	  also	   appears	   to	  have	   tumour	   suppressor	   functions	   in	   several	   non-­‐haematopoietic	  
malignancies.	  It	  is	  down-­‐regulated	  in	  renal,	  endometrial,	  prostate,	  breast,	  lung,	  ovarian	  and	  




pancreatic	  carcinomas	  (Florio	  et	  al.	  2005,	  Dong	  et	  al.	  2007,	  Hempel	  et	  al.	  2007,	  Turley	  et	  al.	  
2007,	  Finger	  et	  al.	  2008b,	  Gordon	  et	  al.	  2008,	  Margulis	  et	  al.	  2008,	  Cooper	  et	  al.	  2010).	  This	  
loss	   of	   TGFβR3	   expression	   often	   results	   in	   decreased	   responsiveness	   to	   TGFβ	   signalling	  
(Cooper	  et	  al.	  2010),	  although	  in	  some	  cases	  the	  effects	  are	  independent	  of	  canonical	  TGFβ	  
signalling,	   for	   instance	   TGFβR3	   signals	   through	   the	  MAPK	   pathway	   to	   cause	   apoptosis	   in	  
renal	  cell	  carcinoma	  cells	  (Margulis	  et	  al.	  2008).	  	  
	  
1.6.10.2	  Dysregulation	  of	  TGFβ	  signalling	  in	  B	  cell	  malignancies	  	  
Unlike	   in	   carcinomas,	   TGFβ	   seems	   to	   only	   have	   tumour	   suppressive	   functions	   in	  
haematopoietic	  cells,	  since	  although	  increased	  TGFβ	  levels	  are	  seen	  in	  some	  haematopoietic	  
malignancies,	   there	   is	   no	   evidence	   that	   this	   is	   correlated	   with	   more	   aggressive	   disease	  
(Dong	  and	  Blobe	  2006).	  	  
	  
Burkitt	  Lymphoma	  
Although	  several	  EBV-­‐negative	  BL	  lines,	  including	  Ramos	  and	  BL41,	  undergo	  apoptosis	  after	  
TGFβ	   treatment	   (Chaouchi	   et	   al.	   1995),	   TGFβ	   can	   also	   induce	   growth	   arrest	   in	   BL.	   Some	  
studies	  have	   shown	  both	  TGFβ-­‐induced	  G1	  arrest	  and	  apoptosis	  occurring	   in	   the	   same	  BL	  
cell	  lines	  (MacDonald	  et	  al.	  1996,	  Schrantz	  et	  al.	  1999).	  However,	  in	  a	  study	  investigating	  the	  
effect	   of	   TGFβ	   in	   multiple	   BL	   lines,	   the	   majority	   of	   EBV-­‐negative	   BL	   underwent	  
predominantly	  apoptosis	  rather	  than	  G1	  arrest	  (Inman	  and	  Allday	  2000b).	  	  
	  
TGFβ	  can	  induce	  apoptosis	  by	  several	  different	  mechanisms	  in	  BL	  cells,	  including	  activation	  
of	  caspase	  3,	  which	  results	   in	  cleavage	  of	  poly	  ADP-­‐ribose	  polymerase	  (PARP)	  (Saltzman	  et	  
al.	  1998,	  Schrantz	  et	  al.	  1999,	  Inman	  and	  Allday	  2000a).	  TGFβ	  also	  induces	  BIK,	  a	  BH3-­‐only	  
pro-­‐apoptotic	   protein,	   and	   represses	   BCL-­‐XL,	   a	   pro-­‐survival	   factor,	   in	   BL	   (Saltzman	   et	   al.	  
1998,	  Spender	  et	  al.	  2009).	  A	  more	  recent	  study	  has	  shown	  that	  TGFβ	  can	  also	  induce	  early	  
apoptosis	   in	  BL	  cells	  via	  up-­‐regulation	  of	  p53-­‐upregulated	  modulator	  of	  apoptosis	   (PUMA)	  
(Spender	  et	  al.	  2013).	  Expression	  of	  CD20	  is	  required	  for	  survival	  of	  Ramos	  cells,	  and	  TGFβ	  
leads	  to	  reduced	  expression	  of	  CD20,	  thus	  this	  is	  another	  mechanism	  by	  which	  TGFβ	  induces	  
apoptosis	  in	  BL	  cells	  (Kawabata	  et	  al.	  2013).	  
	  




The	   EBV-­‐negative	   BL	   line	   BL2	   lacks	   expression	   of	   BIM	   but	   still	   undergoes	   apoptosis	   with	  
TGFβ	  treatment,	  and	  TGFβ	  does	  not	  induce	  expression	  of	  BIM	  in	  several	  EBV-­‐negative	  BL	  cell	  
lines,	  suggesting	  that	  TGFβ-­‐induced	  apoptosis	  does	  not	  occur	  via	  BIM	  in	  these	  cells	  (Spender	  
et	   al.	   2009).	  However,	   Bim	   is	   induced	   by	   TGFβ	   in	   the	  murine	   B	   cell	   lymphoma	   line	  WEHI	  
(Wildey	  et	  al.	  2003),	  and	  thus	  human	  and	  murine	  B	  lymphoma	  cell	  lines	  may	  have	  different	  
mechanisms	   of	   TGFβ-­‐induced	   apoptosis.	   It	   has	   been	   suggested	   that	   this	   differential	  
response	   may	   be	   due	   to	   a	   difference	   in	   sequence	   of	   the	   BIK	   promoter,	   as	   the	   human	  
promoter	   has	   a	   SMAD	   binding	   element	   whereas	   the	  murine	   and	   rat	   promoters	   lack	   this	  
sequence	   (Spender	   et	   al.	   2009).	   Thus	   Spender	   and	   Inman	   hypothesise	   that	   TGFβ-­‐induced	  
apoptosis	   occurs	   via	   up-­‐regulation	   of	   Bim	   in	   the	   mouse	   but	   via	   up-­‐regulation	   of	   BIK	   in	  
human	   BL	   (Spender	   et	   al.	   2009).	   Bik	   antagonises	  MCL-­‐1,	   which	   in	   turn	   inhibits	   BAX/BAK	  
(Shimazu	  et	  al.	  2007),	  and	  therefore	  TGFβ-­‐mediated	  induction	  of	  BIK	  relieves	  the	  inhibition	  
of	  BAX/BAK,	  resulting	  in	  apoptosis	  via	  the	  intrinsic	  pathway.	  	  	  
	  
In	  BL	   cells,	   in	  which	   c-­‐Myc	   is	   deregulated,	   the	  mechanism	  of	   TGFβ-­‐induced	  growth	  arrest	  
appears	  to	  be	  different	  from	  that	  in	  epithelial	  cells,	  although	  the	  exact	  mechanism	  varies	  for	  
specific	  cell	  lines.	  In	  contrast	  to	  epithelial	  cells,	  where	  TGFβ	  down-­‐regulates	  Id	  expression,	  in	  
B	   cells	   TGFβ	   induces	   Id2	   and	   Id3	   (Kee	  et	   al.	   2001,	   Sugai	   et	   al.	   2003)	   and	   in	  BL	   cells	   TGFβ	  
causes	  induction	  of	  Id1	  and	  Id2	  (Spender	  and	  Inman	  2009b).	  	  
	  
The	  EBV-­‐negative	  BL	  cell	  line	  CA46	  responds	  to	  TGFβ	  by	  cell	  cycle	  arrest	  but	  not	  apoptosis,	  
despite	  induction	  of	  BIK	  (Inman	  and	  Allday	  2000b,	  Spender	  et	  al.	  2009).	  However,	  these	  cells	  
also	   fail	   to	   undergo	   apoptosis	   in	   response	   to	   anti-­‐IgM	   (Kaptein	   et	   al.	   1996);	   this	  may	   be	  
explained	  by	  their	  very	  low	  expression	  of	  Bim	  (Clybouw	  et	  al.	  2008)	  and	  in	  particular	  lack	  of	  
BAX	   expression	   (Spender	   et	   al.	   2009).	   The	   mechanism	   of	   TGFβ-­‐induced	   growth	   arrest	   in	  
CA46	   BL	   cells	   occurs	   independently	   of	   c-­‐Myc	   repression,	   Id	   repression	   and	   p15	   and	   p21	  
induction;	  instead	  in	  these	  cells	  TGFβ	  represses	  E2F1	  leading	  to	  growth	  arrest	  (Spender	  and	  
Inman	  2009b).	  However,	  TGFβ	  induces	  p21	  in	  Ramos,	  an	  EBV-­‐negative	  BL	  line	  (Di	  Bartolo	  et	  
al.	  2008)	  and	  thus	  the	  mechanism	  of	  TGFβ-­‐induced	  arrest	  may	  differ	  between	  BL	  cell	  lines.	  	  
The	  down-­‐regulation	  of	  E2F1	  by	  TGFβ1	  was	  confirmed	  in	  a	  human	  B	  lymphoma	  RL	  and	  the	  
CA46	  BL	  cell	  lines	  (Chen	  et	  al.	  2012),	  leading	  to	  reduced	  levels	  of	  p14ARF,	  in	  turn	  preventing	  




mutant	  p53	  from	  inducing	  p21	  –	  thus	  this	  is	  another	  mechanism	  by	  which	  TGFβ	  can	  induce	  
growth	  arrest	  in	  B	  lymphoma	  cells	  (Chen	  et	  al.	  2012).	  	  
	  
Chronic	  lymphocytic	  leukaemia	  
B	  cell	  chronic	  lymphocytic	  leukaemia	  (CLL)	  is	  an	  accumulation	  of	  clonal	  mature	  B	  cells	  that	  
are	   largely	   non-­‐cycling	   in	   vivo.	   	   B	   cells	   extracted	   from	   peripheral	   blood	   (PB)	   of	   healthy	  
individuals,	  or	   from	  umbilical	   cord	  blood,	   show	   increased	  apoptosis	  with	  TGFβ	   treatment,	  
whereas	   B	   cells	   extracted	   from	   peripheral	   blood	   of	   CLL	   patients	   are	   resistant	   to	   TGFβ-­‐
induced	  apoptosis	  (Douglas	  et	  al.	  1997,	  Lagneaux	  et	  al.	  1998).	  B	  cells	  extracted	  from	  PB	  of	  
healthy	   individuals	   are	   not	   able	   to	   survive	   for	   long	   in	   culture	   and	   do	   not	   proliferate;	  
however,	  they	  will	  proliferate	  for	  a	  short	  time	  (a	  few	  days)	  if	  stimulated	  with	  certain	  agents	  
such	  as	  PMA,	  IL2	  or	  anti-­‐Ig;	  freshly	  extracted	  B	  cells	  from	  CLL	  patients	  can	  also	  be	  stimulated	  
to	  proliferate	  by	  these	  agents,	  and	  in	  some	  cases	  TGFβ	  inhibits	  their	  proliferation,	  whereas	  
cells	   from	  other	  patients	   are	   completely	   resistant	   to	   the	  anti-­‐proliferative	  effects	  of	   TGFβ	  
(Lotz	  et	  al.	  1994,	  DeCoteau	  et	  al.	  1997,	  Douglas	  et	  al.	  1997,	  Lagneaux	  et	  al.	  1997,	  Schiemann	  
et	  al.	  2004).	  This	  TGFβ-­‐sensitivity	  or	  resistance	  does	  not	  appear	  to	  obviously	  correlate	  with	  
disease	  stage,	  although	  the	  numbers	  of	  patients	  were	  small	  in	  all	  these	  studies.	  No	  change	  
in	   expression	   of	   TGFβR2	   has	   been	   detected	   in	   CLL	   cells,	   whereas	   specific	   decrease-­‐of-­‐
function	  mutations	  of	  TGFβR1,	  without	  alteration	  in	  mRNA	  expression,	  have	  been	  identified	  
in	   TGFβ-­‐resistant	   CLL	   cases	   (Schiemann	   et	   al.	   2004).	   Lagneaux	   et	   al	   show	   a	   significant	  
reduction	  in	  TGFβR	  expression	  in	  TGFβ-­‐resistant	  compared	  to	  TGFβ-­‐sensitive	  CLL	  cells,	  but	  it	  
is	  not	   clear	  which	  TGFβR	  were	  being	  measured	   (Lagneaux	  et	  al.	   1997).	   In	   some	  cases	  CLL	  
cells	  thus	  develop	  resistance	  to	  the	  tumour	  suppressive	  effects	  of	  TGFβ	  in	  vitro,	  presumably	  
allowing	  them	  to	  escape	  immune	  regulation	  in	  vivo;	  nevertheless,	  this	  does	  not	  seem	  to	  be	  
required	  for	  CLL	  progression.	  It	  could	  be	  hypothesised	  that	  in	  those	  which	  remain	  sensitive	  
to	   TGFβ,	   other	   apoptotic	   tumour	   suppressor	   pathways	   are	   de-­‐regulated,	   for	   instance	  
deregulation	  of	  the	  p53	  pathway	  as	  a	  result	  of	  deletions	  on	  the	  short	  arm	  of	  chromosome	  
17	  are	  associated	  with	  a	  particularly	  poor	  prognosis	  in	  CLL	  (Swerdlow	  et	  al.	  2008).	  None	  of	  
the	  quoted	  studies	  on	  TGFβ	  sensitivity	  in	  CLL	  have	  investigated	  this.	  	  	  	  
	  
B	   cells	   from	   CLL	   patients,	   as	   well	   as	   B	   cells	   extracted	   from	   blood	   of	   healthy	   volunteers,	  
express	  TGFβ1	  mRNA	  and	   secrete	  TGFβ1,	  with	  TGFβ1	  generally	  detectable	  within	  plasma.	  




There	  are	  conflicting	  results	  for	  whether	  or	  not	  the	  level	  of	  TGFβ1	  is	  increased	  in	  plasma	  of	  
CLL	  patients	  compared	  to	  normal	  controls	  (Kremer	  et	  al.	  1992,	  Lotz	  et	  al.	  1994,	  Douglas	  et	  
al.	   1997).	   However,	   decreased	   plasma	   TGFβ1	   levels	   have	   been	   shown	   to	   correlate	   with	  
disease	  progression	  (Friedenberg	  et	  al.	  1999).	  
	  
Two	   studies	   have	   reported	   increased	   TGFβR3	   expression	   in	   B	   cells	   from	   CLL	   patients	  
compared	  with	   normal	   or	  memory	  B	   cells	   on	   gene	   expression	  profiling	   (Klein	   et	   al.	   2001,	  
Jelinek	  et	  al.	  2003),	  although	  the	  mechanism	  for	  this	  does	  not	  thus	  far	  appear	  to	  have	  been	  
further	  explored.	  
	  
Diffuse	  Large	  B	  cell	  Lymphoma	  
A	  study	  comparing	  two	  diffuse	  large	  B	  cell	  lymphoma	  (DLBCL)	  cell	  lines	  showed	  that	  one	  was	  
resistant	  to	  TGFβ	  signalling	  and	  lacked	  expression	  of	  TGFβR2	  on	  the	  cell	  surface	  compared	  
to	  the	  TGFβ-­‐responsive	  line	  (Chen	  et	  al.	  2007).	   In	  the	  TGFβ-­‐sensitive	  line,	  which	  expressed	  
TGFβR2,	   TGFβ	   induced	   phosphorylation	   of	   Smad2	   and	   Smad3,	   and	   ectopically	   expressed	  
TGFβR2	  also	  led	  to	  TGFβ-­‐mediated	  induction	  of	  phosphorylated	  Smad2/3	  (Chen	  et	  al.	  2007).	  
Therefore,	   lack	  of	  TGFβR2	  could	  be	  a	  mechanism	  contributing	   to	   tumour	  development.	   In	  	  
DLBCL	   biopsy	   samples,	   TGFβR2	   was	   relatively	   over-­‐expressed	   in	   activated	   B	   cell-­‐like	  
(thought	  to	  be	  derived	  from	  a	  post-­‐GC	  B	  cell,	  and	  which	  have	  a	  worse	  prognosis)	  compared	  
to	  GC-­‐like	  subtype	  (Alizadeh	  et	  al.	  2000).	  It	  is	  possible	  that	  in	  those	  with	  TGFβR2	  expression,	  
other	   apoptotic	   pathways	   had	   been	   deregulated,	   which	   if	   required	   for	   chemotherapy-­‐
induced	   apoptosis	   could	   lead	   to	   relative	   chemotherapy	   resistance	   and	   hence	   a	   worse	  
prognosis.	  	  	  
	  
Multiple	  Myeloma	  	  
In	  multiple	  myeloma,	  both	   the	  myeloma	  cells	  and	  surrounding	  bone	  marrow	  stromal	  cells	  
secrete	  more	  TGFβ	  than	  normal	  B	  cells	  (Urashima	  et	  al.	  1996).	  	  More	  recently,	  TGFβR3	  was	  
shown	  to	  be	  down-­‐regulated	  in	  multiple	  myeloma,	  with	  its	  restoration	  leading	  to	  inhibition	  
of	  cell	  growth	  and	  proliferation.	  However,	   the	  mechanism	  of	   this	  was	  via	  up-­‐regulation	  of	  
p21	   and	   p27	   when	   TGFβR3	   was	   expressed	   rather	   than	   by	   the	   enhancement	   of	   ligand-­‐
presentation	  by	  TGFβR3	  (Lambert	  et	  al.	  2011).	  	  
	  




1.6.11	  BMP	  signalling	  in	  normal	  B	  cells	  and	  malignancies	  	  
Relatively	   little	   is	   known	   about	   the	   effects	   of	   BMPs	   in	   B	   cells.	   BMP2,	   BMP4	   and	   BMP7	  
control	   differentiation	   of	   haematopoietic	   progenitors	   (Bhatia	   et	   al.	   1999,	   Detmer	   and	  
Walker	  2002,	  Chadwick	  et	   al.	   2003)	   and	  BMP2,	  BMP4	  and	  BMP6	   inhibit	   differentiation	  of	  
mature	  B	  cells	  into	  plasma	  cells	  (Huse	  et	  al.	  2011).	  BMP6	  inhibits	  proliferation	  of	  B	  lymphoid	  
progenitors	  (Kersten	  et	  al.	  2006)	  and	  of	  resting	  B	  cells	  stimulated	  to	  proliferate	  by	  anti-­‐IgM	  
(Kersten	  et	  al.	  2005).	  Resting	  B	  cells,	   including	  both	  naïve	  and	  memory	  B	  cells,	  express	  the	  
BMP	  receptors	  ALK2	  and	  BMPRIB	  (ALK6).	   In	   these	  cells,	  BMP6	   induced	  phosphorylation	  of	  
Smad1/5/8	  and	  induction	  of	  Id1	  (Kersten	  et	  al.	  2005).	  Another	  study	  showed	  expression	  of	  
ALK2	  and	  BMPRIA	  (ALK3)	  in	  memory	  B	  cells	  (Seckinger	  et	  al.	  2009).	  Treatment	  of	  naïve	  and	  
memory	  B	  cells	  with	  CD40	  ligand	  and	  IL-­‐21	  led	  to	  induction	  of	  ALK2	  expression,	  which	  would	  
enhance	  signalling	  by	  BMP6	  and	  BMP7	  (Huse	  et	  al.	  2011).	  	  
	  
Although	  BMPs	  are	  of	  major	  importance	  in	  the	  regulation	  of	  bone	  and	  cartilage	  formation,	  
there	   is	   also	   limited	   evidence	   to	   suggest	   they	  may	   be	   important	   in	   development	   of	   non-­‐
haematopoietic	   malignancies,	   including	   promotion	   of	   invasiveness	   and	   metastasis.	  
However,	   the	   data	   are	   generally	   conflicting,	   with	   several	   studies	   also	   showing	   tumour	  
suppressive	  properties	   in	  vitro	  and	   in	  vivo	  [reviewed	  in	  (Thawani	  et	  al.	  2010)].	  Few	  studies	  
have	   investigated	   the	   effects	   of	   BMP	   signalling	   in	   B	   cell	   malignancies;	   these	   have	   been	  
restricted	   to	   myeloma,	   presumably	   because	   of	   the	   propensity	   for	   myeloma	   to	   alter	   the	  
processes	  of	  bone	  formation	  and	  resorption,	   leading	  clinically	   to	   lytic	  bone	   lesions.	  BMP2,	  
BMP4,	   BMP6	   and	   BMP7	   have	   been	   shown	   to	   be	   anti-­‐proliferative	   and	   pro-­‐apoptotic	   in	  
myeloma	   cells	   (Kawamura	   et	   al.	   2000,	   Hjertner	   et	   al.	   2001,	   Ro	   et	   al.	   2004,	   Fukuda	   et	   al.	  
2006b,	  Seckinger	  et	  al.	  2009,	  Holien	  et	  al.	  2012).	  In	  myeloma	  cell	  lines	  which	  were	  resistant	  
to	  the	  growth-­‐inhibitory	  effects	  of	  BMP2	  and	  BMP4,	  due	  to	  a	  lack	  of	  type	  I	  BMP	  receptors	  
ALK3	   and	   ALK6,	   it	   was	   demonstrated	   that	   BMP5,	   BMP6	   and	   BMP7	   were	   anti-­‐









1.7	  Effects	  of	  EBV	  infection	  on	  TGFβ	  signalling	  
1.7.1	  Effects	  of	  EBV	  on	  TGFβ-­‐induced	  apoptosis	  and	  inhibition	  of	  proliferation	  	  
Many	  studies	  have	  investigated	  the	  effects	  of	  EBV	  on	  TGFβ	  signalling	  in	  B	  cells;	  however,	  the	  
majority	  have	  assessed	  responses	  to	  TGFβ	  rather	  than	  TGFβ	  signalling	  itself.	  Several	  studies	  
have	   measured	   the	   inhibition	   of	   proliferation	   of	   cells	   by	   TGFβ,	   but	   without	   determining	  
whether	   this	   occurs	   via	   increased	   apoptosis	   or	   by	   growth	   arrest.	   Apoptosis	   and	   growth	  
arrest	   are	   both	   regulated	   by	  multiple	   pathways	   (see	   sections	   1.5.2	   and	   1.5.3),	   and	   latent	  
EBV	   affects	   many	   components	   of	   these.	   Furthermore,	   these	   studies	   have	   been	   done	   in	  
many	  different	  cell	  lines,	  which	  are	  mostly	  tumour-­‐derived,	  and	  therefore	  characteristics	  of	  
the	  particular	  tumours	  may	  account	  for	  some	  of	  the	  discrepancies	  between	  studies.	  	  	  
	  
Many	  investigators	  have	  shown	  that	  the	  presence	  of	  latency	  III	  EBV	  in	  B	  cells	  renders	  them	  
resistant	  to	  the	  effects	  of	  TGFβ	  (Kehrl	  et	  al.	  1986,	  Blomhoff	  et	  al.	  1987,	  Janssen	  et	  al.	  1990,	  
Altiok	  et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  1992,	  Altiok	  et	  al.	  1993,	  Arvanitakis	  et	  al.	  
1995,	  MacDonald	  et	  al.	  1996,	  Inman	  and	  Allday	  2000b).	  In	  some	  cases,	  TGFβ	  even	  appeared	  
to	   increase	   the	   proliferation	   of	   EBV-­‐infected	   cells	   (Blomhoff	   et	   al.	   1987).	   EBV-­‐negative	   B	  
cells,	  and	  B	  cells	  expressing	   latency	   I	   (type	   I	  BL)	  generally	   remain	  sensitive	   to	   the	  growth-­‐
inhibitory	  effects	  of	  TGFβ	   (Blomhoff	  et	  al.	  1987,	  Smeland	  et	  al.	  1987,	   Janssen	  et	  al.	  1990,	  
Altiok	  et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  1993,	  Arvanitakis	  et	  al.	  1995,	  Chaouchi	  et	  
al.	  1995,	  MacDonald	  et	  al.	  1996,	  Inman	  and	  Allday	  2000b).	  However,	  there	  have	  been	  some	  
reported	  exceptions,	  for	  example	  Akata,	  a	  group	  I	  EBV-­‐positive	  BL	  cell	  line,	  was	  resistant	  to	  
the	   effects	   of	   TGFβ	   (Fukuda	   et	   al.	   2006a,	   Chen	   et	   al.	   2007).	   There	   are	   also	   some	  
discrepancies	   between	   studies,	   for	   instance	   Raji	   cells	   (type	   III	   BL)	   were	   sensitive	   to	   the	  
effects	  of	  TGFβ	  in	  (Fukuda	  et	  al.	  2006a),	  but	  resistant	  in	  (Wang	  et	  al.	  2008)	  and	  in	  the	  EBV-­‐
negative	  BL	  line	  Ramos	  TGFβ	  can	  induce	  apoptosis	  (Chaouchi	  et	  al.	  1995,	  Inman	  and	  Allday	  
2000b,	  Di	  Bartolo	  et	  al.	  2008,	  Kawabata	  et	  al.	  2013),	  cell	  cycle	  arrest	  (Blomhoff	  et	  al.	  1987,	  
Altiok	  et	  al.	  1993)	  or	  be	  resistant	  to	  TGFβ	  even	  at	  high	  doses	  (Wang	  et	  al.	  2008).	  	  
	  
Previous	   studies	   investigating	   the	   effect	   of	   individual	   latent	   proteins	   on	   TGFβ	   responses	  
have	  largely	  focussed	  on	  LMP1,	  since	  this	  had	  been	  shown	  to	  be	  transforming	  in	  rodent	  cells	  
and	  nude	  mice	  (Wang	  et	  al.	  1985).	  These	  studies	  were	  mostly	  done	  by	  stable	  transfection	  of	  




EBV-­‐negative	   BL	   cell	   lines	   with	   an	   LMP1	   expression	   vector,	   and	   have	   shown	   discrepant	  
results	   for	   whether	   or	   not	   LMP1	   expression	   was	   sufficient	   for	   resistance	   to	   the	   growth-­‐
inhibitory	  effects	  of	  TGFβ	  (Wang	  et	  al.	  1988,	  Altiok	  et	  al.	  1991,	  Arvanitakis	  et	  al.	  1995,	  Inman	  
and	   Allday	   2000b).	   Expression	   of	   LMP1	   alone	   in	   other	   cell	   types,	   including	   fibroblasts,	  
epithelial	  cells	  and	  hepatoma	  cells,	  however,	  was	  sufficient	  for	  resistance	  to	  TGFβ-­‐induced	  
growth	   inhibition	   (Takanashi	   et	   al.	   1999,	   Lo	  et	   al.	   2010).	   Similarly,	   LMP2A	  expression	   in	   a	  
gastric	   carcinoma	   cell	   line	   was	   sufficient	   to	   completely	   inhibit	   TGFβ-­‐induced	   apoptosis,	  
whereas	  in	  the	  EBV-­‐negative	  BL	  line	  Ramos	  LMP2A	  expression	  only	  partially	  blocked	  TGFβ-­‐
induced	  apoptosis	   (Fukuda	  and	  Longnecker	  2004).	  Thus	  although	  LMP1	  or	  LMP2A	  may	  be	  
sufficient	  to	  block	  the	  effects	  of	  TGFβ	  in	  epithelial	  cells,	  the	  situation	  in	  B	  cells	  is	  less	  clear.	  	  
	  
There	  has	  been	  no	  investigation	  until	  now	  of	  the	  effect	  of	  expression	  of	  the	  EBNA3	  proteins	  
on	  sensitivity	  to	  TGFβ	  or	  TGFβR	  expression,	  even	  though	  EBNA3	  proteins	  are	  expressed	   in	  
latency	  III,	  which	  had	  been	  shown	  to	  confer	  resistance	  to	  TGFβ.	  	  	  
	  
1.7.2	  Effects	  of	  EBV	  on	  expression	  of	  TGFβR1	  and	  TGFβR2	  
Relatively	   few	   studies	   have	   investigated	   possible	   mechanisms	   of	   the	   resistance	   to	   TGFβ	  
induced	   by	   full	   latent	   EBV	   expression	   in	   B	   cells.	   Where	   TGFβR	   expression	   has	   been	  
investigated,	   there	   have	   again	   been	   discordant	   results:	   although	   some	   suggested	   down-­‐
regulation	  of	  TGFβR2,	  correlating	  with	  TGFβ	  resistance,	  in	  group	  III	  BL	  lines	  and	  LCLs	  (Kehrl	  
et	  al.	  1989,	  Inman	  and	  Allday	  2000b,	  Fukuda	  et	  al.	  2006a),	  one	  study	  showed	  reductions	  in	  
expression	   of	   both	   TGFβR1	   and	   TGFβR2	   in	   TGFβ-­‐resistant	   lines	   (Kumar	   et	   al.	   1991)	   and	  
others	  investigated	  only	  for	  TGFβR1	  but	  not	  TGFβR2	  expression	  (Altiok	  et	  al.	  1991,	  Altiok	  et	  
al.	  1993).	  Yet	  others	  have	  shown	  no	  difference	  in	  TGFβR	  expression	  between	  TGFβ-­‐sensitive	  
and	   -­‐resistant	   cell	   lines	   (Fukuda	   and	   Longnecker	   2004)	   or	   have	   claimed	   to	   show	   no	  
difference,	   although	   the	   data	   were	   not	   shown	   (Arvanitakis	   et	   al.	   1995,	   Horndasch	   et	   al.	  
2002).	  Furthermore,	  the	  mechanism	  of	  decreased	  TGFβR2	  expression	  by	  EBV	  in	  B	  cells,	  if	  it	  
does	  occur,	  is	  not	  fully	  established,	  including	  how	  its	  down-­‐regulation	  occurs	  and	  which	  EBV	  
latent	  proteins	  are	  responsible.	  	  
	  




The	   effect	   of	   EBV	   on	   expression	   of	   TGFβRs	   has	   been	   investigated	   in	   other	   cell	   types.	   In	  
LMP1-­‐expressing	  murine	  fibroblasts,	  TGFβR2	  mRNA	  expression	  was	  reported	  to	  be	  similar	  in	  
a	   TGFβ-­‐resistant	   clone	   and	   a	   TGFβ-­‐sensitive	   clone,	   although	   the	   data	   were	   not	   shown	  
(Takanashi	   et	   al.	   1999).	   In	   human	   gastric	   carcinoma	   and	   normal	   gastric	   epithelial	   cells,	  
expression	  of	  TGFβR1	  and	  TGFβR2	  were	  similar	  in	  TGFβ-­‐responsive	  and	  resistant	  cell	  lines	  by	  
northern	  and	  western	  blot;	  however,	  no	  loading	  controls	  were	  shown	  for	  their	  western	  blot,	  
and	  expression	  of	  the	  housekeeping	  gene	  GAPDH	  was	  highly	  variable	  between	  cell	  lines	  on	  
the	  northern	  blot	  (Fukuda	  et	  al.	  2001).	  In	  a	  further	  study	  by	  the	  same	  group,	  it	  is	  stated	  that	  
the	   LMP1-­‐expressing	   HSC39	   human	   gastric	   carcinoma	   cells,	   which	   were	   resistant	   to	   the	  
effects	  of	  TGFβ,	  expressed	  TGFβR1	  and	  TGFβR2,	  although	  no	  details	  are	  given	  of	  the	  method	  
by	  which	  this	  was	  analysed	  (Fukuda	  et	  al.	  2002).	  
	  
1.7.3	  Effects	  of	  EBV	  on	  TGFβ	  signalling	  
Few	   studies	   have	   investigated	   the	   effects	   of	   EBV	   on	   TGFβ	   signalling,	   as	   opposed	   to	   its	  
growth	   inhibitory	   effects;	   these	   have	   been	   done	   mostly	   in	   non-­‐lymphoid	   cells.	   LMP1	  
expression	  impaired	  TGFβ	  signalling,	  as	  detected	  by	  a	  TGFβ-­‐responsive	  reporter	  plasmid,	  in	  
epithelial	  cells	  and	  fibroblasts	  (Prokova	  et	  al.	  2002,	  Mori	  et	  al.	  2003).	  LMP1	  expression	  was	  
also	  sufficient	  to	  block	  induction	  of	  TGFβ	  target	  genes	  p21	  or	  p15	  in	  epithelial	  cells	  (Fukuda	  
et	  al.	  2002,	  Mori	  et	  al.	  2003,	  Lo	  et	  al.	  2010).	  	  
	  
Some	   studies	   have	   investigated	   the	   effect	   of	   EBV	   or	   its	   latent	   proteins	   in	   B	   cells	   on	  
downstream	  effects	  of	  TGFβ	  including	  ERK	  phosphorylation,	  p38	  phosphorylation	  (Fukuda	  et	  
al.	   2006a)	   and	   junB	   expression	   (Arvanitakis	   et	   al.	   1995).	   However,	   it	  was	   not	   shown	   that	  
these	   effects	   occurred	   via	   Smad	   pathways.	   Indeed,	   the	   TGFβ-­‐mediated	   activation	   of	   the	  
MAPK/ERK	   pathway	   and	   of	   p38	   are	   thought	   to	   be	   predominantly	   Smad-­‐independent	  
processes	  (Derynck	  and	  Zhang	  2003).	  As	  far	  as	  can	  be	  determined,	  therefore,	  no	  published	  
studies	   have	   investigated	   the	   effects	   of	   EBV	   directly	   on	   TGFβ	   signalling,	   as	   detected	   by	  
Smad2	  or	  Smad3	  phosphorylation	  or	  a	  TGFβ-­‐responsive	  reporter,	  in	  B	  cells.	  	  
	  




1.7.4	  Effects	  of	  EBV	  on	  TGFβ-­‐induced	  immunoglobulin	  production	  
Another	  important	  function	  of	  TGFβ	  in	  the	  immune	  system	  is	  that	  it	  promotes	  switching	  to	  
IgA	   but	   blocks	   class	   switching	   to	   all	   other	   isotypes	   (van	   Vlasselaer	   et	   al.	   1992).	   TGFβ	  
treatment	  inhibited	  production	  of	  IgG	  and	  IgM	  in	  tonsillar	  B	  cells	  treated	  with	  IL2	  (Kehrl	  et	  
al.	  1986)	  and	  in	  B	  cells	  that	  had	  been	  induced	  to	  secrete	  	  IgG	  and	  IgM	  by	  EBV	  infection,	  at	  up	  
to	  30	  days	  post-­‐infection	  (Machold	  et	  al.	  1993).	  However,	  established	  LCLs	  are	  resistant	  to	  
this	  TGFβ-­‐mediated	  inhibition	  of	  Ig	  production	  (Kehrl	  et	  al.	  1986,	  Altiok	  et	  al.	  1994).	  	  
	  
1.7.5	  Induction	  of	  lytic	  EBV	  replication	  by	  TGFβ	  and	  BMP	  signalling	  	  
In	  EBV-­‐infected	  BL	  cell	  lines	  including	  Raji,	  Mutu	  I,	  Daudi	  and	  P3HR1-­‐BL,	  TGFβ	  promotes	  EBV	  
lytic	  cycle	  activation,	  as	  detected	  by	  expression	  of	  IE	  genes	  such	  as	  BZLF1.	  This	  was	  reported	  
to	  occur	  via	  the	  MAPK/ERK	  pathway	  (Fahmi	  et	  al.	  2000).	  TGFβ	  also	  induced	  a	  slight	  increase	  
in	  EA	  expression	  in	  Akata	  cells	  (di	  Renzo	  et	  al.	  1994),	  whereas	  another	  study	  demonstrated	  
resistance	  to	  TGFβ-­‐induced	  EBV	  reactivation	  in	  Akata	  (Fukuda	  et	  al.	  2006a).	  This	  resistance	  
correlated	   with	   lack	   of	   TGFβR2	   expression	   and	   was	   reversed	   by	   TGFβR2	   overexpression,	  
suggesting	  TGFβ-­‐induced	  lytic	  reactivation	  is	  mediated	  by	  TGFβR2	  (Fukuda	  et	  al.	  2006a).	  	  
	  
TGFβ	   induces	  both	   apoptosis	   and	   lytic	   cycle	   induction	   in	   type	   I	   EBV-­‐infected	  BL	   cell	   lines.	  
However,	  individual	  cells	  with	  TGFβ-­‐induced	  BZLF1	  expression	  were	  protected	  against	  TGFβ-­‐
induced	   apoptosis.	   A	   caspase	   inhibitor	   blocked	   apoptosis	   but	   had	   no	   effect	   on	   lytic	   gene	  
induction,	  suggesting	  that	  lytic	  induction	  and	  apoptosis	  occur	  via	  separate	  pathways	  (Inman	  
et	  al.	  2001).	  	  
	  
BMP2,	   BMP6	   and	   BMP7	   can	   also	   reactivate	   EBV,	   in	   Mutu	   I	   (latency	   I)	   but	   not	   Mutu	   III	  
(latency	  III)	  BL	  cells.	  The	  mechanism	  for	  resistance	  to	  BMP-­‐induced	  EBV	  reactivation	  may	  be	  
via	  miR-­‐155,	  which	  has	  increased	  expression	  in	  latency	  III,	  since	  overexpression	  of	  miR-­‐155	  
in	  Mutu	  I	  cells	  inhibited	  BMP-­‐induced	  EBV	  lytic	  reactivation	  (Yin	  et	  al.	  2010).	  	  
	  
	   	  




1.8	  Specific	  background	  to	  this	  project	  
Shortly	  before	  this	  project	  started,	  members	  of	  the	  laboratory	  had	  performed	  a	  microarray	  
analysis	  to	  investigate	  the	  effect	  of	  the	  EBNA3	  proteins	  on	  expression	  of	  cellular	  genes	  in	  B	  
cells,	   including	   in	   two	   EBV-­‐negative	   BL	   cell	   lines,	   BL2	   and	   BL31,	   as	   well	   as	   in	   EBNA3B	  
knockout	  versus	  wild-­‐type	  LCLs	  [www.epstein-­‐barrvirus.org.uk	  and	  (White	  et	  al.	  2010)].	  This	  
showed	   that	   in	   BL	   cells,	   EBV	   strongly	   down-­‐regulated	   TGFβR2	   and	   also	   up-­‐regulated	  
TGFβR3.	  Using	   cell	   lines	  with	   deletions	   of	   individual	   EBNA3	  proteins,	   it	  was	   shown	   in	   the	  
microarray	   that	   EBNA3B	   and	   EBNA3C	   both	   appeared	   to	   be	   necessary	   for	   the	   effects	   on	  
TGFβR2	  and	  TGFβR3.	  	  
	  
Relatively	  little	  was	  known	  about	  the	  effects	  of	  TGFβ	  and,	  in	  particular,	  BMP	  signalling	  in	  B	  
cells.	  Although	  many	  previous	  publications	  had	  shown	  that	  BL	  cells	  and	  LCLs	  expressing	  the	  
full	   set	   of	   latent	   proteins	   were	   resistant	   to	   the	   anti-­‐proliferative	   and/or	   pro-­‐apoptotic	  
effects	  of	   TGFβ,	   few	  had	  addressed	   the	  mechanisms	  of	   this.	   There	  was	   some	  controversy	  
about	  whether	  or	  not	  this	  was	  due	  to	  the	  down-­‐regulation	  of	  TGFβR2	  by	  EBV	  (Kehrl	  et	  al.	  
1986,	  Kehrl	  et	  al.	  1989,	  Altiok	  et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  1993,	  Arvanitakis	  et	  
al.	   1995,	   Inman	   and	   Allday	   2000b,	   Horndasch	   et	   al.	   2002,	   Fukuda	   and	   Longnecker	   2004,	  
Fukuda	  et	  al.	  2006a).	   In	  addition,	  even	   in	   the	  cases	  where	  EBV	  had	  been	  shown	  to	  down-­‐
regulate	  TGFβR2,	  it	  was	  not	  known	  which	  particular	  latent	  genes	  were	  responsible	  for	  these	  
effects	   or	   the	   mechanism	   for	   this	   down-­‐regulation.	   Furthermore,	   recent	   work	   in	   the	  
laboratory	   had	   shown	   that	   the	   repression	   by	   latent	   EBV	  of	   two	  other	   tumour	   suppressor	  
genes,	   BIM	   and	   p16INK4A,	   occurred	   via	   polycomb-­‐mediated	   transcriptional	   repression.	  
Therefore	  it	  was	  hypothesised	  that	  the	  repression	  of	  TGFβR2	  by	  EBV	  may	  occur	  by	  a	  similar	  
mechanism,	  albeit	  involving	  cooperation	  of	  a	  different	  pair	  of	  EBNA3	  proteins.	  	  
	  
At	  the	  start	  of	  this	  project,	  no	  studies	  had	  previously	  investigated	  the	  effect	  of	  EBV	  infection	  
on	   TGFβR3	  expression,	   and	   the	   consequences	  of	   its	   up-­‐regulation	  were	  not	   known.	   Since	  
TGFβR3	   is	   a	   co-­‐receptor	   for	   BMP	   signalling,	   it	  was	   hypothesised	   that	   EBV	  may	   alter	   BMP	  
signalling	  as	  well	  as	  TGFβ	  signalling,	  and	  that	  this	  could	  also	  have	  important	  consequences	  
including	  possible	  promotion	  of	  lymphomagenesis.	  At	  the	  time,	  there	  was	  very	  little	  data	  on	  
BMP	  signalling	  in	  B	  cells,	  as	  discussed	  above.	  	  
	  




1.8.1	  Aims	  of	  this	  project	  
The	  specific	  aims	  of	  this	  project	  were:	  
1. To	  investigate	  the	  effects	  of	  EBV	  on	  TGFβ	  signalling,	  as	  distinct	  from	  TGFβ	  responses	  
2. To	   investigate	   the	   mechanism	   by	   which	   EBV	   down-­‐regulates	   TGFβR2,	   including	  
which	   latent	   proteins	   are	   responsible,	   and	   whether	   this	   occurs	   via	   polycomb-­‐
mediated	  repression	  
3. To	  investigate	  the	  effects	  of	  EBV	  on	  expression	  of	  TGFβR3	  
4. To	   investigate	   whether	   the	   up-­‐regulation	   of	   TGFβR3	   by	   EBV	   results	   in	   changes	   to	  
BMP	  signalling	  




 	  	  	  Materials	  and	  Methods	  Chapter	  2
	  
All	  chemical	  grade	  reagents	  were	  supplied	  by	  BDH	  chemicals,	  UK	  and	  were	  of	  AnalaR	  grade	  
purity	  unless	  otherwise	  stated.	  	  
2.1	  Solutions	  and	  Buffers	   	  
Unless	  otherwise	  stated,	  all	  solutions	  were	  prepared	  in	  ddH2O.	  
	  
6x	  Agarose	  gel	  loading	  buffer	  
20%	  (w/v)	  sucrose	  
0.1%	  (w/v)	  Bromophenol	  blue	  




0.2	  M	  NaOH	  
	  
Blocking	  solution	  for	  western	  blots	  
5%	  (w/v)	  skimmed	  milk	  powder	  (Sigma	  Aldrich,	  UK)	  in	  TBS-­‐Tween	  
For	  certain	  antibodies,	  5%	  BSA	  (Sigma	  Aldrich,	  UK)	  in	  TBS-­‐Tween	  	  
	  
β-­‐Estradiol	  
1mM	   (1000x)	   stock	  was	   prepared	   by	   diluting	   10mM	  β-­‐Estradiol	   (gift	   from	  Claudio	   Elgueta	  
Karstegl,	  Paul	  Farrell	  laboratory)	  in	  95-­‐100%	  ethanol,	  stored	  at	  -­‐20oC.	  
	  
4-­‐hydroxytamoxifen	  (4HT)	  	  
4mM	  (10	  000x)	  stock	  was	  prepared	  by	  re-­‐suspending	  5mg	  of	  4HT	  (Sigma)	  in	  3.22	  ml	  of	  95-­‐
100%	  ethanol.	  Aliquots	  of	  the	  stock	  were	  stored	  at	  –20oC	  in	  the	  dark.	  
	  
LB	  Agar	  	  
1%	  (w/v)	  Bactotryptone	  
1%	  (w/v)	  Yeast	  extract	  
0.5%	  (w/v)	  NaCl	  
1.5%	  (w/v)	  Agar	  




Lysis	  buffer	  with	  phosphatase	  inhibitors	  
Tris	  pH	  7.4	  50mM	  
NaCl	  250mM	  	  
NP40	  0.1%	  	  
EDTA	  5mM	  	  
NaF	  50mM	  	  
PMSF	  1mM	  
Protease	  inhibitor	  cocktail	  1x	  
	  
PMSF	  (phenylmethylsulfonylfluoride)	  
Dissolved	  at	  100mM	  in	  isopropanol	  and	  stored	  in	  aliquots	  at	  –20°C	   	  
	  
Protease	  Inhibitor	  Cocktail	  Solution	  	  
Protease	   inhibitor	   cocktail	   (Complete	   tablets,	   Roche)	   was	   made	   up	   to	   25x	   in	   ddH2O	   and	  
stored	  in	  aliquots	  at	  -­‐20°C.	  
	  
10x	  SDS	  Running	  Buffer	  for	  SDS-­‐PAGE	  	  
250mM	  Tris	   	   	  
1.92M	  Glycine	  
1%	  (w/v)	  SDS	  
	  
2x	  SDS	  Sample	  Buffer	  
100mM	  Tris-­‐HCl	  (pH	  6.8)	  
20%	  (v/v)	  Glycerol	  
1%	  (v/v)	  β-­‐mercaptoethanol	  
1%	  (w/v)	  SDS	  




0.1%	  Triton	  x	  100	  
50mM	  EDTA	   	   	   	   	   	  
50mM	  Tris	  pH8	  
	  





1.2%	  (w/v)	  Bactotryptone	  
2.4%	  (w/v)	  Yeast	  extract	  
0.4%	  (v/v)	  Glycerol	  
5%	  (v/v)	  20x	  KPB	  (potassium	  phosphate	  buffer)	  
	  
10x	  TBE	  (Tris-­‐Borate-­‐EDTA)	  Buffer	  
89mM	  Tris	  




20mM	  Tris	  	  
140mM	  NaCl	  
0.1%	  (v/v)	  Tween-­‐20	  (Sigma	  Aldrich,	  UK)	  
	  
TE	  	  
10mM	  Tris-­‐HCl	  pH	  7.5	  
1mM	  EDTA	  pH	  8	  
	  
Transfer	  Buffer	  for	  Western	  Blots	  
233ml	  EtOH	  
100ml	  10	  x	  running	  buffer	  	  
667	  ml	  ddH2O	  
	  
	   	  




2.2	  Cell	  culture	  and	  harvesting	  
2.2.1	  BL	  cell	  lines	  and	  LCLs	  used	  in	  this	  project	  
The	  cell	  lines	  used	  were	  infected	  with	  BAC-­‐derived	  mutant	  viruses	  as	  previously	  used	  in	  the	  
laboratory	  (Anderton	  et	  al.	  2008,	  White	  et	  al.	  2010,	  White	  et	  al.	  2012).	  For	  simplification	  the	  
panel	  of	  BL31,	  BL2	  and	  LCL	  cell	  lines	  are	  named	  throughout	  the	  report	  as	  shown	  in	  table	  2.1.	  
	  
Cell	  line	  name	  	   Allday	  lab.	  name	   Ref.	   	   Cell	  line	  name	   Allday	  lab.	  name	   Ref.	  
BL31	   BL31	   1	   	   BL31	  EBNA3C	  rev	   BL31-­‐3Crev-­‐2	   2	  
BL31	  WT	  (1)	   BL31-­‐wtBAC-­‐2	   2	   	   BL31	  E3	  KO	  1	   BL31-­‐E3KO-­‐2.1	   3	  
BL31	  WT	  2	   BL31-­‐wtBAC-­‐4	   3	   	   BL31	  E3	  KO	  2	   BL31-­‐E3KO-­‐3.2	   3	  
BL31	  WT	  3	   BL31-­‐wtBAC-­‐3	   3	   	   BL31	  E3	  rev	   BL31-­‐E3rev-­‐2.1	   3	  
BL31	  EBNA2	  KO	  (G)	   BL31-­‐E2KO-­‐GK	   4	   	   BL31	  LMP1	  KO	   	   	   6	  
BL31	  EBNA2	  KO	  1	   BL31-­‐E2KO-­‐1.1	   5	   	   BL31	  LMP1	  KO	  2	   	   6	  
BL31	  EBNA2	  KO	  2	   BL31-­‐E2KO-­‐2.1	   5	   	   BL31	  LMP2A	  KO	  1	   	   6	  
BL31	  EBNA2	  rev	   BL31-­‐E2rev-­‐1.1	   5	   	   BL31	  LMP2A	  KO	  2	   	   6	  
BL31	  EBNA3A	  KO	  1	   BL31-­‐3AKO-­‐4	   3	   	   BL2	   BL2	   1	  
BL31	  EBNA3A	  KO	  2	   BL31-­‐3AKO-­‐1.1	   2	   	   BL2	  WT	   BL2-­‐wtBAC-­‐2.1	   2	  
BL31	  EBNA3A	  KO	  3	   BL31-­‐3AKO-­‐3	   3	   	   BL2	  EBNA2	  KO	  (G)	   BL2-­‐E2KO-­‐GK	   4	  
BL31	  EBNA3A	  KO	  4	   BL31-­‐3AKO-­‐1.2	   2	   	   LCL-­‐WT	   LCL-­‐wtBAC-­‐D2.3	   3	  
BL31	  EBNA3A	  rev	   BL31-­‐3Arev-­‐2	   3	   	   LCL-­‐EBNA3B	  KO	  1	   LCL-­‐3BKO-­‐D2.5	   3	  
BL31	  EBNA3B	  KO	  1	   BL31-­‐3BKO-­‐6.2	   3	   	   LCL-­‐EBNA3B	  KO	  2	   LCL-­‐3BKO-­‐D2.4	   3	  
BL31	  EBNA3B	  KO	  2	   BL31-­‐3BKO-­‐1	   2	   	   LCL-­‐EBNA3B	  rev	   LCL-­‐3Brev-­‐D2.3	   3	  
BL31	  EBNA3B	  rev	   BL31-­‐3Brev-­‐3	   3	   	   LCL-­‐3CHT	  	   	   7	  
BL31	  EBNA3C	  KO	  1	   BL31-­‐3CKO-­‐5	   3	   	   LCL-­‐3CHT	  (p16-­‐null)	   	   7	  
BL31	  EBNA3C	  KO	  2	   BL31-­‐3CKO-­‐3	   2	   	   	   	   	  
Table	  2.1:	  Cell	  lines	  used	  in	  this	  project	  
KO=knockout,	  rev=revertant.	  References:	  1(Calender	  et	  al.	  1987),	  2(Anderton	  et	  al.	  2008),	  3(White	  et	  al.	  2010),	  
4(Kelly	  et	  al.	  2005),	   5(Ian	  Groves,	  unpublished),	   6(this	  project;	  HEK293	  producer	   lines	  a	  kind	  gift	  of	  Wolfgang	  
Hammerschmidt,	  Münich),	  7(Skalska	  et	  al.	  2013).	  
	  	  
All	   cells	   were	   grown	   in	   RPMI-­‐1640	   medium	   (Gibco),	   all	   supplemented	   with	   penicillin-­‐
streptomycin	  100u/ml,	  with	   additional	   supplementation	  as	   shown	   in	   table	  2.2.	   Cells	  were	  




passaged	  two	  to	  three	  times	  weekly	  by	  diluting	  appropriately	  in	  fresh	  warmed	  medium.	  All	  
cells	  were	  cultured	  at	  37°C	  in	  a	  humidified	  incubator	  with	  10%	  CO2.	  	  
	  
Cell	  line(s)	   Medium	  
Established	  LCLs	  (except	  LCL-­‐3CHT	  
and	  EREB2.5),	  Ramos,	  Akata6,	  
Akata31	  
RPMI	  +	  10%	  FCS	  	  
BL2,	  BL31	   RPMI	  +	  10%	  FCS	  +	  sodium	  pyruvate	  1mM	  (Sigma-­‐
Aldrich)	  +	  alpha-­‐thio-­‐glycerol	  50µM	  (Sigma-­‐Aldrich)	  
BL2	  and	  BL31	  infected	  with	  
recombinant	  BACs	  
RPMI	  +	  10%	  FCS	  +	  sodium	  pyruvate	  1mM	  (Sigma-­‐
Aldrich)	  +	  alpha-­‐thio-­‐glycerol	  50µM	  (Sigma-­‐Aldrich)	  
+	  hygromycin	  B	  100ug/ml	  (Roche)	  
LCL-­‐3CHT	   RPMI	  +	  10%	  FCS	  +	  400nM	  4-­‐hydroxytamoxifen	  (4HT,	  
Sigma)	  
EREB2.5	   RPMI	  +	  10%	  FCS	  +	  1µM	  β-­‐estradiol	  (gift	  from	  
Claudio	  Elgueta	  Karstegl)	  
Newly	  infected	  primary	  B	  cells	  (for	  
first	  month	  after	  infection)	  
RPMI	  +	  15%	  selected	  FCS	  +	  L-­‐glutamine	  2mM	  
Table	  2.2:	  Media	  used	  to	  culture	  B	  cell	  lines	  	  
	  
2.2.2	  Freezing	  and	  thawing	  cells	  
For	   long-­‐term	  storage	  of	   cell	   stocks,	  5	  x	  106	  cells	  were	  pelleted	  and	   re-­‐suspended	   in	  1	  ml	  
freezing	  medium	  (20%	  FCS	  and	  10%	  DMSO	  in	  RPMI).	  The	  cells	  were	  placed	  in	  cryovials	  in	  a	  
freezing	  container,	  then	  transferred	  to	  liquid	  nitrogen	  following	  storage	  at	  -­‐80oC	  overnight.	  
To	   recover	   cells	   from	   liquid	   nitrogen,	   the	   cryovial	   was	   thawed	   at	   37oC	   then	   the	   cells	  
promptly	  re-­‐suspended	  and	  dripped	  slowly	  into	  10ml	  of	  medium.	  Cells	  were	  then	  pelleted,	  
the	  medium	  aspirated	  and	  then	  re-­‐suspended	  in	  fresh	  medium.	  Cells	  recovered	  from	  liquid	  
nitrogen	  were	  generally	  cultured	  for	  at	  least	  ten	  days	  before	  the	  start	  of	  any	  experiment.	  
	  
2.2.3	  Harvesting	  cells	  
For	  all	  experiments,	  viable	  cell	  counts	  were	  performed	  by	  diluting	  cells	  1:1	  with	  0.4%	  trypan	  
blue	   (Sigma	  Aldrich)	  and	  placing	  a	  small	  volume	  on	  a	  haemocytometer.	  Living	  cells,	  which	  




exclude	   trypan	   blue	   dye,	  were	   counted	   under	   a	   light	  microscope.	   Cells	  were	   seeded	   at	   a	  
density	  of	  3	  x	  105/ml	  living	  cells	  24	  hours	  before	  harvesting	  or	  performing	  any	  experiment.	  
For	  RNA	  and	  protein	  extraction,	   cells	  were	  centrifuged	  at	  1300	  x	  g	   for	  4	  minutes	   (min)	  at	  
4oC,	   the	   media	   was	   aspirated	   and	   the	   cell	   pellet	   washed	   with	   cold	   PBS,	   before	   being	  
centrifuged	  again	  at	  1300	  ×	  g	  for	  4	  min	  at	  4oC.	  This	  wash	  was	  repeated,	  the	  supernatant	  was	  
removed	  again,	  and	  the	  pellet	  was	  re-­‐suspended	  in	  1ml	  of	  cold	  PBS	  and	  transferred	  into	  an	  
Eppendorf.	  The	  cells	  were	  then	  centrifuged	  at	  3000	  ×	  g	  for	  4	  min,	  the	  supernatant	  removed,	  
and	   the	  dry	   cell	   pellet	   then	   snap	   frozen	  on	  dry	   ice	  and	   stored	  at	   -­‐80oC	  before	  extraction.	  
When	  the	  pellet	  was	  to	  be	  harvested	  for	  RNA	  extraction,	  the	  pellet	  was	  lysed	  in	  RLT	  buffer	  
(Qiagen)	   containing	  β-­‐mercapto-­‐ethanol	  and	   then	   stored	  at	   -­‐80oC	  before	   subsequent	  RNA	  
extraction.	  	  
	  
2.2.4	  Adherent	  cells	  (HEK293)	  	  
Adherent	  cells	  were	  grown	  in	  RPMI	  +	  10%	  FCS,	  supplemented	  with	  penicillin/streptomycin	  
100U/ml,	   additional	   L-­‐glutamine	   2mM	   (Gibco),	   and	   hygromycin	   B	   100μg/ml	   (Roche).	   The	  
cells	  were	  generally	   split	   twice	  weekly	  as	   follows:	  cells	  were	  washed	  once	   in	  warmed	  PBS	  
and	  then	  incubated	  with	  an	  appropriate	  volume	  of	  0.05%	  trypsin/EDTA	  (Invitrogen)	  at	  37°C	  
until	   cells	  detached	   from	   the	   flasks.	  An	  equal	   volume	  of	   fresh	  medium	  was	  added	   to	  halt	  
further	  trypsinisation	  and	  cells	  were	  then	  split	  at	  between	  1:4	  and	  1:6	  into	  fresh	  flasks.	  The	  
cell	  lines	  used	  are	  shown	  in	  table	  2.3.	  
	  
Cell	  line	   Details	   Source	  
HEK293-­‐delLMP1	  (G204)	   maxi-­‐EBV	   deltaLMP1	   (clone	  
2597.3)	  
Kind	  gift	  of	  Prof.	  
Hammerschmidt	  (ref	  1)	  
HEK293-­‐delLMP2A	  (G212)	   maxi-­‐EBV	   deltaLMP2A	   (clone	  
2525.26)	  
Kind	  gift	  of	  Prof.	  
Hammerschmidt	  (ref	  2)	  
HEK293-­‐HB9I6	   	   Rob	  White,	  Allday	  laboratory	  
HEK293-­‐delEBNA3B	  C14	   	   Rob	  White,	  Allday	  laboratory	  
HEK293-­‐r3B	  M8	   	   Rob	  White,	  Allday	  laboratory	  
Table	  2.3:	  Adherent	  cell	  lines	  used	  in	  this	  project	  	  
1-­‐(Dirmeier	  et	  al.	  2003),	  2-­‐(Mancao	  and	  Hammerschmidt	  2007)	  




2.2.5	  Cytokine	  stimulation	  experiments	  
Recombinant	  Chinese	  hamster	  ovary	  (CHO)-­‐derived	  human	  TGFβ1	  (Peprotech)	  was	  made	  up	  
according	   to	   the	   manufacturer’s	   instructions,	   diluted	   in	   sterile	   BSA	   2mg/ml	   in	   PBS,	   and	  
stored	   in	  aliquots	  at	   -­‐20oC	  until	  use.	  Recombinant	  human	  BMP2,	  BMP4,	  BMP6,	  BMP7	  and	  
BMP9	  (all	  R&D	  systems)	  were	  made	  up	  according	  to	  the	  manufacturer’s	  instructions,	  diluted	  
in	  sterile	  0.5%	  (w/v)	  BSA	  in	  4mM	  HCl	  and	  stored	  in	  aliquots	  at	  -­‐20oC	  until	  use.	  
	  
In	  all	  experiments	  using	  cytokines,	  cells	  were	  seeded	  at	  3	  x	  105/ml	  24	  hours	  prior	  to	  use.	  At	  
time	   zero,	   cells	   were	   re-­‐suspended	   then	   divided	   into	   equal	   volumes	   which	   were	   then	  
treated	   with	   cytokine	   (TGFβ1	   5ng/ml	   except	   where	   otherwise	   specified;	   BMP	  
concentrations	   as	   shown	   in	   figures)	   or	   vehicle	   (untreated;	   BSA	   2mg/ml	   in	   PBS	   for	   TGFβ1	  
experiments	  and	  0.5%	  BSA	  in	  4mM	  HCl	  for	  BMP	  experiments).	  Cells	  were	  harvested	  under	  
identical	  conditions	  for	  the	  cytokine-­‐treated	  and	  untreated	  at	  the	  time	  points	  shown;	  cells	  
harvested	  at	  time	  zero	  were	  not	  treated	  with	  vehicle.	  
	  
2.2.6	  Extraction	  and	  purification	  of	  primary	  B	  cells	  
PBL	   for	   infection	  of	  primary	  B	  cells	  were	   isolated	   from	  buffy	  coat	   residues	   (UK	  NHS	  Blood	  
and	  Transplant)	  by	  density	  gradient	  centrifugation	  using	  Ficoll-­‐Paque.	  Each	  buffy	  coat	  was	  
made	  up	   to	  200ml	  with	   cold	  PBS	  and	   the	   solution	   carefully	   layered	  onto	  Ficoll-­‐Paque	   (GE	  
Healthcare)	  at	  a	  ratio	  of	  1:1	  in	  50ml	  Falcon	  tubes.	  These	  were	  then	  centrifuged	  at	  1300	  x	  g	  
for	  30	  min	  at	  room	  temperature	  with	  the	  brake	  off.	  Leukocytes	  were	  then	  recovered	  from	  
the	  cell-­‐plasma	  interface	  and	  washed	  twice	  with	  100ml	  wash	  buffer	  (RPMI	  +	  1%	  FCS)	  before	  
being	  re-­‐suspended	  in	  wash	  buffer	  to	  perform	  a	  cell	  count.	  
	  
109	  cells	  were	  then	  transferred	  to	  a	  fresh	  Falcon	  tube,	  spun	  at	  1300	  x	  g	  for	  5	  min	  to	  pellet	  
the	   cells,	   then	   re-­‐suspended	   in	   MACS	   running	   buffer	   (PBS-­‐2mM	   EDTA-­‐0.5%	   BSA).	   CD19	  
microbeads	  (Miltenyi	  Biotech)	  were	  added	  and	  the	  mix	  left	  for	  15	  min	  at	  4oC.	  The	  cells	  were	  
centrifuged	   to	   remove	   unbound	  microbeads,	   then	   re-­‐suspended	   in	  MACS	   running	   buffer	  
before	  being	  subjected	  to	  separation	  of	  CD19	  positive	  cells	  (i.e.	  B	  cells)	  by	  positive	  selection	  
using	   the	   AutoMACS	   sorting	   system	   (Miltenyi	   Biotec),	   according	   to	   the	   manufacturer’s	  




instructions.	   The	   cells	   obtained	   were	   then	   re-­‐suspended	   in	   culture	   medium	   at	   2	   x	   106	  
cells/ml	  before	  proceeding	  to	  virus	  infection.	  
	  
A	  small	  sample	  of	  cells	  was	  removed	  for	  CD20	  flow	  cytometry	  analysis	  to	  measure	  the	  purity	  
of	  the	  B	  cell	  population	  obtained	  (see	  section	  2.7.3	  for	  details).	  	  
	  
2.3	   RNA	  extraction,	  reverse	  transcription	  and	  quantitative	  reverse-­‐transcriptase	  PCR	  	  
RNA	  extraction	  from	  cell	  pellets	  was	  performed	  using	  the	  RNeasy	  mini	  kit	  (Qiagen)	  according	  
to	  the	  manufacturer’s	   instructions,	  using	  additional	  on-­‐column	  DNAse	  treatment	   (Qiagen).	  
RNA	   was	   quantified	   using	   the	   Nanodrop	   ND-­‐1000	   spectrophotometer	   and	   appropriately	  
diluted	  in	  RNAse-­‐free	  water	  (Qiagen)	  before	  performing	  qRT-­‐PCR.	  	  
	  
For	  SYBR	  green-­‐based	  assays,	  qRT-­‐PCR	  was	  performed	  either	  in	  a	  one-­‐step	  assay,	  using	  the	  
QuantiFast	  SYBR	  Green	  RT-­‐PCR	  kit	  (Qiagen),	  or	  in	  a	  two-­‐step	  process,	  using	  the	  Superscript	  
III	   First-­‐Strand	   Synthesis	   Supermix	   for	   qRT-­‐PCR	   (Invitrogen)	   for	   reverse	   transcription,	  
followed	   by	   the	   Platinum	   SYBR	   Green	   qPCR	   SuperMix-­‐UDG	   (Invitrogen).	   Reverse	  
transcription	   was	   performed	   on	   a	   standard	   quantity	   of	   RNA	   (usually	   750-­‐1000ng;	   less	   in	  
primary	  B	   cell	   infection	   experiments,	  where	   a	   limited	   amount	  was	   available	   at	   early	   time	  
points),	  according	  to	  the	  manufacturer’s	  instructions.	  For	  several	  experiments,	  analysis	  was	  
done	  by	   both	   one-­‐step	   and	   two-­‐step	   qRT-­‐PCR	  methods	   on	   the	   same	   samples,	   to	   confirm	  
that	  the	  same	  results	  were	  obtained	  with	  both	  methods.	  
	  
qRT-­‐PCR	  analysis	  was	  performed	  by	  the	  standard	  curve	  method,	   in	  each	  experiment	  using	  
six	   serial	  5-­‐fold	  dilutions	  of	  a	  mixture	  containing	  all	   template	  RNA	  or	  cDNA	  samples.	  Each	  
sample	   was	   run	   in	   triplicate	   and	   the	   standard	   deviation	   (SD)	   calculated.	   Error	   bars	   in	   all	  
graphs	   represent	  +/-­‐	   1	   SD.	  qRT-­‐PCR	  was	  performed	  using	   the	  Applied	  Biosystems	  7900HT	  
Fast	   Real-­‐Time	   PCR	   system.	   Product	   specificity	   was	   confirmed	   using	   dissociation	   curve	  
analysis	   in	   each	   qRT-­‐PCR	   run,	   with	   agarose	   gel	   electrophoresis	   used	   initially	   to	   confirm	  
product	   specificity	   for	   each	   primer	   set.	   No-­‐template	   controls	  were	   also	   included	   on	   each	  
plate	  to	  exclude	  contamination	  or	  primer-­‐dimer	  formation.	  	  
	  




The	   PCR	   settings	  were	   as	   follows:	   for	   the	   one-­‐step	  QuantiFast	   assay:	   fast	   (96-­‐well	   plates	  
only):	  10	  min	  at	  50°C	  (reverse	  transcription),	  5	  min	  at	  95°C	  (activation),	  then	  10	  sec	  at	  95°C	  
alternating	  with	  30	  sec	  at	  60°C	  for	  40	  cycles;	  standard	  (384-­‐well	  plates):	  10	  min	  at	  50°C,	  5	  
min	  at	  95°C,	  then	  15	  sec	  at	  95°C	  alternating	  with	  60	  sec	  at	  60°C	  for	  40	  cycles.	  For	  the	  two-­‐
step	  Platinum	  SYBR	  green	  assay	  using	  cDNA	  template:	  2	  min	  at	  50°C,	  10	  min	  at	  95°C,	  then	  15	  
sec	  at	  95°C	  and	  60	  sec	  at	  60°C	  alternating	  for	  40	  cycles.	  
	  
Primer	  sequences	  for	  SYBR	  green-­‐based	  assays	  were	  as	  shown	  in	  table	  2.4.	  All	  primers	  were	  
supplied	  as	  standard	  salt-­‐free	  preparations	  and	  used	  at	  200nM	  final	  concentration	  (Eurofins	  
MWG	  Operon	   or	   Sigma).	   Primers	   for	   qRT-­‐PCR	   for	   GAPDH	  were	   from	  Qiagen	   (QuantiTect	  
Primer	  Assay).	  	  
	  
Primer	  	   Forward	  sequence	   Reverse	  sequence	  
GNB2L1	   GAGTGTGGCCTTCTCCTCTG	   GCTTGCAGTTAGCCAGGTTC	  
TGFβR1	   CTATATCTGCCACAACCGCACTGTC	   CGCCACTTTCCTCTCCAAACTTCTC	  
TGFβR2	   GGCTCAACCACCAGGGCA	   CTCCCCGAGAGCCTGTCCAGA	  
TGFβR3	   TGTGTGCCTCCTGACGAAGC	   AGGCTGCAAACGCAATGCCC	  
SMAD1	   CACAAACATGATGGCGCCT	   TGTGGAGGAGGCATGGAACGC	  
TGFβ1	  	   GATGTCACCGGAGTTGTGCG	   GTGAACCCGTTGATGTCCACTT	  
SMAD5	   CTGCCTCTGACTTGACCCAAT	   AGTCAGTGGCTACCGAAAGAA	  
CDKN2B	   ACTAGTGGAGAAGGTGCGAC	   GCCCATCATCATGACCTGGA	  
BMPR1A	   TAAAGGTGACAGTACACAGGAACA	   TCTATGATGGCAAAGCAATGTCC	  
ID1	   TGGTCGCTGTCTGTCTGAG	   GCCGTTGAGGGTGCTGAG	  
ID2	   ACGACCCGATGAGCCTGCTA	   TCCTGGAGCGCTGGTTCTG	  
RPLPO	   ACTCTGCATTCTCGCTTCCT	   GGACTCGTTTGTACCCGTTG	  
p21CIP1/WAF1	   CTGGAGACTCTCAGGGTCGAA	   GCGGATTAGGGCTTCCTCTT	  
ALAS1	   TCCACTGCAGCAGTACACTACCA	   ACGGAAGCTGTGTGCCATCT	  
CD23	   TGGGACACCACACAGAGTCTAAA	   CCGTGGTGGCTTTCCAAGT	  
TUBB	   CTTCGGCCAGATCTTCAGAC	   AGAGAGTGGGTCAGCTGGAA	  
Table	  2.4:	  Primer	  sequences	  for	  qRT-­‐PCR	  using	  SYBR	  green	  	  
Sequences	  were	  obtained	  from	  the	  following	  sources:	  GNB2L1	  (Zhang	  et	  al.	  2005),	  TGFβR1	  (Bruno	  et	  al.	  1998),	  
TGFβR2	   (Di	   Bartolo	   et	   al.	   2008),	   TGFβR3	   (Konrad	   et	   al.	   2007).	   p21,	   ALAS1	   and	   RPLPO	   –	   Lenka	   Skalska,	   PhD	  
thesis,	  ID1	  and	  ID2	  (Locklin	  et	  al.	  2001),	  BMPRIA	  (Feeley	  et	  al.	  2005),	  TUBB	  (Zhang	  et	  al.	  2005),	  CD23	  –	  Lenka	  
Skalska.	  The	  remaining	  primers	  (SMAD1,	  TGFβ1,	  SMAD5,	  CDKN2B)	  were	  designed	  by	  the	  author	  using	  Primer-­‐
Blast	  (Skaletsky	  2000).	  	  




For	   qRT-­‐PCR	   using	   the	   Taqman	   method,	   cDNA	   was	   amplified	   using	   the	   EfficienSee	   FAST	  
qPCR	  MasterMix	  Plus	  dTTP	  (Eurogentec),	  with	  primers	  (Eurofins	  MWG	  Operon	  or	  Sigma)	  at	  
a	  final	  concentration	  of	  300nM	  and	  probes	  (Eurogentec)	  at	  200nM.	  The	  qPCR	  settings	  were	  
as	  follows:	  2	  min	  at	  50oC,	  10	  min	  at	  95oC,	  then	  15	  sec	  at	  95oC	  alternating	  with	  60	  sec	  at	  60oC	  
for	  40	  cycles.	  The	  sequences	  of	  primers	  and	  probes	  used	  are	  shown	  in	  table	  2.5.	  All	  probes	  
were	  labelled	  with	  6-­‐carboxyfluorescein	  phosphoramidite	  (FAM)	  reporter	  dye	  at	  the	  5ʹ′	  end	  
and	  Black	  hole	  quencher	  1	  (BHQ-­‐1)	  at	  the	  3ʹ′	  end.	  
	  
Transcript	   	   Sequence	  
LMP1	   Exon	  2	  forward	  primer	   AATTTGCACGGACAGGCATT	  
Exon	  3	  reverse	  primer	   AAGGCCAAAAGCTGCCAGAT	  
Probe	  (exon	  2/3)	   TCCAGATACCTAAGACAAGTAAGCACCCGAAGAT	  
LMP2A	  
	  
Exon	  1	  forward	  primer	   CGGGATGACTCATCTCAACACATA	  
Exon	  2	  reverse	  primer	   GGCGGTCACAACGGTACTAACT	  
Probe	  (exon	  2)	   CAGTATGCCTGCCTGTAATTGTTGCGC	  
Table	  2.5:	  Primer	  and	  probe	  sequences	  for	  Taqman	  qRT-­‐PCR	  	  
Sequences	  were	  obtained	  from	  (Bell	  et	  al.	  2006).	  
	   	  




2.4	   Protein	  extraction,	  SDS-­‐PAGE	  and	  Western	  blotting	  
Protein	  was	  extracted	  from	  thawed	  or	  freshly	  harvested	  cell	  pellets	  using	  fresh	  lysis	  buffer	  
with	  phosphatase	  inhibitors.	  A	  volume	  approximately	  equivalent	  to	  1-­‐2	  times	  the	  size	  of	  the	  
pellet	  was	  added,	  mixed	  by	  pipetting	  and	  then	  vortexed	  to	   lyse.	  The	  samples	  were	   left	  on	  
ice	   for	   5-­‐10	   min	   and	   then	   spun	   at	   21,000	   x	   g	   for	   15	   min	   at	   4oC.	   The	   supernatant	   was	  
transferred	   to	   fresh	   tubes	   and	   then	   protein	   quantified	   using	   the	   DC	   protein	   assay	   with	  
bovine	   serum	   albumin	   (BSA)	   standard	   (Bio-­‐Rad	   Laboratories),	   using	   six	   dilutions	   for	   the	  
standard	   curve	   and	   analysed	   on	   the	   Helios	   spectrophotometer	   (Thermo	   Scientific).	   The	  
protein	  samples	  were	  then	  diluted	  appropriately	  in	  lysis	  buffer	  and	  stored	  at	  -­‐80oC	  until	  use.	  
For	  SDS-­‐polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE),	  gels	  were	  made	  according	  to	  table	  
2.6	  using	   the	  Bio-­‐Rad	  mini-­‐Protean	   II	   system.	  Generally	   30µg	  of	   each	  protein	   sample	  was	  
mixed	  with	  an	  equal	  volume	  of	  2x	  SDS	  sample	  buffer,	  heated	  at	  100oC	  for	  7	  min	  to	  denature	  
proteins	  and	  then	  loaded	  into	  SDS-­‐polyacrylamide	  gels	  of	  an	  appropriate	  percentage.	  	  
	  
Alternatively,	  in	  some	  experiments	  whole	  cell	  lysates	  were	  used,	  as	  follows:	  cell	  pellets	  were	  
directly	  lysed	  in	  2x	  SDS	  protein	  sample	  buffer	  and	  then	  sonicated	  to	  lyse	  the	  cells	  (Bioruptor	  
UCD-­‐200,	  Diagenode)	  on	  high	  setting	  for	  15	  min	  (intermittent	  sonication	  –	  30	  seconds	  on,	  
30	  seconds	  off).	  In	  this	  case,	  following	  heating	  at	  100oC	  for	  7	  min	  an	  equal	  volume	  of	  each	  
sample	  was	  loaded	  into	  the	  SDS-­‐polyacrylamide	  gel.	  	  
	  
Electrophoresis	  was	  performed	  at	  150V	  for	  70	  min	  in	  running	  buffer,	  followed	  by	  transfer	  to	  
nitrocellulose	  membrane	  (Whatman	  GmbH,	  Germany)	  at	  100V	  constant	  voltage	  for	  60	  min	  
in	  transfer	  buffer.	  Membranes	  were	  washed	  once	  briefly	  in	  TBS-­‐T	  then	  blocked	  in	  blocking	  
solution	   for	   60	  min	   at	   room	   temperature	   (see	   table	   2.7	   for	   which	   blocking	   solution	   was	  
used).	  Primary	  antibodies	  were	  diluted	  as	  shown	  in	  table	  2.7	  in	  5%	  skimmed	  milk	  or	  5%	  BSA	  
in	   TBS-­‐T	   and	   left	   to	   incubate	   at	   4oC	   overnight	  with	   shaking.	  Membranes	  were	  washed	   as	  
follows:	  two	  changes	  of	  TBS-­‐T	  followed	  by	  two	  ten-­‐minute	  washes,	  and	  then	  incubated	  with	  
appropriate	   HRP-­‐conjugated	   secondary	   antibodies	   (table	   2.8)	   for	   60	  min	   followed	   by	   the	  
same	   wash	   procedure.	   The	   reaction	   was	   developed	   using	   enhanced	   chemiluminescence	  
(ECL)	  Western	  Blotting	  detection	  reagents	  (GE	  Healthcare,	  UK)	  and	  exposed	  on	  Amersham	  
Hyperfilm	   MP	   (GE	   Healthcare).	   The	   size	   of	   proteins	   detected	   was	   compared	   to	   protein	  
markers,	  depending	  on	  the	  size	  of	  proteins	  of	   interest:	  either	  High-­‐Range	  Rainbow	  marker	  




(Amersham),	   combined	   1:1	  with	   2x	   SDS	   sample	   buffer	   and	   boiled	   for	   7	  min	   before	   being	  
loaded,	   or	   Spectra	   multicolour	   broad	   range	   protein	   marker	   (Thermo	   scientific)	   loaded	  
without	  boiling,	  according	  to	  the	  manufacturer’s	  instructions.	  	  
	  
For	   all	  western	   blots	   using	   antibodies	   to	   SMAD	  and	  phosphorylated	   SMAD	   (pSMAD),	   gels	  
were	   prepared	   in	   multiples	   and	   loaded	   with	   the	   same	   samples.	   This	   enabled	   direct	  
comparison	  between	   the	  SMAD	  and	   the	   related	  pSMAD	  without	   stripping	   the	  membrane,	  
since	  the	  two	  forms	  of	  the	  protein	  run	  at	  approximately	  the	  same	  size	  on	  SDS-­‐PAGE.	  Each	  
membrane	  was	  re-­‐probed	  with	  anti-­‐γ-­‐tubulin	  to	  ensure	  that	  equal	  amounts	  of	  each	  sample	  
had	  been	   loaded	   into	   the	   gel.	   In	   all	   figures	   showing	  multiple	   antibodies,	   a	   representative	  










	   Stacking	  gels	   2	  gels	  
Acrylamide/Bis	   1.98	  ml	   2.64	  ml	   3.3	  ml	   	   Acrylamide/Bis	   828	  μl	  
Tris	  pH	  8.8	   2.96	  ml	   2.96	  ml	   2.96	  ml	   	   Tris	  pH	  6.8	   620	  μl	  
10%	  SDS	   79.2	  μl	   79.2	  μl	   79.2	  μl	   	   10%	  SDS	   49.6	  μl	  
ddH2O	   2.96	  ml	   2.3	  ml	   1.64	  ml	   	   ddH2O	   3.47	  ml	  
APS	   26.4	  μl	   26.4	  μl	   26.4	  μl	   	   APS	   24.8	  μl	  
TEMED	   5.3	  μl	   5.3	  μl	   5.3	  μl	   	   TEMED	   5	  μl	  
Table	  2.6:	  Resolving	  and	  stacking	  gels	  for	  SDS-­‐PAGE	  
	   	  




Antibody	   Species/type	   Manufacturer	   Dilution	  
Anti-­‐SMAD1	   Rabbit	  polyclonal	   Cell	  Signaling	  9743	   1:1000	  
Anti-­‐SMAD2	   Rabbit	  polyclonal	   Invitrogen	  51-­‐1300	   1:200	  
Anti-­‐SMAD2	   Mouse	  monoclonal	   Cell	  Signaling	  3103	   1:1000	  
Anti-­‐SMAD5	   Rabbit	  polyclonal	   Cell	  Signaling	  9517	   1:1000	  
Anti-­‐Phospho-­‐SMAD1	  (ser	  206)	   Rabbit	  polyclonal	   Cell	  Signaling	  9553	   1:500	  
Anti-­‐Phospho-­‐SMAD5	  (ser	  463/465)	  
[EP728(2)AY]	  
Rabbit	  monoclonal	   Abcam	  76296	   1:1000	  
Anti-­‐phospho-­‐SMAD1	  (ser	  463/465),	  
5	  (ser	  463/465)	  and	  8	  (ser	  426/428)	  
Rabbit	  polyclonal	   Cell	  Signaling	  9511	   1:1000	  
Anti-­‐phospho-­‐SMAD2	  (ser	  465/467)	   Rabbit	  polyclonal	   Cell	  Signaling	  3101	   1:1000	  
Anti-­‐gamma-­‐tubulin	  (GTU-­‐88)	   Mouse	  monoclonal	   Sigma-­‐Aldrich	  T6557	   1:10,000	  
Anti-­‐PARP	   Rabbit	  polyclonal	   Boehringer	  Mannheim	  	  
1	  835	  238	  
1:5000	  
Anti-­‐EBNA2	  (clone	  PE2)	   Mouse	  monoclonal	   Dako	  M7004	  
(discontinued)	  
1:500	  
Anti-­‐EBNA2	  (clone	  PE2)	   Mouse	  monoclonal	   Abcam	  ab49498	   1:500	  
Anti-­‐EBNA3A	   Sheep	  polyclonal	   Exalpha	  F115p	   1:1000	  
Anti-­‐EBNA3B	  3B(2)6C9	   Rat	  monoclonal	   Allday	  lab	   1:10	  
Anti-­‐EBNA3C	  (A10)	   Mouse	  monoclonal	   Gillian	   Parker	   (Allday	  
lab)1	  
1:10	  
Anti-­‐LMP1	  CS1-­‐4	   Mouse	  monoclonal	   Dako	  M0897	   1:500	  
Anti-­‐EBNA-­‐LP	  4D3	   Mouse	  monoclonal	   Yasushi	  Kawaguchi2	   1:1000	  
Anti-­‐EBNA1	   Human	  serum	  
(polyclonal)	  
Prof.	  Paul	  Farrell	   1:750	  
Anti-­‐LMP2A	  (14B7)	   Rat	  monoclonal	   Abcam	  ab59026	   1:1000	  
Anti-­‐TGFβR3	  (D11G10)	   Rabbit	  monoclonal	   Cell	  Signaling	  5544	   1:1000	   (in	  
5%BSA)	  
Table	  2.7:	  Primary	  antibodies	  for	  western	  blotting	  	  
All	  were	  diluted	  in	  5%	  milk/TBS-­‐T	  unless	  otherwise	  stated.	  1-­‐(Maunders	  et	  al.	  1994),	  2-­‐(Shaku	  et	  al.	  2005).	  
	   	  




Antibody	   Manufacturer	   Dilution	  
Polyclonal	  goat	  anti-­‐rabbit	  Ig/HRP	   Dako	  P0448	   1:2000	  
Polyclonal	  rabbit	  anti-­‐rat	  Ig/HRP	   Dako	  P0450	   1:2000	  
Rabbit	  anti-­‐sheep	  Ig/HRP	   Dako	  P0163	   1:2000	  
ECL	  sheep	  anti-­‐mouse	  IgG	  HRP	   GE	  Healthcare	  NA931	   1:2000	  
Rabbit	  anti-­‐human	  (anti-­‐IgA,	  -­‐IgG,	  -­‐IgM,	  -­‐κ/λ)	  	   Dako	  P0212	   1:2000	  
Table	  2.8:	  Secondary	  antibodies	  for	  western	  blotting	  
	  All	  secondary	  antibodies	  were	  diluted	  in	  5%	  milk/TBS-­‐T.	  
	  
2.5	   Chromatin	  immunoprecipitation	  (ChIP)	  
For	  ChIP	  analysis,	  cells	  were	  seeded	  at	  3	  x	  105/ml	  24	  h	  before	  the	  experiment	  and	  then	  3.6	  x	  
106	   cells	  were	   fixed	   in	   1%	   formaldehyde	   (Sigma-­‐Aldrich)	   for	   10	  min	  before	  washing	   three	  
times	  with	  ice-­‐cold	  1x	  PBS	  containing	  phosphatase	  inhibitors	  [PMSF	  1µM,	  aprotinin	  1µg/ml	  
(Sigma-­‐Aldrich)	   and	   Pepstatin	   A	   1µg/ml	   (Sigma-­‐Aldrich)	   final	   concentrations].	   Cell	   pellets	  
were	  snap	  frozen	  on	  dry	  ice	  then	  stored	  at	  -­‐80°C	  until	  the	  assay	  was	  performed.	  	  
	  
ChIP	   was	   performed	   using	   the	   ChIP	   assay	   kit	   (Millipore)	   according	   to	   the	  manufacturer’s	  
instructions.	   Sonication	   (Bioruptor	   UCD-­‐200,	   Diagenode)	   was	   performed	   for	   12.5	   min	  
(intermittent	  sonication	  with	  30	  sec	  on,	  30	  sec	  off)	  to	  obtain	  sheared	  chromatin	  with	  DNA	  of	  
200-­‐1000bp	   in	   length	   (Kostas	   Paschos,	   personal	   communication).	   The	   adequacy	   of	  
sonication	  was	  assessed	  by	  running	  the	  sonicated	  samples,	  after	  cross-­‐link	  reversal,	  on	  a	  2%	  
agarose	  gel.	  The	  antibodies	  used	  are	  shown	  in	  table	  2.9.	  Rabbit	  IgG	  (Millipore)	  was	  used	  as	  a	  
control	  (2μl	  per	  ChIP).	  
	  
Antibody	   Manufacturer	   Species	   Amount	  per	  ChIP	  
Anti-­‐H3K27Me3	   Millipore	  17-­‐622	   Rabbit	   4µg	  
Anti-­‐H3K9Ac	   Millipore	  17-­‐658	   Rabbit	   5µg	  
Anti-­‐H3K4Me3	   Millipore	  17-­‐614	   Rabbit	   3µg	  
Anti-­‐SUZ12	   Abcam	  ab12073	   Rabbit	   4µg	  
Table	  2.9:	  Antibodies	  used	  for	  chromatin	  immunoprecipitation	  
	  




Precipitated	  DNA	  was	  purified	  using	   the	  Qiaquick	  gel	   extraction	  kit	   (Qiagen),	   according	   to	  
the	  manufacturer’s	  instructions.	  DNA	  was	  eluted	  in	  ddH2O	  and	  then	  stored	  at	  -­‐20°C	  prior	  to	  
qPCR	  analysis.	  	  
	  
qPCR	  was	  performed	  using	  the	  Platinum	  SYBR	  Green	  qPCR	  SuperMix-­‐UDG	  (Invitrogen),	  using	  
dissociation	  curve	  analysis	  to	  check	  the	  specificity	  of	  product,	  with	  primer	  sequences	  shown	  
in	  table	  2.10.	  The	  qPCR	  settings	  were	  as	  follows:	  2	  min	  at	  50°C,	  10	  min	  at	  95°C,	  then	  15	  sec	  
at	   95°C	   and	   60	   sec	   at	   60°C	   alternating	   for	   40	   cycles.	   Once	   standard	   curves	   had	   been	  
performed	  initially	  to	  ensure	  that	  the	  primer	  sets	  had	  comparable	  efficiencies,	  analysis	  was	  
performed	  in	  triplicate	  using	  the	  delta-­‐delta	  Ct	  method.	  IgG	  controls	  were	  also	  used	  in	  every	  
case;	   however,	   the	   results	   with	   these	   were	   negligible	   in	   all	   cases	   and	   hence	   results	   are	  
expressed	   as	   fold	   enrichment	   relative	   to	   input.	  All	   samples	  were	   run	   in	   triplicate	   and	   the	  
standard	   deviation	   calculated	   (shown	   as	   error	   bars	   in	   the	   graphs).	   For	   marks	   of	   active	  
transcription	  (H3K4Me3	  and	  H3K9Ac),	  actin	  or	  glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  
(GAPDH)	   were	   used	   as	   positive	   controls	   and	   γ-­‐globin	   or	   myoglobin	   used	   as	   negative	  
controls,	   whereas	   for	   marks	   of	   repressed	   transcription	   (H3K27Me3	   and	   SUZ12),	   actin	   or	  
GAPDH	  were	  used	  as	  negative	  controls	  and	  γ-­‐globin	  or	  myoglobin	  were	  positive	  controls.	  
	   	  




	   Forward	  primer	  sequence	   Reverse	  primer	  sequence	  
TGFβR2	  set	  1	   AGCTTGGGTGCTAGGTGGAGCA	   GGCAAGGGTTTGTGCCAGGGT	  
TGFβR2	  set	  2	   AAAATGTTTTTCTTTAGGTCGAAGT	   CCAGGTGATCAATATGTACATTAAA	  
TGFβR2	  set	  3	   GAGAGAGCTAGGGGCTGG	   CTCAACTTCAACTCAGCGCTGC	  
TGFβR2	  set	  4	   GGACCACTCACCCGACTTCT	   CCGCTGCACATCGTCCTGT	  
TGFβR2	  set	  5	  	   TCCTGGAGACGGCCACGCTT	   TGCCAAGGCGTCAGTGGAGC	  
TGFβR3	  dis	  1	   CCCCACCAGCCTCACAGGGAT	   GGGGCACTGTGCTCATCTCGC	  
TGFβR3	  dis	  2	   GCCTGAAGCTGCGCATGGTCT	   TGCTTCCTTGTGTGTGCTGGC	  
TGFβR3	  prox1	   AGGACGTCGCACAGGCACAG	   TACCGGCGTTACCCGGAGGT	  
TGFβR3	  prox2	   GGGGAGAGGGCAAGAGGCTGT	   GGGGACTCGCTCCCTCAAACG	  
TGFβR3	  prox3	   GCGTGACAGCTTCGGTGGGA	   GAACGCAAACCGCGTCCGTG	  
TGFβR3	  prox4	   TTCCTCAGCGGAGAGCGGCA	   GCTGAAAGATGGGAGAAGATGCATGG	  
SMAD1	  A	   GTGCGGGGGAGTTGGCATCA	   TCGAGTAGGTAACCTTGTTGCTCCA	  
SMAD1	  B	   AAGTCCGCTCCACCGGGACTAAA	   CCCCACGCCCCGTTTCTTCCT	  
SMAD1	  C	   CTCGTGCTCCCACACGGACG	   TGGGACGCGGCATGAAGGGA	  
SMAD1	  D	   CGGCCCCAGCAAGCCTCTTT	   GAGACGCAGCGGGTGTAGGC	  
SMAD1	  E	   GGGGAGGAGGAACAAATGCCTGC	   GAAGGAACGCGCCTTTACTGGT	  
Actin	   TGCACTGTGCGGCGAAGC	   TCGAGCCATAAAAGGCAA	  
GAPDH	   CGGCTACTAGCGGTTTTACG	   AAGAAGATGCGGCTGACTGT	  
γ-­‐globin	   GCCTTGACCAATAGCCTTGACA	   GAAATGACCCATGGCGTCTG	  
Myoglobin	   GGAGAAAGAAGGGGAATCACAT	   GATAAATATAGCCAACGCCACA	  
Table	  2.10:	  Primer	  sequences	  for	  ChIP-­‐qPCR	  
With	   the	   exception	   of	   TGFβR2	   set	   3	   (see	   below),	   the	   TGFβR2	   and	   TGFβR3	   primers	   were	   designed	   by	   the	  
author,	  with	  the	  initial	  help	  of	  Kostas	  Paschos	  (Allday	  lab),	  using	  MethPrimer	  (Li	  and	  Dahiya	  2002)	  and	  Primer-­‐
Blast	  (Skaletsky	  2000).	  The	  SMAD1	  primers	  were	  designed	  by	  the	  author.	  References	  for	  the	  other	  primer	  sets	  
are	   as	   follows:	   TGFβR2	   set	   3	   (Di	   Bartolo	   et	   al.	   2008),	   actin	   (He	   and	  Margolis	   2002),	   γ-­‐globin	   (Bottardi	   et	   al.	  
2003),	  myoglobin	  (Noer	  et	  al.	  2009)	  and	  GAPDH	  (Everett	  et	  al.	  2007).	  
	  
2.5.1	  Agarose	  gel	  electrophoresis	  
Agarose	  gels	  were	  made	  with	  1%	  or	  2%	  agarose	  dissolved	  in	  1x	  TBE	  depending	  on	  the	  size	  of	  
the	  DNA	  fragment	  of	  interest.	  Staining	  SYBRsafe	  (Invitrogen,	  UK)	  was	  added	  to	  the	  mixture.	  
Samples	  were	  mixed	  with	   the	  appropriate	  volume	  of	  6x	  agarose	  gel	   loading	  buffer	  before	  
loading	   and	   running	   in	   1x	   TBE	   running	   buffer	   at	   80V	   for	   approximately	   1	   hour	   before	  




visualization	  on	  a	  UV	  trans-­‐illuminator.	  In	  all	  cases	  a	  1kb	  or	  100bp	  DNA	  ladder	  (New	  England	  
Biolabs,	  UK)	  was	  used	  as	  a	  marker	  and	  run	  alongside	  DNA	  samples.	  
	  
2.6	  	   DNA	  methylprecipitation	  analysis	  
Genomic	   DNA	  was	   extracted	   from	   harvested	   cell	   pellets	   using	   the	  Qiagen	   Blood	   and	   Cell	  
culture	  Midi	  kit,	  according	  to	  the	  manufacturer’s	  protocol,	  using	  5	  x	  106	  cells	  per	  sample	  re-­‐
suspended	   in	   sterile	   PBS	   and	  using	  Qiagen	  protease.	   The	  extracted	  DNA	  was	  precipitated	  
with	  isopropanol,	  washed	  once	  with	  ice-­‐cold	  70%	  ethanol,	  spun	  at	  >5000	  x	  g	  for	  10	  min	  at	  
4oC,	  the	  supernatant	  aspirated,	  the	  remainder	  air-­‐dried	  and	  then	  the	  DNA	  re-­‐suspended	  in	  
ddH2O.	  The	  DNA	  concentration	  was	  checked	  using	  the	  Nanodrop	  spectrophotometer,	  then	  
all	  samples	  were	  diluted	  to	  10ng/μl	  in	  ddH2O	  for	  sonication.	  The	  samples	  were	  sonicated	  for	  
12.5	  min	  on	  high	  setting,	  as	  before,	  followed	  by	  analysis	  on	  a	  2%	  agarose	  gel	  to	  check	  the	  
adequacy	  of	   sonication	   to	   fragments	  of	   <1000bp	   in	   size.	   Precipitation	  of	  methylated	  DNA	  
was	   performed	   using	   the	   Methylcollector	   Ultra	   kit	   (Active	   Motif)	   according	   to	   the	  
manufacturer’s	   instructions,	   using	   100ng	   of	   sonicated	   DNA	   per	   sample.	   Fully	   in	   vitro	  
methylated	  Jurkat	  DNA	  (Active	  Motif)	  was	  used	  as	  a	  positive	  control.	  Two	  negative	  controls	  
were	  used:	  one	  sonicated	  genomic	  DNA	  extracted	  from	  PBMCs	  extracted	  from	  the	  blood	  of	  
a	   healthy	   donor,	   which	   are	   known	   to	   be	   unmethylated	   [Kostas	   Paschos,	   personal	  
communication	  and	  (Paschos	  et	  al.	  2009)]	  and	  a	  sample	  in	  which	  ddH2O	  was	  added	  instead	  
of	   the	   His-­‐MBD2b	   protein	   complex.	   The	   samples	   obtained	   were	   then	   purified	   using	   the	  
Qiaquick	  gel	  extraction	  kit	   (Qiagen),	  according	  to	  the	  manufacturer’s	   instructions.	  Samples	  
were	   eluted	   in	   ddH2O	   then	   stored	   at	   -­‐20oC	   until	   qPCR	   could	   be	   performed.	   qPCR	   was	  
performed	  as	  for	  ChIP-­‐qPCR,	  with	  results	  expressed	  relative	  to	  input.	  	  
	  
2.7	   Flow	  cytometry	  
2.7.1	  Propidium	  iodide	  (PI)	  staining	  	  
Approximately	  2	  x	  106	  cells	  were	  harvested	  per	  condition	  and	  washed	  three	  times	  in	  ice-­‐cold	  
1x	  PBS.	  Cells	  were	  then	  re-­‐suspended	  into	  80%	  ethanol,	  which	  had	  been	  pre-­‐chilled	  to	  -­‐20°C,	  
and	  mixed	  by	  vortexing.	  Cells	  were	   then	  stored	  at	   -­‐20°C	   for	  up	   to	  seven	  days	  before	   flow	  
cytometric	  (FC)	  analysis.	  Prior	  to	  FC,	  cells	  were	  centrifuged	  at	  900	  x	  g	  for	  4	  min,	  the	  ethanol	  
removed	  and	   then	   the	   cells	   re-­‐suspended	   in	  1	   x	  PBS	   containing	  8μg/ml	  RNase	  A	   (Qiagen)	  




and	  18μg/ml	  propidium	   iodide	   (Sigma-­‐Aldrich);	  samples	  were	   left	  on	   ice	   in	  the	  dark	   for	  at	  
least	  one	  hour	  before	  proceeding	  to	  FC	  analysis.	  FC	  was	  performed	  using	  the	  FACSCanto	  II	  
machine	  (BD	  Biosciences)	  and	  the	  data	  analysed	  using	  FlowJo	  software	  (Treestar,	  Ashland,	  
OR,	  USA).	  	  	  
	  
2.7.2	  Combined	  Draq5	  and	  live-­‐dead	  fixable	  staining	  
Approximately	  1	  x	  106	  cells	  were	  harvested	  per	  condition	  and	  washed	  three	  times	  in	  ice-­‐cold	  
1x	  PBS.	  Cells	  were	  then	  re-­‐suspended	  into	  ice-­‐cold	  PBS	  containing	  Live/dead	  Fixable	  Violet	  
Stain	   1µl/ml	   (Invitrogen)	   and	   left	   on	   ice	   in	   the	   dark	   for	   30	  min.	   The	   samples	   were	   then	  
centrifuged,	  washed	  once	  with	  1x	  PBS	  and	  once	  with	  1x	  PBS	  containing	  1%	  BSA	  before	  being	  
re-­‐suspended	  in	  80%	  ethanol	  (pre-­‐chilled	  to	  -­‐20oC)	  whilst	  vortexing.	  Samples	  were	  then	  left	  
on	  ice	  in	  the	  dark	  for	  60	  minutes.	  They	  were	  then	  centrifuged	  at	  1500	  x	  g	  for	  5	  min	  at	  4oC,	  
the	  ethanol	  aspirated	  and	  the	  cells	  re-­‐suspended	  in	  1	  x	  PBS-­‐BSA	  1%	  and	  left	  for	  10-­‐15	  min	  at	  
room	   temperature.	   They	   were	   then	   centrifuged,	   PBS-­‐BSA	   removed	   and	   the	   cells	   re-­‐
suspended	  in	  1x	  PBS	  containing	  Draq5	  2μl/ml	  (Biostatus)	  and	  RNase	  A	  10μg/ml	  (Qiagen),	  left	  
in	   the	  dark	   at	   room	   temperature	   for	   30-­‐60	  min	  before	  proceeding	   to	   FC	   analysis.	   FC	  was	  
performed	  using	  either	   the	  FACSCanto	   II	   or	   the	   LSR	   II	  machine	   (both	  BD	  Biosciences)	   and	  
data	  analysed	  using	  Flowjo	  software,	  as	  above.	  	  
	  
2.7.3	  CD20	  staining	  for	  analysis	  of	  purity	  of	  primary	  B	  cell	  separation	  
106	   cells	   were	   removed	   from	   each	   sample	   of	   purified	   primary	   B	   cells,	   centrifuged	   then	  
washed	   once	   with	   ice-­‐cold	   1x	   PBS/0.5%	   BSA	   (PBS-­‐BSA)	   before	   re-­‐suspending	   in	   PBS-­‐BSA	  
containing	  10μg	  of	  human	  IgG.	  The	  samples	  were	  left	  on	  ice	  for	  15	  min	  before	  adding	  anti-­‐
CD20	  APC	  5µl	   per	   sample	   (eBioscience).	   Samples	  were	   then	   left	   on	   ice	   in	   the	  dark	   for	   60	  
min,	  washed	   twice	  with	  PBS-­‐BSA	  before	  being	   re-­‐suspended	   in	  MACS	   running	  buffer	   then	  
proceeding	   to	   FC	   analysis.	   The	   percentage	   of	   CD20+ve	   cells	   were	   analysed	   by	   FC	   on	   the	  
DAKO	  CyanADP	  cytometer.	  	  
	  
2.8	  Episomal	  rescue	  from	  293	  cells	  to	  verify	  BACS	  
HEK293	  cells,	  containing	  recombinant	  BACS,	  were	  established	  and	  selected	  with	  hygromycin	  
(100μg/ml)	  before	  harvesting	  cells	  for	  extraction	  of	  low-­‐molecular	  weight	  DNA	  for	  episomal	  




rescue	   and	   pulsed-­‐field	   gel	   analysis	   of	   BAC	   restriction	   digests,	   in	   order	   to	   verify	   the	   BAC	  
constructs.	  	  
	  
2.8.1	  Low	  molecular	  weight	  DNA	  extraction	  
293	   cell	   clones	   were	   grown	   to	   approximately	   80%	   confluence	   in	   a	   flask,	   washed	   and	  
trypsinised	  whilst	  re-­‐passaging,	  as	  described	  previously,	  and	  then	  the	  cells	  remaining	  after	  
passage	  were	  pelleted,	  washed	  in	  PBS	  and	  then	  the	  pellet	  snap	  frozen	  and	  stored	  at	  -­‐80oC	  
until	  use.	  The	   frozen	  cell	  pellet	  was	   subsequently	   thawed	  and	   then	   re-­‐suspended	   in	  60	  µl	  
STET.	   Cells	  were	   lysed	   by	   addition,	  while	   vortexing,	   of	   130	  µl	   alkaline	   SDS.	   This	  was	   then	  
neutralised	   by	   the	   addition,	   while	   vortexing,	   of	   110	   µl	   7.5M	   ammonium	   acetate.	   The	  
mixture	  was	  incubated	  on	  ice	  for	  5	  min	  before	  centrifuging	  at	  18,000	  x	  g	  for	  30	  min	  at	  4oC.	  
The	   cleared	   lysate	   was	   transferred	   to	   fresh	   Eppendorfs	   in	   order	   to	   proceed	   to	   phenol-­‐
chloroform	  extraction.	  	  	  
	  
The	  cleared	  cell	  lysate	  was	  transferred	  to	  a	  1.5	  ml	  MaXtract	  High	  Density	  Gel	  tube	  (Qiagen),	  
200	  µl	   of	   Phenol:Chloroform:Isoamyl	   alcohol	   (25:24:1;	   Sigma)	   added	  and	   the	   tube	   rapidly	  
inverted	  for	  30	  s	  to	  mix	  before	  centrifuging	  at	  9500	  x	  g	  for	  6	  min.	  The	  upper	  aqueous	  layer	  
was	   then	   transferred	   to	   a	   new	   MaXtract	   Gel	   tube,	   using	   a	   cut-­‐off	   tip,	   and	   200	   µl	   of	  
chloroform	  was	   added.	   The	   tube	  was	   again	   inverted	   to	  mix	   and	   centrifuged	   for	   6	  min	   at	  
9500	   x	   g.	   The	   upper	   aqueous	   layer	   was	   transferred	   to	   a	   fresh	   Eppendorf	   and	   the	   DNA	  
precipitated	   by	   addition	   of	   670	   µl	   of	   100%	   ethanol,	   followed	   by	   centrifugation	   for	   30	  
minutes	   at	   maximum	   speed,	   then	   washed	   with	   200	   µl	   of	   70%	   ethanol.	   The	   pellet	   of	  
episomal	   DNA	   was	   allowed	   to	   air-­‐dry	   for	   15	   min	   before	   being	   re-­‐suspended	   in	   50	   µl	   TE	  
containing	  5	  µg/ml	  RNase	  A.	  
	  
2.8.2	  Transformation	  	  
1	   µl	   of	   this	   low	   molecular	   weight	   DNA	   preparation	   was	   added	   to	   20	   µl	   of	   Electromax	  
electrocompetent	  DH10B	  E.	   coli	   (Invitrogen)	  on	   ice.	   This	  was	  electroporated	  at	  1.8	   kV,	  25	  
µFD	  and	  200	  Ω	  using	  a	  Gene	  pulser	   (BioRad)	  before	  400	  µl	  of	  SOC	  (Invitrogen)	  was	  added	  
and	   the	  mixture	   placed	   in	   a	   shaking	   incubator	   at	   37oC	   for	   1	   hour	   to	   recover.	   The	   entire	  




culture	   volume	   was	   plated	   onto	   LB	   agar	   containing	   chloramphenicol	   and	   incubated	  
overnight	  at	  37oC.	  Colonies	  were	  chosen	  for	  miniprep	  DNA	  isolation.	  	  
	  
2.8.3	  Small	  scale	  isolation	  of	  plasmid	  DNA	  (‘Minipreps’)	  	  
Single	  bacterial	  colonies	  were	  picked	  into	  1.5ml	  superbroth	  containing	  chloramphenicol	  12.5	  
μg/ml	   and	   grown	   overnight	   at	   37oC	   in	   a	   shaking	   incubator.	   Samples	   were	   centrifuged	   at	  
1500	  x	  g	  for	  4	  min	  at	  RT	  to	  pellet	  the	  bacteria.	  The	  supernatant	  was	  removed	  by	  aspiration.	  
70μl	  STET	  was	  added	  to	  the	  pellet,	  which	  was	  re-­‐suspended	  by	  vortexing.	  200μl	  of	  alkaline	  
SDS	  was	  added	  while	  vortexing.	  While	  still	  vortexing	  150μl	  of	  7.5M	  ammonium	  acetate	  was	  
added,	   before	   transferring	   the	   sample	   immediately	   to	   ice.	   Samples	  were	   left	   on	   ice	   for	   5	  
minutes,	   and	   then	   centrifuged	  at	   18,000	   x	  g	   for	   20	  min	   at	   4oC	   in	   a	  pre-­‐cooled	   rotor.	   The	  
supernatant	  was	  then	  poured	  into	  a	  fresh	  Eppendorf.	  240μl	  isopropanol	  was	  added	  and	  the	  
DNA	   precipitated	   by	   inversion.	   The	   sample	   was	   centrifuged	   at	   room	   temperature	   for	   6	  
minutes	  at	  9,500	  x	  g.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  washed	  in	  200μl	  of	  70%	  
ethanol	   and	   then	   centrifuged	  at	  9,500	   x	  g	   for	   a	   further	  3	  min.	   The	   supernatant	  was	   then	  
aspirated	   and	   the	   pellet	   air-­‐dried	   for	   approximately	   15	   min	   before	   the	   DNA	   was	   re-­‐
suspended	  in	  50μl	  TE	  supplemented	  with	  5μg/ml	  RNase	  A.	  The	  samples	  were	  then	  stored	  at	  
4oC	  until	  restriction	  enzyme	  digest	  and	  pulsed-­‐field	  gel	  electrophoresis	  were	  performed.	  
	  
2.8.4	  Restriction	  Enzyme	  Digests	  	  
Restriction	  enzyme	  digests	  were	  carried	  out	  using	  the	  following	  reagents,	  made	  up	  to	  15µl	  
with	  ddH2O:	  
	   5µl	  DNA	  
	   1.5µl	  10x	  restriction	  enzyme	  buffer	  
	   0.75µl	  20x	  BSA	  
To	  this	  was	  added	  a	  small	  amount	  (<0.5µl)	  of	  appropriate	  restriction	  enzyme,	  BamHI	  or	  NHeI	  
(New	  England	  Biolabs)	  and	  the	  digest	  was	  incubated	  for	  3	  hours	  at	  37oC.	  
	  
2.8.5	  Pulsed-­‐field	  gel	  electrophoresis	  	  
Pulsed-­‐field	  gels	  were	  run	  in	  a	  Bio-­‐Rad	  CHEF	  DR	  II	  system.	  Gels	  were	  made	  with	  1%	  agarose	  
dissolved	   in	   0.5x	   TBE	   (without	   Ethidium	  Bromide)	   and	  were	   run	   in	   2	   L	   of	   0.5x	   TBE.	   A	   1:1	  




mixture	  of	  λ	  DNA-­‐BstEII	  and	  λ	  DNA	  mono	  cut	  mix	  ladders	  (New	  England	  Biolabs)	  were	  used	  
as	  size	  markers	  to	  run	  alongside	  DNA	  samples.	  Both	  DNA	  samples	  and	  ladders	  were	  mixed	  
with	  an	  appropriate	  volume	  of	  6x	  agarose	  gel	  loading	  buffer	  and	  the	  λ–based	  ladders	  were	  
heated	  at	  50oC	  for	  10	  min	  prior	  to	  loading.	  The	  settings	  for	  pulsed-­‐field	  gel	  electrophoresis	  
of	  EBV-­‐BACs	  were	  as	  follows:	  
Initial	  Sweep	  Time	  	  	   1	  sec	   	   	  
Final	  Sweep	  Time	   	   10	  sec	  
Voltage	   	   	   6	  V/cm	  	  
Running	  time	   	   14	  hours	  
Running	  temperature	   14oC	  
When	  the	  run	  was	  complete,	  the	  gel	  was	  stained	  with	  Ethidium	  Bromide	  at	  a	  concentration	  
of	   0.5	   µg/ml	   in	   0.5x	   TBE	   for	   45	   min,	   with	   gentle	   agitation,	   before	   visualisation	   on	   a	   UV	  
transilluminator.	  
	  
2.9	  	   Production	  of	  recombinant	  virus	  from	  producer	  lines	  and	  infection	  of	  cells	  
Once	   the	   integrity	   of	   the	   BAC	   constructs	   had	   been	   checked	   as	   described	   above,	   HEK293	  
producer	   cell	   lines	   were	   induced	   to	   produce	   virus	   by	   transient	   transfection	   of	   BZLF1	  
(Countryman	  and	  Miller	  1985,	  Hammerschmidt	  and	  Sugden	  1988,	  Delecluse	  et	  al.	  1998)	  and	  
BALF4	  (Neuhierl	  et	  al.	  2002).	  The	  cells	  were	  seeded	  in	  a	  10cm	  dish.	  Two	  days	  later,	  each	  dish	  
was	  transfected	  with	  0.5	  µg	  BZLF1	  and	  0.5	  µg	  BALF4	  (1	  µg	  in	  total)	  by	  the	  LID	  transfection	  
method.	  
	  
2.9.1	  Transfection	  of	  EBV-­‐BACs	  into	  293	  cells	  (LID	  transfection	  system)	  	  
The	   LID	   transfection	   system	   consists	   of	   Lipofectin	   Reagent	   (Invitrogen),	   Integrin-­‐Targeting	  
Peptide	  6	  (Hart	  et	  al.	  1998)	  and	  DNA.	  For	  1	  μg	  of	  plasmid	  DNA,	  0.75	  μl	  of	  Lipofectin	  Reagent	  
(1	  mg/ml)	  was	  combined	  with	  40	  μl	  Peptide	  6	  (0.1	  mg/ml)	  and	  left	  to	  stand	  for	  5	  min.	  This	  
solution	  was	  added	   to	  1	  μg	  of	  plasmid	  DNA	   [made	  up	   to	  100	  μl	   in	  OptiMEM	  (Invitrogen)]	  
and	   left	   for	   20	  min.	   The	  medium	  was	   then	   removed	   from	   the	   cells	   in	   the	   10cm	  dish	   and	  
carefully	  replaced	  with	  the	  entire	  LID	  transfection	  mixture	  which	  had	  been	  made	  up	  to	  5	  ml	  
with	   OptiMEM.	   Cells	   were	   incubated	   at	   37oC	   for	   6	   hours	   after	   which	   the	   transfection	  




mixture	  was	  replaced	  with	  4	  ml	  of	  fresh	  RPMI/10%	  FCS	  +	  L-­‐glutamine.	  This	  was	  then	  left	  to	  
incubate	  for	  four	  days	  before	  harvesting	  the	  supernatant.	  	  
	  
The	  virus-­‐containing	  supernatant	  was	  then	  harvested	  and	  filtered	  through	  a	  0.45	  µm	  filter.	  
Infectivity	   of	   the	   supernatant	   was	   assayed	   by	   infection	   of	   Raji-­‐BL	   cells	   (Green	   Raji	   Units,	  
GRU)	  (Dirmeier	  et	  al.	  2003).	  Ten-­‐fold	  dilutions	  of	  viral	  supernatant	  (1	  ml,	  0.1	  ml	  and	  0.01	  ml	  
made	  up	  to	  1	  ml	  volume	  using	  RPMI/10%	  FCS)	  were	  used	  to	   infect	  105	  Raji	  cells	   in	  0.5	  ml	  
RPMI/10%	   FCS.	   After	   2	   days,	   0.5	   ml	   of	   RPMI/10%	   FCS	   containing	   20	   nM	   phorbol	   12-­‐
tetradecanoate	  13-­‐acetate	  (TPA;	  Sigma)	  and	  5	  mM	  sodium	  n-­‐butyrate	  (Sigma)	  was	  added	  to	  
the	  cells,	  in	  order	  to	  enhance	  GFP	  expression.	  The	  next	  day,	  the	  viral	  titre	  was	  estimated	  by	  
counting	  the	  number	  of	  GFP-­‐positive	  Raji	  cells	  in	  various	  dilutions	  of	  viral	  supernatant	  using	  
fluorescence	  microscopy.	  
	  
2.9.2	  Infection	  of	  EBV-­‐negative	  BL	  cells	  
The	   EBV-­‐negative	   BL	   cell	   line	   BL31	   was	   infected	   with	   recombinant	   and	   wild-­‐type	   EBV	  
generated	   from	  EBV-­‐BACs.	  500µl	  of	   viral	   supernatant	   from	   the	   relevant	  293	  producer	   cell	  
line	  was	  added	  to	  105	  BL	  cells	  in	  1ml	  of	  growth	  medium,	  in	  duplicate	  for	  each	  virus.	  After	  48	  
hours,	  cells	  were	  selected	   in	  Hygromycin	  at	  a	  concentration	  of	  250µg/ml	   to	  produce	  EBV-­‐
converted	   BL	   lines.	   Cells	  were	  monitored	   periodically	   for	   GFP	   expression	   by	   fluorescence	  
microscopy.	  Once	  cell	  lines	  were	  established,	  the	  Hygromycin	  concentration	  was	  reduced	  to	  
100µg/ml.	   Expression	  of	   EBV	   latent	  proteins	  was	   validated	  by	  western	  blotting	  of	   protein	  
extracts.	  
	  
2.9.3	  Infection	  of	  purified	  primary	  B	  cells	  
CD19-­‐purified	  B	  cells	  were	  seeded	  at	  2	  x	  106	  cells/ml	  in	  5ml	  of	  medium	  in	  a	  25cm2	  flask,	  then	  
1.5-­‐2.0	  x106	  infectious	  units	  of	  virus	  (approx.	  1x	  105	  units	  for	  wild-­‐type	  virus)	  were	  added	  to	  
the	  cultures.	  When	  cells	  were	  harvested	  at	  early	  time	  points,	  the	  volume	  of	  culture	  removed	  
was	  replaced	  with	  an	  equal	  volume	  of	  fresh	  medium.	  	  





 	  	  	  The	  effects	  of	  EBV	  infection	  on	  TGFβ	  receptor	  expression	  Chapter	  3
and	  TGFβ	  signalling	  in	  BL31	  cells	  
3.1	  Introduction	  
TGFβ	  signalling	  is	  known	  to	  be	  dysregulated	  in	  many	  malignancies	  (Elliott	  and	  Blobe	  2005),	  
and	  EBV	  infection	  renders	  B	  cells	  resistant	  to	  the	  effects	  of	  TGFβ	  (Kehrl	  et	  al.	  1986,	  Blomhoff	  
et	  al.	  1987,	  Janssen	  et	  al.	  1990,	  Altiok	  et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  1992,	  Altiok	  
et	  al.	  1993,	  Arvanitakis	  et	  al.	  1995,	  MacDonald	  et	  al.	  1996,	  Inman	  and	  Allday	  2000b).	  It	  has	  
previously	  been	  shown	  that	  TGFβR2	  is	  down-­‐regulated	  in	  B	  cell	  lines	  which	  are	  resistant	  to	  
the	  effects	  of	  TGFβ	   (Fukuda	  et	  al.	  2006a,	  Chen	  et	  al.	  2007)	   including	  those	  expressing	  the	  
latency	   III	   products	   of	   EBV	   (Inman	   and	   Allday	   2000b).	   However,	   other	   studies	   have	  
investigated	  only	  TGFβR1	  expression	  (Altiok	  et	  al.	  1991,	  Altiok	  et	  al.	  1993),	  have	  shown	  that	  
both	   TGFβR1	   and	   TGFβR2	   expression	   are	   reduced	   (Kumar	   et	   al.	   1991)	   or	   that	   TGFβR	  
expression	  appeared	  not	  to	  be	  altered	  by	  EBV	  (Arvanitakis	  et	  al.	  1995).	  	  
	  
Exon	  microarray	   analyses	   of	   the	   effect	   EBNA3	   proteins	   have	   on	   cellular	   gene	   expression	  
suggested	  that	  TGFβR2	   is	  down-­‐regulated	  by	  EBV	   in	  BL31	  cells,	  with	  EBNA3B	  and	  EBNA3C	  
apparently	  cooperating	  [www.epstein-­‐barrvirus.org.uk	  and	  (White	  et	  al.	  2010)].	  In	  addition,	  
other	   work	   by	   this	   group	   had	   shown	   that	   EBNA3	   proteins	   cooperate	   to	   regulate	   many	  
cellular	  genes,	  via	  epigenetic	  mechanisms	  (Anderton	  et	  al.	  2008,	  Paschos	  et	  al.	  2009,	  White	  
et	   al.	   2010,	   Paschos	   et	   al.	   2012,	   Skalska	   et	   al.	   2013).	   TGFβR2	   has	   been	   shown	   to	   be	  
repressed	   epigenetically	   in	   various	   other	   types	   of	   tumour	   including	   non-­‐small	   cell	   lung	  
carcinoma,	   prostate	   carcinoma	   and	   primary	   effusion	   lymphoma	   (PEL)	   (Zhang	   et	   al.	   2004,	  
Zhao	  et	  al.	  2005,	  Di	  Bartolo	  et	  al.	  2008).	  
	  
Therefore,	  the	  detailed	  mechanism	  of	  down-­‐regulation	  of	  TGFβR2	  by	  EBV	  in	  BL31	  cells	  was	  
investigated	  and	  described	   in	   this	  chapter,	   including	  which	   latent	  proteins	  are	   responsible	  
and	  whether	  this	  occurs	  via	  epigenetic	  repression	  of	  gene	  transcription.	  The	  effect	  of	  this	  on	  
TGFβ	   signalling	   was	   also	   investigated,	   as	   well	   as	   the	   effect	   on	   the	   expression	   of	   the	   co-­‐
receptor	  TGFβR3.	  




3.2	  The	  effect	  of	  EBV	  latent	  proteins	  on	  TGFβR2	  transcription	  in	  the	  context	  of	  latent	  EBV	  
infection	  of	  B	  cells	  
3.2.1	  EBV	  down-­‐regulates	  TGFβR2	  in	  BL31	  cells,	  with	  EBNA2,	  EBNA3B	  and	  EBNA3C	  being	  
necessary	  
Microarray	   analysis	   had	   suggested	   that	   in	   BL31	   cells,	   derived	   from	   an	   EBV-­‐negative	   BL,	  
latent	  EBV	  down-­‐regulates	  TGFβR2,	  and	  that	  EBNA3B	  and	  EBNA3C	  were	  necessary	  for	  this	  
[www.epstein-­‐barrvirus.org.uk	  (White	  et	  al.	  2010)].	  Therefore	  a	  panel	  of	  uninfected,	  B95.8-­‐
BAC	  EBV	  (here	  called	  wild-­‐type)	  and	  recombinant	  virus-­‐infected	  BL31	  cells	  was	  investigated	  
for	  TGFβR2	  expression	  by	  extracting	  RNA	  and	  performing	  qRT-­‐PCR.	  This	  confirmed	  that	  EBV	  
latent	  gene	  expression	  down-­‐regulates	  TGFβR2	  mRNA	  in	  BL31	  cells	  (fig.	  3.1A).	  	  
	  
When	  EBNA3B	  and	  EBNA3C	  were	  deleted,	  expression	  was	  partially	  restored,	  suggesting	  that	  
these	   latent	   proteins	   cooperate	   in	   the	   repression.	   The	   involvement	   of	   EBNA3A	   was	   less	  
clear,	   as	   EBNA3A	  KO	  1	   appeared	   to	  behave	   like	  wild-­‐type,	   suggesting	   that	   EBNA3A	   is	   not	  
necessary	   for	   the	   repression,	   whereas	   in	   EBNA3A	   KO	   2	   partial	   de-­‐repression	   was	   seen	  
suggesting	   that	   in	   this	   case	   EBNA3A	  may	   be	   necessary	   (fig.	   3.1A).	   This	   will	   be	   discussed	  
further	   in	  section	  4.6.	   In	  all	   the	   revertants,	   repression	  was	  again	  seen,	  similar	   to	   infection	  
with	  wild-­‐type	  virus.	  	  
	  
Surprisingly,	  the	  deletion	  of	  EBNA2	  also	  had	  a	  profound	  effect,	  with	  partial	  de-­‐repression	  of	  
TGFβR2,	  suggesting	  that	  EBNA2	  also	  cooperates	  with	  EBNA3B	  and	  EBNA3C	  in	  the	  repression	  
of	  TGFβR2	  (fig.	  3.1A).	  Although	  EBNA2	  has	  been	  shown	  to	  cooperate	  with	  EBNA3	  proteins	  in	  
regulating	   cellular	   gene	   expression,	   in	   most	   cases	   these	   genes	   are	   activated	   by	   EBNA2	  
(Spender	  et	  al.	  2002,	  Maier	  et	  al.	  2006,	  Spender	  et	  al.	  2006,	  Zhao	  et	  al.	  2006);	  however,	  in	  
one	  of	  these	  studies	  EBNA2	  was	  shown	  to	  repress	  a	   limited	  number	  of	  genes	  (Maier	  et	  al.	  
2006).	  In	  order	  to	  confirm	  the	  effect	  of	  EBNA2	  deletion,	  the	  expression	  of	  TGFβR2	  was	  also	  
investigated	  in	  cells	  derived	  from	  a	  different	  BL,	  BL2.	  Again	  EBV-­‐negative,	  wild-­‐type	  infected	  
and	   those	   infected	  with	   EBNA2	   KO	   virus	  were	   compared.	   This	   also	   showed	   repression	   of	  
TGFβR2	   by	   wild-­‐type	   EBV,	   with	   de-­‐repression	   in	   EBNA2	   KO,	   confirming	   that	   EBNA2	   is	  
necessary	  for	  TGFβR2	  repression	  (fig.	  3.1B).	  




Despite	   multiple	   attempts	   using	   a	   wide	   variety	   of	   commercially	   available	   antibodies	   to	  
TGFβR2,	  none	  were	  found	  to	  be	  satisfactory	  for	  investigation	  of	  TGFβR2	  protein	  expression	  



























Figure	  3.1:	  Expression	  of	  TGFβR2	  mRNA	  in	  panels	  of	  BL31	  and	  BL2	  cell	  lines	  
(A)	  qRT-­‐PCR	  on	  a	  panel	  of	  BL31	  cell	   lines	  including	  uninfected	  and	  infected	  with	  wild-­‐type	  or	  mutant	  virus	  as	  
indicated.	  (B)	  qRT-­‐PCR	  for	  TGFβR2	  in	  uninfected,	  wild-­‐type	  EBV-­‐infected	  and	  EBNA2	  KO-­‐infected	  BL2	  cells.	  The	  
values,	   also	   shown	   above	   bars	   for	   clarification	   in	   figure	   3.1A,	   represent	   the	   ratio	   of	   expression	   to	   the	  
endogenous	  control	  gene	  GNB2L1.	  Data	  shown	  are	   from	  an	  experiment	   in	  which	   the	  pattern	  of	  variation	  of	  
values	   for	  uninfected,	  knockout	  and	  wild-­‐type/revertant	   infected	  cell	   lines	   is	   representative	  of	  at	   least	   three	  
separate	   experiments.	   The	   error	   bars	   represent	   standard	   deviations	   from	   triplicate	   qPCR	   reactions.	   Despite	  




0.12	   0.15	  
2.65	  
3.01	  























































3.2.2	  The	  down-­‐regulation	  of	  TGFβR2	  occurs	  via	  polycomb-­‐mediated	  repression	  
It	   had	   been	   previously	   shown	   that	   EBNA3A	   and	   EBNA3C	   cooperate	   to	   down-­‐regulate	  
BCL2L11,	  the	  gene	  coding	  for	  the	  pro-­‐apoptotic	  protein	  BIM,	   in	  BL31	  cells,	  and	  p16INK4A,	   in	  
LCLs	   (Paschos	   et	   al.	   2009,	   Skalska	   et	   al.	   2010,	   Paschos	   et	   al.	   2012).	   Furthermore,	   DNA	  
hypermethylation	  of	   TGFβR2	  has	  been	  demonstrated	   in	   response	   to	   induction	  of	   LANA,	   a	  
latent	  nuclear	  protein	  of	  KSHV,	  in	  association	  with	  reduction	  in	  histone	  H4	  acetylation	  of	  the	  
TGFβR2	  promoter	  (Di	  Bartolo	  et	  al.	  2008).	  Therefore	  it	  was	  hypothesised	  that	  the	  repression	  
of	  TGFβR2	  by	  EBV	  may	  occur	  via	  epigenetic	  mechanisms.	  	  
	  
Initially,	  chromatin	  immunoprecipitation	  (ChIP)	  was	  performed	  for	  H3K9Ac,	  a	  mark	  of	  active	  
transcription,	   on	   the	   panel	   of	   BL31	   cell	   lines	   including	   uninfected	   and	   cells	   infected	  with	  
wild-­‐type	  or	  mutant	   EBV.	  Analysis	   of	   the	  precipitated	  DNA	  was	  performed	  by	  qPCR	  using	  
several	  sets	  of	  primers	  across	  the	  TGFβR2	  promoter	  (fig.	  3.2A).	  H3K9Ac	  was	  shown	  to	  peak	  
at	   primer	   set	   4,	   approximately	   500	   bases	   downstream	   from	   the	   TSS,	   in	   uninfected	   BL31	  
cells.	   EBV	   reduces	   H3K9Ac,	   and	   this	   was	   partially	   recovered	   when	   EBNA2,	   EBNA3B	   or	  
EBNA3C	   are	   deleted,	   and	   reduced	   again	   in	   revertants	   (fig.	   3.2B).	   These	   findings	   were	  
consistent	  with	  the	  mRNA	  data	  (fig.	  3.1A).	  For	  the	  EBNA3A	  KOs,	  however,	  the	  involvement	  is	  
again	   unclear;	   in	   this	   case	   both	   cell	   lines	   seem	   to	   have	   an	   intermediate	   phenotype	   (fig.	  
3.2B).	  
	  
ChIP	  was	   then	  performed	   for	   the	   repressive	  mark	  H3K27Me3.	  This	   showed	  an	   increase	   in	  
the	  deposition	  of	  H3K27Me3	   induced	  by	  EBV	   infection,	  with	   similar	   values	  across	   the	   five	  
primer	  sets	  suggesting	  a	  broader	  peak	  than	  for	  H3K9Ac	  (fig.	  3.2C).	  When	  EBNA2,	  EBNA3B	  or	  
EBNA3C	  were	   deleted,	  H3K27Me3	  was	   reduced	   again,	   although	   in	   both	   EBNA3B	   KO	   lines	  
and	   EBNA3C	   KO	   2	   the	   reduction	   was	   not	   to	   the	   same	   level	   as	   in	   uninfected	   BL31.	   Both	  
EBNA3A	  KO	  lines	  showed	  an	  intermediate	  level	  of	  H3K27Me3.	  The	  revertant	  virus-­‐infected	  
cells	  showed	  levels	  of	  H3K27Me3	  similar	  to	  those	  infected	  with	  WT	  EBV,	  with	  the	  exception	  
of	  EBNA3C	  revertant,	  which	  showed	  reduced	  levels	  compared	  to	  wild-­‐type	  in	  this	  particular	  
experiment.	  	  
	  
Since	   H2K27Me3	   is	   deposited	   by	   polycomb	   repressive	   complex	   2	   (PRC2),	   ChIP	   was	   then	  
performed	  for	  SUZ12,	  a	  component	  of	  the	  PRC2	  complex	  (fig.	  3.2D).	  This	  showed	  that	  little	  




or	  no	  SUZ12	  is	  bound	  in	  uninfected	  BL31	  but	  that	  latent	  EBV	  increases	  SUZ12	  binding,	  with	  a	  
peak	  at	  primer	  set	  4.	  Levels	  were	  reduced	  again	  in	  EBNA2	  KO,	  EBNA	  3B	  KO	  2	  and	  EBNA3C	  KO	  
1,	  and	  recovered	  in	  the	  revertants	  with	  similar	  values	  to	  wild-­‐type	  infected	  cells.	  The	  other	  
cell	  lines	  showed	  intermediate	  levels	  of	  SUZ12	  binding.	  For	  both	  EBNA3A	  KO	  cell	  lines	  used,	  
SUZ12	   levels	   were	   increased,	   although	   for	   EBNA3A	   KO	   1	   the	   level	   of	   SUZ12	   binding	  was	  
intermediate	  (fig.	  3.2D).	  	  	  	  
	  
The	   binding	   of	   SUZ12	   generally	   correlates	   with	   H3K27Me3,	   in	   turn	   correlating	   with	  
repression	  of	  TGFβR2	  mRNA	  transcription.	  Taken	  together,	  these	  findings	  suggest	  that	  EBV	  
down-­‐regulates	  TGFβR2	  by	  PRC2-­‐mediated	  repression	  leading	  to	  gene	  silencing.	  	  
	   	  




























































































































































































































Figure	  3.2:	  ChIP	  for	  histone	  modifications	  at	  the	  TGFβR2	  promoter	  in	  a	  panel	  of	  BL31	  cell	  lines	  
(A)	   Schematic	   diagram	   of	   the	   TGFβR2	   promoter	   showing	   the	   location	   of	   products	   of	   primer	   sets	   used,	   the	  
putative	   transcription	   start	   site	   (TSS)	   and	   CpG	   islands.	   The	   coloured	   blocks	   represent	   the	   primer	   pairs	   1-­‐5,	  
shown	  as	  bars	  from	  left	  to	  right	  for	  each	  cell	  line	  in	  figs.	  B-­‐D.	  (B-­‐D)	  qPCRs	  showing	  ratio	  of	  histone	  modification	  
to	  input	  DNA	  at	  the	  TGFβR2	  promoter	  for	  (B)	  H3K9Ac	  (C)	  H3K27Me3	  and	  (D)	  SUZ12.	  Data	  shown	  are	  from	  an	  
experiment	   in	   which	   the	   pattern	   of	   variation	   of	   values	   for	   uninfected,	   knockout	   and	   wild-­‐type/revertant	  
infected	  cell	   lines	   is	   representative	  of	  at	   least	   two	  separate	  experiments.	  The	  error	  bars	   represent	   standard	  
deviations	  from	  triplicate	  qPCR	  reactions	  for	  both	  input	  and	  IP.	  	  
	  
	   	  




3.2.3	  H3K4Me3	  is	  present	  in	  all	  cell	  lines,	  suggesting	  that	  TGFβR2	  is	  a	  bivalent	  promoter	  
ChIP	   was	   then	   performed	   for	   H3K4Me3,	   also	   a	   mark	   of	   active	   transcription.	   It	   has	   been	  
shown	  that	  certain	  genes,	  particularly	   those	  which	  are	   important	   in	  embryonic	  stem	  cells,	  
have	   large	   areas	   of	   H3K27Me3	  with	   smaller	   areas	   of	   H3K4Me3	  within.	   It	   is	   thought	   that	  
these	   ‘bivalent	   domains’	   are	  poised	   for	   activation	  or	   repression	   (Bernstein	   et	   al.	   2006).	   It	  
was	  hypothesised	  that	  TGFβR2,	  being	  important	  in	  embryonic	  development,	  may	  be	  such	  a	  
domain.	  Although	  H3K4Me3	  does	  appear	   to	  vary	  according	  to	  the	  presence	  or	  absence	  of	  
EBV,	  even	  in	  the	  presence	  of	  EBV	  it	  remains	  (fig.	  3.3).	  In	  those	  cell	  lines	  in	  which	  the	  level	  of	  
H3K4Me3	  appears	  to	  be	  reduced,	  the	  level	  of	  GAPDH	  is	  also	  lower,	  suggesting	  the	  reduction	  
is	  due	  to	  the	  ChIP	  rather	  than	  being	  regulated	  by	  EBV	  itself.	  	  
	  
The	  peak	  of	  H3K4Me3	  is	  around	  primer	  set	  4,	  as	  seen	  for	  H3K9Ac	  and	  SUZ12	  (figs.	  3.3,	  3.2B	  
and	  3.2D).	  H3K27Me3,	  however,	  generally	   shows	  a	  broad	  peak	  with	  significant	  deposition	  
across	  all	  primer	  sets	  used	  (fig.	  3.2C).	  Therefore,	  in	  EBV-­‐infected	  BL31,	  there	  appears	  to	  be	  a	  
broad	  deposition	   of	  H3K27Me3	   across	   the	   promoter,	  with	   a	   concomitant	   smaller	   peak	   of	  
H3K4Me3,	   consistent	   with	   TGFβR2	   being	   a	   bivalent	   promoter.	   An	   Encyclopaedia	   of	   DNA	  
elements	  (ENCODE)	  search	  confirms	  increased	  deposition	  of	  both	  of	  these	  epigenetic	  marks	  
around	  the	  TSS	  for	  TGFβR2	  in	  an	  LCL,	  GM12878	  (http://genome.ucsc.edu/ENCODE).	  This	  is	  
consistent	  with	  TGFβR2	  being	  important	  in	  embryonic	  development.	   	  









Figure	  3.3:	  ChIP	  for	  H3K4Me3	  at	  the	  TGFβR2	  promoter	  in	  a	  panel	  of	  BL31	  cell	  lines	  
(A)	   Schematic	   diagram	   of	   the	   TGFβR2	   promoter	   showing	   the	   location	   of	   products	   of	   primer	   sets	   used,	   the	  
putative	   transcription	   start	   site	   (TSS)	   and	   CpG	   islands.	   The	   coloured	   blocks	   represent	   the	   primer	   pairs	   1-­‐5,	  
shown	  as	  bars	  from	  left	  to	  right	  for	  each	  cell	  line	  in	  figure	  B.	  (B)	  qPCR	  showing	  ratio	  of	  H3K4Me3	  to	  input	  DNA	  
at	   the	   TGFβR2	   promoter,	   using	   the	   five	   primer	   sets	   as	   shown	   in	   A,	   and	   control	   promoter	   primers	   GAPDH	  
(active)	  and	  globin	  (repressed).	  The	  error	  bars	  represent	  standard	  deviations	  from	  triplicate	  qPCR	  reactions	  for	  
both	  input	  and	  IP.	  
	  
3.2.4	  In	  BL31	  cell	  lines,	  DNA	  methylation	  of	  TGFβR2	  does	  not	  occur	  
H3K27Me3,	   deposited	   by	   PRC2,	   leads	   to	   gene	   silencing.	   This	   in	   turn	   has	   been	   shown	   to	  
increase	  the	  likelihood	  of	  subsequent	  DNA	  methylation,	  a	  more	  stable	  repressive	  epigenetic	  
mark,	  by	  approximately	  12-­‐fold	  (Widschwendter	  et	  al.	  2007).	  Therefore	  it	  was	  hypothesised	  
that	  CpG	  methylation	  of	  TGFβR2	  may	  occur	  in	  some	  EBV-­‐infected	  cell	  lines	  in	  which	  TGFβR2	  
is	   repressed.	   CpG	  methylation	  was	   sought	   using	   a	  method	   based	   on	   the	  methylated	   CpG	  
island	  recovery	  assay	  (MIRA)	  (Rauch	  and	  Pfeifer	  2010),	  using	  a	  histidine-­‐tagged	  recombinant	  
methyl-­‐binding	  protein	  complex	  (MBD2b/MBD3L1)	  that	  specifically	  binds	  methylated	  CpGs	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a	   positive	   control,	   fragmented	  DNA	   from	   Jurkat	   cells	  which	   had	   been	   fully	  methylated	   in	  
vitro	   was	   used,	   with	   a	   negative	   control	   in	   which	   only	   the	   magnetic	   beads	   were	   added,	  
without	  any	  His-­‐MBD2b/MBD3L1	  protein	  complex.	  
	  
This	  showed	  that	  there	  was	  no	  DNA	  methylation	  at	   this	   locus	   in	  any	  of	   the	  BL31	  cell	   lines	  
(fig.	  3.4).	  As	  expected,	  the	  positive	  control	  showed	  DNA	  methylation	  only	  in	  the	  CpG	  island,	  
at	  primer	  sets	  3	  and	  4	  (see	  fig.	  3.2A).	  The	  lack	  of	  DNA	  methylation	  in	  these	  cell	  lines	  may	  be	  
because	   they	   have	   been	   infected	   with	   EBV	   in	   vitro	   relatively	   recently,	   and	   so	   DNA	  
methylation	  has	  not	  yet	  occurred,	  or	  because	  PRC2	  is	  active	  and	  H3K4Me3	  is	  also	  present.	  
Similar	  findings	  were	  seen	  for	  BIM	  in	  a	  similar	  panel	  of	  BL31	  cells	  infected	  with	  recombinant	  













Figure	  3.4:	  Methylated	  DNA	  precipitation	  at	  the	  TGFβR2	  promoter	  in	  a	  panel	  of	  BL31	  cell	  lines	  	  
Methylated	  DNA	  was	  precipitated	  followed	  by	  qPCR	  using	  primer	  sets	  2,	  3	  and	  4,	  as	  shown	  in	  figure	  3.2A,	  for	  
the	  cell	  lines	  shown,	  as	  a	  well	  as	  a	  positive	  (POS)	  and	  a	  negative	  control	  (NEG).	  The	  colours	  of	  the	  bars	  are	  the	  
same	   as	   those	   of	   the	   blocks	   in	   the	   schematic	   diagram	   of	   the	   TGFβR2	   promoter	   shown	   in	   figure	   3.2A.	   The	  
positive	  control	  was	  a	  fully	  in	  vitro	  methylated	  Jurkat	  cell	  line.	  Values	  are	  shown	  as	  ratios	  to	  input	  DNA	  and	  are	  
representative	  of	  two	  separate	  experiments.	  The	  error	  bars	  represent	  standard	  deviations	  from	  triplicate	  qPCR	  
reactions.	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3.2.5	   In	   some	   B	   cell	   lines	   showing	   repression	   of	   TGFβR2,	   DNA	   methylation	   of	   TGFβR2	  
occurs	  and	  may	  replace	  H3K27	  trimethylation	  
Since	   DNA	  methylation	   of	   BIM	   had	   been	   demonstrated	   in	   other	   cell	   lines	   including	   EBV-­‐
positive	  BL	  (Paschos	  et	  al.	  2009),	  a	  further	  set	  of	  B	  cell	   lines	  were	  investigated	  for	  TGFβR2	  
expression	   and	   DNA	   methylation	   of	   TGFβR2.	   Since	   DNA	   methylation	   of	   the	   TGFβR2	  
promoter	  region	  has	  been	  demonstrated	  in	  PEL	  cell	  lines	  (Di	  Bartolo	  et	  al.	  2008)	  and	  a	  TGFβ-­‐
resistant	  DLBCL	  cell	  line	  DB	  as	  well	  as	  Akata	  (Chen	  et	  al.	  2007),	  it	  was	  hypothesised	  that	  in	  
some	  cell	  lines	  where	  TGFβR2	  was	  repressed,	  DNA	  methylation	  may	  coexist	  with,	  or	  possibly	  
replace,	  H3K27Me3.	  	  
	  
TGFβR2	  expression	  was	  repressed,	  similar	  to	  BL31-­‐WT,	  in	  Akata6,	  Akata31,	  LCL-­‐WT	  and	  LCL-­‐
X50.7,	   but	  was	   not	   repressed	   in	   Ramos	   (fig.	   3.5A).	   For	   the	   LCLs,	   this	  was	   consistent	  with	  
previous	  findings,	  since	  LCLs	  are	  known	  to	  resist	  the	  effects	  of	  TGFβ	  and	  in	  which	  TGFβR2	  is	  
repressed	  [see	  chapter	  6,	  fig.	  6.1	  and	  (Kumar	  et	  al.	  1991,	  Inman	  and	  Allday	  2000b)].	  Ramos,	  
an	   EBV-­‐negative	   BL	   cell	   line,	   has	   previously	   been	   shown	   to	   express	   TGFβR2	   (Inman	   and	  
Allday	   2000b,	   Fukuda	   and	   Longnecker	   2004)	   and	   to	   be	   sensitive	   to	   the	   effects	   of	   TGFβ	  
(Blomhoff	  et	  al.	  1987,	  Altiok	  et	  al.	  1993,	  Chaouchi	  et	  al.	  1995,	  Saltzman	  et	  al.	  1998,	  Fukuda	  
and	  Longnecker	  2004,	  Di	  Bartolo	  et	  al.	  2008).	  	  
	  
The	  Akata	  cell	   line	  was	  originally	  isolated	  from	  an	  EBV-­‐positive	  BL	  from	  a	  Japanese	  patient	  
and	   expressed	   latency	   I,	   i.e.	   EBNA1	   only.	   However,	   after	   serial	   passage	   in	   vitro	   selected	  
clones	   from	   the	   original	   Akata	   line	   became	   EBNA1-­‐negative,	   i.e.	   lost	   the	   EBV	   episome,	  
whereas	   other	   clones	   remained	   EBNA1-­‐positive	   (Shimizu	   et	   al.	   1994).	   Akata6	   is	   an	   EBV-­‐
positive	   (latency	   I)	   clone	   whereas	   Akata31	   is	   an	   EBV-­‐negative	   clone,	   having	   lost	   its	   EBV	  
episome	  (Jenkins	  et	  al.	  2000).	  The	  Akata	  cell	  line	  has	  previously	  been	  shown	  to	  be	  resistant	  
to	  the	  effects	  of	  TGFβ	  and	  have	  reduced	  expression	  of	  TGFβR2	  (Inman	  and	  Allday	  2000b).	  
	  
When	   DNA	   methylation	   was	   investigated,	   it	   was	   found	   that	   of	   those	   cell	   lines	   in	   which	  
TGFβR2	  was	  repressed,	  DNA	  methylation	  was	  seen	  in	  both	  Akata	  cell	   lines	  and	  in	  the	  long	  
established	   LCL	   X50-­‐7,	   but	   not	   in	   BL31-­‐WT	   (as	   seen	   also	   in	   figure	   3.4)	   or	   in	   the	   recently	  
made	  LCL-­‐WT	  (fig.	  3.5B).	   In	  this	  case,	  DNA	  extracted	  from	  PBMCs	  was	  included	  as	  another	  
negative	  control	  (in	  addition	  to	  beads	  without	  protein	  complex),	  as	  these	  are	  known	  to	  be	  




unmethylated	  [K.	  Paschos,	  personal	  communication	  and	  (Paschos	  et	  al.	  2009)].	  As	  expected	  
this	   showed	   no	   DNA	   methylation	   (fig.	   3.5B).	   In	   BL31	   and	   Ramos,	   in	   which	   TGFβR2	   was	  
expressed,	  as	  expected	  DNA	  methylation	  did	  not	  occur	  at	  this	  locus.	  	  
	  
ChIP	  for	  H3K27Me3	  was	  performed	  in	  the	  same	  set	  of	  cell	  lines.	  This	  showed	  that,	  of	  those	  
lines	  with	  repressed	  TGFβR2,	  H3K27Me3	  was	  seen	  in	  BL31-­‐WT	  (as	  before	  in	  fig.	  3.2C),	  LCL-­‐
WT	  and	  also	   to	   some	  degree	   in	   LCL	  X50-­‐7	   (fig.	   3.5C).	  However,	  no	   increase	   in	  H3K27Me3	  
was	  seen	  in	  either	  of	  the	  Akata	  cell	  lines	  despite	  repression	  of	  TGFβR2.	  This	  suggests	  that	  in	  
the	  Akata	  cell	   lines,	  DNA	  methylation	  has	  replaced	  H3K27Me3	  as	  a	  more	  stable	  repressive	  
epigenetic	   modification.	   In	   BL31-­‐WT	   and	   the	   recently	   established	   LCL-­‐WT,	   TGFβR2	  
repression	   is	   associated	   with	   H3K27Me3	   but	   no	   DNA	  methylation,	   whereas	   in	   LCL	   X50-­‐7	  
there	  is	  a	  combination	  of	  H3K27Me3	  and	  DNA	  methylation	  associated	  with	  the	  repression	  of	  
TGFβR2.	   In	  BL31	  and	  Ramos	  H3K27Me3	  was	  not	   increased,	   consistent	  with	  TGFβR2	  being	  
expressed	  in	  these	  cell	  lines.	  	  
	  
Since	   Akata6	   and	   Akata31	   showed	   DNA	  methylation	   at	   the	   TGFβR2	   promoter,	   these	   cell	  
lines	  were	  further	  investigated	  using	  the	  full	  set	  of	  primers	  in	  order	  to	  determine	  which	  part	  
of	  the	  promoter	  region	  was	  methylated.	  This	  showed	  that	  in	  both	  cell	  lines,	  like	  the	  in	  vitro	  
fully	  methylated	  Jurkat	  DNA	  positive	  control,	  CpG	  methylation	  occurs	  at	  both	  predicted	  CpG	  
islands	  and	  not	  in	  the	  other	  regions	  analysed.	  The	  peak	  of	  CpG	  methylation	  occurred	  at	  the	  
region	   covered	   by	   primer	   set	   4,	   i.e.	   towards	   the	   distal	   end	   of	   the	   largest	   CpG	   island	   (fig.	  
3.6A-­‐B).	  	  
	   	  



























Figure	  3.5:	  TGFβR2	  mRNA	  expression,	  H3K27Me3	  and	  DNA	  methylation	  in	  a	  panel	  of	  B	  cell	  lines	  	  
(A)	  qRT-­‐PCR	  for	  TGFβR2.	  The	  values	  represent	  the	  ratio	  of	  expression	  to	  the	  endogenous	  control	  gene	  GNB2L1.	  
Data	  shown	  are	  representative	  of	  at	  least	  two	  experiments.	  The	  error	  bars	  represent	  standard	  deviations	  from	  
triplicate	   qPCR	   reactions.	   (B)	  Methylated	  DNA	   precipitation	   at	   the	   TGFβR2	   promoter:	  Methylated	  DNA	  was	  
precipitated	  followed	  by	  qPCR	  using	  primer	  set	  4,	  as	  shown	  in	  figure	  3.2A,	  for	  the	  cell	  lines	  shown,	  as	  a	  well	  as	  
a	  positive	  and	  a	  negative	  control.	  The	  positive	  control	  was	  a	  fully	  in	  vitro	  methylated	  Jurkat	  cell	  line.	  Values	  are	  
shown	  as	  ratios	  to	  input	  DNA.	  The	  error	  bars	  represent	  standard	  deviations	  from	  triplicate	  qPCR	  reactions.	  (C)	  
ChIP	  for	  H3K27Me3	  at	  the	  TGFβR2	  promoter.	  The	  coloured	  bars	  represent	  the	  values	  at	  primer	  pairs	  1-­‐5,	  the	  
locations	  of	  which	  were	  shown	  in	  figure	  3.2A.	  qPCR	  showing	  ratio	  of	  H3K27Me3	  to	  input	  DNA	  at	  the	  TGFβR2	  
promoter	  for	  the	  cell	  lines	  shown.	  Data	  shown	  are	  representative	  of	  at	  least	  two	  experiments.	  The	  error	  bars	  

























































































Figure	  3.6:	  Location	  of	  methylated	  DNA	  precipitation	  at	  the	  TGFβR2	  promoter	  for	  Akata6	  and	  Akata31	  cell	  
lines	  	  
(A)	   Schematic	   diagram	   of	   the	   TGFβR2	   promoter	   showing	   the	   location	   of	   products	   of	   primer	   sets	   used,	   the	  
putative	   transcription	   start	   site	   (TSS)	   and	   CpG	   islands.	   The	   coloured	   blocks	   represent	   the	   primer	   pairs	   1-­‐5,	  
shown	  as	  bars	  from	  left	  to	  right	  for	  each	  cell	  line	  in	  figure	  B.	  (B)	  Methylated	  DNA	  was	  precipitated	  followed	  by	  
qPCR	  using	  all	  primer	  sets	  as	  shown	  in	  (A),	  for	  Akata6	  and	  Akata31	  as	  a	  well	  as	  a	  positive	  (POS)	  and	  a	  negative	  
control	  (NEG).	  The	  positive	  control	  was	  a	  fully	  in	  vitro	  methylated	  Jurkat	  cell	  line.	  Values	  are	  shown	  as	  ratios	  to	  
input	  DNA,	  with	  error	  bars	  representing	  standard	  deviations	  from	  triplicate	  qPCR	  reactions.	  	  
	  











































3.3	  The	  effect	  of	  EBV	  latency	  on	  TGFβ	  signalling	  
3.3.1	  Latent	  EBV	  leads	  to	  suppression	  of	  signalling	  in	  response	  to	  TGFβ1;	  EBNA2,	  EBNA3B	  
and	  EBNA3C	  are	  necessary	  
Canonical	   signalling	   in	   response	   to	   TGFβ	   occurs	   via	   TGFβR1	   and	   TGFβR2	   and	   results	   in	  
phosphorylation	  of	  SMAD2	  and/or	  SMAD3.	  Since	  EBV	  down-­‐regulates	  TGFβR2,	  the	  effect	  of	  
this	  on	  TGFβ	  signalling	  was	  investigated	  in	  the	  panel	  of	  BL31	  cell	  lines.	  An	  initial	  time	  course	  
was	   performed	   in	   which	   BL31	   and	   BL31-­‐WT	   were	   treated	   with	   TGFβ1	   5ng/ml	   (hereafter	  
referred	   to	   as	   TGFβ)	   and	   samples	   harvested	   for	   protein	   extraction	   at	   intervals	   up	   to	   48	  
hours.	  SDS-­‐PAGE	  followed	  by	  western	  blot	  showed	  phosphorylation	  of	  SMAD2	  (pSMAD2)	  in	  
response	  to	  TGFβ	  in	  BL31,	  seen	  at	  15	  minutes	  and	  maintained	  for	  48	  hours	  after	  treatment	  
(fig	  3.7A).	  The	  full	  panel	  of	  cell	  lines	  was	  therefore	  treated	  to	  see	  what	  effect	  EBV	  infection,	  
and	   deletion	   of	   the	   individual	   latent	   proteins,	   had	   on	   TGFβ	   signalling	   as	   detected	   by	  
pSMAD2.	  
	  
This	   showed	   that	   when	   infected	   with	   wild-­‐type	   EBV,	   TGFβ	   did	   not	   induce	   the	  
phosphorylation	  of	  SMAD2	  (pSMAD2),	  i.e.	  signalling	  was	  suppressed.	  When	  EBNA2,	  EBNA3B	  
or	  EBNA3C	  were	  deleted,	  pSMAD2	  was	  restored	  (fig.	  3.7B-­‐D).	  These	  findings	  are	  consistent	  
with	   the	   repression	  of	   TGFβR2	  mRNA	   levels	  by	   the	   cooperation	  of	   these	   latent	  proteins	   -­‐	  
EBNA2,	   EBNA3B	   and	   EBNA3C	   (fig.	   3.1A).	   Therefore,	   these	   proteins	   cooperate	   to	   down-­‐
regulate	  TGFβR2,	  which	  results	  in	  loss	  of	  TGFβ	  signalling	  via	  the	  canonical	  SMAD2	  pathway.	  	  
	  
Id	   proteins	   are	   downstream	   targets	   of	   both	   TGFβ	   and	   BMP	   signalling,	   for	   example	   TGFβ	  
induces	   Id2	   and	   Id3	   in	   pro-­‐B	   cells,	   inhibiting	   their	   growth	   and	   survival	   (Kee	   et	   al.	   2001).	  
BMPs	   induce	   Id	   expression	   in	   several	   cell	   types	   (Katagiri	   et	   al.	   2002,	   Korchynskyi	   and	   ten	  
Dijke	  2002,	   Lopez-­‐Rovira	  et	   al.	   2002),	   however	   the	  effect	  of	   TGFβ	  on	   Id	  expression	   varies	  
according	  to	  the	  cell	  type	  and	  TGFβ	  concentration	  (Ruzinova	  and	  Benezra	  2003).	  In	  epithelial	  
cells,	  TGFβ	  represses	  Id	  proteins	  (Ling	  et	  al.	  2002)	  but	  in	  BLs	  it	  induces	  these	  (Spender	  and	  
Inman	  2009b).	   The	  effect	   of	   TGFβ	  on	  expression	  of	   ID1	   and	   ID2	  was	   investigated	   in	  BL31	  
cells.	  Both	  ID1	  and	  ID2	  were	  induced	  after	  two	  hours’	  exposure	  to	  TGFβ,	  but	  not	  by	  vehicle	  
alone.	   However,	   consistent	   with	   the	   repression	   of	   TGFβR2	   and	   suppression	   of	   TGFβ	  
signalling	  by	  EBV	  in	  BL31	  cells,	  ID1	  and	  ID2	  were	  not	  induced	  in	  the	  EBV-­‐infected	  cells	  (fig.	  
3.8A-­‐B).	  
































































Figure	  3.7:	  The	  effect	  of	  exogenous	  TGFβ1	  on	  SMAD2	  phosphorylation	  in	  BL31	  cells	  
(A)	  Western	  blot	  analysis	  showing	  the	  effect	  of	  exogenous	  TGFβ1	  treatment	   (5ng/ml)	  over	   time	  on	   levels	  of	  
phosphorylated	  SMAD2	  (pSMAD2)	  in	  uninfected	  BL31	  cells.	  (B-­‐D)	  Western	  blot	  analysis	  showing	  the	  effect	  of	  
48	  hours’	   treatment	  with	  exogenous	  TGFβ1	   (5ng/ml)	  on	   levels	  of	  phosphorylated	  SMAD2	   (pSMAD2)	   in	  BL31	  
cells	   infected	  with	  recombinant	  EBV.	  Levels	  are	  compared	  to	  those	  at	  time	  0	  without	  any	  treatment,	  and	  48	  
hours	  with	  vehicle	  (2mg/ml	  BSA	  in	  PBS)	  only.	  SMAD2	  levels	  are	  shown	  for	  comparison	  and	  γ-­‐tubulin	  was	  used	  






















Figure	  3.8:	  TGFβ1	  leads	  to	  induction	  of	  ID1	  and	  ID2	  two	  hours	  after	  treatment	  in	  uninfected,	  but	  not	  in	  EBV-­‐
infected,	  BL31	  cells	  
	  qRT-­‐PCR	   for	   (A)	   ID1	   and	   (B)	   ID2	   in	   uninfected	   and	   EBV-­‐infected	   BL31	   cells	   with	   time	   after	   treatment	  with	  
TGFβ1	   or	   vehicle.	   Values	   are	   expressed	   as	   ratios	   to	   the	   endogenous	   control	   gene	  GNB2L1,	   with	   error	   bars	  
representing	  standard	  deviations	  of	  triplicate	  qPCR	  reactions.	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3.3.2	   In	   BL31	   cells,	   p15INK4B	   is	   not	   induced	   by	   TGFβ;	   however,	   latent	   EBV	   infection	  
increases	  its	  expression	  
TGFβ	  is	  known	  to	   induce	  p15INK4B	  (hereafter	  referred	  to	  as	  p15)	   in	  epithelial	  cells,	  and	  this	  
results	   in	   growth	   arrest	   (Hannon	   and	   Beach	   1994).	   The	   effect	   of	   TGFβ	   treatment	   on	   p15	  
expression	  was	  investigated	  in	  uninfected	  and	  wild-­‐type	  EBV	  infected	  BL31	  cells,	  measuring	  
p15	  mRNA	  by	  qRT-­‐PCR.	   This	   showed	   that,	   although	  wild-­‐type	  EBV	  appears	   to	  up-­‐regulate	  
basal	   p15	   expression,	   there	   is	   no	   induction	   of	   p15	   in	   response	   to	   TGFβ	   (fig.	   3.9).	   These	  
samples	  were	  taken	  at	  the	  same	  time	  as	  protein	  samples	  taken	  for	  pSMAD2	  analysis,	  as	  well	  
as	   RNA	   for	   ID1	   and	   ID2	   expression	   (fig.	   3.8A-­‐B),	   showing	   that	   TGFβ	   was	   active,	   inducing	  
pSMAD2,	  ID1	  and	  ID2.	  Thus,	  although	  p15	  expression	  is	  markedly	  repressed	  in	  BL31,	  it	  is	  up-­‐
regulated	   by	   latent	   EBV;	   however,	   consistent	  with	   other	   studies	   in	   BL	   cells	   (Spender	   and	  
Inman	   2009b),	   p15	   is	   not	   induced	   by	   TGFβ	   in	   BL31	   cells.	   p15	   has	   been	   shown	   to	   be	  
frequently	  methylated	  (and	  hence	  repressed)	  in	  BL	  (Klangby	  et	  al.	  1998).	  The	  effects	  of	  EBV	  
on	  p15	  expression	  will	  be	  discussed	  in	  more	  detail	  in	  section	  6.4.2.	  
	  
	  
Figure	  3.9:	  TGFβ1	  does	  not	  induce	  p15INK4B	  in	  BL31	  cells,	  but	  EBV	  infection	  increases	  its	  expression	  
qPCR	   for	   p15INK4B	   (CDKN2B)	  with	   time	   after	   treatment	   in	   uninfected	   and	  wild-­‐type	   EBV	   infected	   BL31	   cells.	  
cDNA	  samples	  used	  were	  the	  same	  as	  in	  figure	  3.8,	  confirming	  that	  TGFβ1	  did	  induce	  ID1	  and	  ID2	  expression,	  
but	  not	  p15,	   in	   these	  cells.	  Values	  are	  expressed	  as	   ratios	   to	  GNB2L1,	  with	  error	  bars	   representing	  standard	  



























3.3.3	  EBV	  does	  not	  significantly	  alter	  TGFβR1	  expression	  in	  BL31	  cells	  
TGFβ	   signalling	   occurs	   via	   TGFβR2	   and	   TGFβR1.	   Having	   shown	   that	   EBV	   down-­‐regulates	  
TGFβR2	  and	  leads	  to	  ablation	  of	  TGFβ	  signalling,	  it	  was	  also	  important	  to	  exclude	  an	  effect	  
of	   EBV	   on	   TGFβR1	   expression.	   Therefore	   qRT-­‐PCR	   was	   performed	   for	   TGFβR1	   in	   the	   full	  
panel	  of	  BL31	  cell	  lines.	  This	  showed	  very	  little	  variation	  in	  TGFβR1	  expression	  between	  the	  
cell	  lines	  (fig.	  3.10).	  Hence	  EBV	  does	  not	  significantly	  alter	  TGFβR1	  expression,	  and	  thus	  the	  




Figure	  3.10:	  Expression	  of	  TGFβR1	  mRNA	  in	  a	  panel	  of	  BL31	  cell	  lines	  	  
qRT-­‐PCR	   on	   a	   panel	   of	   BL31	   cell	   lines	   including	   uninfected	   and	   infected	   with	   wild-­‐type	   or	   mutant	   virus	   as	  
indicated.	  The	  values	  represent	  the	  ratio	  of	  expression	  to	  the	  endogenous	  control	  gene	  GNB2L1.	  Data	  shown	  
are	   from	   an	   experiment	   in	   which	   the	   pattern	   of	   variation	   of	   values	   for	   uninfected,	   knockout	   and	   wild-­‐
type/revertant	   infected	   cell	   lines	   is	   representative	   of	   at	   least	   two	   separate	   experiments.	   The	   error	   bars	  
represent	  standard	  deviations	  from	  triplicate	  qPCR	  reactions.	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3.4	  The	  effects	  of	  EBV	  and	  its	  latent	  proteins	  on	  TGFβR3	  expression	  	  
3.4.1	   Latent	   EBV	   up-­‐regulates	   TGFβR3	   expression	   in	   BL31	   cells;	   EBNA2,	   EBNA3B	   and	  
EBNA3C	  are	  necessary	  
Microarray	  analysis	  had	  suggested	  that	  EBV,	  in	  addition	  to	  repressing	  TGFβR2,	  up-­‐regulates	  
TGFβR3	   in	   BL31	   cells	   [www.epstein-­‐barrvirus.org.uk	   and	   (White	   et	   al.	   2010)].	   Thus	   the	  
expression	   of	   TGFβR3	  mRNA	  was	   investigated	   by	   qRT-­‐PCR	   in	   the	   panel	   of	   BL31	   cell	   lines.	  
This	   confirmed	   that	   EBV	   up-­‐regulates	   TGFβR3	   (fig.	   3.11A).	   When	   EBNA2,	   EBNA3B	   and	  
EBNA3C	   are	   deleted,	   the	   up-­‐regulation	   is	   reduced,	   and	   in	   the	   revertants	   it	   is	   again	   seen.	  
Western	   blots	   were	   also	   performed	   for	   TGFβR3	   protein	   expression	   on	   extracts	   from	   the	  
same	  cell	   lines.	  This	  confirmed	  the	  up-­‐regulation	  of	  TGFβR3	  by	  EBV,	  with	  EBNA2,	  EBNA3B	  





















Figure	  3.11:	  EBNA2,	  EBNA3B	  and	  EBNA3C	  cooperate	  to	  up-­‐regulate	  TGFβR3	  expression	  in	  BL31	  cells	  	  
(A)	  qRT-­‐PCR	  for	  TGFβR3	  in	  a	  panel	  of	  BL31	  cell	  lines	  including	  uninfected	  and	  infected	  with	  wild-­‐type	  or	  mutant	  
virus	  as	  indicated.	  The	  values,	  also	  shown	  above	  bars	  for	  clarification,	  represent	  the	  ratio	  of	  expression	  to	  the	  
endogenous	  control	  gene	  GNB2L1.	  Data	  shown	  are	   from	  an	  experiment	   in	  which	   the	  pattern	  of	  variation	  of	  
values	   for	  uninfected,	  knockout	  and	  wild-­‐type/revertant	   infected	  cell	   lines	   is	   representative	  of	  at	   least	   three	  
separate	   experiments.	   The	   error	   bars	   represent	   standard	   deviations	   from	   triplicate	   qPCR	   reactions.	   (B)	  
Western	   blot	   for	   TGFβR3	   in	   whole	   cell	   lysates	   from	   the	   same	   cell	   lines,	   with	   γ-­‐tubulin	   shown	   as	   a	   loading	  






























3.4.2	  The	  up-­‐regulation	  of	  TGFβR3	  by	  EBV	  in	  BL31	  cells	  is	  also	  epigenetically	  mediated	  
Having	   shown	   that	   the	   repression	   of	   TGFβR2	   by	   EBV	   occurs	   by	   epigenetic	   mechanisms	  
involving	   histone	   modifications,	   the	   mechanism	   of	   up-­‐regulation	   of	   TGFβR3	   was	  
investigated	   by	   performing	   qPCR	   using	   primers	   across	   the	   TGFβR3	   promoters,	   using	   the	  
same	   ChIP	   samples	   as	   had	   been	   investigated	   for	   the	   TGFβR2	   promoter	   (see	   figs.	   3.2	   and	  
3.3).	  	  
	  
TGFβR3	  has	  two	  promoters,	  proximal	  and	  distal,	  with	  the	  proximal	  one	  being	  predominantly	  
used	  in	  most	  human	  tissues	  (Cooper	  et	  al.	  2010).	  There	  are	  several	  small	  CpG	  islands	  around	  
both	   promoters	  with	   one	   larger	   one	   (of	   over	   1000	   bp)	   around	   the	   proximal	   transcription	  
start	  site	  (fig.	  3.12A).	  Primer	  sets	  were	  designed	  to	  cover	  both	  promoter	  regions.	  	  
	  
ChIP	  for	  H3K9Ac,	  a	  mark	  of	  active	  transcription,	  showed	  increased	  H3K9Ac	  in	  wild-­‐type	  and	  
revertant-­‐infected	  cells,	  and	  was	   low	   in	  EBNA2,	  EBNA3B	  and	  EBNA3C	  KO	  cells	   (fig.	  3.12B),	  
consistent	  with	   the	  mRNA	   results	   (fig.	  3.11A).	   For	  EBNA3A	  KO	  1,	  H3K9Ac	  was	   low	  but	   for	  
EBNA3A	  KO	  2	  the	  level	  was	  intermediate	  (fig.	  3.12B);	  however,	  variations	  in	  gene	  expression	  
between	   the	  different	  EBNA3A	  KO	  cell	   lines	  have	  previously	  been	  demonstrated	   [see	   figs.	  
3.1A,	  3.2B-­‐D	  and	  (White	  et	  al.	  2010)].	  	  
	  
ChIP	   for	   H3K27Me3	   showed	   relatively	   high	   levels	   in	   uninfected	   BL31	   cells,	   that	   were	  
reduced	  in	  wild-­‐type	  and	  revertant	  infected	  cells,	  and	  partially	  restored	  levels	  in	  EBNA2	  KO,	  
EBNA3B	  KO,	  EBNA3C	  KO	  and	  both	  EBNA3A	  KO	  lines	  (fig.	  3.12C).	  Thus,	  with	  the	  exception	  of	  
the	  EBNA3A	  KOs,	  as	  will	  be	  discussed	  further	  in	  section	  4.6,	  the	  results	  for	  H3K27Me3	  were	  
generally	   opposite	   to	   those	   for	   H3K9Ac,	   consistent	   with	   H3K27Me3	   being	   a	   mark	   of	  
transcriptional	  repression	  in	  the	  uninfected	  BL31	  cells.	  	  
	  
ChIP	   for	   H3K4Me3,	   another	  mark	   of	   active	   transcription,	   showed	   a	  moderate	   increase	   in	  
wild-­‐type	   and	   revertant	   cell	   lines,	   with	   reduced	   levels	   in	   EBNA2,	   EBNA3A,	   EBNA3B	   and	  
EBNA3C	   KOs	   (fig.	   3.12D),	   again	   consistent	   with	   the	   mRNA	   findings	   (fig.	   3.11A)	   with	   the	  
exception	  of	  EBNA3A	  KOs.	  However,	  the	  variation	  between	  cell	  lines	  was	  much	  less	  marked	  
than	   for	   other	   histone	   modifications,	   suggesting	   that	   TGFβR3	   might	   also	   be	   a	   bivalent	  
promoter	  (see	  section	  3.2.3).	  	  




In	  all	  ChIPs	  performed,	  variation	  between	  cell	  lines	  was	  only	  seen	  at	  the	  proximal	  promoter,	  
with	   levels	  of	  all	  histone	  modifications	  being	   low	  at	   the	  distal	  promoter	   (figures	  3.12B-­‐D).	  
This	   is	   consistent	   with	   the	   regulation	   of	   TGFβR3	   by	   EBV	   in	   BL	   cells	   acting	   through	   the	  
proximal	  promoter.	  	  
	  
For	   all	   ChIPs,	   the	   peak	   of	   binding	   was	   seen	   at	   the	   primer	   set	   ‘proximal	   3’	   (shown	   in	  
turquoise),	   at	   the	   distal	   end	   of	   the	  main	   proximal	   CpG	   island,	   i.e.	   downstream	   from	   the	  
proximal	   promoter	   (fig.	   3.12A-­‐D).	   In	   contrast	   to	   the	   findings	   for	   TGFβR2,	   H3K27Me3	   also	  
showed	   a	   peak	   around	   this	   region,	   rather	   than	   being	   equally	   distributed	   across	   the	  
promoter	   as	  was	   seen	   for	   TGFβR2	   (fig.	   3.2).	  However,	   the	   region	   covered	  by	   the	   TGFβR2	  
promoter	  primers	  was	  smaller	  than	  that	  covered	  by	  the	  TGFβR3	  proximal	  promoter	  primers	  
(approximately	   2000bp	   and	   3000bp	   respectively),	   i.e.	   the	   primer	   set	   products	   were	   all	  
within	  500bp	  of	  each	  other	  for	  TGFβR2,	  whereas	  for	  TGFβR3	  there	  was	  a	  distance	  of	  around	  
1000bp	  between	  the	  products	  of	  primer	  sets	  proximal	  2,	  3	  and	  4.	  
	  
Taken	  together,	  these	  findings	  suggest	  that	  the	  regulation	  of	  TGFβR3	  by	  EBV	  also	  occurs	  via	  










	   	  



















































































































































































































Figure	  3.12:	  ChIP	  for	  histone	  modifications	  at	  the	  TGFβR3	  promoters	  in	  a	  panel	  of	  BL31	  cell	  lines	  
(A)	  Schematic	  diagram	  of	  distal	  and	  proximal	  TGFβR3	  promoters	  showing	  the	   location	  of	  products	  of	  primer	  
sets	  used,	  the	  putative	  transcription	  start	  sites	  (TSS)	  and	  CpG	  islands.	  The	  coloured	  blocks	  represent	  the	  primer	  
pairs	   shown	  as	  bars	   from	   left	   to	   right	   for	  each	  cell	   line	   in	   figures	  B-­‐D.	   (B-­‐D)	   qPCRs	   showing	   ratio	  of	  histone	  
modification	   to	   input	  DNA	  at	   the	  TGFβR3	  promoters	   for	   (B)	  H3K9Ac	   (C)	  H3K27Me3	  and	   (D)	  H3K4Me3.	  Data	  
shown	  are	  from	  an	  experiment	  in	  which	  the	  pattern	  of	  variation	  of	  values	  for	  uninfected,	  knockout	  and	  wild-­‐
type/revertant	   infected	   cell	   lines	   is	   representative	   of	   at	   least	   two	   separate	   experiments.	   The	   error	   bars	  




	   	  




3.4.3	  What	  is	  the	  relationship	  between	  TGFβR2	  and	  TGFβR3	  in	  BL31	  cells?	  
In	   BL31	   cells,	   EBV	   represses	   TGFβR2	   and	   up-­‐regulates	   TGFβR3.	   The	   same	   latent	   proteins	  
(EBNA2,	  EBNA3B	  and	  EBNA3C)	  appear	  to	  cooperate	   in	  the	  regulation	  of	  both	  these	  genes.	  
Thus	   in	   the	  majority	  of	  cell	   lines	  TGFβR2	  and	  TGFβR3	  appear	   to	  be	  reciprocally	   regulated,	  
with	   the	   exception	   of	   some	   of	   the	   EBNA3A	   KO	   lines.	   The	   mechanism	   of	   the	   apparent	  
reciprocality	  was	  therefore	  examined.	  	  
	  
It	   has	  been	   shown,	   in	  breast	   and	  ovarian	   cancer	   cells,	   that	   TGFβ1	   treatment	   leads	   to	   the	  
down-­‐regulation	  of	  TGFβR3	  by	  a	  direct	  effect	  on	  the	  TGFβR3	  proximal	  promoter,	  with	  this	  
process	  being	  dependent	  on	  TGFβR1	  and	  pSMAD2/3	  (Hempel	  et	  al.	  2008).	  It	  was	  therefore	  
hypothesised	  that,	  if	  a	  similar	  process	  occurs	  in	  B	  cells,	  TGFβ1	  present	  in	  medium	  produced	  
by	   autocrine	   secretion	   (and/or	   present	   in	   the	   serum)	   could	   result	   in	   down-­‐regulation	   of	  
TGFβR3	   in	   B	   cells	   where	   TGFβ	   signalling	   via	   pSMAD2	   is	   active,	   i.e.	   in	   primary	   B	   cells	   or	  
uninfected	  BL31	   cells.	  However,	  when	  TGFβR2	   is	   repressed	  by	   latent	   EBV,	   as	   in	  wild-­‐type	  
LCLs	  (see	  chapter	  6)	  or	  BL31-­‐WT,	  leading	  to	  suppression	  of	  TGFβ	  signalling	  via	  pSMAD2,	  this	  
process	  may	  no	   longer	  occur	   and	   thus	  TGFβR3	  would	  be	  de-­‐repressed.	   The	   current	   study	  
has	   shown	   that	  TGFβR1	  expression	   is	  not	  altered	   significantly	  by	  EBV	  or	  any	  of	   the	   latent	  
proteins	  investigated	  (fig.	  3.10).	  Therefore	  if	  this	  effect	  occurs	  it	  may	  be	  via	  TGFβR2	  rather	  
than	  TGFβR1.	  	  
	  
BL31	  cells	  were	  investigated	  to	  see	  whether	  TGFβ1-­‐induced	  repression	  of	  TGFβR3	  may	  occur	  
in	  a	  similar	  manner	  to	  that	  seen	  in	  the	  carcinoma	  cell	  lines	  described	  by	  Hempel	  et	  al	  (2008).	  
If	   this	   is	   the	   case,	   blocking	   TGFβ	   signalling	   by	   any	  means	  would	   lead	   to	   de-­‐repression	   of	  
TGFβR3.	   Thus	  EBV-­‐negative	  BL31	   cells	  were	   treated	  with	   SB431542,	   a	   specific	   inhibitor	  of	  
TGFβR1,	  or	  a	  DMSO	  control	  for	  30	  minutes,	  followed	  by	  treatment	  with	  TGFβ1	  or	  vehicle	  for	  
6	   hours,	   based	   upon	   the	   findings	   of	   Hempel	   et	   al	   that	   TGFβR3	   was	   maximally	   down-­‐
regulated	  by	  6	  hours	  after	  treatment	  with	  TGFβ1.	  Samples	  were	  then	  harvested	  for	  RNA,	  in	  
order	   to	   measure	   TGFβR3	   expression,	   and	   protein,	   in	   order	   to	   confirm	   that	   SB431542	  
treatment	  had	  blocked	  TGFβ	  signalling.	  
Treatment	  with	  SB431542	  was	  able	  to	  completely	  block	  TGFβ-­‐induced	  pSMAD2	  (fig.	  3.13B)	  
and	  caused	  a	  greater	   than	   two-­‐fold	   increase	   in	  TGFβR3	  expression	   (fig.	  3.13A).	  Therefore,	  
this	  could	  be	  consistent	  with	  TGFβ1	  causing	  repression	  of	  TGFβR3	  transcription	  in	  BL31	  cells.	  














Figure	  3.13:	  Treatment	  of	  EBV-­‐negative	  BL31	  cells	  with	  the	  TGFβR1	  inhibitor	  SB431542	  blocks	  TGFβ-­‐induced	  
pSMAD2	  and	  leads	  to	  an	  increase	  in	  TGFβR3	  mRNA	  	  
An	  equal	  number	  of	  BL31	  cells	  were	   treated	  with	  10μM	  SB431542	  or	  DMSO	  alone	   for	  30	  minutes	  and	   then	  
each	   sample	   split	   into	   two,	   of	  which	   one	  was	   treated	  with	   TGFβ1	   5ng/ml	   and	   the	   other	  with	   vehicle	   alone	  
(2mg/ml	  BSA	  in	  PBS).	  Samples	  were	  harvested	  after	  a	  further	  six	  hours	  for	  RNA	  and	  protein	  extraction.	  (A)	  qRT-­‐
PCR	   for	   TGFβR3	   in	   cells	   treated	  with	   or	  without	   SB431542	   for	   30	  minutes	   followed	  by	   vehicle	   alone	   for	   six	  
hours.	   (B)	  Western	   blot	   for	   pSMAD2	   after	   treatment	  with	   SB431542	   dose	   or	   DMSO	   control	   for	   30	  minutes	  
followed	  by	  TGFβ1	  5ng/ml	  or	  vehicle	  for	  6	  hours.	  SMAD2	  is	  shown	  for	  comparison,	  with	  γ-­‐tubulin	  as	  a	  loading	  
control.	  	  
	  
If	  this	  TGFβ1-­‐induced	  repression	  of	  TGFβR3	  occurs	  in	  BL31	  cells,	  then	  when	  TGFβ	  signalling	  
is	   blocked	   by	   repression	   of	   TGFβR2,	   this	   repression	   would	   no	   longer	   occur	   and	   hence	  
TGFβR3	   would	   be	   de-­‐repressed.	   Therefore,	   when	   TGFβR2	   is	   not	   repressed	   and	   so	   TGFβ	  
signalling	   occurs	   (as	   in	   EBNA3B,	   EBNA3C	   and	   EBNA2	   KOs),	   then	   TGFβ1	   can	   continue	   to	  
repress	   TGFβR3	   so	   it	   is	   not	   up-­‐regulated	   in	   these	   cells.	   Generally	   TGFβR3	   would	   be	  
expressed	  whenever	   TGFβR2	   is	   repressed.	  However,	   and	  particularly	  where	   expression	  of	  
receptors	  is	  only	  partially	  repressed/partially	  up-­‐regulated,	  there	  may	  be	  differences	  in	  the	  
degree	   of	   repression	   of	   TGFβR3	   depending	   on	   the	   amount	   of	   TGFβ1	   available.	   TGFβ1	   is	  
present	  in	  serum,	  and	  in	  this	  study	  all	  experiments	  were	  conducted	  with	  cells	  proliferating	  
in	  medium	  containing	  FCS,	   since	   it	  was	   felt	   that	  depriving	   them	  of	   serum	  may	  alter	  many	  
processes	  within	  the	  cells.	  However,	  all	  the	  recombinant	  EBV-­‐infected	  BL31	  cell	   lines	  were	  
grown	  in	  the	  same	  media	  and	  generally	  when	  an	  experiment	  was	  performed	  the	  same	  batch	  
of	  medium	  containing	  FCS	  was	  used	   for	  all	   cell	   lines.	  Thus	  although	   there	  may	  have	  been	  
differences	  between	  cell	   lines	   in	  the	  amounts	  of	  TGFβ1	  present	  within	  the	  medium,	  these	  
are	   likely	   to	   have	   been	   small.	   In	   addition,	   the	   doses	   of	   exogenous	   TGFβ1	   used	   were	  





















generally	   high	   and	   thus	   likely	   to	   overcome	   any	   effect	   of	   variation	   in	   TGFβ1	   between	   cell	  
lines.	  	  
	  
As	  well	  as	  TGFβ1	  being	  present	  in	  serum,	  however,	  there	  is	  also	  autocrine	  production	  by	  B	  
cells	   (Kehrl	   et	   al.	   1986,	   Spender	   et	   al.	   2009).	   Therefore,	   in	   order	   to	   investigate	   the	  
differences	  between	  cell	  lines	  where	  TGFβR2	  was	  not	  fully	  repressed	  and	  the	  up-­‐regulation	  
of	  TGFβR3	  did	  not	  inversely	  correlate	  with	  the	  down-­‐regulation	  of	  TGFβR2,	  i.e.	  particularly	  
the	   EBNA3A	   KO	   cell	   lines,	   it	   was	   considered	   whether	   differences	   in	   autocrine	   TGFβ1	  
production	  could	  account	   for	   the	  discrepancies.	  TGFβ1	  expression	  was	   investigated	   in	   the	  
panel	  of	  BL31	  cell	  lines;	  however,	  because	  of	  time	  constraints,	  ELISA	  for	  secreted	  TGFβ1	  was	  
not	  performed.	  
	  	  	  	  	  
Although	  TGFβ1	  was	  possibly	  up-­‐regulated	  by	  EBV,	  the	  difference	  was	  relatively	  small	  and	  
there	  was	  no	  clear	  pattern	  of	  alteration	  of	  its	  expression	  by	  any	  particular	  latent	  protein	  (fig.	  
3.14).	  This	  suggests	  that	  EBV	  does	  not	  significantly	  alter	  autocrine	  TGFβ1	  production	  (with	  
the	  caveat	   that	  ELISA	  was	  not	  performed	  to	  confirm	  TGFβ1	  secretion),	  and	   therefore	   that	  
differences	   in	   TGFβ1	   expression	   are	   unlikely	   to	   explain	   the	   lack	   of	   reciprocality	   between	  












Figure	  3.14:	  EBV	  does	  not	  significantly	  alter	  TGFβ1	  mRNA	  expression	  	  
qRT-­‐PCR	  for	  TGFβ1	  mRNA	  in	  the	  panel	  of	  wild-­‐type	  and	  recombinant	  EBV-­‐infected	  BL31	  cell	   lines.	  Values	  are	  
expressed	  as	  ratios	  to	  the	  endogenous	  control	  gene	  GNB2L1	  with	  error	  bars	  representing	  standard	  deviation	  of	  
triplicate	  qPCR	  reactions.	  Data	  shown	  are	  from	  an	  experiment	  in	  which	  the	  pattern	  of	  variation	  of	  values	  for	  



















EBV	   down-­‐regulates	   TGFβR2	   via	   PRC2-­‐mediated	   transcriptional	   repression,	   leading	   to	  
suppression	  of	  TGFβ	  signalling,	  in	  BL31	  cells	  
This	   study	   has	   shown	   that	   wild-­‐type	   EBV	   infection	   leads	   to	   repression	   of	   TGFβR2	   and	  
suppression	  of	  canonical	  TGFβ	  signalling,	  as	  indicated	  by	  phosphorylation	  of	  SMAD2.	  Many	  
previous	  studies	  had	  shown	  that	  EBV	  infection	  leads	  to	  resistance	  to	  TGFβ-­‐induced	  growth	  
inhibition	  or	  apoptosis	  in	  B	  cells	  and	  other	  cell	  types.	  Although	  some	  studies	  in	  B	  cells	  had	  
suggested	  that	  EBV	  down-­‐regulates	  TGFβR2	  (Inman	  and	  Allday	  2000b,	  Fukuda	  et	  al.	  2006a,	  
Chen	  et	  al.	  2007),	  others	  suggested	  that	  the	  effect	  of	  EBV	  on	  TGFβ	  responses	  was	  not	  due	  to	  
changes	  in	  levels	  of	  TGFβ	  receptors	  (Arvanitakis	  et	  al.	  1995).	  In	  addition,	  some	  studies	  had	  
suggested	  that	  TGFβR1	  and	  TGFβR2	  were	  both	  reduced	  by	  EBV	  (Kumar	  et	  al.	  1991)	  or	  had	  
only	  investigated	  TGFβR1	  but	  not	  TGFβR2	  (Altiok	  et	  al.	  1991,	  Altiok	  et	  al.	  1993).	  However,	  no	  
previous	  studies	  in	  B	  cells	  appear	  to	  have	  investigated	  the	  effect	  of	  EBV	  on	  TGFβ	  signalling,	  
as	  detected	  by	  phosphorylation	  of	   SMAD	  proteins,	   use	  of	   a	   TGFβ–responsive	   reporter,	   or	  
changes	  in	  transcription	  of	  known	  TGFβ	  target	  genes.	  As	  well	  as	  confirming	  the	  repression	  
of	  TGFβR2	  by	  EBV,	  the	  current	  study	  has	  demonstrated	  that	  the	  same	  latent	  proteins	  which	  
are	   necessary	   for	   its	   transcriptional	   repression	   are	   also	   necessary	   for	   the	   loss	   of	   TGFβ	  
signalling,	  as	  measured	  by	  SMAD2	  phosphorylation.	  This	  suggests	  that	  the	  phosphorylation	  
of	  SMAD2	  is	  dependent	  on	  a	  threshold	  level	  of	  TGFβR2	  expression.	  	  
	  
Alterations	   in	   components	   of	   TGFβ	   signalling,	   including	  mutations	   of	   TGFβR2,	   have	   been	  
found	  in	  many	  tumour	  types	  [reviewed	  in	  (Elliott	  and	  Blobe	  2005,	  Dong	  and	  Blobe	  2006)].	  In	  
addition,	   epigenetically	   mediated	   changes	   are	   increasingly	   recognised	   as	   a	   cause	   of	  
malignancies	   including	   haematopoietic	   tumours.	   EBV	   had	   been	   shown	   to	   repress	   other	  
tumour	  suppressor	  genes	  by	  polycomb-­‐mediated	  repression	  (Paschos	  et	  al.	  2009,	  Skalska	  et	  
al.	  2010,	  Paschos	  et	  al.	  2012).	  Therefore	  the	  mechanism	  of	  repression	  of	  TGFβR2	  by	  EBV	  was	  
investigated.	  This	  showed	  that	  the	  transcriptional	  repression	  of	  TGFβR2	  is	  accompanied	  by	  
increased	  deposition	  of	   the	   repressive	  mark	  H3K27Me3,	   reduced	  deposition	  of	   the	   active	  
mark	  H3K9Ac,	  and	  increased	  binding	  of	  SUZ12,	  one	  of	  the	  main	  components	  of	  PRC2	  which	  
mediates	  H3K27Me3	   (fig.	   3.2).	   These	   changes	   in	  histone	  modifications	   generally	   correlate	  
with	   the	   changes	   in	   transcription	   that	   occur	   when	   individual	   latent	   genes	   are	   deleted.	  




Therefore,	   EBV	   down-­‐regulates	   another	   tumour	   suppressor	   gene,	   TGFβR2,	   by	   polycomb-­‐
mediated	  repression.	  	  
	  
Significance	  of	  DNA	  methylation	  
CpG	  hypermethylation	  of	  promoter	  regions	   is	   increasingly	  seen	  to	  occur	   in	  many	  tumours,	  
and	  several	  treatments	  currently	  in	  clinical	  practice	  for	  haematopoietic	  malignancies	  target	  
epigenetic	   lesions	   including	   DNA	   methylation,	   particularly	   in	   myelodysplastic	   syndrome	  
(Khan	   et	   al.	   2013).	   CpG	  methylation	   of	   the	   TGFβR2	   promoter	   has	   been	   demonstrated	   in	  
cancers	  of	  the	  lung,	  prostate,	  stomach	  and	  oesophagus	  as	  well	  as	  in	  some	  B	  cell	  lymphoma	  
and	  PEL	  cell	  lines	  (Zhang	  et	  al.	  2004,	  Zhao	  et	  al.	  2005,	  Di	  Bartolo	  et	  al.	  2008,	  Yamashita	  et	  al.	  
2008b,	   Dong	   et	   al.	   2012,	   Guo	   et	   al.	   2012).	   TGFβR2	   has	   also	   been	   found	   to	   be	  
hypermethylated	   in	   DNA	   extracted	   from	   patient	   samples,	   and	   associated	   with	   a	   worse	  
prognosis,	  in	  multiple	  myeloma	  patients	  (de	  Carvalho	  et	  al.	  2009).	  Deposition	  of	  H3K27Me3	  
is	  thought	  to	  precede	  DNA	  methylation	  and	  increase	  the	  likelihood	  of	  it	  occurring,	  with	  DNA	  
methylation	   being	   a	   more	   stable	   repressive	   epigenetic	   mark	   than	   histone	   modifications	  
(Schlesinger	  et	  al.	  2007,	  Widschwendter	  et	  al.	  2007).	  
	  
In	  the	  panel	  of	  BL31	  cell	  lines,	  although	  H3K27Me3	  varied	  according	  to	  the	  EBV	  latent	  genes	  
expressed,	  no	  DNA	  CpG	  methylation	  was	   seen	   (fig.	  3.4).	   Investigation	  of	   some	  other	  EBV-­‐
positive	  and	  negative	  cell	  lines,	  including	  LCLs,	  showed	  that	  DNA	  methylation	  of	  the	  TGFβR2	  
promoter	   occurs	   in	   Akata6,	   Akata31	   and	   LCL	   X50-­‐7,	   but	   not	   in	   BL31-­‐WT	   or	   a	   recently	  
established	  LCL-­‐WT,	  even	  though	  TGFβR2	  was	  also	  repressed	  in	  these.	  Akata6	  and	  Akata31	  
both	  showed	  DNA	  methylation	  of	  the	  CpG	  islands	  of	  the	  TGFβR2	  promoter	  region,	  without	  
H3K27Me3	   deposition,	   whereas	   LCL	   X50-­‐7	   showed	   intermediate	   levels	   of	   both	   DNA	  
methylation	  and	  H3K27Me3	  (fig.	  3.5B-­‐C).	  	  	  
	  
The	   original	   Akata	   cell	   line	  was	   established	   from	  an	   EBV-­‐positive	   BL	   (Takada	   et	   al.	   1991).	  
Recently	   after	   isolation	   from	  biopsy	   samples,	   BLs	   usually	   express	   latency	   I,	   i.e.	   are	   of	   the	  
group	  I	  phenotype	  (Rowe	  et	  al.	  1987).	  Akata6	  and	  Akata31	  are	  distinct	  clones	  of	  the	  original	  
Akata	  cell	  line,	  with	  Akata6	  having	  remained	  EBV-­‐positive	  (type	  I	  latency),	  whereas	  Akata31	  
had	  lost	  its	  episome	  during	  culture	  and	  thus	  become	  EBV-­‐negative	  (Jenkins	  et	  al.	  2000).	  The	  
DNA	  methylation	  and	  consequent	  repression	  of	  TGFβR2	  in	  both	  these	  cell	  lines	  suggests	  that	  




this	   occurred	   at	   an	   earlier	   stage	   in	   tumour	   development,	   for	   example	   as	   cells	   enter	   the	  
germinal	   centre	   where	   the	   full	   latency	   III	   set	   of	   genes	   would	   have	   been	   transiently	  
expressed	   (Thorley-­‐Lawson	   and	   Gross	   2004).	   In	   this	   case,	   the	   previous	   exposure	   to	  
EBNA2/EBNA3B/EBNA3C	  could	  have	   resulted	   in	  polycomb-­‐mediated	   repression	  of	  TGFβR2	  
and	   subsequent	  DNA	  methylation,	   resulting	   in	   a	  more	   stable	   repression	  of	   TGFβR2.	   Since	  
this	  is	  heritable,	  TGFβR2	  would	  have	  remained	  repressed	  by	  DNA	  methylation	  in	  continuous	  
culture,	  even	  though	  the	  EBV	  episome	  was	  completely	   lost	  (in	  the	  case	  of	  Akata31)	  or	  the	  
expression	  reverted	  to	  type	  I	  (in	  Akata6).	  	  
	  
The	  Akata	   cell	   line	   has	   previously	   been	   shown	   to	   be	   resistant	   to	   the	   effects	   of	   TGFβ	   and	  
have	  reduced	  expression	  of	  TGFβR2	  (Inman	  and	  Allday	  2000b,	  Fukuda	  et	  al.	  2006a).	  Akata	  
cells	  treated	  with	  the	  HDAC	  inhibitor	  trichostatin	  A	  (TSA),	  however,	  showed	  restoration	  of	  
TGFβR2	  expression	  and	  in	  turn	  restoration	  of	  sensitivity	  to	  TGFβ-­‐induced	  growth	  inhibition	  
(Fukuda	   et	   al.	   2006a).	   In	   another	   study,	   Akata	   cells	   treated	   with	   the	   DNMT	   inhibitor	   5-­‐
azacytidine	   became	   responsive	   to	   TGFβ	   with	   induction	   of	   pSMAD2	   and	   TGFβ-­‐induced	  
growth	   inhibition	   (Chen	  et	  al.	  2007).	  These	  observations	  are	  consistent	  with	   repression	  of	  
TGFβR2	  by	  epigenetic	  mechanisms	  including	  histone	  deacetylation	  and	  DNA	  methylation.	  	  
	  
EBNA3B	  and	  EBNA3C	  cooperate	  in	  the	  repression	  of	  TGFβR2	  
The	  work	  leading	  up	  to	  this	  project	  included	  a	  microarray	  analysis	   investigating	  the	  effects	  
of	   the	   EBNA3	   proteins	   on	   cellular	   gene	   expression,	   which	   suggested	   that	   EBNA3B	   and	  
EBNA3C	  cooperate	  to	  down-­‐regulate	  TGFβR2	  [www.epstein-­‐barrvirus.org.uk	  and	  (White	  et	  
al.	   2010)].	   However,	   preliminary	   investigations	   suggested	   that,	   as	   well	   as	   EBNA3B	   and	  
EBNA3C,	   EBNA2	   was	   necessary	   for	   the	   repression	   of	   TGFβR2	   in	   BL31	   cells.	   This	   was	  
unexpected,	  as	  EBNA2	  generally	  transactivates	  transcription	  and	  up-­‐regulates	  both	  viral	  and	  
cellular	   gene	   expression.	   Previous	   microarray	   analyses	   in	   LCLs	   conditionally	   expressing	  
EBNA2	  had	   indicated	   that,	   although	   EBNA2	  does	   regulate	   a	   significant	   number	   of	   cellular	  
genes	   directly	   or	   indirectly,	   these	   were	   all	   induced	   rather	   than	   repressed	   by	   EBNA2	  
(Spender	  et	  al.	  2002,	  Spender	  et	  al.	  2006,	  Zhao	  et	  al.	  2006).	  A	  study	  in	  EBV-­‐negative	  BL	  lines	  
expressing	  a	  conditional	  EBNA2	  protein,	  however,	  showed	  18	  genes	  that	  were	  repressed	  by	  
EBNA2,	  including	  cell	  surface	  markers	  such	  as	  CD79b	  and	  CD52,	  but	  none	  of	  these	  were	  part	  
of	  TGFβ	  signalling	  pathways	  (Maier	  et	  al.	  2006).	  EBNA2	  had	  been	  shown	  to	  cooperate	  with	  




EBNA3C	   in	   regulating	   multiple	   cellular	   genes	   in	   LCLs,	   although	   again	   these	   all	   largely	  
involved	  up-­‐regulation	  rather	  than	  repression	  by	  EBNA2	  (Zhao	  et	  al.	  2011).	  
	  
The	  EBNA3	  proteins	  are	  transcriptional	  regulators	  and	  have	  been	  shown	  both	  to	  induce	  or	  
repress	  multiple	   genes.	   Since	   they	   are	   probably	   targeted	   to	  DNA	  by	   cellular	   transcription	  
factors,	  it	  is	  clear	  that	  they	  can	  act	  to	  alter	  transcription.	  A	  global	  ChIP-­‐seq	  analysis	  in	  Mutu	  
III	  cells	  showed	  many	  binding	  sites	  for	  EBNA3C	  at	  cellular	  gene	  promoters	  (McClellan	  et	  al.	  
2012),	  and	  EBNA3C	  binding	  has	  been	  demonstrated	  at	  the	  promoters	  of	  the	  genes	  encoding	  
BIM	  and	  p16INK4A	   (Paschos	  et	   al.	   2012,	   Skalska	  et	   al.	   2013).	  Although	   in	   the	   current	   study	  
attempts	   to	  demonstrate	  binding	  of	   EBNA3C	   to	   the	   TGFβR2	  promoter	  were	  unsuccessful,	  
nevertheless	   it	   is	   likely	   that	   this	   could	   occur	   and	   be	   a	   mechanism	   for	   the	   repression	   of	  
TGFβR2.	   Other	   investigators	   in	   the	   laboratory	   are	   currently	   investigating	   the	   binding	   of	  
EBNA3B	  to	  gene	  promoters.	  	  
	  
There	   is	   extensive	   cooperation	   between	   EBNA3	   proteins,	  with	   EBNA3B/C	   together	   down-­‐
regulating	  145	  genes	  and	  up-­‐regulating	  144	  genes	  (White	  et	  al.	  2010).	  A	  recent	  microarray	  
comparing	  gene	  expression	  in	  different	  BL	  types	  confirmed	  the	  down-­‐regulation	  of	  TGFβR2	  
in	   latency	   III	   compared	   to	   latency	   I	   and	   in	  Wp-­‐restricted	   compared	   to	   latency	   I	   clones	   of	  
Awia-­‐BL,	   i.e.	   consistent	   with	   down-­‐regulation	   by	   EBNA3	   proteins	   (Kelly	   et	   al.	   2013).	   The	  
microarray	  for	  genes	  regulated	  by	  EBNA3C	  in	  Mutu	  III	  cells,	  however,	  did	  not	  show	  TGFβR2	  
to	  be	  significantly	  regulated	  by	  EBNA3C	  (McClellan	  et	  al.	  2012).	  
	  
The	  up-­‐regulation	  of	  TGFβR3	  by	  EBV	  and	  relationship	  between	  TGFβR2	  and	  TGFβR3	  
In	   addition	   to	   the	   down-­‐regulation	   of	   TGFβR2,	   this	   study	   has	   also	   shown	   that	   EBV	   up-­‐
regulates	  the	  co-­‐receptor	  TGFβR3	  in	  BL31	  cells	  (fig.	  3.11).	  	  
	  
The	  regulation,	  at	  least	  by	  EBNA3B	  and	  EBNA3C,	  also	  occurs	  via	  epigenetic	  regulation	  of	  the	  
proximal	   promoter.	   Consistent	   with	   these	   findings	   for	   EBNA3C,	   a	   recently	   published	  
microarray	   investigating	   genes	   regulated	   by	   EBNA3C	   alone	   in	   a	   B	   cell	   line	   showed	   up-­‐
regulation	  of	  TGFβR3	  of	  over	  4-­‐fold	  by	  EBNA3C	  (McClellan	  et	  al.	  2012),	  and	  up-­‐regulation	  by	  
EBNA3C	  has	  also	  been	  demonstrated	  in	  3CHT-­‐LCLs,	  as	  will	  be	  discussed	  in	  chapter	  6	  (Skalska	  
et	  al.	  2013).	  




Initial	  findings	  in	  this	  study	  suggested	  that	  EBNA3B,	  EBNA3C,	  and	  EBNA2	  cooperate	  to	  both	  
down-­‐regulate	   TGFβR2	  and	  up-­‐regulate	   TGFβR3	   (fig.	   3.11A-­‐B).	   This	   led	   to	   the	  question	  of	  
whether	  TGFβR2	  and	  TGFβR3	  could	  be	  reciprocally	  regulated	  in	  some	  way.	  However,	  more	  
detailed	  analysis	  showed	  some	  subtle	  differences	  between	  the	  regulation	  of	  the	  two	  genes.	  	  
The	   involvement	   of	   EBNA3A	   in	   regulation	   of	   both	   genes	   is	   unclear,	   as	   will	   be	   discussed	  
further	  in	  section	  4.6.	  
	  
Nevertheless,	  since	  in	  most	  other	  cases	  the	  expression	  of	  the	  two	  genes	  does	  appear	  to	  be	  
reciprocal,	   it	   was	   hypothesised	   that	   they	   could	   somehow	   be	   co-­‐regulated.	   It	   had	   been	  
shown	   in	   carcinoma	  cell	   lines	   that	  TGFβ1	  could	   repress	   transcription	  of	  TGFβR3,	  acting	  at	  
the	  proximal	  TGFβR3	  promoter,	   in	  a	  TGFβR1-­‐dependent	  mechanism	   (Hempel	  et	  al.	  2008).	  
Treatment	  of	   EBV-­‐negative	  BL31	   cells,	   in	  which	  TGFβR3	  expression	  had	  been	   found	   to	  be	  
low,	   with	   the	   TGFβR1	   inhibitor	   SB431542,	   led	   to	   a	   2.5-­‐fold	   increase	   in	   TGFβR3	   mRNA	  
expression	  by	  six	  hours	  post	  treatment	  (fig.	  3.13A),	  with	  the	  expected	  concomitant	  blockade	  
of	   TGFβ	   signalling	   as	   detected	   by	   pSMAD2	   (fig.	   3.13B).	   This	   suggests	   that	   TGFβ1-­‐induced	  
transcriptional	   repression	  of	  TGFβR3	  may	  also	  occur	   in	  B	  cells,	  with	   the	  TGFβR1	   inhibition	  
and	   consequent	   disruption	   of	   signalling	   resulting	   in	   relief	   of	   the	   repression.	   If	   this	   is	   the	  
case,	  then	  EBV	  infection	  of	  BL31	  cells,	  which	  leads	  to	  repression	  of	  TGFβR2	  and	  suppression	  
of	  TGFβ	  signalling,	  would	  also	  cause	  de-­‐repression	  of	  TGFβR3.	  When	  EBNA3B,	  EBNA3C,	  or	  
EBNA2	  are	  deleted,	  TGFβR2	   is	  de-­‐repressed,	  TGFβ	  signalling	  occurs	  and	  so	  TGFβ1	   is	  again	  
able	  to	  repress	  TGFβR3,	  thus	  TGFβR3	  expression	  is	   low.	  Therefore	  the	  findings	  for	  most	  of	  
the	   cell	   lines	   could	  be	   consistent	  with	  TGFβ1-­‐mediated	   repression	  of	  TGFβR3	  occurring	   in	  
BL31,	  with	  the	  exception	  of	  some	  EBNA3A	  KO	  lines.	  In	  these	  cell	  lines	  TGFβR2	  and	  TGFβR3	  
were	  not	  reciprocal,	  and	  it	  was	  confirmed	  that	  this	  was	  not	  due	  to	  changes	  in	  expression	  of	  
TGFβR1	   (fig.	  3.10)	  or	   in	  autocrine	  TGFβ1	  mRNA	  expression	   (fig.	  3.14),	   although	   the	  actual	  
secreted	  TGFβ1	  (by	  ELISA)	  was	  not	  investigated.	  	  
	  
The	   regulation	   of	   TGFβR3	   also	   appears	   to	   be	   epigenetic,	   as	   variations	   in	   the	   histone	  
modifications	  H3K27Me3,	  H3K9Ac	  and	  H3K4Me3	  were	  found,	  generally	  consistent	  with	  the	  
transcriptional	   TGFβR3	   expression,	   between	   the	   different	   BL31	   cell	   lines	   (fig	   3.12).	   The	  
relationship	  between	  TGFβR2	  and	  TGFβR3	  expression	  will	  be	  discussed	  further	  in	  chapter	  6.	  	  
	  




The	  significance	  of	  the	  up-­‐regulation	  of	  TGFβR3	  by	  EBV	  
What	  are	  the	  possible	  effects	  of	  TGFβR3	  up-­‐regulation?	  In	  many	  solid	  malignancies	  TGFβR3	  
has	  been	  shown	  to	  have	  tumour	  suppressive	  functions,	  and	  its	  expression	  is	  lost	  or	  reduced	  
in	  several	  such	  malignancies,	  in	  some	  cases	  resulting	  in	  increased	  invasiveness	  (Dong	  et	  al.	  
2007,	   Hempel	   et	   al.	   2007,	   Turley	   et	   al.	   2007,	   Finger	   et	   al.	   2008b,	   Gordon	   et	   al.	   2008,	  
Margulis	   et	   al.	   2008).	   Little	   is	   known	   about	   its	   effects	   in	   B	   cells.	   It	   also	   has	   tumour	  
suppressive	  functions,	  inhibiting	  cell	  growth	  and	  proliferation,	  in	  myeloma	  cells,	  in	  which	  its	  
expression	   is	   decreased	   (Lambert	   et	   al.	   2011).	   However,	   it	   has	   been	   shown	   to	   be	   up-­‐
regulated	  in	  CLL	  cells	  relative	  to	  normal	  B	  cells	  suggesting	  it	  may	  have	  a	  different,	  possibly	  
tumour	  promoting,	  role	  in	  these	  cells	  (Klein	  et	  al.	  2001,	  Jelinek	  et	  al.	  2003).	  	  
	  
TGFβR3	   is	   specifically	   required	   for	   response	   to	  TGFβ2	  and	   inhibin,	   since	   these	   ligands	  are	  
unable	  to	  bind	  to	  their	  type	  2	  receptors	  without	  the	  presence	  of	  TGFβR3	  (Lopez-­‐Casillas	  et	  
al.	  1993,	  Lewis	  et	  al.	  2000).	  Thus	   further	  work	  could	  be	  done	   to	   investigate	   the	  effects	  of	  
EBV	  on	   signalling	   by	   TGFβ2	   as	  well	   as	   activin/inhibins;	   because	  of	   time	   constraints,	   these	  
were	  not	  investigated	  in	  this	  study.	  	  	  
	  
In	  murine	  haematopoietic	  progenitor	  cells	  which	  responded	  to	  TGFβ1,	  TGFβ1	  appeared	  to	  
bind	  only	  to	  TGFβR1,	  suggesting	  that	  TGFβR3	  may	  not	  be	  expressed,	  or	  possibly	  that	  TGFβ1	  
did	   not	   bind	   to	   it	   (Ohta	   et	   al.	   1987).	   It	   has	   been	   suggested	   that	   on	   haematopoietic	   cells	  
endoglin	  may	  be	  the	  main	  co-­‐receptor	  used	  rather	  than	  TGFβR3,	  since	  haematopoietic	  cells	  
do	  not	  respond	  to	  TGFβ2	  which	  requires	  TGFβR3	  to	   facilitate	   its	  binding	  to	  TGFβR2	  (Dong	  
and	  Blobe	  2006).	  However,	  TGFβR3	  has	  been	  shown	  to	  be	  expressed	  on	  B	  cell	  precursors	  in	  
B	  cell	  acute	  lymphoblastic	  leukaemia,	  although	  this	  may	  represent	  aberrant	  expression	  due	  
to	  the	  tumour	  (Buske	  et	  al.	  1998).	  
	  
Since	  it	  is	  a	  co-­‐receptor	  for	  BMP	  signalling	  as	  well	  as	  TGFβ	  signalling,	  one	  possibility	  is	  that	  it	  
enhances	  or	  inhibits	  BMP	  signalling;	  this	  will	  be	  addressed	  in	  chapter	  7.	  	  






 	  	  	  The	   effects	   of	   LMP1	   and	   LMP2A	   deletion	   on	   TGFβR2	  Chapter	  4
transcription	  and	  TGFβ	  signalling	  	  
4.1	  Introduction	  
As	   briefly	   discussed	   in	   section	   3.2.1,	   the	   apparent	   involvement	   of	   EBNA2	   in	   TGFβR2	  
repression	   and	   suppression	   of	   TGFβ	   signalling	  was	   surprising.	   Since	   EBNA2	   transactivates	  
LMP1	   and	   LMP2A	   it	   was	   hypothesised	   that	   the	   changes	   may	   in	   fact	   be	   due	   to	   one	   (or	  
possibly	  both)	  of	  these	  latent	  proteins	  rather	  than	  (or	  as	  well	  as)	  EBNA2	  itself.	  Therefore	  it	  
was	   important	   to	   try	   to	   distinguish	   the	   effects	   of	   EBNA2,	   LMP1	   and	   LMP2A	   on	   TGFβR2	  
expression	   and	   TGFβ	   signalling.	   In	   order	   to	   facilitate	   this,	   recombinant	   viruses	   containing	  
deletions	  of	  LMP1	  and	  LMP2A,	  made	   in	   the	  same	  BAC-­‐derived	  system	  used	  above	   for	   the	  
EBNA2	  and	  EBNA3	  KO	   lines,	  were	  obtained	  as	  a	  kind	  gift	   from	  Wolfgang	  Hammerschmidt,	  
Münich,	  Germany.	  Unfortunately	  these	  viruses	  did	  not	  become	  available	  until	  relatively	  late	  
in	  the	  course	  of	  the	  project.	  
	  
4.2	  Infection	  of	  BL31	  cells	  to	  make	  BL31	  LMP1	  KO	  and	  BL31	  LMP2A	  KO	  cell	  lines	  	  
Viruses	   were	   obtained	   in	   the	   form	   of	   producer	   lines	   (HEK293	   cells)	   containing	   the	  
recombinant	  BACs.	  The	  BAC	  constructs	  were	  verified	  by	  episomal	  rescue,	  restriction	  enzyme	  
digestion	  and	  pulsed-­‐field	  gel	  electrophoresis,	  confirming	  the	  predicted	  size	  differences	  of	  
certain	  bands	  distinguishing	  wild-­‐type,	  LMP1	  KO	  and	  LMP2A	  KO	  recombinant	  BACS	  (fig.	  4.1).	  
Recombinant	   virus	   was	   then	   induced	   from	   the	   producer	   lines	   and	   used	   to	   infect	   EBV-­‐
negative	  BL31	  cells.	  The	  established	  BL31	  LMP1	  KO	  1	  and	  2	  lines	  were	  established	  from	  two	  
separate	  infections	  with	  the	  same	  virus,	  similarly	  for	  the	  BL31	  LMP2A	  KO	  1	  and	  2	  lines.	  	  BL31	  
LMP2A	  KO	  1	  was	  slower	  to	  grow	  out	  than	  the	  other	  three	  cell	   lines,	  which	  were	  similar	   in	  
their	  time	  to	  establishment.	  	  
	  
	   	  

















Figure	  4.1:	  Validation	  of	  LMP1	  and	  LMP2A	  knockout	  EBV-­‐BACs	  	  
DNA	  from	  the	  LMP1	  KO,	  LMP2A	  KO	  and	  a	  wild-­‐type	  EBV-­‐BAC	  were	  analysed	  by	  restriction	  digestion	  with	  Nhe1	  
and	  BamH1	  followed	  by	  pulsed	  field	  gel	  electrophoresis.	  A	  mixture	  of	  λ-­‐DNA	  BstEII	  and	  λ-­‐DNA	  mono	  cut	  mix	  
ladders	   (NEB)	   were	   used	   as	   a	   size	   marker,	   with	   the	   size	   of	   selected	   bands	   shown.	   Bands	   whose	   sizes	   are	  
changed	  by	   the	  deletion	  of	   LMP1	  and	  LMP2A	  are	   indicated	  by	  coloured	  arrows.	  Red	  =	  band	  present	  only	   in	  
LMP2A	  KO,	  black	  =	  band	  present	  only	  in	  LMP1	  KO,	  and	  blue	  =	  band	  present	  only	  in	  WT.	  For	  Nhe1,	  LMP1	  KO	  is	  
distinguished	  by	  absence	  of	  a	  band	  present	  in	  both	  WT	  and	  LMP2A	  KO,	  shown	  by	  purple	  arrow.	  
	  
	  
Once	   established,	   the	   expression	   of	   EBV	   latent	   proteins	   in	   the	   BL31	   LMP1	   KO	   and	   BL31	  
LMP2A	  KO	  cell	   lines	  were	  investigated,	  to	  ensure	  that	  they	  lacked	  expression	  of	  LMP1	  and	  
LMP2A	  as	  appropriate	  and	  to	  ensure	  that	  lack	  of	  expression	  of	  the	  relevant	  protein	  did	  not	  
significantly	   alter	   expression	  of	   other	   latent	  proteins.	   This	   showed	   that	   the	   LMP1	  KO	  and	  
LMP2A	  KO	   lines	  generally	  expressed	   similar	   amounts	  of	   EBNA1,	  EBNA2,	  EBNA3A,	  EBNA3B	  
and	   EBNA3C,	   with	   the	   exception	   of	   LMP1	   KO	   2	   which	   expressed	   slightly	   higher	   levels	   of	  
EBNA1,	  EBNA2,	  EBNA3A	  and	  EBNA3B	  than	  the	  other	  cell	  lines	  (fig.	  4.2A).	  In	  addition,	  EBNA-­‐
LP	  was	   present	   in	   all	   cell	   lines	   but	   in	   varying	   amounts,	   in	   particular	   the	   LMP2A	   KOs	   had	  
increased	  amounts	  of	  EBNA-­‐LP.	  However,	  the	  level	  of	  EBNA-­‐LP	  expressed	  in	  LCLs	   is	  known	  
to	   be	   highly	   variable.	   Although	   the	   LMP1	   KOs	   express	   LMP2A,	   expression	   levels	   varied	  
between	   the	   two	   different	   LMP1	   KO	   lines,	   being	   greater	   in	   LMP1	   KO	   2	   (fig.	   4.2A).	   This	  
finding	  was	  also	  confirmed	  at	  the	  RNA	  level	  by	  qRT-­‐PCR	  for	  LMP2A	  (fig.	  4.2B).	  The	  western	  
blot	   for	   LMP2A	  appeared	   to	   show	   faint	   bands	   in	   uninfected	  BL31	   and	   in	   both	   LMP2A	  KO	  





lines	  (fig.	  4.2A).	  However,	  this	  was	  suspected	  to	  be	  due	  to	  high	  background	  signal;	  this	  was	  
confirmed	  by	   the	   complete	  absence	  of	   LMP2A	  mRNA	  expression	  by	  qRT-­‐PCR	   in	   these	   cell	  
lines	  (fig.	  4.2B).	  	  
	  
By	   western	   blot,	   neither	   of	   the	   LMP2A	   KO	   lines	   appeared	   to	   express	   LMP1	   (fig.	   4.2A),	  
although	  a	  long	  exposure	  showed	  a	  very	  low	  expression	  of	  LMP1	  in	  LMP2A	  KO	  2	  (fig.	  4.2D).	  
qRT-­‐PCR	  confirmed	  that	  LMP2A	  KO	  1	  lacked	  any	  LMP1	  expression	  whereas	  LMP2A	  KO	  2	  had	  
a	  very	  low	  level	  of	  expression	  (fig.	  4.2C).	  	  
	   	  













































Figure	  4.2:	  Expression	  of	  EBV	  latent	  proteins	  in	  BL31	  LMP1	  KO	  and	  BL31	  LMP2A	  KO	  cell	  lines	  
(A)	  Western	  blot	  for	  EBNA1,	  EBNA2,	  EBNA3A,	  EBNA3B,	  EBNA3C,	  LMP1,	  LMP2A	  and	  EBNA-­‐LP	  in	  BL31,	  BL31-­‐WT	  
EBV	  and	  the	  two	  LMP1	  KO	  and	  LMP2A	  KO	  cell	   lines.	  γ-­‐tubulin	   is	  shown	  as	  a	   loading	  control.	   (B)	  qRT-­‐PCR	  for	  
LMP2A	  in	  LMP1	  and	  LMP2A	  KO	  cell	  lines.	  (C)	  qRT-­‐PCR	  for	  LMP1	  in	  LMP1	  and	  LMP2A	  KO	  lines.	  Values	  are	  shown	  
as	  ratios	  to	  the	  endogenous	  control	  gene	  GNB2L1	  with	  error	  bars	  representing	  standard	  deviation	  of	  triplicate	  
qPCR	  reactions.	  	  (D)	  Western	  blot	  for	  LMP1	  in	  selected	  cell	  lines	  showing	  a	  faint	  band	  of	  LMP1	  in	  LMP2A	  KO	  2.	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4.3	  LMP1	  and	  LMP2A	  are	  necessary	  for	  the	  repression	  of	  TGFβR2	  and	  suppression	  of	  TGFβ	  
signalling	  in	  BL31	  cells	  
Once	  the	  BL31	  LMP1	  KO	  and	  BL31	  LMP2A	  KO	  cell	  lines	  were	  established,	  they	  were	  used	  to	  
investigate	   the	   effects	   of	   LMP1	   and	   LMP2A	   deletion	   on	   TGFβR2	   expression	   and	   TGFβ	  
signalling.	   qRT-­‐PCR	   for	   TGFβR2	   showed	   expression	   in	   all	   LMP1	   KO	   and	   LMP2A	   KO	   lines,	  
although	  this	  was	  higher	  in	  LMP2A	  KO	  than	  LMP1	  KO	  lines	  (fig.	  4.3A).	  Treatment	  of	  LMP1	  KO	  
and	  LMP2A	  KO	  cell	  lines	  with	  TGFβ1	  resulted	  in	  restoration	  of	  TGFβ	  signalling	  as	  detected	  by	  
pSMAD2,	  consistent	  with	  the	  de-­‐repression	  of	  TGFβR2	  seen	  in	  these	  cell	  lines	  (fig.	  4.3B).	  
	  
The	   effects	   of	   LMP1	   or	   LMP2A	   deletion,	   as	   well	   as	   deletion	   of	   the	   whole	   EBNA3	   locus	  
(EBNA3	  KO),	  on	  TGFβ-­‐induced	  ID1	  mRNA	  expression	  was	  also	  investigated.	  This	  showed	  that	  
when	  EBNA3,	  LMP1	  or	  LMP2A	  were	  deleted,	  TGFβ	  treatment	  induced	  ID1	  expression	  at	  two	  
hours	   (fig.	   4.3C).	  No	   induction	  of	   ID1	  was	   seen	   for	  wild-­‐type	  or	   EBNA3	   revertant-­‐infected	  
cells.	  Expression	  of	  ID2	  was	  also	  investigated	  in	  a	  similar	  manner	  and	  showed	  similar	  results;	  
however,	  for	  clarity	  only	   ID1	  data	   is	  shown	  here	  (fig.	  4.3C).	  This	  supports	  the	  findings	  that	  
EBNA3	   proteins,	   LMP1	   and	   LMP2A	   cooperate	   to	   suppress	   TGFβ	   signalling.	   These	   findings	  
suggest	  that	  LMP1	  and	  LMP2A	  both	  cooperate	  with	  EBNA3s	  in	  the	  repression	  of	  TGFβR2	  and	  
consequent	  suppression	  of	  TGFβ	  signalling.	  	  	  
	   	  





























Figure	   4.3:	   LMP1	  KO	   and	   LMP2A	  KO	   show	  de-­‐repression	   of	   TGFβR2	   and	   restoration	   of	   TGFβ	   signalling	   as	  
detected	  by	  phosphorylation	  of	  SMAD2	  and	  induction	  of	  ID1	  expression	  
(A)	  qRT-­‐PCR	  for	  TGFβR2	  mRNA	  in	  the	  cell	  lines	  shown.	  Values	  are	  shown	  as	  ratios	  to	  the	  endogenous	  control	  
gene	  GNB2L1	  with	  error	  bars	  representing	  standard	  deviation	  of	  triplicate	  qPCR	  reactions.	  (B)	  Western	  blot	  for	  
pSMAD2	   after	   two	   hours	   of	   treatment	  with	   TGFβ1	   5ng/ml	   or	   vehicle	   (2mg/ml	   BSA	   in	   PBS).	   Total	   SMAD2	   is	  
shown	   for	   comparison,	   with	   γ-­‐tubulin	   as	   a	   loading	   control.	   (C)	   qRT-­‐PCR	   for	   ID1	   expression	   in	   the	   cell	   lines	  
shown	  after	  two	  hours’	  treatment	  with	  TGFβ1	  5ng/ml	  or	  vehicle.	  Values	  shown	  are	  the	  ratio	  of	  expression	  at	  
two	  hours	  to	  that	  at	  time	  zero,	  showing	  increased	  induction	  of	  ID1	  with	  TGFβ	  treatment	  compared	  to	  vehicle	  
in	  uninfected	  BL31,	   EBNA3	  KO,	   LMP1	  KO	  and	   LMP2A	  KO	  but	  no	   induction	  with	  TGFβ	   in	  wild-­‐type	  or	  EBNA3	  
revertant-­‐infected	  BL31.	  Values	  were	  calculated	  as	   ratios	   to	   the	  endogenous	  control	  gene	  GNB2L1	  and	   then	  

































































4.4	   The	   effects	   on	   TGFβR2	   expression	   and	   TGFβ	   signalling	   seen	   in	   EBNA2	   KO	   lines	   are	  
probably	  due	  to	  a	  combined	  effect	  of	  LMP1	  and	  LMP2A	  
The	  LMP1	  KO	  and	  LMP2A	  KO	  lines	  were	  established	  in	  an	  attempt	  to	  ascertain	  whether	  the	  
effects	  seen	  in	  the	  EBNA2	  KO	  cell	   lines	  were	  due	  to	  EBNA2	  itself,	  or	  through	  LMP1	  and/or	  
LMP2A.	   The	   EBNA2	   KO	   cell	   lines	   showed	   de-­‐repression	   of	   TGFβR2	   and	   consequent	  
restoration	  of	  TGFβ	  signalling	  via	  pSMAD2	  (see	  figs.	  3.1	  and	  3.7B).	  The	  same	  phenotype	  was	  
also	  seen	  for	  both	  LMP1	  KO	  and	  LMP2A	  KO	  cell	  lines	  (figs.	  4.3A-­‐B).	  Therefore,	  in	  order	  to	  try	  
to	  establish	  which	  of	  EBNA2,	  LMP1	  and	  LMP2A	  is/are	  responsible	  for	  the	  repression,	  it	  was	  
necessary	  to	  consider	  the	  expression	  levels	  of	  these	  latent	  proteins	  in	  the	  EBNA2	  KO,	  LMP1	  
KO	  and	  LMP2A	  KO	  lines.	  	  	  
	  
As	  previously	  described,	  EBNA2	  deletion	  is	  expected	  to	  result	  in	  reduced	  or	  no	  expression	  of	  
LMP1	   and	   LMP2A.	   Three	   different	   BL31	   EBNA2	   KO	   lines	   were	   investigated,	   the	   first	  
(designated	  EBNA2	  KO	  (G))	  made	  by	  Gemma	  Kelly	  (Kelly	  et	  al.	  2005)	  and	  the	  other	  two	  by	  
Ian	  Groves	   (Allday	   laboratory,	  unpublished	  data).	  Expression	  of	  EBNA2,	  the	  EBNA3s,	  LMP1	  
and	  LMP2A	  were	  first	  investigated	  in	  the	  two	  EBNA2	  KO	  lines	  that	  had	  been	  more	  recently	  
established	   in	   the	   laboratory	   (EBNA2	   KO	   1	   and	   EBNA2	   KO	   2),	   along	   with	   the	   LMP1	   and	  
LMP2A	   KO	   cell	   lines	   (fig.	   4.4A).	   As	   expected,	   both	   EBNA2	   KO	   1	   and	   EBNA2	   KO	   2	   lines	  
appeared	   to	   lack	   expression	   of	   LMP1	   by	   western	   blot	   (fig.	   4.4A).	   However,	   in	   another	  
experiment,	  western	  blot	  for	  LMP1	  expression	  in	  all	  three	  different	  EBNA2	  KO	  lines	  showed	  
that	  BL31	  EBNA2	  KO	  (G)	  had	  significant	  amounts	  of	  LMP1,	  and	  BL31	  EBNA2	  KO	  1	  appeared	  
to	  have	  low	  expression	  of	  LMP1;	  in	  contrast	  EBNA2	  KO	  2	  had	  no	  apparent	  LMP1	  expression	  
(fig.	  4.4B).	  The	  apparent	  discrepancy	  between	  the	  results	  for	  EBNA2	  KO	  1	  in	  terms	  of	  LMP1	  
expression	  (between	  figures	  4.4A	  and	  4.4B)	  may	  be	  explained	  by	  having	  a	  longer	  exposure	  
in	  figure	  4.4B,	  although	  LMP1	  expression	  is	  also	  known	  to	  vary	  with	  the	  state	  of	  proliferation	  
of	   cells	   (Boos	   et	   al.	   1990);	   this	  may	   also	   explain	   the	  differences	   in	   LMP1	  expression	   seen	  
between	  treated	  and	  untreated	  samples	  of	  each	  EBNA2	  KO	  cell	  line	  (fig.	  4.4B).	  Nevertheless,	  
qRT-­‐PCR	  for	  LMP1	  in	  all	  three	  EBNA2	  KO	  lines	  confirmed	  low	  LMP1	  mRNA	  expression	  in	  both	  
BL31	  EBNA2	  KO	  1	  and	  BL31	  EBNA2	  KO	  2,	  but	  high	  expression	  of	  LMP1	  mRNA	  in	  BL31	  EBNA2	  
KO	   (G)	   (fig.	   4.4C).	   All	   three	   EBNA2	   KO	   lines	   were	   confirmed	   to	   have	   a	   very	   low	   level	  
expression	  of	  LMP2A	  mRNA	  (fig.	  4.4D).	  The	  LMP2A	  protein	  levels	  in	  EBNA2	  KO	  1	  and	  EBNA2	  
KO	  2	  lines	  were	  consistent	  with	  this	  (fig.	  4.4A).	  	  








































Figure	  4.4:	  Expression	  of	  LMP1	  and	  LMP2A	  in	  EBNA2	  KO	  BL31	  cell	  lines	  	  
(A)	  Western	  blot	  for	  EBNA1,	  EBNA2,	  EBNA3A,	  EBNA3B,	  EBNA3C,	  LMP1	  and	  LMP2A	  in	  EBNA2	  and	  LMP	  KO	  cell	  
lines.	  γ-­‐tubulin	  is	  shown	  as	  a	  loading	  control.	  	  (B)	  Western	  blot	  for	  LMP1	  expression	  in	  BL31,	  BL31-­‐WT	  and	  all	  
three	   EBNA2	   KO	   lines	   plus	   EBNA2	   revertant,	   at	   48	   hours	   after	   treatment	  with	   TGFβ1	   5ng/ml	   or	   vehicle.	   γ-­‐
tubulin	  is	  shown	  as	  a	  loading	  control.	  (C)	  qRT-­‐PCR	  for	  LMP1	  and	  (D)	  qRT-­‐PCR	  for	  LMP2A	  in	  all	  three	  EBNA2	  KO	  
cell	   lines	  as	  well	   as	  BL31,	  BL31-­‐WT	  and	  EBNA2	   revertant.	  Values	  are	  expressed	  as	   ratios	   to	   the	  endogenous	  






















































As	  shown	  previously,	   the	  LMP1	  KO	  lines	  express	  high	   levels	  of	  EBNA2	  (fig.	  4.4A),	  no	  LMP1	  
and	   some	   LMP2A	   (fig.	   4.4A-­‐D).	   The	   LMP2A	   KO	   lines	   express	   high	   levels	   of	   EBNA2	   but	  
no/very	  low	  LMP1	  and	  no	  LMP2A	  (fig.	  4.4A-­‐D).	  
	  
Since	   all	   three	   EBNA2	   KO	   lines,	   both	   LMP1	   KO	   and	   both	   LMP2A	   KO	   lines	   all	   show	   de-­‐
repression	   of	   TGFβR2	   and	   restoration	   of	   TGFβ	   signalling	   (figs.	   3.1,	   3.7A	   and	   4.3A-­‐C),	   the	  
significance	   of	   the	   findings	   were	   considered	   for	   each	   of	   the	   three	   latent	   proteins	   LMP1,	  
LMP2A	  and	  EBNA2	  in	  turn;	  table	  4.1	  is	  a	  summary	  of	  the	  relevant	  findings	  for	  all	  EBNA2	  KO,	  
LMP1	  KO	  and	  LMP2A	  KO	  lines.	  	  
	  






TGFβR2	  expression	   TGFβ	  
signalling	  
BL31	   -­‐	   -­‐	   -­‐	   Expressed	   present	  
BL31-­‐WT	  EBV	   ++	   ++	   ++	   Repressed	   absent	  
EBNA2	  KO	  1	   -­‐	   -­‐	   +	   De-­‐repressed	   present	  
EBNA2	  KO	  2	   -­‐	   +/-­‐	   +	   De-­‐repressed	   present	  
EBNA2	  KO	  (G)	   -­‐	   +++	   +	   De-­‐repressed	   present	  
LMP1	  KO	  1	   ++	   -­‐	   +	  	   Partially	  de-­‐repressed	   present	  
LMP1	  KO	  2	   ++	   -­‐	   ++	   Slightly	  de-­‐repressed	   present	  
LMP2A	  KO	  1	   ++	   -­‐	   -­‐	   De-­‐repressed	  	   present	  
LMP2A	  KO	  2	   ++	   -­‐	   -­‐	   De-­‐repressed	   present	  
Table	   4.1:	   Summary	   of	   effects	   of	   EBNA2,	   LMP1	   and	   LMP2A	   deletion	   on	   TGFβR2	   expression	   and	   TGFβ	  
signalling	  in	  BL31	  cells	  
	  
Firstly,	   it	  was	   considered	  whether	   the	   effects	   seen	   in	   all	   these	   cell	   lines	   could	   be	   due	   to	  
LMP1.	  In	  support	  of	  this,	  these	  effects	  are	  seen	  in	  LMP1	  KOs,	  which	  express	  significant	  levels	  
of	  both	  EBNA2	  and	  LMP2A.	  Therefore,	  LMP1	  is	  definitely	  necessary	  for	  the	  down-­‐regulation	  
of	  TGFβR2	  and	  suppression	  of	  TGFβ	  signalling	  by	  EBV.	  However,	  the	  same	  effects	  are	  seen	  in	  
EBNA2	  KO	  (G),	  which	  expresses	  high	  levels	  of	  LMP1,	  and	  therefore	  the	  effects	  seen	  in	  EBNA2	  
KO	  lines	  cannot	  be	  entirely	  due	  to	  LMP1.	  Hence	  it	  is	  likely	  that	  LMP1	  plus	  either	  EBNA2	  or	  
LMP2A	  are	  necessary.	  	  
	  





Next,	  it	  was	  considered	  whether	  the	  effects	  could	  be	  due	  to	  LMP2A.	  The	  EBNA2	  KO	  lines	  all	  
express	  very	  low	  levels	  of	  LMP2A,	  even	  though	  they	  have	  varying	  expression	  of	  LMP1,	  yet	  all	  
show	   de-­‐repression	   of	   TGFβR2	   and	   restoration	   of	   TGFβ	   signalling.	   This	   suggests	   that	   the	  
phenotype	   could	   be	   due	   to	   LMP2A.	   LMP2A	   KOs	   show	   more	   marked	   de-­‐repression	   of	  
TGFβR2	   than	   the	   LMP1	   KOs.	   This	   in	   turn	   suggests	   that	   combined	   deletion	   of	   LMP1	   and	  
LMP2A	  has	  a	  greater	  effect	   than	   that	  of	   LMP1	  KO	  alone,	  and	   therefore	   supports	  a	  model	  
where	  the	  effects	  of	  LMP1	  and	  LMP2A	  are	  combined.	  Furthermore,	  compared	  to	  LMP1	  KO	  
1,	  LMP1	  KO	  2	  has	  more	  LMP2A	  and	  less	  de-­‐repression	  of	  TGFβR2	  (figs.	  4.2A-­‐B	  and	  4.3A);	  this	  
also	   supports	   an	   effect	   of	   LMP2A	   on	   TGFβR2	   repression.	   However,	   the	   effects	   seen	   in	  
EBNA2	  KO,	  LMP1	  KO	  and	  LMP2A	  KO	  cell	  lines	  cannot	  be	  due	  to	  LMP2A	  alone,	  because	  the	  
LMP1	  KOs	  show	  the	  same	  phenotype	  despite	  expressing	  significant	  amounts	  of	  LMP2A.	  
	  
TGFβR2	  is	  completely	  de-­‐repressed	  –	  expressed	  at	  the	  same	  level	  as	  in	  uninfected	  BL31	  cells	  
-­‐	   in	   LMP2A	   KOs,	   suggesting	   that	   loss	   of	   LMP1	   and	   LMP2A	   together	   are	   enough	   to	   fully	  
restore	   TGFβR2	   expression.	   These	   cell	   lines	   express	   normal	   amounts	   of	   EBNA2.	   Hence	   it	  
seems	   likely	   that	   LMP1	   and	   LMP2A	   cooperate	   (with	   EBNA3B	   and	   EBNA3C)	   to	   repress	  
TGFβR2,	  but	  nevertheless	  an	  additional	  effect	  of	  EBNA2	  cannot	  be	  completely	  excluded.	  	  
	  
4.5	  LMP2A,	  and	  to	  a	  lesser	  extent	  LMP1,	  are	  required	  for	  the	  up-­‐regulation	  of	  TGFβR3	  in	  
BL31	  cells	  
Since	  the	  same	  set	  of	  latent	  proteins,	  including	  EBNA2,	  initially	  appeared	  to	  cooperate	  in	  the	  
up-­‐regulation	  of	  TGFβR3	  as	  in	  the	  repression	  of	  TGFβR2,	  the	  LMP1	  and	  LMP2A	  KO	  BL31	  cell	  
lines	  were	  analysed	  for	  TGFβR3	  expression.	  This	  showed	  that	  TGFβR3	  expression	  remained	  
low,	  similar	  to	  uninfected	  BL31,	  in	  LMP1	  KO	  1	  and	  both	  LMP2A	  KO	  lines	  (fig.	  4.5).	  However,	  
partial	  up-­‐regulation	  of	  TGFβR3	  was	  seen	  in	  LMP1	  KO	  2,	  which	  has	  higher	  levels	  of	  LMP2A	  
than	   LMP1	   KO	   1	   (see	   fig.	   4.2A-­‐B).	   Taken	   together,	   these	   findings	   suggest	   that	   LMP2A	   is	  
necessary	   for	   the	   up-­‐regulation	   of	   TGFβR3.	   However,	   since	   TGFβR3	   is	   only	   partially	   up-­‐
regulated	  in	  LMP1	  KO	  2,	  which	  has	  high	  expression	  of	  LMP2A	  and	  of	  EBNA2	  (fig.	  4.2A),	  this	  
suggests	   that	   LMP1	   may	   also	   contribute	   to	   the	   up-­‐regulation	   of	   TGFβR3.	   Since	   all	   three	  
EBNA2	  KO	   lines	  have	   low	   levels	  of	   LMP2A,	   the	   finding	   that	  TGFβR3	   is	  not	  up-­‐regulated	   in	  
EBNA2	   KOs	   is	   consistent	  with	   LMP2A	   being	   necessary	   for	   the	   up-­‐regulation.	   However,	   in	  





EBNA2	  KO	  (G),	  which	  has	  high	  expression	  of	  LMP1,	  but	  very	  low	  LMP2A	  expression,	  TGFβR3	  
expression	  remains	  low,	  suggesting	  that	  LMP2A	  makes	  a	  greater	  contribution	  than	  LMP1	  to	  
the	  up-­‐regulation	  of	  TGFβR3.	  Nevertheless,	   since	   it	  has	  not	  been	  possible	   to	   investigate	  a	  
cell	  line	  that	  expresses	  LMP2A	  without	  expressing	  EBNA2,	  it	  is	  again	  not	  possible	  to	  exclude	  
some	  effect	   from	  EBNA2	   itself	   upon	  up-­‐regulation	   of	   TGFβR3.	  Unfortunately,	   the	   TGFβR3	  
antibody	  for	  western	  blot	  was	  poor,	  with	  high	  background,	  and	  despite	  several	  attempts	  no	  
adequate	  western	  blot	  could	  be	  performed	  in	  the	  LMP1	  and	  LMP2A	  KO	  cell	  lines.	  	  Table	  4.2	  










Figure	  4.5:	  TGFβR3	  mRNA	  expression	  in	  EBNA2	  KO,	  LMP1	  KO	  and	  LMP2A	  KO	  BL31	  cell	  lines	  
qRT-­‐PCR	  for	  TGFβR3,	  with	  values	  (shown	  above	  each	  bar)	  expressed	  as	  ratio	  to	  the	  endogenous	  control	  gene	  
GNB2L1.	   Error	   bars	   represent	   standard	   deviation	   of	   triplicate	   qPCR	   reactions.	   Data	   shown	   are	   from	   an	  
experiment	   in	  which	   the	   pattern	   of	   variation	   of	   values	   for	   uninfected,	   knockout	   and	  wild-­‐type	   infected	   cell	  
lines	  is	  representative	  of	  three	  separate	  experiments.	  	  
	  
BL31	  cell	  line	   EBNA2	  expression	   LMP1	  expression	   LMP2A	  expression	   TGFβR3	  
BL31	   -­‐	   -­‐	   -­‐	   Low	  
BL31-­‐WT	  EBV	   ++	   ++	   ++	   High	  
EBNA2	  KO	  1	   -­‐	   -­‐	   +	   Low	  
EBNA2	  KO	  2	   -­‐	   +/-­‐	   +	   Low	  
EBNA2	  KO	  (G)	   -­‐	   +++	   +	   Low	  
LMP1	  KO	  1	   ++	   -­‐	   +	   Low	  
LMP1	  KO	  2	   ++	   -­‐	   ++	   Intermediate	  
LMP2A	  KO	  1	   ++	   -­‐	   -­‐	   Low	  
LMP2A	  KO	  2	   ++	   -­‐	   -­‐	   Low	  


















































4.6	  The	  variation	  in	  involvement	  of	  EBNA3A	  in	  regulation	  of	  TGFβR2	  and	  TGFβR3	  	  
As	  noted	  in	  section	  3.2.1,	  there	  was	  variation	  between	  the	  different	  EBNA3A	  KO	  cell	  lines	  in	  
TGFβR2	  expression	  (fig.	  3.1A),	  also	  seen	  in	  the	  levels	  of	  binding	  in	  the	  ChIP	  assay	  (see	  figs.	  
3.2D	  and	  3.12B).	  	  	  
	  
To	  investigate	  this	  further,	  TGFβR2	  expression	  was	  investigated	  several	  times	  in	  the	  full	  set	  
of	   four	   BL31	   EBNA3A	   KO	   cell	   lines	   available	   –	   see	   figure	   4.6A	   for	   representative	   data.	  
Although	  there	  was	  some	  minor	  variation	  between	  experiments,	  generally	  EBNA3A	  KOs	  1,	  3	  
and	   4	   behaved	   like	   wild-­‐type	   EBV,	   i.e.	   TGFβR2	   was	   repressed	   in	   these,	   suggesting	   that	  
EBNA3A	  is	  not	  necessary	  for	  the	  repression.	  However,	  in	  EBNA3A	  KO	  2	  TGFβR2	  was	  partially	  
de-­‐repressed,	  but	  generally	  to	  a	  lower	  extent	  than	  for	  EBNA2,	  EBNA3B	  or	  EBNA3C	  KOs	  (fig.	  
4.6A),	   although	   in	   the	  particular	   experiment	   shown	   in	   fig.	   3.1A	   the	   level	   of	   de-­‐repression	  
was	  approaching	  that	  of	  the	  EBNA2,	  EBNA3B	  and	  EBNA3C	  KOs	  (fig.	  3.1A).	  	  	  
	  
Similarly,	   for	   TGFβR3	   expression	   and	   ChIP	   data,	   there	   was	   some	   variation	   between	   the	  
different	  EBNA3A	  KO	  cell	  lines	  (figs.	  3.11A-­‐B	  and	  3.12B-­‐D).	  When	  all	  four	  available	  EBNA3A	  
KO	  lines	  were	  investigated	  for	  TGFβR3	  expression,	  they	  were	  generally	  seen	  to	  fall	  into	  two	  
distinct	   groups:	   EBNA3A	   KO	   1	   and	   KO	   3	   showed	   low	   levels	   of	   TGFβR3,	   behaving	   like	  
uninfected	  BL31,	  whereas	  EBNA3A	  KO	  2	  and	  KO	  4	  showed	  up-­‐regulation	  of	  TGFβR3	  like	  wild-­‐
type	  EBV-­‐infected	  BL31	  (fig.	  4.6B).	  There	  was	  a	  difference	  in	  the	  way	  in	  which	  these	  cell	  lines	  
were	   originally	   grown	   out:	   EBNA3A	   KOs	   1	   and	   3	   were	   grown	   out	   initially	   in	   medium	  
supplemented	   with	   sodium	   pyruvate	   and	   alpha-­‐thioglycerol,	   whereas	   KOs	   2	   and	   4	   were	  
grown	   out	   without	   these	   and	   took	   a	   long	   time	   to	   grow	   out	   [Rob	   White,	   personal	  
communication	   and	   (White	   et	   al.	   2010)].	   Similar	   clustering	   into	   these	   two	  distinct	   groups	  
was	   noted	   for	   many	   genes	   in	   the	   original	   microarray	   [www.epstein-­‐barrvirus.org.uk	   and	  
(White	  et	  al.	  2010)].	  However,	  this	  was	  not	  the	  case	  for	  TGFβR3	  in	  the	  microarray,	  in	  which	  
TGFβR3	   was	   up-­‐regulated	   in	   all	   four	   EBNA3A	   KO	   lines,	   suggesting	   that	   EBNA3A	   was	   not	  
necessary	  (fig.	  4.6D).	  The	  findings	  for	  TGFβR2	  were	  also	  generally	  different	  from	  those	  in	  the	  
microarray,	  since	  in	  the	  microarray	  TGFβR2	  expression	  did	  cluster	  into	  two	  separate	  groups,	  
with	  TGFβR2	  being	  fully	  repressed	   in	  two	  cell	   lines	  and	  partially	  de-­‐repressed	   in	  the	  other	  
two	  (fig.	  4.6C).	  	   	  






































































































Figure	  4.6:	  The	  expression	  of	  TGFβR2	  and	  TGFβR3	  varies	  markedly	  between	  different	  BL31	  EBNA3A	  KO	  cell	  
lines	  	  
qRT-­‐PCR	  for	  (A)	  TGFβR2	  and	  (B)	  and	  TGFβR3	  in	  the	  panel	  of	  EBNA3A	  KO	  BL31	  cell	   lines,	  with	  BL31,	  BL31-­‐WT	  
and	  EBNA3A	  revertant.	  Values	  are	  expressed	  as	  ratios	  to	  the	  endogenous	  control	  gene	  GNB2L1,	  with	  error	  bars	  
representing	  standard	  deviation	  of	  triplicate	  qPCR	  reactions.	  Data	  shown	  are	  from	  an	  experiment	  in	  which	  the	  
pattern	   of	   variation	   of	   values	   for	   uninfected,	   knockout	   and	   wild-­‐type/revertant	   infected	   cell	   lines	   is	  
representative	   of	   at	   least	   three	   separate	   experiments.	   (C-­‐D)	   Microarray	   expression	   of	   (C)	   TGFβR2	   and	   (D)	  
TGFβR3	  in	  BL31	  cells	  infected	  with	  wild-­‐type	  (WT,	  including	  revertants)	  and	  EBNA3A	  KO,	  EBNA3B	  KO,	  EBNA3C	  
KO	  and	  total	  EBNA3	  KO	  viruses.	  The	  vertical	  axis	   represents	  quantity	  of	  mRNA	  on	  a	   log2	  scale.	  A	  value	  of	  <3	  
generally	   indicates	   that	   a	   gene	   is	   not	   detectably	   expressed.	   Each	   point	   represents	   a	   single	   cell	   line.	   From	  
[www.epstein-­‐barrvirus.org.uk	  and	  (White	  et	  al.	  2010)].	  	  
	  





In	  order	  to	  investigate	  other	  possible	  reasons	  for	  the	  differences	  in	  expression	  between	  the	  
EBNA3A	  KO	  cell	  lines,	  it	  was	  hypothesised	  that	  this	  may	  be	  due	  to	  differences	  in	  expression	  
of	  LMP2A,	  as	  this	  had	  been	  shown	  to	  alter	  TGFβR2	  and	  TGFβR3	  expression.	  Western	  blot	  for	  
LMP2A	   in	   the	  panel	  of	   EBNA3A,	  EBNA3B	  and	  EBNA3C	  KO	  and	   revertant	   cell	   lines	   showed	  
marked	  differences	  in	  expression	  between	  the	  different	  EBNA3A	  KO	  cell	   lines,	  whereas	  for	  
the	  EBNA3B	  KO	  and	  EBNA3C	  KO	  lines	  expression	  levels	  were	  similar	  to	  each	  other	  and	  to	  the	  
revertants	  and	  wild-­‐type	  viruses	  (fig.	  4.7).	  In	  particular,	  EBN3A	  KO	  3	  has	  extremely	  low	  levels	  
of	  LMP2A	  expression,	  and	  EBN3A	  KO	  2	  also	  has	  reduced	  levels	  compared	  to	  the	  other	  cell	  
lines.	  However,	  these	  findings	  do	  not	  explain	  the	  differences	  in	  behaviour	  of	  the	  EBNA3A	  KO	  
lines	  for	  either	  TGFβR2	  or	  TGFβR3	  expression.	  	  
	  
It	  was	  also	  determined	  whether	  differences	  in	  TGFβR2	  or	  TGFβR3	  expression	  could	  be	  due	  
to	  differences	  in	  proliferation	  rate	  at	  the	  time	  of	  experiments;	  however,	  no	  correlation	  was	  
identified	  between	  the	  cell	  count	  24	  hours	  prior	  to	  harvest	  and	  the	  TGFβR2	  expression	  in	  a	  
particular	   experiment	   (data	   not	   shown);	   nevertheless,	   it	   was	   generally	   observed	   that	   the	  
EBNA3A	  KO	  2	  and	  4	  cell	  lines,	  particularly	  EBNA3A	  KO	  2,	  proliferated	  at	  a	  significantly	  slower	  
rate	   than	   other	   cell	   lines,	   correlating	  with	   the	   original	   rate	   of	   outgrowth	   of	   the	   cell	   lines	  
(White	  et	  al.	  2010).	  However,	  it	  is	  not	  clear	  how	  the	  differences	  in	  proliferation	  rate	  would	  









Figure	  4.7:	  LMP2A	  expression	  varies	  between	  EBNA3A	  KO	  cell	  lines	  	  
Western	  blot	  for	  LMP2A	  in	  a	  panel	  of	  EBNA3A,	  EBNA3B	  and	  EBN3C	  KO	  cell	  lines	  and	  their	  revertants.	  γ-­‐tubulin	  
is	  shown	  as	  a	  loading	  control.	  	  
	   	  





4.7	  Discussion	  	  
The	  involvement	  of	  LMP1	  and	  LMP2A	  in	  repression	  of	  TGFβR2	  
Since	   the	  EBNA2	  KO	  cell	   lines	  also	   showed	  expression	  of	  TGFβR2	  and	   restoration	  of	  TGFβ	  
signalling	  (figs.	  3.1A-­‐B	  and	  3.7B),	  this	  led	  to	  an	  investigation	  of	  whether	  LMP1	  and/or	  LMP2A	  
might	  be	   responsible,	   since	  EBNA2	  drives	   the	  expression	  of	   LMP1	  and	  LMP2A.	  To	  explore	  
their	  role,	  LMP1	  KO	  and	  LMP2A	  KO	  viruses	  were	  used	  to	  infect	  EBV-­‐negative	  BL31	  cells,	  thus	  
establishing	  new	  BL31	  LMP1	  KO	  and	  BL31	  LMP2A	  KO	  cell	  lines.	  Investigation	  of	  the	  effects	  of	  
LMP1	   and	   LMP2A	   deletion	   suggested	   that	   both	   LMP1	   and	   LMP2A	   are	   necessary	   for	   the	  
repression	  of	  TGFβR2	  and	  suppression	  of	  TGFβ	  signalling	  (figs.	  4.3A-­‐C),	  although	  an	  effect	  of	  
EBNA2	  itself	  also	  could	  not	  be	  entirely	  excluded.	  
	  
LMP1	  and	  LMP2A	  are	  both	  membrane	  receptors	  and	  thus	  do	  not	  have	  direct	  transcription	  
factor	   activity.	   In	   epithelial	   cells	   LMP1	   and	   LMP2A	   cooperate	   to	   regulate	   microRNA	  
expression	  (Du	  et	  al.	  2011),	  and	  synergistic	  cooperation	  between	  LMP1	  and	  LMP2A	  has	  also	  
been	  shown	  to	  promote	  carcinogenesis	  in	  a	  transgenic	  mouse	  model	  (Shair	  et	  al.	  2012).	  	  In	  
addition,	  LMP2A	  has	  been	  shown	  to	  augment	  signalling	  by	  LMP1	  indirectly	  in	  epithelial	  cells,	  
by	  reducing	  the	  turnover	  of	  LMP1	  (Dawson	  et	  al.	  2001).	  	  
	  
However,	  the	  two	  proteins	  can	  also	  sometimes	  have	  non-­‐synergistic	  effects	  in	  B	  cells.	  LMP1	  
requires	   co-­‐expression	   of	   LMP2A	   for	   NFκB	   activation	   in	   B	   cells,	   suggesting	   that	   LMP1	   is	  
dependent	   on	   the	   presence	   of	   LMP2A	   for	   its	   function,	   rather	   than	   the	   two	   working	  
synergistically	   (Guasparri	   et	   al.	   2008).	   In	   a	   transgenic	  mouse	  model,	   LMP1	   alone	   induced	  
expression	  of	  TRAF2	  (TNF-­‐receptor	  associated	  factor	  2)	  in	  B	  cells,	  but	  when	  LMP2A	  was	  co-­‐
expressed	  with	  LMP1	  this	  induction	  was	  no	  longer	  seen.	  It	  is	  thought	  therefore	  that	  LMP2A	  
modulates	   the	   hyperproliferation	   of	   B	   cells	   caused	   by	   LMP1,	   as	   TRAF2	   mediates	   cell	  
proliferation	  via	  NFκB	  activation	  (Vrazo	  et	  al.	  2012).	  	  
	  
In	  B	  cells,	  LMP1	  and	  LMP2A	  both	  alter	  several	  signalling	  pathways	  and	  thus	  can	  alter	  gene	  
transcription	   indirectly.	  A	  microarray	  analysis	  of	  splenic	  CD19	  positive	  B	  cells	   in	  transgenic	  
mice	  expressing	  LMP1,	  LMP2A	  or	  both	  showed	  that	  LMP2A	  expression	  regulated	  3808	  B	  cell	  
genes,	  LMP1	  alone	  regulated	  1660	  genes	  and	  co-­‐expression	  of	  LMP1	  and	  LMP2A	  regulated	  





1656	  genes.	  Of	  genes	  regulated	  by	  co-­‐expression	  of	  LMP1	  and	  LMP2A,	  30%	  were	  uniquely	  
regulated	  by	  the	  co-­‐expression	  of	  LMP1	  and	  LMP2A	  (Shair	  and	  Raab-­‐Traub	  2012).	  	  
	  
In	   the	   transgenic	   mouse	   model	   microarray	   analysis,	   components	   of	   the	   TGFβ	   signalling	  
pathway	  were	  altered	  by	  LMP2A	  expression	  (39	  genes	  within	  the	  pathway)	  and	  by	  LMP1/2A	  
expression	  (18	  genes	  within	  the	  pathway)	  but	  none	  by	  LMP1	  alone.	  Although	  all	  the	  data	  for	  
these	   genes	   is	   not	   available,	   there	   is	   a	   suggestion	   that	   LMP2A	   expression	   alone	   down-­‐
regulated	  TGFβR2	  in	  this	  system	  (Shair	  and	  Raab-­‐Traub	  2012),	  i.e.	  that	  LMP2A	  alone	  may	  be	  
sufficient	  to	  down-­‐regulate	  TGFβR2,	  but	  the	  addition	  of	  LMP1	  did	  not	  alter	  this.	  However,	  in	  
the	   current	   study	   expression	   of	   both	   LMP1	   and	   LMP2A	   appears	   to	   contribute	   to	   the	  
repression	  of	  TGFβR2	  -­‐	  although	  because	  of	  the	  variations	  in	  expression	  of	  the	  other	  latent	  
proteins	  in	  the	  knockout	  cell	  lines	  it	  is	  not	  possible	  to	  be	  entirely	  sure	  of	  the	  contribution	  of	  
each.	  Ideally,	  to	  determine	  which	  of	  EBNA2,	  LMP1	  or	  LMP2A	  are	  necessary	  for	  repression	  of	  
TGFβR2,	  cell	  lines	  would	  be	  needed	  which	  express	  full	  amounts	  of	  every	  latent	  protein	  but	  
none	  of	   the	  protein	  of	   interest,	   i.e.	   LMP1+/LMP2A+/EBNA2-­‐,	   EBNA2+	   LMP1+	   LMP2A-­‐	   and	  
EBNA2+/LMP2A+/LMP1-­‐.	  However,	  in	  the	  current	  study	  only	  one	  of	  these	  combinations	  was	  
available,	  namely	  LMP1	  KO	  2	  which	  had	  full	  expression	  of	  EBNA2	  and	  LMP2A;	  all	  the	  other	  
EBNA2/LMP1/LMP2A	  KO	  lines	  had	  reduced	  expression	  of	  an	  additional	  latent	  protein	  to	  that	  
which	  was	  knocked	  out	   (see	   table	  4.1).	  The	   reasons	   for	   lack	  of/reduced	  expression	  of	   the	  
additional	  latent	  proteins	  in	  the	  knockouts	  will	  be	  discussed	  further	  below.	  	  
	  
In	  summary,	  EBNA3B,	  EBNA3C,	  LMP1	  and	  LMP2A	  cooperate	  to	  up-­‐regulate	  TGFβR3,	  as	  well	  
as	  down-­‐regulate	  TGFβR2,	  although	  the	  contribution	  of	  LMP1	  appears	  to	  be	  less	  than	  that	  of	  
LMP2A.	  
	  
LMP1	  expression	  in	  the	  EBNA2	  KO	  and	  LMP2A	  KO	  lines	  
The	  initial	  finding	  that	  EBNA2	  KO	  cell	  lines	  also	  showed	  de-­‐repression	  of	  TGFβR2	  led	  to	  the	  
hypothesis	  that	  the	  changes	  may	  have	  been	  due	  to	  LMP1	  or	  LMP2A,	  since	  EBNA2	  generally	  
transactivates	   LMP1,	   LMP2A	   and	   LMP2B.	   Prior	   to	   that	   the	   findings	   were	   confirmed	   by	  
investigating	  all	   three	  BL31	  EBNA2	  KO	   lines.	   In	  all	   three,	  TGFβR2	  was	  expressed	  and	  TGFβ	  
signalling	   restored.	   However,	   investigation	   of	   the	   expression	   of	   LMP1	   in	   these	   cell	   lines	  
surprisingly	  showed	  that	  EBNA2	  KO	  (G)	  had	  full	  expression	  of	  LMP1	  at	  both	  RNA	  and	  protein	  





levels	   (fig.	   4.4B-­‐C).	   Of	   the	   other	   two	   lines,	   EBNA2	   KO	   1	   also	   had	   a	   low	   level	   of	   LMP1	  
expression,	  but	  EBNA2	  KO	  2	  did	  not	  (figs.	  4.4A-­‐C).	  
	  
When	  the	  BL31	  EBNA2	  KO	  (G)	  cell	  line	  was	  first	  established,	  it	  was	  confirmed	  that	  it	  did	  not	  
express	  any	  EBNA2	  or	  LMP1	  protein	  (Kelly	  et	  al.	  2005);	  yet	  in	  the	  experiments	  performed	  in	  
the	   current	   study,	   LMP1	   is	   expressed	  at	   a	   significant	   level	   (fig.	   4.4B-­‐C).	   This	   suggests	   that	  
over	   time,	   with	   repeated	   passage	   in	   vitro,	   the	   BL31	   EBNA2	   KO	   (G)	   cell	   line	   has	   acquired	  
expression	  of	  LMP1	  –	  and	  this	  in	  turn	  suggests	  that	  LMP1	  expression	  may	  provide	  a	  growth	  
advantage.	  LMP1	  functions	   in	  multiple	  ways	  to	  protect	  cells	  from	  apoptosis	  (Henderson	  et	  
al.	  1991,	  Faqing	  et	  al.	  2005,	  Kim	  et	  al.	  2012),	  as	  well	  as	  to	  protect	  cells	  from	  ligands	  which	  
inhibit	   proliferation	   (Takanashi	   et	   al.	   1999,	   Lo	   et	   al.	   2010,	   De	   Leo	   et	   al.	   2011).	   Thus	   the	  
acquisition	  of	  LMP1	  expression	  in	  a	  sub-­‐clone	  would	  provide	  a	  growth	  advantage	  in	  culture.	  	  	  
During	   these	   experiments	   it	   was	   noticeable	   that	   the	   EBNA2	   KO	   cell	   lines	   generally	  
proliferated	  more	  rapidly	  than	  wild-­‐type	  or	  other	  knockout	  cell	  lines.	  However,	  there	  was	  no	  
obvious	  difference	  between	  the	  growth	  rates	  of	  the	  particular	  EBNA2	  KO	  lines,	  although	  this	  
was	  not	  formally	  investigated.	  	  
	  
In	  type	  III	  latency	  transcription	  of	  LMP1	  is	  under	  control	  of	  EBNA2,	  as	  EBNA2	  regulates	  the	  
viral	  LMP1	  promoter	  (Wang	  et	  al.	  1990b).	  However,	  in	  type	  II	  latency	  EBNA2	  is	  not	  present,	  
so	   transcription	   of	   LMP1	   must	   occur	   via	   an	   alternative	   mechanism.	   In	   a	   reporter	   assay	  
system,	  CCAAT	  enhancer	  binding	  protein	  (C/EBP)	  was	  shown	  to	  activate	  the	  LMP1	  promoter	  
independently	  of	  EBNA2	  	  (Noda	  et	  al.	  2011).	  In	  B	  cells,	  LMP1	  can	  be	  induced	  in	  the	  absence	  
of	  EBNA2	  by	  treatment	  with	  IL-­‐4,	  IL-­‐10,	  IL-­‐13	  or	  CD40	  ligand	  	  (Kis	  et	  al.	  2005,	  Kis	  et	  al.	  2006,	  
Kis	  et	  al.	  2011).	  In	  addition,	  it	  has	  been	  shown	  that	  exposure	  to	  IL-­‐21	  induces	  LMP1,	  without	  
EBNA2	  induction,	  in	  B	  cells	  (Kis	  et	  al.	  2010).	  	  
	  
In	  the	  presence	  of	  EBNA2	  (i.e.	  in	  latency	  III),	  EBNA3C	  can	  enhance	  or	  inhibit	  the	  activation	  of	  
the	  LMP1	  promoter	  by	  EBNA2,	  depending	  on	  the	  cell	  type	  and	  growth	  conditions	  (Marshall	  
and	  Sample	  1995,	  Lin	  et	  al.	  2002).	  EBNA3C	  maintains	  the	  level	  of	  LMP1	  (Allday	  and	  Farrell	  
1994)	  and	  binds	  to	  and	  regulates	  the	  bidirectional	  LMP1/LMP2B	  promoter	  (Jimenez-­‐Ramirez	  
et	  al.	  2006).	  Thus	  in	  EBNA2	  KO	  lines,	  EBNA3C	  could	  drive	  expression	  of	  LMP1	  in	  the	  absence	  
of	   EBNA2.	  However,	   the	  major	   caveat	   is	   that	   all	   the	   EBNA3C	  experiments	  were	  based	  on	  





transient	  reporter	  assays	  and	  in	  KO	  and	  conditional	  lines,	  EBNA3C	  does	  not	  appear	  to	  alter	  
LMP1	  expression.	  
	  
It	   is	   not	   clear	   exactly	   how	   BL31	   EBNA2	   KO	   (G)	   would	   have	   acquired	   an	   initial	  
mutation/epigenetic	  lesion	  enabling	  it	  to	  express	  LMP1.	  It	  would	  be	  interesting	  to	  sequence	  
the	  LMP1	   region	   in	   the	  BL31	  EBNA2	  KO	   (G)	   line,	  as	  used	   in	   the	  current	   study,	   in	  order	   to	  
ascertain	  whether	  and	  how	  the	  sequence	  differs	  from	  that	  of	  the	  original	  cell	   line	  (Kelly	  et	  
al.	  2005).	  
	  
The	  two	  BL31	  LMP2A	  KO	  cell	   lines,	  LMP2A	  KO	  1	  and	  LMP2A	  KO	  2,	  were	  also	  unexpectedly	  
found	  to	  express	  no,	  or	  extremely	  low	  LMP1,	  respectively	  at	  both	  mRNA	  and	  protein	  levels	  
(fig.	  4.2A,C-­‐D).	  The	  reason	   for	   this	  was	  not	  clear.	  However,	   in	  a	   recent	  study	   investigating	  
the	  effects	  of	  LMP2A	  and	  LMP2B	  on	  early	  EBV	  infection	  of	  primary	  B	  cells,	  using	  the	  same	  
LMP2A	   KO	   virus	   construct	   as	   in	   the	   current	   study,	   LMP1	   expression	   was	   reduced	   with	  
viruses	   lacking	   LMP2A	   alone,	   or	   lacking	   both	   LMP2A	   and	   LMP2B,	   compared	   to	   wild-­‐type	  
virus	   in	   the	   first	   six	   days	   after	   infection	   (particularly	   for	   the	   double	   LMP2A/2B	   knockout	  
virus),	  although	  this	  difference	  was	  not	  statistically	   significant.	  When	  primary	  B	  cells	  were	  
infected	   with	   the	   viruses	   in	   the	   presence	   of	   soluble	   Ig	   as	   a	   BCR	   stimulating	   agent,	   the	  
expression	   of	   LMP1	   mRNA	   was	   significantly	   reduced	   in	   the	   LMP2A	   KO,	   and	   even	   more	  
markedly	   in	   the	  LMP2A/B	  KO,	  compared	  to	  wild-­‐type	  virus.	  This	  was	  despite	  similar	  LMP1	  
mRNA	  expression	  in	  wild-­‐type,	  LMP2A	  KO	  and	  LMP2A/B	  KO	  cell	  lines	  in	  the	  BAC-­‐containing	  
HEK293	  cells	  (Wasil	  et	  al.	  2013).	  Nevertheless,	  the	  reason	  for	  this	  is	  unclear.	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cell	  cycle	  arrest	  in	  BL31	  cells	  
5.1	  Introduction	  
TGFβ1	   generally	   induces	   apoptosis	   or	   cell	   cycle	   arrest	   in	  B	   cells,	   and	   several	   studies	   have	  
shown	  that	  latency	  III	  EBV	  protects	  against	  these	  effects.	  However,	  the	  exact	  mechanism	  of	  
this	  is	  not	  fully	  understood,	  in	  particular	  whether	  TGFβ-­‐mediated	  apoptosis	  or	  arrest	  occurs	  
via	  TGFβR2	  and	  pSMAD2.	  TGFβ	  has	  been	  shown	  to	  induce	  cell	  cycle	  arrest	  in	  EBV-­‐negative	  
BL	   (Blomhoff	   et	   al.	   1987,	   Smeland	   et	   al.	   1987,	  Wang	   et	   al.	   1988,	   Arvanitakis	   et	   al.	   1995,	  
Chaouchi	  et	  al.	  1995,	  MacDonald	  et	  al.	  1996,	  Inman	  and	  Allday	  2000b).	  This	  has	  also	  been	  
demonstrated	  in	  some	  group	  I	  EBV-­‐positive	  BLs,	  which	  express	  only	  EBNA1	  (MacDonald	  et	  
al.	   1996,	   Inman	   and	  Allday	   2000b).	  However,	   EBV-­‐positive	   BL	   lines	   are	   resistant	   to	   TGFβ-­‐
induced	   growth	   arrest	   (Blomhoff	   et	   al.	   1987,	   Altiok	   et	   al.	   1991,	   Kumar	   et	   al.	   1991,	  
Arvanitakis	  et	  al.	  1995,	  MacDonald	  et	  al.	  1996,	  Inman	  and	  Allday	  2000b).	  	  
	  
In	   epithelial	   cells,	   TGFβ-­‐induced	   apoptosis	   is	   dependent	   on	   or	   enhanced	   by	   SMAD3	  
(Yanagisawa	   et	   al.	   1998,	   Kim	   et	   al.	   2002,	   Yang	   et	   al.	   2002).	   Although	   the	   importance	   of	  
phosphorylated	  SMAD3	  for	  TGFβ-­‐induced	  apoptosis	  had	  also	  been	  shown	  in	  murine	  B	  cells	  
(Wildey	  et	  al.	  2003),	  at	  the	  start	  of	  this	  study	  the	  importance	  of	  SMAD3	  relative	  to	  SMAD2	  
for	   apoptosis	   in	   human	  B	   cells	  was	   not	   known.	   Furthermore,	  many	   cellular	   pathways	   are	  
involved	   in	   regulation	   of	   apoptosis	   and	   growth	   arrest,	   and	   thus	   TGFβ	   may	   induce	   these	  
effects	  via	  non-­‐canonical	  pathways	  or	  by	  cross-­‐talk	  with	  other	  signalling	  pathways.	  	  
	  
Latent	  EBV	  infection	  protects	  against	  apoptosis	  induced	  by	  many	  other	  agents	  [reviewed	  in	  
(Allday	  2009,	  Spender	  and	  Inman	  2011)].	  For	  example,	  EBV	  prevents	  apoptosis	  in	  response	  
to	  ionomycin	  or	  staurosporine	  by	  blocking	  the	  accumulation	  of	  pro-­‐apoptotic	  NOXA	  (Yee	  et	  
al.	   2011),	   EBNA3A	   and	   EBNA3C	   cooperate	   to	   repress	   pro-­‐apoptotic	   BIM	   (Anderton	   et	   al.	  
2008,	   Paschos	   et	   al.	   2009),	   and	   expression	   of	   LMP1	   and	   LMP2A	   are	   protective	   against	  
apoptosis,	  via	  activation	  of	  NFκB,	  PI3K/Akt	  and	  ERK/MAPK	  pathways	  (Henderson	  et	  al.	  1991,	  
Portis	   and	  Longnecker	  2004,	  Mancao	  and	  Hammerschmidt	  2007).	   Therefore,	   the	  effect	  of	  




EBV	   on	   TGFβ-­‐induced	   apoptosis/arrest	  may	   not	   occur	   directly	   via	   alterations	   in	   canonical	  
TGFβ	  signalling.	  
	  
In	  this	  chapter	  the	  effect	  of	  latent	  EBV	  on	  TGFβ-­‐induced	  apoptosis	  and/or	  growth	  arrest	  was	  
investigated	   in	   BL31	   cells.	   The	   effect	   of	   deletion	   of	   individual	   latent	   proteins	   was	  
investigated,	   in	  order	   to	  determine	  whether	   the	  repression	  of	  TGFβR2	  and	  suppression	  of	  
signalling	  via	  pSMAD2	  was	  associated	  with	   the	  protection	  against	  TGFβ-­‐induced	  apoptosis	  
or	  growth	  arrest.	  	  
	  
5.2	  Latent	  EBV	  protects	  against	  TGFβ-­‐induced	  apoptosis	  in	  BL31	  cells	  
TGFβ	  is	  generally	  pro-­‐apoptotic	  and/or	  anti-­‐proliferative	  in	  B	  cells,	  although	  the	  effect	  varies	  
depending	  on	   the	  particular	   cell	   line,	   even	  among	  BL-­‐derived	   cell	   lines	   (Inman	  and	  Allday	  
2000b).	  In	  addition,	  some	  studies	  have	  shown	  that	  both	  G1	  arrest	  and	  apoptosis	  can	  occur	  
in	  the	  same	  cell	  line	  in	  response	  to	  TGFβ,	  via	  distinct	  mechanisms,	  with	  G1	  arrest	  followed	  
by	  subsequent	  apoptosis	  (MacDonald	  et	  al.	  1996,	  Schrantz	  et	  al.	  1999).	  The	  effect	  of	  TGFβ	  
on	  BL31	  survival	  was	  not	  known.	  	  
	  
The	   presence	   of	   latency	   III	   EBV	   expression	   generally	   confers	   resistance	   to	   the	   effects	   of	  
TGFβ,	  and	  therefore	  it	  was	  hypothesised	  that	  BL31	  cells	  would	  undergo	  either	  apoptosis	  or	  
G1	  arrest	  in	  response	  to	  TGFβ,	  and	  this	  would	  be	  abrogated	  by	  EBV	  infection.	  EBV-­‐negative	  
BL31	   and	   B95.8-­‐BAC	   infected	   BL31	   cells	   (BL31-­‐WT)	   were	   initially	   treated	   with	   TGFβ	   at	   a	  
concentration	  of	  5ng/ml	  or	  vehicle	  alone.	  Samples	  were	  then	  harvested	  at	  various	  times	  up	  
to	  48	  hours.	  Samples	  were	  analysed	  by	  western	  blot	  for	  total	  and	  cleaved	  poly	  ADP	  ribose	  
polymerase	   (PARP),	   a	   measure	   of	   apoptosis,	   as	   well	   as	   propidium	   iodide	   (PI)	   staining	  
analysis	  by	  flow	  cytometry	  (FC)	  to	  show	  the	  DNA	  content.	  	  
	  
Treatment	   of	   BL31	   and	   BL31-­‐WT	   with	   TGFβ	   or	   vehicle	   for	   48	   hours	   revealed	   that	   TGFβ	  
induced	  PARP	  cleavage	  in	  uninfected	  BL31,	  but	  in	  BL31-­‐WT,	  PARP	  remained	  uncleaved	  and	  
thus	  no	  apoptosis	  occurred	  (fig.	  5.1A).	  When	  the	  samples	  were	  analysed	  by	  PI	  staining	  and	  
FC	  for	  DNA	  content,	  there	  was	  a	  modest	  increase	  in	  the	  sub-­‐G1	  component	  in	  TGFβ-­‐treated	  
compared	   to	   untreated	   BL31	   at	   48	   hours	   (10.3%	   versus	   4.6%,	   fig.	   5.1B,	   upper	   figures),	  




consistent	   with	   apoptosis	   having	   occurred.	   However,	   this	   was	   not	   as	   marked	   as	   has	  
generally	  been	  seen	  for	  apoptosis	  induced	  by	  TGFβ1	  or	  other	  agents	  in	  other	  cell	  lines	  [see	  
for	  instance	  (Inman	  and	  Allday	  2000b)].	  This	  may	  be	  because	  cells	  are	  dying	  in	  all	  phases	  of	  
the	   cell	   cycle,	   i.e.	   PARP	   cleavage	   does	   not	   correlate	   entirely	   with	   sub-­‐G1	   on	   FC	   analysis,	  
although	   a	   previous	   study	   generally	   found	   good	   correlation	   between	   these	   within	   each	  
particular	   cell	   line	   (Inman	   and	   Allday	   2000b).	   In	   BL31-­‐WT,	   no	   difference	   in	   the	   cell	   cycle	  
profile	  was	  seen	  with	  or	  without	  exogenous	  TGFβ1	  (fig.	  5.1B,	   lower	   figures).	  These	  results	  
together	   suggest	   that	   in	  BL31	  TGFβ	   induces	  apoptosis,	   and	   that	  wild-­‐type	  EBV	  suppresses	  













	   	  




























Figure	  5.1:	  TGFβ1	  induces	  apoptosis	  in	  EBV-­‐uninfected	  BL31	  cells,	  but	  wild-­‐type	  EBV	  protects	  against	  this	  	  
(A)	  Western	  blot	  for	  PARP	  in	  uninfected	  and	  wild-­‐type	  EBV-­‐infected	  (BL31-­‐WT)	  BL31	  cells	  before	  (time	  0)	  and	  
48	  hours	  after	  treatment	  with	  TGFβ1	  5ng/ml	  or	  vehicle	  (2mg/ml	  BSA	  in	  PBS,	  -­‐TGFβ1).	  γ-­‐tubulin	  is	  shown	  as	  a	  
loading	  control.	  (B)	  Cell	  cycle	  analysis	  by	  propidium	  iodide	  staining	  and	  FC	  in	  uninfected	  (upper)	  and	  wild-­‐type	  
infected	   (lower)	   BL31	   cells	   treated	   with	   TGFβ1	   5ng/ml	   (left	   side)	   or	   vehicle	   alone	   (right	   side),	   showing	   an	  














5.3	  EBNA3B	  and	  EBNA3C	  are	  not	  necessary	  for	  protection	  against	  TGFβ-­‐induced	  apoptosis	  
It	   was	   hypothesised	   that	   TGFβ-­‐induced	   apoptosis	   in	   BL31	   may	   occur	   via	   TGFβR2	   and	  
induction	   of	   pSMAD2,	   and	   therefore	   that	   the	   same	   latent	   proteins	   which	   cooperate	   to	  
repress	   TGFβR2	   and	   suppress	   TGFβ	   signalling	   would	   protect	   against	   TGFβ-­‐induced	  
apoptosis.	   The	   effect	   of	   EBNA3B	   and	   EBNA3C	   deletion	   on	   TGFβ-­‐induced	   apoptosis	   were	  
investigated.	  
	  
The	  panel	  of	  EBNA3B	  KO	  and	  EBNA3C	  KO,	  as	  well	  as	  respective	  revertants	  to	  wild-­‐type,	  BL31	  
cell	  lines	  were	  treated	  with	  TGFβ	  or	  vehicle	  for	  48	  hours	  and	  samples	  harvested,	  as	  before,	  
for	  western	   blot	   for	   PARP	   and	   for	   PI-­‐stained	   FC	   analysis.	   This	   showed	   that	   there	  was	   no	  
PARP	  cleavage	  in	  EBNA3B	  KO	  or	  EBNA3C	  KO,	  as	  seen	  in	  the	  revertants,	  whereas	   increased	  
PARP	  cleavage	  was	  again	  seen	  in	  uninfected	  BL31	  treated	  with	  TGFβ1	  compared	  to	  vehicle,	  
consistent	   with	   TGFβ-­‐induced	   apoptosis	   (fig.	   5.2A).	   Analysis	   of	   the	   same	   cell	   lines	   by	   PI-­‐
stained	  FC	  showed	  no	  difference	  in	  the	  cell	  cycle	  profile	  between	  TGFβ	  or	  vehicle	  treatment	  
in	   EBNA3B	   or	   EBNA3C	   KOs	   (fig.	   5.2B).	   These	   findings	   suggest	   that,	   although	   EBNA3B	   and	  
EBNA3C	   are	   necessary	   for	   the	   repression	   of	   TGFβR2	   and	   suppression	   of	   signalling	   via	  
pSMAD2,	   they	   are	   not	   necessary	   for	   protection	   against	   TGFβ-­‐induced	   apoptosis	   in	   BL31	  








	   	  










































Figure	  5.2:	  TGFβ1	  does	  not	  induce	  apoptosis	  or	  G1	  arrest	  in	  EBNA3B	  KO	  or	  EBNA3C	  KO	  BL31	  cells	  
(A)	  Western	  blot	  for	  PARP	  in	  the	  cell	   lines	  shown	  after	  48	  hours’	  treatment	  with	  TGFβ1	  5ng/ml	  or	  vehicle.	  γ-­‐
tubulin	   is	   shown	  as	  a	   loading	  control.	   (B)	  Cells	  were	   treated	  with	  TGFβ1	  5ng/ml	  or	  vehicle	   for	  48	  hours	  and	  
then	   samples	   harvested,	   stained	  with	   propidium	   iodide	   and	   analysed	   by	   FC.	   This	   experiment	  was	   repeated	  
three	   times	   in	   two	   different	   EBNA3B	   KO	   and	   EBNA3C	   KO	   BL31	   cell	   lines	   as	   well	   as	   revertants,	   with	  
representative	  data	  shown	  here.	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5.4	  In	  EBNA2	  KO	  BL31	  cells,	  TGFβ	  induces	  growth	  arrest	  but	  not	  apoptosis	  
The	  effects	  of	  EBNA2	  KO	  on	  TGFβ-­‐induced	  apoptosis/growth	  arrest	  were	  assessed	  initially	  at	  
time	   points	   up	   to	   48	   hours,	   using	   the	   BL31	   EBNA2	   KO	   (G)	   cell	   line.	   This	   showed	   that	   in	  
EBNA2	   KO	   (G),	   no	   increased	   PARP	   cleavage	   occurred	   with	   TGFβ1	   treatment	   at	   any	   time	  
point	   (fig.	   5.3).	   This	   lack	   of	   TGFβ-­‐induced	   apoptosis	   in	   EBNA2	   KO	   cells	   occurred	   despite	  
restoration	   of	   signalling	   via	   pSMAD2	   (see	   fig	   3.7B).	   This	   suggests	   that	   EBNA2	   is	   not	  
necessary	   for	   the	   resistance	   to	   TGFβ-­‐induced	   apoptosis,	   even	   though	   it	   is	   necessary	   for	  








Figure	  5.3:	  TGFβ1	  does	  not	  induce	  PARP	  cleavage	  in	  BL31	  EBNA2	  KO	  (G)	  cells	  with	  up	  to	  48	  hours	  treatment	  
Western	  blot	  for	  PARP	  in	  BL31	  EBNA2	  KO	  (G)	  cells	  at	  the	  times	  shown	  after	  treatment	  with	  TGFβ1	  5ng/ml	  or	  
vehicle	  alone	  (2mg/ml	  BSA	  in	  PBS).	  γ-­‐tubulin	  is	  shown	  as	  a	  loading	  control.	  	  
	  
The	   same	   samples	  were	   analysed	   by	   PI	   FC,	   along	  with	  wild-­‐type	   infected	   and	   uninfected	  
BL31	   cells.	   Surprisingly,	   this	   showed	   that	   TGFβ1	   induced	   a	   partial	   G1	   arrest,	   rather	   than	  
apoptosis,	   compared	   to	   those	   treated	  with	   vehicle	   alone,	   in	   EBNA2	   KO	   cells.	   After	   these	  
experiments	  were	   first	  done,	  a	  colleague	   in	   the	   laboratory	  had	  established	   two	  new	  BL31	  
EBNA2	   KO	   cell	   lines,	   here	   named	   EBNA2	   KO	   1	   and	   EBNA2	   KO	   2,	   as	   well	   as	   an	   EBNA2	  
revertant	  (Ian	  Groves,	  unpublished).	  In	  order	  to	  confirm	  the	  findings	  seen	  in	  BL31	  EBNA2	  KO	  
(G),	  the	  newly	  established	  cell	  lines	  were	  investigated	  alongside	  it	  by	  treatment	  with	  TGFβ1	  
for	  48	  hours	  with	  similar	  analysis.	  This	  showed	  that	  TGFβ	  induced	  G1	  arrest	  in	  all	  three	  BL31	  
EBNA2	  KO	  lines	  (fig.	  5.4B).	  No	  difference	  in	  cell	  cycle	  profile	  was	  seen	  with	  TGFβ1	  compared	  
to	  vehicle	  alone	  in	  the	  EBNA2	  revertant,	  as	  in	  BL31-­‐WT,	  and	  in	  uninfected	  BL31	  an	  increase	  
in	   sub-­‐G1,	   consistent	  with	  apoptosis,	  was	  again	   seen	   (fig.	  5.4A).	  No	   significant	   increase	   in	  
the	   sub-­‐G1	   component	   occurred	   with	   TGFβ1	   in	   any	   of	   the	   EBNA2	   KO	   lines	   (fig.	   5.4B),	  
suggesting	  that	  TGFβ1	  did	  not	  induce	  apoptosis	  in	  EBNA2	  KO,	  as	  shown	  for	  EBNA2	  KO	  (G)	  by	  
PARP	  cleavage	   (fig.	  5.3).	   Therefore,	   the	  effect	  of	  TGFβ	   in	  EBNA2	  KO	  cells	  was	  different	   to	  




either	   wild-­‐type	   EBV-­‐infected	   or	   uninfected	   BL31	   cells,	   with	   TGFβ	   inducing	   a	   partial	   G1	  
arrest	  but	  not	  apoptosis.	  This	  suggests	  that	  EBNA2	  may	  be	  necessary	  for	  the	  cells	  to	  proceed	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Figure	  5.4:	  TGFβ1	  induces	  G1	  arrest	  in	  EBNA2	  KO	  BL31	  cell	  lines	  	  
FC	  analysis	   for	  DNA	   content	   in	   (A)	   BL31,	  BL31-­‐WT,	   EBNA2	   revertant	   and	   (B)	   three	  EBNA2	  KO	   cell	   lines.	   Cell	  
numbers	  are	  shown	  on	  the	  y	  axis	  and	  PI	  staining	  for	  DNA	  content	  on	  the	  x	  axis.	  Cells	  were	  treated	  with	  TGFβ1	  
5ng/ml	  (left)	  or	  vehicle	  (right)	  and	  harvested	  after	  48	  hours	  for	  PI	  staining	  and	  FC	  analysis.	  The	  percentages	  of	  
cells	  in	  each	  phase	  of	  the	  cell	  cycle	  (sub-­‐G1,	  G1,	  S	  and	  G2/M	  from	  left	  to	  right	  in	  each	  histogram)	  are	  indicated.	  
This	  is	  representative	  data	  from	  experiments	  performed	  three	  times.	  	  















5.5	  Resistance	  to	  PARP	  cleavage	  varies	  with	  LMP1	  expression	  in	  EBNA2	  KO	  cell	  lines	  
As	  shown	  in	  fig.	  5.4,	  the	  effect	  of	  TGFβ	  treatment	  was	  investigated	  in	  three	  different	  BL31	  
EBNA2	  KO	  lines.	  All	  three	  EBNA2	  KO	  cell	  lines	  showed	  some	  growth	  arrest	  induced	  by	  TGFβ1	  
after	   PI	   staining	   and	   FC	   analysis	   (fig.	   5.4B).	   However,	   the	   initial	   time	   course	   for	   PARP	  
cleavage	  had	  only	  been	  done	  in	  the	  EBNA2	  KO	  (G)	  cell	  line,	  showing	  no	  PARP	  cleavage	  at	  any	  
time	  point	  (fig.	  5.3).	   In	  order	  to	  confirm	  this	   lack	  of	  PARP	  cleavage	  in	  the	  other	  EBNA2	  KO	  
lines,	   western	   blots	   were	   performed	   for	   PARP	   after	   48	   hours’	   treatment	   with	   TGFβ1	   or	  
vehicle	  using	  extracts	  from	  all	  three	  EBNA2	  KO	  lines.	  This	  showed	  some	  differences	  between	  
the	  cell	  lines,	  with	  moderately	  increased	  PARP	  cleavage	  with	  TGFβ1	  compared	  to	  vehicle	  in	  
the	   two	   recently	   established	   BL31	   EBNA2	   KO	   cell	   lines,	   although	   the	   degree	   of	   PARP	  
cleavage	   remained	  markedly	   less	   than	   for	   uninfected	   BL31	   cells	   (fig.	   5.5).	   Again	   no	   PARP	  
cleavage	   was	   seen	   in	   the	   longer	   established	   EBNA2	   KO	   line,	   EBNA2	   KO	   (G).	   In	   this	  
experiment	   significant	   PARP	   cleavage	   was	   seen	   in	   BL31	   cells	   even	   after	   treatment	   with	  
vehicle	  alone,	  suggesting	  a	  high	  baseline	  level	  of	  apoptosis	   in	  these	  cells.	  Although	  a	  small	  
amount	   of	   PARP	   cleavage	   was	   also	   seen	   in	   BL31-­‐WT,	   this	   was	   similar	   with	   and	   without	  
TGFβ1	   treatment,	   again	   indicating	   some	   baseline	   apoptosis	   occurring	   in	   these	   cells,	   but	  
nevertheless	  suggesting	  that	  EBV	  protects	  against	  apoptosis	  specifically	  induced	  by	  TGFβ1.	  	  
	  
EBNA2	  can	  transactivate	  LMP1	  and	  LMP2A,	  and	  thus	  EBNA2	  KO	  cell	  lines	  would	  be	  expected	  
to	  have	  a	  marked	  reduction	  in	  expression	  of	  these	  latent	  proteins.	  Several	  previous	  studies	  
have	  investigated	  the	  effect	  of	  LMP1	  on	  TGFβ-­‐induced	  growth	  inhibition	  and	  apoptosis	  in	  B	  
cells,	  with	  some	  studies	  suggesting	   that	  LMP1	   is	  necessary	   for	   resistance	  to	  TGFβ-­‐induced	  
growth	  inhibition	  (Arvanitakis	  et	  al.	  1995)	  and	  apoptosis	  (Arvanitakis	  et	  al.	  1995,	  Kenney	  et	  
al.	   2001)	   but	   others	   suggesting	   it	   is	   neither	   necessary	   nor	   sufficient	   (Inman	   and	   Allday	  
2000b).	  
	  
Therefore,	  it	  was	  hypothesised	  that	  variable	  LMP1	  expression	  in	  the	  EBNA2	  KO	  lines	  might	  
result	   in	   differential	   amounts	   of	   TGFβ-­‐induced	   apoptosis.	   Hence,	   the	   LMP1	   expression	   in	  
these	   cell	   lines	   was	   investigated	   by	   performing	   western	   blot	   (fig.	   5.5).	   This	   showed	   that	  
LMP1	  expression	  varied	  between	  the	  three	  EBNA2	  KO	  lines,	  in	  particular	  that	  EBNA2	  KO	  (G)	  
surprisingly	   expressed	   significant	   amounts	   of	   LMP1.	   Moreover,	   there	   appeared	   to	   be	   an	  
inverse	   correlation	   between	   the	   level	   of	   expression	   of	   LMP1	   and	   the	   degree	   of	   TGFβ1-­‐




induced	   PARP	   cleavage	   in	   these	   three	   cell	   lines,	   with	   EBNA2	   KO	   (G)	   having	   full	   LMP1	  
expression	  and	  no	  TGFβ-­‐induced	  PARP	  cleavage,	  EBNA2	  KO	  1	  having	  an	  intermediate	  level	  
of	  both,	  and	  EBNA2	  KO	  2	  having	  no	  detectable	  LMP1	  expression	  and	  also	   the	  most	  TGFβ-­‐
induced	  PARP	  cleavage	  of	  the	  three	  cell	  lines	  (fig.	  5.5).	  However,	  it	  was	  observed	  that	  even	  
in	  EBNA2	  KO	  2,	  the	  degree	  of	  PARP	  cleavage	  was	  much	  less	  than	  for	  uninfected	  BL31.	  These	  
findings	  led	  to	  the	  hypothesis	  that	  LMP1	  may	  protect	  against	  TGFβ-­‐induced	  apoptosis.	  LMP1	  
is	   known	   to	   promote	   survival	   by	   several	   mechanisms,	   including	   up-­‐regulation	   of	   BCL2,	  
induction	  of	  c-­‐FLIP	  and	  inhibition	  of	  BAX	  (Henderson	  et	  al.	  1991,	  Grimm	  et	  al.	  2005,	  Allday	  
2009,	  Spender	  and	  Inman	  2011).	  Taken	  together	  with	  the	  previous	  findings	  in	  section	  5.4,	  it	  
was	  hypothesised	   that	   LMP1	  protects	  against	  TGFβ-­‐induced	  apoptosis	  whereas	  EBNA2,	  or	  
possibly	   LMP2A	   since	   this	   is	   also	   transactivated	  by	   EBNA2,	   protects	   against	   TGFβ-­‐induced	  













Figure	  5.5:	  TGFβ-­‐induced	  PARP	  cleavage	  varies	  with	  LMP1	  expression	  in	  EBNA2	  KO	  BL31	  cell	  lines	  
Western	  blot	  for	  PARP	  and	  LMP1	  expression	  after	  48	  hours’	  treatment	  with	  TGFβ1	  5ng/ml	  or	  vehicle	  (2mg/ml	  
BSA	  in	  PBS)	  in	  BL31,	  wild-­‐type	  EBV-­‐infected,	  three	  different	  EBNA2	  KO	  and	  the	  EBNA2	  revertant	  BL31	  cell	  lines.	  
γ-­‐tubulin	  was	  used	  as	  a	  loading	  control.	  	  	  	  
	  
5.6	  LMP2A	  is	  necessary	  for	  protection	  against	  TGFβ-­‐induced	  growth	  arrest	  
As	  described	  earlier	   in	  section	  5.4,	  the	  EBNA2	  KO	  lines	  all	  showed	  TGFβ-­‐induced	  G1	  arrest	  
(fig.	   5.4B),	   but	   varied	   in	   their	   response	   in	   terms	  of	   PARP	   cleavage,	  with	   the	   cell	   line	  with	  
more	  LMP1	  apparently	  being	  protected	  from	  TGFβ-­‐induced	  PARP	  cleavage	  (fig.	  5.5),	  leading	  
to	  the	  hypothesis	  that	  LMP1	  may	  protect	  against	  TGFβ-­‐induced	  apoptosis.	  In	  addition,	  since	  
all	  EBNA2	  KO	   lines	  showed	  G1	  arrest	  with	  TGFβ,	   regardless	  of	   their	  LMP1	  expression,	   this	  




suggested	   that	   EBNA2,	   or	   possibly	   LMP2A,	   may	   be	   necessary	   for	   the	   cells	   to	   proceed	  
through	  a	  G1	  checkpoint.	  	  
	  
Therefore	  the	  LMP1	  KO	  and	  LMP2A	  KO	  BL31	  cell	  lines	  were	  treated	  for	  48	  hours	  with	  TGFβ	  
or	  vehicle,	  with	  samples	  then	  harvested	  for	  protein	  extraction,	  SDS-­‐PAGE	  and	  western	  blot	  
for	  PARP,	  as	  well	  as	  for	  cell	  cycle	  analysis	  by	  FC,	  in	  this	  case	  using	  Draq5	  as	  the	  DNA	  stain.	  FC	  
analysis	  showed	  that	  there	  was	  no	  difference	  in	  cell	  cycle	  profile	  between	  TGFβ	  treated	  and	  
untreated	  for	  both	  LMP1	  KO	   lines	   (fig.	  5.6A).	  Western	  blot	  also	  showed	  no	  PARP	  cleavage	  
with	  TGFβ	  in	  either	  of	  the	  LMP1	  KO	  lines	  (fig.	  5.6B).	  These	  findings	  suggest	  that	  LMP1	  is	  not	  
necessary	  for	  protection	  against	  TGFβ-­‐induced	  apoptosis.	  	  	  
	  
Both	  LMP2A	  KO	  lines,	  however,	  showed	  G1	  arrest	  with	  TGFβ	  (fig.	  5.7A),	  similar	  to	  that	  seen	  
in	  EBNA2	  KO	   lines	   (fig.	  5.4B).	   There	  was	  no	   increase	   in	   the	   sub-­‐G1	  component	  with	  TGFβ	  
and	   again	   no	   increase	   in	   PARP	   cleavage	   with	   TGFβ	   in	   the	   LMP2A	   KO	   lines	   (figs.	   5.7A-­‐B).	  	  
These	   findings	   suggest	   that	   LMP2A	   is	   necessary	   for	   cells	   to	   proceed	   through	   the	   G1	  
checkpoint,	  but	  is	  also	  not	  necessary	  for	  protection	  against	  TGFβ-­‐induced	  apoptosis.	  	  
	  
The	  findings	  for	  PARP	  cleavage	  in	  the	  three	  different	  EBNA2	  KO	  lines	  (fig.	  5.5)	  had	  suggested	  
that	   LMP1	   might	   protect	   against	   TGFβ-­‐induced	   apoptosis.	   If	   that	   were	   the	   case	   then	   it	  
would	  be	  expected	  that	  increased	  PARP	  cleavage	  would	  be	  seen	  with	  TGFβ	  in	  the	  LMP1	  KO	  
lines.	   However,	   no	   increased	   PARP	   cleavage	  was	   seen	   in	   either	   LMP1	   KO	   line,	   suggesting	  
that	   LMP1	   alone	   is	   not	   necessary	   for	   protection	   against	   TGFβ-­‐induced	   apoptosis.	  
Nevertheless,	   it	   remains	  possible	  that	  the	  presence	  of	  either	  LMP1	  or	  EBNA2	  are	  required	  
for	  protection	  against	  TGFβ-­‐induced	  apoptosis,	  since	   increased	  PARP	  cleavage	  was	  seen	   in	  
cells	  lacking	  both	  EBNA2	  and	  LMP1	  (BL31	  EBNA2	  KO	  2,	  fig.	  5.5)	  but	  not	  in	  the	  LMP1	  KO	  lines	  
which	  are	  deficient	  only	  in	  LMP1	  but	  not	  EBNA2	  (fig.	  5.6A-­‐B).	  
	  
	  
	   	  






























Figure	  5.6:	  TGFβ1	  does	  not	  induce	  apoptosis	  or	  G1	  arrest	  in	  LMP1	  KO	  BL31	  cells	  	  
The	   two	   LMP1	   KO	   cell	   lines,	   along	   with	   BL31	   and	   BL31-­‐WT,	   were	   treated	   with	   TGFβ1	   5ng/ml	   or	   vehicle	  
(2mg/ml	  BSA	  in	  PBS)	  for	  48	  hours	  followed	  by	  harvesting	  for	  protein	  extraction	  and	  FC	  analysis.	  (A)	  FC	  for	  cell	  
cycle	  DNA	  content	  after	  staining	  with	  Draq5	  in	  both	  BL31	  LMP1	  KO	  cell	  lines	  treated	  with	  TGFβ1	  (left	  side)	  or	  
vehicle	  (right	  side).	  Percentages	  of	  cells	  in	  each	  phase	  of	  the	  cell	  cycle	  are	  shown	  in	  tables.	  	  (B)	  Western	  blot	  
for	  PARP	  in	  both	  LMP1	  KO	  lines	  with	  TGFβ	  or	  vehicle,	  with	  time	  0	  shown	  for	  comparison,	  as	  well	  as	  BL31	  and	  
BL31-­‐WT.	  γ-­‐tubulin	  was	  used	  as	  a	  loading	  control.	  	  









































Figure	  5.7:	  TGFβ1	  induces	  G1	  arrest	  but	  not	  apoptosis	  in	  LMP2A	  KO	  BL31	  cells	  	  
The	   two	   LMP2A	   KO	   cell	   lines,	   along	   with	   BL31	   and	   BL31-­‐WT,	   were	   treated	   with	   TGFβ1	   5ng/ml	   or	   vehicle	  
(2mg/ml	  BSA	  in	  PBS)	  for	  48	  hours	  followed	  by	  harvesting	  for	  protein	  extraction	  and	  FC	  analysis.	  (A)	  FC	  for	  cell	  
cycle	  DNA	  content	  after	  staining	  with	  Draq5	  in	  both	  BL31	  LMP2A	  KO	  cell	  lines	  treated	  with	  TGFβ1	  (left	  side)	  or	  
vehicle	  (right	  side).	  Percentages	  of	  cells	  in	  each	  phase	  of	  the	  cell	  cycle	  are	  shown	  in	  tables.	  (B)	  Western	  blot	  for	  
PARP	   in	  both	  LMP2A	  KO	   lines	  with	  TGFβ	  or	  vehicle,	  with	   time	  0	  shown	  for	  comparison,	  as	  well	  as	  BL31	  and	  
BL31-­‐WT.	  γ-­‐tubulin	  was	  used	  as	  a	  loading	  control.	  	  













In	   summary,	   TGFβ	   appears	   to	   induce	   apoptosis,	   but	   not	   G1	   arrest,	   in	   EBV-­‐negative	   BL31	  
cells,	  as	  detected	  by	  PARP	  cleavage	  (fig.	  5.1A).	  However,	  as	  noted	  previously,	  the	  effect	  of	  
TGFβ1	  on	  the	  sub-­‐G1	  component	  by	  FC	  analysis	  seemed	  to	  be	   less	  marked	  than	  has	  been	  
observed	   for	   other	   cell	   lines	   by	   previous	   investigators	   [for	   example	   (Inman	   and	   Allday	  
2000b)]	   (fig.	   5.1B).	   The	   presence	   of	   wild-­‐type	   EBV	   is	   protective	   from	   TGFβ-­‐induced	  
apoptosis	  (figs.	  5.1A-­‐B).	  
	  
When	  the	  effects	  of	  individual	  latent	  proteins	  on	  this	  were	  investigated,	  firstly	  this	  showed	  
that	  EBNA3B	  and	  EBNA3C	  deletion	  do	  not	  lead	  to	  TGFβ-­‐induced	  apoptosis	  or	  growth	  arrest,	  
hence	  EBNA3B	  and	  EBNA3C	  are	  not	  needed	  for	  protection	  against	  TGFβ-­‐induced	  apoptosis	  
or	  arrest	  (fig.	  5.2A-­‐B).	  However,	  they	  are	  both	  necessary	  for	  the	  repression	  of	  TGFβR2	  and	  
suppression	  of	  TGFβ	  signalling	  via	  pSMAD2	  (figs.	  3.1A	  and	  3.7C-­‐D).	  	  
	  
When	   the	   effect	   of	   EBNA2	   deletion	  was	   investigated,	   this	   showed	   that	   TGFβ	   induced	  G1	  
arrest,	  without	  any	  increase	  in	  sub-­‐G1,	  in	  all	  three	  EBNA2	  KO	  cell	  lines	  (fig.	  5.4B).	  However,	  	  
the	  three	  cell	  lines	  showed	  differing	  amounts	  of	  PARP	  cleavage	  induced	  by	  TGFβ,	  with	  some	  
increased	  PARP	  cleavage	  in	  EBNA2	  KO	  1	  and	  particularly	  EBNA2	  KO	  2,	  but	  no	  PARP	  cleavage	  
in	  BL31	  EBNA2	  KO	  (G)	  (fig.	  5.5).	  These	  findings	  suggest	  that	   increased	  PARP	  cleavage	  does	  
not	  always	  correlate	  with	  an	  increase	  in	  cell	  cycle	  sub-­‐G1	  component	  in	  these	  cells	  –	  as	  was	  
also	  suggested	  by	  the	  marked	  PARP	  cleavage	  but	  less	  dramatic	  increase	  in	  sub-­‐G1	  in	  TGFβ-­‐
treated	  BL31	  cells	  (figs.	  5.1A-­‐B).	  	  
	  
In	  view	  of	  these	  differences	  between	  PARP	  cleavage	  and	  cell	  cycle	  analysis	  in	  BL31,	  several	  
attempts	  were	  made	  to	  repeat	  the	  FC	  analysis	  in	  BL31	  cells.	  In	  more	  recent	  attempts,	  it	  was	  
noted	  that	  TGFβ	  treatment	  also	  did	  not	  induce	  PARP	  cleavage	  as	  significantly	  as	  previously	  
(fig.	  5.8A	  compared	  with	  fig.	  5.1A).	  It	  was	  hypothesised	  that	  the	  apparent	  reduction	  in	  TGFβ	  
sensitivity	   in	  PARP	   cleavage	  may	  be	  due	   to	   the	  BL31	   cells	   having	  developed	   resistance	   to	  
TGFβ	  during	  continued	  culture.	  Therefore	  a	  batch	  of	  BL31	  cells	  that	  had	  been	  cryopreserved	  
at	   a	   similar	   time	   to	   that	   used	   for	   the	   initial	   experiments	   (as	   seen	   in	   fig.	   5.1)	   was	   re-­‐
established	  from	  frozen	  and	  then	  investigated	  in	  a	  similar	  manner	  alongside	  the	  batch	  that	  
had	  been	  more	  recently	  tested.	  However,	  the	  original	  batch	  of	  BL31	  cells	  also	  yielded	  similar	  
results,	   i.e.	  a	  much	   less	  marked	   increase	   in	  PARP	  cleavage	   than	  previously.	  Additionally	   in	  




the	  more	   recent	  experiments,	   the	   increase	   in	   sub-­‐G1	  after	  TGFβ	   treatment	  was	  even	   less	  
significant	  than	  originally.	  	  
	  
In	   these	  experiments,	  even	  though	  the	  batch	  of	  TGFβ	  was	  different	   from	  that	  used	   in	   the	  
initial	  experiments	  (but	  from	  the	  same	  manufacturer),	  TGFβ	  still	  caused	  strong	  induction	  of	  
pSMAD2	  in	  BL31	  cells.	  A	  fresh	  batch	  of	  TGFβ1	  also	  yielded	  the	  same	  results,	  suggesting	  the	  
findings	   were	   not	   due	   to	   lack	   of	   potency	   of	   the	   particular	   batch	   of	   TGFβ1.	   In	   addition,	  
experiments	  were	  attempted	  with	  a	  higher	  dose	  of	  TGFβ1	  (10ng/ml	  rather	  than	  5ng/ml)	  and	  
a	  72	  hour	  time	  point	  was	  used.	  Still,	   there	  was	  generally	   little	  difference	  between	  treated	  
and	  untreated	  BL31	  in	  terms	  of	  PARP	  cleavage	  or	  sub-­‐G1	  component.	  	  
	  
In	  a	  further	  attempt	  to	  investigate	  the	  effects	  of	  TGFβ,	  BL31	  cells	  were	  also	  stained	  with	  a	  
live-­‐dead	  stain	  prior	   to	  FC	  analysis,	  since	   it	  was	  hypothesised	  that	  TGFβ	  could	  be	   inducing	  
cell	  death	  without	  the	  characteristic	  pattern	  of	  DNA	  fragmentation	  seen	  in	  apoptosis.	  Live-­‐
dead	  staining	  confirmed	  an	  increased	  proportion	  of	  dead	  cells	  after	  treatment	  of	  BL31	  cells	  
with	   TGFβ	   compared	   to	   vehicle	   (fig.	   5.8B,	   upper	   figures).	   However,	   when	   the	   same	   cells	  
(including	   both	   live	   and	  dead	   components)	  were	   analysed	  by	   cell	   cycle	   profile,	   there	  was	  
little	  difference	  in	  the	  profiles,	  in	  particular	  no	  increase	  in	  the	  sub-­‐G1	  component	  (fig.	  5.8B,	  
lower	  figures).	  	  
	  
Review	   of	   laboratory	   records	   showed	   that	   the	   batch	   of	   foetal	   calf	   serum	   (FCS)	   used	   to	  
supplement	  media	  for	  growth	  of	  all	  cell	  lines	  in	  the	  laboratory	  had	  changed	  shortly	  after	  the	  
initial	  set	  of	  experiments	  on	  TGFβ-­‐induced	  apoptosis	  were	  done,	  fairly	  early	  in	  the	  course	  of	  
this	   project.	   The	   second	   batch	   of	   serum	   had	   been	   used	   for	   all	   subsequent	   experiments.	  
Therefore	  it	  seems	  likely	  that	  some	  factor	  in	  the	  serum	  rendered	  cells	  relatively	  resistant	  to	  
the	  apoptotic	  effects	  of	  TGFβ,	  whilst	  maintaining	  the	  effects	  of	  TGFβ	  on	  pSMAD2.	  TGFβ	  was	  
still	  able	  to	  cause	  increased	  death	  in	  the	  cells	  (fig.	  5.8B);	  however,	  since	  this	  had	  not	  been	  
investigated	  in	  the	  original	  experiments	  it	  is	  not	  known	  whether	  the	  newer	  batch	  of	  serum	  
had	  also	  altered	  the	  amount	  of	  TGFβ-­‐induced	  cell	  death.	  These	   findings	   therefore	  suggest	  
that	  TGFβ-­‐induced	  death,	  PARP	  cleavage	  and	  sub-­‐G1	  component	  do	  not	  always	  correlate,	  at	  
least	  in	  BL31	  cells.	  	  
	   	  






































Figure	  5.8:	  TGFβ-­‐induced	  PARP	  cleavage,	  sub-­‐G1	  component	  and	  cell	  death	  do	  not	  correlate	  in	  BL31	  cells	  	  
(A)	  Western	  blot	  for	  PARP	  cleavage	  at	  time	  zero,	  untreated	  and	  after	  48	  hours’	  treatment	  with	  TGFβ1	  5ng/ml	  
or	  vehicle	   (2mg/ml	  BSA	   in	  PBS)	   in	  EBV-­‐negative	  BL31	  cells.	   γ-­‐tubulin	   is	   shown	  as	  a	   loading	  control.	   (B)	  BL31	  
cells	  were	  harvested	  48	  hours	   after	   treatment	  with	  TGFβ1	   (left	   side)	  or	   vehicle	   (-­‐TGFβ1,	   right	   side),	   stained	  
dually	   with	   violet	   live-­‐dead	   fixable	   stain	   and	   Draq5,	   then	   subjected	   to	   flow	   cytometric	   analysis,	   showing	  
proportions	  of	  live	  and	  dead	  cells	  (upper	  figures)	  with	  cell	  cycle	  DNA	  content	  (lower	  figures).	  	   	  










TGFβ	   is	   anti-­‐proliferative	   and/or	   promotes	   apoptosis	   in	   most	   cell	   types,	   with	   the	   effect	  
varying	  according	  to	  cell	  type	  and	  context.	  TGFβ	  can	  induce	  both	  G1	  arrest	  and	  apoptosis	  in	  
the	  same	  cells	  (MacDonald	  et	  al.	  1996,	  Schrantz	  et	  al.	  1999).	  Having	  shown	  that	  EBV	  down-­‐
regulates	   TGFβR2	   leading	   to	   suppression	   of	   signalling,	   the	   effects	   of	   EBV	   latent	   protein	  
expression	  on	  TGFβ	  responses	  were	  investigated	  in	  BL31	  cells.	  
	  
The	  effects	  of	  EBV	  infection	  on	  TGFβ-­‐induced	  apoptosis	  
Initial	  experiments	  showed	  that	  TGFβ	  induced	  a	  very	  modest	  level	  of	  apoptosis,	  as	  shown	  by	  
PARP	  cleavage	  and	  an	   increased	  sub-­‐G1	  component	  revealed	  by	  FC	  analysis,	   in	  uninfected	  
BL31	  cells	  (fig.	  5.1).	  BL31	  cells	   infected	  with	  wild-­‐type	  EBV	  were	  resistant	  to	  TGFβ-­‐induced	  
apoptosis,	  confirming	  previous	  reports	  that	   full	  EBV	  expression	   is	  protective	  against	  TGFβ-­‐
induced	  apoptosis	  in	  BLs	  (fig.	  5.1)	  (Inman	  and	  Allday	  2000b,	  Inman	  et	  al.	  2001).	  
	  
The	   effects	   of	   the	   individual	   latent	   proteins	   were	   then	   investigated,	   since	   it	   was	  
hypothesised	  that	  the	  down-­‐regulation	  of	  TGFβR2	  may	  lead	  to	  resistance	  to	  TGFβ-­‐induced	  
apoptosis.	  The	  responses	  to	  TGFβ	  in	  the	  different	  cell	  lines	  are	  summarised	  in	  table	  5.1.	  	  
	  
Cell	  line	   EBNA2	   LMP1	   LMP2A	   EBNA3B	   EBNA3C	   TGFβ	  response	  
BL31	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   Apoptosis	  
BL31-­‐WT	   +	   +	   +	   +	   +	   No	  effect	  
EBNA3B	  KO	   +	   +	   +	   -­‐	   +	   No	  effect	  
EBNA3C	  KO	   +	   +	   +	   +	   -­‐	   No	  effect	  
EBNA2	  KO	  (G)	   -­‐	   +	   -­‐	   +	   +	   G1	  arrest	  
EBNA2	  KO	  1/2	   -­‐	   -­‐	   -­‐	   +	   +	   Arrest	  +	  apoptosis	  
LMP1	  KO	   +	   -­‐	   +	   +	   +	   No	  effect	  
LMP2A	  KO	   +	   -­‐	   -­‐	   +	   +	   G1	  arrest	  
	  
Table	  5.1:	  Summary	  of	  TGFβ	  responses	  in	  selected	  BL31	  cell	  lines,	  indicating	  expression	  levels	  of	  the	  relevant	  
EBV	  latent	  proteins	  
	  +	  =	  protein	  expressed,	  -­‐	  =	  expression	  low	  or	  absent.	  
	  




In	  EBNA3B	  KO	  and	  EBNA3C	  KO	  cells,	  no	  increased	  apoptosis	  or	  G1	  arrest	  was	  seen	  (fig.	  5.2),	  
suggesting	   that	   these	   latent	   proteins,	   although	   necessary	   for	   repression	   of	   TGFβR2	   and	  
suppression	   of	   signalling	   (figs.	   3.1A	   and	   3.7C-­‐D),	   are	   not	   necessary	   for	   the	   resistance	   to	  
TGFβ-­‐induced	  apoptosis	  or	  growth	  arrest.	  	  
	  
TGFβ	  induced	  G1	  arrest	  in	  all	  three	  EBNA2	  KO	  lines	  by	  PI	  FC	  analysis	  (fig.	  5.4C).	  Western	  blot	  
for	   PARP	   showed	   some	   TGFβ-­‐induced	   PARP	   cleavage	   in	   those	   cells	   lacking	   or	   having	   low	  
expression	   of	   LMP1,	   whereas	   EBNA2	   KO	   (G),	   which	   had	   full	   expression	   of	   LMP1,	   did	   not	  
show	  any	  PARP	  cleavage	  (fig.	  5.5).	  This	  suggested	  that	  LMP1	  was	  required	  to	  protect	  against	  
TGFβ-­‐induced	  apoptosis.	  However,	  when	  the	  BL31	  LMP1	  KO	  lines	  were	  treated	  with	  TGFβ,	  
no	  apoptosis	  was	  seen	  by	  PARP	  cleavage	  or	  FC	  (figs.	  5.6),	  despite	  the	  fact	  that	  TGFβR2	  was	  
de-­‐repressed,	  with	  restoration	  of	  signalling	  via	  phosphorylation	  of	  SMAD2,	  in	  these	  cell	  lines	  
(figs.	  4.3A-­‐B).	  Thus	  the	  results	  for	  the	  effect	  of	  LMP1	  on	  apoptosis	   initially	  appeared	  to	  be	  
discrepant.	  However,	   looking	  at	   the	  summary	   in	  table	  5.1,	   it	   is	  possible	  that	  expression	  of	  
either	   LMP1	   or	   EBNA2	   is	   needed	   for	   protection	   against	   TGFβ-­‐induced	   apoptosis,	   since	  
apoptosis	  occurs	  when	  neither	  are	  expressed,	  whereas	  when	  either	  one	  is	  expressed	  TGFβ	  
does	  not	  induce	  apoptosis.	  	  
	  
LMP1	  promotes	  protection	  against	  apoptosis	  by	  multiple	  mechanisms	  [reviewed	   in	   (Allday	  
2009,	   Spender	   and	   Inman	   2011)],	   including	   up-­‐regulation	   of	   the	   anti-­‐apoptotic	   proteins	  
BCL2,	   BFL1	   and	  MCL-­‐1	   (Henderson	   et	   al.	   1991,	   D'Souza	   et	   al.	   2004,	   Kim	   et	   al.	   2012),	   via	  
activation	  of	  NFκB,	  which	  is	  generally	  pro-­‐survival.	  LMP1	  also	  inhibits	  BAX/BAK	  and	  induces	  
expression	   of	   c-­‐FLIP,	   which	   inhibits	   extrinsic	   apoptotic	   pathways.	   Furthermore,	   LMP1	   up-­‐
regulates	  expression	  of	  miR-­‐155,	  which	   inhibits	  pro-­‐apoptotic	  PUMA.	  EBNA2,	  on	  the	  other	  
hand,	  has	  more	  limited	  anti-­‐apoptotic	  effects,	  but	  does	  induce	  anti-­‐apoptotic	  BFL1	  (Pegman	  
et	  al.	  2006).	  
	  
Although	  the	  mechanisms	  of	  TGFβ-­‐induced	  apoptosis	  in	  B	  cells	  are	  not	  yet	  fully	  understood,	  
those	  that	  have	  been	  elucidated	  include	  several	  mechanisms	  which	  are	  directly	  antagonistic	  
to	  the	  effects	  of	  LMP1.	  For	  example,	  TGFβ	  up-­‐regulates	  PUMA,	  via	  SMAD3	  (Spender	  et	  al.	  
2013),	   up-­‐regulates	   BIK,	   which	   in	   turn	   inhibits	   the	   anti-­‐apoptotic	   protein	   MCL-­‐1,	   and	  
represses	  BCL-­‐XL	  (Saltzman	  et	  al.	  1998,	  Spender	  et	  al.	  2009).	  TGFβ	  also	  inhibits	  NFκB,	  leading	  




to	  apoptosis	  in	  B	  cells	  (Arsura	  et	  al.	  1996).	  TGFβ	  and	  LMP1	  therefore	  have	  opposing	  effects	  
on	   NFκB	   activation.	   TGFβ	   also	   activates	   BAX/BAK,	   whereas	   LMP1	   inhibits	   it.	   Therefore	   it	  
would	  be	  predicted	  that	  LMP1	  expression	  could	  inhibit	  TGFβ-­‐induced	  apoptosis.	  	  	  
	  
LMP2A	  also	  has	  several	  means	  of	  protection	  against	  apoptosis,	  including	  activation	  of	  NFκB,	  
again	   leading	   to	   induction	   of	   anti-­‐apoptotic	   proteins	   BCL2	   and	   BFL1.	   LMP2A	   also	   inhibits	  
apoptosis	   via	   induction	   of	   BCL-­‐XL	   (Portis	   and	   Longnecker	   2004,	   Bultema	   et	   al.	   2009).	   In	  
addition,	   LMP2A	   inhibits	   BIM,	   via	   MAPK/ERK.	   However,	   in	   the	   current	   study,	   LMP2A	  
expression	  was	  not	  necessary	  to	  protect	  against	  TGFβ-­‐induced	  apoptosis	  (see	  table	  5.1	  and	  
figs.	  5.7A-­‐B).	  	  
	  
In	   the	   current	   study,	   deletion	   of	   individual	   latent	   proteins	   including	   EBNA3B,	   EBNA3C,	  
EBNA2,	   LMP1	  and	  LMP2A	  did	  not	   result	   in	  TGFβ-­‐induced	  apoptosis	   in	  any	   case	   (see	   table	  
5.1).	  TGFβ-­‐induced	  apoptosis	  has	  been	  previously	   shown	   to	  occur	  via	  SMAD3	   in	  epithelial	  
cells	  (Yanagisawa	  et	  al.	  1998,	  Kim	  et	  al.	  2002,	  Yang	  et	  al.	  2002),	  a	  murine	  B	  cell	  line	  (Wildey	  
et	  al.	  2003)	  and	  more	  recently	  human	  BL	  cell	  lines	  (Spender	  et	  al.	  2013).	  However,	  in	  those	  
cell	   lines	   in	  which	  TGFβR2	  is	  repressed,	   it	  would	  be	  predicted	  that	  TGFβ	  would	  not	   induce	  
phosphorylation	   of	   SMAD3,	   although	   this	   was	   not	   investigated	   in	   this	   study	   due	   to	   time	  
constraints;	  the	  correlation	  between	  TGFβ-­‐induced	  phosphorylation	  of	  pSMAD3	  and	  TGFβ-­‐
induced	   apoptosis	   in	  BL31	   cells	   could	  be	   investigated	   in	   future.	  Nevertheless,	   the	   current	  
findings	  suggest	  that	  TGFβ-­‐induced	  apoptosis	  may	  occur	  via	  a	  non-­‐canonical	  TGFβ	  pathway	  
not	   involving	  TGFβR2,	   for	  example	  by	   cross-­‐talk	  with	  other	   intracellular	  pathways	   such	  as	  
PI3K,	  MAPK,	  or	  other	  Smad-­‐independent	  TGFβ	  responses.	  	  
	  
Furthermore,	   EBV	   blocks	   apoptosis	   by	   multiple	   mechanisms	   [reviewed	   in	   (Allday	   2009,	  
Spender	   and	   Inman	   2011)],	   including	   those	   involving	   LMP1,	   LMP2A	   and	   EBNA2	   as	   already	  
described.	   In	   addition,	   EBNA3A	   and	   EBNA3C	   cooperate	   to	   repress	   pro-­‐apoptotic	   BIM,	   and	  
EBV	   inhibits	   pro-­‐apoptotic	  NOXA.	  miR-­‐BART5	   inhibits	   PUMA,	   and	   BHRF1	   also	   inhibits	   BAX.	  
EBNA1	   is	   anti-­‐apoptotic,	   by	   lowering	   p53	   levels	   and	   inhibiting	   p53-­‐induced	   apoptosis	  
(Kennedy	   et	   al.	   2003,	   Saridakis	   et	   al.	   2005)	   and	   EBV	   miRNAs	   can	   protect	   BL	   cells	   from	  
apoptosis	   (Vereide	   et	   al.	   2013).	   Therefore,	   these	   other	   mechanisms	   may	   also	   alter	   the	  
apoptotic	   response	   to	   TGFβ,	   possibly	   explaining	  why	   very	   little	   apoptosis	  was	   seen	   in	   cell	  




lines	  other	  than	  EBV-­‐negative	  BL31.	  Hence,	  even	  when	  particular	  latent	  proteins	  are	  deleted,	  
the	  remaining	  latent	  proteins	  can	  protect	  against	  TGFβ-­‐induced	  apoptosis.	  
	  
LMP2A	  expression	  in	  a	  gastric	  carcinoma	  cell	  line	  was	  sufficient	  to	  completely	  inhibit	  TGFβ-­‐
induced	   apoptosis,	   whereas	   in	   the	   EBV-­‐negative	   BL	   line	   Ramos,	   LMP2A	   expression	   only	  
partially	   blocked	   TGFβ-­‐induced	   apoptosis	   (Fukuda	   and	   Longnecker	   2004).	   Thus	   although	  
LMP1	  or	  LMP2A	  may	  be	  sufficient	  to	  block	  TGFβ-­‐induced	  apoptosis	   in	  epithelial	  cells,	  they	  
appear	   to	   have	   only	   a	   partial	   effect	   in	   B	   cells,	   suggesting	   that	   other	   latent	   proteins	  
contribute	  in	  B	  cells.	  	  
	  
The	  effects	  of	  EBV	  infection	  on	  TGFβ-­‐mediated	  inhibition	  of	  proliferation	  	  
Although	  many	  studies	  have	  investigated	  the	  effects	  of	  EBV	  on	  responses	  to	  TGFβ	  in	  B	  cells,	  
these	   have	  mostly	   investigated	   the	   anti-­‐proliferative	   rather	   than	   pro-­‐apoptotic	   effects	   of	  
TGFβ.	   In	  EBV-­‐negative	  BLs,	  different	   responses	  are	   seen	   for	   individual	   cell	   lines,	   and	  even	  
within	  the	  same	  cell	  line	  in	  different	  studies,	  for	  example	  in	  the	  Ramos	  cell	  line	  (Blomhoff	  et	  
al.	  1987,	  Altiok	  et	  al.	  1993,	  Chaouchi	  et	  al.	  1995,	  Inman	  and	  Allday	  2000b,	  Di	  Bartolo	  et	  al.	  
2008,	  Wang	  et	  al.	  2008,	  Kawabata	  et	  al.	  2013).	  Several	  studies	  have	  shown	  that	  full	  latency	  
III	   EBV	  expression	   leads	   to	   resistance	   to	   the	  anti-­‐proliferative	  effects	  of	  TGFβ	   (Kehrl	  et	  al.	  
1986,	  Blomhoff	  et	  al.	  1987,	  Janssen	  et	  al.	  1990,	  Altiok	  et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  
et	   al.	   1992,	  Altiok	   et	   al.	   1993,	  Arvanitakis	   et	   al.	   1995,	  MacDonald	   et	   al.	   1996,	   Inman	   and	  
Allday	  2000b).	  	  
	  
In	   the	  current	  study,	  TGFβ1	   induced	  G1	  arrest	   in	  all	   three	  EBNA2	  KO	  and	  both	  LMP2A	  KO	  
BL31	  cell	  lines	  (see	  figs.	  5.4B	  and	  5.7A).	  These	  were	  all	  characterised	  by	  low	  or	  no	  expression	  
of	   LMP2A	   (see	   table	  5.1).	   The	   remaining	   cell	   lines,	   including	  EBNA3B	  KO,	  EBNA3C	  KO	  and	  
LMP1	   KOs,	   did	   not	   undergo	   arrest	   (or	   apoptosis)	   with	   TGFβ1	   (figs.	   5.2	   and	   5.6).	   These	  
findings	  suggest	  that	  LMP2A	  expression	   is	  protective	  against	  TGFβ-­‐induced	  arrest,	   i.e.	   that	  
LMP2A	  expression	  drives	  progression	  through	  the	  G1	  checkpoint.	  	  
	  
In	  epithelial	  cells,	  TGFβ-­‐induced	  cell	  cycle	  arrest	  occurs	  via	  repression	  of	  Id	  proteins	  (Ling	  et	  
al.	  2002).	  TGFβ-­‐also	  down-­‐regulates	  c-­‐Myc,	  which	  normally	  represses	  p15	  and	  p21,	  leading	  
to	   induction	  of	  p15/p21	  and	  hence	  cell	  cycle	  arrest	  (Alexandrow	  et	  al.	  1995,	  Warner	  et	  al.	  




1999).	  However,	   in	   B	   cells	   TGFβ	   generally	   induces	   rather	   than	   represses	   Id	   expression:	   in	  
murine	  B	  lymphoid	  progenitors	  TGFβ	  induces	  Id3	  expression,	  resulting	  in	  G1	  arrest	  (Kee	  et	  
al.	  2001)	  and	   in	  human	  EBV-­‐negative	  BL	  cell	   lines,	  TGFβ	   induces	   Id1	  and	   Id2	  (Spender	  and	  
Inman	  2009b).	  The	  mechanism	  of	  TGFβ-­‐induced	  growth	  arrest	   in	  CA46	  BL,	  however,	   is	  by	  
repression	  of	  E2F1,	  rather	  than	  via	  c-­‐Myc	  repression,	  Id	  repression	  or	  induction	  of	  p15/p21;	  
(Spender	  and	   Inman	  2009b).	  However,	  TGFβ	   induces	  p21	   in	  Ramos,	  another	  EBV-­‐negative	  
BL	  line	  (Di	  Bartolo	  et	  al.	  2008),	  which	  has	  also	  been	  shown	  to	  undergo	  G1	  arrest	  with	  TGFβ	  
(Blomhoff	  et	  al.	  1987,	  Altiok	  et	  al.	  1993).	  Thus	  the	  mechanism	  of	  TGFβ-­‐induced	  arrest	  differs	  
between	  BL	  cell	  lines,	  reflecting	  the	  fact	  that	  they	  are	  tumour	  cell	  lines	  in	  which	  normal	  cell	  
cycle	  control	  mechanisms	  have	  already	  been	  deregulated.	  	  
	  
LMP1	  expression	  in	  other	  cell	  types	  including	  fibroblasts,	  epithelial	  cells	  and	  hepatoma	  cells	  
led	  to	  Id1	  induction	  and	  resistance	  to	  the	  anti-­‐proliferative	  effect	  of	  TGFβ	  (Takanashi	  et	  al.	  
1999,	   Lo	   et	   al.	   2010).	   LMP1	   expression	   was	   sufficient	   to	   inhibit	   TGFβ-­‐mediated	   p21	  
induction	  and	  cell	  cycle	  arrest	  in	  epithelial	  cells	  (Fukuda	  et	  al.	  2002,	  Lo	  et	  al.	  2010).	  
	  
The	   effect	   of	   LMP1	   expression	   alone	   in	   EBV-­‐negative	   BL	   cell	   lines	   is	   less	   clear,	   with	  
conflicting	  results	  seen	  even	  in	  the	  same	  BL41	  background.	  LMP1	  expression	  was	  sufficient	  
(Arvanitakis	  et	  al.	  1995),	  or	  not	  sufficient	  (Altiok	  et	  al.	  1991)	  to	  confer	  resistance	  to	  the	  anti-­‐
proliferative	  effects	  of	  TGFβ;	  the	  discrepant	  results	  may	  be	  explained	  by	  the	  3-­‐4-­‐fold	  lower	  
dose	   of	   TGFβ	   used	   in	   the	   first	   study	   (Arvanitakis	   et	   al.	   1995),	   suggesting	   that	   LMP1	  
expression	   may	   lead	   to	   partial	   resistance	   to	   TGFβ.	   However,	   expression	   of	   LMP1	   in	   a	  
different	  EBV-­‐negative	  BL	  cell	   line,	  Louckes,	  surprisingly	   led	  to	  an	  enhanced	  effect	  of	  TGFβ	  
on	  cell	  cycle	  arrest	  (Wang	  et	  al.	  1988).	  	  
	  
Expression	  of	  EBNA2	  in	  BL41	  cells,	   investigated	  in	  a	  single	  study,	  was	  also	  not	  sufficient	  to	  
cause	  resistance	  to	  the	  anti-­‐proliferative	  effect	  of	  TGFβ	  (Altiok	  et	  al.	  1991).	  
	  
Previous	  studies	  have	  investigated	  the	  anti-­‐proliferative	  effects	  of	  TGFβ	  in	  BL	  cell	  lines	  which	  
are	   infected	  with	  EBV	  lacking	  full	  EBNA2,	  and	  therefore	  LMP,	  expression,	   including	  P3HR1,	  
Daudi	   and	   Jijoye.	   In	   most	   cases	   these	   cell	   lines	   have	   been	   sensitive	   to	   TGFβ-­‐induced	  
inhibition	   of	   proliferation	   (Altiok	   et	   al.	   1991,	   Altiok	   et	   al.	   1993,	   Arvanitakis	   et	   al.	   1995,	  




Fukuda	  et	  al.	  2006a),	  although	  in	  two	  studies	  it	  was	  noted	  that	  higher	  doses	  of	  TGFβ	  were	  
required	  to	  inhibit	  proliferation	  of	  P3HR1	  than	  EBV-­‐negative	  BL	  cell	  lines,	  (Altiok	  et	  al.	  1993,	  
Arvanitakis	  et	  al.	  1995).	  Another	  study	  in	  P3HR1	  showing	  resistance	  to	  the	  anti-­‐proliferative	  
effects	  of	  TGFβ1	  had	  used	  up	   to	  10-­‐fold	   lower	  doses	   (Kumar	  et	  al.	   1991).	   Taken	   together	  
these	   studies	   suggest	   that	  P3HR1	  has	  partial	   resistance	   to	   the	  anti-­‐proliferative	  effects	  of	  
TGFβ1.	   However,	   Ramos-­‐AW,	   another	   BL	  with	   EBV	   lacking	   full	   expression	   of	   EBNA2,	   was	  
entirely	   resistant	   to	   the	   effects	   of	   TGFβ1	   (arrest	   and	   apoptosis)	   even	   at	   high	   doses	  
(Blomhoff	  et	  al.	  1987,	  Inman	  and	  Allday	  2000b);	  this	  is	  likely	  to	  be	  due	  to	  the	  nature	  of	  that	  
particular	  cell	  line.	  	  
	  
The	  current	  study	   in	  the	  BL31	  cell	   line	  has	  confirmed	  TGFβ-­‐mediated	   induction	  of	   ID1	  and	  
ID2	  mRNA	  expression,	  but	  no	  induction	  of	  p15	  (figs.	  3.8	  and	  3.9).	  In	  cells	  infected	  with	  wild-­‐
type	  EBV,	  no	   induction	  of	   ID1	  or	   ID2	  occurred,	   suggesting	   that	   EBV	  blocks	   this	   effect	   (fig.	  
3.8).	  However,	  deletion	  of	  the	  whole	  EBNA3	  locus,	  LMP1	  or	  LMP2A,	  led	  to	  TGFβ-­‐mediated	  
induction	  of	  ID1	  and	  ID2,	  suggesting	  that	  these	  latent	  proteins	  are	  necessary	  to	  inhibit	  TGFβ-­‐
mediated	  induction	  of	  ID1	  and	  ID2	  (fig.	  4.3C).	  These	  same	  latent	  proteins	  are	  necessary	  for	  
the	   repression	   of	   TGFβR2	   and	   loss	   of	   TGFβ	   signalling	   suggesting	   that	   TGFβ-­‐mediated	  
induction	  of	  ID1	  and	  ID2	  occurs	  via	  TGFβR2	  and	  phosphorylation	  of	  SMAD2.	  However,	  LMP1	  
deletion	  allowed	  TGFβ-­‐mediated	  induction	  of	  ID1/2,	  as	  well	  as	  phosphorylation	  of	  SMAD2,	  
yet	   did	   not	   result	   in	   cell	   cycle	   arrest	   or	   apoptosis	   with	   TGFβ1	   (figs.	   4.3B-­‐C	   and	   5.6).	  
Therefore,	  although	  in	  other	  cell	  types	  LMP1	  alone	  appears	  to	  be	  sufficient	  to	  protect	  cells	  
from	  TGFβ-­‐induced	  growth	  inhibition,	  in	  B	  cells	  LMP1	  has	  not	  consistently	  been	  found	  to	  be	  
sufficient	  for	  protection.	  In	  the	  current	  study,	  LMP1	  has	  been	  shown	  not	  to	  be	  necessary	  for	  
protection	  against	  TGFβ-­‐induced	  growth	  arrest.	  Several	  papers	  published	  during	  the	  course	  
of,	  or	  since	  completion	  of,	  this	  project	  have	  suggested	  that	  the	  anti-­‐proliferative	  effects	  of	  
TGFβ	  in	  normal	  B	  cells	  and	  B	  cell	   lymphomas	  may	   in	  fact	  be	  mediated	  via	  a	  non-­‐canonical	  
signalling	   pathway	   in	   which	   TGFβ	   induces	   phosphorylation	   of	   SMAD1/5	   (Bakkebo	   et	   al.	  
2010,	  Rai	  et	  al.	  2010,	  Liu	  et	  al.	  2012,	  Jiang	  and	  Aguiar	  2014),	  which	  had	  also	  been	  suggested	  
previously	   for	   SMAD1	   (Munoz	   et	   al.	   2004).	   One	   of	   these	   studies	   also	   showed	   a	   lack	   of	  
correlation	   between	   TGFβ-­‐induced	   phosphorylation	   of	   SMAD2	   and	   its	   anti-­‐proliferative	  
effects	  in	  B	  cells,	  and	  suggested	  that	  TGFβ-­‐mediated	  anti-­‐proliferative	  effects	  via	  pSMAD1/5	  
may	  also	  involve	  activation	  of	  the	  p38	  kinase	  pathway	  (Bakkebo	  et	  al.	  2010).	  




Overexpression	   of	   TGFβR2	   in	   the	   Akata	   cell	   line,	   which	   lacked	   endogenous	   TGFβR2	  
expression,	  resulted	  in	  two	  distinct	  clones	  with	  differing	  levels	  of	  TGFβR2	  expression.	  Both	  
clones	   were	   sensitive	   to	   the	   anti-­‐proliferative	   effects	   of	   TGFβ,	   whereas	   only	   the	   clone	  
expressing	  higher	  levels	  of	  TGFβR2	  also	  underwent	  apoptosis,	  suggesting	  that	  TGFβ-­‐induced	  
apoptosis	   occurs	   via	   TGFβR2	   but	   that	   expression	   of	   TGFβR2	   must	   exceed	   a	   particular	  
threshold	  for	  the	  apoptotic	  response	  (Fukuda	  et	  al.	  2006a).	  Furthermore,	  the	  cell	  line	  CA46	  
does	  not	  undergo	  apoptosis	  with	  TGFβ	  despite	   induction	  of	  BIK;	   instead,	   it	   undergoes	  G1	  
arrest.	  It	  lacks	  expression	  of	  BAX	  hence	  is	  unable	  to	  undergo	  apoptosis	  (Spender	  et	  al.	  2009).	  
Taken	   together,	   these	   studies	   suggest	   that	   TGFβ	   induces	  G1	   arrest	   by	   default,	   but	   that	   if	  
certain	  other	  conditions	  are	  present,	   including	  TGFβR2	  expression	  above	  a	  threshold,	  then	  
the	   predominant	   response	   is	   of	   apoptosis.	   This	   may	   be	   equivalent	   to	   the	   situation	   in	  
hepatocytes,	  where	  Smad3	  overexpression	   leads	   to	  apoptosis,	  but	   in	   the	  presence	  of	  Akt,	  
which	   sequesters	   unphosphorylated	   Smad3	   rendering	   it	   unable	   to	   accumulate	   in	   the	  
nucleus,	  TGFβ	  instead	  induces	  arrest	  (Conery	  et	  al.	  2004,	  Remy	  et	  al.	  2004).	  
	  
Discordance	  between	  PARP	  cleavage	  and	  sub-­‐G1	  component	  on	  FC	  analysis	  
In	  the	  current	  study,	  initial	  experiments	  showed	  almost	  complete	  cleavage	  of	  PARP	  in	  BL31	  
after	  48	  hours	  of	  TGFβ;	  however,	  the	  increase	  in	  sub-­‐G1	  component	  by	  FC	  was	  less	  marked	  
(fig.	   5.1A-­‐B).	   Furthermore,	   although	   EBNA2	  KOs	   1	   and	  2	   showed	  a	   small	   degree	  of	   TGFβ-­‐
induced	  PARP	  cleavage	  (fig.	  5.5),	  TGFβ	  did	  not	  induce	  any	  increase	  in	  sub-­‐G1	  on	  FC	  analysis	  
in	  these	  cells	  (fig.	  5.4).	   In	   later	  experiments,	  although	  there	  was	  still	  some	  increased	  PARP	  
cleavage	  with	  TGFβ	  in	  BL31,	  and	  an	  increase	  in	  the	  proportion	  of	  dead	  cells,	  there	  appeared	  
to	  be	  no	  change	  in	  the	  cell	  cycle	  profile	  with	  TGFβ	  (fig.	  5.8).	  Therefore,	  in	  these	  cells	  PARP	  
cleavage	   appeared	   to	   be	   more	   sensitive	   than	   FC	   analysis	   for	   detection	   of	   apoptosis.	   An	  
explanation	  may	  be	  that	  some	  cells	  have	  undergone	  apoptosis	  from	  the	  G2/M	  phase,	  since	  
this	  would	   not	   reduce	   the	   DNA	   content	   sufficiently	   for	   the	   cells	   to	   appear	   in	   the	   sub-­‐G1	  
component.	   In	  the	  EBV-­‐negative	  BL	  cell	   line	  BL41,	  treatment	  with	  TGFβ	   induced	  apoptosis	  
mainly	   from	   the	   G1	   but	   also	   from	   the	   G2/M	   phases	   of	   the	   cell	   cycle	   (Inman	   and	   Allday	  
2000a).	  
	  
In	   later	  experiments	   in	  the	  course	  of	  this	  project,	   the	  amount	  of	  both	  TGFβ-­‐induced	  PARP	  
cleavage	  and	  sub-­‐G1	  on	  FC	  became	  less	  marked	  than	  originally	  (figs.	  5.1	  and	  5.8).	  This	  was	  




thought	  to	  be	  due	  to	  a	  change	  in	  the	  serum	  used	  to	  supplement	  the	  media	  in	  which	  the	  cells	  
were	  grown,	  but	  did	  not	  alter	  the	  occurrence	  of	  TGFβ-­‐induced	  G1	  arrest	  in	  the	  relevant	  cell	  
lines,	   confirming	   that	   arrest	   and	   apoptosis	   occur	   via	   distinct	   pathways	   as	   previously	  
demonstrated	   in	   B	   cells	   (Chaouchi	   et	   al.	   1995,	   Schrantz	   et	   al.	   1999,	   Inman	   and	   Allday	  
2000a).	  The	  apparent	  resistance	  to	  the	  effects	  of	  TGFβ	  after	  the	  serum	  change	  did	  not	  alter	  
the	  induction	  of	  SMAD2	  phosphorylation,	  suggesting	  that	  some	  factor	  in	  the	  second	  serum,	  





















 	  	  	  The	   effects	   of	   EBV	   on	   TGFβR	   expression	   and	   TGFβ	  Chapter	  6
signalling	  in	  newly	  infected	  primary	  B	  cells	  and	  LCLs	  
6.1	  Introduction	  
Chapters	   3	   and	   4	   investigated	   TGFβ	   signalling	   and	   expression	   of	   TGFβR2/TGFβR3	   in	   BL31	  
cells	  plus	  or	  minus	  infection	  with	  latent	  EBV.	  However,	  EBV-­‐infected	  BL31	  cells	  are	  derived	  
from	  highly	   selected	   tumour	   cells,	  whereas	   LCLs	  are	  derived	   from	  normal	  primary	  B	   cells.	  
Therefore	  it	  was	  important	  to	  see	  whether	  similar	  findings	  are	  seen	  early	  after	  infection	  of	  
primary	   B	   cells	   and	   in	   established	   LCLs,	   although	   it	   is	   harder	   to	   investigate	   the	   effects	   of	  
individual	   latent	  proteins	  since	  several	  of	  them	  are	  required	  for	  the	  transformation	  to	  and	  
maintenance	  of	   LCLs.	   In	   addition,	   several	   previous	   studies	   on	   the	   effects	   of	   EBV	  on	   TGFβ	  
responses	   have	   been	   done	   in	   established	   LCLs,	   which	   may	   also	   have	   undergone	   clonal	  
selection	   in	  culture	  and	  thus	  may	  be	  heterogeneous	  (Heath	  et	  al.	  2012).	  Therefore,	   in	  this	  
chapter	   the	   effects	   of	   EBV	   infection	   early	   after	   infection	   of	   normal	   primary	   B	   cells	   was	  
investigated,	  as	  well	  as	  the	  effects	  in	  established	  LCLs.	  	  
	  
LCLs	  are	  known	  to	  resist	  the	  effects	  of	  TGFβ	  (Blomhoff	  et	  al.	  1987,	  Janssen	  et	  al.	  1990,	  Altiok	  
et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  1992,	  Altiok	  et	  al.	  1993,	  Inman	  and	  Allday	  2000b,	  
Kenney	  et	  al.	  2001,	  Horndasch	  et	  al.	  2002)	  and	  it	  had	  been	  shown	  that	  expression	  of	  TGFβR2	  
is	   repressed	   in	   LCLs	   (Inman	   and	   Allday	   2000b).	   Having	   shown	   that	   four	   latent	   proteins	  
cooperate	  to	  repress	  TGFβR2,	  the	  question	  was	  therefore	  whether	  the	  same	  latent	  proteins	  
repress	  TGFβR2	  early	  after	  infection	  of	  primary	  B	  cells	  and	  in	  established	  LCLs.	  
	  
In	   addition,	   since	   EBV	   also	   up-­‐regulates	   TGFβR3	   in	   BL31	   cells	   and	   the	   findings	   in	   BL31	  
suggested	   that	   TGFβR2	   and	   TGFβR3	  may	   be	   reciprocally	   regulated,	   this	   was	   investigated	  
further	  in	  infected	  primary	  B	  cells	  and	  LCLs.	  
	   	  




6.2	  Regulation	  of	  TGFβR2,	  and	  TGFβ	  signalling,	  in	  newly	  infected	  B	  cells	  and	  LCLs	  
6.2.1	  TGFβR2	   is	  epigenetically	   repressed	  by	  EBV	   in	   LCLs,	   leading	   to	   suppression	  of	  TGFβ	  
signalling	  	  
In	  BL31	  cells,	  EBV	  down-­‐regulates	  TGFβR2,	  and	  the	  same	  latent	  proteins	  are	  necessary	  for	  
suppression	  of	  signalling	  via	  pSMAD2	  as	  for	  down-­‐regulation	  of	  TGFβR2,	  suggesting	  that	  the	  
down-­‐regulation	  of	  TGFβR2	  leads	  to	  the	  suppression	  of	  signalling	  (see	  chapter	  3,	  figs.	  3.1A	  
and	  3.7).	  	  
	  
In	   order	   to	   confirm	   that	   TGFβR2	   is	   also	   repressed	   in	   LCLs,	   as	   has	   been	   shown	   previously	  
(Inman	   and	   Allday	   2000b),	   qRT-­‐PCR	   was	   performed	   for	   TGFβR2	   in	   several	   different	   LCLs	  
carrying	  wild-­‐type	  EBV,	   established	  at	   different	   times	  using	  primary	  B	   cells	   from	  different	  
donors,	   and	   compared	   to	   expression	   in	  wild-­‐type	   EBV-­‐infected	   and	  uninfected	  BL31	   cells.	  
This	   confirmed	   the	   down-­‐regulation	   of	   TGFβR2	   in	   LCLs,	   to	   a	   similar	   level	   as	   in	  wild-­‐type-­‐
infected	  BL31	  cells	  (representative	  data	  is	  shown	  in	  fig.	  6.1A).	  
	  
The	   effect	   on	   TGFβ	   signalling	   was	   also	   investigated	   by	   western	   blot	   for	   pSMAD2	   in	   cells	  
treated	   with	   TGFβ1	   or	   vehicle	   alone.	   This	   showed	   that	   in	   wild-­‐type	   LCLs,	   TGFβ	   does	   not	  
induce	   pSMAD2,	   as	   seen	   in	  wild-­‐type	   infected	   BL31	   cells	   (fig.	   6.1B),	  whereas	   TGFβ1	   does	  
induce	   pSMAD2	   in	   uninfected	   BL31	   as	   seen	   previously	   (see	   fig.	   3.7).	   This	   suppression	   of	  
TGFβ	  signalling	  is	  consistent	  with	  the	  repression	  of	  TGFβR2	  by	  EBV	  in	  LCLs.	  	  
	  
Chromatin	  immunoprecipitation	  was	  performed	  for	  H3K27Me3	  at	  the	  TGFβR2	  promoter,	  in	  
order	   to	   determine	   whether	   the	   repression	   is	   also	   epigenetically	   mediated	   in	   LCLs.	   This	  
showed	  H3K27Me3	  on	  the	  TGFβR2	  promoter,	  in	  a	  similar	  pattern	  to	  but	  to	  a	  slightly	  lesser	  
amplitude	  than	  in	  BL31-­‐WT	  (fig.	  6.1C-­‐D).	  This	  suggests	  that	  the	  down-­‐regulation	  of	  TGFβR2	  
in	  LCLs	  is	  also	  associated	  with	  polycomb-­‐mediated	  repression,	  as	  in	  BL31	  cells.	  	  	   	  

































Figure	  6.1:	  TGFβR2	  is	  epigenetically	  repressed	  in	  LCLs	  established	  with	  wild-­‐type	  EBV,	  leading	  to	  suppression	  
of	  TGFβ	  signalling	  
(A)	   qRT-­‐PCR	   for	   TGFβR2	   in	   BL31,	   BL31-­‐WT	   and	   a	   wild-­‐type	   LCL.	   Values	   are	   expressed	   as	   a	   ratio	   to	   the	  
endogenous	   control	   gene	   GNB2L1,	   with	   error	   bars	   representing	   standard	   deviation	   of	   triplicate	   qPCR	  
reactions.	  This	  is	  representative	  data	  of	  experiments	  performed	  several	  times	  in	  at	  least	  three	  different	  wild-­‐
type	  LCLs.	  (B)	  Western	  blot	  for	  pSMAD2	  in	  BL31,	  BL31-­‐WT	  and	  LCL-­‐WT	  one	  hour	  after	  treatment	  with	  TGFβ1	  
5ng/ml	   or	   vehicle	   (2mg/ml	  BSA	   in	   1xPBS,	   labelled	   ‘-­‐TGFβ1’).	   Total	   SMAD2	   is	   shown	   for	   comparison,	  with	   γ-­‐
tubulin	  as	  a	  loading	  control.	  This	  is	  representative	  data	  from	  experiments	  performed	  at	  least	  three	  times	  using	  
different	   LCLs.	   (C)	   Schematic	   diagram	   of	   the	   TGFβR2	   promoter	   region	   showing	   the	   location	   of	   products	   of	  
primer	  sets	  used,	  the	  putative	  transcription	  start	  site	  (TSS)	  and	  CpG	  islands.	  The	  coloured	  blocks	  represent	  the	  
primer	   pairs	   1-­‐5,	   shown	   as	   bars	   from	   left	   to	   right	   for	   each	   cell	   line	   in	   figure	   D.	   (D)	   ChIP	   followed	   by	   qPCR	  
showing	  ratio	  of	  H3K27Me3	  to	  input	  DNA	  at	  the	  TGFβR2	  promoter	  using	  the	  five	  primer	  sets	  shown	  in	  (C),	  and	  
control	  promoter	  primers	  myoglobin	   (repressed)	  and	  GAPDH	   (active).	  The	  values	   for	  GAPDH	  were	  negligible	  
and	  so	  are	  not	  shown	  in	  the	  chart.	  The	  error	  bars	  represent	  standard	  deviations	  from	  triplicate	  qPCR	  reactions	  
for	  both	  input	  and	  IP.	  The	  LCL	  data	  is	  representative	  from	  experiments	  performed	  three	  times.	  	  








































6.2.2	  TGFβR2	  is	  down-­‐regulated	  by	  EBV	  upon	  infection	  of	  primary	  B	  cells	  	  
In	  order	  to	  investigate	  further	  the	  repression	  of	  TGFβR2	  in	  normal	  B	  cells	   infected	  by	  EBV,	  
purified	  primary	  B	  cells	  were	  infected	  with	  wild-­‐type	  EBV	  and	  TGFβR2	  expression	  measured	  
by	  qRT-­‐PCR	  with	  time	  after	  infection,	  as	  LCLs	  became	  established	  (arbitrarily	  considered	  to	  
occur	  at	  40	  days	  post-­‐infection).	  This	  showed	  that	  TGFβR2	  expression	  was	  high	  in	  uninfected	  
primary	  resting	  B	  cells	  but	  was	  gradually	  repressed	  after	  EBV	  infection,	  with	  near	  maximal	  
repression	   occurring	   by	   around	   21	   days	   post-­‐infection	   and	   persisting	   after	   this	   time	   (fig.	  
6.2).	  This	  confirms	  the	  down-­‐regulation	  of	  TGFβR2	  by	  EBV	  and	  is	  consistent	  with	  LCLs	  having	  
little	  or	  no	  detectable	  TGFβR2	  mRNA	  (fig.	  6.1A).	  	  
	  
	  
Figure	  6.2:	  EBV	  down-­‐regulates	  TGFβR2	  expression	  after	  infection	  of	  primary	  B	  cells	  	  
qRT-­‐PCR	   for	   TGFβR2	   with	   time	   after	   infection	   of	   purified	   primary	   B	   cells	   with	   wild-­‐type	   EBV.	   The	   values	  
represent	  the	  ratio	  of	  expression	  to	  the	  mean	  of	  values	  of	  two	  endogenous	  control	  gene	  GNB2L1	  and	  RPLPO	  
(‘norm’).	  Data	  shown	  are	  from	  one	  of	  two	  separate	  infection	  experiments,	  in	  which	  the	  pattern	  of	  variation	  of	  
values	  is	  representative.	  The	  error	  bars	  represent	  standard	  deviations	  from	  triplicate	  qPCR	  reactions.	  	  
	  
6.2.3	  EBNA3B	  deletion	  leads	  to	  de-­‐repression	  of	  TGFβR2	  and	  an	  increase	  in	  TGFβ	  signalling	  
in	  LCLs	  
Since	  EBNA3B,	  EBNA3C,	   LMP1	  and	  LMP2A	  appear	   to	   cooperate	   in	   the	  down-­‐regulation	  of	  
TGFβR2	  in	  BL31	  cells,	   it	  was	  hypothesised	  that	  the	  same	  latent	  proteins	  may	  cooperate	  to	  
down-­‐regulate	   TGFβR2	   in	   LCLs.	   In	   LCLs,	   the	   effect	   of	   deletion	   of	   certain	   individual	   latent	  
proteins	   cannot	   be	   directly	   assessed	   as	   some	   (EBNA1,	   EBNA2,	   LMP1	   and	   EBNA3C)	   are	  
absolutely	  necessary	  for	  the	  transformation	  of	  B	  cells	  by	  EBV	  into	  LCLs	  (Cohen	  et	  al.	  1989,	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transformation	  of	  B	  cells	   to	  LCLs,	   it	   is	  possible	   to	  establish	  EBNA3B	  KO	  LCLs,	  and	   thus	   the	  
effect	  of	  EBNA3B	  deletion	  on	  TGFβR2	  expression	  was	  investigated	  in	  newly	  infected	  B	  cells	  
and	  established	  LCLs.	  
	  
Initially,	   purified	   primary	   B	   cells	   were	   infected	   with	   wild-­‐type,	   EBNA3B	   KO	   and	   EBNA3B	  
revertant	  viruses	  and	  samples	  harvested	  at	  various	  time	  points	  for	  RNA	  extraction	  and	  qRT-­‐
PCR	  for	  TGFβR2	  mRNA	  (fig.	  6.3A).	  Although	  the	  repression	  of	  TGFβR2	  was	  slower	  initially	  for	  
wild-­‐type	  than	  EBNA3B	  KO	  or	  revertant	  EBV,	  similar	  levels	  of	  TGFβR2	  repression	  were	  seen	  
by	  around	  25	  days	  after	   infection	  for	  all	   three	  viruses	  (fig	  6.3A).	  This	   initial	  difference	  was	  
likely	  to	  be	  due	  to	  a	  difference	  in	  titres	  of	  virus	  used	  to	  infect	  the	  primary	  B	  cells,	  as	  the	  titre	  
of	   wild-­‐type	   virus	   was	   approximately	   20-­‐fold	   lower	   than	   either	   EBNA3B	   KO	   or	   revertant	  
viruses.	  However,	  the	  titres	  of	  EBNA3B	  KO	  and	  revertant	  were	  more	  comparable,	  but	  with	  
that	  for	  EBNA3B	  KO	  being	  slightly	  higher	  than	  for	  the	  revertant	  (WT	  4	  x104	  GRU/ml,	  EBNA3B	  
KO	  1.0	  x	  106	  GRU/ml;	  EBNA3B	  revertant	  0.75	  x	  106	  GRU/ml).	  It	  was	  observed	  that,	  from	  days	  
10-­‐28	   post-­‐infection,	   there	   was	   slightly	   less	   repression	   of	   TGFβR2	   in	   EBNA3B	   KO	   than	  
revertant	  despite	  EBNA3B	  KO	  being	  of	  slightly	  higher	  titre	  (fig.	  6.3A).	  After	  day	  28,	  however,	  
TGFβR2	  appeared	  to	  be	  profoundly	  repressed	  by	  all	  three	  viruses	  (fig.	  6.3A).	  	  	  
	  
mRNA	  was	  extracted	  from	  the	  LCLs	  established	  from	  primary	  B	  cells	   infected	  by	  wild-­‐type,	  
EBNA3B	  KO	  and	  EBNA3B	  revertant	  viruses	  at	  six	  weeks	  post-­‐infection	  and	  analysed	  by	  qRT-­‐
PCR.	  This	  showed	  that	  although	  TGFβR2	  expression	  was	  low	  for	  all	  three	  viruses,	  there	  was	  
some	  relaxation	  of	  repression	  in	  EBNA3B	  KO	  compared	  to	  wild-­‐type	  and	  revertant	  –	  infected	  
cells,	  suggesting	  that	  EBNA3B	  may	  contribute	  to	  the	  repression	  of	  TGFβR2	  in	  LCLs,	  although	  
this	  contribution	  appears	  to	  be	  minor	  (fig.	  6.3B).	  
	  
The	  effect	  of	  EBNA3B	  deletion	  on	  TGFβ	  signalling	  was	  also	  investigated	  at	  around	  six	  weeks	  
post-­‐infection	   using	   the	   wild-­‐type,	   EBNA3B	   KO	   and	   revertant	   LCLs	   established	   from	   the	  
infections	   of	   primary	   B	   cells.	   This	   showed	   that	   signalling,	   as	   detected	   by	   pSMAD2,	   was	  
increased	   in	  EBNA3B	  KO	  compared	  to	  wild-­‐type	  or	   revertant	  LCLs,	  consistent	  with	   the	  de-­‐
repression	   of	   TGFβR2	   in	   these	   cells	   (fig.	   6.3C).	   The	   level	   of	   pSMAD2	   was	   somewhat	  
surprising	  as,	  despite	  the	   level	  of	  TGFβR2	  appearing	  to	  be	  markedly	  repressed	  overall,	   the	  




de-­‐repression	   seen	   in	   EBN3B	   KO	   LCLs	   compared	   to	   wild-­‐type	   was	   sufficient	   to	   restore	  

































Figure	  6.3:	  EBNA3B	  deletion	   leads	   to	  a	  modest	  de-­‐repression	  of	  TGFβR2	  and	   increased	  TGFβ	  signalling	  via	  
pSMAD2	  
(A)	  qRT-­‐PCR	  for	  TGFβR2	  with	  time	  after	  infection	  of	  purified	  primary	  B	  cells	  with	  wild-­‐type	  (WT),	  EBNA3B	  KO	  
and	   EBNA3B	   revertant	   virus.	   The	   values	   represent	   the	   ratio	   of	   expression	   to	   the	   mean	   of	   values	   of	   two	  
endogenous	   control	   gene	  GNB2L1	   and	   RPLPO	   (‘norm’).	   The	   error	   bars	   represent	   standard	   deviations	   from	  
triplicate	  qPCR	  reactions.	  (B)	  qRT-­‐PCR	  for	  TGFβR2	  in	  WT,	  EBNA3B	  KO	  and	  EBNA3B	  revertant	  LCLs	  at	  6	  weeks	  
post-­‐infection.	  The	  values	  represent	  the	  ratio	  of	  expression	  to	  the	  endogenous	  control	  gene	  GNB2L1.	  The	  error	  
bars	   represent	   standard	   deviations	   from	   triplicate	   qPCR	   reactions.	   (C)	  Western	   blot	   for	   pSMAD2	   in	   the	   cell	  
lines	  as	  in	  (B)	  before	  treatment	  (time	  0)	  and	  one	  hour	  after	  treatment	  with	  TGFβ1	  10ng/ml	  or	  vehicle	  (2mg/ml	  
BSA	   in	  1xPBS),	  at	  6	  weeks	  post-­‐infection.	  Total	  SMAD2	   is	   shown	   for	  comparison,	  with	  γ-­‐tubulin	  as	  a	   loading	  
control.	  All	  data	  shown	  are	  from	  one	  experiment,	  in	  which	  the	  pattern	  of	  variation	  of	  values	  for	  the	  cell	  lines	  is	  
















































6.2.4	  TGFβR2	  remains	  repressed	  after	  withdrawal	  of	  4HT	  in	  3CHT-­‐LCLs	  established	  in	  the	  
presence	  of	  4HT	  
Next,	  the	  effect	  of	  non-­‐functional	  EBNA3C	  on	  TGFβR2	  expression	  was	  investigated	  in	  LCLs,	  
since	   EBNA3C	   is	   necessary	   for	   the	   repression	  of	   TGFβR2	   in	   BL31	   cells	   (fig.	   3.1A).	   Because	  
EBNA3C	   is	   required	   for	   transformation	  of	   normal	   B	   cells	   into	   LCLs,	   and	   therefore	  when	  B	  
cells	  are	  infected	  with	  EBNA3C	  KO	  virus	  they	  are	  unable	  to	  survive	  or	  grow	  out	  to	  become	  
LCLs	  (Tomkinson	  et	  al.	  1993),	  a	  recombinant	  EBV	  conditional	  for	  EBNA3C	  function	  was	  used.	  	  
A	   conditional	   system	   has	   been	   developed	   in	   which	   EBNA3C	   is	   fused	   to	   a	   modified,	   4-­‐
hydroxytamoxifen	   (4HT)-­‐dependent	   murine	   oestrogen	   receptor.	   This	   3CHT	   virus,	   created	  
from	  a	  B95.8	  virus	   in	   the	  BAC	  system,	  has	  been	  used	   to	   infect	  primary	  B	  cells	   in	  order	   to	  
establish	  3CHT-­‐LCLs	  (Skalska	  et	  al.	  2010).	  These	  LCLs	  express	  EBNA3C-­‐HT,	  a	  modified	  form	  of	  
EBNA3C,	  which	  is	  functional	  only	  when	  4HT	  is	  present	  in	  the	  growth	  medium.	  When	  4HT	  is	  
withdrawn,	   EBNA3C-­‐HT	   is	   sequestered	   and	   degraded,	   and	   the	   LCLs	   gradually	   stop	  
proliferating	  due	  to	  the	  absence	  of	  functional	  EBNA3C	  and	  concomitant	  increase	  in	  p16INK4A	  
(Maruo	  et	  al.	  2006,	  Skalska	  et	  al.	  2010).	  
	  
The	  effect	  of	  deactivating	  EBNA3C	  on	  TGFβR2	  expression	  was	  investigated	  using	  this	  system.	  
A	  3CHT-­‐LCL,	  which	  had	  been	  established	  from	  infection	  of	  normal	  donor	  B	  cells,	  was	  grown	  
continuously	   with	   4HT,	   thus	   expressing	   functional	   EBNA3C.	   	   The	   cells	   were	   washed	   and	  
grown	  subsequently	  in	  medium	  with	  or	  without	  4HT	  for	  21	  days,	  with	  samples	  harvested	  at	  
day	  0	  and	  21	  days	  post	  withdrawal	  or	  continuation	  of	  4HT	  (cell	  treatments,	  harvesting	  and	  
RNA	   extraction	   performed	   by	   Lenka	   Skalska).	   qRT-­‐PCR	   for	   TGFβR2	   expression	   in	   these	  
samples,	   along	   with	   BL31	   and	   BL31-­‐WT	   for	   comparison,	   showed	   that	   TGFβR2	   remained	  
profoundly	  repressed,	  with	  values	  similar	  to	  those	  at	  day	  0,	  even	  21	  days	  after	  withdrawal	  
of	  4HT	  (fig.	  6.4).	  The	  degree	  of	  repression	  was	  also	  similar	  to	  that	  seen	  in	  BL31-­‐WT.	  	  
	  
Since	  functional	  EBNA3C	  had	  been	  shown	  to	  be	  withdrawn	  by	  day	  21	  after	  4HT	  withdrawal	  
in	  these	  cells	   (Skalska	  et	  al.	  2010),	   the	  findings	  would	  suggest	  that	  withdrawal	  of	  4HT	  and	  
hence	  functional	  EBNA3C	  does	  not	  lead	  to	  de-­‐repression	  of	  TGFβR2,	  and	  thus	  that	  EBNA3C	  
is	  not	  necessary	  for	  the	  repression	  of	  TGFβR2	  in	  LCLs.	  However,	  EBNA3C	  has	  been	  shown	  to	  
repress	  BIM	  and	  p16INK4A	  by	  polycomb-­‐mediated	  repression	  and	  to	  bind	  to	  multiple	  cellular	  
promoters	  suggesting	  direct	  repression	  (Paschos	  et	  al.	  2009,	  Skalska	  et	  al.	  2010,	  McClellan	  




et	   al.	   2012,	   Paschos	   et	   al.	   2012,	   Skalska	   et	   al.	   2013).	   Thus	   it	   remains	   possible	   that	   prior	  
exposure	  to	  EBNA3C	  (when	  the	  cells	  were	  previously	  grown	  in	  the	  presence	  of	  4HT)	  could	  
have	   led	  to	  epigenetic	  repression	  of	  TGFβR2,	  with	  TGFβR2	  then	  remaining	  repressed	  even	  
after	  functional	  EBNA3C	  was	  removed.	  	  	  
	  
	  
Figure	  6.4:	  In	  3CHT-­‐LCLs	  established	  with	  4HT,	  TGFβR2	  remains	  repressed	  despite	  withdrawal	  of	  4HT	  
LCLs	  were	  established	  from	  a	  donor	  with	  wild-­‐type	  p16,	   in	  the	  presence	  of	  4HT.	  Cells	  were	  harvested	  at	  day	  
zero	  and	  then	  half	  of	  the	  cells	  were	  grown	  continuously	  in	  4HT	  whereas	  the	  other	  half	  were	  washed	  and	  then	  
subsequently	   grown	   in	   medium	  without	   4HT.	   After	   21	   days,	   samples	   were	   harvested	   from	   each.	   RNA	   was	  
extracted	  and	   then	  qRT-­‐PCR	   for	  TGFβR2	  was	  performed	  with	   these	   samples	  as	  well	   as	  uninfected	  and	  wild-­‐
type	   infected	  BL31.	  Values	  (shown	  above	  the	  bars)	  are	  expressed	  as	  a	  ratio	  to	  the	  endogenous	  control	  gene	  
GNB2L1,	   with	   error	   bars	   representing	   standard	   deviation	   of	   triplicate	   qPCR	   reactions	   (LCL	   samples	   grown,	  
harvested	  and	  RNA	  extracted	  by	  Lenka	  Skalska).	  
	  
6.2.5	   In	  3CHT-­‐LCLs	  established	   in	  a	  p16-­‐null	  background,	  without	  ever	  being	  exposed	   to	  
4HT	  and	  thus	  EBNA3C,	  TGFβR2	  is	  moderately	  de-­‐repressed,	  leading	  to	  restoration	  of	  TGFβ	  
signalling	  
In	   order	   to	   test	   the	   hypothesis	   that	   in	   LCLs,	   TGFβR2	   remains	   epigenetically	   repressed	  
following	   previous	   exposure	   to	   EBNA3C,	   it	  would	   be	   necessary	   to	   obtain	   an	   LCL	   that	   had	  
never	  been	  exposed	  to	  EBNA3C.	  As	  previously	  mentioned,	  EBNA3C	  is	  absolutely	  required	  for	  
B	   cell	   transformation	   by	   EBV	   (Tomkinson	   et	   al.	   1993)	   and	   thus	   it	   would	   theoretically	   be	  
impossible	   to	  obtain	  an	  LCL	   in	  which	  EBNA3C	  had	  never	  been	  expressed.	  However,	  at	   the	  
time	   this	  work	  was	  being	  undertaken,	   colleagues	   in	   the	   laboratory	  were	   investigating	   the	  
effects	   of	   EBNA3C	   on	   repression	   of	   p16INK4A	   and	   had	   hypothesised	   that	   the	   repression	   of	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p16INK4A	  may	   be	   the	   reason	  why	   EBNA3C	   is	   required	   for	   B	   cell	   transformation.	   Therefore	  
they	  had	  obtained	  B	   cells	   from	  an	   individual	  with	  a	  homozygous	  deletion	   in	  CDKN2A,	   the	  
gene	  encoding	  p16INK4A,	  and	  infected	  these	  B	  cells	  with	  the	  3CHT	  virus,	  both	  in	  the	  presence	  
and	  absence	  of	  4HT.	  As	  predicted,	  in	  the	  p16-­‐null	  background	  they	  were	  able	  to	  successfully	  
establish	   LCLs	   even	   in	   the	   absence	   of	   4HT,	   and	   thus	   the	   resultant	   p16-­‐null	   3CHT-­‐LCLs	  
(established	  without	   4HT)	   would	   have	   never	   expressed	   functional	   EBNA3C	   (Skalska	   et	   al.	  
2013).	  	  
	  
Therefore,	  TGFβR2	  expression	  was	  investigated	  in	  these	  cells,	  based	  on	  the	  hypothesis	  that	  
EBNA3C	   represses	   TGFβR2	   epigenetically,	   and	   this	   would	   be	  maintained	   in	   progeny	   cells	  
even	   if	   4HT	   is	  withdrawn.	   If	   this	   hypothesis	  were	   correct,	   then	   in	   the	   p16-­‐null	   3CHT-­‐LCLs	  
TGFβR2	  would	   be	   de-­‐repressed	   in	   those	   cells	  which	   had	   never	   been	   exposed	   to	   4HT	   and	  
hence	  EBNA3C.	  Samples	  were	  harvested	  at	  42	  days	  after	   infection	  of	  p16-­‐null	  B	  cells	  with	  
3CHT	  virus,	  and	  subsequently	  cultured	  with	  or	  without	  4HT	   in	  the	  medium	  (infections	  and	  
harvesting	  of	   samples	  performed	  by	  Rob	  White).	   RNA	  was	  extracted	   from	   these	   samples,	  
followed	  by	  qRT-­‐PCR	  for	  TGFβR2.	  In	  those	  cells	  which	  had	  never	  been	  exposed	  to	  EBNA3C,	  
there	  was	   at	   least	   a	   two-­‐fold	   de-­‐repression	  of	   TGFβR2,	   although	   compared	   to	   uninfected	  
BL31s	  the	  expression	  remained	  low	  (fig.	  6.5A-­‐B).	  This	  suggests	  that	  EBNA3C	  does	  contribute	  
to	  the	  repression	  of	  TGFβR2	  in	  LCLs	  although,	  similarly	  to	  EBNA3B,	  the	  effect	  is	  small.	  
	  
In	  EBNA3B	  KO	  LCLs,	  the	  de-­‐repression	  of	  TGFβR2	  led	  to	  an	  increase	  in	  pSMAD2	  after	  TGFβ1	  
treatment	  compared	  to	  that	  seen	   in	  wild-­‐type	  or	  revertant	  LCLs	   (fig.	  6.3B-­‐C),	  even	  though	  
the	  overall	   expression	  of	   TGFβR2	  was	   very	   low	   relative	   to	  uninfected	  primary	  B	   cells	   (fig.	  
6.3A).	   Therefore,	   the	   effects	   of	   EBNA3C	   expression	   on	   TGFβ	   signalling	  were	   investigated.	  
Using	  the	  p16-­‐null	  3CHT-­‐LCLs	  that	  had	  been	  established	  with	  or	  without	  4HT	  (as	  shown	  in	  
figs.	   6.5A-­‐B),	   a	   crossover	   experiment	   was	   performed	   by	   Rob	   White	   in	   which	   the	   two	  
established	  LCLs	  (p16-­‐null	  3CHT	  established	  with	  and	  without	  4HT)	  were	  then	  each	  divided	  
into	   two	   and	   subsequently	   grown	  with	   or	  without	   4HT	   in	   the	  medium.	   This	   created	   four	  
different	  conditions:	  	  (1)	  never	  exposed	  to	  4HT,	  (2)	  grown	  out	  for	  3	  months	  without	  4HT	  but	  
then	  4HT	  added,	  (3)	  grown	  out	  continuously	  with	  4HT,	  or	  (4)	  grown	  out	  with	  4HT	  but	  then	  
4HT	  withdrawn.	  Samples	  harvested	  from	  these	  at	  30	  days	  after	  changeover	  of	  the	  medium	  
were	   investigated	  by	  qRT-­‐PCR	  for	  TGFβR2	  (fig.	  6.5C).	  This	  showed	  that	  TGFβR2	  expression	  




was	  again	  generally	  low	  in	  all	  conditions,	  but	  in	  those	  LCLs	  established	  initially	  without	  4HT,	  
TGFβR2	   was	   slightly	   higher	   than	   those	   established	   with	   4HT.	   However,	   the	   addition	   or	  
withdrawal	   of	   4HT	   after	   the	   LCLs	   had	   been	   established	   did	   not	   really	   alter	   TGFβR2	  
expression	  (fig.	  6.5C),	   i.e.	  values	  were	  similar	  for	  both	  ‘never	  exposed’	  conditions	  and	  also	  
for	  both	  conditions	  grown	  out	  with	  4HT.	  	  This	  suggests	  that	  the	  absence	  of	  EBNA3C	  as	  LCLs	  
are	   being	   established	   may	   lead	   to	   less	   repression	   of	   TGFβR2,	   but	   once	   the	   LCLs	   are	  
established	  the	  addition	  or	  withdrawal	  of	  EBNA3C	  does	  not	  alter	  TGFβR2	  expression.	  This	  is	  
consistent	  with	  the	  findings	  in	  3CHT-­‐LCLs	  established	  in	  a	  p16-­‐wild-­‐type	  background,	  where	  
withdrawal	  of	  4HT	  did	  not	  alter	  TGFβR2	  expression	  (fig.	  6.4).	  	  
	  
p16-­‐null	  3CHT-­‐LCLs	  grown	  under	  the	  four	  conditions	  as	  described	  above	  were	  investigated	  
for	   TGFβ	   signalling,	   by	   treatment	   with	   TGFβ1	   or	   vehicle	   for	   one	   hour,	   followed	   by	  
harvesting,	   protein	   extraction,	   SDS-­‐PAGE	   and	   Western	   blot	   for	   pSMAD2	   (fig.	   6.5D).	   This	  
showed	   that	   in	   cells	   grown	   out	  without	   4HT,	   there	  was	   greater	   induction	   of	   pSMAD2	   by	  
TGFβ1	   than	   those	   LCLs	   grown	   out	   in	   the	   presence	   of	   4HT.	   However,	   the	   addition	   or	  
withdrawal	  of	  4HT	  subsequent	  to	  establishment	  of	  the	  LCLs	  seemed	  to	  have	  no	  effect.	  These	  
findings	  were	  consistent	  with	  the	  slight	  de-­‐repression	  of	  TGFβR2	  seen	  in	  cells	  established	  in	  
the	  absence	  of	  4HT	  (fig.	  6.5C).	  	  
	  
Taken	   together,	   these	   results	   suggest	   that	   initial	   exposure	   to	   EBNA3C	   in	   LCLs	   leads	   to	   a	  
more	  profound	  repression	  of	  TGFβR2,	  with	  consequent	  suppression	  of	  TGFβ	  signalling,	  than	  
in	  LCLs	  which	  have	  never	  been	  exposed	  to	  functional	  EBNA3C.	   	  This	  effect	  persists	  despite	  
subsequent	   exposure	   to,	   or	   removal	   of,	   EBNA3C.	   This	   could	   be	   consistent	   with	   the	  
repression	   of	   TGFβR2	   by	   EBNA3C	   being	   epigenetically	   mediated	   as	   discussed	   in	   section	  
6.2.4.	  	  
	  
The	   expression	   of	   TGFβR2	   in	   p16-­‐null	   cells	   even	  without	   EBNA3C	   exposure,	   as	  well	   as	   in	  
EBNA3B	  KO	  LCLs,	   is	   low	   in	  comparison	   to	  uninfected	  primary	  B	  cells	   (figs.	  6.3A	  and	  6.5A),	  
suggesting	  that	  the	  contributions	  of	  both	  EBNA3B	  and	  EBNA3C	  to	  the	  initial	  repression	  are	  
minimal	  in	  LCLs.	  Thus	  it	  is	  likely	  that,	  in	  LCLs,	  other	  latent	  protein(s)	  may	  contribute	  more	  to	  
the	   repression	  of	  TGFβR2	   than	  EBNA3B	  or	  EBNA3C.	   Since	   in	  BL31	  cells,	   LMP1	  and	  LMP2A	  
also	  both	  appear	  to	  contribute	  (see	  chapter	  4),	  one	  or	  both	  of	  these	  may	  also	  contribute	  in	  




LCLs.	  However,	  it	  is	  interesting	  to	  note	  that	  although	  the	  expression	  level	  of	  TGFβR2	  remains	  
generally	   low	  even	   in	   the	   absence	  of	   EBNA3B	  or	   functional	   EBNA3C,	   this	   level	   of	   TGFβR2	  
expression	   is	   nevertheless	   sufficient	   to	   allow	   TGFβ	   signalling	   via	   pSMAD2.	   Furthermore,	  
what	   appears	   to	   be	   only	   a	   slight	   de-­‐repression	   of	   TGFβR2	   in	   the	   absence	   of	   EBNA3B	   or	  
functional	   EBNA3C	   leads	   to	   a	   definite	   increase	   in	   TGFβ-­‐induced	   pSMAD2	   (figs.	   6.3C	   and	  
6.5D).	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Figure	  6.5:	  In	  3CHT-­‐LCLs	  established	  in	  a	  p16-­‐null	  background,	  which	  have	  never	  been	  exposed	  to	  4HT	  and	  
therefore	   never	   expressed	   functional	   EBNA3C,	   there	   is	   a	   modest	   de-­‐repression	   of	   TGFβR2	   leading	   to	  
increased	  TGFβ	  signalling	  	  
(A-­‐B)	  Primary	  B	  cells	  from	  a	  donor	  homozygous	  for	  a	  deletion	  of	  p16	  (‘p16-­‐null’)	  were	  infected	  with	  3CHT	  virus,	  
half	   with	   and	   half	   without	   4HT	   in	   the	   medium.	   3CHT-­‐LCL	   samples	   were	   harvested	   6	   weeks	   after	   infection	  
(infections	   and	   harvesting	   performed	   by	   Rob	   White).	   RNA	   extraction,	   reverse	   transcription	   and	   qPCR	   for	  
TGFβR2	  were	   performed	   along	   with	   samples	   from	   BL31,	   BL31-­‐WT	   and	   a	   wild-­‐type	   LCL	   for	   comparison.	   (B)	  
shows	  an	  enlarged	  version	  of	  the	  data	  shown	  in	  (A)	  for	  the	  p16-­‐null	  3CHT-­‐LCL	  cell	   lines	  established	  with	  and	  
without	   4HT.	   (C)	   The	   p16-­‐null	   3CHT-­‐LCLs	   established	   with	   4HT	   for	   3	   months	   were	   then	   divided	   into	   two	  
samples	   in	   which	   4HT	   was	   continued	   (‘continuous	   4HT’)	   or	   withdrawn	   (‘grown	   out	   with	   4HT,	   then	   4HT	  
withdrawn’).	  At	  the	  same	  time,	  the	  cells	  that	  were	  established	  without	  4HT	  then	  had	  it	  added	  (‘never	  exposed	  
then	  4HT	  added’)	  or	  growth	  was	   continued	   in	  medium	  without	  4HT	   (‘never	  exposed	   to	  4HT’).	  30	  days	  after	  
these	  changes	  samples	  were	  harvested	  (cells	  grown	  and	  harvested	  by	  Rob	  White).	  RNA	  was	  extracted	  and	  qRT-­‐
PCR	   performed	   for	   TGFβR2.	   Values	   are	   expressed	   as	   a	   ratio	   to	   the	   endogenous	   control	   gene	  GNB2L1,	  with	  
error	  bars	  representing	  standard	  deviation	  of	  triplicate	  qPCR	  reactions.	  (D)	  The	  four	  sets	  of	  cells	  as	  in	  (C)	  were	  
frozen	   down	   then	   re-­‐established	   in	   the	   appropriate	  media.	   Once	   established,	   equal	   numbers	   of	   each	  were	  
harvested	  at	  time	  zero	  then	  treated	  for	  one	  hour	  with	  TGFβ1	  10ng/ml	  or	  vehicle	  (2mg/ml	  BSA	  in	  PBS)	  before	  
harvesting.	  Protein	  was	  extracted	  followed	  by	  SDS-­‐PAGE	  and	  western	  blot	  for	  SMAD2	  and	  pSMAD2	  in	  parallel.	  
γ-­‐tubulin	  was	  used	  as	  a	  loading	  control.	  	  
	  
	   	  




6.2.6	  Effects	  of	  EBNA3A	  KO,	  EBNA3C	  KO	  and	  total	  EBNA3	  KO	  on	  TGFβR2	  expression	  early	  
after	  infection	  of	  primary	  B	  cells	  
Having	   investigated	  the	  effects	  of	  EBNA3B	  and	  EBNA3C	  on	  TGFβR2	  expression	   in	  LCLs,	  the	  
effect	   of	   EBNA3A	   was	   also	   investigated.	   Although	   EBNA3A	   was	   originally	   thought	   to	   be	  
required	  for	  B	  cell	  transformation	  to	  LCLs,	  more	  recent	  work	  had	  shown	  that	  it	  is	  possible	  to	  
establish	  EBNA3A	  KO	  LCLs	  when	  feeder	  cells	  are	  present	  (Tomkinson	  et	  al.	  1993,	  Hertle	  et	  al.	  
2009,	   Skalska	   et	   al.	   2010).	   Colleagues	   in	   the	   laboratory	   had	   made	   several	   attempts	   to	  
establish	  EBNA3A	  KO	  LCLs,	  and	   the	   success	  of	   this	  was	   rather	  variable,	   such	   that	   in	  many	  
cases	   it	  was	   not	   possible	   to	   establish	  wild-­‐type,	   EBNA3A	  KO	   and	   revertant	   LCLs	   all	   in	   the	  
same	   donor	   background.	   Therefore	   the	   EBNA3A	   KO	   LCLs	   obtained	   were	   very	  
heterogeneous.	  Preliminary	  investigations	  of	  expression	  of	  TGFβR2	  in	  EBNA3A	  KO	  compared	  
to	  wild-­‐type/revertant	  LCLs	  in	  several	  sets	  of	  LCLs	  by	  qRT-­‐PCR	  showed	  very	  heterogeneous	  
results	  and	  therefore	  these	  were	  not	  investigated	  further.	  	  
	  
Primary	  B	  cell	   infections	  were	  also	  performed	  (with	  the	  help	  of	  Rob	  White)	  using	  EBNA3A	  
KO	  and	  revertant,	  EBNA3C	  KO	  and	  revertant,	  total	  EBNA3	  KO	  and	  revertant,	  and	  3CHT	  with	  
and	  without	  4HT,	  viruses	  in	  mixed	  random	  donor	  (i.e.	  p16	  wild-­‐type)	  B	  cells.	  Samples	  were	  
harvested	   at	   various	   time	   points	   after	   infection	   and	   RNA	   extraction	   and	   qRT-­‐PCR	   were	  
performed	  for	  TGFβR2	  (fig.	  6.6).	  As	  expected,	  the	  cells	  infected	  with	  EBNA3C	  KO,	  EBNA3	  KO	  
and	  3CHT	  virus	  (without	  4HT),	  and	  also	  those	  infected	  with	  EBNA3A	  KO	  virus	  in	  this	  case,	  did	  
not	  survive	  beyond	  days	  14-­‐18	  and	  thus	  it	  is	  not	  possible	  to	  see	  the	  effect	  of	  these	  KOs	  on	  
TGFβR2	   repression	   at	   the	   time	   at	  which	   TGFβR2	   is	   fully	   repressed	   by	  wild-­‐type/revertant	  
viruses,	  i.e.	  around	  day	  21	  (fig.	  6.6).	  Nevertheless,	  up	  to	  the	  point	  when	  these	  cells	  die	  the	  
TGFβR2	  expression	  generally	  seemed	  to	  be	  similar	  to	  that	  in	  the	  wild-­‐types	  and	  revertants,	  
supporting	  the	  earlier	  findings	  that	  none	  of	  the	  EBNA3	  proteins	  appear	  to	  have	  a	  large	  effect	  
on	  TGFβR2	  expression	  in	  LCLs.	  The	  cells	  infected	  with	  3CHT	  virus	  (without	  4HT)	  also	  died	  by	  
14	  days	  post-­‐infection,	  as	  expected.	  In	  these	  cells,	  TGFβR2	  expression	  appeared	  to	  follow	  a	  
similar	  pattern	   to	  EBNA3B	  KO	   (i.e.	   slightly	  de-­‐repressed	  compared	   to	  wild-­‐type/revertants	  
up	   to	   this	   time	   point),	   possibly	   suggesting	   a	   small	   effect	   of	   EBNA3C	   on	   the	   repression	   of	  
TGFβR2.	  However,	  these	  data	  should	  be	  interpreted	  with	  caution	  since	  the	  virus	  titres	  used	  
were	  not	  all	   equivalent.	   In	  addition,	   the	  3CHT	  virus	   tends	   to	  be	   slightly	   less	  efficient	   than	  
other	  wild-­‐type/revertant	   viruses,	   presumably	   due	   to	   the	   fusion	   altering	   the	   efficiency	   of	  




EBNA3C	  [data	  not	  shown	  plus	  (Skalska	  et	  al.	  2010,	  Skalska	  et	  al.	  2013)],	  and	  hence	  this	  could	  
explain	  why	   TGFβR2	   appears	   to	   be	   slightly	   less	   repressed	   in	   these	   cells	   than	   in	   the	  wild-­‐
types	   and	   revertants;	   indeed,	   the	   graph	   for	   3CHT	   virus	   with	   4HT	   also	   shows	   slightly	   less	  
repression	   of	   TGFβR2	   than	   the	   other	  wild-­‐types/revertants	   at	   all	   time	   points	   (pale	   green	  
line,	  fig.	  6.6).	  	  
	  
Since	   TGFβR2	   is	   repressed	   by	   all	   the	   recombinant	   viruses	   used,	   it	   is	   possible	   that	   this	  
repression	  could	  be	  due	  to	  B	  cell	  activation	  per	  se	  rather	  than	  to	  EBV	  itself.	  However,	  in	  an	  
experiment	   to	   compare	   EBV	   infection	   of	   PBMCs	   with	   activation	   by	   CD40L	   and	   IL-­‐4	   (to	  
activate	   the	  B	  cells),	  TGFβR2	  mRNA	   levels	  were	   similar	  with	  EBV	   infection	  and	  CD40L/IL-­‐4	  
treatment	   at	   2	   days	   post-­‐infection/activation	   but	   by	   day	   4,	   TGFβR2	   mRNA	   started	   to	  
increase	   again	   in	   the	   CD40L-­‐activated	   samples,	   and	   continued	   to	   increase	   up	   to	   day	   7,	  
whereas	   TGFβR2	   expression	   continued	   to	   decrease	   as	   shown	   here	   (Lenka	   Skalska,	  
unpublished	  data).	  Therefore	  the	  continued	  repression	  of	  TGFβR2	  appears	  to	  be	  an	  effect	  of	  













Figure	   6.6:	   EBNA3A	   and	   EBNA3C	   are	   not	   necessary	   for	   the	   down-­‐regulation	   of	   TGFβR2	   by	   EBV	   in	   newly	  
infected	  primary	  B	  cells	  	  
Purified	  primary	  B	  cells	  were	  obtained	  from	  random	  donors	  (p16	  wild-­‐type)	  and	  equal	  numbers	  infected	  with	  
each	  of	  the	  recombinant	  viruses	  shown	  (EBNA3A,	  EBNA3B,	  EBNA3C	  and	  total	  EBNA3	  locus	  deletions	  and	  their	  
revertants,	  as	  well	  as	  conditional	  3CHT	  with/without	  4HT),	  followed	  by	  harvesting	  at	  intervals,	  RNA	  extraction,	  
and	  qRT-­‐PCR	  for	  TGFβR2.	  Values	  are	  expressed	  as	  ratios	  to	  the	  endogenous	  control	  gene	  GNB2L1,	  with	  error	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6.2.7	  In	  EREB2.5	  cells,	  TGFβR2	  is	  de-­‐repressed	  upon	  withdrawal	  of	  β-­‐estradiol	  
Since	  LMP1	  and	  LMP2A	  cooperate	  in	  the	  down-­‐regulation	  of	  TGFβR2	  in	  BL31	  cells,	  the	  effect	  
of	  these	  in	  LCLs	  was	  investigated,	  to	  the	  extent	  that	  this	  was	  possible.	  EBNA2	  is	  absolutely	  
required	   for	   B	   cell	   immortalisation,	   and	   thus	   it	   is	   not	   possible	   to	   make	   EBNA2	   KO	   LCLs	  
(Cohen	  et	  al.	  1989).	  Although	  LMP1	  was	  originally	  thought	  to	  be	  absolutely	  required	  for	  B	  
cell	  transformation	  (Kaye	  et	  al.	  1993),	  subsequent	  work	  has	  shown	  that	  LMP1	  expression	  is	  
needed	  for	  cellular	  proliferation,	  and	  in	  fact	  not	  absolutely	  required	  for	  transformation,	  but	  
that	   transformation	   efficiency	   is	   severely	   reduced	   without	   its	   expression	   (Dirmeier	   et	   al.	  
2003);	  therefore	  it	  is	  extremely	  difficult	  to	  make	  LMP1	  KO	  LCLs.	  	  
	  
In	   order	   to	   try	   to	   investigate	   the	   effects	   of	   EBNA2	   expression	   in	   LCLs,	   Kempkes	   et	   al	  
developed	  the	  EREB2.5	  cell	   line,	  an	  LCL	   in	  which	  EBNA2	   is	   fused	  to	  an	  oestrogen	  receptor	  
such	  that	  expression	  of	  EBNA2	  is	  conditional	  upon	  the	  presence	  of	  oestrogen	  in	  the	  medium	  
(Kempkes	   et	   al.	   1995).	   When	   oestrogen	   is	   withdrawn	   from	   these	   cells,	   they	   stop	  
proliferating	  and	  a	   significant	  proportion	  become	  apoptotic.	  However,	  approximately	  50%	  
remain	  viable	  for	  up	  to	  five	  days,	  arrested	  in	  G1,	  during	  which	  time	  re-­‐addition	  of	  oestrogen	  
can	   re-­‐induce	   DNA	   synthesis.	   In	   EREB2.5	   cells,	   the	   amount	   of	   EBNA2-­‐oestrogen	   receptor	  
(EBNA2-­‐ER)	   fusion	   protein	   is	   also	   reduced	   after	   withdrawal	   of	   oestrogen,	   again	   through	  
sequestration	  and	  degradation.	  Kempkes	  et	  al	  demonstrated	  that	  withdrawal	  of	  oestrogen	  
from	  EREB2.5	  cells	  also	  led	  to	  a	  reduction	  in	  LMP1,	  as	  predicted,	  since	  EBNA2	  transactivates	  
LMP1	   (Kempkes	   et	   al.	   1995).	   Presumably	   LMP2A	   would	   be	   reduced	   upon	   withdrawal	   of	  
oestrogen,	  in	  a	  similar	  manner.	  	  
	  
EREB2.5	   cells	   were	   used	   to	   investigate	   the	   effects	   of	   oestrogen	   withdrawal	   on	   the	  
expression	  of	  TGFβR2.	  Equal	  numbers	  of	  proliferating	  EREB2.5	  cells	  were	  either	  seeded	  into	  
a	  new	  flask	  containing	  medium	  with	  β-­‐estradiol	  (an	  oestrogen),	  or	  washed	  twice	  in	  PBS	  and	  
then	  re-­‐suspended	   in	  RPMI	  medium	  without	  β-­‐estradiol.	  Samples	  were	  harvested	   for	  RNA	  
and	  protein	  extraction	  on	  day	  0,	  after	  washing	  and	  re-­‐suspension,	  and	  subsequently	  at	  24	  
hour	  intervals	  to	  day	  4.	  SDS-­‐PAGE	  followed	  by	  western	  blot	  showed	  that	  as	  β-­‐estradiol	  was	  
withdrawn,	  expression	  of	  EBNA2-­‐ER	  gradually	  decreased	  from	  day	  2	  onwards,	  although	  the	  
expression	  of	  EBNA2-­‐ER	  was	  also	  notably	  lower	  in	  the	  cells	  grown	  with	  β-­‐estradiol	  at	  day	  0;	  
the	   reason	   for	   this	   is	   not	   clear	   although	   possibly	   reflects	   the	   difference	   in	   treatment	   in	  




terms	  of	  washing	  the	  ‘without	  estradiol’	  cells	  (fig.	  6.7).	  The	  loading	  was	  the	  same	  for	  both,	  
as	  the	   level	  of	  γ-­‐tubulin	  shown	   is	  on	  the	  western	  blot	  performed	  for	  EBNA2.	  As	  expected,	  
since	  EBNA2	  transactivates	  LMP1	  and	  LMP2A,	  the	  expression	  of	  these	  were	  reduced	  by	  1-­‐2	  
days	  after	  β-­‐estradiol	  withdrawal.	  Expression	  of	  LMP1	  and	  LMP2A	  was	  similar	  on	  day	  zero	  in	  
the	  samples	  both	  with	  and	  without	  β-­‐estradiol	  (fig.	  6.7).	  	  
	  
RNA	   was	   extracted	   and	   then	   qRT-­‐PCR	   performed	   for	   TGFβR2	   expression	   (fig.	   6.7).	   Since	  
upon	   withdrawal	   of	   oestrogen,	   many	   of	   the	   EREB2.5	   cells	   die,	   primer	   sets	   for	   several	  
endogenous	  control	  (normalisation)	  genes	  (GAPDH,	  ALAS1,	  TUBB,	  RPLPO	  and	  GNB2L1)	  were	  
used.	  The	  values	  for	  all	  normalisation	  genes	  varied	  between	  samples:	  for	  ALAS1,	  TUBB	  and	  
GAPDH	  the	  values	  all	  gradually	  decreased	  from	  days	  1-­‐4,	  whereas	  the	  values	  for	  RPLPO	  and	  
GNB2L1	   varied	   between	   samples	   but	   did	   not	   show	   a	   gradual	   decline	  with	   time	   (data	   not	  
shown).	  The	  data	  were	   therefore	  analysed	   first	  using	  each	  normalisation	  gene	   separately,	  
and	   in	   all	   cases	   TGFβR2	   was	   seen	   to	   gradually	   increase	   with	   time	   after	   oestrogen	  
withdrawal.	  Therefore,	  for	  each	  sample	  the	  mean	  of	  the	  values	  for	  all	  normalisation	  genes	  
was	  calculated	  and	  the	  values	  shown	  in	  the	  histogram	  are	  therefore	  expressed	  as	  a	  ratio	  to	  
this	  mean	  normalisation	  value	  (‘norm’)	  (fig.	  6.7).	  	  
	  
With	  this	  caveat	  in	  mind,	  TGFβR2	  expression	  appeared	  to	  gradually	  increase	  with	  time	  after	  
β-­‐estradiol	  withdrawal.	   In	  this	  case	  the	  expression	  at	  RNA	  level	  was	  similar	  at	  day	  0	  in	  the	  
cells	   with	   and	   without	   β-­‐estradiol	   (in	   contrast	   to	   the	   apparent	   EBNA2-­‐ER	   expression	   by	  
western	  blot;	  fig.	  6.7).	  The	  gradual	  de-­‐repression	  of	  TGFβR2	  could	  be	  due	  to	  the	  decreasing	  
expression	   of	   EBNA2,	   LMP1	   and/or	   LMP2A	   in	   these	   cells;	   it	   is	   not	   possible	   to	   determine	  
which	  of	  the	  latent	  proteins	  is	  responsible.	  Indeed,	  it	  is	  also	  possible	  that	  the	  withdrawal	  of	  
β-­‐estradiol	   alters	   the	   expression	   of	   EBNA3	   proteins;	   however	   this	   cannot	   be	   accurately	  
determined	  due	  to	  the	  relatively	  long	  half-­‐life	  of	  the	  EBNA3	  proteins,	  over	  24	  hours	  (Touitou	  
et	   al.	   2005).	   In	   addition,	   since	   there	   were	   significant	   changes	   in	   expression	   of	   all	  
normalisation	  genes	  used,	  likely	  to	  be	  as	  a	  result	  of	  significant	  cell	  death,	  it	  is	  also	  possible	  
that	  the	  de-­‐repression	  of	  TGFβR2	  could	  be	  due	  to	  other	  processes	  occurring	  in	  the	  cells	  as	  a	  
result	   of	   death	   or	   apoptosis.	   In	   addition,	   the	   gradual	   decline	   of	   values	   for	   some	   of	   the	  
normalisation	  genes	  could	  cause	  an	  artificial	  increase	  in	  TGFβR2	  expression,	  since	  the	  values	  
are	  expressed	  as	  the	  ratio	  of	  TGFβR2	  value	  to	  endogenous	  control.	  	  





















Figure	  6.7:	  TGFβR2	  is	  de-­‐repressed	  upon	  withdrawal	  of	  β-­‐estradiol	  in	  EREB2.5	  cells	  	  
EREB2.5	  cells	  were	  grown	  in	  the	  presence	  of	  β-­‐estradiol	  and	  then	  equal	  numbers	  taken	  on	  day	  zero.	  One	  set	  
was	   washed	   twice	   with	   PBS	   and	   then	   re-­‐suspended	   in	   fresh	   medium	   without	   β-­‐estradiol	   (-­‐β-­‐EST)	   and	   the	  
others	   were	   re-­‐suspended	   in	   fresh	   medium	   containing	   β-­‐estradiol	   (+β-­‐EST).	   Samples	   were	   harvested	   for	  
protein	   and	   RNA	   on	   day	   0	   (after	  washing)	   and	   then	   at	   24-­‐hour	   intervals	   for	   four	   days.	   RNA	  was	   extracted,	  
reverse	  transcribed	  and	  then	  qPCR	  performed	  for	  TGFβR2.	  The	  values	  are	  expressed	  as	  a	  ratio	  to	  the	  mean	  of	  
five	   endogenous	   control	   genes	   (GAPDH,	   ALAS1,	   TUBB,	   RPLPO	   and	   GNB2L1),	   with	   error	   bars	   representing	  
standard	  deviation	  of	  triplicate	  qPCR	  reactions.	  SDS-­‐PAGE	  and	  western	  blot	  was	  performed	  for	  EBNA2	  (in	  this	  
case	  detected	  as	  the	  EBNA2-­‐ER	  fusion	  protein	  at	  a	  higher	  molecular	  weight	  than	  standard	  EBNA2),	  LMP1	  and	  
























Since	  LMP1	  and	  LMP2A	  were	  shown	  to	  cooperate	  with	  EBNA3B	  and	  EBNA3C	  in	  causing	  the	  
repression	  of	  TGFβR2	  in	  BL31	  cells	  (chapter	  4),	  an	  attempt	  was	  also	  made	  to	  produce	  LMP2A	  
KO	  LCLs	  in	  order	  to	  investigate	  the	  specific	  effect	  of	  LMP2A	  deletion.	  It	  should	  theoretically	  
be	   possible	   to	   produce	   LMP2A	   KO	   LCLs	   because	   LMP2A	   is	   not	   strictly	   necessary	   for	   cell	  
transformation/immortalisation	   (Longnecker	   et	   al.	   1993a,	   Longnecker	   et	   al.	   1993b),	   and	  
other	  groups	  have	  successfully	  made	  LMP2A	  KO	  LCLs.	  However,	  there	  is	  some	  discrepancy	  
as	   to	  whether	   lack	  of	  LMP2A	  reduces	   the	  efficiency	  of	   immortalisation,	  with	  some	  groups	  
showing	  that	  LMP2A	  contributes	  to	  the	  efficiency	  (Brielmeier	  et	  al.	  1996,	  Wasil	  et	  al.	  2013),	  
whereas	   others	   have	   shown	   it	   to	   be	   completely	   dispensable	   (Longnecker	   et	   al.	   1992,	  
Longnecker	  et	  al.	  1993a,	  Longnecker	  et	  al.	  1993b,	  Speck	  et	  al.	  1999).	  	  
	  
Unfortunately	   the	  attempted	  outgrowth	  of	  LMP2A	  KO	  LCLs	  by	   infection	  of	  primary	  B	  cells	  
was	  unsuccessful	  in	  the	  current	  study	  and,	  due	  to	  time	  constraints,	  could	  not	  be	  repeated.	  
Nevertheless	   this	  would	   be	   important	   to	   investigate	   in	   future	  work.	   Primary	   B	   cells	  were	  
also	  infected	  with	  LMP1	  KO	  virus,	  but	  outgrowth	  of	  these	  was	  unsuccessful;	  as	  mentioned	  in	  
section	  6.2.7,	  it	   is	  extremely	  difficult	  to	  make	  LMP1	  KO	  LCLs,	  having	  been	  achieved	  only	  at	  
very	   low	  frequency	   in	  the	  presence	  of	  a	   layer	  of	  fibroblasts	  as	  feeder	  cells	   (Dirmeier	  et	  al.	  
2003).	  It	  was	  also	  hypothesised	  that	  if	  LMP1	  and/or	  LMP2A	  also	  contribute	  to	  the	  repression	  
of	  TGFβR2	  in	  LCLs,	  it	  could	  be	  that	  the	  full	  repression	  of	  TGFβR2	  does	  not	  occur	  until	  around	  
day	  21	  post-­‐infection	  because	  LMP1	  and/or	  LMP2A	  have	  to	  reach	  a	  certain	  expression	  level	  
before	  they	  have	  these	  effects.	   It	  has	  been	  previously	  shown	  that	  the	  EBNA3	  proteins	  are	  
expressed	   fully	   early	   (2-­‐3	   days)	   after	   infection	   of	   B	   cells	   [(Nikitin	   et	   al.	   2010)	   and	  
unpublished	  data,	  Allday	   laboratory],	  whereas	  LMP1	   is	  not	  fully	  expressed	  until	  around	  21	  
days	  post-­‐infection	  (Price	  et	  al.	  2012).	  	  
	   	  




6.3	  The	  regulation	  of	  TGFβR3	  by	  EBV	  in	  newly	  infected	  B	  cells	  and	  LCLs	  
6.3.1	   EBV	   up-­‐regulates	   TGFβR3	   in	   LCLs;	   however,	   this	   occurs	   later	   than	   the	   down-­‐
regulation	  of	  TGFβR2	  after	  infection	  of	  primary	  B	  cells	  with	  EBV	  
In	   BL31	   cells,	   EBV	   was	   shown	   to	   up-­‐regulate	   TGFβR3	   in	   addition	   to	   repressing	   TGFβR2	  
(chapter	  3).	  The	  results	  in	  BL31	  cells	  suggested	  that	  TGFβR2	  and	  TGFβR3	  expression	  may	  be	  
reciprocally	  regulated,	  although	  there	  were	  some	  cell	   lines	   in	  which	  this	  did	  not	  appear	  to	  
be	   the	   case	   (particularly	   EBNA3A	   KOs	   1-­‐3,	   see	   section	   4.6).	   Therefore	   the	   expression	   of	  
TGFβR3	  was	  also	  investigated	  in	  LCLs.	  	  
	  
Since	  EBV	  had	  been	  shown	   to	  gradually	   repress	  TGFβR2	  after	   infection	  of	  primary	  B	  cells,	  
leading	   to	   repression	   and	   loss	   of	   TGFβ	   signalling	   in	   established	   LCLs,	   it	  was	   hypothesised	  
that	   TGFβR3	   would	   be	   up-­‐regulated	   by	   EBV	   over	   a	   similar	   time	   period	   after	   infection	   of	  
primary	  B	  cells.	  qRT-­‐PCR	  for	  TGFβR3	  was	  performed	  at	  various	  time	  points	  after	  infection	  of	  
primary	  B	  cells	   (fig.	  6.8B).	  Surprisingly,	  over	  the	  first	   few	  days	  after	   infection,	  TGFβR3	  was	  
actually	   down-­‐regulated,	   reaching	   a	   nadir	   at	   day	   11.	  However,	   from	   this	   time	  on	   TGFβR3	  
started	   to	   increase,	   and	   therefore	   harvesting	   of	   samples	   for	   RNA	   extraction	   and	  
quantification	  of	  TGFβR2	  and	  TGFβR3	  expression	  was	  continued	  for	  an	  extended	  period,	  up	  
to	   11	   weeks	   post-­‐infection	   of	   primary	   B	   cells.	   This	   showed	   that	   TGFβR2	   was	   completely	  
repressed	  by	  around	  30	  days	  post-­‐infection.	  However,	  TGFβR3	  expression,	  after	   the	   initial	  
decrease,	   increased	  very	  gradually,	   reaching	  a	  plateau	  after	  around	  70	  days	  post-­‐infection	  
(fig.	  6.8B).	  	  
	  
This	  suggests	  that	  although	  EBV	  (or	  possibly	  the	  process	  of	  B	  cell	  activation)	  initially	  down-­‐
regulates	  TGFβR3,	   the	  subsequent	  up-­‐regulation	  may	  be	  due	   to	  a	  clonal	   selection	  process	  
rather	  than	  due	  to	  a	  direct	  effect	  of	  EBV.	  Although	  this	  effect	  was	  seen	  in	  most	  of	  the	  wild-­‐
type	   and	   revertant	   viruses	   used,	   there	  was	   one	   revertant	   cell	   line,	   in	   one	   experiment,	   in	  
which	  TGFβR3	  was	  not	  up-­‐regulated	  by	  day	  42	   (see	  chapter	  7,	   fig.	  7.10C).	  However,	   since	  
that	   experiment	   was	   not	   continued	   for	   an	   extended	   period,	   it	   remains	   possible	   that	   up-­‐
regulation	  of	  TGFβR3	  could	  have	  occurred	  later.	  Nevertheless,	  this	   lack	  of	  up-­‐regulation	  of	  
TGFβR3	  by	  42	  days	  post-­‐infection	  could	  support	   the	  hypothesis	   that	   this	  occurs	   indirectly,	  
possibly	   via	   a	   clonal	   selection	   process.	   Since	   up-­‐regulation	   of	   TGFβR3	   did	   occur	   in	   the	  




majority	  of	  wild-­‐type	  and	  revertant	  LCLs	  it	  seems	  likely	  that,	  if	  it	  occurs	  via	  clonal	  selection,	  
EBV	  infection	  has	  created	  conditions	  which	  are	  highly	  favourable	  for	  this	  to	  occur.	  	  
	  
It	   is	   also	   possible	   that	   the	   down-­‐regulation	   of	   TGFβR2	   itself	   somehow	   favours	   the	   up-­‐
regulation	  of	  TGFβR3,	  especially	   in	  view	  of	  the	  reciprocal	  nature	  of	  expression	  seen	   in	  the	  
majority	  of	  BL31	  cell	  lines.	  However,	  after	  primary	  B	  cell	  infections	  TGFβR3	  starts	  to	  increase	  
before	  TGFβR2	  is	  fully	  repressed;	  nevertheless	  it	  could	  be	  that	  once	  TGFβR2	  is	  repressed	  to	  
a	   certain	   level	   then	   TGFβR3	   can	   increase.	   This	   could	   be	   via	   the	  mechanism	   discussed	   in	  






















Figure	  6.8:	  The	  up-­‐regulation	  of	  TGFβR3	  occurs	  later	  than	  the	  down-­‐regulation	  of	  TGFβR2	  after	  infection	  of	  
primary	  B	  cells	  with	  wild-­‐type	  EBV	  
qRT-­‐PCR	  for	  (A)	  TGFβR2	  and	  (B)	  TGFβR3	  expression	  with	  time	  after	  infection	  of	  primary	  B	  cells	  with	  wild-­‐type	  
EBV.	  The	  values	   represent	   the	   ratio	   to	   the	  endogenous	  control	  gene	  GNB2L1.	  Error	  bars	   represent	   standard	  
deviation	   of	   triplicate	   qPCR	   reactions.	   Data	   shown	   are	   from	   one	   of	   two	   separate	   infection	   experiments,	   in	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6.3.2	  EBNA3B	  is	  necessary	  for	  the	  up-­‐regulation	  of	  TGFβR3	  in	  LCLs	  
Since	  EBNA3B	  is	  necessary	  for	  the	  up-­‐regulation	  of	  TGFβR3	  in	  BL31	  cells	  (fig.	  3.11A-­‐B),	  the	  
effect	   of	   EBNA3B	   deletion	   on	   TGFβR3	   expression	   was	   investigated	   in	   LCLs.	   qRT-­‐PCR	   for	  
TGFβR3	   in	   established	   wild-­‐type,	   EBNA3B	   KO	   and	   revertant	   LCLs	   showed	   that	   in	   both	  
EBNA3B	  KO	  lines,	  TGFβR3	  expression	  is	  low,	  whereas	  it	  is	  up-­‐regulated	  in	  the	  wild-­‐type	  and	  
revertant	   LCLs	   (fig.	   6.9A).	   This	   suggests	   that	  EBNA3B	   is	  necessary	   for	   the	  up-­‐regulation	  of	  
TGFβR3	  in	  LCLs.	  	  	  
	  
qRT-­‐PCR	   for	   TGFβR3	   in	   primary	   B	   cells	   infected	   with	   wild-­‐type	   and	   EBNA3B	   KO	   viruses	  
showed	   that	   after	   around	   day	   11	   TGFβR3	   was	   gradually	   up-­‐regulated	   by	   wild-­‐type	   EBV;	  
however,	  this	  up-­‐regulation	  did	  not	  occur	  in	  EBNA3B	  KO	  cells,	  with	  expression	  remaining	  at	  
a	  steady	   low	   level	   (fig.	  6.9B).	  These	   findings	  suggest	   that	  EBNA3B	   is	  necessary	   for	   the	  up-­‐

















Figure	  6.9:	  EBNA3B	  is	  necessary	  for	  the	  up-­‐regulation	  of	  TGFβR3	  in	  LCLs	  
(A)	  qRT-­‐PCR	  for	  TGFβR3	  in	  a	  set	  of	  established	  wild-­‐type,	  EBNA3B	  KO	  and	  EBNA3B	  revertant	  LCLs.	  (B)	  qRT-­‐PCR	  
for	  TGFβR3	  expression	  with	  time	  after	  infection	  of	  primary	  B	  cells	  by	  wild-­‐type	  or	  EBNA3B	  KO	  LCLs.	  The	  values	  
represent	   the	   ratio	   to	   the	   endogenous	   control	   gene	   GNB2L1.	   Error	   bars	   represent	   standard	   deviation	   of	  
triplicate	  qPCR	  reactions.	  The	  data	  shown	  are	  representative	  of	  experiments	  performed	  at	  least	  three	  times	  (A)	  














































6.3.3	  EBNA3C	  also	  contributes	  to	  the	  up-­‐regulation	  of	  TGFβR3	  in	  LCLs	  
In	  order	  to	  determine	  the	  effect	  of	  EBNA3C	  deletion	  on	  TGFβR3	  expression	  in	  LCLs,	  this	  was	  
initially	   investigated	   in	   3CHT-­‐LCLs	   established	   by	   infection	   of	   p16-­‐null	   donor	   B	   cells	   with	  
3CHT	  virus	   in	  the	  presence	  of	  4HT	  and	  thus	  established	  with	  EBNA3C	  present	  (see	  section	  
6.2.5	   for	   explanation).	   Once	   these	   p16	   wild-­‐type	   3CHT-­‐LCLs	   were	   established	   (at	  
approximately	  three	  months	  post-­‐infection),	  4HT	  was	  withdrawn	  from	  some	  of	  the	  cells	  for	  
a	   period	   of	   30	   days,	   then	   re-­‐added;	   at	   the	   same	   time	   those	   in	   which	   growth	   had	   been	  
continued	   in	   4HT	   then	   had	   4HT	   withdrawn	   –	   see	   figure	   6.10A	   for	   the	   outline	   of	   this	  
experiment,	   performed	   by	   Rob	   White,	   showing	   the	   timings	   at	   which	   samples	   were	  
harvested.	  RNA	  was	  then	  extracted	  and	  qRT-­‐PCR	  performed	  for	  TGFβR3	  on	  these	  samples.	  
This	  showed	  that	  TGFβR3	  expression	  was	  relatively	  high	  in	  the	  established	  3CHT-­‐LCLs	  with	  
4HT	   (at	   day	   0	   of	   this	   experiment,	   see	   fig.	   6.10A-­‐B),	   and	   then	   expression	   decreased	  
significantly	  by	  5	  days	  after	  4HT	  was	  withdrawn,	  with	  slight	  further	  decreases	  to	  day	  37	  (fig.	  
6.10B).	  When	  4HT	  was	  re-­‐added,	  there	  was	  a	  slight	  increase	  in	  TGFβR3	  expression	  by	  day	  5	  
but	  a	  more	  marked	   increase	  by	  day	  33.	  Repeated	  withdrawal	   led	  to	  a	  similar	   reduction	   in	  
TGFβR3	  expression	  by	  33	  days	  post-­‐withdrawal	  (fig.	  6.10B).	  Similar	  findings	  were	  seen	  in	  the	  
array	  data	  using	  the	  same	  samples	   (fig.	  6.10C)	   [www.epstein-­‐barrvirus.org.uk	  and	   (Skalska	  
et	   al.	   2013)].	   Thus,	   in	   contrast	   to	   the	   findings	   for	   TGFβR2,	   TGFβR3	  expression	   appears	   to	  
vary	  directly	  according	  to	  EBNA3C	  expression	  and	  continues	  to	  be	  regulated	  thus	  even	  after	  
exposure	   to	   EBNA3C	   has	   occurred.	   In	   addition,	   the	   results	   suggest	   that	   the	   decrease	   in	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Figure	   6.10:	   In	   p16-­‐null	   3CHT-­‐LCLs	   established	   in	   the	   presence	   of	   4HT,	   TGFβR3	   expression	   varies	   with	  
subsequent	  4HT	  exposure	  	  
(A)	  Schematic	  diagram	  of	  experimental	  procedure	  (as	  performed	  by	  Rob	  White).	  Peripheral	  blood	  lymphocytes	  
(PBLs)	  from	  a	  donor	  with	  a	  homozygous	  mutation	  of	  p16	  (p16-­‐null	  PBLs)	  were	  infected	  with	  3CHT	  virus	  in	  the	  
presence	  of	  4HT.	  Once	  LCLs	  were	  established	  (after	  three	  months	  grown	  with	  4HT),	  the	  cells	  were	  divided	  into	  
two:	  half	  were	  washed	  and	  then	  grown	   in	  medium	  without	  4HT	  (day	  0,	  4HT	  withdrawn),	  and	  the	  remainder	  
continued	  to	  be	  grown	  with	  4HT.	  30	  days	  after	   this	  change	  samples	  were	  harvested	   for	  RNA	  from	  both	  sets	  
(4HT	  withdrawn	  or	  4HT	  continued),	   then	   two	  days	   later	   (i.e.	  day	  32)	   the	  media	  were	  changed	  again	   so	   that	  
those	  previously	  growing	  with	  4HT	  were	  washed	  and	  then	  grown	  without	  it	  (upper	  blue	  line,	  4HT	  withdrawn)	  
and	  those	  growing	  without	  it	  for	  the	  past	  32	  days	  had	  4HT	  re-­‐added	  (4HT	  re-­‐added,	  lower	  red	  line).	  Samples	  
were	   then	   harvested	   for	   RNA	   at	   day	   +5	   and	   day	   +33	   of	   these	   changes,	   i.e.	   days	   37	   and	   65	   of	   the	   whole	  
experiment.	  Block	  arrows	  show	  the	  timing	  of	  samples	  for	  RNA,	  with	  the	  colours	  of	  the	  arrows	  represented	  in	  
the	  chart	  in	  (B).	  Days	  shown	  in	  red	  relate	  to	  the	  timing	  of	  the	  second	  change	  in	  conditions,	  i.e.	  the	  re-­‐addition	  
of	  4HT.	  Figure	  adapted	  from	  (Skalska	  et	  al.	  2013).	  (B)	  qRT-­‐PCR	  for	  TGFβR3	  expression	  showing	  variation	  as	  4HT	  
is	  withdrawn	  (blue)	  or	  re-­‐added	  (red),	  with	  the	  timings	  as	  shown	  in	  (A).	  The	  values	  are	  expressed	  as	  a	  ratio	  to	  
the	   endogenous	   control	   gene	   GNB2L1,	   with	   error	   bars	   representing	   standard	   deviation	   of	   triplicate	   qPCR	  
reactions.	   This	   experiment	   was	   performed	   in	   parallel	   in	   three	   separate	   LCLs	   established	   using	   two	  
independently	   derived	   3CHT	   viruses	   to	   infect	   PBLs	   from	   a	   single	   p16-­‐null	   donor,	   with	   representative	   data	  
shown	   here.	   cDNA	   samples	   were	   obtained	   from	   Rob	   White	   and	   qPCRs	   performed	   by	   the	   author.	   (C)	  
Microarray	  data	  showing	  the	  results	  for	  all	  cell	  lines,	  from	  the	  experiment	  as	  shown	  in	  (A)	  and	  (B).	  Each	  point	  
represents	  a	  single	  cell	  line,	  with	  the	  values	  on	  the	  y	  axis	  representing	  mRNA	  expression.	  From	  www.epstein-­‐







	   	  




The	  effect	  of	  EBNA3C	  on	  TGFβR3	  expression	  was	  also	  investigated	  in	  3CHT-­‐LCLs	  established	  
without	  4HT	  in	  a	  p16-­‐null	  background,	  so	  that	  the	  effect	  of	  having	  never	  been	  exposed	  to	  
EBNA3C	  could	  be	  seen.	  Samples	  harvested	  at	  three	  months	  post-­‐infection	  of	  PBL	  with	  3CHT	  
virus	  showed	  that	  TGFβR3	  expression	  was	  higher	  in	  those	  cells	  grown	  out	  in	  the	  presence	  of	  
4HT,	   and	   thus	   expressing	   functional	   EBNA3C,	   than	   those	   which	   had	   never	   expressed	  
functional	  EBNA3C	  (fig.	  6.11A).	  	  	  
	  
qRT-­‐PCR	   for	   TGFβR3	   was	   then	   performed	   in	   samples	   from	   a	   time	   course	   experiment	   in	  
which	  p16-­‐null	  3CHT-­‐LCLs	  had	  been	  established	  initially	  in	  the	  presence	  or	  absence	  of	  4HT,	  
as	  above.	  Once	  the	  LCLs	  were	  established	  (at	  around	  three	  months	  post-­‐infection),	  at	  day	  
zero	  in	  this	  experiment,	  the	  growth	  conditions	  were	  then	  changed	  such	  that	  each	  of	  the	  two	  
cell	  lines	  (grown	  out	  with	  versus	  without	  4HT)	  were	  divided	  into	  two,	  and	  one	  continued	  to	  
be	  grown	  with	  4HT	  but	  the	  other	  was	  washed	  and	  then	  grown	  without	  4HT.	  Thus	  there	  were	  
four	   conditions	   (as	   also	   described	   in	   section	   6.2.5):	   (1)	   never	   exposed	   to	   4HT,	   (2)	   never	  
exposed	  to	  4HT	  but	   then	  exposed	  once	  LCLs	  were	  established,	   (3)	  grown	  out	   initially	  with	  
4HT	  but	  then	  4HT	  withdrawn	  upon	  establishment	  of	  LCLs,	  and	  lastly	  (4)	  continuously	  grown	  
out	  with	  4HT.	  This	  experiment	  was	  performed	  by	  Rob	  White,	  but	   the	  RNA	  extraction	  and	  
qRT-­‐PCR	  were	  all	  performed	  by	  the	  author.	  
	  
This	   showed	   that,	   as	   before,	   TGFβR3	   expression	  was	   increased	   in	   established	   LCLs	   grown	  
out	  with	   4HT,	   i.e.	   with	   EBNA3C,	   compared	   to	   those	  without.	   Then	   after	   the	  media	  were	  
changed	  over,	  those	  newly	  or	  continuously	  expressing	  functional	  EBNA3C	  showed	  a	  gradual	  
increase	   in	   TGFβR3	   expression,	   whereas	   those	   no	   longer	   or	   never	   exposed	   to	   EBNA3C	  
showed	   declining	   TGFβR3	   expression	   (fig.	   6.11B).	   These	   findings	   suggest	   that	   EBNA3C	   is	  
necessary	   for	   the	   up-­‐regulation	   of	   TGFβR3	   seen	   in	   LCLs	   but	   that,	   in	   contrast	   to	   TGFβR2,	  
TGFβR3	  expression	  continues	  to	  vary	  directly	  with	  the	  presence	  or	  absence	  of	  EBNA3C.	  The	  
regulation	   of	   TGFβR3	   by	   EBNA3C	   in	   LCLs	   is	   consistent	   with	   the	   findings	   of	   Skalska	   et	   al,	  
where	  in	  p16-­‐null	  3CHT-­‐LCLs	  established	  in	  the	  presence	  of	  4HT	  and	  in	  which	  4HT	  was	  then	  
withdrawn	   for	   four	  weeks,	   TGFβR3	  was	   shown	   to	   be	   down-­‐regulated	   over	   two-­‐fold,	   thus	  
confirming	  the	  induction	  of	  TGFβR3	  by	  EBNA3C	  (Skalska	  et	  al.	  2013).	  	  
	  
	  



















Figure	  6.11:	  TGFβR3	  expression	  is	  increased	  in	  p16-­‐null	  3CHT-­‐LCLs	  established	  in	  the	  presence	  of	  4HT,	  and	  is	  
continuously	  regulated	  by	  4HT	  exposure	  
(A)	  qRT-­‐PCR	   for	   TGFβR3	   expression	   approximately	   three	  months	   post-­‐infection	   of	   p16-­‐null	   PBLs	  with	   3CHT	  
virus	  either	  without	  (never	  exposed)	  or	  with	  4HT	  in	  the	  medium.	  (B)	  Following	  establishment	  of	  p16-­‐null	  3CHT-­‐
LCLs	   in	   the	  presence	  or	  absence	  of	  4HT	  at	  around	  three	  months	  post-­‐infection,	  4HT	  was	   then	  withdrawn	  or	  
continued	   in	   those	   established	   with	   it,	   or	   added	   or	   not	   to	   those	   established	   without	   it.	   Samples	   were	  
harvested	  at	   time	  points	  after	   these	  changes	   for	  RNA	  extraction,	   reverse	  transcription	  and	  qPCR	  for	  TGFβR3	  
expression.	  All	   values	   are	   expressed	   as	   ratio	   to	   the	   endogenous	   control	   gene	  GNB2L1.	   Error	   bars	   represent	  
standard	   deviation	   of	   triplicate	   qPCR	   reactions.	   Cells	   established,	   time	   course	   performed	   and	   samples	  
harvested	  by	  Rob	  White;	  RNA	  extractions	  and	  qRT-­‐PCR	  done	  by	  the	  author.	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Experiments	   to	   investigate	   the	   expression	   of	   TGFβR3	   in	   EBNA3A	   KO	   LCLs	   showed	   no	  
consistent	   effect	   (data	   not	   shown),	   as	   has	   been	  previously	   described	   for	   TGFβR2	   (section	  
6.2.6).	   The	   effect	   of	   EBNA3A	   KO,	   EBNA3	   KO,	   EBNA3C	   KO	   and	   EBNA3CHT	   (without	   4HT)	  
viruses	   on	   TGFβR3	   expression	   after	   infection	   of	   purified	   primary	   B	   cells	   were	   also	  
investigated,	  but	  as	  expected	  the	  cells	  infected	  with	  these	  viruses	  all	  died	  before	  the	  time	  at	  
which	  TGFβR3	  expression	  increased	  above	  baseline	  in	  wild-­‐type	  LCLs,	  hence	  the	  data	  are	  not	  
shown	  here.	  	  
	  
6.3.4	  EBNA2,	  LMP1	  and/or	  LMP2A	  may	  also	  contribute	  to	  the	  up-­‐regulation	  of	  TGFβR3	  in	  
LCLs	  
Since	   LMP1	  and	   LMP2A	  also	  appeared	   to	   cooperate	  with	  EBNA3B	  and	  EBNA3C	   in	   the	  up-­‐
regulation	   of	   TGFβR3	   in	   BL31	   cells,	   the	   effect	   of	   this	   was	   also	   investigated	   in	   LCLs.	   The	  
expression	   of	   TGFβR3	   was	   also	   investigated	   in	   EREB2.5	   cells	   by	   qRT-­‐PCR,	   in	   the	   same	  
experiment	  as	  described	  in	  section	  6.2.7	  (see	  fig.	  6.7).	  Bearing	  in	  mind	  the	  constraints	  of	  the	  
EREB2.5	  cell	  system,	  including	  the	  variability	  in	  endogenous	  control	  expression,	  as	  discussed	  
previously	  (section	  6.2.7),	  this	  showed	  that	  TGFβR3	  expression	  appeared	  to	  be	  reduced	  by	  
withdrawal	   of	   β-­‐estradiol,	   correlating	   with	   the	   reduction	   in	   functional	   EBNA2	   and	  
LMP1/LMP2A	   expression	   (fig.	   6.12).	   However,	   TGFβR3	   was	   slightly	   reduced	   in	   the	   cells	  
without	   β-­‐estradiol	   compared	   to	   with	   estradiol	   even	   on	   day	   0,	   the	   reason	   for	   which	   is	  
unclear.	   TGFβR3	   expression	   decreased	   markedly	   even	   by	   day	   one	   post	   withdrawal	   of	   β-­‐
estradiol.	  This	  could	  be	  consistent	  with	  the	  expression	  of	  LMP2A,	  which	  appeared	  to	  reduce	  
sooner	  than	  the	  reduction	  of	  LMP1	  or	  EBNA2.	  It	  is	  not	  clear	  why	  at	  day	  4	  the	  expression	  of	  
TGFβR3	  was	   seen	   to	   increase	   again	   (fig.	   6.12).	   Nevertheless,	   as	   discussed	   previously,	   the	  
findings	  in	  EREB2.5	  cells	  are	  difficult	  to	  interpret	  for	  several	  reasons	  (see	  section	  6.2.7),	  but	  
could	  be	  consistent	  with	  a	  role	  for	  LMP2A,	  LMP1	  and/or	  possibly	  EBNA2	  in	  the	  up-­‐regulation	  











































Figure	  6.12:	  EBNA2,	  LMP1	  and/or	  LMP2A	  contribute	  to	  the	  up-­‐regulation	  of	  TGFβR3	  in	  LCLs	  
qRT-­‐PCR	   for	  TGFβR3	   in	  EREB2.5	   cells	   in	  which	  β-­‐estradiol	  has	  been	  withdrawn	   for	  4	  days	   (see	   figure	  6.7	   for	  
details	   of	   experimental	   procedures).	   The	   values	   are	   expressed	   as	   a	   ratio	   to	   the	   mean	   of	   values	   of	   5	  
endogenous	  control	  genes.	  Western	  blot	  for	  EBNA2,	  LMP1	  and	  LMP2A	  in	  samples	  harvested	  at	  the	  same	  time	  



























6.3.5	  EBV	  does	  not	  significantly	  alter	  expression	  of	  TGFβ1	  or	  TGFβR1	  after	  primary	  B	  cell	  
infection	  	  
In	   BL31	   cells,	   TGFβR2	   and	   TGFβR3	   appeared	   to	   be	   reciprocally	   regulated	   (figs.	   3.1A	   and	  
3.11A),	  although	  some	  differences	  were	  noted,	  especially	  for	  EBNA3A	  KO	  lines	  (section	  4.6,	  
fig.	   4.6A-­‐D).	   In	   BL31	   cells,	   a	   possible	   mechanism	   for	   the	   reciprocal	   expression	   was	  
demonstrated	   by	   a	   two-­‐fold	   de-­‐repression	   of	   TGFβR3	   in	   the	   presence	   of	   the	   TGFβR1	  
inhibitor	  SB431542	  (fig.	  3.13),	  suggesting	  that	  TGFβ1	  may	  repress	  TGFβR3	  when	  signalling	  is	  
active,	  as	  has	  been	  reported	  in	  breast	  and	  ovarian	  cancer	  cells	  (Hempel	  et	  al.	  2008).	  In	  BL31	  
cells	  infected	  with	  wild-­‐type	  EBV,	  TGFβR2	  is	  repressed	  and	  signalling	  suppressed;	  this	  could	  
lead	  to	  the	  relief	  of	  TGFβ1-­‐mediated	  TGFβR3	  repression	  and	  hence	  to	  the	  up-­‐regulation	  of	  
TGFβR3	   whenever	   TGFβR2	   is	   repressed	   to	   the	   point	   where	   signalling	   is	   suppressed	   (see	  
section	  3.4.3).	  	  
	  
In	  view	  of	  this	  it	  was	  important	  to	  investigate	  whether	  the	  expression	  of	  TGFβ1	  or	  TGFβR1	  
vary	  after	  EBV	   infection	  of	  primary	  B	  cells,	   as	   significant	   changes	   in	   these	  could	  also	  alter	  
TGFβR3	  expression	  if	  this	  TGFβ1-­‐mediated	  repression	  of	  TGFβR3	  does	  occur	  in	  B	  cells.	  qRT-­‐
PCR	  for	  TGFβR1	  and	  TGFβ1	  were	  performed	   in	   the	  samples	  harvested	  after	  primary	  B	  cell	  
infection	  with	  wild-­‐type	  EBV,	  as	  previously	  shown	  for	  TGFβR2	  and	  TGFβR3	  (for	  example	  figs.	  
6.2	  and	  6.8).	  This	  showed	  that,	  although	  there	  is	  some	  minor	  variation	  in	  TGFβ1	  and	  TGFβR1	  
expression	  in	  the	  first	  14	  days	  or	  so	  (which	  could	  be	  explained	  by	  the	  variation	  in	  expression	  
of	  the	  normalisation	  controls),	  overall	  EBV	  infection	  does	  not	  have	  a	  significant	  effect	  on	  the	  
expression	  of	   TGFβ1	  or	   TGFβR1	   (fig.	   6.13).	   Since	   the	  medium	  used	   for	   these	  experiments	  
was	  from	  the	  same	  batch	  throughout	  the	  duration	  of	  the	  experiment,	  there	  is	  also	  unlikely	  
to	   have	   been	   significant	   variation	   in	   the	   amount	   of	   exogenous	   TGFβ1	   to	   which	   the	   cells	  
were	  exposed,	  although	  this	  was	  not	  formally	  checked.	  	  
	  
Nevertheless,	   it	   remains	   possible	   that	   once	   TGFβR2	   is	   repressed	   below	   a	   critical	   level,	   at	  
which	   signalling	   via	   pSMAD2	   is	   suppressed,	   the	   repression	   of	   TGFβR3	   by	   exogenous	   and	  
autocrine	  TGFβ1	  could	  be	  relieved	  and	  hence	  this	  is	  why	  TGFβR3	  subsequently	  increases.	  In	  
EBNA3B	  KO	  LCLs	  and	  p16-­‐null	  3CHT-­‐LCLs,	  even	  though	  TGFβR2	  remains	  relatively	  repressed,	  
TGFβ	  signalling	  via	  pSMAD2	  still	  occurs	  and	  thus	  TGFβ1	  would	  still	  repress	  TGFβR3.	  
	  






Figure	  6.13:	  TGFβ1	  and	  TGFβR1	  expression	  do	  not	  vary	  significantly	  after	  EBV	  infection	  of	  primary	  B	  cells	  
	  qRT-­‐PCR	   for	   TGFβ1,	   TGFβR1,	   TGFβR2	   and	   TGFβR3	   mRNA	   expression	   with	   time	   after	   infection	   of	   purified	  
primary	  B	  cells	  with	  wild-­‐type	  EBV.	  Values	  are	  all	  expressed	  as	  a	  ratio	  to	  the	  mean	  of	  the	  normalisation	  genes	  
GNB2L1	   and	  RPLPO.	   Error	   bars	   represent	   standard	   deviation	   of	   triplicate	   qPCR	   reactions.	   Values	   are	   shown	  



























6.4	  The	  effects	  of	  TGFβ	  on	  apoptosis/arrest	  and	  p15INK4B	  expression	  in	  LCLs	  
6.4.1	  Wild-­‐type	  LCLs	  are	  resistant	  to	  TGFβ-­‐induced	  apoptosis	  and	  show	  no	  change	  in	  the	  
cell	  cycle	  with	  TGFβ	  treatment	  
It	   has	   previously	   been	   shown	   that	   LCLs	   are	   resistant	   to	   the	   anti-­‐proliferative	   and	   pro-­‐
apoptotic	   effects	   of	   TGFβ1	   (Blomhoff	   et	   al.	   1987,	   Janssen	   et	   al.	   1990,	   Altiok	   et	   al.	   1991,	  
Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  1992,	  Altiok	  et	  al.	  1993,	  Inman	  and	  Allday	  2000b,	  Kenney	  et	  
al.	   2001,	  Horndasch	  et	   al.	   2002).	   Therefore,	   in	   order	   to	   confirm	   this,	  wild-­‐type	   LCLs	  were	  
treated	  with	  TGFβ1	  or	  vehicle	  for	  48	  hours	  and	  the	  samples	  analysed	  for	  PARP	  cleavage	  by	  
SDS-­‐PAGE	   and	   western	   blot	   as	   well	   as	   by	   propidium	   iodide	   (PI)	   stained	   FC	   for	   cell	   cycle	  
analysis.	   As	   expected,	   this	   showed	   no	   induction	   of	   	   apoptosis,	   as	   detected	   by	   increased	  
PARP	  cleavage	  or	  an	  increased	  sub-­‐G1	  component	  on	  cell	  cycle	  analysis,	  nor	  of	  G1	  arrest,	  by	  


















Figure	  6.14:	  TGFβ1	  does	  not	  induce	  apoptosis	  or	  G1	  arrest	  in	  wild-­‐type	  LCLs	  
(A)	  Western	  blot	  for	  PARP	  after	  48	  hours’	  treatment	  with	  TGFβ1	  5ng/ml	  or	  vehicle,	  with	  γ-­‐tubulin	  shown	  as	  a	  
loading	  control.	  (B)	  Cell	  cycle	  analysis	  by	  propidium	  iodide	  staining	  and	  FC	  in	  LCL-­‐WT	  after	  48	  hours’	  treatment	  
with	  TGFβ1	  5ng/ml	  or	  vehicle.	  	   	  
+TGFβ1	   -­‐	   TGFβ1	  
A	  
B	   C	  




6.4.2	   p15INK4B	   expression	   is	   repressed	   by	   EBNA3C,	   but	   TGFβ	   does	   not	   induce	   p15INK4B	   in	  
LCLs	  	  
Investigation	  of	  binding	  of	  EBNA3C	  to	  regions	  around	  the	  p14ARF/p15INK4B/p16INK4A	  locus	  had	  
shown	   binding	   of	   EBNA3C	   proximal	   to	   the	   TSS	   of	   CDKN2B,	   the	   gene	   encoding	   p15INK4B,	  
suggesting	   that	   EBNA3C	   or	   EBNA3A	   may	   coordinately	   repress	   p15INK4B	   and	   p16INK4A	  
(hereafter	   referred	   to	  as	  p15	  and	  p16	   respectively)	   (Skalska	  et	  al.	   2013).	   Therefore	   it	  was	  
hypothesised	  that	  if	  EBV	  represses	  p15,	  this	  may	  also	  be	  an	  additional	  means	  of	  altering	  the	  
response	   to	  TGFβ,	   since	  p15	   is	  a	  known	  target	  of	  TGFβ	  whose	   induction	   in	  epithelial	   cells	  
results	  in	  growth	  arrest	  	  (Hannon	  and	  Beach	  1994,	  Reynisdottir	  et	  al.	  1995).	  
	  
qRT-­‐PCR	  was	   performed	   for	   CDKN2B	   (p15)	  mRNA	   expression	   in	   a	   panel	   of	   LCLs	   including	  
wild-­‐type,	   EBNA3B	   KO	   and	   revertant,	   and	   in	   the	   set	   of	   p16-­‐null	   3CHT-­‐LCLs	   under	   four	  
conditions	   as	   described	   in	   section	   6.2.5.	   This	   showed	   that	   in	   wild-­‐type,	   EBNA3B	   KO	   and	  
EBNA3B	   revertant	   LCLs,	   p15	   was	   repressed	   (fig.	   6.15A).	   However,	   in	   p16-­‐null	   3CHT-­‐LCL	  
grown	  with	  continued	  4HT,	  the	  repression	  was	  slightly	   less	  than	  for	  the	  wild-­‐type/EBNA3B	  
KO/revertant.	  For	  the	  other	  conditions	   in	  p16-­‐null	  3CHT-­‐LCLs,	  a	  marked	  de-­‐repression	  was	  
seen	  in	  the	  cells	  which	  had	  never	  been	  exposed	  to	  4HT	  and	  therefore	  EBNA3C.	  Cells	  which	  
had	  been	  initially	  exposed	  to	  4HT	  but	  it	  was	  then	  withdrawn,	  as	  well	  as	  those	  in	  which	  4HT	  
was	   not	   present	   initially	   but	   was	   subsequently	   added,	   had	   an	   intermediate	   level	   of	   de-­‐
repression	   (fig.	   6.15A).	   These	   findings	   suggest	   that	   EBNA3C	  does	   indeed	   repress	  p15.	   The	  
effects	   of	   TGFβ	   on	   induction	   of	   p15	   was	   then	   investigated	   in	   these	   same	   cell	   lines,	   by	  
treating	  with	  TGFβ1	  10ng/ml	  or	   vehicle	   alone	   for	   two	  hours	   and	   then	  harvesting	   for	  RNA	  
and	  protein.	  qRT-­‐PCR	  was	  performed	  for	  p15	  (CDKN2B),	  and	  in	  each	  case	  the	  results	  were	  
expressed	  as	  the	  fold	  change	  in	  p15	  expression,	  i.e.	  the	  ratio	  of	  the	  value	  after	  two	  hours’	  
treatment	  with	  TGFβ1	  or	  vehicle	  to	  that	  at	  time	  zero,	  untreated	  (fig.	  6.15B).	  This	  showed	  no	  
induction	  of	  p15	  by	  TGFβ	  treatment	  in	  any	  cell	  line.	  
	  
Hence	  even	   though	  EBNA3C	   represses	  p15,	  and	   thus	  p15	   is	  de-­‐repressed	  when	  cells	  have	  
never	  been	  exposed	  to	  EBNA3C,	  TGFβ	  does	  not	  induce	  p15	  expression	  even	  though	  in	  this	  
case	  it	  does	  induce	  pSMAD2.	  This	  suggests	  that,	  although	  induction	  of	  p15	  is	  an	  important	  
means	  of	  TGFβ-­‐induced	  growth	  arrest	   in	  epithelial	  cells	   (Reynisdottir	  et	  al.	  1995,	   Iavarone	  
and	  Massague	  1997),	  this	  does	  not	  appear	  to	  be	  a	  mechanism	  used	  in	  B	  cells.	  TGFβ	  does	  not	  




induce	   p15	   in	   BL	   cells	   [(Spender	   and	   Inman	   2009b)	   and	   fig.	   3.9].	   Furthermore,	   in	   LCLs	  
conditional	   for	  EBNA2	  and	  Myc,	   in	   the	  absence	  of	  EBNA2	  TGFβ	   induced	   Id3	  and	   junB	  and	  
caused	  growth	  arrest,	  without	   induction	  of	  p15	  or	  p21,	  suggesting	  that	  growth	  arrest	  also	  
occurs	  independently	  of	  p15	  in	  LCLs	  (Horndasch	  et	  al.	  2002).	  p15	  acts	  by	  inhibiting	  the	  cyclin	  
dependent	   kinase	   inhibitors	   CDK4	   and	   CDK6,	   leading	   to	   cell	   cycle	   arrest.	   However,	  
mutations	   of	   p15	   are	   found	   in	   many	   malignancies	   and	   in	   several	   cell	   types	   CDK4/CDK6	  
inhibition	  can	  occur	  via	  other	  mechanisms,	  hence	  induction	  of	  p15	  does	  not	  always	  occur	  in	  

















	   	  




































Figure	  6.15:	  p15INK4B	  is	  repressed	  by	  EBNA3C	  but	  is	  not	  induced	  by	  TGFβ	  in	  LCLs	  	  
(A)	  Baseline	  expression,	  without	  any	  TGFβ1	  treatment,	  of	  CDKN2B	  (p15INK4B)	  mRNA	  measured	  by	  qRT-­‐PCR	  in	  all	  
the	   LCLs	  as	   shown.	   (B)	   Expression	  of	   p15INK4B	   after	   treatment	  with	   TGFβ1	  10ng/ml	   or	   vehicle	   alone	   for	   two	  
hours	   in	   the	   set	   of	   LCLs	   shown,	   as	   in	   (A).	   Values	   are	   expressed	   as	   a	   ratio	   of	   the	   value	   after	   two	   hours’	  
treatment	  with	  TGFβ	  (blue)	  or	  vehicle	  (2mg/ml	  BSA	  in	  PBS,	  shown	  in	  red)	  to	  that	  at	  time	  zero,	  untreated,	  with	  
each	   value	   calculated	   as	   the	   ratio	   to	   the	   endogenous	   control	   gene	  GNB2L1.	   Error	   bars	   represent	   standard	  


















































































EBV	  represses	  TGFβR2	  in	  LCLs,	  leading	  to	  suppression	  of	  TGFβ	  signalling	  via	  pSMAD2	  	  
It	   was	   previously	   known	   that	   LCLs	   are	   resistant	   to	   some	   of	   the	   obvious	   effects	   of	   TGFβ	  
(Blomhoff	  et	  al.	  1987,	  Janssen	  et	  al.	  1990,	  Altiok	  et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  
1992,	  Altiok	  et	  al.	  1993,	  Inman	  and	  Allday	  2000b,	  Kenney	  et	  al.	  2001,	  Horndasch	  et	  al.	  2002),	  
and	   that	   TGFβR2	   is	  down-­‐regulated	   in	   LCLs	   (Kumar	  et	   al.	   1991,	   Inman	  and	  Allday	  2000b),	  
although	  other	  studies	  had	  not	  shown	  a	  reduction	  in	  TGFβR2	  (Horndasch	  et	  al.	  2002)	  or	  did	  
not	   specifically	   investigate	   TGFβR2	   expression	   (Altiok	   et	   al.	   1991,	   Altiok	   et	   al.	   1993).	   The	  
current	  study	  has	  confirmed	  the	  repression	  of	  TGFβR2	  at	  the	  mRNA	  level	  in	  established	  LCLs	  
(fig.	  6.1A)	  and	  also	  shown	  that	  EBV	  represses	  TGFβR2	  after	  infection	  of	  primary	  B	  cells	  with	  
EBV	  (fig.	  6.2),	  as	  well	  as	  showing	  that	  the	  repression	  leads	  to	  suppression	  of	  TGFβ	  signalling	  
via	  pSMAD2	  in	  LCLs	  (fig.	  6.1B).	  	  
	  
This	  study	  has	  also	  investigated	  which	  latent	  proteins	  are	  responsible	  for	  the	  repression	  of	  
TGFβR2.	  When	   EBNA3B	   is	   deleted,	   some	   de-­‐repression	   of	   TGFβR2	   is	   seen,	   both	   in	   stable	  
LCLs	   and	   after	   primary	   B	   cell	   infections	   (figs.	   6.3A-­‐B).	   However,	   the	   effect	   of	   EBNA3B	  
deletion	   on	   TGFβR2	   mRNA	   levels	   appears	   only	   moderate,	   in	   that	   TGFβR2	   expression	   in	  
EBNA3B	  KO	  LCLs	  remains	  very	  low	  compared	  to	  that	  in	  uninfected	  primary	  B	  cells	  (figs.	  6.3A-­‐
B).	   Nevertheless,	   deletion	   of	   EBNA3B	   leads	   to	   a	   clear	   increase	   in	   TGFβ-­‐induced	   pSMAD2,	  
suggesting	   that	   this	   apparently	   modest	   de-­‐repression	   of	   TGFβR2	   is	   sufficient	   to	   restore	  
signalling	  (fig.	  6.3C).	  
	  
Although	  EBNA3C	   is	   required	   to	   transform	  B	   cells	   to	   LCLs,	   and	  hence	   it	   is	   not	  possible	   to	  
establish	  EBNA3C	  KO	  LCLs	   in	   ‘normal’	  B	  cells,	   the	  effect	  of	  EBNA3C	  expression	  on	  TGFβR2	  
expression	   in	   LCLs	   could	   be	   investigated	   using	   a	   conditional	   EBNA3C-­‐modified	   oestrogen	  
receptor	   fusion	   protein	   system	   that	   depends	   on	   the	   presence	   of	   4HT	   in	   the	  medium	   for	  
EBNA3C	  function.	  When	  these	  cells	  (in	  a	  wild-­‐type	  p16	  B	  cell	  background)	  were	  established	  
with	  4HT,	   i.e.	  with	  EBNA3C	  present,	   TGFβR2	  was	   repressed,	   as	   expected	   since	   these	   cells	  
should	   be	   equivalent	   to	  wild-­‐type	   LCLs.	   However,	   surprisingly,	   when	   4HT	  was	  withdrawn	  
from	  these	  cells,	  after	  such	  time	  that	  EBNA3C	  would	  no	  longer	  be	  functional,	  the	  expression	  
of	  TGFβR2	  was	  unchanged	   (fig.	  6.4).	  There	  were	   two	  possible	  explanations	   for	   this:	  either	  
that	  EBNA3C	  does	  not	   contribute	   to	   the	   repression	  of	  TGFβR2	   in	   LCLs,	  unlike	   in	  BL31s,	  or	  




alternatively	  that	  the	  previous	  exposure	  to	  EBNA3C	  as	  the	  cells	  were	  becoming	  established	  
was	  able	  to	  maintain	  repression	  of	  TGFβR2	  even	  after	  EBNA3C	  was	  removed.	  	  	  	  
	  
Fortunately,	  at	   this	   time,	   colleagues	   in	   the	   laboratory	  had	  developed	  a	   similar	   conditional	  
system	  in	  which	  LCLs	  could	  be	  established	  in	  the	  absence	  of	  EBNA3C,	  by	  using	  B	  cells	  from	  
an	   individual	  deficient	   in	  p16.	  Using	  this	  system,	   the	  p16-­‐null	  3CHT-­‐LCL,	   it	  was	  possible	   to	  
demonstrate	  some	  de-­‐repression	  of	  TGFβR2	  in	  those	  cells	  which	  had	  never	  been	  exposed	  to	  
4HT,	  thus	  to	  functional	  EBNA3C,	  compared	  to	  those	  cells	  established	  with	  4HT	  (fig.	  6.5A-­‐B).	  
This	   de-­‐repression	   again	   appeared	   to	   be	   minimal,	   with	   overall	   expression	   of	   TGFβR2	  
remaining	   markedly	   lower	   than	   in	   primary	   B	   cells.	   However,	   this	   minimal	   level	   of	   de-­‐
repression	  again	  appeared	  to	  be	  sufficient	  to	  restore	  TGFβ	  signalling	  via	  pSMAD2	   in	  those	  
cells	  which	  had	  been	  established	  without	   4HT	   compared	   to	   those	   established	  with	   it	   (fig.	  
6.5D).	  	  Furthermore,	  it	  was	  observed	  that	  once	  the	  p16-­‐null	  3CHT-­‐LCL	  cells	  were	  established	  
with	  or	  without	  4HT,	  subsequent	  changing	  of	  growth	  conditions	  by	  addition	  or	  withdrawal	  
of	  4HT	  did	  not	  significantly	  alter	  TGFβR2	  expression	  or	  TGFβ	  signalling	  (fig.	  6.5C-­‐D).	  	  
	  
Taken	  together,	  these	  findings	  suggest	  that	  the	  presence	  of	  functional	  EBNA3C	  as	  LCLs	  are	  
established	  contributes	  to	  the	  repression	  of	  TGFβR2	  but,	  once	  established,	  the	  presence	  of	  
EBNA3C	   is	   no	   longer	   required	   to	  maintain	   the	   repression	   and	   consequent	   suppression	   of	  
signalling.	   EBNA3C	  has	   been	   shown	   to	  bind	   to	   the	  promoter	   regions	   of	   several	   repressed	  
genes,	  in	  association	  with	  repressive	  chromatin	  modifications	  (Skalska	  et	  al.	  2010,	  McClellan	  
et	  al.	  2012,	  Paschos	  et	  al.	  2012,	  Skalska	  et	  al.	  2013).	  Hence	  similar	  epigenetic	  mechanisms	  of	  
repression	   of	   TGFβR2,	   which	   are	   heritable	   to	   daughter	   cells,	   could	   explain	   why	   the	  
continued	   presence	   of	   EBNA3C	   is	   no	   longer	   required	   for	  maintenance	   of	   the	   repression.	  
Although	  H3K27Me3	  was	   increased	  on	   the	  TGFβR2	  promoter	   in	  wild-­‐type	  LCLs	   (fig.	  6.1D),	  
due	  to	  time	  constraints	  this	  was	  not	  investigated	  in	  the	  3CHT-­‐LCLs.	  However,	   investigation	  
of	   chromatin	   modifications	   at	   the	   TGFβR2	   could	   be	   performed	   in	   future	   in	   the	   p16-­‐null	  
3CHT-­‐LCLs	   established	  with	   4HT,	   compared	   to	   those	   established	  without	   4HT,	   in	   order	   to	  
confirm	  this	  epigenetic	  repression	  of	  TGFβR2	  by	  EBNA3C.	  
	  
Hence	  EBNA3B	  and	  EBNA3C	  both	  contribute	  to	  the	  repression	  of	  TGFβR2,	  which	  may	  occur	  
via	  epigenetic	  histone	  modifications,	   in	  LCLs	  as	   they	  do	   in	  BL31	  cells.	  This	   in	   turn	   leads	   to	  




suppression	  of	   TGFβ	   signalling.	  However,	   in	   contrast	   to	   the	  marked	   level	   of	   repression	  of	  
TGFβR2	  in	  wild-­‐type	  LCLs	  and	  BL31-­‐WT	  compared	  to	  uninfected	  BL31	  or	  primary	  B	  cells,	  the	  
contributions	   of	   EBNA3B	   and	   EBNA3C	   are	   very	   small	   in	   LCLs.	   This	   is	   in	   contrast	   to	   the	  
findings	   in	   BL31,	   where	   individual	   deletions	   of	   EBNA3B	   or	   EBNA3C	   lead	   to	   increases	   in	  
TGFβR2	   expression	   to	   approximately	   25%	   of	   the	   level	   seen	   in	   uninfected	   BL31	   cells	   (fig.	  
3.1A).	  Thus	   the	  contribution	  of	  both	  EBNA3B	  and	  EBNA3C	   to	   the	   repression	  of	  TGFβR2	   in	  
LCLs	  appears	  to	  be	  much	  more	  modest	  than	   in	  BL31	  cells.	  This	  also	  suggests	  that,	   in	  LCLs,	  
one	   or	   more	   other	   latent	   proteins	   (or	   possibly	   miRNAs)	   may	   be	   responsible	   for	   the	  
repression,	  probably	  having	  a	  greater	  effect	  than	  EBNA3B	  or	  EBNA3C.	  
	  
Since	   in	   BL31	   cells,	   LMP1	   and	   LMP2A	   appear	   to	   cooperate	  with	   EBNA3B	   and	   EBNA3C	   to	  
cause	  repression	  of	  TGFβR2,	  it	  is	  likely	  that	  one	  or	  both	  of	  these	  proteins	  also	  contributes	  to	  
repression	  of	  TGFβR2	   in	  LCLs.	  Unfortunately,	   it	  was	  not	  possible	  to	  produce	  viable	  LMP2A	  
KO	  LCLs	  in	  order	  to	  investigate	  this,	  although	  this	  should	  be	  possible	  and	  has	  been	  achieved	  
by	   other	   groups.	   This	   should	   be	   a	   priority	   for	   future	   work	   leading	   on	   from	   this	   project.	  
Nevertheless,	   investigation	   of	   TGFβR2	   after	   withdrawal	   of	   oestrogen	   in	   the	   conditional	  
oestrogen-­‐dependent	  EREB2.5	  cell	  line	  was	  suggestive	  of	  de-­‐repression	  of	  TGFβR2	  occurring	  
with	  decreasing	  expression	  of	  EBNA2,	  LMP1	  and	  LMP2A	  (fig.	  6.7).	  However,	  since	   in	  these	  
cells	  expression	  of	  all	  three	  latent	  proteins	  was	  reduced	  after	  oestrogen	  withdrawal,	  it	  is	  not	  
possible	  to	  conclude	  which	  specific	   latent	  protein(s)	   is/are	  responsible.	   In	  addition,	  due	  to	  
the	   nature	   of	   the	   EREB2.5	   cell	   line’s	   response	   to	   oestrogen	   withdrawal,	   it	   is	   difficult	   to	  
ascribe	  the	  changes	  in	  TGFβR2	  expression	  purely	  to	  changes	  in	  latent	  gene	  expression	  as	  the	  
cells	   undergo	   multiple	   changes	   after	   oestrogen	   withdrawal,	   reflected	   in	   the	   significant	  
variation	  of	  all	  endogenous	  control	  genes	  used.	  Also,	  the	  effect	  of	  oestrogen	  withdrawal	  on	  
expression/function	   of	   the	   EBNA3s	   could	   not	   be	   investigated	   in	   these	   cells,	   because	  
available	  antibodies	  do	  not	  recognise	  the	  EBNA3	  proteins	  (being	  derived	  from	  type	  2	  P3HR1	  
virus),	  hence	  it	  cannot	  be	  excluded	  that	  the	  de-­‐repression	  of	  TGFβR2	  was	  due	  to	  decreases	  
in	  expression	  of	  EBNA3B	  or	  EBNA3C.	  
	  
After	  primary	  B	  cell	   infection,	  TGFβR2	  expression	  was	  gradually	  reduced,	  reaching	  its	  nadir	  
at	   around	   21	   days	   post-­‐infection	   (fig.	   6.2).	   This	   timing	   is	   consistent	   with	   similar	   studies	  
performed	   by	   other	   laboratory	   members	   for	   BIM,	   Notch2,	   COBLL1,	   ADAM28	   and	  




ADAMDEC1	   expression	   after	   primary	   B	   cell	   infection	   [Lenka	   Skalska	   PhD	   thesis,	   Kostas	  
Paschos	  and	  Jens	  Kalchschmidt,	  unpublished	  data,	  and	  (Skalska	  et	  al.	  2013)].	  Furthermore,	  
in	  a	  microarray	  analysis	  comparing	  gene	  expression	  in	  uninfected	  B	  cells,	  proliferating	  blasts	  
at	   day	   6	   post-­‐infection	   and	   LCLs,	   Price	   et	   al	   found	   that	   TGFβR2	   was	   significantly	   down-­‐
regulated	  between	   the	  proliferating	  blasts	  and	  LCL	  stages,	   rather	   than	   from	  uninfected	   to	  
proliferating	  stages	  (Price	  et	  al.	  2012).	  	  
	  
A	   recent	  study	  has	  shown	  that	  LMP1	  expression	  at	  both	  mRNA	  and	  protein	   levels	  did	  not	  
reach	   steady	   state	  until	   day	   21	  but	   then	  was	   stable	   at	   that	   level	   up	   to	  day	  35,	  when	   the	  
experiment	  was	   terminated	   (Price	   et	   al.	   2012).	   In	   the	   current	   study,	   preliminary	   data	   on	  
mRNA	  expression	  of	  both	  LMP1	  and	  LMP2A	  showed	  a	   similar	  delay	   in	   reaching	  maximum	  
steady	  state	  levels.	  The	  expression	  of	  LMP1	  is	  therefore	  considerably	  delayed	  after	  primary	  
B	  cell	   infection,	   in	  comparison	  to	  EBNA2	  and	  the	  EBNA3s	  which	  are	  fully	  expressed	  within	  
the	   first	   few	   days	   after	   infection	   [Allday	   laboratory	   unpublished	   data	   and	   (Nikitin	   et	   al.	  
2010)].	  Although	   the	  onset	  of	  expression	  of	   LMP2A	  during	  B	   cell	   transformation	  does	  not	  
appear	  to	  have	  been	  previously	  investigated,	  it	  is	  conceivable	  that	  this	  has	  a	  similar	  delay	  in	  
reaching	  full	  expression,	  as	  found	  in	  preliminary	  data	  in	  the	  current	  study.	  	  	  	  
	  
Therefore	  the	  delay	  in	  expression	  of	  LMP1	  and	  LMP2A,	  if	  either	  or	  both	  do	  also	  contribute	  
to	  the	  repression	  of	  TGFβR2	  in	  LCLs,	  may	  partly	  explain	  why	  the	  repression	  is	  not	  maximal	  
until	   around	   21	   days	   post-­‐infection.	   A	   recent	   microarray	   analysis	   in	   splenic	   B	   cells	   also	  
suggested	   that	   LMP2A	   down-­‐regulates	   TGFβR2	   (Shair	   and	   Raab-­‐Traub	   2012).	   To	   further	  
investigate	  the	  contributions	  of	  LMP1	  and	  LMP2A	  to	  TGFβR2	  expression	  in	  LCLs,	  this	  could	  in	  
future	  be	   investigated	  using	  LCLs	  established	  by	  the	  Kempkes	  group	  which	  are	  conditional	  
for	   both	   EBNA2	   expression	   and	   c-­‐Myc	   expression,	   so	   that	   cell	   proliferation	   can	   be	  
maintained	  even	  when	  EBNA2	  is	  withdrawn	  (Horndasch	  et	  al.	  2002).	  Other	  possible	  means	  
of	  investigation	  could	  include	  using	  siRNA	  or	  anti-­‐sense	  to	  LMP1	  or	  LMP2A,	  such	  as	  the	  anti-­‐
sense	  to	  LMP1	  used	  by	  Kenney	  et	  al	  (Kenney	  et	  al.	  1998,	  Kenney	  et	  al.	  2001).	  
	  
The	  effects	  of	  down-­‐regulation	  of	  TGFβR2	  in	  LCLs	  
The	  down-­‐regulation	  of	  TGFβR2	   in	  wild-­‐type	  LCLs	   results	   in	  suppression	  of	  TGFβ	  signalling	  
via	   pSMAD2	   (figs.	   6.1A-­‐B).	   In	   the	   EBNA3B	   KO	   LCLs	   and	   p16-­‐null	   3CHT-­‐LCLs	   established	  




without	   4HT,	   TGFβR2	  was	   only	   slightly	   de-­‐repressed,	  with	   expression	   remaining	   generally	  
low	   compared	   to	   the	  expression	   level	   in	  uninfected	  B	   cells	   or	  BL31	   cells	   (figs.	   6.3A-­‐B	   and	  
6.5A-­‐C).	  However,	  this	  apparent	  slight	  de-­‐repression	  of	  TGFβR2	  led	  to	  a	  definite	  increase	  in	  
TGFβ	  signalling	  via	  pSMAD2	  (figs.	  6.3C	  and	  6.5D).	  The	  reason	  for	  this	  apparent	  discrepancy	  
between	  the	  expression	  of	  TGFβR2	  and	  the	  degree	  of	  pSMAD2	   is	  not	  clear,	  but	   it	  may	  be	  
that	  a	  particular	  threshold	  of	  TGFβR2	  expression	  has	  to	  be	  reached	  for	  signalling	  to	  occur.	  It	  
was	   considered	   whether	   the	   concomitant	   up-­‐regulation	   of	   TGFβR3	   could	   itself	   augment	  
TGFβ	   signalling,	   so	   that	   TGFβ	   signalling	   can	   occur	   even	   with	   low	   expression	   of	   TGFβR2.	  
However,	  in	  the	  EBNA3B	  KO	  LCLs	  and	  the	  3CHT-­‐LCLs	  established	  without	  4HT,	  where	  slight	  
de-­‐repression	   of	   TGFβR2	   was	   seen	   but	   signalling	   was	   restored,	   TGFβR3	   was	   not	   up-­‐
regulated,	  excluding	  this	  as	  a	  possibility.	  	  
	  
In	  addition,	  wild-­‐type	  B95.8-­‐derived	  LCLs	  are	  resistant	  to	  apoptosis	  and	  cell	  cycle	  arrest	  with	  
TGFβ	  treatment	  (fig.	  6.14),	  as	  had	  been	  previously	  shown	  (Blomhoff	  et	  al.	  1987,	  Janssen	  et	  
al.	  1990,	  Altiok	  et	  al.	  1991,	  Kumar	  et	  al.	  1991,	  Altiok	  et	  al.	  1992,	  Altiok	  et	  al.	  1993,	   Inman	  
and	  Allday	  2000b,	  Kenney	  et	  al.	  2001,	  Horndasch	  et	  al.	  2002).	  The	  effects	  of	  TGFβ	  on	  the	  cell	  
cycle	  were	  not	   investigated	   in	   the	  EBNA3B	  KO	  and	  3CHT-­‐LCLs,	  but	   it	  would	  be	   interesting	  
see	  whether	   the	   restoration	  of	   signalling	  seen	   in	   these	  cells	  would	   result	   in	  TGFβ-­‐induced	  
apoptosis	   or	   growth	   inhibition.	   However,	   as	   discussed	   for	   BL31s	   in	   chapter	   5,	   the	   link	  
between	   pSMAD2	   and	   the	   effects	   of	   TGFβ	   (i.e.	   apoptosis/growth	   arrest)	   appear	   to	   be	  
indirect,	  and	  it	   is	  possible	  that	  pSMAD3	  is	  more	  important	  for	  apoptosis	  even	  in	  B	  cells,	  as	  
has	   been	   shown	   for	   epithelial	   cells;	   unfortunately	   pSMAD3	   was	   not	   investigated	   in	   this	  
study.	  	  	  
	  
The	  effects	   of	   EBNA2	  expression	  on	  TGFβ	   responses	  have	  been	  previously	   investigated	   in	  
LCLs	  using	  an	  LCL	  with	  conditional	  expression	  of	  both	  EBNA2	  and	  Myc;	  in	  this	  way	  the	  cells	  
are	  able	  to	  continue	  growing	  even	  in	  the	  absence	  of	  EBNA2.	  When	  EBNA2	  was	  expressed,	  
the	  cells	  became	   resistant	   to	  TGFβ-­‐induced	  growth	   inhibition,	  although	  no	  difference	  was	  
seen	  in	  the	  cell	  cycle	  profiles	  between	  those	  with	  and	  without	  EBNA2,	  so	  the	  mechanism	  of	  
the	   resistance	   to	   TGFβ–induced	   growth	   inhibition	   was	   not	   clear.	   The	   effect	   of	   TGFβ	   on	  
several	  target	  genes	  was	  also	  investigated,	  and	  although	  neither	  p15	  nor	  p21	  were	  induced	  
in	  these	  cells	  under	  any	  condition,	  Id3	  was	  induced	  by	  TGFβ.	  However,	  there	  was	  no	  effect	  




of	   the	  presence	  or	  absence	  of	  EBNA2	  on	   the	   level	  of	   Id3	   induction	  by	  TGFβ.	   	  The	  authors	  
concluded	  that	  the	  presence	  of	  EBNA2	  made	  cells	  resistant	  to	  the	  growth-­‐inhibitory	  effects	  
of	  TGFβ,	  although	  signalling	   (as	  detected	  by	   Id3	   induction)	   still	  occurred	   (Horndasch	  et	  al.	  
2002).	  This	  suggests	  that	  TGFβ	  signalling	  is	  not	  directly	  linked	  to	  its	  growth	  inhibitory	  effects,	  
as	  discussed	  for	  BL31s	  in	  chapter	  5.	  	  
	  
EBV	  also	  up-­‐regulates	  TGFβR3	  in	  LCLs	  
This	  study	  demonstrated	  that	  EBV	  also	  up-­‐regulates	  TGFβR3	  in	  BL31	  cells,	  and	  that	  in	  many	  
cases	   the	   expression	   of	   TGFβR3	   and	   TGFβR2	   appears	   to	   be	   reciprocally	   regulated	   (see	  
chapters	   3	   and	   4).	   Therefore	   the	   expression	   of	   TGFβR3,	   and	   the	   relationship	   between	  
expression	  of	  TGFβR2	  and	  TGFβR3,	  were	  investigated	  in	  LCLs.	  This	  confirmed	  that	  EBV	  does	  
up-­‐regulate	  TGFβR3	  also	   in	  LCLs	   (fig.	  6.8B).	  Although	  after	  primary	  B	   infections,	  TGFβR2	   is	  
repressed	  and	  TGFβR3	  is	  up-­‐regulated	  by	  EBV,	  the	  timing	  of	  these	  changes	  is	  different,	  and	  
it	  was	   surprising	   to	   see	   that	  TGFβR3	  was	   in	   fact	   initially	  down-­‐regulated	  before	  being	  up-­‐
regulated	  later,	  and	  much	  more	  slowly,	  after	  infection	  (fig.	  6.8B).	  Thus	  the	  up-­‐regulation	  of	  
TGFβR3	  occurs	  later	  than	  the	  down-­‐regulation	  of	  TGFβR2.	  
	  
The	  role	  of	  individual	  latent	  proteins	  in	  the	  up-­‐regulation	  of	  TGFβR3	  was	  also	  investigated.	  
EBNA3B	  and	  EBNA3C	  apparently	  cooperate	  in	  this,	  to	  a	  greater	  extent	  for	  the	  up-­‐regulation	  
of	   TGFβR3	   than	   for	   the	   down-­‐regulation	   of	   TGFβR2	   (figs.	   6.9,	   6.10	   and	   6.11).	   The	  
involvement	  of	  LMP1,	  LMP2A	  or	   indeed	  EBNA2	  in	  these	  changes	  in	  LCLs	  could	  not	  be	  fully	  
ascertained	  due	  to	  the	   limitations	  described	  above	  (section	  6.3.4).	  Since	  the	  up-­‐regulation	  
of	  TGFβR3	  occurred	   later	   than	   the	  down-­‐regulation	  of	  TGFβR2,	   this	   suggests	   that	  TGFβR2	  
and	  TGFβR3	  are	  not	  directly	  reciprocally	  regulated,	  at	   least	   in	  LCLs.	   It	   is	  possible	  that	  once	  
TGFβR2	  expression	  falls	  below	  a	  threshold,	  then	  TGFβR3	  is	  up-­‐regulated.	  	  
	  
In	  the	  p16-­‐null	  3CHT-­‐LCLs,	  the	  up-­‐regulation	  of	  TGFβR3	  depends	  on	  the	  presence	  of	  4HT	  in	  
the	   medium,	   i.e.	   the	   continued	   presence	   of	   EBNA3C	   is	   required	   for	   the	   maintenance	   of	  
TGFβR3	  up-­‐regulation	  (figs.	  6.10	  and	  6.11).	   In	  addition,	  after	  4HT	   is	  withdrawn	  from	  these	  
cells,	  TGFβR3	  expression	  decreases	  quickly,	  with	  expression	  similar	  5	  days	  after	  withdrawal	  
to	   that	   at	   33	   days,	   whereas	   following	   addition	   of	   4HT,	   the	   expression	   is	   only	   slightly	  
increased	  by	  5	  days	  but	  more	  so	  at	  33	  days	  (fig.	  6.10B).	  Therefore,	  4HT	  is	  slower	  to	  induce	  




TGFβR3	   than	   its	   withdrawal	   is	   to	   decrease	   it.	   In	   3CHT-­‐LCLs,	   EBNA3C	   expression	   was	   not	  
significantly	   decreased	   until	   7	   days	   after	   withdrawal,	   but	   significant	   amounts	   were	   again	  
expressed	   just	   one	   day	   after	   re-­‐addition	   (Skalska	   et	   al.	   2010),	   and	   thus	   the	   difference	   in	  
timings	  of	  TGFβR3	  expression	  upon	  addition	  or	  withdrawal	  of	  4HT	  are	  not	  due	  to	  variations	  
in	  time	  to	  alter	  EBNA3C	  expression.	  	  
	  
Once	  LCLs	  were	  established	  in	  the	  presence	  of	  4HT,	  and	  thus	  EBNA3C,	  this	  led	  to	  repression	  
of	   TGFβR2,	   which	   was	   not	   reversed	   even	   if	   4HT	   (functional	   EBNA3C)	   was	   subsequently	  
withdrawn	  (figs.	  6.4	  and	  6.5A-­‐C).	  This	  contrasts	  with	  the	  regulation	  of	  TGFβR3	  in	  these	  cells,	  
where	  TGFβR3	  expression	   is	  altered	  fairly	   rapidly	  according	  to	  the	  presence	  or	  absence	  of	  
4HT,	   with	   the	   withdrawal	   of	   4HT	   in	   particular	   leading	   to	   a	   fairly	   rapid,	   near	   maximal,	  
decrease	   in	   TGFβR3	  expression	   even	  before	   EBNA3C	  expression	  has	   been	   completely	   lost	  
(fig.	  6.10).	  
	  
There	  are	  several	  possible	  mechanisms	  for	  the	  up-­‐regulation	  of	  TGFβR3	   in	  LCLs;	   these	  will	  
be	  discussed	  in	  turn.	  Firstly,	  this	  could	  be	  a	  clonal	  selection	  process.	  This	  may	  be	  suggested	  
by	  the	  very	  gradual	  increase	  over	  a	  ten-­‐week	  period	  after	  initial	  infection	  of	  primary	  B	  cells,	  
and	  the	  fact	  that	  down-­‐regulation	  of	  TGFβR3	  is	  seen	  over	  the	  first	  few	  days	  post-­‐infection.	  
In	  further	  support	  of	  this	  clonal	  selection,	  a	  lack	  of	  up-­‐regulation	  of	  TGFβR3,	  despite	  TGFβR2	  
down-­‐regulation,	  was	  seen	  by	  day	  42	  in	  one	  particular	  experiment	  in	  which	  primary	  B	  cells	  
were	  infected	  with	  EBNA3B	  revertant	  (see	  figure	  7.10C).	  However,	  the	  fact	  that	  TGFβR3	  up-­‐
regulation	  occurred	  consistently	  in	  the	  majority	  of	  experiments	  in	  LCLs,	  and	  was	  consistent	  
in	   BL31s,	   suggests	   that	   if	   this	   is	   a	   clonal	   selection	   process	   then	   there	   must	   be	   highly	  
favourable	  conditions	  for	  this	  to	  develop.	  	  
	  
The	  functions	  of	  TGFβR3	  in	  B	  cells	  are	  not	  completely	  understood,	  and	  although	  in	  certain	  
contexts	   it	   can	   inhibit	   TGFβ	   signalling,	   it	   generally	   serves	   to	   enhance	   signalling.	   It	   has	  
tumour	   suppressor	   properties,	   with	   loss	   of	   expression	   occurring	   in	   many	   non-­‐
haematopoietic	  malignancies	  (Florio	  et	  al.	  2005,	  Dong	  et	  al.	  2007,	  Hempel	  et	  al.	  2007,	  Turley	  
et	  al.	  2007,	  Finger	  et	  al.	  2008b,	  Gordon	  et	  al.	  2008,	  Margulis	  et	  al.	  2008,	  Cooper	  et	  al.	  2010),	  
and	  has	  more	  recently	  been	  shown	  to	  be	  tumour	  suppressive	  in	  multiple	  myeloma	  cell	  lines	  
(Lambert	  et	  al.	  2011);	  however,	  its	  expression	  is	  increased	  in	  CLL	  cells	  compared	  to	  normal	  B	  




cells,	   although	   the	   reason	   for	   this	   is	   not	   known	   (Klein	   et	   al.	   2001,	   Jelinek	   et	   al.	   2003).	   In	  
addition,	   it	   is	   essential	   for	   haematopoiesis,	   although	   its	   exact	   functions	   in	   this	   are	   not	  
known	   (Stenvers	   et	   al.	   2003).	   	   Since	   it	   is	   required	   for	   signalling	   by	   TGFβ2	   (Stenvers	   et	   al.	  
2003),	  and	  also	  enhances	  signalling	  by	  activins/inhibins,	   it	   is	  possible	  that	   its	  up-­‐regulation	  
may	  provide	  a	  selective	  advantage	  due	  to	  the	  effects	  of	  one	  of	  these	  ligands.	  	  
	  
EBNA3B	  and	  EBNA3C	  seem	  to	  be	  very	  clearly	  necessary	  for	  the	  up-­‐regulation	  of	  TGFβR3	  so	  
this	  does	  not	  entirely	  fit	  with	  a	  clonal	  selection	  process	  –	  unless	  they	  are	  necessary,	  instead,	  
for	   an	   unknown	   intermediate	   event	   which	   itself	   strongly	   predisposes	   to	   TGFβR3	   up-­‐
regulation.	   Furthermore,	   TGFβR3	   expression	   continues	   to	   vary	   with	   the	   addition	   and	  
removal	   of	   4HT	   in	   p16-­‐null	   3CHT-­‐LCLs	   (figs.	   6.10	   and	   6.11),	   suggesting	   a	   direct	   effect	   of	  
EBNA3C	  on	  TGFβR3	  expression,	  and	  hence	  not	  entirely	  consistent	  with	  the	  hypothesis	  that	  
this	  is	  a	  clonal	  selection	  process.	  	  
	  
The	  second	  possibility	   is	   the	  relief	  of	  TGFβ1-­‐mediated	  repression	  of	  TGFβR3,	  as	  suggested	  
by	  the	  de-­‐repression	  of	  TGFβR3	  upon	  treatment	  of	  EBV-­‐negative	  BL31	  cells	  with	  the	  TGFβR1	  
inhibitor	   SB431542	   (see	   chapter	   3,	   fig.	   3.13).	   If	   this	   were	   the	   case	   in	   LCLs,	   then	   the	  
repression	   of	   TGFβR2	   in	   wild-­‐type	   LCLs,	   leading	   to	   suppression	   of	   TGFβ	   signalling	   via	  
pSMAD2	   (fig.	   6.1A-­‐B),	   would	   block	   the	   TGFβ1-­‐mediated	   repression	   of	   TGFβR3	   and	   hence	  
lead	  to	  up-­‐regulation	  of	  TGFβR3.	  Thus,	  after	  primary	  B	  cell	  infection,	  TGFβR3	  would	  not	  be	  
de-­‐repressed	  until	  TGFβR2	  repression	  reaches	  a	  level	  at	  which	  TGFβ	  signalling	  is	  suppressed	  
enough	  to	  block	  the	  TGFβ1-­‐mediated	  repression	  of	  TGFβR3.	  This	  could	  explain	  why	  the	  up-­‐
regulation	  of	  TGFβR3	  does	  not	  occur	  until	  after	  the	  down-­‐regulation	  of	  TGFβR2	  (fig.	  6.8).	  In	  
addition,	   in	   EBNA3B	   KO	   LCLs	   and	   p16-­‐null	   3CHT-­‐LCLs	   established	   without	   4HT,	   in	   which	  
TGFβR2	   is	   slightly	   de-­‐repressed	   compared	   to	   wild-­‐type,	   and	   in	   which	   this	   is	   sufficient	   to	  
restore	   TGFβ	   signalling	   via	   pSMAD2	   (figs.	   6.3	   and	   6.5),	   TGFβ1-­‐mediated	   repression	   of	  
TGFβR3	  would	  still	  occur	  and	  hence	  TGFβR3	  remains	  repressed.	  Furthermore,	  since	  TGFβ1	  
and	   TGFβR1	   expression	   were	   not	   significantly	   altered	   after	   primary	   B	   cell	   infection	   (fig.	  
6.13),	  the	  main	  variable	  affecting	  the	  TGFβR3	  expression	  after	  primary	  B	  cell	  infection	  would	  
be	   the	  presence	  of	  TGFβ	  signalling	   through	  TGFβR2.	  This	  could	  also	  be	  an	  explanation	   for	  
why	  EBNA3B	  and	  EBNA3C	  seem	  to	  be	  more	  clearly	  involved	  in	  the	  up-­‐regulation	  of	  TGFβR3	  




than	   the	   down-­‐regulation	   of	   TGFβR2,	   i.e.	   that	   the	   TGFβR3	   expression	   is	   related	   to	   the	  
degree	  of	  TGFβ	  signalling,	  rather	  than	  to	  the	  expression	  of	  TGFβR2	  itself.	  	  
	  
However,	   in	   p16-­‐null	   3CHT-­‐LCLs	   established	   with	   4HT,	   TGFβR2	   remains	   repressed,	   with	  
suppression	  of	  TGFβ	  signalling,	  even	  when	  4HT	   is	  subsequently	  withdrawn	  (fig.	  6.4C).	  This	  
would	  be	  expected	   to	  produce	   continued	  de-­‐repression	  of	   TGFβR3,	   i.e.	   TGFβR3	  would	  be	  
up-­‐regulated	   in	   these	   cells	   regardless	   of	   whether	   4HT	   was	   continued	   or	   withdrawn.	  
However,	  this	  is	  not	  the	  case,	  as	  TGFβR3	  expression	  continues	  to	  vary	  with	  the	  presence	  or	  
absence	  of	  4HT,	  and	  thus	  EBNA3C,	  even	  though	  TGFβR2	  does	  not	  vary	  in	  this	  way.	  Therefore	  
the	   findings	   in	   the	   p16-­‐null	   3CHT-­‐LCLs	   established	   without	   4HT	   do	   not	   fit	   with	   the	  
hypothesis	  of	  TGFβ1-­‐mediated	  repression	  of	  TGFβR3.	  	  
	  
A	   third	  mechanism	   is	   that	   the	   up-­‐regulation	   of	   TGFβR3	   by	   EBV	   occurs	   directly,	   i.e.	   is	   not	  
dependent	   on	   TGFβR2	   expression.	   This	   is	   suggested	   by	   the	   fairly	   rapid	   and	   continued	  
variation	  of	  TGFβR3	  expression	   in	  p16-­‐null	  3CHT-­‐LCLs	  as	  4HT	   is	  added	  or	  withdrawn	   from	  
the	  medium	  (figs.	  6.10	  and	  6.11).	  However,	  if	  this	  were	  a	  direct	  effect	  of	  EBV	  (EBNA3C)	  on	  
TGFβR3	  transcription,	  then	  it	  is	  not	  clear	  why	  the	  process	  of	  TGFβR3	  up-­‐regulation	  occurs	  so	  
slowly	   after	   primary	   B	   cell	   infection	   (fig.	   6.8).	   It	   is	   also	   possible	   that	   EBV	   up-­‐regulates	  
TGFβR3	   directly	   via	   epigenetic	  mechanisms	   in	   LCLs,	   in	   a	   similar	  way	   to	   that	   suggested	   in	  
BL31	  cells	  by	   the	  variation	   in	  histone	  modifications	  at	   the	  proximal	  TGFβR3	  promoter	   (fig.	  
3.12),	  although	  this	  has	  not	  been	  investigated	  in	  3CHT-­‐LCLs.	  TGFβR3	  has	  been	  shown	  to	  be	  
de-­‐repressed	  by	   treatment	  with	  TSA	  and	  azacytidine,	   suggesting	   it	   is	  epigenetically	  down-­‐
regulated,	  in	  prostate	  and	  ovarian	  cancer	  (Hempel	  et	  al.	  2007,	  Turley	  et	  al.	  2007).	  	  	  
	  
A	   fourth	   possible	  mechanism	   for	   the	   up-­‐regulation	   of	   TGFβR3	   is	   that	   the	   suppression	   of	  
TGFβ	  signalling	   leads	   the	  cell	   to	   increase	  TGFβR3	   in	  order	   to	   try	   to	   restore	  signalling.	  This	  
could	  occur	  if	  there	  was	  an	  advantage	  to	  the	  cells	  having	  intact	  TGFβ	  signalling	  in	  vitro,	  and	  
thus	  the	  cellular	  response	  to	  lack	  of	  TGFβR2	  and	  consequent	  lack	  of	  signalling	  would	  be	  to	  
up-­‐regulate	   its	   TGFβR3	   in	   order	   to	   try	   to	   augment	   signalling	   from	   any	   remaining	   TGFβR2	  
receptors.	  However,	  there	  is	  no	  evidence	  that	  this	  occurs	  in	  other	  cell	  types,	  for	  instance	  in	  
solid	  tumours/epithelial	  cells	  where	  TGFβR2	  is	  mutated	  or	  repressed	  there	  are	  no	  reports	  of	  
up-­‐regulation	  of	  TGFβR3.	  Furthermore,	   it	   is	   likely	  to	  be	  an	  advantage	  to	  cells	   in	  culture	  to	  




become	  resistant	  to	  TGFβ	  signalling	  which	  could	  otherwise	  limit	  their	  proliferation.	  Also,	  this	  
mechanism	  again	  does	  not	  really	  fit	  with	  the	  findings	  of	  variation	  of	  TGFβR3	  expression	  with	  
presence/absence	  of	  4HT	  in	  3CHT-­‐LCLs.	  	  
	  
Therefore,	  no	  single	  mechanism	  for	  the	  up-­‐regulation	  of	  TGFβR3	  by	  EBV	  appears	  to	  fit	  with	  
all	  the	  findings	  in	  the	  current	  study.	  Nevertheless,	  it	  is	  possible	  that	  a	  combination	  of	  these	  
mechanisms	  may	  occur,	  for	  instance	  the	  TGFβ1-­‐mediated	  repression	  of	  TGFβR3	  occurs	  but	  
there	  is	  an	  additional	  direct	  effect	  of	  EBNA3C	  on	  TGFβR3	  transcription.	  	  	  
	  
As	  discussed	  in	  chapter	  3	  and	  above,	  the	  consequences	  of	  the	  up-­‐regulation	  of	  TGFβR3	  by	  
EBV	  are	  not	  known;	  however,	  one	  possibility	  is	  that	  this	  promotes	  or	  inhibits	  BMP	  signalling.	  
This	  will	  be	  investigated	  in	  the	  next	  chapter,	  chapter	  7.	  
	  
In	  LCLs,	  EBNA3C	  represses	  p15INK4B;	  however,	  TGFβ	  does	  not	  induce	  its	  expression	  in	  LCLs	  
In	  this	  study,	  the	  expression	  of	  p15INK4B	  (referred	  to	  hereafter	  as	  p15)	  was	  also	  investigated	  
in	   LCLs,	   since	  preliminary	   investigations	  by	   colleagues	   in	   the	   laboratory	  had	   revealed	   that	  
EBNA3C	   binds	   to	   the	   promoter	   region	   of	   p15	   (Skalska	   et	   al.	   2013).	   It	   was	   therefore	  
hypothesised	  that	  by	  repressing	  p15	  in	  LCLs,	  EBV	  would	  prevent	  TGFβ-­‐mediated	  induction	  of	  
p15,	  which	   is	  a	  mechanism	  for	  TGFβ-­‐induced	  growth	  arrest	   in	  epithelial	  cells	   (Hannon	  and	  
Beach	   1994).	   This	   study	   confirmed	   that	   p15	   is	   repressed	   in	   wild-­‐type	   LCLs,	   with	   de-­‐
repression	  in	  p16-­‐null	  3CHT-­‐LCLs	  which	  have	  never	  been	  exposed	  to	  4HT	  and	  hence	  EBNA3C	  
(fig.	  6.15A).	  However,	  even	  in	  the	  cell	  lines	  where	  total	  p15	  was	  de-­‐repressed,	  there	  was	  no	  
induction	  of	  p15	  by	  TGFβ	  treatment	  (fig.	  6.15B).	  p15	  was	  similarly	  not	   induced	  by	  TGFβ	  in	  
BL31	   cells,	   when	   pSMAD2,	   Id1	   and	   Id2	  were	   all	   induced	   (fig.	   3.9).	   This	   is	   consistent	  with	  
previous	   findings	   in	   B	   cells,	   in	   which	   TGFβ	   generally	   does	   not	   induce	   p15,	   and	   the	  
mechanism	   of	   TGFβ-­‐induced	   growth	   arrest	   is	   different	   from	   that	   in	   epithelial	   cells	  
(Horndasch	  et	  al.	  2002,	  Spender	  and	   Inman	  2009b).	  Thus	   the	  TGFβ-­‐mediated	   induction	  of	  
p15	  may	  be	  specific	  to	  epithelial	  cells.	  
	  
In	  EBV-­‐negative	  BL31	  cells,	  p15	  expression	  was	  completely	  repressed,	  but	  was	  up-­‐regulated	  
by	  EBV	   (fig.	   3.9).	  Despite	   the	  up-­‐regulation	  by	  EBV	   in	  BL31	   cells,	  no	   induction	  of	  p15	  was	  
seen	  in	  response	  to	  TGFβ	  (fig.	  3.9);	  this	  would	  be	  consistent	  with	  the	  repression	  of	  TGFβR2	  




and	   suppression	   of	   TGFβ	   signalling	   by	   EBV.	   It	   has	   been	   reported	   that	   the	   p15	   promoter	  
often	  shows	  CpG	  methylation,	  consistent	  with	  gene	  silencing,	   in	  BLs	   (Klangby	  et	  al.	  1998).	  
Therefore	  EBV	  infection	  seems	  to	  de-­‐repress	  p15	  in	  BL31	  cells,	  but	  the	  effect	  of	  this	   is	  not	  
known.	  	  
	  
The	  effect	  of	  EBV	  on	  p15	  expression	  is	  therefore	  completely	  different	  in	  BL31	  cells	  and	  LCLs,	  
since	   EBV	   up-­‐regulates	   (or	   de-­‐represses)	   p15	   in	   BL31	   cells,	   yet	   represses	   it	   in	   LCLs.	  
Nevertheless,	  future	  work	  could	  investigate	  the	  apparent	  repression	  of	  p15	  by	  EBNA3A	  and	  
EBNA3C	  in	  LCLs,	  since	  these	  same	  latent	  proteins	  are	  already	  known	  to	  repress	  p16	  and	  thus	  
this	  could	  be	  another	  mechanism	  by	  which	  EBV	  promotes	  lymphomagenesis.	  	  





 	  	  	  The	   effects	   of	   EBV	   on	   BMP	   signalling	   and	   its	   canonical	  Chapter	  7
receptor-­‐mediated	  SMADs	  in	  B	  cells	  
7.1	  Introduction	  
BMP	  signalling	  pathways	  are	  considerably	  more	  diverse	  than	  TGFβ	  signalling,	  involving	  four	  
type	  I	  and	  three	  type	  II	  receptors,	  in	  contrast	  to	  one	  of	  each	  in	  the	  TGFβ	  signalling	  pathway.	  
There	  are	  also	  at	   least	  20	  different	   ligands	   for	  BMP	  receptors.	  At	   the	  start	  of	   this	  project,	  
relatively	  little	  was	  known	  about	  the	  effects	  of	  BMPs	  in	  lymphoid	  cells.	   It	  had	  been	  shown	  
that	  BMP6	  inhibits	  proliferation	  of	  human	  peripheral	  blood	  naïve	  and	  memory	  B	  cells	  that	  
had	  been	  stimulated	  to	  proliferate	  by	  treatment	  with	  anti-­‐IgM	  alone	  or	  with	  CD40L,	  as	  well	  
as	  in	  the	  EBV-­‐negative	  BL	  line	  Ramos	  (Kersten	  et	  al.	  2005).	  BMP6	  also	  inhibits	  proliferation	  
of	   bone	   marrow	   normal	   human	   B	   cell	   progenitor	   cells	   in	   vitro	   (Kersten	   et	   al.	   2006).	   In	  
addition,	   several	   BMP	   ligands	   are	   pro-­‐apoptotic	   or	   anti-­‐proliferative	   in	   myeloma	   cells	  
(Kawamura	  et	  al.	  2000,	  Hjertner	  et	  al.	  2001,	  Ro	  et	  al.	  2004,	  Fukuda	  et	  al.	  2006b,	  Seckinger	  et	  
al.	  2009).	  However,	  the	  effects	  of	  BMPs	  in	  other	  malignant	  B	  cell	  disorders	  or	  EBV-­‐infected	  B	  
cells	  were	  not	  known.	  
	  
BMP	  signalling	   is	   closely	   related	   to	  TGFβ	  signalling,	  and	   the	  current	   study	  has	   shown	   that	  
EBV	   up-­‐regulates	   TGFβR3,	   which	   is	   also	   a	   co-­‐receptor	   for	   BMP	   signalling.	   Thus	   it	   was	  
hypothesised	   that	   the	  up-­‐regulation	  of	  TGFβR3	  by	  EBV	  may	  alter	  BMP	  signalling,	  and	   that	  
this	  may	  in	  turn	  lead	  to	  tumour-­‐promoting	  effects.	  Therefore,	  in	  this	  chapter,	  the	  effects	  of	  
EBV	  on	  BMP	  signalling	  and	  expression	  of	  some	  of	  its	  components	  were	  investigated.	  	  
	  
7.2	  The	  effects	  of	  EBV	  on	  BMP	  signalling	  and	  its	  effectors	  in	  BL31	  cells	  	  
7.2.1	  In	  BL31	  cells,	  latent	  EBV	  leads	  to	  increased	  signalling	  in	  response	  to	  BMP2,	  BMP4	  and	  
BMP6	  but	  not	  BMP7	  or	  BMP9	  	  
TGFβR3	   directly	   binds	  multiple	   ligands,	   including	   BMP2,	   BMP4	   and	   BMP7,	   and	   facilitates	  
their	  binding	  to	  the	  relevant	  type	  II	  receptors,	  therefore	  enhancing	  BMP	  signalling	  (Gatza	  et	  
al.	   2010).	   It	   has	   also	   been	   shown	   that	   TGFβR3	   presents	   BMP2	   to	   the	   type	   I	   receptors	  
BMPRIA	   or	   BMPRIB,	   increasing	   signalling	   by	   BMP2	   (Kirkbride	   et	   al.	   2008).	   Conversely,	  
inhibin,	  an	   inhibitor	  of	  BMP	  signalling,	   requires	  TGFβR3	  for	  binding	  to	   its	   type	   II	   receptors	  





activin	  receptor	  II	  and	  BMPR2	  (Gatza	  et	  al.	  2010).	  Hence	  theoretically	  the	  up-­‐regulation	  of	  
TGFβR3	   could	   also	   result	   in	   enhanced	   inhibition	   of	   BMP	   signalling.	   It	   was	   therefore	  
hypothesised	   that,	  as	  a	  consequence	  of	  up-­‐regulating	  TGFβR3	  expression,	  EBV	  might	  alter	  
BMP	  signalling.	  	  
	  
Uninfected	  and	  wild-­‐type	  EBV	  infected	  BL31	  cells	  were	  treated	  with	  a	  range	  of	  BMP	  ligands.	  
The	  BMPs	  used	  were	  selected	  to	   include	  BMP2,	  BMP4	  and	  BMP7	  because	  they	  have	  been	  
shown	   to	  bind	   to	   TGFβR3,	   as	  well	   as	  BMP6	  as	   it	   has	   been	   shown	   to	  have	  effects	   in	   both	  
normal	   and	  malignant	   B	   cells.	   BMP2	   and	   BMP4	   are	   from	   the	   same	   subgroup	   of	   ligands;	  
similarly	  BMP6	  and	  BMP7	  are	  from	  the	  same	  subgroup	  (Derynck	  and	  Miyazono	  2008).	  BMP9	  
was	  also	  investigated	  as	  it	  was	  predicted	  to	  behave	  somewhat	  differently	  from	  the	  others:	  it	  
is	   from	  a	   third	   subgroup,	  has	  been	  shown	   to	  be	  pro-­‐proliferative	   in	   certain	  cell	   types	  and	  
conditions	  (Herrera	  et	  al.	  2009,	  Herrera	  et	  al.	  2013),	  but	  anti-­‐proliferative	  in	  others	  (David	  et	  
al.	  2007),	  and	  had	  not	  been	  shown	  to	  have	  effects	  in	  lymphoid	  cells.	  	  
	  
A	   preliminary	   experiment	   was	   performed	   using	   BMP4	   at	   two	   different	   concentrations	  
(50ng/ml	   and	   100ng/ml);	   the	   induction	   of	   C-­‐terminal	   phosphorylation	   of	   SMAD1/5/8	  
(pSMAD1/5/8)	   was	   similar	   with	   both	   doses,	   so	   50ng/ml	   was	   used	   in	   subsequent	  
experiments	   (data	  not	  shown).	  For	   the	  other	   ligands,	  a	  single	  dose	  was	  selected	  based	  on	  
previous	   literature	   and	   if	   this	   induced	  pSMAD1/5/8	   in	   preliminary	   experiments,	   the	   same	  
dose	  was	  used	  for	  any	  further	  experiments.	  The	  canonical	  signalling	  response	  to	  ligand	  was	  
assessed	   after	   one	   hour	   of	   treatment	  with	   the	   relevant	   BMP	   or	   an	   equivalent	   volume	   of	  
vehicle	   (0.5%	   BSA	   in	   4mM	   HCl),	   by	   performing	   western	   blot	   for	   total	   SMAD1,	   SMAD5,	  
SMAD1	   linker	   phosphorylation	   (pSMAD1),	   SMAD5	   C-­‐terminal	   phosphorylation	   (pSMAD5)	  
and	   pSMAD1/5/8	   in	   parallel	   (fig.	   7.1).	   No	   commercially	   available	   antibody	   could	   be	  
identified	   for	   SMAD8	   or	   pSMAD8	   and	   the	   antibody	   to	   SMAD5	   proved	   variable	   in	   its	  
successful	  use.	  	  
	  
Although	  total	  SMAD1	  expression	  was	   increased	   in	  EBV-­‐infected,	   relative	   to	  EBV-­‐negative,	  
BL31	  cells	   (see	  section	  7.2.5	   for	   further	  details),	   there	  was	  a	  more	  marked	   increase	   in	   the	  
induction	   of	   pSMAD1	   with	   BMP2,	   BMP4	   and	   BMP6	   in	   EBV-­‐infected	   compared	   to	   EBV-­‐
negative	   BL31	   (fig.	   7.1A-­‐C).	   pSMAD5	   and	   pSMAD1/5/8	   were	   also	   increased	   more	   in	  





response	   to	   BMP	   treatment	   in	   EBV-­‐infected	   than	   uninfected	   BL31	   cells,	   although	   the	  
difference	  between	  these	  was	  less	  marked	  than	  for	  pSMAD1,	  even	  taking	  into	  account	  the	  
increase	  in	  total	  SMAD1	  in	  EBV-­‐infected	  compared	  to	  uninfected	  cells.	  These	  findings	  were	  
consistent	   for	   BMP2,	   BMP4	   and	   BMP6	   (fig.	   7.1A-­‐C).	   However,	   with	   BMP7	   and	   BMP9,	  
although	   there	   was	   a	   slight	   increase	   in	   pSMAD1	   in	   the	   presence	   of	   EBV,	   this	   was	  
commensurate	  with	   the	   increase	   in	   total	   SMAD1	   (fig.	   7.1D-­‐E).	  With	   BMP7	   and	   BMP9,	   no	  
difference	  was	  seen	  in	  the	  induction	  of	  pSMAD5	  whether	  or	  not	  EBV	  was	  present,	  and	  for	  
pSMAD1/5/8	  there	  was	  only	  a	  slight	  increase	  in	  the	  presence	  of	  EBV,	  reflecting	  the	  increase	  
in	  pSMAD1	  as	  a	  result	  of	  increased	  total	  SMAD1.	  	  
	  
It	  was	  noted	  in	  these	  experiments	  that	  generally	  the	  amount	  of	  pSMAD1/5/8	  reflected	  that	  
of	   pSMAD1	   plus	   pSMAD5	   (fig.	   7.1),	   suggesting	   that	   SMAD8	   phosphorylation	   is	   not	  
prominent	   in	   this	   cell	   type,	   as	   has	   been	   found	   previously	   (Bakkebo	   et	   al.	   2010,	   Yin	   et	   al.	  
2010).	  Haematopoietic	  stem	  cells	  also	  express	  SMADs	  1	  and	  5	  but	  not	  SMAD8	  (Bhatia	  et	  al.	  
1999),	  suggesting	  that	  SMAD8	  may	  not	  be	  important	  in	  lymphoid	  cells;	  the	  EBV-­‐negative	  BL	  
cell	   line	   Ramos	   has	   recently	   been	   shown	   to	   lack	   expression	   of	   SMAD8	   (Kawabata	   et	   al.	  
2013).	  	  
	  
SMAD1	  and	   SMAD5	  are	  more	   similar	   to	   each	  other	   (at	   amino	   acid	   level)	   than	   to	   SMAD8.	  
BMP2	  and	  BMP4	  have	  been	  shown	  to	  activate	  SMAD1,	  SMAD5	  and	  SMAD8	  whereas	  BMP6	  
and	  BMP7	  only	  activate	  SMAD1	  and	  SMAD5	  (Ebisawa	  et	  al.	  1999,	  Aoki	  et	  al.	  2001).	   In	  the	  
current	  study,	  for	  BMP2	  and	  BMP4	  the	  effect	  of	  EBV	  was	  particularly	  marked	  for	  induction	  
of	  pSMAD1	  rather	  than	  pSMAD5	  (fig.	  7.1A-­‐B).	  For	  BMP6,	  the	  increased	  induction	  with	  EBV	  
infection	  was	  marked	   for	  both	  pSMAD1	  and	  pSMAD5	   (fig.	  7.1C),	  whereas	   for	  BMP7	   there	  
was	  no	  increase	  in	  induction	  of	  pSMAD1/5	  with	  EBV	  infection	  compared	  to	  uninfected	  (fig.	  
7.1D).	   Generally	   pSMAD1	  was	   found	   to	   be	   constitutively	   present,	   even	   in	   the	   absence	   of	  
exogenous	  BMPs,	  whereas	  pSMAD5	  was	  only	   induced	  with	  BMP	  (fig.	  7.1).	  Furthermore,	   it	  
appears	  that	  in	  BL31	  cells,	  BMP	  treatment	  does	  not	  induce	  pSMAD1,	  i.e.	  there	  is	  no	  increase	  
in	  pSMAD1	  with	  BMP	  compared	  to	  vehicle	  alone	  (fig.	  7.1).	  However,	  in	  the	  presence	  of	  EBV	  
infection,	  BMP2,	  BMP4	  and	  BMP6	  do	  induce	  pSMAD1.	  Although	  the	  constitutive	  pSMAD1	  is	  
likely	   to	   reflect	   background	   linker	   phosphorylation	   by	   MAP	   kinases,	   SMAD1	   linker	  
phosphorylation	  can	  also	  be	  induced	  by	  BMP	  treatment	  (Sapkota	  et	  al.	  2007).	  The	  induction	  





seen	  in	  EBV-­‐infected	  cells	  therefore	  suggests	  that	  EBV	  infection	  enables	  signalling	  by	  BMP2,	  
BMP4	  and	  BMP6.	  
	  
On	  the	  basis	  of	  these	  results,	  as	  well	  as	  the	  known	  binding	  of	  BMP2	  to	  TGFβR3	  and	  because	  
much	  previously	  published	  work	  is	  based	  on	  BMP2,	  it	  was	  decided	  to	  focus	  mainly	  on	  BMP2	  
in	   subsequent	   experiments.	   In	   order	   to	   confirm	   that	   EBV	   increases	   BMP	   signalling	   in	  
response	  to	  BMP2,	  as	  suggested	  by	  the	  increased	  induction	  of	  pSMAD1/5,	  the	  response	  of	  a	  
known	  BMP	  target	  gene	   ID1	  was	  assessed	  by	  qRT-­‐PCR	  (fig.	  7.1F).	   ID1	  expression	  remained	  
extremely	   low	   in	  both	  EBV-­‐infected	  and	  EBV-­‐negative	  BL31	   cells	   in	   the	  absence	  of	  BMP2.	  
However,	   in	   the	   presence	   of	   BMP2,	   ID1	   mRNA	   was	   induced,	   peaking	   at	   two	   hours	   but	  
persisting	   for	   at	   least	   24	   hours.	   It	   should	   be	   noted	   that	   no	   time	   points	   were	   measured	  
between	  2	  and	  24	  hours,	  so	  the	  peak	  reached	  may	  have	  been	  higher	  and	  occurred	  at	  any	  
time	   up	   to	   24	   hours;	   however,	   BMP	   treatment	   has	   previously	   been	   shown	   to	   induce	   ID1	  
mRNA	  maximally	  at	  2	  hours	  in	  resting	  mature	  human	  B	  cells,	  with	  levels	  remaining	  elevated	  
for	  up	  to	  24	  hours	   (Kersten	  et	  al.	  2005).	   In	   the	  current	  study,	   the	  peak	   levels	  of	   ID1	  were	  
higher	   in	  both	  wild-­‐type	  EBV-­‐infected	  cell	   lines	  than	   in	  the	  uninfected	  cell	   line,	  supporting	  











	   	  



































Figure	  7.1:	  EBV	  infection	  leads	  to	  increased	  signalling	  in	  response	  to	  BMP2,	  BMP4	  and	  BMP6,	  but	  not	  BMP7	  
or	  BMP9,	  in	  BL31	  cells	  	  
(A-­‐E):	   Western	   blot	   analysis	   showing	   phosphorylated	   SMAD1	   linker	   region,	   SMAD5	   and	   SMAD1/5/8	   in	  
response	  to	  treatment	  with	  BMP	  ligands	  or	  vehicle	  (0.5%	  BSA	  in	  4mM	  HCl)	  for	  one	  hour.	  Total	  SMAD1	  is	  shown	  
for	   comparison,	   with	   γ-­‐tubulin	   as	   a	   loading	   control.	   (A)	   BMP2	   100ng/ml,	   (B)	   BMP4	   50ng/ml,	   (C)	   BMP6	  
100ng/ml,	  (D)	  BMP7	  100ng/ml	  and	  (E)	  BMP9	  10ng/ml.	  (F):	  qRT-­‐PCR	  for	  mRNA	  expression	  of	  ID1,	  a	  known	  BMP	  
target	  gene,	  with	   time	  after	   treatment	  with	  BMP2	  or	  vehicle	   in	  uninfected	  and	  wild-­‐type	  EBV-­‐infected	  BL31	  
















BL31	  WT	  2	  +vehicle	  
BL31	  WT	  3	  +vehicle	  
BL31	  +BMP2	  
BL31	  WT	  2	  +BMP2	  
BL31	  WT	  3	  +BMP2	  









7.2.2	   EBNA2,	   EBNA3B	   and	   EBNA3C	   are	   unnecessary	   for	   the	   increased	   signalling	   in	  
response	  to	  BMP2	  in	  EBV-­‐infected	  compared	  to	  uninfected	  BL31	  cells	  	  
The	  current	  study	  has	  shown	  that	  EBV	  up-­‐regulates	  TGFβR3	  in	  BL31	  cells,	  with	  reduced	  up-­‐
regulation	   when	   EBNA2,	   EBNA3B	   or	   EBNA3C	   are	   deleted	   (fig.	   3.11A-­‐B).	   Signalling	   in	  
response	   to	   BMP2	   is	   increased	   in	   EBV-­‐infected	   relative	   to	   uninfected	   BL31	   (fig.	   7.1A).	  
Therefore,	   to	   investigate	  whether	   the	   increase	   in	  BMP	   signalling	  occurs	   as	   a	   result	   of	   the	  
increased	  TGFβR3	  expression,	  the	  effect	  of	  deletion	  of	  the	  relevant	  latent	  proteins	  on	  BMP	  
signalling	  was	  investigated.	  A	  panel	  of	  BL31	  cell	  lines	  were	  treated	  with	  BMP2	  or	  vehicle	  for	  
one	  hour	  and	   then	  western	  blot	  performed	   for	  SMAD1,	  SMAD5,	  pSMAD1	   linker,	  pSMAD5	  
and	   pSMAD1/5/8.	   These	   included	   BL31	   infected	   with	   viruses	   with	   deletions	   of	   EBNA2,	  
EBNA3B	   and	   EBNA3C	   as	   well	   as	   their	   respective	   revertants	   (fig.	   7.2).	   Increases	   in	   BMP2-­‐
induced	   pSMAD1	   linker,	   pSMAD5	   and	   pSMAD1/5/8	   were	   seen	   in	   the	   revertants	   (which	  
should	  behave	  as	  wild-­‐type)	  compared	  to	  uninfected	  BL31.	  However,	  when	  EBNA2,	  EBNA3B	  
or	   EBNA3C	   were	   deleted,	   signalling	   remained	   similar	   to	   that	   seen	   in	   the	   revertants	   (fig.	  
7.2A-­‐C).	   This	   suggests	   that	   these	   latent	   proteins	   are	   not	   necessary	   for	   the	   increased	  
responsiveness	   to	   BMP	   signalling	   as	   a	   result	   of	   EBV	   infection.	   Therefore,	   the	   increased	  
signalling	  in	  EBV-­‐infected	  compared	  to	  uninfected	  cells	  is	  unlikely	  to	  occur	  as	  a	  direct	  result	  
of	  the	  increased	  TGFβR3	  expression.	  
	  
It	   was	   also	   noted	   that	   there	   was	   a	   significant	   reduction	   in	   SMAD5	   protein	   level	   in	   EBV-­‐
infected	  (wild-­‐type	  and	  revertant)	  BL31	  compared	  to	  uninfected	  BL31	  (fig.	  7.2);	  this	  will	  be	  
discussed	  further	  in	  section	  7.2.6.	  	  
	   	  




























Figure	  7.2:	  EBNA2,	  EBNA3B	  and	  EBNA3C	  are	  not	  necessary	  for	  the	  increased	  signalling	  in	  response	  to	  BMP2	  
in	  EBV-­‐infected	  compared	  to	  uninfected	  BL31	  cells	  	  
Western	  blot	  analysis	  showing	  the	  effect	  of	  treatment	  with	  exogenous	  BMP2	  (100	  ng/ml)	  or	  vehicle	  (0.5%	  BSA	  
in	  4mM	  HCl)	  for	  one	  hour	  on	  levels	  of	  phosphorylated	  SMAD1	  linker	  (pSMAD1),	  pSMAD5	  and	  pSMAD1/5/8	  in	  a	  
panel	  of	  BL31	  cells	  infected	  with	  recombinant	  virus,	  showing	  the	  effect	  of:	  (A)	  EBNA2	  KO,	  (B)	  EBNA3B	  KO	  and	  
(C)	  EBNA3C	  KO.	  Total	  SMAD1	  and	  SMAD5	  levels	  are	  shown	  for	  comparison	  and	  γ-­‐tubulin	  was	  used	  as	  a	  loading	  
control.	  	  
A	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   C	  





7.2.3	   The	   increased	   BMP	   signalling	   occurring	   in	   EBV-­‐infected	   BL31	   may	   be	   due	   to	   up-­‐
regulation	  of	  BMPR1A	  
Since	  the	  increase	  in	  BMP	  signalling	  is	  unlikely	  to	  be	  via	  the	  up-­‐regulation	  of	  TGFβR3,	  it	  was	  
hypothesised	   that	   EBV	   may	   alter	   one	   of	   the	   other	   components	   of	   the	   BMP	   signalling	  
pathway.	  This	  could	  occur	  via	  several	  mechanisms,	  including	  up-­‐regulation	  of	  type	  I	  or	  type	  
II	   BMP	   receptors.	  Review	  of	  microarray	  data	   suggested	   that	   EBV	  moderately	  up-­‐regulates	  
BMPRIA,	   with	   EBNA3A	   and	   EBNA3C	   contributing	   to	   the	   up-­‐regulation	   (fig.	   7.3B)	  
[www.epstein-­‐barrvirus.org.uk	  and	  (White	  et	  al.	  2010)].	  qRT-­‐PCR	  for	  BMPRIA	   in	  a	  panel	  of	  
BL31	  cell	   lines	  showed	  up-­‐regulation	  by	  EBV,	  with	  the	  possible	  exception	  of	  EBNA3A	  KO	  1	  
(fig.	  7.3A).	  However,	  due	  to	  time	  constraints	   it	  was	  not	  possible	   to	   further	   investigate	  the	  







Figure	  7.3:	  BMPRIA	  (ALK3)	  is	  up-­‐regulated	  by	  EBV	  in	  BL31	  cells	  
(A)	  qRT-­‐PCR	  for	  BMPRIA	  mRNA	  in	  panel	  of	  BL31	  cell	  lines.	  The	  values	  are	  expressed	  relative	  to	  the	  endogenous	  
gene	  GNB2L1.	  Error	  bars	  represent	  standard	  deviations	  from	  triplicate	  qPCR	  reactions.	  (B)	  Microarray	  data	  for	  
BMPRIA	  expression	   in	  uninfected	  BL31	  cells,	  plus	   those	   infected	  with	  wild-­‐type,	  EBNA3A	  KO,	  EBNA3B	  KO,	  or	  
EBNA3C	  KO	  EBV	  (labelled	  WT	  EBV,	  E3A	  KO,	  E3B	  KO	  and	  E3C	  KO	  respectively).	  Each	  point	  represents	  a	  single	  
cell	  line,	  with	  the	  degree	  of	  expression	  shown	  on	  the	  y	  axis.	  From	  [www.epstein-­‐barrvirus.org.uk	  and	  (White	  et	  

























7.2.4	  BMP2	  and	  BMP4,	  but	  not	  BMP6,	  cause	  G1	  growth	  arrest	  in	  both	  uninfected	  and	  EBV-­‐
infected	  BL31	  cells	  
In	  view	  of	  the	  observation	  that	  EBV	  enhances	  BMP	  signalling,	  for	  BMP2,	  BMP4	  and	  BMP6,	  
the	  consequences	  of	  this	  were	  considered.	  It	  had	  been	  shown	  that	  BMP6	  is	  anti-­‐proliferative	  
in	  naïve	  or	  memory	  B	  cells	  (stimulated	  to	  proliferate	  by	  anti-­‐IgM)	  and	  CD10+ve	  B	  progenitor	  
cells	   (Kersten	  et	   al.	   2005,	   Kersten	  et	   al.	   2006),	   that	  BMP6	   is	   anti-­‐proliferative	   in	   the	  EBV-­‐
negative	  BL	   line	  Ramos	   (Kersten	  et	  al.	   2005)	  and	   that	  BMP2,	  BMP4,	  BMP6	  and	  BMP7	  are	  
anti-­‐proliferative	  or	  pro-­‐apoptotic	   in	  myeloma	  cells	   (Kawamura	  et	  al.	  2000,	  Hjertner	  et	  al.	  
2001,	  Ro	  et	  al.	  2004,	  Fukuda	  et	  al.	  2006b,	  Seckinger	  et	  al.	  2009).	  However,	  little	  was	  known	  
about	  the	  effects	  of	  BMP	  ligands	  on	  B-­‐lymphoma,	  including	  EBV-­‐positive	  BL,	  cells	  at	  the	  time	  
these	  investigations	  were	  performed.	  In	  order	  to	  investigate	  the	  functional	  effects	  of	  BMPs	  
in	   BL	   cells,	   and	   to	   see	   whether	   the	   increase	   in	   BMP	   signalling	   by	   EBV	   may	   alter	   this,	  
uninfected	   and	   EBV-­‐infected	   BL31	   cells	   were	   treated	   with	   BMP2,	   BMP4	   and	   BMP6,	   or	  
vehicle,	   for	   48	   hours,	   stained	   with	   propidium	   iodide	   and	   analysed	   by	   FC	   (fig.	   7.4).	   This	  
showed	  that,	  in	  uninfected	  BL31	  cells,	  treatment	  with	  BMP2	  and	  BMP4	  results	  in	  G1	  arrest,	  
as	  indicated	  by	  an	  increase	  in	  the	  G1	  phase	  with	  reductions	  in	  S	  and	  G2/M	  phases	  relative	  to	  
untreated	   cells	   (fig.	   7.4A-­‐B,	   upper	   figures).	   For	  BMP6	   treatment	   (100ng/ml)	   there	  was	  no	  
difference	  between	  the	  profiles	  for	  treated	  versus	  untreated	  BL31	  (fig.	  7.4C,	  upper	  figure),	  
even	  though	  this	  dose	  induced	  pSMAD5	  and	  pSMAD1/5/8	  in	  BL31	  (see	  fig.	  7.1C).	  	  	  	  
	  
When	  EBV-­‐infected	  BL31	  cells	  were	  treated	  with	  BMP2	  and	  BMP4,	  G1	  arrest	  again	  occurred,	  
to	   a	   similar	   degree	   as	   in	   uninfected	   BL31	   cells	   (fig.	   7.4A-­‐B,	   lower	   figures).	   With	   BMP6	  
treatment,	   there	   was	   a	   moderate	   increase	   in	   the	   G1	   and	   decreases	   in	   the	   S	   and	   G2/M	  
components,	   suggesting	   that	   BMP6	   at	   this	   dose	   (100ng/ml)	  may	   cause	   G1	   arrest	   in	   EBV-­‐
infected	  but	  not	  in	  EBV-­‐negative	  BL31	  (fig.	  7.4C,	  lower	  figures),	  although	  it	  did	  induce	  strong	  
phosphorylation	  of	  pSMAD1,	  pSMAD5	  and	  pSMAD1/5/8	  even	  in	  EBV-­‐negative	  BL31	  (see	  fig.	  
7.1C).	  	  
	  
In	  EBV-­‐negative	  BL31,	  there	  was	  also	  noted	  to	  be	  an	  increase	  in	  the	  sub-­‐G1	  component	  with	  
BMP2	  in	  treated	  compared	  to	  untreated	  cells	  (figs.	  7.4A).	  However,	  western	  blot	  for	  PARP	  
cleavage	  as	  a	  measure	  of	  apoptosis	  did	  not	  show	  any	  difference	  in	  PARP	  cleavage	  between	  
BMP2-­‐treated	  and	  untreated	  BL31	  cells	  (fig.	  7.4D).	  	  	  




























Figure	  7.4:	  The	  effects	  of	  BMP2,	  BMP4	  and	  BMP6	  on	  cell	  cycle	  arrest	  and	  apoptosis	  in	  uninfected	  and	  EBV-­‐
infected	  BL31	  cells	  
(A-­‐C)	  Equal	  numbers	  of	  BL31	  and	  wild-­‐type	  EBV-­‐infected	  (BL31	  WT)	  cells	  were	  treated	  with	  BMP	  ligand	  (left-­‐
hand	  figures)	  or	  vehicle	  (0.5%	  BSA	  in	  4mM	  HCl;	  right-­‐hand	  figures)	  for	  48	  hours	  and	  then	  cells	  harvested,	  fixed	  
and	  stained	  with	  propidium	   iodide	  before	  performing	  FC	  analysis	   to	  quantify	   the	  proportion	  of	   cells	   in	  each	  
phase	  of	  the	  cell	  cycle.	  (A)	  BMP2	  (100ng/ml),	  (B)	  BMP4	  (50ng/ml)	  and	  (C)	  BMP6	  (100ng/ml).	  (D)	  The	  effect	  of	  
BMP2	  treatment	  on	  PARP	  cleavage	  in	  uninfected	  and	  EBV-­‐infected	  BL31	  cells.	  BL31	  and	  BL31	  WT	  were	  treated	  
for	  72	  hours	  with	  BMP2	  100ng/ml	  or	   vehicle,	   followed	  by	  protein	  extraction	  and	  western	  blot	   for	   total	   and	  
cleaved	  PARP.	  γ-­‐tubulin	  was	  used	  as	  a	  loading	  control.	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7.2.5	  EBV	  moderately	  up-­‐regulates	  SMAD1	   in	  BL31	  cells,	  due	  to	   the	  combined	  effects	  of	  
EBNA3	  proteins	  and	  LMP2A	  
The	   previous	   experiments	   on	   the	   effect	   of	   EBV	   on	   BMP	   signalling	   in	   BL31	   cells	   had	  
suggested,	  in	  some	  cases,	  that	  SMAD1	  is	  up-­‐regulated	  by	  EBV	  (see	  figs.	  7.1	  and	  7.2),	  hence	  
this	  was	  further	  investigated,	  including	  the	  effect	  of	  the	  individual	  latent	  proteins.	  qRT-­‐PCR	  
for	   SMAD1	   in	   a	   panel	   of	   BL31	   cell	   lines	   showed	   a	   relatively	   high	   baseline	   expression	   in	  
uninfected	   BL31	   with	   a	   moderate	   up-­‐regulation	   by	   EBV	   (fig.	   7.5A).	   These	   findings	   were	  
consistent	   with	   microarray	   data	   in	   BL31	   [www.epstein-­‐barrvirus.org.uk	   and	   (White	   et	   al.	  
2010)].	  SMAD1	  expression	  was	  reduced	  when	  either	  LMP2A,	  or	  the	  entire	  EBNA3	  locus,	  was	  
deleted	  (fig.	  7.5A).	  EBNA2	  deletion	  had	  no	  effect,	  EBNA3B	  deletion	  had	  a	  minimal	  effect	  and	  
EBNA3C	  deletion	  had	  an	  intermediate	  effect.	  EBNA3A	  deletion	  had	  an	  effect	  in	  only	  in	  two	  
out	  of	  four	  cell	  lines	  (EBNA3A	  KOs	  1	  and	  2)	  (fig.	  7.5A).	  Thus	  it	  appears	  that	  the	  up-­‐regulation	  
of	  SMAD1	  involves	  cooperation	  between	  the	  EBNA3	  proteins	  and	  LMP2A.	  	  
	  
Western	  blotting	  for	  SMAD1	  confirmed	  the	  up-­‐regulation	  of	  SMAD1	  in	  EBV-­‐infected	  relative	  
to	  uninfected	  BL31s	  (fig.	  7.5B).	  SMAD1	  was	  again	  reduced	  when	  the	  whole	  EBNA3	  locus	  was	  
deleted,	  or	  when	  LMP2A	  was	  deleted.	  However,	  the	  effects	  for	  individual	  EBNA3s	  were	  less	  
marked.	   In	   particular,	   EBNA3C	   deletion	   had	   a	   greater	   effect	   than	   EBNA3B	   deletion	   in	  
reduction	  of	  SMAD1	  expression	  compared	  to	  wild-­‐type/revertant	  infected	  BL31s	  (fig.	  7.5B).	  	  
	  
In	  order	  to	  investigate	  whether	  the	  lack	  of	  up-­‐regulation	  of	  SMAD1	  in	  EBNA3	  KO	  BL31	  could	  
in	  fact	  be	  due	  to	  lower	  LMP2A	  expression,	  qRT-­‐PCR	  was	  performed	  for	  LMP2A	  in	  these	  cell	  
lines.	   Western	   blot	   for	   LMP2A	   was	   also	   attempted	   for	   these	   cell	   lines;	   however,	   the	  
performance	  of	  the	  antibody	  was	  too	  poor	  to	  interpret	  the	  result.	  Expression	  of	  LMP2A	  by	  
qRT-­‐PCR	  was	  markedly	  lower	  in	  the	  EBNA3	  KO	  than	  wild-­‐type	  or	  revertant	  BL31	  (fig.	  7.5C),	  
hence	  the	  low	  LMP2A	  expression	  may	  be	  contributing	  to	  the	  reduced	  SMAD1	  expression	  in	  
EBNA3	  KO.	  Nevertheless,	  since	  SMAD1	  expression	  is	  lower	  in	  EBNA3	  KO	  (which	  express	  low	  
levels	  of	  LMP2A)	  than	  the	  LMP2A	  KO	  (which	  completely	  lack	  LMP2A),	  it	  is	  likely	  that	  there	  is	  
some	   additional	   contribution	   from	   the	   EBNA3	   proteins	   as	   well	   as	   LMP2A	   to	   the	   up-­‐
regulation	  of	  SMAD1	  in	  BL31	  (fig.	  7.5B).	  	  
	  
	  



























Figure	  7.5:	  EBV	  infection	  up-­‐regulates	  expression	  of	  SMAD1	  in	  BL31	  cells	  	  
(A)	  qRT-­‐PCR	  for	  SMAD1	  in	  a	  panel	  of	  BL31	  cell	  lines,	  including	  those	  infected	  with	  virus	  with	  KO	  of	  the	  entire	  
EBNA3	  locus	  (EBNA3	  KO)	  and	  its	  revertant	  (EBNA3	  rev).	  The	  values	  are	  expressed	  relative	  to	  the	  endogenous	  
gene	  GNB2L1.	  Error	  bars	  represent	  standard	  deviations	   from	  triplicate	  qPCR	  reactions.	   (B)	  Western	  blots	   for	  
SMAD1	  expression	  in	  a	  panel	  of	  BL31	  cell	  lines.	  γ-­‐tubulin	  is	  shown	  as	  a	  loading	  control.	  (C)	  qRT-­‐PCR	  for	  LMP2A	  
mRNA	  in	  EBNA3	  KO	  and	  revertant	  BL31s.	  The	  values	  are	  expressed	  relative	  to	  the	  endogenous	  gene	  GNB2L1.	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7.2.6	  Latent	  EBV	  down-­‐regulates	  SMAD5	  in	  BL31	  cells	  	  
Whilst	   examining	   the	  effects	  of	   EBV	   infection	  on	  BMP-­‐induced	   signalling,	   it	  was	  observed	  
that	  EBV	  down-­‐regulates	  SMAD5	  expression	  in	  BL31	  cells,	  with	  reduced	  protein	  expression	  
shown	  in	  all	  wild-­‐type	  and	  revertant	  infected	  lines	  (figs.	  7.2A-­‐C).	  	  
	  
To	  investigate	  whether	  the	  down-­‐regulation	  of	  SMAD5	  by	  EBV	  occurs	  at	  the	  transcriptional	  
level	   in	   BL31,	   qRT-­‐PCR	   for	   SMAD5	  was	   performed,	   showing	   a	   reduction	   in	   SMAD5	  mRNA	  
with	  EBV	  infection	  (fig.	  7.6A).	  Western	  blot	  for	  SMAD5	  expression	  in	  the	  BL31	  cell	  line	  panel	  
confirmed	   that	   SMAD5	   protein	   expression	   is	   reduced	   in	   wild-­‐type	   EBV-­‐infected	   cells	  
compared	  to	  uninfected	  BL31	  (fig.	  7.6B).	  	  
	  
It	  has	  been	  reported	  that	  microRNA	  155	  (miR-­‐155)	  (encoded	  by	  B	  cell	  integration	  cluster	  or	  
BIC)	   targets	  SMAD5	  (Rai	  et	  al.	  2010,	  Yin	  et	  al.	  2010),	  and	  that	  LMP1	  up-­‐regulates	  miR-­‐155	  
expression	   (Rahadiani	   et	   al.	   2008).	   Indeed	   the	   microarray	   data	   shows	   a	   significant	   up-­‐
regulation	   of	   miR-­‐155	   by	   EBV	   (fig.	   7.6C)	   [www.epstein-­‐barrvirus.org.uk	   and	   (White	   et	   al.	  
2010)].	   It	   is	   therefore	  possible	   that	   the	  up-­‐regulation	  of	  BIC/miR-­‐155	  by	  EBV	   leads	   to	   the	  










Figure	  7.6:	  EBV	  down-­‐regulates	  SMAD5	  and	  up-­‐regulates	  miR-­‐155	  expression	  in	  BL31	  cells	  
(A)	  qRT-­‐PCR	   for	   SMAD5	  mRNA	   in	   BL31	   and	  BL31	  WT.	   The	   values	   are	   expressed	   relative	   to	   the	   endogenous	  
gene	  GNB2L1.	   Error	   bars	   represent	   standard	  deviations	   from	   triplicate	  qPCR	   reactions.	   (B)	  Western	  blot	   for	  
SMAD5,	  with	  γ-­‐tubulin	  as	  a	   loading	  control.	   (C)	  MiR-­‐155	  expression	   in	  BL31	  cell	   lines	   in	  microarray	  analysis.	  
Expression	   of	   miR-­‐155	   in	   BL31	   cells	   uninfected	   or	   infected	   with	   wild-­‐type	   (including	   revertant)	   EBV.	   The	  
vertical	   axis	   represents	  quantity	  of	  RNA	  on	  a	   log2	   scale.	  A	   value	  of	   <3	  generally	   indicates	   that	   a	   gene	   is	   not	  
detectably	  expressed.	  Each	  point	   represents	  a	  single	  cell	   line.	  From	  [www.epstein-­‐barrvirus.org.uk	   (White	  et	  
al.	  2010)].	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Since	  EBV	  up-­‐regulates	   SMAD1	   (section	  7.2.5)	   and	  down-­‐regulates	   SMAD5	   in	  BL31,	   it	  was	  
hypothesised	   that	  EBV	  may	  alter	   the	  downstream	  effectors	  of	  BMP	  signalling	   in	   favour	  of	  
SMAD1	  rather	  than	  SMAD5.	  In	  this	  way,	  the	  target	  gene	  profile	  of	  BMPs	  could	  theoretically	  
be	  altered,	   thus	   changing	   the	  ultimate	  effect	  of	  BMP	  signalling.	   In	   response	   to	  BMP2	  and	  
BMP4,	  pSMAD1	  induction	  is	  increased	  more	  by	  EBV	  than	  pSMAD5	  induction	  (see	  figs.	  7.1A-­‐
B),	  which	  could	  be	  consistent	  with	  EBV	  altering	  the	  SMAD	  usage	  in	  favour	  of	  SMAD1	  rather	  
than	   SMAD5.	   However,	   for	   BMP6,	   both	   pSMAD1	   and	   pSMAD5	   are	  markedly	   increased	   in	  
EBV-­‐infected	  compared	  to	  uninfected	  cells	  (fig.	  7.1C).	  Moreover,	  even	  though	  total	  SMAD5	  
is	   reduced	   by	   wild-­‐type/revertant	   EBV,	   the	   induction	   of	   pSMAD5	   by	   BMP2	   is	   actually	  
increased	   in	  EBV-­‐infected	  compared	   to	  uninfected	  BL31	  cells	   (figs	  7.2A-­‐C),	   suggesting	   that	  
actually	  EBV	  is	  not	  altering	  the	  pattern	  of	  SMADs	  phosphorylated	  upon	  BMP2	  treatment.	  	  
	  
7.2.7	  EBV	  infection	  leads	  to	  abrogation	  of	  non-­‐canonical	  TGFβ-­‐induced	  phosphorylation	  of	  
SMAD5	  in	  BL31	  cells	  
It	  has	  been	  reported	  that	  TGFβ	  ligands	  can	  induce	  phosphorylation	  of	  SMAD1/5	  via	  a	  non-­‐
canonical	  pathway	  in	  B	  cells	  including	  B-­‐lymphoma	  cell	  lines	  (Munoz	  et	  al.	  2004,	  Bakkebo	  et	  
al.	  2010,	  Rai	  et	  al.	  2010,	  Kawabata	  et	  al.	  2013).	  More	  recently	  it	  has	  been	  demonstrated	  that	  
this	  pathway	  is	  important	  for	  TGFβ-­‐induced	  growth	  arrest	  in	  B	  cells,	  enhancing	  the	  induction	  
of	   p15	   and	   p21	   (Jiang	   and	   Aguiar	   2014).	   Therefore	   the	   existence	   of	   such	   a	   pathway	  was	  
investigated	   in	   BL31	   cells,	   in	   order	   to	   see	   whether,	   by	   up-­‐regulating	   SMAD1	   and	   down-­‐
regulating	   SMAD5	   expression,	   EBV	  may	   alter	   this	   non-­‐canonical	   pathway.	  Uninfected	   and	  
wild-­‐type	  EBV-­‐infected	  BL31	  were	   treated	  with	  TGFβ1	  or	   vehicle	   alone	  and	   samples	  were	  
collected	  at	  several	  time	  points	  up	  to	  24	  hours.	  This	  showed	  transient	  induction	  of	  pSMAD5	  
by	  TGFβ1	  at	  2	  hours	  in	  BL31,	  no	  longer	  seen	  at	  later	  time	  points,	  hence	  only	  the	  data	  for	  up	  
to	  6	  hours	  are	  shown	  here.	  This	  effect	  was	  abrogated	  in	  the	  presence	  of	  EBV	  infection	  (fig.	  
7.7).	  	  
	  
As	   shown	   previously,	   EBV	   infection	   increased	   total	   SMAD1	   and	   decreased	   total	   SMAD5.	  
There	   was	   a	   constitutive	   increase	   in	   SMAD1	   linker	   phosphorylation	   (pSMAD1)	   in	   EBV-­‐
infected	   cells,	   not	   induced	   by	   TGFβ1,	   commensurate	   with	   the	   increase	   in	   total	   SMAD1.	  
There	   was	   also	   constitutive	   expression	   of	   pSMAD5	   in	   BL31,	   generally	   reduced	   by	   EBV	  





infection,	  commensurate	  with	  the	  decrease	  in	  total	  SMAD5.	  There	  was	  a	  general	  decrease	  in	  
pSMAD1/5/8	  with	  EBV	  infection,	  reflecting	  the	  more	  marked	  decrease	  in	  total	  SMAD5	  than	  
the	  increase	  in	  total	  SMAD1	  by	  EBV	  (fig.	  7.7).	  	  
	  
Thus,	   although	   a	   non-­‐canonical	   signalling	   response	   does	   occur	   with	   TGFβ	   at	   2	   hours,	  
increasing	   pSMAD5,	   the	   down-­‐regulation	   of	   SMAD5	   and	   up-­‐regulation	   of	   SMAD1	   by	   EBV	  
does	  not	  appear	  to	  result	  in	  a	  switch	  from	  SMAD5	  to	  SMAD1	  usage	  in	  this	  pathway;	  rather,	  
EBV	   infection	   appears	   to	   abrogate	   this	   pathway.	   EBV	   does,	   however,	   alter	   constitutive	  
signalling	   in	  favour	  of	  pSMAD1	  rather	  than	  pSMAD5	  as	  a	  result	  of	  the	  changes	   in	   levels	  of	  














Figure	  7.7:	  A	  non-­‐canonical	  pathway,	   in	  which	  TGFβ	   induces	  phosphorylation	  of	   SMAD5,	   is	   active	   in	  BL31	  
cells	  and	  is	  abrogated	  by	  EBV	  infection	  	  
Equal	  numbers	  of	  BL31	  and	  BL31	  WT	  were	  treated	  with	  TGFβ1	  10ng/ml	  or	  vehicle	  (2mg/ml	  BSA	  in	  sterile	  PBS)	  
for	   up	   to	   6	   hours	   and	   samples	   harvested	   at	   the	   time	   points	   shown.	   Protein	  was	   extracted	   and	   then	   equal	  
amounts	  loaded	  into	  gels	  for	  SDS-­‐PAGE	  followed	  by	  western	  blot	  for	  SMAD1,	  pSMAD1	  linker,	  SMAD5,	  pSMAD5	  










7.3	  The	  effects	  of	  EBV	  on	  BMP	  signalling	  and	  its	  effectors	  in	  LCLs	  	  
7.3.1	  SMAD1	  expression	  is	  increased	  in	  wild-­‐type	  compared	  to	  EBNA3B	  KO	  LCLs	  
The	   effects	   of	   EBV	   on	   BMP	   signalling	   and	   its	   components	  were	   also	   investigated	   in	   LCLs.	  
Microarray	  analysis	  had	  suggested	  that	  SMAD1	  expression	  was	  markedly	   lower	   in	  EBNA3B	  
KO	  compared	  to	  wild-­‐type	  LCLs	  [www.epstein-­‐barrvirus.org.uk	  (White	  et	  al.	  2010)].	  qRT-­‐PCR	  
and	   western	   blot	   analysis	   in	   several	   sets	   of	   established	   EBNA3B	   KO	   compared	   to	   their	  
counterpart	   wild-­‐type	   LCLs	   confirmed	   that	   SMAD1	   expression	   is	   markedly	   reduced	   in	  
EBNA3B	  KO	  LCLs	  (see	  fig.	  7.8	  for	  representative	  data).	  This	  suggested	  that	  EBV	  up-­‐regulates	  



























Figure	  7.8:	  SMAD1	  expression	  is	  markedly	  reduced	  in	  EBNA3B	  KO	  compared	  to	  wild-­‐type	  LCLs	  	  
(A)	  qRT-­‐PCR	  for	  SMAD1	  in	  WT,	  EBNA3B	  KO	  and	  EBNA3B	  revertant	  LCLs.	  The	  values	  are	  expressed	  relative	  to	  
the	   endogenous	   gene	  GNB2L1.	   Error	   bars	   represent	   standard	   deviations	   from	   triplicate	   qPCR	   reactions.	   (B)	  
Western	   blot	   for	   SMAD1	   in	  WT,	   EBNA3B	  KO	   and	   EBNA3B	   revertant	   LCLs,	   also	   showing	   EBNA1	   and	   EBNA3B	  
expression	  plus	  γ-­‐tubulin	  as	  a	   loading	  control.	   The	  blot	   shown	   is	   from	  an	  experiment	   in	  which	   the	  cells	  had	  
been	   treated	   with	   TGFβ1	   5ng/ml	   or	   vehicle	   for	   one	   hour	   before	   harvesting	   cells	   for	   protein	   extraction;	  

































7.3.2	   The	   up-­‐regulation	   of	   SMAD1	   by	   EBNA3B	   in	   LCLs	   is	   associated	   with	   chromatin	  
modifications	  at	  the	  SMAD1	  promoter	  
Having	   previously	   shown	   that	   EBV	   regulates	   both	   TGFβR2	   and	   TGFβR3	   by	   epigenetic	  
mechanisms,	   	  and	  since	  the	  up-­‐regulation	  by	  wild-­‐type	  compared	  to	  EBNA3B	  KO	  LCLs	  was	  
significant,	  the	  question	  was	  addressed	  of	  whether	  SMAD1	  is	  regulated	  by	  similar	  epigenetic	  
mechanisms	   in	   LCLs.	   Therefore	   several	   set	   of	   primers	  were	   designed	   covering	   the	   region	  
including	  the	  transcription	  start	  sites	  of	  the	  majority	  of	  SMAD1	  transcripts.	  Five	  primer	  sets	  
were	   ultimately	   selected	   from	   those	   designed	   (see	   fig.	   7.9A).	   Chromatin	  
immunoprecipitation	   analysis	  was	   performed	   in	   EBNA3B	   KO	   and	  wild-­‐type/revertant	   LCLs	  
for	   H3K27Me3,	   H3K9Ac	   and	   H3K4Me3	   (figs.	   7.9B-­‐D).	   These	   showed	   an	   increase	   in	   the	  
repressive	  mark	  H3K27Me3	   in	  EBNA3B	  KO	  compared	  to	  wild-­‐type	  LCLs,	  with	  reductions	   in	  
the	   activation	   marks	   H3K9Ac	   and	   H3K4Me3.	   For	   H3K27Me3,	   values	   were	   lower	   for	   LCL-­‐
EBNA3B	   revertant	   than	  wild-­‐type;	   however,	   the	   value	   for	   globin	  was	   also	   reduced	   in	   this	  
sample	   compared	   to	   the	  others	   suggesting	   that	   this	   reflects	  a	   reduction	   in	  binding	   in	   this	  
particular	   sample	   (fig.	   7.9B).	   For	   H3K27Me3	   a	   broad	   peak	   was	   seen	   covering	   the	   region	  
tested,	  whereas	  for	  H3K9Ac	  and	  H3K4Me3,	  a	  peak	  was	  seen	  at	  the	  site	  of	  primer	  set	  C,	  near	  
the	   transcription	   start	   site	   of	   transcript	   1	   (figs.	   7.9C-­‐D).	   Taken	   together,	   these	   findings	  
confirm	  that	  SMAD1	  expression	  is	  also	  epigenetically	  regulated	  in	  LCLs.	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Figure	  7.9:	  The	  up-­‐regulation	  of	  SMAD1	  by	  EBNA3B	  in	  LCLs	  is	  epigenetically	  mediated	  	  
(A)	  Schematic	  diagram	  of	  the	  SMAD1	  promoter	  showing	  the	  location	  of	  products	  of	  primer	  sets	  used	  and	  the	  
putative	  transcription	  start	  sites	  (TSS)	  of	  three	  transcripts;	  the	  region	  shown	  covers	  the	  TSS	  of	  the	  majority	  of	  
transcript	   variants	   (www.ensembl.org).	   The	   coloured	   blocks	   represent	   the	   primer	   pairs	   A-­‐E,	   shown	   as	   bars	  
from	  left	  to	  right	  for	  each	  cell	  line	  in	  the	  remaining	  figures.	  (B-­‐D)	  qPCRs	  showing	  ratio	  of	  histone	  modification	  
to	   input	   DNA	   at	   the	   SMAD1	   promoter	   for	   (B)	   H3K27Me3,	   (C)	   H3K9Ac	   and	   (D)	   H3K4Me3.	   The	   results	   are	  
compared	  to	  those	  for	  the	  control	  promoter	  primers	  globin	  (repressed)	  and	  GAPDH	  (active),	  whose	  colours	  are	  
shown	   in	   the	   legends	   on	   each	   chart.	   The	   error	   bars	   represent	   standard	   deviations	   from	   triplicate	   qPCR	  
reactions	  for	  both	  input	  and	  immunoprecipitation.	  	  
	   	  





7.3.3	  EBNA3B	  up-­‐regulates	  SMAD1	  expression	  after	  infection	  of	  primary	  B	  cells	  with	  EBV	  
In	  order	   to	   confirm	   that	  EBV	  up-­‐regulates	  SMAD1,	  with	  EBNA3B	  being	  necessary,	  purified	  
primary	  B	  cells	  were	   infected	  with	  wild-­‐type,	  EBNA3B	  KO	  and	  EBNA3B	  revertant	  virus	  and	  
the	   expression	   of	   SMAD1	   measured	   with	   time	   after	   infection	   by	   qRT-­‐PCR.	   SMAD1	  
expression	  was	   low	  until	  around	  14	  days	  after	   infection,	  when	   levels	  began	   to	   increase	   in	  
the	  wild-­‐type	  and	  revertant	   infected	  cells.	  SMAD1	  expression	  peaked	  at	  28	  days	  and	  then	  
appeared	  to	  reach	  a	  stable	  level	  of	  expression.	  In	  EBNA3B	  KO,	  SMAD1	  remained	  extremely	  
low	  (fig.	  7.10A).	   	   In	  contrast,	  CD23,	  a	  marker	  of	  B	  cell	  activation,	  was	  up-­‐regulated	  by	  day	  
two	  post-­‐infection	  (fig.	  7.10B).	  	  
	  
EBV	   up-­‐regulates	   both	   SMAD1	   and	   TGFβR3.	   In	   BL31	   cells,	   EBNA3s	   (3B/3C)	   and	   LMP2A	  
appear	  to	  be	  necessary	  for	  up-­‐regulation	  of	  both.	  This	  led	  to	  the	  hypothesis	  that	  SMAD1	  and	  
TGFβR3	  may	  be	  co-­‐regulated	  in	  some	  way.	  However,	  the	  correlation	  in	  BL31s	  is	  difficult	  to	  
assess	   since	   the	   expression	   of	   SMAD1	   is	   relatively	   high	   in	   uninfected	   BL31	   cells,	   and	   is	  
increased	   only	  moderately	   by	   EBV	   infection	   (fig.	   7.5),	  whereas	   TGFβR3	   expression	   is	   very	  
low	  in	  uninfected	  BL31	  and	  therefore	  the	  effect	  of	  EBV	  to	  increase	  it	   is	  much	  greater	  than	  
for	  SMAD1	  (fig.	  3.11).	  
	  
The	  same	  question	  was	  therefore	  addressed	  in	  LCLs,	  where	  SMAD1	  and	  TGFβR3	  expression	  
are	   both	   low	   in	   uninfected	  primary	  B	   cells.	  However,	   in	   one	  of	   the	   experiments	   in	  which	  
primary	  B	  cells	  were	  infected	  with	  wild-­‐type,	  EBNA3B	  KO	  or	  revertant	  EBV,	  there	  was	  noted	  
to	   be	   discordance	   between	   SMAD1	   and	   TGFβR3	   up-­‐regulation	   for	   EBNA3B	   revertant:	  
SMAD1	  was	  up-­‐regulated	  by	  both	  wild-­‐type	   and	   revertant	   EBV,	  whereas	   TGFβR3	  was	  not	  
up-­‐regulated	  by	   revertant	   EBV	   in	   this	   case	   (figs.	   7.10A&C).	   This	   suggests	   that	   SMAD1	  and	  
TGFβR3	   are	   not	   directly	   co-­‐regulated.	   Nevertheless	   it	   remains	   possible	   that	   SMAD1	   up-­‐





	   	  




























Figure	  7.10:	  SMAD1	  compared	  with	  CD23	  and	  TGFβR3	  expression	  after	  infection	  of	  purified	  primary	  B	  cells	  
with	  wild-­‐type,	  EBNA3B	  KO	  and	  revertant	  EBV	  
(A-­‐B)	  qRT-­‐PCR	  measuring	  expression	  over	  time	  of	  (A)	  SMAD1	  and	  (B)	  CD23,	  a	  marker	  of	  B	  cell	  activation	  which	  
is	   known	   to	   be	   up-­‐regulated	   by	   EBV	   infection,	   in	   primary	   B	   cells	   infected	   with	   wild-­‐type,	   EBNA3B	   KO	   or	  
EBNA3B	   revertant	   virus.	   (C)	   SMAD1	   and	   TGFβR3	   expression	   are	   not	   directly	   co-­‐regulated	   after	   infection	   of	  
primary	   B	   cells.	   qRT-­‐PCR	   for	   TGFβR3	   expression	  with	   time	   after	   infection	   of	   primary	   B	   cells	  with	  wild-­‐type,	  
EBNA3B	   KO	   and	   EBNA3B	   revertant	   EBV,	   showing	   that	   in	   this	   particular	   experiment	   TGFβR3	   expression	  
remained	   lower	   than	   for	   wild-­‐type	   EBV.	   All	   values	   are	   expressed	   as	   ratio	   to	   the	   endogenous	   control	   gene	  




































































7.3.4	  BMP	  signalling	  still	  occurs	  in	  EBNA3B	  KO	  LCLs	  despite	  the	  lack	  of	  SMAD1	  expression	  
Since	  in	  EBNA3B	  KO	  LCLs,	  expression	  of	  SMAD1	  is	  very	  low,	  it	  seemed	  likely	  that	  this	  could	  
alter	  the	  response	  to	  BMP	  signalling.	  Therefore	  the	  effect	  of	  EBNA3B	  KO	  on	  BMP	  signalling	  
in	  LCLs	  was	   investigated.	   In	  particular,	   it	  was	  again	  hypothesised	  that	  EBV	  may	  promote	  a	  
switch	   from	   use	   of	   SMAD5	   in	   favour	   of	   SMAD1	   as	   downstream	   effectors	   of	   signalling.	  
EBNA3B	  KO	  and	  WT	  LCLs	  were	  treated	  with	  BMP2	  and	  BMP4,	  followed	  by	  protein	  extraction	  
and	  western	   blotting	   for	   SMADs	   1	   and	   5,	   pSMAD1	   linker,	   pSMAD5	   and	   pSMAD1/5/8	   (fig.	  
7.11).	  	  As	  expected,	  this	  showed	  that	  in	  EBNA3B	  KO	  LCLs,	  there	  was	  no	  SMAD1	  present	  and	  
therefore	  no	  pSMAD1	  was	  detected	  after	  BMP	  treatment.	  In	  EBNA3B	  KO	  LCLs,	  total	  SMAD5	  
did	  not	  appear	  to	  be	  altered	  compared	  to	  wild-­‐type	  LCLs.	  However,	  there	  was	  less	  pSMAD5	  
induced	   by	   both	   BMP2	   and	   BMP4	   in	   EBNA3B	   KO	   than	   in	   wild-­‐type	   LCLs.	   	   The	   total	  
pSMAD1/5/8	  was	  also	  reduced	  for	  EBNA3B	  KO	  compared	  to	  wild-­‐type	  LCLs	  (fig.	  7.11).	  Hence	  
BMP	  signalling	   is	  generally	   reduced	   in	  EBNA3B	  KO	  compared	  to	  wild-­‐type	  LCLs,	  disproving	  
the	   hypothesis	   that	   EBV	   promotes	   a	   switch	   from	   SMAD5	   to	   SMAD1	   in	   BMP	   signalling,	   at	  














Figure	  7.11:	  BMP	  signalling	  via	  SMADs	  1,	  5	  and	  8	  is	  reduced	  in	  EBNA3B	  KO	  compared	  to	  wild-­‐type	  LCLs	  
Western	  blot	  analysis	  showing	  the	  effect	  of	  exogenous	  BMP2	  (100	  ng/ml),	  BMP4	  (50	  ng/ml)	  or	  vehicle	  (0.5%	  
BSA	   in	   4mM	   HCl)	   alone	   for	   1	   hour	   on	   levels	   of	   phosphorylated	   SMAD1	   linker	   (pSMAD1),	   pSMAD5	   and	  
pSMAD1/5/8.	  	  Total	  SMAD1	  and	  SMAD5	  levels	  are	  shown	  for	  comparison	  and	  γ-­‐tubulin	  was	  used	  as	  a	  loading	  
control.	  	  	  






EBV	  increases	  signalling	  in	  response	  to	  BMP2,	  BMP4	  and	  BMP6	  in	  BL31	  cells,	  but	  not	  via	  
up-­‐regulation	  of	  TGFβR3	  	  
Since	  EBV	  up-­‐regulates	  TGFβR3,	  and	  TGFβR3	  is	  a	  co-­‐receptor	  for	  BMP	  signalling,	  the	  effect	  
of	   EBV	   on	   BMP	   signalling	  was	   investigated.	   This	   showed	   that	   EBV	   increased	   signalling,	   as	  
detected	  by	  phosphorylation	  of	  SMAD1,	  5	  and	  1/5/8,	  in	  response	  to	  BMP2,	  BMP4	  and	  BMP6	  
(fig.	   7.1A-­‐C).	   However,	   although	   BMP7	   and	   BMP9	   also	   induced	   phosphorylation	   of	  
SMAD1/5,	  EBV	  did	  not	  appear	  to	  increase	  signalling	  in	  response	  to	  these	  ligands	  (fig.	  7.1D-­‐
E).	  When	  the	  effect	  of	  deletion	  of	  the	  individual	  latent	  proteins	  which	  regulate	  TGFβR3	  was	  
investigated,	  however,	   signalling	   in	   response	   to	  BMP2	   remained	  at	   the	   same	   levels	   as	   for	  
wild-­‐type	  EBV	  when	  EBNA2,	  EBNA3B	  or	  EBNA3C	  were	  deleted	  (fig.	  7.2).	  Hence	  the	  increased	  
BMP	  signalling	  in	  EBV	  infection	  is	  not	  a	  direct	  consequence	  of	  the	  up-­‐regulation	  of	  TGFβR3.	  	  
	  
BMPs	  can	  be	  divided	  into	  subgroups	  based	  on	  structural	  similarity	  and	  their	  affinity	  for	  type	  
I	   receptors.	  BMP2	  and	  BMP4	  form	  one	  subgroup,	  binding	  preferentially	   to	  ALK3	  (BMPRIA)	  
and	   ALK6	   (BMPRIB).	   BMP6	   and	   BMP7	   are	   structurally	   related	   members	   of	   a	   second	  
subgroup,	  whose	  members	  bind	  preferentially	   to	  ALK2	  and	  ALK6	  but	  only	  weakly	  to	  ALK3.	  
BMP9	   belongs	   to	   a	   third	   subgroup,	   binding	   to	   ALK1	   and	   ALK2.	   Normal	   B	   cells	   have	   been	  
variably	  shown	  to	  express	  ALK2,	  ALK3	  and	  ALK6,	  suggesting	  that	  they	  can	  respond	  to	  BMP2,	  
BMP4,	  BMP6	  and	  BMP7	  (Kersten	  et	  al.	  2005,	  Seckinger	  et	  al.	  2009).	  
	  
As	   expected,	   BMP2	   and	   BMP4	   showed	   similar	   effects,	   with	   EBV	   infection	   resulting	   in	   a	  
greater	   induction	  of	  phosphorylation	  of	  both	  SMAD1	  and	  SMAD5	  than	   in	  uninfected	  cells,	  
but	   with	   a	   more	   pronounced	   effect	   on	   phosphorylation	   of	   SMAD1	   than	   of	   SMAD5	   (figs.	  
7.1A-­‐B).	  The	  increased	  effects	  by	  EBV	  could	  be	  explained	  by,	  for	  example,	  up-­‐regulation	  of	  
ALK3	   or	   ALK6,	   as	   these	   are	   the	   type	   I	   receptors	   used	   by	   BMP2	   and	   BMP4.	   A	   preliminary	  
investigation	   of	   effects	   of	   EBV	   on	   BMP	   receptors	   suggested	   that	   EBV	   does	   indeed	   up-­‐
regulate	   ALK3	   (BMPRIA)	   in	   BL31	   (fig.	   7.3),	   therefore	   this	  may	   be	   a	   contributing	   factor	   to	  
increased	  BMP	  signalling.	  
	  
EBV	  infection	  markedly	  increased	  the	  induction	  of	  both	  SMAD1	  linker	  phosphorylation	  and	  
C-­‐terminal	  SMAD5	  phosphorylation	  in	  response	  to	  BMP6	  (fig.	  7.1C).	  Although	  BMP7,	  which	  





is	  part	  of	  the	  same	  subgroup,	  induced	  phosphorylation	  of	  SMAD1	  and	  SMAD5,	  EBV	  did	  not	  
appear	   to	   increase	   this	   induction	   (fig.	   7.1D).	   Members	   of	   this	   ligand	   subgroup	   bind	  
preferentially	   to	   ALK2	   and	   ALK6	   but	   only	   weakly	   to	   ALK3.	   Naïve	   B	   cells	   stimulated	   to	  
differentiate	   into	   Ig-­‐producing	   plasmablasts	   by	   treatment	   with	   CD40	   ligand	   and	   IL-­‐21	  
showed	  induction	  of	  ALK2	  expression,	  which	  would	  enhance	  response	  to	  BMP6	  and	  BMP7,	  
but	   the	   inhibition	   of	   this	   induced	   Ig	   production	  was	   greater	   with	   BMP6	   than	  with	   BMP7	  
(Huse	  et	  al.	  2011).	  In	  the	  current	  study	  only	  BMP6,	  but	  not	  BMP7,	  signalling	  was	  enhanced	  
by	  EBV	  (fig.	  7.1C-­‐D).	  Despite	  their	  structural	  similarity	  and	  use	  of	  the	  same	  type	  I	  receptors,	  
BMP6	  and	  BMP7	  can	  have	  different	  effects	  in	  B	  cells.	  In	  naïve	  and	  memory	  B	  cells	  that	  had	  
been	   stimulated	   to	   proliferate	   by	   anti-­‐IgM	   treatment,	   BMP6	   inhibited	   proliferation	   and	  
induced	   only	   a	  minimal	   increase	   in	   apoptosis,	   whereas	   BMP7	   strongly	   induced	   apoptosis	  	  
(Kersten	  et	  al.	  2005,	  Huse	  et	  al.	  2011)	  and	   in	  B-­‐lymphoma	  cell	   lines	  BMP6,	  but	  not	  BMP7,	  
inhibits	  growth	  (Huse	  et	  al.	  2012).	  	  	  
	  
BMP9	  was	   also	   tested	  as	   a	  member	  of	   a	   third	   subgroup.	   It	   uses	  ALK1	  and	  ALK2	  as	   type	   I	  
receptors;	   however,	   ALK1	   is	   expressed	   on	   endothelial	   cells	   and	   fibroblasts	   but	   not	   in	  
haematopoietic	  cells.	  It	  is	  not	  known	  to	  have	  any	  effects	  in	  lymphoid	  cells,	  and	  can	  be	  pro-­‐
proliferative	  in	  some	  circumstances	  (Herrera	  et	  al.	  2009,	  Herrera	  et	  al.	  2013).	  In	  the	  current	  
study,	  it	  induced	  phosphorylation	  of	  SMAD1	  and	  of	  SMAD5,	  but	  EBV	  infection	  had	  no	  effect	  
on	   these	   (fig.	   7.1E).	  Hence	  although	  BMP9	   can	   induce	   signalling	   in	  BL	   cells,	   EBV	  does	  not	  
alter	  this.	  
	  
As	  well	  as	  changes	  in	  expression	  of	  type	  I	  or	  type	  II	  BMP	  receptors,	  possible	  mechanisms	  for	  
the	  enhancement	  of	  BMP	  signalling	  by	  EBV	  could	  include:	  reduced	  availability	  or	  activity	  of	  
extracellular	  BMP	  antagonists	  such	  as	  noggin	  and	  chordin,	  altered	  availability	  or	  activity	  of	  
intracellular	  accessory	  proteins	  which	  control	  access	  of	  R-­‐SMADs	  to	  the	  internal	  portion	  of	  
receptors,	  decreased	  activity	  of	  inhibitory	  SMADs	  (SMAD6	  and	  SMAD7)	  which	  compete	  with	  
R-­‐SMADs	  for	  binding	  to	  type	  I	  receptors,	  or	  increased	  availability	  of	  R-­‐SMADs.	  However,	  for	  
the	   purposes	   of	   this	   study	   the	   exact	   mechanism	   was	   not	   investigated;	   this	   could	   be	  
investigated	  further	  in	  future	  work.	  	  
	  
	  





BMP2	   and	  BMP4,	   but	   not	   BMP6,	   induce	  G1	   arrest	   in	   both	   uninfected	   and	   EBV-­‐infected	  
BL31	  cells	  
At	  the	  start	  of	  this	  project,	  there	  was	  little	  published	  data	  available	  on	  the	  effects	  of	  BMPs	  in	  
B	  cells.	  BMP6	  had	  been	  shown	  to	  be	  anti-­‐proliferative	  in	  lymphoid	  progenitors	  and	  mature	  B	  
cells	   (Kersten	  et	  al.	  2005,	  Kersten	  et	  al.	  2006),	  and	  several	  studies	  had	  shown	  BMPs	  to	  be	  
pro-­‐apoptotic	  and	  anti-­‐proliferative	  in	  myeloma	  cells	  (Kawamura	  et	  al.	  2000,	  Hjertner	  et	  al.	  
2001,	  Ro	  et	  al.	   2004,	   Fukuda	  et	  al.	   2006b,	   Seckinger	  et	  al.	   2009).	   Since	  EBV	   infection	  had	  
been	  shown	  to	  increase	  BMP	  signalling	  in	  BL31	  cells,	  the	  effect	  of	  this	  on	  the	  cell	  cycle	  was	  
investigated.	   BMP2	   and	   BMP4	   caused	   G1	   arrest	   in	   BL31	   cells,	   and	   EBV	   infection	   possibly	  
slightly	  enhanced	  this	  (figs.	  7.4A-­‐B).	  Since	  this	  work	  was	  done,	  BMP2	  and	  BMP4	  have	  been	  
shown	  to	  inhibit	  growth	  of	  several	  B-­‐lymphoma-­‐derived	  cell	  lines	  (Huse	  et	  al.	  2012).	  	  
	  
On	  the	  other	  hand,	  BMP6	  did	  not	  induce	  growth	  arrest	  or	  significant	  apoptosis	  in	  uninfected	  
BL31	  cells	  (fig.	  7.4C).	  This	  is	  in	  contrast	  to	  the	  findings	  of	  BMP6-­‐induced	  growth	  arrest	  seen	  
in	   studies	   on	   normal	   B	   cells	   and,	   more	   recently,	   other	   B-­‐lymphoma	   lines	   (Kersten	   et	   al.	  
2005,	  Huse	  et	  al.	   2011,	  Huse	  et	  al.	   2012),	   as	  well	   as	  BMP6-­‐induced	  apoptosis	   in	   the	  EBV-­‐
negative	  BL	  Ramos	  (Kersten	  et	  al.	  2005).	  However,	  in	  the	  current	  study	  a	  dose	  of	  100ng/ml	  
of	  BMP6	  was	  used,	  which	  was	  nevertheless	  sufficient	  to	  induce	  pSMAD1/5/8.	  It	   is	  possible	  
that	   higher	   doses	   would	   be	   needed	   to	   induce	   growth	   arrest	   and/or	   apoptosis;	   a	   dose-­‐
response	  curve	  showed	  that	  at	  100ng/ml	  inhibition	  of	  proliferation	  in	  Ramos	  cells	  was	  only	  
modest	  whereas	  1000ng/ml	  had	  a	  much	  more	  marked	  effect	   (Kersten	  et	  al.	  2005),	  and	   in	  
the	   later	  studies	  by	  Huse	  et	  al	  a	  dose	  of	  500ng/ml	  was	  used	  (Huse	  et	  al.	  2011,	  Huse	  et	  al.	  
2012).	  	  	  
	  
In	   addition,	   these	   findings	   may	   reflect	   something	   specific	   to	   BL31,	   as	   the	   effects	   were	  
variable	   between	   different	   cell	   lines	   used	   in	   the	   previous	   studies.	   In	   the	   current	   study,	  
although	  BMP6	  did	  not	  cause	  growth	  arrest	  or	  apoptosis	  in	  EBV-­‐negative	  BL31,	  signalling	  in	  
response	   to	  BMP6	  was	  enhanced	  by	  EBV,	  which	   then	  appeared	   to	  enable	  BMP6	   to	   cause	  
growth	   arrest	   (figs.	   7.1C	   and	   7.4C).	   It	   is	   also	   possible	   that	   the	   enhancement	   of	   BMP6	  
signalling	  by	  EBV	  also	  has	  an	  alternative	  effect,	  such	  as	  enhancement	  of	  the	  inhibitory	  effect	  
of	   BMP6	   on	   plasmacytic	   differentiation,	   since	   BMP2,	   BMP4	   and	   in	   particular	   BMP6	   have	  
been	  shown	  to	  inhibit	  differentiation	  of	  mature	  B	  cells	  into	  plasma	  cells	  (Huse	  et	  al.	  2011).	  





Since	   plasmacytic	   differentiation	   would	   favour	   lytic	   infection,	   this	   would	   be	   a	   means	   of	  
promoting	  EBV	  latency,	  rather	  than	  lytic	  infection,	  as	  is	  normally	  the	  case	  in	  memory	  B	  cells.	  	  	  
The	  finding	  that	  EBV-­‐infected	  as	  well	  as	  uninfected	  BL31	  cells	  undergo	  G1	  arrest	  in	  response	  
to	   BMP2	   and	   BMP4	   was	   initially	   surprising,	   since	   the	   effect	   of	   EBV	   on	   BMP	   signalling	   is	  
growth-­‐inhibitory	  whereas	  the	  effects	  of	  EBV	  on	  TGFβ	  signalling	  is	  anti-­‐apoptotic	  or	  growth-­‐
promoting,	  i.e.	  EBV	  appears	  to	  have	  opposing	  effects	  on	  TGFβ	  and	  BMP	  signalling.	  However,	  
the	   significance	   of	   these	   findings	   presumably	   depends	   on	   the	   local	   environment	   in	   vivo.	  
Resistance	  to	  TGFβ	  signalling	  is	  likely	  to	  be	  important	  in	  the	  germinal	  centre	  reaction,	  where	  
TGFβ-­‐induced	  apoptosis	   is	  a	  prominent	  mechanism	  of	  removing	  B	  cells	  which	   lack	  survival	  
signals	  (Spender	  et	  al.	  2009),	  in	  order	  to	  enable	  the	  EBV-­‐infected	  B	  cells	  to	  survive	  and	  thus	  
maintain	   latent	   infection	   in	  memory	  B	  cells.	   It	   is	  possible	   that	  BMP-­‐induced	  growth	  arrest	  
could	  be	  favourable	  in	  another	  part	  of	  the	  lymphoid	  system,	  as	  it	  is	  thought	  that	  infected	  B	  
cells	  continuously	  circulate	  around	  the	  blood	  and	  lymphoid	  organs.	  For	  instance,	  BMP	  levels	  
could	   be	   increased	   in	   the	   peripheral	   blood,	   where	   infected	   B	   cells	   would	   not	   be	  
proliferating.	   The	  BMP	  milieu	   of	   various	   components	   of	   the	   lymphoid	   system	   is	   generally	  
unknown,	  although	  several	  recent	  papers	  by	  a	  Norwegian	  group	  have	  suggested	  that	  BMP	  
signalling	  in	  lymphoid	  cells	  is	  likely	  to	  be	  important	  (Bakkebo	  et	  al.	  2010,	  Huse	  et	  al.	  2011,	  
Huse	   et	   al.	   2012).	   Since	   normal	   B	   cells	   and	   lymphoma	   cells	   express	   BMP	   receptors	   and	  
respond	  to	  BMP	  signalling,	  it	  is	  likely	  that	  BMP	  signalling	  in	  B	  cells,	  and	  the	  effects	  of	  EBV	  on	  
it,	  are	  biologically	  relevant.	  	  
	  
EBV	  up-­‐regulates	  SMAD1	  in	  BL31	  and	  LCLs;	  however,	  the	  mechanism	  for	  this	  appears	  to	  be	  
different	  in	  the	  two	  cell	  types	  
In	   BL31	   cells	   and	   after	   infection	   of	   primary	   B	   cells	   with	   wild-­‐type	   EBV	   to	   produce	   LCLs,	  
SMAD1	  is	  up-­‐regulated	  by	  EBV	  (figs.	  7.5A-­‐B,	  7.10A).	  However,	  in	  BL31s,	  the	  baseline	  SMAD1	  
expression	  is	  relatively	  high	  (fig.	  7.5A-­‐B),	  whereas	  in	  primary	  B	  cells	  it	  is	  low	  (fig.	  7.10A).	  The	  
degree	   of	   up-­‐regulation	   by	  wild-­‐type	   EBV	   in	   LCLs	   is	   therefore	  much	   greater	   than	   in	   BL31	  
cells.	  	  
	  
SMAD1	  expression	  has	  been	  shown	  to	  be	  relatively	   low	   in	  naïve	  and	  memory	  B	  cells	   from	  
peripheral	   blood,	   whereas	   centroblasts	   and	   centrocytes	   have	   higher	   levels,	   although	   it	  
should	   be	   noted	   that	   in	   that	   study	   only	   five	   samples	   per	   cell	   type	   were	   investigated	  





(Bakkebo	  et	  al.	  2010).	  Nevertheless,	   in	  the	  current	  study	  SMAD1	  was	   low	  in	  all	  uninfected	  
primary	  B	  cell	  samples	  (fig.	  7.10A),	  in	  each	  case	  combined	  from	  several	  healthy	  individuals.	  	  
SMAD1	  has	  been	  shown	  to	  be	  overexpressed	  in	  some	  BL	  (Maesako	  et	  al.	  2003,	  Bakkebo	  et	  
al.	  2010)	  and	  in	  some	  cases	  of	  follicular	  lymphoma	  (FL),	  although	  in	  these	  cases	  expression	  
was	  highly	  variable	  between	  different	  tumours	  (Husson	  et	  al.	  2002,	  Munoz	  et	  al.	  2004).	  C-­‐
terminal	  phosphorylation	  of	  SMAD1	  has	  been	  identified	  in	  clinical	  biopsy	  samples	  of	  FL,	  but	  
not	  in	  normal	  lymphoid	  tissue	  (Munoz	  et	  al.	  2004).	  BL	  cell	  lines,	  such	  as	  BL31,	  have	  already	  
acquired	  several	  genetic/epigenetic	  changes	  in	  vivo	  in	  order	  to	  become	  malignant,	  and	  have	  
probably	  undergone	  further	  clonal	  changes	  in	  vitro	  during	  repeated	  passage.	  Since	  SMAD1	  is	  
overexpressed	  in	  several	  B	  cell	  malignancies,	  this	  suggests	  that	  up-­‐regulation	  of	  SMAD1	  may	  
confer	   an	   advantage	   on	   tumour	   cells;	   the	   worse	   prognosis	   seen	   in	   clinical	   FL	   cases	   with	  
SMAD1	   overexpression	   would	   also	   support	   this	   (Harjunpaa	   et	   al.	   2006).	   It	   is	   therefore	  
possible	  that	  the	  high	  baseline	  SMAD1	  expression	  in	  BL31	  (and	  certain	  other	  lymphoma	  cell	  
lines)	  has	  occurred	  via	  a	  clonal	  selective	  process.	  	  
	  
The	   up-­‐regulation	   of	   SMAD1	   by	   EBV	   would	   be	   expected	   to	   increase	   BMP	   signalling	   via	  
pSMAD1.	   In	   the	  current	  study,	  SMAD1	  appears	   to	  be	  constitutively	  phosphorylated	  at	   the	  
linker	  region	  in	  BL31	  cells	  and	  LCLs,	  possibly	  via	  action	  of	  MAP	  kinases	  (Sapkota	  et	  al.	  2007),	  
whereas	  it	  is	  not	  induced	  by	  the	  BMP	  ligands	  tested	  in	  EBV-­‐negative	  BL31s	  (fig.	  7.1)	  or	  wild-­‐
type/revertant	   LCLs	   (fig.	  7.11).	  However,	   in	  BL31	  cells	   infected	  with	  wild-­‐type	  EBV,	  BMP2,	  
BMP4	   and	   BMP6	   do	   increase	   induction	   of	   SMAD1	   linker	   phosphorylation	   compared	   to	  
vehicle	  alone	  (figs.	  7.1A-­‐C).	  	  Thus	  EBV	  appears	  to	  enable	  these	  BMPs	  to	  induce	  SMAD1	  linker	  
phosphorylation.	  C-­‐terminal	  phosphorylation	  of	   SMAD1	  alone	  was	  not	   investigated	   in	   this	  
study;	  however,	   it	   is	   possible	   that	  EBV	  may	  also	  enable	  or	  enhance	   this.	   This	  may	  have	  a	  
specific	  effect,	  for	  instance	  if	  pSMAD1	  targets	  specific	  genes	  not	  targeted	  by	  pSMAD5.	  The	  
differential	  effects	  of	  C-­‐terminal	  phosphorylation	  of	  SMAD1	  versus	  SMAD5	  on	  target	  genes	  
are	  not	  known,	  but	  this	  could	  be	  investigated	  in	  future	  work.	  	  
	  
Another	   possibility	   is	   that	   by	   increasing	   SMAD1,	   EBV	   increases	   the	   amount	   of	   SMAD1	  
available	   for	  non-­‐canonical	  TGFβ	  signalling.	  However,	  TGFβ1	  did	  not	   increase	   induction	  of	  
SMAD1	   linker	   phosphorylation	   compared	   with	   vehicle	   whether	   or	   not	   EBV	   infection	   was	  
present	   (fig.	   7.7),	   although	   TGFβ1	   has	   been	   shown	   to	   induce	   linker	   phosphorylation	  





(Sapkota	   et	   al.	   2007).	   Furthermore,	   in	   BL31	   cells	   EBV	   infection	   led	   to	   a	   decrease	   in	  
constitutive	   pSMAD1/5/8	   consistent	   with	   the	   decrease	   in	   SMAD5	   expression,	   with	   no	  
induction	  of	  pSMAD1/5/8	  by	  TGFβ	  seen	  in	  EBV-­‐infected	  cells	  (fig.	  7.7).	  Hence	  EBV	  infection	  
probably	   does	   not	   lead	   to	   TGFβ-­‐mediated	   induction	   of	   C-­‐terminal	   phosphorylation	   of	  
SMAD1	  in	  BL31	  cells.	  The	  effect	  of	  TGFβ1	  on	  pSMAD1/5	  in	  LCLs	  was	  not	  investigated,	  but	  it	  
would	   be	   interesting	   to	   see	   whether	   non-­‐canonical	   induction	   of	   pSMAD1/5	   with	   TGFβ	  
occurs	  in	  LCLs.	  Moreover,	  if	  this	  non-­‐canonical	  signalling	  occurs	  via	  TGFβR2,	  this	  would	  not	  
be	   expected	   to	   occur	   in	   wild-­‐type	   LCLs	   since	   TGFβR2	   is	   repressed	   and	   canonical	   TGFβ	  
signalling	  suppressed	  (see	  figs.	  6.1A-­‐B).	  	  
	  
A	  third	  possibility	  is	  that	  by	  increasing	  SMAD1,	  EBV	  may	  increase	  competition	  with	  canonical	  
TGFβ-­‐responsive	   SMAD2	   and/or	   SMAD3	   for	   binding	   to	   SMAD4.	   This	   would	   be	   relevant	   if	  
both	  BMPs	  and	  TGFβ	  were	  acting	  at	  same	  time,	  in	  which	  case	  excess	  pSMAD1	  would	  reduce	  
TGFβ	   signalling	   via	   pSMAD2/3	   and	   hence	   enhance	   resistance	   to	   TGFβ;	   however,	   a	   recent	  
study	  has	  suggested	  that	  the	  opposite	  occurs	  if	  cells	  are	  co-­‐stimulated	  with	  TGFβ	  and	  BMP	  
ligands,	  with	  TGFβ	  repressing	  BMP-­‐induced	  target	  gene	  transcription	  (Gronroos	  et	  al.	  2012).	  
Nevertheless,	  as	  the	  converse	  was	  not	  specifically	  investigated,	  it	  remains	  possible	  that	  the	  
up-­‐regulation	   of	   SMAD1,	   and	   enhancement	   of	   BMP-­‐induced	   pSMAD1,	   by	   EBV	   may	   be	  
another	  mechanism	  for	  reducing	  canonical	  TGFβ	  signalling,	   in	  addition	  to	  down-­‐regulation	  
of	  TGFβR2.	  	  
	  
It	  has	  been	  shown	  that	  SMAD1	  is	  necessary	  for	  the	  anti-­‐proliferative	  effects	  of	  TGFβ1	  and	  
enhances	  the	  anti-­‐proliferative	  effect	  of	  BMP2,	  without	  being	  absolutely	  necessary	  for	  this	  
(Munoz	   et	   al.	   2004).	   In	   this	   case	   SMAD1	   would	   be	   acting	   as	   a	   tumour	   suppressor	   and	  
therefore	   it	   would	   be	   advantageous	   to	   the	   cells	   to	   lose	   SMAD1	   expression	   rather	   than	  
increasing	   it,	   so	   it	   is	   unclear	   why	   there	   would	   be	   advantage	   to	   tumour	   cells	   or	   EBV	   in	  
increasing	   SMAD1	   expression.	   In	   the	   current	   study,	   BMP2	   caused	   growth	   arrest	   in	   both	  
uninfected	  and	  EBV-­‐infected	  BL31	  cells	  (fig.	  7.4A),	  consistent	  with	  the	  expression	  of	  SMAD1.	  	  
When	  the	  effects	  of	  individual	  latent	  proteins	  on	  SMAD1	  expression	  were	  investigated,	  the	  
extent	  to	  which	  EBNA3B	  and	  EBNA3C	  were	  involved	  in	  the	  up-­‐regulation	  were	  different	   in	  
BL31	  and	  LCLs:	  in	  LCLs,	  there	  was	  a	  marked	  requirement	  for	  EBNA3B	  for	  the	  up-­‐regulation,	  
whereas	   in	  BL31,	  although	  a	   loss	  of	  up-­‐regulation	  was	   seen	  when	   the	  entire	  EBNA3	   locus	  





was	  deleted,	  there	  was	  only	  a	  minimal	  effect	  for	  EBNA3B,	  and	  a	  modest	  effect	  for	  EBNA3C	  
(fig.	   7.5A-­‐B);	   in	   addition,	   LMP2A	  was	   required	   for	   the	   up-­‐regulation	   of	   SMAD1.	   Hence	   in	  
BL31	  cells,	  EBNA3B,	  EBNA3C	  and	  LMP2A	  apparently	  cooperate	  to	  up-­‐regulate	  SMAD1.	  This	  
is	   consistent	   with	   the	   recent	   finding	   that	   SMAD1	   expression	   is	   increased	   in	   EBNA3-­‐
expressing,	  Wp-­‐restricted	   versus	   latency	   I	   Awia-­‐BL	   (Kelly	   et	   al.	   2013),	   i.e.	   up-­‐regulated	  by	  
the	  EBNA3	  proteins.	  	  
	  
After	   infection	   of	   primary	   B	   cells	   with	   EBV,	   it	   was	   EBNA3B	   that	   had	   the	  major	   effect	   on	  
SMAD1	  expression;	  in	  the	  absence	  of	  EBNA3B,	  SMAD1	  expression	  remained	  extremely	  low	  
(fig.	   7.10A).	   In	   stable	   LCLs,	   EBNA3B	   KO	   again	   have	   extremely	   low	   SMAD1	   expression	  
compared	   to	  wild-­‐type	   or	   revertant	   LCLs	   (fig.	   7.8A-­‐B).	   Unfortunately	   the	   effect	   of	   LMP2A	  
deletion	   on	   the	   expression	   of	   SMAD1	   after	   infection	   of	   primary	   B	   cells	   could	   not	   be	  
investigated,	   but	   this	   should	   be	   done	   in	   future	   work.	   The	   involvement	   of	   specific	   latent	  
proteins	  in	  the	  up-­‐regulation	  of	  SMAD1	  is	  therefore	  different	  between	  BL31	  cells	  and	  LCLs.	  
In	  BL31s,	  EBNA3B	  is	  much	  less	  clearly	  involved	  than	  in	  LCLs,	  and	  the	  other	  EBNA3	  proteins	  
do	  not	  appear	  to	  be	  involved	  in	  LCLs.	  	  
	  
The	  up-­‐regulation	  of	  SMAD1	  by	  EBV	  after	   infection	  of	  primary	  B	  cells	  does	  not	  occur	  until	  
around	   11-­‐14	   days	   after	   infection	   (fig.	   7.10A).	   The	   timing	   of	   this	   is	   consistent	   between	  
experiments	  and,	  although	  delayed	  in	  comparison	  to	  other	  genes	  up-­‐regulated	  by	  EBV	  (fig.	  
7.10B),	   it	   occurs	   too	   soon	   after	   infection	   to	   represent	   a	   clonal	   selection	   process;	   the	   up-­‐
regulation	   of	   TGFβR3	   in	   LCLs,	   however,	   occurs	  more	   gradually	   over	   a	   longer	   time	  period,	  
suggesting	  that	  this	  may	  be	  due	  to	  clonal	  selection	  (see	  chapter	  6).	  	  
	  
It	  was	  hypothesised	  that	  the	  up-­‐regulation	  of	  SMAD1	  by	  EBV	  may	  lead	  to	  increased	  use	  of	  
pSMAD1	  and	  reduced	  use	  of	  pSMAD5	   in	  response	  to	  BMP	  signalling.	  However,	   in	  EBNA3B	  
KO	  LCLs,	  as	  expected	  BMPs	  do	  not	   induce	  pSMAD1	   (since	  SMAD1	  expression	   is	  extremely	  
low	  in	  the	  absence	  of	  EBNA3B),	  but	  surprisingly,	  the	  induction	  of	  pSMAD5	  was	  also	  less	   in	  
EBNA3B	   KO	   than	  wild-­‐type/revertant	   LCLs	   (fig.	   7.11).	   Hence	   BMP	   signalling	  was	   generally	  
reduced	  when	  SMAD1	  was	  poorly	  expressed;	  the	  reason	  for	  this	  is	  not	  clear.	  	  
	  
	  





EBV	  down-­‐regulates	  SMAD5	  in	  BL31	  cells	  	  
In	   the	  experiments	   investigating	   the	  effects	  of	  EBV	  on	  BMP	  signalling	   in	  BL31	  cells,	   it	  was	  
observed	   that	   the	  expression	  of	   SMAD5	  was	   reduced	  by	  EBV	   (figs	  7.2).	   Therefore	   SMAD5	  
expression	  was	  investigated	  by	  qRT-­‐PCR	  and	  western	  blot	  (fig.	  7.6A-­‐B).	  This	  confirmed	  that	  
SMAD5	  is	  down-­‐regulated	  by	  wild-­‐type/revertant	  EBV	  in	  BL31	  cells.	  	  
	  
MicroRNA	   155	   (miR-­‐155)	   has	   been	   shown	   to	   be	   overexpressed	   in	   DLBCL,	   particularly	   the	  
activated	  B	  cell	  type,	  which	  has	  a	  poorer	  prognosis	  (Eis	  et	  al.	  2005)	  and	  it	  has	  been	  shown	  to	  
bind	  to	  the	  3’UTR	  of	  SMAD5,	  repressing	  SMAD5	  protein	  expression	  (Rai	  et	  al.	  2010,	  Yin	  et	  al.	  
2010).	   LMP1	   up-­‐regulates	   miR-­‐155	   (Rahadiani	   et	   al.	   2008).	   Microarray	   analysis	   showed	  
marked	  up-­‐regulation	  of	  miR-­‐155	  by	  EBV	  in	  BL31	  (fig.	  7.6C),	  consistent	  with	  up-­‐regulation	  of	  
miR-­‐155	  by	  LMP1	  [www.epstein-­‐barrvirus.org.uk	  and	  (White	  et	  al.	  2010)].	  
	  
Repression	   of	   SMAD5	   by	   expression	   of	  microRNAs	  which	   target	   it	   or	   by	   shRNA-­‐mediated	  
knockdown	  rendered	  Ramos	  and	  DLBCL	  cell	   lines	  resistant	  to	  the	  growth-­‐inhibitory	  effects	  
of	   TGFβ	   (Rai	   et	   al.	   2010,	   Liu	   et	   al.	   2012),	   suggesting	   that	   SMAD5,	   and	   TGFβ-­‐induced	  
phosphorylation	  of	   it,	   is	  necessary	   for	  TGFβ-­‐induced	  growth	   inhibition,	   recently	  confirmed	  
by	  the	  same	  group	  (Jiang	  and	  Aguiar	  2014).	  SMAD5	  knockdown	  also	  resulted	  in	  resistance	  to	  
the	  growth-­‐inhibitory	  effects	  of	  BMP2/BMP4,	   suggesting	   that	   SMAD5	  may	  have	  a	   tumour	  
suppressive	   function	   in	   lymphoid	   cells	   (Rai	   et	   al.	   2010).	   Thus	   EBV-­‐mediated	   repression	   of	  
SMAD5	  would	   result	   in	   resistance	   to	   the	   growth-­‐inhibitory	   effects	   of	   TGFβ	   and	   BMP2/4.	  
However,	   in	   the	   current	   study,	   BMP2	   and	   BMP4	   resulted	   in	   growth	   arrest	   in	   both	   EBV-­‐
negative	  and	  –positive	  BL31	  (figs.	  7.4A-­‐B).	  This	   is	  consistent	  with	  the	  fact	  that,	  although	  in	  
BL31-­‐WT	  SMAD5	  was	  markedly	  repressed,	  pSMAD5	  was	  still	  strongly	  induced	  by	  BMP2	  (fig.	  
7.2).	  	  	  
	  
A	   non-­‐canonical	   signalling	   pathway	   is	   seen	   in	   BL31s,	   in	   which	   TGFβ	   induces	  
phosphorylation	   of	   SMAD5;	   this	   pathway	   is	   abrogated	   by	   EBV,	   suggesting	   that	   it	   may	  
occur	  via	  TGFβR2	  
It	  has	  been	  previously	  shown	  that	  SMAD1	  phosphorylation	  can	  occur	  in	  response	  to	  TGFβ1	  
in	  various	  epithelial	  and	  endothelial	  cell	  lines.	  In	  most	  cases	  this	  requires	  the	  combination	  of	  
TGFβR1,	  one	  of	  the	  BMP	  type	  I	  receptors	  and	  TGFβR2	  (Goumans	  et	  al.	  2002,	  Goumans	  et	  al.	  





2003,	  Liu	  et	  al.	  2009,	  Wrighton	  et	  al.	  2009).	  	  This	  alternative	  pathway	  appears	  to	  require	  a	  
higher	   dose	   of	   TGFβ1,	   be	   activated	   later	   after	   TGFβ1	   stimulation	   and	   be	   sustained	   for	   a	  
shorter	  time	  than	  canonical	  TGFβ1	  signalling	  via	  SMAD2/3;	  hence	  it	  has	  been	  proposed	  that	  
this	  pathway	  has	  a	  distinct	  function	  from	  either	  the	  canonical	  TGFβ	  pathway	  via	  SMAD2/3	  or	  
the	  canonical	  BMP	  pathway	  via	  SMAD1/5/8	  (Wrighton	  et	  al.	  2009).	  Distinct	  functions	  have	  
been	  shown	  for	  the	  non-­‐canonical	  pathway	  in	  endothelial	  and	  epithelial	  cells	  (Goumans	  et	  
al.	  2002,	  Daly	  et	  al.	  2008).	  	  
	  
TGFβ-­‐induced	   phosphorylation	   of	   SMAD1	   and/or	   SMAD5	   has	   also	   been	   demonstrated	   in	  
several	  different	  B	  cell	   lymphoma	  cell	   lines	  (Munoz	  et	  al.	  2004,	  Bakkebo	  et	  al.	  2010,	  Rai	  et	  
al.	   2010)	   as	   well	   as	   primary	   human	   B	   cells	   (Bakkebo	   et	   al.	   2010).	   TGFβ1-­‐induced	  
phosphorylation	  of	  SMAD1	  and/or	  SMAD5	  has	  been	  shown	  to	  occur	  from	  30	  minutes	  after	  
treatment,	   peaking	   at	   one	   hour	   but	   lasting	   for	   between	   2	   and	   6	   hours	   post-­‐treatment	  
(Munoz	  et	  al.	  2004,	  Bakkebo	  et	  al.	  2010).	  	  	  
	  
TGFβR2	   was	   found	   to	   be	   necessary	   for	   this	   pathway	   in	   B-­‐lymphoma	   cells	   (Munoz	   et	   al.	  
2004),	   whereas	   the	   findings	   of	   Rai	   et	   al	   suggested	   that	   both	   TGFβR1	   and	   TGFβR2	   were	  
important	   (Rai	  et	  al.	  2010).	  The	  pathway	  was	  also	  partially	  blocked	  by	   inhibition	  of	   type	   I	  
BMPRs,	  supporting	  the	  proposition	  of	  Daly	  et	  al	  that	  heteromultimeric	  receptor	  complexes	  
are	  involved	  (Daly	  et	  al.	  2008).	  In	  lymphoma	  cell	  lines	  in	  which	  TGFβ-­‐induced	  pSMAD1/5	  did	  
not	  occur,	  reduced	  levels	  of	  TGFβR1	  and/or	  TGFβR2	  expression	  were	  demonstrated.	  The	  cell	  
lines	   in	   which	   TGFβ	   induced	   pSMAD1/5	   also	   showed	   induction	   of	   pSMAD2,	   and	   all	   were	  
sensitive	  to	  TGFβ-­‐induced	  growth	  inhibition	  (Bakkebo	  et	  al.	  2010).	  	  
	  
Since	  this	  pathway	  involves	  SMAD1	  and	  SMAD5,	  it	  was	  hypothesised	  that	  this	  pathway	  may	  
also	  occur	  in	  BL31	  cells	  and	  that,	  if	  so,	  the	  up-­‐regulation	  of	  SMAD1	  and	  down-­‐regulation	  of	  
SMAD5	   by	   EBV	   may	   alter	   this.	   Treatment	   of	   BL31	   cells	   with	   TGFβ	   induced	   transient	  
phosphorylation	   of	   SMAD5	   at	   two	   hours,	   with	   pSMAD5	   levels	   returning	   to	   baseline	   at	   4	  
hours	  and	  beyond	   (fig.	  7.7).	  Thus	   the	  non-­‐canonical	  pathway	  occurs	   in	  EBV-­‐negative	  BL31	  
cells	  as	  has	  been	  seen	   in	  other	  B	  cell	   lines.	  Although	  Rai	  et	  al	   (2010)	  used	  an	  antibody	   to	  
pSMAD1	  and/or	   5,	   they	  went	  on	   to	  demonstrate	  by	   co-­‐immunoprecipitation	   experiments	  
that	   the	   effect	   occurred	   predominantly	   through	   SMAD5,	   whereas	   Munoz	   et	   al	   (2004)	  





showed	  induction	  of	  pSMAD1,	  but	  did	  not	  investigate	  pSMAD5,	  and	  Bakkebo	  et	  al	  (2010)	  did	  
not	  distinguish	  between	  pSMAD1	  and	  pSMAD5.	  	  
	  
In	  EBV-­‐infected	  BL31,	  no	  induction	  of	  pSMAD5	  was	  seen	  with	  TGFβ	  (fig.	  7.7),	  suggesting	  that	  
EBV	   abrogates	   this	   non-­‐canonical	   pathway	   in	   a	   similar	  way	   to	   its	   abrogation	   of	   canonical	  
TGFβ	   signalling.	   This	   suggests	   that	   the	   non-­‐canonical	   pathway	   may	   also	   be	   mediated	   by	  
TGFβR2,	  as	  EBV	  down-­‐regulates	  TGFβR2	  (see	  chapter	  3).	  Due	  to	  time	  constraints,	  the	  effect	  
of	   deletion	  of	   the	   individual	   latent	   proteins	   on	   this	  was	  not	   investigated,	   but	   if	   the	   same	  
proteins	   appeared	   to	   be	   involved	   as	   for	   the	   down-­‐regulation	   of	   TGFβR2,	   that	   would	   be	  
consistent	   with	   the	   hypothesis	   that	   this	   is	   mediated	   by	   TGFβR2.	   Within	   this	   pathway,	  
however,	  EBV	  increased	  the	  constitutive	  phosphorylation	  of	  the	  SMAD1	  linker	  and	  reduced	  
the	   constitutive	   C-­‐terminal	   phosphorylation	   of	   SMAD5,	   as	   well	   as	   that	   of	   SMAD1/5/8,	  
generally	   correlating	   with	   the	   increases	   in	   total	   SMAD1	   and	   total	   SMAD5	   respectively.	   It	  
remains	   possible	   that	   EBV	   alters	   constitutive	   signalling	   in	   favour	   of	   SMAD1	   rather	   than	  
SMAD5	   C-­‐terminal	   phosphorylation	   and	   activation,	   as	   a	   result	   of	   the	   changes	   in	   levels	   of	  
total	   SMAD1	   and	   SMAD5;	   however	   it	   is	   not	   known	  what	   the	   downstream	   effects	   of	   this	  
would	  be.	  





 	  	  	  Discussion	  Chapter	  8
8.1	   Latent	   EBV	   leads	   to	   PRC2-­‐mediated	   repression	   of	   TGFβR2	   and	   suppression	   of	   TGFβ	  
signalling	  via	  SMAD2	  
This	  study	  has	  shown	  that	  latent	  EBV	  infection	  leads	  to	  down-­‐regulation	  of	  TGFβR2	  in	  both	  
BL31	  cells	  and	  established	  LCLs,	  and	  leads	  to	  near-­‐complete	  repression	  by	  approximately	  21	  
days	  after	   infection	  of	  purified	  primary	  B	  cells.	  TGFβR2	  binding	   to	  TGFβR1	   is	  necessary	   to	  
propagate	  signals	  from	  TGFβ	  ligands.	  Accordingly,	  the	  down-­‐regulation	  of	  TGFβR2	  in	  these	  
cell	  types	  leads	  to	  suppression	  of	  TGFβ	  signalling	  via	  phosphorylation	  of	  SMAD2.	  
	  
TGFβ	  signalling	   is	  generally	   tumour	  suppressive,	  being	  pro-­‐apoptotic	  and	  anti-­‐proliferative	  
in	   B	   cells	   and	   most	   other	   cell	   types.	   EBV	   has	   been	   shown	   to	   repress	   other	   tumour	  
suppressor	   genes,	   including	   BIM	   and	   p16INK4A,	   via	   epigenetic	   mechanisms	   including	  
polycomb-­‐mediated	   repression	   (Paschos	   et	   al.	   2009,	   Skalska	   et	   al.	   2010,	   Paschos	   et	   al.	  
2012).	   The	   transcriptional	   repression	   of	   TGFβR2	   by	   EBV	   was	   accompanied	   by	   increased	  
H3K27Me3	   deposition	   and	   binding	   of	   SUZ12,	   a	   component	   of	   PRC2,	   to	   the	   TGFβR2	  
promoter.	   Therefore	   this	   study	   has	   demonstrated	   polycomb-­‐mediated,	   epigenetic,	  
repression	  by	  EBV	  of	  another	  TSG	  in	  addition	  to	  p16INK4A	  and	  BIM.	  
	  
H3K27Me3	   can	   increase	   the	   likelihood	   of	   the	   more	   stable	   epigenetic	   repression	   by	   CpG	  
methylation	   of	   DNA.	   In	   certain	   cell	   lines	   DNA	   hypermethylation	   of	   the	   TGFβR2	   promoter	  
occurred,	   in	   some	   cases	   replacing	  H3K27Me3,	   causing	   repression	   of	   TGFβR2.	   In	   future,	   it	  
would	   be	   interesting	   to	   investigate	   for	   DNA	   methylation	   at	   this	   locus	   in	   tumour	   biopsy	  
samples.	  
	  
8.2	   The	   cooperation	   between	   EBNA3B,	   EBNA3C,	   LMP1	   and	   LMP2A	   in	   the	   repression	   of	  
TGFβR2	  
By	  using	  a	  panel	  of	   EBV-­‐negative	  BL31	   cells	   infected	  with	  BAC-­‐derived	   recombinant	  EBVs,	  
this	   study	   aimed	   to	   identify	   which	   latent	   proteins	   are	   responsible	   for	   the	   repression	   of	  
TGFβR2.	   In	   initial	   experiments,	   when	   EBNA2,	   EBNA3B	   or	   EBNA3C	   were	   deleted,	   de-­‐
repression	  of	  TGFβR2	  was	  seen,	  as	  well	  as	  restoration	  of	  TGFβ	  signalling	  via	  phosphorylation	  





of	  SMAD2,	  suggesting	  cooperation	  between	  these	  three	  latent	  proteins	  in	  the	  repression	  of	  
TGFβR2.	  
	  
The	   EBNA3	   proteins	   are	   a	   closely	   related	   set	   of	   proteins	   that	   regulate	   transcription	   of	  
multiple	   cellular	   genes,	   by	   targeting	   DNA	   via	   interaction	   with	   RBP-­‐Jκ	   and	   probably	   other	  
transcription	  factors.	  Several	  recent	  studies	  have	  demonstrated	  binding	  sites	  of	  EBNA3C	  to	  
target	  gene	  promoters	  and	  distal	  regulatory	  elements	  (e.g.	  enhancers)	  (Skalska	  et	  al.	  2010,	  
McClellan	  et	  al.	  2012,	  Paschos	  et	  al.	  2012,	  McClellan	  et	  al.	  2013).	  The	  EBNA3	  proteins	  often	  
cooperate	   in	   regulation	   of	   target	   genes,	   with	   the	   extent	   of	   cooperation	   revealed	   by	   an	  
exome	   microarray	   analysis	   (Paschos	   et	   al.	   2009,	   Skalska	   et	   al.	   2010,	   White	   et	   al.	   2010,	  
Paschos	   et	   al.	   2012,	   Skalska	   et	   al.	   2013).	   An	   attempt	   to	   show	   binding	   of	   EBNA3C	   to	   the	  
TGFβR2	   promoter	   was	   unsuccessful,	   however	   this	   has	   been	   shown	   for	   other	   genes	  
repressed	   by	   EBNA3C	   (Skalska	   et	   al.	   2010,	   McClellan	   et	   al.	   2012,	   Paschos	   et	   al.	   2012,	  
McClellan	   et	   al.	   2013,	   Skalska	   et	   al.	   2013)	   and	   other	   members	   of	   the	   laboratory	   are	  
currently	  investigating	  binding	  of	  EBNA3B	  to	  promoters.	  	  
	  
The	  effect	  of	   EBNA3B	  deletion	  was	   also	   investigated	   In	   LCLs	   and	  primary	  B	   cell	   infections	  
with	   EBNA3B	   KO	   virus,	   since	   EBNA3B	   is	   dispensable	   for	   transformation	   (Tomkinson	   et	   al.	  
1993).	   Initial	   experiments	   suggested	   an	   extremely	   moderate	   de-­‐repression	   of	   TGFβR2	   in	  
EBNA3B	  KO	  compared	  to	  wild-­‐type	  LCLs.	  However,	  even	  though	  the	  degree	  of	  de-­‐repression	  
was	  small,	  this	  led	  a	  to	  a	  definite	  increase	  in	  the	  amount	  of	  pSMAD2,	  suggesting	  that	  the	  de-­‐
repression	  was	   enough	   to	   bring	   TGFβR2	   expression	   above	   a	   threshold	   required	   for	   TGFβ	  
signalling.	  
	  
Investigation	   of	   the	   effect	   of	   EBNA3C	   in	   LCLs	   was	   more	   difficult,	   since	   EBNA3C	   was	  
previously	   thought	   to	  be	  absolutely	   required	   for	   transformation	   to	   LCLs	   (Tomkinson	  et	  al.	  
1993).	   Therefore	   initial	   experiments	   were	   done	   using	   3CHT-­‐LCLs,	   which	   have	   conditional	  
expression	   of	   functional	   EBNA3C,	   established	   from	   donor	   B	   cells	   with	   wild-­‐type	   p16INK4A.	  
This	  showed	  that	  TGFβR2	  remained	  repressed	  even	  after	  withdrawal	  of	  functional	  EBNA3C,	  
suggesting	  that	  EBNA3C	  was	  not	  necessary	   for	   the	  repression	   in	  LCLs,	  unlike	   in	  BL31	  cells.	  
However,	  the	  known	  epigenetic	  mechanism	  of	  repression	  by	  EBNA3C	  in	  BL31	  cells	  led	  to	  the	  
alternative	  hypothesis	  that	  previous	  exposure	  to	  functional	  EBNA3C	  would	  repress	  TGFβR2	  





and	   that	   since	   this	   is	   epigenetic,	   the	   repression	   would	   persist	   even	   after	   withdrawal	   of	  
EBNA3C	   function.	   Fortuitously,	   at	   this	   time	   other	   colleagues	   in	   the	   laboratory	   were	  
investigating	  the	  effect	  of	  EBNA3C	  on	  p16INK4A	  and	  had	  therefore	  obtained	  B	  cells	   from	  an	  
individual	  with	  a	  homozygous	  mutation	  of	  p16INK4A	   (Skalska	  et	  al.	  2013).	   Infection	  of	  these	  
cells	  with	  3CHT-­‐EBV	  was	  able	  to	  successfully	  produce	  LCLs	  even	  in	  the	  absence	  of	  4HT,	  and	  
thus	  which	  had	  never	  expressed	  functional	  EBNA3C.	  By	  investigating	  these	  cells,	  and	  other	  
sets	  which	  had	  been	  established	  with	  4HT	  but	  then	  had	  4HT	  withdrawn,	  the	  current	  study	  
was	   able	   to	   confirm	   the	   hypothesis	   of	   prior	   exposure	   to	   EBNA3C	   leading	   to	   persistent	  
repression	  of	  TGFβR2.	  Similarly	  to	  the	  case	  with	  EBNA3B	  KO,	  the	  degree	  of	  de-­‐repression	  of	  
TGFβR2	   in	   those	  cells	  which	  had	  never	  been	  exposed	   to	  4HT,	  and	   therefore	  EBNA3C,	  was	  
very	  moderate;	  however,	  this	  was	  again	  sufficient	  to	  lead	  to	  a	  definite	  increase	  in	  signalling	  
via	   phosphorylation	   of	   SMAD2.	   In	   future,	   investigation	   of	   chromatin	  modifications	   at	   the	  
TGFβR2	   promoter	   could	   be	   performed	   in	   the	   p16-­‐null	   3CHT-­‐LCLs	   established	   with	   4HT	  
compared	   to	   without	   4HT,	   in	   order	   to	   confirm	   this	   epigenetic	   repression	   of	   TGFβR2	   by	  
EBNA3C.	  
	  
The	  apparent	  involvement	  of	  EBNA2	  in	  repression	  of	  TGFβR2	  and	  suppression	  of	  signalling	  
in	   BL31	   cells	   was	   surprising,	   as	   EBNA2	   generally	   up-­‐regulates	   cellular	   genes	   and	   has	  
opposing	  effects	  to	  the	  EBNA3	  proteins,	  which	  are	  transcriptional	  repressors.	  This	  led	  to	  the	  
hypothesis	   that	   in	   fact	  LMP1	  and/or	  LMP2A	  were	   involved	   in	   the	   repression,	   since	  EBNA2	  
transactivates	  their	  expression.	  Therefore,	  towards	  the	  end	  of	  the	  project,	  LMP1	  and	  LMP2A	  
KO	  viruses	  were	  obtained	  and	  used	  to	  produce	  BL31	  LMP1	  KO	  and	  BL31	  LMP2A	  KO	  cell	  lines,	  
established	   in	   a	   similar	  manner	   to	   the	  other	   recombinant-­‐infected	  BL31	   cell	   lines	   used	   in	  
this	  project.	  Investigation	  of	  latent	  protein	  expression	  in	  these	  cell	   lines,	  however,	  showed	  
that	   the	   LMP2A	  KO	   lines	  also	   lacked	  expression	  of	   LMP1,	  and	   the	   two	  different	   LMP1	  KO	  
lines	  expressed	  LMP2A	  in	  different	  amounts.	  
	  
Investigation	   of	   TGFβR2	   expression	   and	   TGFβ	   signalling	   showed	   de-­‐repression	   of	   TGFβR2	  
and	   restoration	  of	   signalling	   in	  both	   LMP1	  KO	  and	  LMP2A	  KO	   lines.	  Although	  an	  effect	  of	  
EBNA2	   itself	  also	  could	  not	  entirely	  be	  excluded,	  due	  to	  the	  nature	  of	  expression	  of	  other	  
latent	  proteins	  in	  all	  these	  cell	  lines	  (see	  chapter	  4	  for	  full	  explanation),	  it	  therefore	  seems	  





likely	  that	  both	  LMP1	  and	  LMP2A	  cooperate,	  with	  EBNA3B	  and	  EBNA3C,	  in	  the	  repression	  of	  
TGFβR2	  and	  suppression	  of	  TGFβ	  signalling.	  	  
	  
LMP1	   and	   LMP2A	   are	   both	   membrane	   proteins	   and	   have	   many	   similar	   effects,	   both	  
mimicking	  signalling	  processes	  (those	  of	  CD40L	  and	  BCR	  respectively)	  that	  promote	  survival	  
of	  infected	  B	  cells	  within	  germinal	  centres,	  thus	  enabling	  infected	  cells	  to	  survive	  and	  reach	  
the	  memory	  B	  cell	  stage.	  This	  is	  necessary	  according	  to	  the	  Thorley-­‐Lawson	  model,	  in	  which	  
EBV	  uses	  normal	  B	  cell	  developmental	  pathways	  to	  establish	  latency	  (Thorley-­‐Lawson	  2001,	  
Thorley-­‐Lawson	   and	   Gross	   2004,	   Thorley-­‐Lawson	   et	   al.	   2013).	   LMP1	   and	   LMP2A	   are	  
expressed	  in	  latency	  II,	  found	  in	  HL	  and	  NPC,	  as	  well	  as	  latency	  III,	  found	  in	  tumours	  in	  the	  
setting	   of	   immunosuppression.	   They	   both	   activate	   other	   cellular	   signalling	   pathways,	  
including	   the	   generally	   pro-­‐survival	   NFκB,	   and	   they	   both	   have	   several	   different	   anti-­‐
apoptotic	   effects.	   Recent	   microarray	   studies	   in	   transgenic	   mice	   have	   shown	   that	   they	  
cooperate	   to	   regulate	   many	   cellular	   genes,	   and	   together	   cooperate	   to	   enhance	  
carcinogenesis	  (Shair	  et	  al.	  2012);	  however,	  in	  lymphoid	  cells	  their	  combined	  effects	  can	  be	  
synergistic	  or	   in	  some	  cases	  antagonistic	   (Shair	  and	  Raab-­‐Traub	  2012).	  Unlike	  the	  EBNA3s,	  
they	  do	  not	  alter	   transcription	  through	  DNA	  binding	   factors,	  as	   they	  are	   found	  on	  the	  cell	  
membrane.	  However,	  since	  they	  do	  alter	  transcription	  of	  multiple	  cellular	  genes,	  this	  is	  likely	  
to	   occur	   via	   their	   effects	   on	   other	   cellular	   pathways.	   Thus	   it	   is	   feasible	   that	   they	   could	  
cooperate	  to	  alter	  transcription	  of	  TGFβR2.	  	  
	  
Few	   studies,	   if	   any,	   have	   previously	   demonstrated	   the	   combined	   effects	   of	   EBNA3s	   and	  
LMPs	   in	   regulation	  of	   gene	  expression,	  but	   it	   seems	   likely	   that	  many	  more	  genes	  may	  be	  
regulated	   in	   this	   way.	   Previous	   studies	   have	   tended	   to	   focus	   either	   on	   the	   effects	   of	  
individual	  latent	  proteins,	  expressed	  in	  isolation	  in	  EBV-­‐negative	  cells,	  or	  have	  investigated	  
the	   effects	   of	   deletion	   of	   latent	   proteins	   on	   cellular	   gene	   expression.	   Since	   these	   studies	  
have	  shown	  cooperation	  between	  EBNA3	  proteins	  (Anderton	  et	  al.	  2008,	  Skalska	  et	  al.	  2010,	  
White	  et	  al.	  2010,	  Maruo	  et	  al.	  2011,	  Skalska	  et	  al.	  2013),	  between	  LMP1	  and	  LMP2A	  (Shair	  
et	  al.	  2012,	  Shair	  and	  Raab-­‐Traub	  2012),	  or	  between	  EBNA2	  and	  EBNA3C	  (Zhao	  et	  al.	  2011),	  
it	  seems	  entirely	  feasible	  that	  more	  cooperation	  could	  be	  found	  between	  LMPs	  and	  EBNA3s.	  
Now	  that	  the	  LMP1	  and	  LMP2A	  KO	  BL31	  cell	   lines	  have	  been	  established,	  the	  cooperation	  
between	  these	  latent	  proteins	  and	  EBNA3	  proteins	  in	  regulation	  of	  cellular	  gene	  expression	  





could	   be	   used	   in	   a	   similar	   microarray-­‐based	   approach	   as	   used	   by	   White	   and	   colleagues	  
(White	  et	  al.	  2010).	   Ideally	  such	  a	  study	  would	  also	   investigate	  the	  revertants	  to	  wild-­‐type	  
from	  each	  knockout,	  in	  order	  to	  confirm	  that	  nothing	  else	  is	  altered	  apart	  from	  the	  gene	  of	  
interest;	  this	  was	  done	  for	  the	  EBNA3s	  study,	  but	  revertants	  for	  the	  LMP1	  KO	  and	  LMP2A	  KO	  
BACs	   used	   in	   the	   current	   study	   were	   not	   available.	   A	   limitation	   of	   such	   experiments,	  
however,	  is	  that	  often	  deletion	  of	  one	  latent	  gene	  seems	  to	  affect	  expression	  of	  others,	  for	  
instance	  as	   shown	  here	   for	   the	  EBNA3	  KO	   cell	   lines	  which	   also	   lacked	   LMP2A	  expression,	  
and	  the	  LMP2A	  KO	  lines	  that	  lack	  LMP1	  expression.	  	  
	  
Unfortunately	   in	   the	  current	  study	  an	  attempt	   to	   infect	  primary	  B	  cells	  with	   the	  LMP1	  KO	  
and	  LMP2A	  KO	  viruses,	  to	  investigate	  their	  involvement	  in	  repression	  of	  TGFβR2	  also	  in	  LCLs,	  
was	  unsuccessful,	  but	   this	  experiment	  could	  be	   re-­‐attempted.	  Using	   the	  EREB2.5	  cell	   line,	  
withdrawal	  of	  β-­‐estradiol	  from	  the	  medium,	  and	  hence	  withdrawal	  of	  functional	  EBNA2	  as	  
well	  as	  LMP1	  and	  LMP2A,	  resulted	  in	  de-­‐repression	  of	  TGFβR2,	  suggesting	  that	  one	  or	  more	  
of	  these	  latent	  proteins	  may	  also	  repress	  TGFβR2	  in	  LCLs.	  However,	  this	  approach	  had	  many	  
limitations,	   since	   the	   cells	   undergo	   arrest,	   and	   approximately	   half	   die	   by	   apoptosis,	   upon	  
withdrawal	   of	   estradiol	   (Kempkes	   et	   al.	   1995),	   and	   the	   EBNA3	   expression	   could	   not	   be	  
investigated	  in	  them	  due	  to	  the	  lack	  of	  appropriate	  (type	  2	  EBV-­‐specific)	  antibodies	  as	  well	  
as	  the	  relatively	  long	  half-­‐life	  of	  the	  EBNA3	  proteins.	  	  	  
	  
8.3	  The	  up-­‐regulation	  of	  TGFβR3	  by	  EBV	  
This	   study	   has	   confirmed	   that	   EBV,	   in	   addition	   to	   down-­‐regulating	   TGFβR2,	   up-­‐regulates	  
TGFβR3	  expression	   in	  BL31	  cells	  and	  LCLs.	   In	  BL31	  cells	  the	  same	  latent	  proteins,	  EBNA3B,	  
EBNA3C,	   LMP1	  and	   LMP2A	  are	   also	   responsible	   for	   the	  up-­‐regulation	  of	   TGFβR3.	   In	  most	  
cases	   the	   expression	   of	   TGFβR2	   and	   TGFβR3	   appeared	   to	   be	   reciprocal,	   and	   the	   ChIP	   for	  
H3K27me3	   and	   H3K9Ac	   were	   generally	   also	   reciprocal,	   although	   there	   were	   some	  
exceptions	   in	   the	   EBNA3A	   KO	   lines,	   which	   as	   described	   in	   section	   4.6	   were	   rather	  
heterogeneous.	  This	  apparently	   reciprocal	  nature	  of	  expression	   led	   to	   the	  hypothesis	   that	  
TGFβR2	   and	   TGFβR3	   were	   somehow	   co-­‐regulated.	   TGFβ1–mediated	   transcriptional	  
repression	   of	   TGFβR3,	   via	   the	   TGFβR3	   proximal	   promoter,	   had	   been	   shown	   in	  
breast/ovarian	  carcinoma	  cell	   lines	   (Hempel	  et	  al.	  2008).	  Treatment	  of	  BL31	  cells	  with	  the	  





specific	   TGFβR1	   inhibitor	   SB431542	   led	   to	   a	   2.5-­‐fold	   increase	   in	   transcription	   of	   TGFβR3,	  
suggesting	   that	   a	   similar	  mechanism	  may	  be	   present	   in	   BL31	   cells.	   This	   could	   explain	   the	  
reciprocal	   expression	   of	   TGFβR2	   and	   TGFβR3,	   as	   once	   TGFβR2	   expression	   falls	   below	   a	  
threshold,	  so	  that	  signalling	  is	  repressed,	  this	  TGFβ1-­‐mediated	  repression	  of	  TGFβR3	  would	  
no	  longer	  occur,	  allowing	  de-­‐repression	  of	  TGFβR3.	  	  
	  
After	  infection	  of	  primary	  B	  cells	  there	  was	  an	  initial	  down-­‐regulation	  of	  TGFβR3	  in	  the	  first	  
7-­‐10	   days.	   TGFβR3	   expression	   then	   increased	   very	   gradually,	   and	   this	   gradual	   increase	  
appeared	  to	  start	  only	  after	  the	  repression	  of	  TGFβR2	  had	  reached	  a	  certain	  level.	  This	  may	  
also	  be	  consistent	  with	  de-­‐repression	  of	  TGFβR3	  as	  a	  result	  of	   loss	  of	  TGFβ	  signalling	  once	  
TGFβR2	   is	   repressed	   below	   a	   threshold,	   supported	   by	   the	   relatively	   stable	   expression	   of	  
TGFβ1	   mRNA	   after	   B	   cell	   infection.	   However,	   the	   very	   slow	   increase	   in	   TGFβR3	   also	  
suggested	   a	   possible	   clonal	   selection	   process,	   especially	   as	   in	   one	   particular	   experiment	  
TGFβR3	  was	  not	  up-­‐regulated	  by	  six	  weeks	   in	  one	  revertant	  cell	   line,	  even	  though	  TGFβR2	  
was	  near	  maximally	  repressed	  by	  four	  weeks	  post-­‐infection	  in	  that	  experiment.	  	  
	  
The	   consequences	   of	   TGFβR3	   up-­‐regulation	   are	   not	   known.	   A	   recent	   study	   showed	   low	  
TGFβR2	  and	  high	  TGFβR3	  expression	  in	  several	  B	  cell	  lymphoma	  lines,	  although	  in	  the	  small	  
number	  of	  primary	  B-­‐NHL	  tumour	  samples	  tested,	  TGFβR3	  expression	  was	  low	  (Yang	  et	  al.	  
2013).	  This	  again	  could	  be	  due	  to	  clonal	  selection	  within	  culture	  of	  the	  cell	  lines	  and	  may	  not	  
occur	  in	  vivo.	  However,	  increased	  TGFβR3	  has	  also	  been	  shown	  in	  CLL,	  possibly	  suggesting	  a	  
tumour	  promoting	  effect,	  in	  two	  studies	  (Klein	  et	  al.	  2001,	  Jelinek	  et	  al.	  2003).	  	  
	  
In	  non-­‐haematopoietic	  malignancies	  TGFβR3	  is	  generally	  tumour	  suppressive	  and	  has	  been	  
shown	   to	  be	  down-­‐regulated	   in	  many	  different	   epithelial	  malignancies	   (Florio	   et	   al.	   2005,	  
Dong	  et	  al.	  2007,	  Hempel	  et	  al.	  2007,	  Turley	  et	  al.	  2007,	  Finger	  et	  al.	  2008b,	  Gordon	  et	  al.	  
2008,	  Margulis	  et	  al.	  2008,	  Cooper	  et	  al.	  2010).	   It	   is	  possible	   that	   the	  cellular	   response	   to	  
loss	  of	  TGFβR2	  is	  to	  increase	  TGFβR3	  in	  order	  to	  try	  to	  augment	  remaining	  TGFβ	  signalling;	  
however	  there	  is	  no	  evidence	  that	  this	  occurs	  in	  other	  cell	  types	  such	  as	  epithelial	  cells	  and	  
so	   seems	   an	   unlikely	   explanation.	   TGFβR3	   is	   a	   co-­‐receptor	   for	   BMP	   signalling	   as	   well	   as	  
activin/inhibin	   signalling	   and	   is	   specifically	   required	   for	   TGFβ2	   signalling.	   Therefore	   it	   is	  
possible	  that	  by	  up-­‐regulating	  TGFβR3,	  EBV	  is	  altering	  one	  of	  these	  pathways,	  but	  there	  was	  





not	  sufficient	  time	  to	  investigate	  any	  of	  them	  in	  this	  study.	  Only	  the	  possibility	  that	  it	  would	  
alter	   BMP	   signalling	   was	   investigated	   (see	   chapter	   7),	   but	   although	   EBV	   increased	   BMP	  
signalling,	   the	   mechanism	   was	   not	   via	   the	   up-­‐regulation	   of	   TGFβR3.	   The	   significance	   of	  
TGFβR3	  up-­‐regulation	  is	  therefore	  still	  not	  known.	  Nevertheless,	   it	  would	  be	  interesting	  to	  
investigate	   whether	   increased	   TGFβR3	   expression	   is	   seen	   in	   tumours,	   especially	   EBV-­‐
positive	   lymphomas,	  as	  this	  could	  possibly	  represent	  a	  marker	  for	  EBV-­‐positivity	  or	  even	  a	  
target	  for	  therapy.	  	  
	  
8.4	  The	  effects	  of	  EBV	  on	  BMP	  signalling	  and	  SMAD1/5	  expression	  
In	   chapter	   7,	   the	   effects	   of	   EBV	   on	   BMP	   signalling	  were	   investigated.	   At	   the	   start	   of	   the	  
project	  very	  little	  was	  known	  about	  the	  effects	  of	  BMPs	  in	  B	  cells,	  but	  during	  the	  course	  of	  
the	   project,	   several	   papers	   were	   published	   investigating	   expression	   of	   BMPs	   and	   BMP	  
receptors	  in	  B	  cells	  and	  lymphomas	  (Bakkebo	  et	  al.	  2010,	  Huse	  et	  al.	  2011,	  Huse	  et	  al.	  2012),	  
suggesting	  that	  BMP	  signalling	  may	  be	  important	  in	  the	  B	  cell	  system.	  	  
	  
Treatment	   with	   BMP2	   and	   BMP4,	   which	   act	   preferentially	   via	   ALK3	   (BMPRIA)	   and	   ALK6,	  
induced	  phosphorylation	  of	  SMAD1/5	  and	  G1	  arrest	   in	  BL31	  cells.	  EBV	   infection	  enhanced	  
SMAD1	   linker	   phosphorylation,	   but	   not	   SMAD5	   phosphorylation,	   in	   response	   to	   BMP2/4.	  
Preliminary	  investigations	  also	  suggested	  that	  EBV	  up-­‐regulates	  expression	  of	  BMPRIA/ALK3,	  
which	  would	  be	  expected	  to	  enhance	  signalling	  and	  the	  effects	  of	  BMP2/4,	  as	  was	  seen.	  
	  
BMP6	  also	  induced	  pSMAD1/5	  in	  BL31	  cells	  but	  did	  not	  induce	  G1	  arrest	  at	  the	  dose	  used.	  In	  
the	   presence	   of	   EBV	   infection,	   the	   induction	   of	   both	   SMAD1	   linker	   phosphorylation	   and	  
SMAD5	  C-­‐terminal	  phosphorylation	  by	  BMP6	  was	  increased,	  and	  BMP6	  did	  induce	  cell	  cycle	  
arrest.	  BMP6	  acts	  preferentially	  via	  ALK2	  and	  ALK6	  and	  binds	  only	  weakly	  to	  ALK3.	  	  
	  
EBV	   infection	  was	  also	   found	   to	   robustly	  up-­‐regulate	   SMAD1	  expression	   in	  both	   LCLs	   and	  
BL31	  cells,	  although	  the	  latent	  proteins	  involved	  seem	  to	  be	  different	  between	  the	  two	  cell	  
types.	   In	  BL31	  cells	  LMP2A,	  EBNA3C	  and	  to	  a	   lesser	  extent	  EBNA3B	  were	  required	   for	   the	  
up-­‐regulation.	  In	  LCLs	  and	  primary	  B	  cells,	  however,	  this	  was	  clearly	  an	  effect	  of	  EBNA3B,	  as	  
SMAD1	  expression	  remained	  extremely	  low	  in	  EBNA3B	  KO	  LCLs.	  In	  LCLs	  the	  up-­‐regulation	  of	  





SMAD1	   by	   EBNA3B	   also	   appears	   to	   be	   via	   epigenetic	   regulation	   of	   transcription.	  
Interestingly,	  the	  up-­‐regulation	  of	  SMAD1	  expression	  after	  primary	  B	  cell	  infection	  does	  not	  
occur	  until	  around	  14	  days	  post-­‐infection,	  whereas	  EBNA3B	  would	  be	  fully	  expressed	  in	  the	  
first	   few	   days.	   LMP1	   is	   generally	   not	   fully	   expressed	   until	   much	   later	   than	   the	   EBNA3	  
proteins	  after	  primary	  B	  cell	   infection,	  with	  maximal	  expression	  seen	  at	  around	  3-­‐4	  weeks.	  
LMP1	   and	   LMP2A	   mRNA	   expression	   were	   both	   slow	   to	   increase	   in	   the	   current	   study,	  
reaching	  maximum	  at	  around	  25-­‐30	  days	  post-­‐infection	  (data	  not	  shown).	  Thus	  it	  is	  possible	  
that	  LMP2A	  also	  contributes	  to	  the	  up-­‐regulation	  of	  SMAD1,	  hence	  why	  this	  is	  delayed	  until	  
around	  14	  days	  post-­‐infection.	   This	   could	  be	   investigated	   in	   future	  by	   infecting	  primary	  B	  
cells	  with	  LMP2A	  KO	  virus	  and	  thus	  hopefully	  establishing	  LMP2A	  KO	  LCLs.	  The	  other	  latent	  
proteins	  have	  a	   very	  minimal	   contribution,	   if	   any,	   to	   the	  up-­‐regulation	  of	   SMAD1	   in	   LCLs.	  
However,	   in	  BL31	  cells,	   the	  overall	  up-­‐regulation	  of	  SMAD1	  by	  EBV	   is	   less	  marked	   than	   in	  
LCLs,	  although	  this	  may	  be	  partly	  because	  BL31	  have	  a	  relatively	  high	  baseline	  expression.	  	  
	  
EBV	  infection	  was	  also	  found	  to	  down-­‐regulate	  SMAD5	  in	  BL31	  in	  preliminary	  experiments.	  
This	  could	  be	  via	  the	  up-­‐regulation	  of	  BIC/miR-­‐155	  by	  LMP1	  (Rahadiani	  et	  al.	  2008),	  which	  
would	   lead	   to	   reduced	   SMAD5	   expression	   (Rai	   et	   al.	   2010),	   but	   the	  mechanism	  was	   not	  
investigated	  in	  the	  current	  study	  because	  of	  time	  constraints.	  The	  up-­‐regulation	  of	  SMAD1	  
and	  down-­‐regulation	  of	  SMAD5	  by	  EBV	  led	  to	  the	  hypothesis	  that	  EBV	  may	  alter	  expression	  
of	  BMP	  target	  genes	  by	  altering	  SMAD	  usage.	  In	  addition,	  a	  non-­‐canonical	  pathway	  involving	  
TGFβ-­‐mediated	  induction	  of	  phosphorylated	  SMAD1/5	  had	  been	  shown	  in	  many	  cell	  types,	  
more	  recently	  including	  B	  cells	  (Munoz	  et	  al.	  2004,	  Bakkebo	  et	  al.	  2010,	  Rai	  et	  al.	  2010,	  Jiang	  
and	  Aguiar	   2014),	   and	   it	  was	  hypothesised	   that	   EBV	  may	   alter	   this;	   this	  will	   be	  discussed	  
further	  below.	  	  	  
	  
In	   EBV-­‐negative	   BL31	   cells,	   very	   little	   phosphorylation	   of	   the	   SMAD1	   linker	   was	   seen,	  
whereas	  in	  the	  presence	  of	  EBV	  infection	  this	  phosphorylation	  was	  induced	  by	  BMP2,	  BMP4	  
and	   BMP6,	   but	   not	   BMP7	   or	   BMP9.	   Phosphorylation	   of	   SMAD5	  was	   strongly	   induced	   by	  
BMP2	  and	  BMP4	   in	  EBV-­‐negative	  BL31,	  and	  only	  slightly	   increased	  with	  EBV	   infection	   (fig.	  
7.1).	  With	  BMP6,	   however,	   there	  was	   very	   little	   phosphorylation	  of	   SMAD5	   in	   uninfected	  
BL31,	  but	   this	  was	  markedly	   increased	   in	  EBV-­‐infected	  cells.	  BMP6-­‐induced	  G1	  arrest	  was	  
seen	   in	   EBV-­‐infected	   but	   not	   in	   EBV-­‐negative	   BL31,	   whereas	   both	   EBV-­‐infected	   and	   –





uninfected	  BL31	  cells	  underwent	  G1	  arrest,	  in	  conjunction	  with	  strong	  induction	  of	  SMAD5	  
phosphorylation,	  after	  BMP2/4	  treatment.	  In	  those	  experiments	  the	  levels	  of	  pSMAD5	  were	  
generally	   similar	   to	   those	   for	  pSMAD1/5/8,	   suggesting	   that	   SMAD5	   is	   the	  predominant	  R-­‐
SMAD	  used	   in	   these	   cells.	   Taken	   together,	   these	   findings	   suggest	   that	  phosphorylation	  of	  
SMAD5	  is	  important	  for	  BMP-­‐induced	  growth	  arrest.	  	  
	  
8.5	  TGFβ-­‐induced	  phosphorylation	  of	  SMAD1/5	  in	  B	  cells	  
TGFβ-­‐induced	  phosphorylation	  of	   SMAD1/5	  has	   recently	   been	   shown	   to	   be	   important	   for	  
TGFβ-­‐induced	  cell	  cycle	  arrest,	   in	  murine	  B	  cells	  and	  B	  lymphoma	  cell	   lines	  (Bakkebo	  et	  al.	  
2010,	  Rai	  et	  al.	  2010,	  Jiang	  and	  Aguiar	  2014),	  although	  a	  role	  for	  SMAD1	  in	  BMP	  and	  TGFβ	  
induced	  arrest	  had	  also	  been	  suggested	  previously	  (Munoz	  et	  al.	  2004).	  Although	  Rai	  et	  al	  
(2010)	   used	   an	   antibody	   to	   phosphorylated	   SMAD1	   and/or	   SMAD5,	   they	   went	   on	   to	  
demonstrate	   by	   co-­‐immunoprecipitation	   experiments	   that	   TGFβ-­‐induced	   pSMAD1/5	  
occurred	  predominantly	  through	  SMAD5,	  whereas	  Munoz	  et	  al	  (2004)	  showed	  induction	  of	  
phosphorylated	   SMAD1,	   but	   did	   not	   investigate	   phosphorylation	  of	   SMAD5.	   Furthermore,	  
Bakkebo	  et	  al	   (2010)	  did	  not	  distinguish	  between	  phosphorylation	  of	  SMAD1	  and	  SMAD5.	  
Jiang	  and	  Aguiar	  (2014)	  showed	  that	  knockdown	  of	  SMAD5	  by	  miR-­‐155	  or	  by	  siRNA	  led	  to	  
loss	  of	  TGFβ-­‐induced	  p15INK4B/p21CIP1/WAF1	   induction	  and	  concomitant	  cell	   cycle	  arrest;	   this	  
also	  occurred	   in	  one	  cell	   line	  which	  completely	   lacked	  SMAD1	  expression,	   suggesting	   that	  
SMAD1	  was	  not	  necessary.	  Thus	  it	  is	  not	  entirely	  clear	  whether	  TGFβ-­‐induced	  arrest	  occurs	  
only	   via	   SMAD5	   (as	   suggested	   by	   the	   Aguiar	   group	   studies)	   or	   whether	   SMAD1	   can	   also	  
contribute,	  as	  suggested	  by	  the	  Munoz	  study	  (Munoz	  et	  al.	  2004).	  
	  
In	   the	   current	   study,	   TGFβ-­‐induced	  phosphorylation	  of	   SMAD5	  was	   confirmed	   in	  BL31,	   at	  
two	  hours	  post	  treatment,	  but	  was	  not	  sustained	  beyond	  this	  time	  point.	  Previous	  studies	  
had	   shown	   that	   the	  TGFβ-­‐induced	  phosphorylation	  of	   SMAD5	  was	   similarly	   short-­‐lived.	   In	  
EBV-­‐infected	   BL31,	   no	   induction	   of	   pSMAD5	   was	   seen	   with	   TGFβ,	   suggesting	   that	   EBV	  
abrogates	  this	  non-­‐canonical	  pathway	   in	  a	  similar	  way	  to	   its	  abrogation	  of	  canonical	  TGFβ	  
signalling.	  This	  suggests	  that	  the	  non-­‐canonical	  pathway	  may	  also	  be	  mediated	  by	  TGFβR2,	  
as	  EBV	  down-­‐regulates	  TGFβR2.	  
	  





Although	  EBV	  infection	  increased	  constitutive	  SMAD1	  linker	  phosphorylation	  and	  decreased	  
constitutive	   SMAD5	   C-­‐terminal	   phosphorylation,	   these	   seemed	   to	   be	   commensurate	  with	  
the	  total	  SMAD1/5	  levels	  in	  BL31	  and	  so	  it	  did	  not	  appear	  that	  EBV	  was	  promoting	  a	  switch	  
from	   use	   of	   SMAD5	   to	   SMAD1	   in	   this	   non-­‐canonical	   TGFβ	   pathway.	   In	   EBNA3B	   KO	   LCLs,	  
treatment	  with	  BMPs	  surprisingly	  led	  to	  a	  general	  reduction	  in	  BMP	  signalling	  in	  EBNA3B	  KO	  
compared	   to	  wild-­‐type	  LCLs,	  with	   reductions	  of	  phosphorylated	  SMAD5	  as	  well	  as	  SMAD1	  
linker	   phosphorylation.	   Again	   the	   consequence	   of	   this	   is	   not	   clear;	   it	   may	   alter	   the	  
responsiveness	  to	  TGFβ	  or	  BMPs	  in	  EBNA3B	  KO	  LCLs,	  although	  a	  preliminary	  experiment	  did	  
not	  show	  any	  difference	   in	  cell	   cycle	  profile	  between	  EBNA3B	  KO	  and	  wild-­‐type	  LCLs	  with	  
TGFβ	  or	  BMP	  treatment	  (data	  not	  shown).	  However,	  due	  to	  time	  constraints	  this	  experiment	  
was	  only	  attempted	  on	  one	  occasion	  and	  should	  be	  repeated,	  ideally	  in	  conjunction	  with	  an	  
array	   analysis	   to	   investigate	   the	   BMP	   and	   TGFβ	   target	   gene	   profile	   of	   wild-­‐type	   versus	  
EBNA3B	  KO	  LCLs	  when	  treated	  with	  TGFβ	  and	  BMP	  ligands.	  In	  addition,	  siRNA	  could	  be	  used	  
to	   knock	   down	   expression	   of	   SMAD1	   and	   SMAD5	   separately,	   in	   order	   to	   investigate	   the	  
hypothesis	  that	  EBV	  changes	  the	  target	  gene	  profile	  by	  altering	  SMAD1/5	  expression.	  Even	  if	  
this	   were	   confirmed	   not	   to	   alter	   the	   cell	   cycle	   profile	   in	   response	   to	   TGFβ/BMPs,	   it	   is	  
possible	   that	   the	   change	   in	   SMAD	   expression	   alters	   other	   cellular	   processes	   such	   as	  
differentiation.	  	  
	  
8.6	  The	  effects	  of	  EBV	  on	  TGFβ-­‐induced	  arrest	  and	  apoptosis	  
Prior	   to	   this	   work,	   the	   majority	   of	   studies	   on	   the	   effects	   of	   EBV	   on	   TGFβ	   signalling	   had	  
investigated	  the	  effects	  on	  cellular	  responses	  to	  TGFβ.	  TGFβ	  generally	  promotes	  apoptosis	  
and/or	   is	   anti-­‐proliferative,	   and	   multiple	   studies	   had	   suggested	   that	   cells	   expressing	   full	  
latency	   III	   EBV	   were	   resistant	   to	   the	   anti-­‐proliferative	   effects	   of	   EBV.	   However,	   the	  
mechanisms	   for	   this	   were	   not	   entirely	   understood,	   with	   only	   a	   few	   studies	   investigating	  
expression	  of	  TGFβR1	  and/or	  TGFβR2,	  often	  showing	  discrepant	  results.	  These	  studies	  had	  
been	  done	  in	  several	  different	  cell	   types,	   largely	  tumour	  cell	   lines	  which	  may	  have	  altered	  
cell	  cycle/apoptotic	  pathways	  anyway	  as	  part	  of	  the	  tumour	  development,	  and	  which	  may	  
have	  acquired	  further	  changes	  by	  clonal	  selection	  in	  culture.	  	  
	  





Several	  studies	  had	  shown	  that	  LCLs	  were	  resistant	  to	  the	  effects	  of	  TGFβ.	  Although	  LCLs	  are	  
more	  reflective	  of	  the	  situation	  in	  vivo,	  they	  are	  still	  subject	  to	  changes	  during	  culture	  (Lee	  
et	   al.	   2010).	   However,	   investigation	   of	   the	   EBV-­‐negative	   counterpart	   to	   LCLs	   is	   more	  
problematic;	  most	  previous	  studies	  used	  murine	  B	  cells	  isolated	  from	  spleen,	  murine	  B	  cell	  
lymphoma	  cell	  lines,	  again	  subject	  to	  the	  problems	  of	  tumour	  cells	  and	  selection	  in	  culture,	  
or	  used	  human	  B	  cells	   isolated	   from	  peripheral	  blood	  or	   from	  tonsillar	  extracts.	  However,	  
there	   appear	   to	   be	   some	   differences	   in	   TGFβ	   responsiveness	   and	   apoptotic	   pathways	  
between	  human	  and	  murine	  B	  cells	  (Spender	  et	  al.	  2013).	  Furthermore,	  the	  mature	  B	  cells	  
used	  in	  these	  studies	  would	  have	  been	  quiescent	  and	  therefore	  some	  means	  was	  required	  
of	   artificially	   inducing	   their	  proliferation	  before	   investigating	   the	  effects	  of	   TGFβ.	   In	   some	  
cases	  B	  lymphoma	  cell	  lines	  were	  used,	  including	  BL,	  DLBCL,	  unspecified	  B	  cell	  lymphomas,	  
or	   CLL	   cells,	   but	   these	   are	   all	   subject	   to	   the	   biases	   of	   tumours	   and	   cell	   lines	   as	   already	  
described.	  	  
	  
The	   current	   study,	   having	   shown	   that	   EBNA3B,	   EBNA3C,	   LMP1	   and	   LMP2A	   cooperate	   to	  
repress	  TGFβR2	  and	  suppress	  signalling	   in	  BL	  cells,	   investigated	   the	  effects	  of	  knockout	  of	  
these	   latent	   proteins	   on	   TGFβ-­‐induced	   apoptosis	   and/or	   cell	   cycle	   arrest,	   since	   it	   was	  
hypothesised	  that	  the	  same	  latent	  proteins	  may	  be	  protective	  against	  the	  effects	  of	  TGFβ.	  
However,	  TGFβ	   treatment	  of	   the	  panel	  of	  BL31	  cell	   lines	   showed	   that	  although	  BL31	  cells	  
underwent	  apoptosis	  with	  TGFβ,	  none	  of	   the	  KO	  cell	   lines	   showed	  apoptosis	   to	   the	   same	  
degree.	  TGFβ-­‐induced	  apoptosis	  may	  occur	  via	  SMAD3,	  which	  was	  not	   investigated	   in	   this	  
study,	  or	  via	  SMAD-­‐independent	  pathways	  involving	  cross-­‐talk	  with	  other	  cellular	  pathways;	  
the	  mechanism	  could	  be	  investigated	  further	  in	  future.	  This	  study	  has	  similar	  limitations	  to	  
previous	   studies,	   as	   it	   used	   a	   tumour	   cell	   line	   that	   already	   has	   alterations	   in	   cell	   cycle	  
regulation.	  Furthermore,	  it	  is	  very	  important	  to	  remember	  that	  EBV	  has	  multiple	  effects	  on	  
apoptotic	  pathways	  (Allday	  2009,	  Spender	  and	  Inman	  2011,	  Allday	  2013)	  and	  these	  may	  also	  
alter	  the	  final	  responses	  of	  B	  cells	  to	  TGFβ.	  It	  is	  likely	  that	  anti-­‐apoptotic	  effects	  of	  other	  EBV	  
latent	  proteins	  can	  protect	  B	  cells	  from	  TGFβ-­‐induced	  apoptosis	  even	  when	  individual	  latent	  
genes	  are	  deleted	  such	  that	  TGFβ	  signalling	  is	  restored.	  	  
	  
In	   agreement	  with	  previous	   studies,	   BL31-­‐WT	  and	   LCL-­‐WT	   showed	  no	   apoptosis	   or	   arrest	  
with	  TGFβ	  treatment.	  Several	  of	  the	  BL31	  recombinant	  cell	  lines	  did,	  however,	  undergo	  G1	  





cell	   cycle	   arrest	  with	   TGFβ,	   in	   contrast	   to	   the	   apoptosis	   seen	   in	   uninfected	   cells.	   The	   cell	  
lines	  that	  underwent	  G1	  arrest	  all	  lacked	  LMP2A	  expression,	  suggesting	  that	  LMP2A	  may	  be	  
required	   to	   inhibit	   the	   anti-­‐proliferative	   effects	   of	   TGFβ.	   LMP2A	   is	   known	   to	   have	   anti-­‐
apoptotic	  effects,	  but	  little	  is	  known	  of	  its	  effects	  on	  cell	  cycle	  progression.	  	  
	  
As	   described	   above,	   a	   recent	   study	   in	   murine	   B	   cells	   and	   human	   DLBCL	   cell	   lines	   had	  
demonstrated	   that	   TGFβ	   induced	   p15INK4B	   and	   p21CIP1/WAF1,	   as	   well	   as	   reduction	   in	  
phosphorylation	  of	  Rb,	  leading	  to	  arrest	  (Jiang	  and	  Aguiar	  2014).	  Knockdown	  of	  SMAD5	  by	  
siRNA	   or	   via	   overexpression	   of	  miR-­‐155,	   which	   the	   same	   group	   had	   previously	   shown	   to	  
target	   SMAD5	   (Rai	   et	   al.	   2010),	   led	   to	   interruption	   of	   the	   TGFβ-­‐induced	   induction	   of	  
p15INK4B/	  p21CIP1/WAF1	   and	   cell	   cycle	   arrest,	   suggesting	   that	   SMAD5	  was	   required	   for	   TGFβ-­‐
induced	   arrest.	   However,	   in	   the	   EBV-­‐negative	   BL	   line	   CA46,	   which	   is	   unable	   to	   undergo	  
apoptosis	  due	  to	  lack	  of	  BAX	  expression,	  Spender	  and	  Inman	  had	  shown	  that	  the	  mechanism	  
of	  TGFβ-­‐induced	  arrest	  occurred	   independently	  of	  p15INK4B/	  p21CIP1/WAF1	   induction,	   instead	  
occurring	   via	   repression	   of	   E2F1	   (Spender	   and	   Inman	   2009b).	   In	   another	   study,	   TGFβ	   did	  
induce	  p21CIP1/WAF1	  expression	  in	  the	  EBV-­‐negative	  BL	  cell	  line	  Ramos	  (Di	  Bartolo	  et	  al.	  2008).	  	  
In	   the	   current	   study,	   TGFβ	   treatment	   did	   not	   induce	   p15INK4B	   in	   either	   BL31	   or	   LCLs.	   The	  
differences	  between	  studies	  may	  reflect	  different	  arrest	  mechanisms	  between	  BL	  (as	  used	  in	  
the	  current	  study	  and	  in	  (Spender	  and	  Inman	  2009b)	  and	  DLBCL	  lines	  or	  murine	  B	  cells	  (as	  
used	  in	  Jiang	  and	  Aguiar	  2014).	  	  
	  
8.7	  The	  significance	  of	  BMP	  signalling	  in	  B	  cell	  biology	  and	  B	  cell	  malignancies	  
The	  significance	  of	  the	  increased	  BMP	  signalling	  and	  concomitant	  cell	  cycle	  arrest	  by	  EBV	  is	  
not	  known,	  and	  there	   is	   limited	   information	  available	  about	  the	  expression	  and	  activity	  of	  
BMPs	  within	  the	  peripheral	   lymphoid	  system.	   Initially	  BMPs	  were	  thought	  to	  be	  produced	  
only	  in	  bone,	  by	  osteoclasts,	  but	  it	  has	  since	  been	  shown	  that	  they	  are	  expressed	  by	  various	  
other	  cell	  types,	  including	  within	  the	  bone	  marrow	  where	  they	  are	  important	  for	  controlling	  
haematopoiesis	  (Bhatia	  et	  al.	  1999,	  Passa	  et	  al.	  2011).	  BMP7	  is	  expressed	  in	  normal	  B	  cells	  
(Detmer	  et	  al.	  1999),	  and	  tonsillar	  centroblasts/centrocytes	  also	  showed	  high	  expression	  of	  
BMP7,	  with	  low	  BMP6	  expression	  (Huse	  et	  al.	  2012).	  In	  several	  B	  lymphoma	  cell	  lines	  BMP2	  
expression	  was	  undetectable,	  whereas	  BMP4	  expression	  varied	  between	  cell	  lines	  (Huse	  et	  





al.	   2012).	   Naïve	   and	   memory	   B	   cells	   express	   ALK2,	   ALK3	   and	   ALK6	   (Kersten	   et	   al.	   2005,	  
Seckinger	   et	   al.	   2009)	   and	   so	  would	   be	   expected	   to	   respond	   to	   BMP2,	   BMP4,	   BMP6	   and	  
BMP7.	  	  
	  
The	  studies	  described	  above	  have	  investigated	  BMP	  expression	  by	  B	  cells	  themselves,	  which	  
would	   be	   important	   for	   autocrine/paracrine	   signalling.	   However,	   it	   is	   also	   possible	   that	  
secretion	  of	  BMPs	  by	  other	  cell	  types,	  such	  as	  stromal	  cells	  and	  other	   immune	  cells,	  could	  
occur	   in	   different	   compartments	   of	   the	   lymphoid	   system.	   Since	   EBV	   enhances	   the	   anti-­‐
proliferative	  effects	  of	  BMP2,	  BMP4	  and	  BMP6,	  signalling	  by	   these	   ligands	   is	  probably	  not	  
prominent	  in	  GCs	  otherwise	  this	  would	  inhibit	  proliferation	  of	  EBV-­‐infected	  cells.	  However,	  
it	  is	  possible	  that	  in	  another	  part	  of	  the	  lymphoid	  system,	  it	  may	  be	  advantageous	  for	  EBV	  to	  
enhance	   the	   anti-­‐proliferative	   effects	   of	   these	   BMPs.	   BMP2,	   BMP4	   and	   BMP6	   inhibit	  
differentiation	   of	   mature	   B	   cells	   into	   plasma	   cells	   (Huse	   et	   al.	   2011),	   so	   perhaps	   EBV	  
enhances	   this	   inhibition,	   thus	  maintaining	   latency	  by	  preventing	  differentiation	   to	  plasma	  
cells	  which	  would	  result	  in	  lytic	  infection.	  Alternatively,	  BMP2,	  BMP6	  and	  BMP7	  can	  induce	  
EBV	  lytic	  replication	  in	  latency	  I	  but	  not	  latency	  III	  infected	  Mutu	  (BL)	  cells	  in	  vitro	  (Yin	  et	  al.	  
2010),	  so	  it	  is	  possible	  that	  BMPs	  may	  be	  more	  active	  in	  the	  oropharynx	  thus	  enhancing	  lytic	  
replication	  where	  it	  is	  desired.	  	  
	  
A	   few	  studies	  have	   investigated	   the	  expression	  of	  BMPs	   in	   tumour	   samples	   from	  patients	  
with	   B	   cell	  malignancies.	   BMP4	   and	   BMP6	   are	   secreted	   by	   the	  malignant	   plasma	   cells	   of	  
myeloma	   patients	   (Grcevic	   et	   al.	   2010),	  with	   another	   study	   showing	   BMP6	   expression	   by	  
both	   normal	   plasma	   cells	   and	   myeloma	   cell	   lines	   (Seckinger	   et	   al.	   2009).	   BMP6	   inhibits	  
proliferation	   of	   myeloma	   cells,	   and	   high	   BMP6	   expression	   was	   associated	   with	   a	   better	  
prognosis	   (Seckinger	   et	   al.	   2009),	   suggesting	   that	   autocrine/paracrine	  BMP	   signalling	  may	  
limit	   proliferation	   in	   myeloma	   cells.	   However,	   BMP2,	   BMP4	   and	   BMP6	   were	   all	   able	   to	  
partially	   protect	   myeloma	   cells	   from	   apoptosis	   induced	   by	   the	   proteasome	   inhibitor	  
bortezomib,	   which	   is	   used	   as	   part	   of	   the	   treatment	   for	   myeloma	   (Grcevic	   et	   al.	   2010).	  
Furthermore,	   increased	   BMP7	   expression	   has	   been	   found	   at	   relapse	   in	   mantle	   cell	  
lymphoma	   (MCL),	   suggesting	   selective	   survival	   of	   BMP7-­‐expressing	   cells	   after	   initial	  
chemotherapy.	   The	   increased	   BMP7	   expression	   correlated	   with	   resistance	   to	   both	  
bortezomib	  and	  cytarabine,	  although	  the	  numbers	  were	  small	  in	  this	  study	  (Camara-­‐Clayette	  





et	  al.	  2013).	  Thus	   it	   is	  possible	  that	  BMPs	  may	   limit	  proliferation,	  but	  also	  by	   inducing	  cell	  
cycle	  arrest	  may	  render	  cells	  relatively	  resistant	  to	  chemotherapy.	  	  
	  
It	  would	  be	  interesting	  to	  further	  investigate	  the	  expression	  of	  BMPs	  and	  their	  receptors	  in	  
different	  lymphoid	  tissues,	  for	  example	  by	  immunohistochemistry	  of	  human	  tonsillar	  tissue	  
and	   lymphoma	   biopsy	   samples.	   In	   addition,	   ELISA	   for	   BMPs	   could	   be	   performed	   on	  
peripheral	  blood	  of	  healthy	   volunteers,	   compared	  with	  patients	  with	  active	   lymphoma,	   in	  
order	  to	  investigate	  the	  relevance	  of	  BMP	  signalling	  in	  B	  cell	  malignancies.	  	  
	  
8.8	  The	  importance	  of	  suppressing	  TGFβ	  signalling	  in	  lymphoma	  development	  
For	  a	  tumour	  to	  develop,	  it	  needs	  to	  switch	  off	  TSGs	  within	  the	  cell	  itself,	  but	  also	  needs	  to	  
alter	   its	   microenvironment	   to	   favour	   tumour	   growth,	   for	   instance	   by	   evading	   immune	  
responses.	   EBV,	   along	   with	   other	   gamma-­‐herpesviruses	   and	   other	   tumour	   viruses,	   has	  
evolved	  multiple	  mechanisms	  to	  suppress	  TSGs,	  allowing	  infected	  cells	  to	  survive	  in	  order	  to	  
establish	   latency.	   In	  addition	  EBV	  has	  evolved	  several	  means	  of	  avoiding	  host	  cell	   immune	  
responses,	   again	   important	   to	   allow	   survival	   of	   the	   infected	   cell.	   By	   switching	   off	   TGFβ	  
signalling	  EBV	  is	  achieving	  both	  of	  these	  aims,	  as	  this	  allows	  the	  infected	  cell	  to	  survive	  the	  	  
GC	  environment	  in	  order	  to	  get	  into	  the	  memory	  B	  cell	  pool	  and	  thereby	  establish	  latency,	  
from	  where	  it	  can	  infect	  other	  hosts,	  and	  also	  inhibits	  T	  cell	   immune	  responses.	  Successful	  
viruses	  aim	  to	   transmit	  virus	  widely	  between	  hosts,	   ideally	  without	   threatening	   the	   life	  of	  
the	  host.	  Herpesviruses,	  including	  EBV,	  are	  highly	  successful	  at	  this,	  as	  demonstrated	  by	  the	  
fact	  that	  most	  people	  are	  latently	  infected	  with	  EBV,	  in	  a	  worldwide	  distribution,	  and	  most	  
are	  asymptomatic	  and	  yet	  continue	  to	  shed	  virus	  so	  that	  new	  hosts	  can	  become	  infected.	  	  
	  
In	   order	   to	   establish	   latency,	   however,	   EBV	   must	   stimulate	   B	   cells	   to	   differentiate	   into	  
hyper-­‐proliferating	  lymphoblasts,	  within	  the	  GC,	  requiring	  expressing	  of	   its	   latent	  proteins,	  
including	   pro-­‐survival	   LMP1	   and	   LMP2A,	   in	   order	   to	   survive	   in	   the	   pro-­‐apoptotic	   GC	  
environment.	   Expression	   of	   the	   EBNA3	   proteins	   is	   then	   switched	   off,	   once	   the	   cell	   is	  
proliferating,	  as	  EBNA3A	  and	  EBNA3C	  are	  highly	  oncogenic	  and	  immunogenic.	  However,	  the	  
physiological	  GC	  environment	  is	  high-­‐risk	  since	  double	  strand	  breaks	  (DSBs)	  and	  mutations	  
are	   induced	  as	  part	   of	   SHM;	   it	   is	   no	   coincidence	   that	   so	  many	  different	   lymphomas	   arise	  





from	  cells	  within	  the	  GC.	  Under	  normal	  circumstances,	  the	  majority	  of	  cells	  with	  abnormal	  
DNA	   would	   quickly	   be	   destroyed	   by	   pro-­‐apoptotic	   mechanisms	   within	   the	   GC.	   However,	  
expression	   of	   EBV	   latent	   proteins	  might	   enable	   cells	   to	   tolerate	   certain	  mutations,	  which	  
would	   otherwise	   result	   in	   destruction	   of	   the	   affected	   cell.	   Therefore	   EBV	   infection	   can	  
substitute	  for	  some	  additional	  mutations	  which	  occur	  in	  the	  development	  of	  tumours,	  thus	  
increasing	  the	  likelihood	  of	  tumour	  development,	  even	  though	  this	  is	  not	  the	  ‘intention’	  of	  
the	  virus.	  	  
	  
TGFβ	   signalling	   is	   an	   important	   component	  of	   apoptotic	  mechanisms	  within	  GC	  B	   cells,	   in	  
the	  process	  of	  ‘death	  by	  neglect’.	  Therefore	  switching	  off	  TGFβ	  signalling	  helps	  the	  infected	  
cells	   to	   survive	   the	   GC	   environment.	   In	   addition,	   TGFβ	   signalling	   is	   generally	   immuno-­‐
suppressive,	  by	  suppressing	  T	  cell	  responses.	  Tumour	  cells,	  including	  lymphoma	  cells,	  often	  
continue	  to	  secrete	  TGFβ,	  which	  can	  inhibit	  T	  cells	  thus	  inhibiting	  the	  immune	  response	  to	  
tumour.	  Meanwhile	  the	  tumour	  itself	  has	  become	  resistant,	  by	  switching	  off	  TGFβ	  signalling,	  
so	  is	  able	  to	  proliferate	  without	  being	  destroyed	  by	  this	  arm	  of	  the	  immune	  system.	  	  
	  
Herpesviruses	  have	  developed	  multiple	  mechanisms	  for	  targeting	  TGFβ	  signalling,	  including	  
via	  epigenetic	  regulation	  and	  miRNAs.	  KSHV	  LANA	  epigenetically	  silences	  TGFβR2	  in	  PEL	  cell	  
lines	  (Di	  Bartolo	  et	  al.	  2008)	  and	  the	  virus	  also	  secretes	  a	  miRNA	  which	  targets	  TGFβR2	  (Lei	  
et	   al.	   2012).	   In	   addition,	   another	   miRNA	   produced	   by	   KSHV	   targets	   SMAD5	   and	   thus	  
suppresses	  the	  non-­‐canonical	  TGFβ	  signalling	  pathway	  when	  ectopically	  expressed	  in	  Ramos	  
(Liu	  et	  al.	  2012).	  	  MiR-­‐155	  is	  induced	  by	  EBV,	  and	  KSHV	  and	  Marek’s	  disease	  virus	  (MDV,	  an	  
oncogenic	  herpesvirus	  found	  in	  chickens),	  encode	  homologues	  of	  miR-­‐155	  (Yin	  et	  al.	  2010).	  
miR-­‐155	  is	  a	  known	  oncogenic	  miRNA	  (oncomiR),	  with	  expression	  leading	  to	  development	  of	  
high	  grade	   lymphoma	   in	  a	   transgenic	  mouse	  model	   (Costinean	  et	  al.	   2006),	   and	  has	  been	  
shown	   to	   be	   overexpressed	   in	   DLBCL	   (Eis	   et	   al.	   2005).	   Thus	   epigenetic	   and/or	   miRNA-­‐
induced	   changes	   to	   TGFβ	   signalling	   are	   commonly	   used	   by	   oncogenic	   herpesviruses	   to	  
enable	   them	   to	   reach	   latency	   -­‐	   but	   in	   doing	   so,	   these	   changes	   may	   promote	   tumour	  
development.	  	  
	  
Furthermore,	  other	  oncogenic	  viruses	  alter	  TGFβ	  signalling,	   for	  example	  overexpression	  of	  
adenovirus	   E1A	   leads	   to	   down-­‐regulation	   of	   TGFβR2	   (Tarakanova	   and	   Wold	   2003)	   and	  





inhibits	   TGFβ-­‐mediated	   induction	   of	   p15	   and	   p21	   (Datto	   et	   al.	   1997).	   The	   Tax	   protein	   of	  
HTLV1	  represses	  TGFβ	  signalling	  by	  interfering	  with	  recruitment	  of	  the	  co-­‐activator	  p300	  to	  
SMAD-­‐responsive	  elements	  (Mori	  et	  al.	  2001)	  and	  a	  viral	  protein	  of	  hepatitis	  C	   inhibits	  the	  
DNA-­‐binding	   ability	   of	   SMAD3	   interfering	  with	   SMAD3-­‐mediated	   transcriptional	   activation	  
(Cheng	  et	  al.	  2004).	  	  
	  
8.9	  Clinical	  implications	  of	  the	  findings	  in	  this	  project	  
Transfection	   of	   the	   EBV-­‐negative	   BL	   cell	   line	   Ramos	   with	   dominant-­‐negative	   TGFβR2,	  
leading	  to	  suppression	  of	  SMAD2	  phosphorylation,	  resulted	  in	  increased	  tumour	  growth	  and	  
decreased	   apoptosis	   in	   vivo,	   demonstrating	   the	   importance	   of	   inhibition	   of	   TGFβ-­‐induced	  
apoptosis	   in	  promoting	   tumour	  development	   (Kawabata	  et	  al.	  2013).	  Therefore,	   inhibition	  
of	  TGFβ	  signalling,	  which	   is	   tumour	  suppressive,	   is	  a	  mechanism	  for	  promoting	   lymphoma	  
development.	   It	   could	   be	   hypothesised	   that	   suppression	   of	   TGFβ	   signalling	  might	   also	   be	  
also	  found	  in	  non-­‐EBV-­‐associated	  B	  cell	  lymphomas.	  
	  
In	  a	  gene	  expression	  profiling	  study	  of	  DLBCL,	  TGFβR2	  expression	  was	  higher	  in	  the	  activated	  
B	  cell-­‐like,	  which	  have	  a	  worse	  prognosis,	   than	   the	  GC-­‐like	   subtype	   (Alizadeh	  et	  al.	  2000).	  
Tumours	   may	   use	   several	   alternative	   mechanisms	   to	   evade	   apoptosis,	   for	   example	  
suppressing	   TGFβ	   signalling	   in	   one	   particular	   tumour,	   or	   mutating	   p53	   in	   another.	   The	  
mechanism	   of	   disruption	   of	   apoptosis	   may	   alter	   the	   tumour’s	   responsiveness	   to	  
chemotherapy.	  For	  many	  chemotherapy	  agents,	  the	  exact	  mechanism	  by	  which	  they	  induce	  
apoptosis	  are	  not	  entirely	  understood.	  
	  
The	   treatment	   of	   lymphomas,	   and	   other	  malignancies,	   is	  moving	  more	   towards	   targeted	  
therapies,	   amidst	   recognition	   that	   even	   within	   a	   particular	   type	   of	   tumour	   there	   are	  
differences	   in	   the	  acquired	  abnormalities	  between	   individual	   tumours,	   and	  even	  between	  
different	   sub-­‐clones	   within	   the	   same	   tumour.	   Treatment	   of	   lymphomas	   was	   previously	  
based	  on	  chemotherapy,	  which	  has	  non-­‐specific	  cytotoxic	  effects;	  however,	  the	  introduction	  
of	   the	   anti-­‐CD20	   monoclonal	   antibody	   Rituximab	   revolutionised	   treatment	   of	   B	   cell	  
lymphomas,	  which	  commonly	  express	  CD20.	  Several	  drugs	  now	  in	  development	  or	  in	  early	  
clinical	   trials	   inhibit	   specific	   signalling	  pathways	  within	  B	   cells,	   such	  as	  PI3K	   inhibitors	  and	  





BCR	  antagonists.	  The	  suppression	  of	  TGFβ	  signalling	  by	  EBV	  suggests	  that	  another	  means	  of	  
targeting	  EBV-­‐positive	  tumours	  could	   involve	  activation	  of	  TGFβR2	  and	  thus	  restoration	  of	  
TGFβ	  signalling.	  Several	  compounds	  targeting	  TGFβ	  signalling	  are	  currently	  in	  development,	  
but	  unfortunately	  all	  are	  aimed	  at	  inhibiting	  TGFβ	  signalling,	  due	  to	  the	  tumour-­‐promoting	  
effects	   of	   TGFβ	   in	   several	   carcinomas	   (Smith	   et	   al.	   2012).	   Nevertheless,	   if	   suppression	   of	  
TGFβ	  signalling	  were	  found	  to	  be	  a	  mechanism	  used	  by	  many	  B	  cell	  malignancies,	  it	  should	  
theoretically	   be	   possible	   to	   develop	   a	   pharmaceutical	   means	   of	   restoring	   signalling.	   The	  
importance	   of	   TGFβ	   signalling	   disruption	   in	   development	   of	   lymphomas	   has	   not	   been	  
systematically	   investigated,	   thus	   it	  would	  be	   interesting	   to	   investigate	   tumour	  biopsies	   of	  
EBV-­‐positive	  and	  negative	  lymphomas	  to	  see	  whether	  this	  occurs.	  	  
	  
Since	   this	   study	  has	   shown	   that	   EBV	   induces	   epigenetic	   repression	  of	   TGFβR2,	   associated	  
with	   decreased	   H3K9Ac	   and	   increased	   H3K27Me3,	   this	   suggest	   that	   drugs	   targeting	  
epigenetic	   modifications	   may	   be	   beneficial	   in	   EBV-­‐associated	   lymphomas.	   Such	   drugs	  
include	  HDAC	  inhibitors,	  DNMT	  inhibitors	  and	  histone	  methyltransferase	  inhibitors.	  Several	  
such	   drugs	   have	   been	   investigated	   in	   early	   clinical	   trials	   in	   lymphomas	   and	   other	   B	   cell	  
malignancies	   [reviewed	   in	   (Hassler	   et	   al.	   2013)].	   These	   drugs	   would	   have	   the	   additional	  
benefit	  of	  stimulating	  lytic	  viral	  infection	  and	  so	  could	  be	  combined	  with	  anti-­‐viral	  therapy.	  
DNMT	   inhibitors,	   such	   as	   azacytidine,	   are	   already	   in	   clinical	   use	   for	   the	   treatment	   of	  
myelodysplastic	  syndrome	  (Fenaux	  et	  al.	  2009)	  and	  the	  HDAC	  inhibitor	  vorinostat	  is	  licensed	  
in	  the	  USA	  for	  treatment	  of	  cutaneous	  T-­‐cell	  lymphoma	  (Hassler	  et	  al.	  2013).	  
	  	  
8.10	  Directions	  for	  future	  work	  	  	  
This	  study	  has	  raised	  several	  questions	  for	  further	  investigation:	  
1. What	  are	  the	  consequences	  of	  the	  up-­‐regulation	  of	  TGFβR3?	  In	  particular,	  does	  this	  
alter	  cellular	  responses	  to	  TGFβ2,	  activins	  and/or	  inhibins?	  
2. How	   and	   to	  what	   extent	   do	   the	   EBNA3	   proteins	   and	   LMPs	   together	   cooperate	   in	  
regulating	  gene	  expression?	  Do	  LMP1	  and	  LMP2A	  cooperate	  via	  modulation	  of	  other	  
cellular	  signalling	  cascades	  such	  as	  NFκB	  or	  PI3K/Akt?	  	  	  
3. Are	  LMP1	  and	  LMP2A	  also	   required	   for	  TGFβR2	   repression	  and/or	  TGFβR3/SMAD1	  
up-­‐regulation	  in	  LCLs?	  	  





4. What	   are	   the	   consequences	   of	   EBV	   up-­‐regulating	   SMAD1	   and	   down-­‐regulating	  
SMAD5	  –	  does	   this	   alter	   responses	   to	  BMPs	  and/or	  non-­‐canonical	   TGFβ	   signalling,	  
particularly	  in	  terms	  of	  cell	  cycle	  arrest?	  Does	  this	  alter	  the	  BMP	  target	  gene	  profile?	  	  
5. What	  are	  the	  mechanisms	  of	  TGFβ-­‐induced	  arrest	  and	  apoptosis	  in	  B	  cells	  -­‐	  are	  these	  
mediated	  via	  SMAD3,	  or	  by	  non-­‐SMAD	  pathways?	  
6. Do	   biopsy	   samples	   of	   lymphoma	   (especially	   EBV-­‐positive,	   but	   also	   EBV-­‐negative)	  
show	  DNA	  methylation	  of	  TGFβR2?	  Are	  TGFβR3	  and	  SMAD1	  expression	  increased	  in	  
EBV-­‐positive	   tumours?	   Does	   TGFβR2	   repression	   replace	   deregulation	   of	   other	  
tumour	   suppressor	   pathways,	   e.g.	   p53	   mutations,	   and	   if	   so	   is	   this	   of	   prognostic	  
relevance?	  	  	  
7. Does	   EBV,	   via	   EBNA3C,	   repress	   p15	   in	   a	   similar	   way	   to	   p16,	   and	   what	   are	   the	  
consequences	  of	  this?	  
	  
	   	  





8.11	  Summary	  of	  the	  main	  findings	  of	  this	  study	  
	  
Figure	  8.1:	  The	  effects	  of	  latent	  EBV	  infection	  on	  TGFβ	  and	  BMP	  signalling	  
The	  effects	  of	  latent	  EBV	  infection	  on	  TGFβ	  signalling	  (left	  side	  of	  figure)	  and	  on	  BMP	  signalling	  (right	  side),	  as	  
demonstrated	  in	  this	  study,	  are	  shown.	  The	  effects	  of	  EBV	  on	  TGFβ	  signalling	  are	  generally	  inhibitory,	  shown	  in	  
red,	  whereas	   the	  effects	  of	   EBV	  on	  BMP	   signalling	   components	   are	   generally	   enhancing	   (black	   arrows).	   The	  
latent	  proteins	  EBNA3B,	  EBNA3C,	  LMP1	  and	  LMP2A	  cooperate	  to	  repress	  transcription	  of	  TGFβR2,	   leading	  to	  
suppression	   of	   TGFβ-­‐induced	   phosphorylation	   of	   SMAD2	   (pSMAD2)	   and	   hence	   inhibition	   of	   TGFβ-­‐mediated	  
induction	   of	   target	   genes	   ID1	   and	   ID2.	   However,	   even	   though	   knockout	   of	   EBNA3B,	   EBNA3C,	   LMP1	   and/or	  
LMP2A	   leads	   to	   restoration	  of	  TGFβR2	  expression	  and	  TGFβ-­‐induced	  pSMAD2,	   this	  does	  not	   result	   in	  TGFβ-­‐
induced	  apoptosis.	  This	  is	  likely	  to	  be	  because	  EBV	  has	  multiple	  mechanisms	  to	  protect	  the	  cell	  from	  apoptosis.	  
Knockout	  of	  LMP2A,	  but	  not	  the	  other	  latent	  genes,	  results	  in	  TGFβ-­‐induced	  cell	  cycle	  arrest,	  suggesting	  that	  
LMP2A	   protects	   against	   this.	   EBNA3B,	   EBNA3C,	   LMP1	   and	   LMP2A	   also	   cooperate	   in	   transcriptional	   up-­‐
regulation	  of	  TGFβR3,	  possibly	  via	  relief	  of	  TGFβ1-­‐mediated	  transcriptional	  repression	  of	  TGFβR3.	  	  
The	   effects	   of	   EBV	   on	   BMP	   signalling	   are	   generally	   opposite	   to	   those	   for	   BMP	   signalling,	   as	   seen	   in	   other	  
cellular	  systems.	  EBV	  infection	  enhances	  phosphorylation	  of	  SMAD1/5/8	  by	  BMP2,	  BMP4	  and	  BMP6,	  leading	  to	  
enhancement	  of	  BMP-­‐induced	  cell	  cycle	  arrest	  and	  enhanced	  induction	  of	  ID1	  expression.	  This	  enhancement	  
of	   BMP	   signalling	   by	   EBV	  may	   be	   due	   to	   up-­‐regulation	   of	   BMPRIA,	   but	   is	   not	   due	   to	   the	   up-­‐regulation	   of	  
TGFβR3.	  EBV	   infection	  also	   leads	  to	  up-­‐regulation	  of	  SMAD1	  but	  down-­‐regulation	  of	  SMAD5	  expression.	  The	  
effects	  of	  EBV	  on	  TGFβ	  signalling	  via	  SMAD3	  were	  not	   investigated	  in	  this	  study,	  and	  SMAD8	  is	  probably	  not	  
important/expressed	  in	  B	  cells.	  	  	  	  	  





8.12	  Final	  conclusions	  
In	   summary,	   this	   thesis	   has	   shown	   that	   EBV	   represses	   TGFβ	   signalling	   via	   polycomb-­‐
mediated	   repression	   of	   TGFβR2,	   and	   has	   indicated	  which	   latent	   proteins	   are	   responsible.	  
This	  repression	  involves	  cooperation	  between	  two	  EBNA3	  proteins	  (EBNA3B	  and	  EBNA3C)	  as	  
well	   as	   two	   latent	  membrane	  proteins,	   LMP1	  and	   LMP2A,	   suggesting	   there	  may	  be	  more	  
cooperation	   between	   these	   different	   types	   of	   latent	   protein	   than	   has	   previously	   been	  
shown.	   The	   suppression	   of	   TGFβ	   signalling	   is	   presumably	   a	   mechanism	   used	   by	   EBV	   to	  
promote	  survival	  of	  infected	  B	  cells	  in	  order	  to	  establish	  latency	  and	  long-­‐term	  persistence;	  
however,	  in	  doing	  this	  EBV	  also	  increases	  the	  risk	  of	  lymphoma	  development.	  	  	  
	  
Furthermore,	   this	   thesis	   has	   demonstrated	   that	   EBV	   up-­‐regulates	   expression	   of	   the	   co-­‐
receptor	   TGFβR3,	   although	   the	   significance	   of	   this	   is	   not	   yet	   known.	   EBV	   also	   increases	  
signalling	   in	   response	   to	   BMP2,	   BMP4	   and	   BMP6,	   although	   not	   by	   the	   up-­‐regulation	   of	  
TGFβR3.	  It	  also	  up-­‐regulates	  SMAD1	  expression,	  although	  it	   is	  not	  yet	  clear	  how	  this	  alters	  
BMP	  signalling	  responses	  or	  non-­‐canonical	  TGFβ	  signalling.	  
	  
The	   repression	   of	   TGFβR2	   and	   suppression	   of	   TGFβ	   signalling,	   as	  well	   as	   up-­‐regulation	   of	  
TGFβR3	  and	  SMAD1,	  has	  been	  demonstrated	   in	  an	  EBV-­‐negative	  BL	  cell	   line	   infected	  with	  
BAC-­‐derived	   recombinant	   viruses,	   after	   infection	   of	   purified	   primary	   B	   cells	   and	   in	  
established	   LCLs.	   The	   findings	   on	   BMP	   responses	   in	   B	   cells	   suggest	   that	   BMP	   signalling	   is	  
likely	   to	   be	   important	   in	   B	   cell	   biology,	   a	   field	   that	   has	   been	   hitherto	   overlooked,	   but	   is	  







Alberts,	  B.,	  A.	  Johnson,	  J.	  Lewis,	  M.	  Raff,	  K.	  Roberts	  and	  P.	  Walter	  (2008).	  Molecular	  Biology	  of	  the	  
Cell,	  Garland	  Science.	  
Alexandrow,	  M.	  G.,	  M.	   Kawabata,	  M.	  Aakre	   and	  H.	   L.	  Moses	   (1995).	  Overexpression	  of	   the	   c-­‐Myc	  
oncoprotein	   blocks	   the	   growth-­‐inhibitory	   response	   but	   is	   required	   for	   the	   mitogenic	   effects	   of	  
transforming	  growth	  factor	  beta	  1.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  92(8):	  3239-­‐3243.	  
Alizadeh,	  A.	  A.,	  M.	  B.	  Eisen,	  R.	  E.	  Davis,	  C.	  Ma,	  I.	  S.	  Lossos,	  A.	  Rosenwald,	  J.	  C.	  Boldrick,	  H.	  Sabet,	  T.	  
Tran,	  X.	  Yu,	  J.	  I.	  Powell,	  L.	  Yang,	  G.	  E.	  Marti,	  T.	  Moore,	  J.	  Hudson,	  Jr.,	  L.	  Lu,	  D.	  B.	  Lewis,	  R.	  Tibshirani,	  
G.	  Sherlock,	  W.	  C.	  Chan,	  T.	  C.	  Greiner,	  D.	  D.	  Weisenburger,	   J.	  O.	  Armitage,	  R.	  Warnke,	  R.	   Levy,	  W.	  
Wilson,	  M.	  R.	  Grever,	  J.	  C.	  Byrd,	  D.	  Botstein,	  P.	  O.	  Brown	  and	  L.	  M.	  Staudt	  (2000).	  Distinct	  types	  of	  
diffuse	  large	  B-­‐cell	  lymphoma	  identified	  by	  gene	  expression	  profiling.	  Nature	  403(6769):	  503-­‐511.	  
Allday,	  M.	   J.	   (2009).	   How	   does	   Epstein-­‐Barr	   virus	   (EBV)	   complement	   the	   activation	   of	  Myc	   in	   the	  
pathogenesis	  of	  Burkitt's	  lymphoma?	  Semin	  Cancer	  Biol	  19(6):	  366-­‐376.	  
Allday,	   M.	   J.	   (2013).	   EBV	   finds	   a	   polycomb-­‐mediated,	   epigenetic	   solution	   to	   the	   problem	   of	  
oncogenic	  stress	  responses	  triggered	  by	  infection.	  Front	  Genet	  4:	  212.	  
Allday,	  M.	   J.,	   D.	   H.	   Crawford	   and	   J.	   A.	   Thomas	   (1993).	   Epstein-­‐Barr	   virus	   (EBV)	   nuclear	   antigen	   6	  
induces	  expression	  of	  the	  EBV	  latent	  membrane	  protein	  and	  an	  activated	  phenotype	  in	  Raji	  cells.	   J	  
Gen	  Virol	  74	  (	  Pt	  3):	  361-­‐369.	  
Allday,	   M.	   J.	   and	   P.	   J.	   Farrell	   (1994).	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   EBNA3C/6	   expression	  
maintains	  the	  level	  of	  latent	  membrane	  protein	  1	  in	  G1-­‐arrested	  cells.	  J	  Virol	  68(6):	  3491-­‐3498.	  
Altiok,	   A.,	   M.	   T.	   Bejarano,	   G.	   Klein	   and	   E.	   Klein	   (1992).	   Effect	   of	   TGF-­‐beta	   1	   on	   the	   EBV-­‐induced	  
transformation	  of	  human	  lymphocyte	  cultures.	  Int	  J	  Cancer	  50(5):	  772-­‐776.	  
Altiok,	  A.,	  M.	  T.	  Bejarano,	  F.	  Ruscetti,	  E.	  Altiok,	  G.	  Klein	  and	  E.	  Klein	   (1991).	  Effect	  of	   transforming	  
growth	  factor-­‐beta	  1	  and	  -­‐beta	  2	  on	  the	  proliferation	  of	  Burkitt	   lymphoma	  and	  lymphoblastoid	  cell	  
lines.	  Growth	  Factors	  4(2):	  117-­‐128.	  
Altiok,	  A.,	  L.	  Di	  Renzo	  and	  E.	  Altiok	  (1994).	  Influence	  of	  transforming	  growth	  factor-­‐beta	  (TGF-­‐beta)	  
on	  the	  immunoglobulin	  production	  by	  EBV-­‐infected	  B	  cell	  cultures.	  Immunol	  Lett	  43(3):	  199-­‐202.	  
Altiok,	  A.,	  B.	  Ehlin-­‐Henriksson	  and	  E.	  Klein	  (1993).	  Correlation	  between	  the	  growth-­‐inhibitory	  effect	  
of	  TGF-­‐beta	  1	  and	  phenotypic	  characteristics	  in	  a	  panel	  of	  B-­‐cell	  lines.	  Int	  J	  Cancer	  55(1):	  137-­‐140.	  
Anderson,	  L.	  J.	  and	  R.	  Longnecker	  (2008).	  EBV	  LMP2A	  provides	  a	  surrogate	  pre-­‐B	  cell	  receptor	  signal	  
through	  constitutive	  activation	  of	  the	  ERK/MAPK	  pathway.	  J	  Gen	  Virol	  89(Pt	  7):	  1563-­‐1568.	  
Anderton,	  E.,	   J.	  Yee,	  P.	  Smith,	  T.	  Crook,	  R.	  E.	  White	  and	  M.	  J.	  Allday	  (2008).	  Two	  Epstein-­‐Barr	  virus	  
(EBV)	   oncoproteins	   cooperate	   to	   repress	   expression	   of	   the	   proapoptotic	   tumour-­‐suppressor	   Bim:	  
clues	  to	  the	  pathogenesis	  of	  Burkitt's	  lymphoma.	  Oncogene	  27(4):	  421-­‐433.	  
Andres,	  J.	  L.,	  K.	  Stanley,	  S.	  Cheifetz	  and	  J.	  Massague	  (1989).	  Membrane-­‐anchored	  and	  soluble	  forms	  
of	   betaglycan,	   a	   polymorphic	   proteoglycan	   that	   binds	   transforming	   growth	   factor-­‐beta.	   J	   Cell	   Biol	  






Anzano,	  M.	  A.,	  A.	  B.	  Roberts,	   J.	  M.	   Smith,	  M.	  B.	   Sporn	  and	   J.	   E.	  De	   Larco	   (1983).	   Sarcoma	  growth	  
factor	   from	   conditioned	  medium	   of	   virally	   transformed	   cells	   is	   composed	   of	   both	   type	   alpha	   and	  
type	  beta	  transforming	  growth	  factors.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  80(20):	  6264-­‐6268.	  
Aoki,	   H.,	  M.	   Fujii,	   T.	   Imamura,	   K.	   Yagi,	   K.	   Takehara,	  M.	   Kato	   and	   K.	  Miyazono	   (2001).	   Synergistic	  
effects	  of	  different	  bone	  morphogenetic	  protein	  type	  I	  receptors	  on	  alkaline	  phosphatase	  induction.	  
J	  Cell	  Sci	  114(Pt	  8):	  1483-­‐1489.	  
Arsura,	  M.,	  M.	  Wu	  and	  G.	  E.	  Sonenshein	  (1996).	  TGF	  beta	  1	  inhibits	  NF-­‐kappa	  B/Rel	  activity	  inducing	  
apoptosis	  of	  B	  cells:	  transcriptional	  activation	  of	  I	  kappa	  B	  alpha.	  Immunity	  5(1):	  31-­‐40.	  
Arvanitakis,	   L.,	   N.	   Yaseen	   and	   S.	   Sharma	   (1995).	   Latent	   membrane	   protein-­‐1	   induces	   cyclin	   D2	  
expression,	  pRb	  hyperphosphorylation,	   and	   loss	  of	   TGF-­‐beta	  1-­‐mediated	  growth	   inhibition	   in	   EBV-­‐
positive	  B	  cells.	  J	  Immunol	  155(3):	  1047-­‐1056.	  
Attisano,	  L.	  and	  J.	  L.	  Wrana	  (2000).	  Smads	  as	  transcriptional	  co-­‐modulators.	  Curr	  Opin	  Cell	  Biol	  12(2):	  
235-­‐243.	  
Babcock,	   G.	   J.,	   L.	   L.	   Decker,	   R.	   B.	   Freeman	   and	   D.	   A.	   Thorley-­‐Lawson	   (1999).	   Epstein-­‐barr	   virus-­‐
infected	  resting	  memory	  B	  cells,	  not	  proliferating	  lymphoblasts,	  accumulate	  in	  the	  peripheral	  blood	  
of	  immunosuppressed	  patients.	  J	  Exp	  Med	  190(4):	  567-­‐576.	  
Bae,	  H.	  W.,	  A.	  G.	  Geiser,	  D.	  H.	  Kim,	  M.	  T.	  Chung,	  J.	  K.	  Burmester,	  M.	  B.	  Sporn,	  A.	  B.	  Roberts	  and	  S.	  J.	  
Kim	  (1995).	  Characterization	  of	  the	  promoter	  region	  of	  the	  human	  transforming	  growth	  factor-­‐beta	  
type	  II	  receptor	  gene.	  J	  Biol	  Chem	  270(49):	  29460-­‐29468.	  
Bakkebo,	  M.,	  K.	  Huse,	  V.	  I.	  Hilden,	  E.	  B.	  Smeland	  and	  M.	  P.	  Oksvold	  (2010).	  TGF-­‐beta-­‐induced	  growth	  
inhibition	  in	  B-­‐cell	  lymphoma	  correlates	  with	  Smad1/5	  signalling	  and	  constitutively	  active	  p38	  MAPK.	  
BMC	  Immunol	  11:	  57.	  
Balfour,	  H.	  H.,	  Jr.,	  O.	  A.	  Odumade,	  D.	  O.	  Schmeling,	  B.	  D.	  Mullan,	  J.	  A.	  Ed,	  J.	  A.	  Knight,	  H.	  E.	  Vezina,	  W.	  
Thomas	   and	   K.	   A.	  Hogquist	   (2013).	   Behavioral,	   virologic,	   and	   immunologic	   factors	   associated	  with	  
acquisition	   and	   severity	   of	   primary	   Epstein-­‐Barr	   virus	   infection	   in	   university	   students.	   J	   Infect	   Dis	  
207(1):	  80-­‐88.	  
Bell,	   A.	   I.,	   K.	   Groves,	   G.	   L.	   Kelly,	   D.	   Croom-­‐Carter,	   E.	   Hui,	   A.	   T.	   Chan	   and	   A.	   B.	   Rickinson	   (2006).	  
Analysis	   of	   Epstein-­‐Barr	   virus	   latent	   gene	   expression	   in	   endemic	   Burkitt's	   lymphoma	   and	  
nasopharyngeal	  carcinoma	  tumour	  cells	  by	  using	  quantitative	  real-­‐time	  PCR	  assays.	  J	  Gen	  Virol	  87(Pt	  
10):	  2885-­‐2890.	  
Ben-­‐Sasson,	  S.	  A.	  and	  G.	  Klein	  (1981).	  Activation	  of	  the	  Epstein-­‐Barr	  virus	  genome	  by	  5-­‐aza-­‐cytidine	  
in	  latently	  infected	  human	  lymphoid	  lines.	  Int	  J	  Cancer	  28(2):	  131-­‐135.	  
Berger,	   S.	   L.,	   T.	   Kouzarides,	   R.	   Shiekhattar	   and	   A.	   Shilatifard	   (2009).	   An	   operational	   definition	   of	  
epigenetics.	  Genes	  Dev	  23(7):	  781-­‐783.	  
Bernabeu,	   C.,	   J.	   M.	   Lopez-­‐Novoa	   and	   M.	   Quintanilla	   (2009).	   The	   emerging	   role	   of	   TGF-­‐beta	  
superfamily	  coreceptors	  in	  cancer.	  Biochim	  Biophys	  Acta	  1792(10):	  954-­‐973.	  
Bernstein,	   B.	   E.,	   T.	   S.	   Mikkelsen,	   X.	   Xie,	  M.	   Kamal,	   D.	   J.	   Huebert,	   J.	   Cuff,	   B.	   Fry,	   A.	  Meissner,	  M.	  
Wernig,	  K.	  Plath,	  R.	  Jaenisch,	  A.	  Wagschal,	  R.	  Feil,	  S.	  L.	  Schreiber	  and	  E.	  S.	  Lander	  (2006).	  A	  bivalent	  






Bhatia,	   M.,	   D.	   Bonnet,	   D.	   Wu,	   B.	   Murdoch,	   J.	   Wrana,	   L.	   Gallacher	   and	   J.	   E.	   Dick	   (1999).	   Bone	  
morphogenetic	  proteins	  regulate	  the	  developmental	  program	  of	  human	  hematopoietic	  stem	  cells.	  J	  
Exp	  Med	  189(7):	  1139-­‐1148.	  
Blobe,	  G.	  C.,	   X.	   Liu,	   S.	   J.	   Fang,	  T.	  How	  and	  H.	   F.	   Lodish	   (2001a).	  A	  novel	  mechanism	   for	   regulating	  
transforming	   growth	   factor	   beta	   (TGF-­‐beta)	   signaling.	   Functional	   modulation	   of	   type	   III	   TGF-­‐beta	  
receptor	   expression	   through	   interaction	  with	   the	   PDZ	   domain	   protein,	  GIPC.	   J	   Biol	   Chem	  276(43):	  
39608-­‐39617.	  
Blobe,	  G.	  C.,	  W.	  P.	  Schiemann,	  M.	  C.	  Pepin,	  M.	  Beauchemin,	  A.	  Moustakas,	  H.	  F.	   Lodish	  and	  M.	  D.	  
O'Connor-­‐McCourt	  (2001b).	  Functional	  roles	  for	  the	  cytoplasmic	  domain	  of	  the	  type	  III	  transforming	  
growth	   factor	   beta	   receptor	   in	   regulating	   transforming	   growth	   factor	   beta	   signaling.	   J	   Biol	   Chem	  
276(27):	  24627-­‐24637.	  
Blomhoff,	   H.	   K.,	   E.	   Smeland,	   A.	   S.	   Mustafa,	   T.	   Godal	   and	   R.	   Ohlsson	   (1987).	   Epstein-­‐Barr	   virus	  
mediates	  a	  switch	   in	  responsiveness	  to	  transforming	  growth	  factor,	  type	  beta,	   in	  cells	  of	  the	  B	  cell	  
lineage.	  Eur	  J	  Immunol	  17(2):	  299-­‐301.	  
Bodescot,	  M.	  and	  M.	  Perricaudet	  (1986).	  Epstein-­‐Barr	  virus	  mRNAs	  produced	  by	  alternative	  splicing.	  
Nucleic	  Acids	  Res	  14(17):	  7103-­‐7114.	  
Boos,	  H.,	  M.	  Stoehr,	  M.	  Sauter	  and	  N.	  Mueller-­‐Lantzsch	  (1990).	  Flow	  cytometric	  analysis	  of	  Epstein-­‐
Barr	  virus	  (EBV)	  latent	  membrane	  protein	  expression	  in	  EBV-­‐infected	  Raji	  cells.	  J	  Gen	  Virol	  71	  (	  Pt	  8):	  
1811-­‐1815.	  
Bornkamm,	  G.	  W.	   and	  W.	  Hammerschmidt	   (2001).	  Molecular	   virology	  of	   Epstein-­‐Barr	   virus.	  Philos	  
Trans	  R	  Soc	  Lond	  B	  Biol	  Sci	  356(1408):	  437-­‐459.	  
Bottardi,	   S.,	   A.	   Aumont,	   F.	   Grosveld	   and	   E.	  Milot	   (2003).	   Developmental	   stage-­‐specific	   epigenetic	  
control	  of	  human	  beta-­‐globin	  gene	  expression	  is	  potentiated	  in	  hematopoietic	  progenitor	  cells	  prior	  
to	  their	  transcriptional	  activation.	  Blood	  102(12):	  3989-­‐3997.	  
Brenet,	  F.,	  P.	  Kermani,	  R.	  Spektor,	  S.	  Rafii	  and	  J.	  M.	  Scandura	  (2013).	  TGFbeta	  restores	  hematopoietic	  
homeostasis	  after	  myelosuppressive	  chemotherapy.	  J	  Exp	  Med	  210(3):	  623-­‐639.	  
Brielmeier,	  M.,	  J.	  Mautner,	  G.	  Laux	  and	  W.	  Hammerschmidt	  (1996).	  The	  latent	  membrane	  protein	  2	  
gene	  of	  Epstein-­‐Barr	   virus	   is	   important	   for	  efficient	  B	   cell	   immortalization.	   J	  Gen	  Virol	  77	   (	  Pt	  11):	  
2807-­‐2818.	  
Bristow,	  R.	   E.,	   R.	   L.	   Baldwin,	   S.	  D.	   Yamada,	  M.	  Korc	   and	  B.	   Y.	   Karlan	   (1999).	  Altered	  expression	  of	  
transforming	  growth	  factor-­‐beta	  ligands	  and	  receptors	  in	  primary	  and	  recurrent	  ovarian	  carcinoma.	  
Cancer	  85(3):	  658-­‐668.	  
Brooks,	   J.	  M.,	   S.	   P.	   Lee,	   A.	  M.	   Leese,	  W.	  A.	   Thomas,	  M.	   Rowe	   and	  A.	   B.	   Rickinson	   (2009).	   Cyclical	  
expression	  of	  EBV	  latent	  membrane	  protein	  1	  in	  EBV-­‐transformed	  B	  cells	  underpins	  heterogeneity	  of	  
epitope	  presentation	  and	  CD8+	  T	  cell	  recognition.	  J	  Immunol	  182(4):	  1919-­‐1928.	  
Brown,	  K.	  A.,	   J.	  A.	   Pietenpol	   and	  H.	   L.	  Moses	   (2007).	  A	   tale	  of	   two	  proteins:	   differential	   roles	   and	  
regulation	  of	  Smad2	  and	  Smad3	  in	  TGF-­‐beta	  signaling.	  J	  Cell	  Biochem	  101(1):	  9-­‐33.	  
Bruno,	  E.,	  S.	  K.	  Horrigan,	  D.	  Van	  Den	  Berg,	  E.	  Rozler,	  P.	  R.	  Fitting,	  S.	  T.	  Moss,	  C.	  Westbrook	  and	  R.	  






inhibitory	  effects	  of	   transforming	  growth	   factor-­‐beta	  on	  human	  hematopoiesis.	  Blood	  91(6):	  1917-­‐
1923.	  
Bultema,	   R.,	   R.	   Longnecker	   and	   M.	   Swanson-­‐Mungerson	   (2009).	   Epstein-­‐Barr	   virus	   LMP2A	  
accelerates	  MYC-­‐induced	  lymphomagenesis.	  Oncogene	  28(11):	  1471-­‐1476.	  
Burkitt,	  D.	  (1958).	  A	  sarcoma	  involving	  the	  jaws	  in	  African	  children.	  Br	  J	  Surg	  46(197):	  218-­‐223.	  
Buske,	   C.,	   D.	   Becker,	  M.	   Feuring-­‐Buske,	  H.	  Hannig,	   F.	  Griesinger,	  W.	  Hiddemann	   and	  B.	  Wormann	  
(1998).	  TGF-­‐beta	  and	  its	  receptor	  complex	  in	  leukemic	  B-­‐cell	  precursors.	  Exp	  Hematol	  26(12):	  1155-­‐
1161.	  
Cai,	   X.,	   A.	   Schafer,	   S.	   Lu,	   J.	   P.	   Bilello,	   R.	   C.	  Desrosiers,	   R.	   Edwards,	  N.	   Raab-­‐Traub	  and	  B.	   R.	   Cullen	  
(2006).	  Epstein-­‐Barr	  virus	  microRNAs	  are	  evolutionarily	  conserved	  and	  differentially	  expressed.	  PLoS	  
Pathog	  2(3):	  e23.	  
Calender,	  A.,	  M.	  Billaud,	  J.	  P.	  Aubry,	  J.	  Banchereau,	  M.	  Vuillaume	  and	  G.	  M.	  Lenoir	  (1987).	  Epstein-­‐
Barr	  virus	  (EBV)	  induces	  expression	  of	  B-­‐cell	  activation	  markers	  on	  in	  vitro	  infection	  of	  EBV-­‐negative	  
B-­‐lymphoma	  cells.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  84(22):	  8060-­‐8064.	  
Callan,	  M.	  F.,	  L.	  Tan,	  N.	  Annels,	  G.	  S.	  Ogg,	  J.	  D.	  Wilson,	  C.	  A.	  O'Callaghan,	  N.	  Steven,	  A.	  J.	  McMichael	  
and	  A.	   B.	   Rickinson	   (1998).	  Direct	   visualization	  of	   antigen-­‐specific	   CD8+	  T	   cells	   during	   the	  primary	  
immune	  response	  to	  Epstein-­‐Barr	  virus	  In	  vivo.	  J	  Exp	  Med	  187(9):	  1395-­‐1402.	  
Camara-­‐Clayette,	  V.,	  S.	  Koscielny,	  S.	  Roux,	  T.	  Lamy,	  J.	  Bosq,	  M.	  Bernard,	  T.	  Fest,	  V.	  Lazar,	  G.	  Lenoir	  
and	   V.	   Ribrag	   (2013).	   BMP7	   Expression	   Correlates	  with	   Secondary	   Drug	   Resistance	   in	  Mantle	   Cell	  
Lymphoma.	  PLoS	  One	  8(9):	  e73993.	  
Cancian,	   L.,	   R.	   Bosshard,	  W.	   Lucchesi,	   C.	   E.	   Karstegl	   and	   P.	   J.	   Farrell	   (2011).	   C-­‐terminal	   region	   of	  
EBNA-­‐2	  determines	  the	  superior	  transforming	  ability	  of	  type	  1	  Epstein-­‐Barr	  virus	  by	  enhanced	  gene	  
regulation	  of	  LMP-­‐1	  and	  CXCR7.	  PLoS	  Pathog	  7(7):	  e1002164.	  
Cao,	  R.,	   Y.	   Tsukada	  and	  Y.	   Zhang	   (2005).	   Role	  of	  Bmi-­‐1	   and	  Ring1A	   in	  H2A	  ubiquitylation	   and	  Hox	  
gene	  silencing.	  Mol	  Cell	  20(6):	  845-­‐854.	  
Cao,	  R.,	  L.	  Wang,	  H.	  Wang,	  L.	  Xia,	  H.	  Erdjument-­‐Bromage,	  P.	  Tempst,	  R.	  S.	  Jones	  and	  Y.	  Zhang	  (2002).	  
Role	   of	   histone	   H3	   lysine	   27	   methylation	   in	   Polycomb-­‐group	   silencing.	   Science	   298(5595):	   1039-­‐
1043.	  
Chadwick,	  K.,	  L.	  Wang,	  L.	  Li,	  P.	  Menendez,	  B.	  Murdoch,	  A.	  Rouleau	  and	  M.	  Bhatia	  (2003).	  Cytokines	  
and	   BMP-­‐4	   promote	   hematopoietic	   differentiation	   of	   human	   embryonic	   stem	   cells.	  Blood	   102(3):	  
906-­‐915.	  
Chang,	   L.	   K.	   and	   S.	   T.	   Liu	   (2000).	   Activation	   of	   the	   BRLF1	   promoter	   and	   lytic	   cycle	   of	   Epstein-­‐Barr	  
virus	  by	  histone	  acetylation.	  Nucleic	  Acids	  Res	  28(20):	  3918-­‐3925.	  
Chaouchi,	   N.,	   L.	   Arvanitakis,	  M.	   T.	   Auffredou,	   D.	   A.	   Blanchard,	   A.	   Vazquez	   and	   S.	   Sharma	   (1995).	  
Characterization	   of	   transforming	   growth	   factor-­‐beta	   1	   induced	   apoptosis	   in	   normal	   human	  B	   cells	  
and	  lymphoma	  B	  cell	  lines.	  Oncogene	  11(8):	  1615-­‐1622.	  
Cheifetz,	   S.,	   H.	   Hernandez,	   M.	   Laiho,	   P.	   ten	   Dijke,	   K.	   K.	   Iwata	   and	   J.	   Massague	   (1990).	   Distinct	  
transforming	   growth	   factor-­‐beta	   (TGF-­‐beta)	   receptor	   subsets	   as	   determinants	   of	   cellular	  






Chen,	   G.,	   P.	   Ghosh,	   T.	   O'Farrell,	   R.	   Munk,	   L.	   J.	   Rezanka,	   C.	   Y.	   Sasaki	   and	   D.	   L.	   Longo	   (2012).	  
Transforming	   growth	   factor	   beta1	   (TGF-­‐beta1)	   suppresses	   growth	   of	   B-­‐cell	   lymphoma	   cells	   by	  
p14(ARF)-­‐dependent	  regulation	  of	  mutant	  p53.	  J	  Biol	  Chem	  287(27):	  23184-­‐23195.	  
Chen,	  G.,	  P.	  Ghosh,	  H.	  Osawa,	  C.	  Y.	  Sasaki,	  L.	  Rezanka,	  J.	  Yang,	  T.	  J.	  O'Farrell	  and	  D.	  L.	  Longo	  (2007).	  
Resistance	  to	  TGF-­‐beta	  1	  correlates	  with	  aberrant	  expression	  of	  TGF-­‐beta	  receptor	  II	  in	  human	  B-­‐cell	  
lymphoma	  cell	  lines.	  Blood	  109(12):	  5301-­‐5307.	  
Chen,	  W.,	  K.	  C.	  Kirkbride,	  T.	  How,	  C.	  D.	  Nelson,	  J.	  Mo,	  J.	  P.	  Frederick,	  X.	  F.	  Wang,	  R.	  J.	  Lefkowitz	  and	  
G.	   C.	   Blobe	   (2003).	   Beta-­‐arrestin	   2	  mediates	   endocytosis	   of	   type	   III	   TGF-­‐beta	   receptor	   and	   down-­‐
regulation	  of	  its	  signaling.	  Science	  301(5638):	  1394-­‐1397.	  
Chen,	  Y.	  G.,	  A.	  Hata,	  R.	  S.	  Lo,	  D.	  Wotton,	  Y.	  Shi,	  N.	  Pavletich	  and	  J.	  Massague	  (1998).	  Determinants	  of	  
specificity	  in	  TGF-­‐beta	  signal	  transduction.	  Genes	  Dev	  12(14):	  2144-­‐2152.	  
Cheng,	  P.	   L.,	  M.	  H.	  Chang,	  C.	  H.	  Chao	  and	  Y.	  H.	   Lee	   (2004).	  Hepatitis	  C	  viral	  proteins	   interact	  with	  
Smad3	   and	   differentially	   regulate	   TGF-­‐beta/Smad3-­‐mediated	   transcriptional	   activation.	  Oncogene	  
23(47):	  7821-­‐7838.	  
Chijioke,	  O.,	   T.	   Azzi,	   D.	  Nadal	   and	   C.	  Munz	   (2013).	   Innate	   immune	   responses	   against	   Epstein	   Barr	  
virus	  infection.	  J	  Leukoc	  Biol	  94(6):	  1185-­‐1190.	  
Choy,	  E.	  Y.,	  K.	  L.	  Siu,	  K.	  H.	  Kok,	  R.	  W.	  Lung,	  C.	  M.	  Tsang,	  K.	  F.	  To,	  D.	  L.	  Kwong,	  S.	  W.	  Tsao	  and	  D.	  Y.	  Jin	  
(2008).	  An	  Epstein-­‐Barr	  virus-­‐encoded	  microRNA	  targets	  PUMA	  to	  promote	  host	  cell	  survival.	  J	  Exp	  
Med	  205(11):	  2551-­‐2560.	  
Clybouw,	  C.,	  B.	  McHichi,	  S.	  Mouhamad,	  M.	  T.	  Auffredou,	  M.	  F.	  Bourgeade,	  S.	  Sharma,	  G.	  Leca	  and	  A.	  
Vazquez	  (2005).	  EBV	  infection	  of	  human	  B	  lymphocytes	  leads	  to	  down-­‐regulation	  of	  Bim	  expression:	  
relationship	  to	  resistance	  to	  apoptosis.	  J	  Immunol	  175(5):	  2968-­‐2973.	  
Clybouw,	  C.,	  B.	  E.	  McHichi,	  A.	  Hadji,	  A.	  Portier,	  M.	  T.	  Auffredou,	  D.	  Arnoult,	  G.	  Leca	  and	  A.	  Vazquez	  
(2008).	   TGFbeta-­‐mediated	   apoptosis	   of	   Burkitt's	   lymphoma	   BL41	   cells	   is	   associated	   with	   the	  
relocation	  of	  mitochondrial	  BimEL.	  Oncogene	  27(24):	  3446-­‐3456.	  
Cohen,	   J.	   I.,	   F.	  Wang,	   J.	  Mannick	   and	   E.	   Kieff	   (1989).	   Epstein-­‐Barr	   virus	   nuclear	   protein	   2	   is	   a	   key	  
determinant	  of	  lymphocyte	  transformation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  86(23):	  9558-­‐9562.	  
Conery,	  A.	  R.,	  Y.	  Cao,	  E.	  A.	  Thompson,	  C.	  M.	  Townsend,	  Jr.,	  T.	  C.	  Ko	  and	  K.	  Luo	  (2004).	  Akt	  interacts	  
directly	  with	  Smad3	  to	  regulate	  the	  sensitivity	  to	  TGF-­‐beta	  induced	  apoptosis.	  Nat	  Cell	  Biol	  6(4):	  366-­‐
372.	  
Cooper,	   S.	   J.,	  H.	   Zou,	   S.	  N.	   Legrand,	   L.	  A.	  Marlow,	  C.	  A.	   von	  Roemeling,	  D.	  C.	  Radisky,	  K.	   J.	  Wu,	  N.	  
Hempel,	  V.	  Margulis,	  H.	  W.	  Tun,	  G.	  C.	  Blobe,	  C.	  G.	  Wood	  and	   J.	  A.	  Copland	   (2010).	   Loss	  of	   type	   III	  
transforming	   growth	   factor-­‐beta	   receptor	   expression	   is	   due	   to	   methylation	   silencing	   of	   the	  
transcription	  factor	  GATA3	  in	  renal	  cell	  carcinoma.	  Oncogene	  29(20):	  2905-­‐2915.	  
Cordier,	  M.,	  A.	  Calender,	  M.	  Billaud,	  U.	  Zimber,	  G.	  Rousselet,	  O.	  Pavlish,	  J.	  Banchereau,	  T.	  Tursz,	  G.	  
Bornkamm	  and	  G.	  M.	  Lenoir	  (1990).	  Stable	  transfection	  of	  Epstein-­‐Barr	  virus	  (EBV)	  nuclear	  antigen	  2	  
in	   lymphoma	   cells	   containing	   the	   EBV	   P3HR1	   genome	   induces	   expression	   of	   B-­‐cell	   activation	  






Costinean,	  S.,	  N.	  Zanesi,	  Y.	  Pekarsky,	  E.	  Tili,	  S.	  Volinia,	  N.	  Heerema	  and	  C.	  M.	  Croce	  (2006).	  Pre-­‐B	  cell	  
proliferation	   and	   lymphoblastic	   leukemia/high-­‐grade	   lymphoma	   in	   E(mu)-­‐miR155	   transgenic	  mice.	  
Proc	  Natl	  Acad	  Sci	  U	  S	  A	  103(18):	  7024-­‐7029.	  
Countryman,	  J.	  and	  G.	  Miller	  (1985).	  Activation	  of	  expression	  of	  latent	  Epstein-­‐Barr	  herpesvirus	  after	  
gene	  transfer	  with	  a	  small	  cloned	  subfragment	  of	  heterogeneous	  viral	  DNA.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  
82(12):	  4085-­‐4089.	  
Countryman,	  J.	  K.,	  L.	  Gradoville	  and	  G.	  Miller	  (2008).	  Histone	  hyperacetylation	  occurs	  on	  promoters	  
of	   lytic	   cycle	   regulatory	   genes	   in	   Epstein-­‐Barr	   virus-­‐infected	   cell	   lines	   which	   are	   refractory	   to	  
disruption	  of	  latency	  by	  histone	  deacetylase	  inhibitors.	  J	  Virol	  82(10):	  4706-­‐4719.	  
Crawford,	   D.	   H.	   (2001).	   Biology	   and	   disease	   associations	   of	   Epstein-­‐Barr	   virus.	   Philos	   Trans	   R	   Soc	  
Lond	  B	  Biol	  Sci	  356(1408):	  461-­‐473.	  
D'Souza,	   B.	   N.,	   L.	   C.	   Edelstein,	   P.	  M.	   Pegman,	   S.	  M.	   Smith,	   S.	   T.	   Loughran,	   A.	   Clarke,	   A.	  Mehl,	  M.	  
Rowe,	   C.	   Gelinas	   and	   D.	   Walls	   (2004).	   Nuclear	   factor	   kappa	   B-­‐dependent	   activation	   of	   the	  
antiapoptotic	   bfl-­‐1	   gene	  by	   the	   Epstein-­‐Barr	   virus	   latent	  membrane	  protein	   1	   and	   activated	  CD40	  
receptor.	  J	  Virol	  78(4):	  1800-­‐1816.	  
Daly,	   A.	   C.,	   R.	   A.	   Randall	   and	   C.	   S.	   Hill	   (2008).	   Transforming	   growth	   factor	   beta-­‐induced	   Smad1/5	  
phosphorylation	   in	   epithelial	   cells	   is	   mediated	   by	   novel	   receptor	   complexes	   and	   is	   essential	   for	  
anchorage-­‐independent	  growth.	  Mol	  Cell	  Biol	  28(22):	  6889-­‐6902.	  
Dambaugh,	  T.,	  K.	  Hennessy,	  L.	  Chamnankit	  and	  E.	  Kieff	  (1984).	  U2	  region	  of	  Epstein-­‐Barr	  virus	  DNA	  
may	  encode	  Epstein-­‐Barr	  nuclear	  antigen	  2.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  81(23):	  7632-­‐7636.	  
Danial,	  N.	  N.	  and	  S.	  J.	  Korsmeyer	  (2004).	  Cell	  death:	  critical	  control	  points.	  Cell	  116(2):	  205-­‐219.	  
Datto,	  M.	   B.,	   P.	   P.	  Hu,	   T.	   F.	   Kowalik,	   J.	   Yingling	   and	   X.	   F.	  Wang	   (1997).	   The	   viral	   oncoprotein	   E1A	  
blocks	  transforming	  growth	  factor	  beta-­‐mediated	  induction	  of	  p21/WAF1/Cip1	  and	  p15/INK4B.	  Mol	  
Cell	  Biol	  17(4):	  2030-­‐2037.	  
Datto,	  M.	  B.,	  Y.	  Li,	  J.	  F.	  Panus,	  D.	  J.	  Howe,	  Y.	  Xiong	  and	  X.	  F.	  Wang	  (1995).	  Transforming	  growth	  factor	  
beta	  induces	  the	  cyclin-­‐dependent	  kinase	  inhibitor	  p21	  through	  a	  p53-­‐independent	  mechanism.	  Proc	  
Natl	  Acad	  Sci	  U	  S	  A	  92(12):	  5545-­‐5549.	  
Dave,	  S.	  S.,	  K.	  Fu,	  G.	  W.	  Wright,	  L.	  T.	  Lam,	  P.	  Kluin,	  E.	  J.	  Boerma,	  T.	  C.	  Greiner,	  D.	  D.	  Weisenburger,	  A.	  
Rosenwald,	  G.	  Ott,	  H.	  K.	  Muller-­‐Hermelink,	  R.	  D.	  Gascoyne,	  J.	  Delabie,	  L.	  M.	  Rimsza,	  R.	  M.	  Braziel,	  T.	  
M.	  Grogan,	   E.	   Campo,	   E.	   S.	   Jaffe,	   B.	   J.	  Dave,	  W.	   Sanger,	  M.	  Bast,	   J.	  M.	  Vose,	   J.	  O.	  Armitage,	   J.	  M.	  
Connors,	  E.	  B.	  Smeland,	  S.	  Kvaloy,	  H.	  Holte,	  R.	  I.	  Fisher,	  T.	  P.	  Miller,	  E.	  Montserrat,	  W.	  H.	  Wilson,	  M.	  
Bahl,	  H.	  Zhao,	  L.	  Yang,	  J.	  Powell,	  R.	  Simon,	  W.	  C.	  Chan	  and	  L.	  M.	  Staudt	  (2006).	  Molecular	  diagnosis	  of	  
Burkitt's	  lymphoma.	  N	  Engl	  J	  Med	  354(23):	  2431-­‐2442.	  
David,	  L.,	  C.	  Mallet,	  S.	  Mazerbourg,	  J.	  J.	  Feige	  and	  S.	  Bailly	  (2007).	  Identification	  of	  BMP9	  and	  BMP10	  
as	  functional	  activators	  of	  the	  orphan	  activin	  receptor-­‐like	  kinase	  1	  (ALK1)	  in	  endothelial	  cells.	  Blood	  
109(5):	  1953-­‐1961.	  
Dawson,	  C.	  W.,	  J.	  H.	  George,	  S.	  M.	  Blake,	  R.	  Longnecker	  and	  L.	  S.	  Young	  (2001).	  The	  Epstein-­‐Barr	  virus	  







de	  Caestecker,	  M.	   (2004).	   The	   transforming	   growth	   factor-­‐beta	   superfamily	  of	   receptors.	  Cytokine	  
Growth	  Factor	  Rev	  15(1):	  1-­‐11.	  
de	  Caestecker,	  M.	  P.,	  W.	  T.	   Parks,	  C.	   J.	   Frank,	  P.	  Castagnino,	  D.	  P.	  Bottaro,	  A.	  B.	  Roberts	   and	  R.	   J.	  
Lechleider	   (1998).	  Smad2	   transduces	  common	  signals	   from	  receptor	   serine-­‐threonine	  and	   tyrosine	  
kinases.	  Genes	  Dev	  12(11):	  1587-­‐1592.	  
de	  Carvalho,	   F.,	  G.	  W.	  Colleoni,	  M.	  S.	  Almeida,	  A.	   L.	  Carvalho	  and	  A.	   L.	  Vettore	   (2009).	  TGFbetaR2	  
aberrant	  methylation	  is	  a	  potential	  prognostic	  marker	  and	  therapeutic	  target	   in	  multiple	  myeloma.	  
Int	  J	  Cancer	  125(8):	  1985-­‐1991.	  
De	  Leo,	  A.,	  G.	  Arena,	  C.	  Stecca,	  M.	  Raciti	  and	  E.	  Mattia	  (2011).	  Resveratrol	  Inhibits	  Proliferation	  and	  
Survival	   of	   Epstein	   Barr	   Virus-­‐Infected	   Burkitt's	   Lymphoma	   Cells	   Depending	   on	   Viral	   Latency	  
Program.	  Mol	  Cancer	  Res	  9(10):	  1346-­‐1355.	  
DeCoteau,	  J.	  F.,	  P.	  I.	  Knaus,	  H.	  Yankelev,	  M.	  D.	  Reis,	  R.	  Lowsky,	  H.	  F.	  Lodish	  and	  M.	  E.	  Kadin	  (1997).	  
Loss	  of	  functional	  cell	  surface	  transforming	  growth	  factor	  beta	  (TGF-­‐beta)	  type	  1	  receptor	  correlates	  
with	  insensitivity	  to	  TGF-­‐beta	  in	  chronic	  lymphocytic	  leukemia.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  94(11):	  5877-­‐
5881.	  
Dehay,	  C.	  and	  H.	  Kennedy	  (2007).	  Cell-­‐cycle	  control	  and	  cortical	  development.	  Nat	  Rev	  Neurosci	  8(6):	  
438-­‐450.	  
Delecluse,	  H.	  J.,	  T.	  Hilsendegen,	  D.	  Pich,	  R.	  Zeidler	  and	  W.	  Hammerschmidt	  (1998).	  Propagation	  and	  
recovery	  of	  intact,	  infectious	  Epstein-­‐Barr	  virus	  from	  prokaryotic	  to	  human	  cells.	  Proc	  Natl	  Acad	  Sci	  U	  
S	  A	  95(14):	  8245-­‐8250.	  
Dennler,	  S.,	  S.	  Itoh,	  D.	  Vivien,	  P.	  ten	  Dijke,	  S.	  Huet	  and	  J.	  M.	  Gauthier	  (1998).	  Direct	  binding	  of	  Smad3	  
and	  Smad4	  to	  critical	  TGF	  beta-­‐inducible	  elements	  in	  the	  promoter	  of	  human	  plasminogen	  activator	  
inhibitor-­‐type	  1	  gene.	  EMBO	  J	  17(11):	  3091-­‐3100.	  
Derynck,	  R.	  and	  K.	  Miyazono	  (2008).	  The	  TGF-­‐β	  Family,	  Cold	  Spring	  Harbor	  Laboratory	  Press.	  
Derynck,	  R.	  and	  Y.	  E.	  Zhang	  (2003).	  Smad-­‐dependent	  and	  Smad-­‐independent	  pathways	  in	  TGF-­‐beta	  
family	  signalling.	  Nature	  425(6958):	  577-­‐584.	  
Desruisseau,	  S.,	  J.	  Palmari,	  C.	  Giusti,	  S.	  Romain,	  P.	  M.	  Martin	  and	  Y.	  Berthois	  (2006).	  Determination	  
of	   TGFbeta1	  protein	   level	   in	   human	  primary	   breast	   cancers	   and	   its	   relationship	  with	   survival.	  Br	   J	  
Cancer	  94(2):	  239-­‐246.	  
Detmer,	  K.,	  T.	  A.	  Steele,	  M.	  A.	  Shoop	  and	  H.	  Dannawi	  (1999).	  Lineage-­‐restricted	  expression	  of	  bone	  
morphogenetic	  protein	  genes	   in	  human	  hematopoietic	   cell	   lines.	  Blood	  Cells	  Mol	  Dis	  25(5-­‐6):	  310-­‐
323.	  
Detmer,	   K.	   and	   A.	   N.	   Walker	   (2002).	   Bone	   morphogenetic	   proteins	   act	   synergistically	   with	  
haematopoietic	   cytokines	   in	   the	  differentiation	  of	  haematopoietic	  progenitors.	  Cytokine	  17(1):	  36-­‐
42.	  
Deveraux,	  Q.	  L.,	  N.	  Roy,	  H.	  R.	  Stennicke,	  T.	  Van	  Arsdale,	  Q.	  Zhou,	  S.	  M.	  Srinivasula,	  E.	  S.	  Alnemri,	  G.	  S.	  
Salvesen	  and	  J.	  C.	  Reed	  (1998).	  IAPs	  block	  apoptotic	  events	  induced	  by	  caspase-­‐8	  and	  cytochrome	  c	  






Deveraux,	  Q.	  L.,	  R.	  Takahashi,	  G.	  S.	  Salvesen	  and	  J.	  C.	  Reed	  (1997).	  X-­‐linked	  IAP	  is	  a	  direct	  inhibitor	  of	  
cell-­‐death	  proteases.	  Nature	  388(6639):	  300-­‐304.	  
Di	  Bartolo,	  D.	   L.,	  M.	  Cannon,	  Y.	   F.	   Liu,	  R.	  Renne,	  A.	  Chadburn,	  C.	  Boshoff	  and	  E.	  Cesarman	   (2008).	  
KSHV	  LANA	  inhibits	  TGF-­‐beta	  signaling	  through	  epigenetic	  silencing	  of	  the	  TGF-­‐beta	  type	  II	  receptor.	  
Blood	  111(9):	  4731-­‐4740.	  
di	  Renzo,	  L.,	  A.	  Altiok,	  G.	  Klein	  and	  E.	  Klein	  (1994).	  Endogenous	  TGF-­‐beta	  contributes	  to	  the	  induction	  
of	  the	  EBV	  lytic	  cycle	  in	  two	  Burkitt	  lymphoma	  cell	  lines.	  Int	  J	  Cancer	  57(6):	  914-­‐919.	  
Dirmeier,	   U.,	   B.	   Neuhierl,	   E.	   Kilger,	   G.	   Reisbach,	   M.	   L.	   Sandberg	   and	  W.	   Hammerschmidt	   (2003).	  
Latent	   membrane	   protein	   1	   is	   critical	   for	   efficient	   growth	   transformation	   of	   human	   B	   cells	   by	  
epstein-­‐barr	  virus.	  Cancer	  Res	  63(11):	  2982-­‐2989.	  
Doetzlhofer,	  A.,	  H.	  Rotheneder,	  G.	  Lagger,	  M.	  Koranda,	  V.	  Kurtev,	  G.	  Brosch,	  E.	  Wintersberger	  and	  C.	  
Seiser	  (1999).	  Histone	  deacetylase	  1	  can	  repress	  transcription	  by	  binding	  to	  Sp1.	  Mol	  Cell	  Biol	  19(8):	  
5504-­‐5511.	  
Dominguez-­‐Sola,	  D.,	  G.	  D.	  Victora,	  C.	  Y.	  Ying,	  R.	  T.	  Phan,	  M.	  Saito,	  M.	  C.	  Nussenzweig	  and	  R.	  Dalla-­‐
Favera	   (2012).	  The	  proto-­‐oncogene	  MYC	   is	   required	   for	  selection	   in	   the	  germinal	  center	  and	  cyclic	  
reentry.	  Nat	  Immunol	  13(11):	  1083-­‐1091.	  
Dong,	   M.	   and	   G.	   C.	   Blobe	   (2006).	   Role	   of	   transforming	   growth	   factor-­‐beta	   in	   hematologic	  
malignancies.	  Blood	  107(12):	  4589-­‐4596.	  
Dong,	  M.,	  T.	  How,	  K.	  C.	  Kirkbride,	  K.	  J.	  Gordon,	  J.	  D.	  Lee,	  N.	  Hempel,	  P.	  Kelly,	  B.	  J.	  Moeller,	  J.	  R.	  Marks	  
and	  G.	  C.	  Blobe	  (2007).	  The	  type	   III	  TGF-­‐beta	  receptor	  suppresses	  breast	  cancer	  progression.	  J	  Clin	  
Invest	  117(1):	  206-­‐217.	  
Dong,	   Z.,	   W.	   Guo,	   Y.	   Guo,	   G.	   Kuang	   and	   Z.	   Yang	   (2012).	   Concordant	   promoter	   methylation	   of	  
transforming	   growth	   factor-­‐beta	   receptor	   types	   I	   and	   II	   occurs	   early	   in	   esophageal	   squamous	   cell	  
carcinoma.	  Am	  J	  Med	  Sci	  343(5):	  375-­‐381.	  
Douglas,	  R.	  S.,	  R.	  J.	  Capocasale,	  R.	  J.	  Lamb,	  P.	  C.	  Nowell	  and	  J.	  S.	  Moore	  (1997).	  Chronic	  lymphocytic	  
leukemia	   B	   cells	   are	   resistant	   to	   the	   apoptotic	   effects	   of	   transforming	   growth	   factor-­‐beta.	   Blood	  
89(3):	  941-­‐947.	  
Du,	  Z.	  M.,	  L.	  F.	  Hu,	  H.	  Y.	  Wang,	  L.	  X.	  Yan,	  Y.	  X.	  Zeng,	  J.	  Y.	  Shao	  and	  I.	  Ernberg	  (2011).	  Upregulation	  of	  
MiR-­‐155	   in	   nasopharyngeal	   carcinoma	   is	   partly	   driven	   by	   LMP1	   and	   LMP2A	   and	   downregulates	   a	  
negative	  prognostic	  marker	  JMJD1A.	  PLoS	  One	  6(4):	  e19137.	  
Ebisawa,	   T.,	   M.	   Fukuchi,	   G.	   Murakami,	   T.	   Chiba,	   K.	   Tanaka,	   T.	   Imamura	   and	   K.	   Miyazono	   (2001).	  
Smurf1	   interacts	  with	  transforming	  growth	  factor-­‐beta	  type	  I	  receptor	  through	  Smad7	  and	   induces	  
receptor	  degradation.	  J	  Biol	  Chem	  276(16):	  12477-­‐12480.	  
Ebisawa,	  T.,	  K.	  Tada,	   I.	  Kitajima,	  K.	  Tojo,	  T.	  K.	  Sampath,	  M.	  Kawabata,	  K.	  Miyazono	  and	  T.	   Imamura	  
(1999).	   Characterization	   of	   bone	   morphogenetic	   protein-­‐6	   signaling	   pathways	   in	   osteoblast	  
differentiation.	  J	  Cell	  Sci	  112	  (	  Pt	  20):	  3519-­‐3527.	  
Egle,	  A.,	  A.	  W.	  Harris,	  P.	  Bouillet	  and	  S.	  Cory	  (2004).	  Bim	  is	  a	  suppressor	  of	  Myc-­‐induced	  mouse	  B	  cell	  






Eis,	   P.	   S.,	   W.	   Tam,	   L.	   Sun,	   A.	   Chadburn,	   Z.	   Li,	   M.	   F.	   Gomez,	   E.	   Lund	   and	   J.	   E.	   Dahlberg	   (2005).	  
Accumulation	  of	  miR-­‐155	  and	  BIC	  RNA	  in	  human	  B	  cell	  lymphomas.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  102(10):	  
3627-­‐3632.	  
Elliott,	  R.	  L.	  and	  G.	  C.	  Blobe	  (2005).	  Role	  of	  transforming	  growth	  factor	  Beta	  in	  human	  cancer.	  J	  Clin	  
Oncol	  23(9):	  2078-­‐2093.	  
Epstein,	  M.	  A.,	  B.	  G.	  Achong	  and	  Y.	  M.	  Barr	  (1964).	  VIRUS	  PARTICLES	  IN	  CULTURED	  LYMPHOBLASTS	  
FROM	  BURKITT'S	  LYMPHOMA.	  Lancet	  1(7335):	  702-­‐703.	  
Epstein,	  M.	   A.	   and	   Y.	  M.	   Barr	   (1964).	   CULTIVATION	   IN	   VITRO	   OF	   HUMAN	   LYMPHOBLASTS	   FROM	  
BURKITT'S	  MALIGNANT	  LYMPHOMA.	  Lancet	  1(7327):	  252-­‐253.	  
Esteller,	  M.	  (2007).	  Cancer	  epigenomics:	  DNA	  methylomes	  and	  histone-­‐modification	  maps.	  Nat	  Rev	  
Genet	  8(4):	  286-­‐298.	  
Evans,	   A.	   S.,	   J.	   C.	   Niederman	   and	   R.	  W.	  McCollum	   (1968).	   Seroepidemiologic	   studies	   of	   infectious	  
mononucleosis	  with	  EB	  virus.	  N	  Engl	  J	  Med	  279(21):	  1121-­‐1127.	  
Everett,	  R.	  D.,	  J.	  Murray,	  A.	  Orr	  and	  C.	  M.	  Preston	  (2007).	  Herpes	  simplex	  virus	  type	  1	  genomes	  are	  
associated	  with	  ND10	  nuclear	  substructures	  in	  quiescently	  infected	  human	  fibroblasts.	  J	  Virol	  81(20):	  
10991-­‐11004.	  
Fahmi,	  H.,	   C.	   Cochet,	   Z.	  Hmama,	  P.	  Opolon	  and	   I.	   Joab	   (2000).	   Transforming	   growth	   factor	  beta	  1	  
stimulates	   expression	   of	   the	   Epstein-­‐Barr	   virus	   BZLF1	   immediate-­‐early	   gene	   product	   ZEBRA	   by	   an	  
indirect	  mechanism	  which	  requires	  the	  MAPK	  kinase	  pathway.	  J	  Virol	  74(13):	  5810-­‐5818.	  
Faqing,	  T.,	  H.	  Zhi,	  Y.	  Liqun,	  T.	  Min,	  G.	  Huanhua,	  D.	  Xiyun	  and	  C.	  Ya	  (2005).	  Epstein-­‐Barr	  virus	  LMP1	  
initiates	   cell	   proliferation	   and	   apoptosis	   inhibition	   via	   regulating	   expression	   of	   Survivin	   in	  
nasopharyngeal	  carcinoma.	  Exp	  Oncol	  27(2):	  96-­‐101.	  
Fear,	   D.	   J.	   (2013).	  Mechanisms	   regulating	   the	   targeting	   and	   activity	   of	   activation	   induced	   cytidine	  
deaminase.	  Curr	  Opin	  Immunol	  25(5):	  619-­‐628.	  
Feederle,	  R.,	  E.	   J.	  Bartlett	  and	  H.	   J.	  Delecluse	   (2010).	  Epstein-­‐Barr	  virus	  genetics:	   talking	  about	   the	  
BAC	  generation.	  Herpesviridae	  1(1):	  6.	  
Feeley,	  B.	  T.,	   S.	  C.	  Gamradt,	  W.	  K.	  Hsu,	  N.	   Liu,	   L.	  Krenek,	  P.	  Robbins,	   J.	  Huard	  and	   J.	  R.	   Lieberman	  
(2005).	   Influence	  of	  BMPs	  on	  the	   formation	  of	  osteoblastic	   lesions	   in	  metastatic	  prostate	  cancer.	   J	  
Bone	  Miner	  Res	  20(12):	  2189-­‐2199.	  
Fenaux,	   P.,	   G.	   J.	   Mufti,	   E.	   Hellstrom-­‐Lindberg,	   V.	   Santini,	   C.	   Finelli,	   A.	   Giagounidis,	   R.	   Schoch,	   N.	  
Gattermann,	   G.	   Sanz,	   A.	   List,	   S.	   D.	   Gore,	   J.	   F.	   Seymour,	   J.	   M.	   Bennett,	   J.	   Byrd,	   J.	   Backstrom,	   L.	  
Zimmerman,	  D.	  McKenzie,	  C.	  Beach	  and	  L.	  R.	  Silverman	  (2009).	  Efficacy	  of	  azacitidine	  compared	  with	  
that	   of	   conventional	   care	   regimens	   in	   the	   treatment	   of	   higher-­‐risk	  myelodysplastic	   syndromes:	   a	  
randomised,	  open-­‐label,	  phase	  III	  study.	  Lancet	  Oncol	  10(3):	  223-­‐232.	  
Feng,	   X.	   H.	   and	   R.	   Derynck	   (1997).	   A	   kinase	   subdomain	   of	   transforming	   growth	   factor-­‐beta	   (TGF-­‐
beta)	   type	   I	   receptor	   determines	   the	   TGF-­‐beta	   intracellular	   signaling	   specificity.	   EMBO	   J	   16(13):	  
3912-­‐3923.	  
Feng,	   X.	   H.	   and	   R.	   Derynck	   (2005).	   Specificity	   and	   versatility	   in	   tgf-­‐beta	   signaling	   through	   Smads.	  






Finger,	   E.	  C.,	  N.	   Y.	   Lee,	  H.	   J.	   You	  and	  G.	  C.	  Blobe	   (2008a).	   Endocytosis	  of	   the	   type	   III	   transforming	  
growth	   factor-­‐beta	   (TGF-­‐beta)	   receptor	   through	   the	   clathrin-­‐independent/lipid	   raft	   pathway	  
regulates	  TGF-­‐beta	  signaling	  and	  receptor	  down-­‐regulation.	  J	  Biol	  Chem	  283(50):	  34808-­‐34818.	  
Finger,	  E.	  C.,	  R.	  S.	  Turley,	  M.	  Dong,	  T.	  How,	  T.	  A.	  Fields	  and	  G.	  C.	  Blobe	  (2008b).	  TbetaRIII	  suppresses	  
non-­‐small	  cell	  lung	  cancer	  invasiveness	  and	  tumorigenicity.	  Carcinogenesis	  29(3):	  528-­‐535.	  
Florio,	  P.,	  P.	  Ciarmela,	  F.	  M.	  Reis,	  P.	  Toti,	   L.	  Galleri,	  R.	  Santopietro,	  E.	  Tiso,	  P.	  Tosi	  and	  F.	  Petraglia	  
(2005).	   Inhibin	   alpha-­‐subunit	   and	   the	   inhibin	   coreceptor	   betaglycan	   are	   downregulated	   in	  
endometrial	  carcinoma.	  Eur	  J	  Endocrinol	  152(2):	  277-­‐284.	  
Frederick,	  J.	  P.,	  N.	  T.	  Liberati,	  D.	  S.	  Waddell,	  Y.	  Shi	  and	  X.	  F.	  Wang	  (2004).	  Transforming	  growth	  factor	  
beta-­‐mediated	   transcriptional	   repression	   of	   c-­‐myc	   is	   dependent	   on	   direct	   binding	   of	   Smad3	   to	   a	  
novel	  repressive	  Smad	  binding	  element.	  Mol	  Cell	  Biol	  24(6):	  2546-­‐2559.	  
Friedenberg,	   W.	   R.,	   S.	   A.	   Salzman,	   S.	   M.	   Phan	   and	   J.	   K.	   Burmester	   (1999).	   Transforming	   growth	  
factor-­‐beta	  and	  multidrug	  resistance	  in	  chronic	  lymphocytic	  leukemia.	  Med	  Oncol	  16(2):	  110-­‐118.	  
Fruehling,	   S.	   and	   R.	   Longnecker	   (1997).	   The	   immunoreceptor	   tyrosine-­‐based	   activation	   motif	   of	  
Epstein-­‐Barr	  virus	  LMP2A	  is	  essential	  for	  blocking	  BCR-­‐mediated	  signal	  transduction.	  Virology	  235(2):	  
241-­‐251.	  
Fukuda,	  M.,	  K.	  Ikuta,	  K.	  Yanagihara,	  M.	  Tajima,	  H.	  Kuratsune,	  T.	  Kurata	  and	  T.	  Sairenji	  (2001).	  Effect	  
of	   transforming	  growth	   factor-­‐beta1	  on	  the	  cell	  growth	  and	  Epstein-­‐Barr	  virus	   reactivation	   in	  EBV-­‐
infected	  epithelial	  cell	  lines.	  Virology	  288(1):	  109-­‐118.	  
Fukuda,	  M.,	  H.	  Kurosaki	  and	  T.	  Sairenji	  (2006a).	  Loss	  of	  functional	  transforming	  growth	  factor	  (TGF)-­‐
beta	  type	  II	  receptor	  results	  in	  insensitivity	  to	  TGF-­‐beta1-­‐mediated	  apoptosis	  and	  Epstein-­‐Barr	  virus	  
reactivation.	  J	  Med	  Virol	  78(11):	  1456-­‐1464.	  
Fukuda,	  M.,	  W.	  Kurosaki,	  K.	  Yanagihara,	  H.	  Kuratsune	  and	  T.	  Sairenji	  (2002).	  A	  mechanism	  in	  Epstein-­‐
Barr	   virus	   oncogenesis:	   inhibition	   of	   transforming	   growth	   factor-­‐beta	   1-­‐mediated	   induction	   of	  
MAPK/p21	  by	  LMP1.	  Virology	  302(2):	  310-­‐320.	  
Fukuda,	  M.	   and	   R.	   Longnecker	   (2004).	   Latent	  membrane	   protein	   2A	   inhibits	   transforming	   growth	  
factor-­‐beta	   1-­‐induced	   apoptosis	   through	   the	   phosphatidylinositol	   3-­‐kinase/Akt	   pathway.	   J	   Virol	  
78(4):	  1697-­‐1705.	  
Fukuda,	  N.,	  M.	  Saitoh,	  N.	  Kobayashi	  and	  K.	  Miyazono	  (2006b).	  Execution	  of	  BMP-­‐4-­‐induced	  apoptosis	  
by	  p53-­‐dependent	  ER	  dysfunction	   in	  myeloma	  and	  B-­‐cell	  hybridoma	  cells.	  Oncogene	  25(25):	  3509-­‐
3517.	  
Fukushima,	  D.,	  R.	  Butzow,	  A.	  Hildebrand	  and	  E.	  Ruoslahti	  (1993).	  Localization	  of	  transforming	  growth	  
factor	  beta	  binding	   site	   in	  betaglycan.	  Comparison	  with	   small	   extracellular	  matrix	  proteoglycans.	   J	  
Biol	  Chem	  268(30):	  22710-­‐22715.	  
Gatza,	  C.	  E.,	  S.	  Y.	  Oh	  and	  G.	  C.	  Blobe	  (2010).	  Roles	  for	  the	  type	  III	  TGF-­‐beta	  receptor	  in	  human	  cancer.	  
Cell	  Signal	  22(8):	  1163-­‐1174.	  
Ghosh,	  S.	  K.,	  S.	  P.	  Perrine,	  R.	  M.	  Williams	  and	  D.	  V.	  Faller	  (2012).	  Histone	  deacetylase	  inhibitors	  are	  
potent	  inducers	  of	  gene	  expression	  in	  latent	  EBV	  and	  sensitize	  lymphoma	  cells	  to	  nucleoside	  antiviral	  






Gloghini,	   A.,	   R.	   Dolcetti	   and	   A.	   Carbone	   (2013).	   Lymphomas	   occurring	   specifically	   in	   HIV-­‐infected	  
patients:	  From	  pathogenesis	  to	  pathology.	  Semin	  Cancer	  Biol	  23(6):	  457-­‐467.	  
Gordon,	   K.	   J.,	   M.	   Dong,	   E.	   M.	   Chislock,	   T.	   A.	   Fields	   and	   G.	   C.	   Blobe	   (2008).	   Loss	   of	   type	   III	  
transforming	  growth	  factor	  beta	  receptor	  expression	  increases	  motility	  and	  invasiveness	  associated	  
with	   epithelial	   to	   mesenchymal	   transition	   during	   pancreatic	   cancer	   progression.	   Carcinogenesis	  
29(2):	  252-­‐262.	  
Gottschalk,	  S.,	  H.	  E.	  Heslop	  and	  C.	  M.	  Rooney	  (2005).	  Adoptive	   immunotherapy	  for	  EBV-­‐associated	  
malignancies.	  Leuk	  Lymphoma	  46(1):	  1-­‐10.	  
Gottschalk,	   S.,	   C.	   Y.	   Ng,	  M.	   Perez,	   C.	   A.	   Smith,	   C.	   Sample,	  M.	   K.	   Brenner,	   H.	   E.	   Heslop	   and	   C.	  M.	  
Rooney	   (2001).	   An	   Epstein-­‐Barr	   virus	   deletion	   mutant	   associated	   with	   fatal	   lymphoproliferative	  
disease	  unresponsive	  to	  therapy	  with	  virus-­‐specific	  CTLs.	  Blood	  97(4):	  835-­‐843.	  
Goumans,	  M.	  J.,	  G.	  Valdimarsdottir,	  S.	  Itoh,	  F.	  Lebrin,	  J.	  Larsson,	  C.	  Mummery,	  S.	  Karlsson	  and	  P.	  ten	  
Dijke	  (2003).	  Activin	  receptor-­‐like	  kinase	  (ALK)1	  is	  an	  antagonistic	  mediator	  of	  lateral	  TGFbeta/ALK5	  
signaling.	  Mol	  Cell	  12(4):	  817-­‐828.	  
Goumans,	   M.	   J.,	   G.	   Valdimarsdottir,	   S.	   Itoh,	   A.	   Rosendahl,	   P.	   Sideras	   and	   P.	   ten	   Dijke	   (2002).	  
Balancing	  the	  activation	  state	  of	  the	  endothelium	  via	  two	  distinct	  TGF-­‐beta	  type	  I	  receptors.	  EMBO	  J	  
21(7):	  1743-­‐1753.	  
Grcevic,	  D.,	  R.	  Kusec,	  N.	  Kovacic,	  A.	  Lukic,	  I.	  K.	  Lukic,	  S.	  Ivcevic,	  D.	  Nemet,	  R.	  S.	  Seiwerth,	  S.	  K.	  Ostojic,	  
P.	   I.	   Croucher	   and	   A.	   Marusic	   (2010).	   Bone	   morphogenetic	   proteins	   and	   receptors	   are	   over-­‐
expressed	   in	   bone-­‐marrow	   cells	   of	   multiple	   myeloma	   patients	   and	   support	   myeloma	   cells	   by	  
inducing	  ID	  genes.	  Leuk	  Res	  34(6):	  742-­‐751.	  
Grimm,	  T.,	  S.	  Schneider,	  E.	  Naschberger,	  J.	  Huber,	  E.	  Guenzi,	  A.	  Kieser,	  P.	  Reitmeir,	  T.	  F.	  Schulz,	  C.	  A.	  
Morris	   and	   M.	   Sturzl	   (2005).	   EBV	   latent	   membrane	   protein-­‐1	   protects	   B	   cells	   from	   apoptosis	   by	  
inhibition	  of	  BAX.	  Blood	  105(8):	  3263-­‐3269.	  
Gronroos,	   E.,	   I.	   J.	   Kingston,	   A.	   Ramachandran,	   R.	   A.	   Randall,	   P.	   Vizan	   and	   C.	   S.	   Hill	   (2012).	  
Transforming	  growth	  factor	  beta	  inhibits	  bone	  morphogenetic	  protein-­‐induced	  transcription	  through	  
novel	  phosphorylated	  Smad1/5-­‐Smad3	  complexes.	  Mol	  Cell	  Biol	  32(14):	  2904-­‐2916.	  
Grundhoff,	  A.	  and	  C.	  S.	  Sullivan	  (2011).	  Virus-­‐encoded	  microRNAs.	  Virology	  411(2):	  325-­‐343.	  
Guasparri,	   I.,	   D.	   Bubman	   and	   E.	   Cesarman	   (2008).	   EBV	   LMP2A	   affects	   LMP1-­‐mediated	   NF-­‐kappaB	  
signaling	  and	  survival	  of	  lymphoma	  cells	  by	  regulating	  TRAF2	  expression.	  Blood	  111(7):	  3813-­‐3820.	  
Guo,	  W.,	  Z.	  Dong,	  Y.	  Guo,	  G.	  Kuang,	  Z.	  Yang	  and	  B.	  Shan	  (2012).	  Concordant	  repression	  and	  aberrant	  
methylation	   of	   transforming	   growth	   factor-­‐beta	   signaling	   pathway	   genes	   occurs	   early	   in	   gastric	  
cardia	  adenocarcinoma.	  Mol	  Biol	  Rep	  39(10):	  9453-­‐9462.	  
Hadinoto,	  V.,	  M.	  Shapiro,	  C.	  C.	  Sun	  and	  D.	  A.	  Thorley-­‐Lawson	  (2009).	  The	  dynamics	  of	  EBV	  shedding	  
implicate	  a	  central	  role	  for	  epithelial	  cells	  in	  amplifying	  viral	  output.	  PLoS	  Pathog	  5(7):	  e1000496.	  
Hammerschmidt,	  W.	  and	  B.	  Sugden	  (1988).	  Identification	  and	  characterization	  of	  oriLyt,	  a	  lytic	  origin	  
of	  DNA	  replication	  of	  Epstein-­‐Barr	  virus.	  Cell	  55(3):	  427-­‐433.	  
Hammerschmidt,	  W.	  and	  B.	  Sugden	   (1989).	  Genetic	  analysis	  of	   immortalizing	   functions	  of	  Epstein-­‐






Hannigan,	  A.,	  P.	  Smith,	  G.	  Kalna,	  C.	  Lo	  Nigro,	  C.	  Orange,	  D.	  I.	  O'Brien,	  R.	  Shah,	  N.	  Syed,	  L.	  C.	  Spender,	  
B.	  Herrera,	  J.	  K.	  Thurlow,	  L.	  Lattanzio,	  M.	  Monteverde,	  M.	  E.	  Maurer,	  F.	  M.	  Buffa,	  J.	  Mann,	  D.	  C.	  Chu,	  
C.	  M.	  West,	  M.	  Patridge,	  K.	  A.	  Oien,	  J.	  A.	  Cooper,	  M.	  C.	  Frame,	  A.	  L.	  Harris,	  L.	  Hiller,	  L.	  J.	  Nicholson,	  M.	  
Gasco,	   T.	   Crook	   and	  G.	   J.	   Inman	   (2010).	   Epigenetic	   downregulation	  of	   human	  disabled	  homolog	  2	  
switches	  TGF-­‐beta	  from	  a	  tumor	  suppressor	  to	  a	  tumor	  promoter.	  J	  Clin	  Invest	  120(8):	  2842-­‐2857.	  
Hannon,	  G.	   J.	  and	  D.	  Beach	   (1994).	  p15INK4B	   is	  a	  potential	  effector	  of	  TGF-­‐beta-­‐induced	  cell	   cycle	  
arrest.	  Nature	  371(6494):	  257-­‐261.	  
Harada,	  S.	  and	  E.	  Kieff	  (1997).	  Epstein-­‐Barr	  virus	  nuclear	  protein	  LP	  stimulates	  EBNA-­‐2	  acidic	  domain-­‐
mediated	  transcriptional	  activation.	  J	  Virol	  71(9):	  6611-­‐6618.	  
Harjunpaa,	  A.,	  M.	  Taskinen,	  M.	  Nykter,	  M.	  L.	  Karjalainen-­‐Lindsberg,	  H.	  Nyman,	  O.	  Monni,	  S.	  Hemmer,	  
O.	   Yli-­‐Harja,	   S.	   Hautaniemi,	   S.	   Meri	   and	   S.	   Leppa	   (2006).	   Differential	   gene	   expression	   in	   non-­‐
malignant	   tumour	   microenvironment	   is	   associated	   with	   outcome	   in	   follicular	   lymphoma	   patients	  
treated	  with	  rituximab	  and	  CHOP.	  Br	  J	  Haematol	  135(1):	  33-­‐42.	  
Hart,	  P.	   J.,	  S.	  Deep,	  A.	  B.	  Taylor,	  Z.	  Shu,	  C.	  S.	  Hinck	  and	  A.	  P.	  Hinck	   (2002).	  Crystal	  structure	  of	   the	  
human	  TbetaR2	  ectodomain-­‐-­‐TGF-­‐beta3	  complex.	  Nat	  Struct	  Biol	  9(3):	  203-­‐208.	  
Hart,	  S.	  L.,	  C.	  V.	  Arancibia-­‐Carcamo,	  M.	  A.	  Wolfert,	  C.	  Mailhos,	  N.	  J.	  O'Reilly,	  R.	  R.	  Ali,	  C.	  Coutelle,	  A.	  J.	  
George,	  R.	  P.	  Harbottle,	  A.	  M.	  Knight,	  D.	  F.	  Larkin,	  R.	  J.	  Levinsky,	  L.	  W.	  Seymour,	  A.	  J.	  Thrasher	  and	  C.	  
Kinnon	  (1998).	  Lipid-­‐mediated	  enhancement	  of	  transfection	  by	  a	  nonviral	   integrin-­‐targeting	  vector.	  
Hum	  Gene	  Ther	  9(4):	  575-­‐585.	  
Hassler,	  M.	  R.,	  A.	  I.	  Schiefer	  and	  G.	  Egger	  (2013).	  Combating	  the	  epigenome:	  epigenetic	  drugs	  against	  
non-­‐Hodgkin's	  lymphoma.	  Epigenomics	  5(4):	  397-­‐415.	  
Hawkins,	   J.	   B.,	   E.	   Delgado-­‐Eckert,	   D.	   A.	   Thorley-­‐Lawson	   and	  M.	   Shapiro	   (2013).	   The	   Cycle	   of	   EBV	  
Infection	  Explains	  Persistence,	  the	  Sizes	  of	  the	  Infected	  Cell	  Populations	  and	  Which	  Come	  under	  CTL	  
Regulation.	  PLoS	  Pathog	  9(10):	  e1003685.	  
He,	   G.	   and	   D.	   M.	   Margolis	   (2002).	   Counterregulation	   of	   chromatin	   deacetylation	   and	   histone	  
deacetylase	  occupancy	  at	  the	  integrated	  promoter	  of	  human	  immunodeficiency	  virus	  type	  1	  (HIV-­‐1)	  
by	  the	  HIV-­‐1	  repressor	  YY1	  and	  HIV-­‐1	  activator	  Tat.	  Mol	  Cell	  Biol	  22(9):	  2965-­‐2973.	  
Heath,	  E.,	  N.	  Begue-­‐Pastor,	  S.	  Chaganti,	  D.	  Croom-­‐Carter,	  C.	  Shannon-­‐Lowe,	  D.	  Kube,	  R.	  Feederle,	  H.	  
J.	  Delecluse,	  A.	  B.	  Rickinson	  and	  A.	  I.	  Bell	  (2012).	  Epstein-­‐Barr	  virus	  infection	  of	  naive	  B	  cells	  in	  vitro	  
frequently	   selects	   clones	  with	  mutated	   immunoglobulin	   genotypes:	   implications	   for	   virus	   biology.	  
PLoS	  Pathog	  8(5):	  e1002697.	  
Heldin,	  C.	  H.	  and	  A.	  Moustakas	  (2012).	  Role	  of	  Smads	  in	  TGFbeta	  signaling.	  Cell	  Tissue	  Res	  347(1):	  21-­‐
36.	  
Hemann,	  M.	  T.,	  A.	  Bric,	  J.	  Teruya-­‐Feldstein,	  A.	  Herbst,	  J.	  A.	  Nilsson,	  C.	  Cordon-­‐Cardo,	  J.	  L.	  Cleveland,	  
W.	  P.	   Tansey	  and	  S.	  W.	   Lowe	   (2005).	   Evasion	  of	   the	  p53	   tumour	   surveillance	  network	  by	   tumour-­‐
derived	  MYC	  mutants.	  Nature	  436(7052):	  807-­‐811.	  
Hempel,	  N.,	  T.	  How,	  S.	   J.	  Cooper,	  T.	  R.	  Green,	  M.	  Dong,	   J.	  A.	  Copland,	  C.	  G.	  Wood	  and	  G.	  C.	  Blobe	  
(2008).	   Expression	   of	   the	   type	   III	   TGF-­‐beta	   receptor	   is	   negatively	   regulated	   by	   TGF-­‐beta.	  






Hempel,	  N.,	  T.	  How,	  M.	  Dong,	  S.	  K.	  Murphy,	  T.	  A.	  Fields	  and	  G.	  C.	  Blobe	  (2007).	  Loss	  of	  betaglycan	  
expression	  in	  ovarian	  cancer:	  role	  in	  motility	  and	  invasion.	  Cancer	  Res	  67(11):	  5231-­‐5238.	  
Henderson,	   S.,	   M.	   Rowe,	   C.	   Gregory,	   D.	   Croom-­‐Carter,	   F.	   Wang,	   R.	   Longnecker,	   E.	   Kieff	   and	   A.	  
Rickinson	   (1991).	   Induction	   of	   bcl-­‐2	   expression	   by	   Epstein-­‐Barr	   virus	   latent	   membrane	   protein	   1	  
protects	  infected	  B	  cells	  from	  programmed	  cell	  death.	  Cell	  65(7):	  1107-­‐1115.	  
Henle,	  G.,	  W.	  Henle	  and	  V.	  Diehl	  (1968).	  Relation	  of	  Burkitt's	  tumor-­‐associated	  herpes-­‐ytpe	  virus	  to	  
infectious	  mononucleosis.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  59(1):	  94-­‐101.	  
Hennino,	   A.,	   M.	   Berard,	   P.	   H.	   Krammer	   and	   T.	   Defrance	   (2001).	   FLICE-­‐inhibitory	   protein	   is	   a	   key	  
regulator	  of	  germinal	  center	  B	  cell	  apoptosis.	  J	  Exp	  Med	  193(4):	  447-­‐458.	  
Herrera,	  B.,	  M.	  Garcia-­‐Alvaro,	  S.	  Cruz,	  P.	  Walsh,	  M.	  Fernandez,	  C.	  Roncero,	   I.	   Fabregat,	  A.	  Sanchez	  
and	   G.	   J.	   Inman	   (2013).	   BMP9	   is	   a	   proliferative	   and	   survival	   factor	   for	   human	   hepatocellular	  
carcinoma	  cells.	  PLoS	  One	  8(7):	  e69535.	  
Herrera,	   B.,	  M.	   van	   Dinther,	   P.	   Ten	   Dijke	   and	   G.	   J.	   Inman	   (2009).	   Autocrine	   bone	  morphogenetic	  
protein-­‐9	   signals	   through	   activin	   receptor-­‐like	   kinase-­‐2/Smad1/Smad4	   to	   promote	   ovarian	   cancer	  
cell	  proliferation.	  Cancer	  Res	  69(24):	  9254-­‐9262.	  
Hertle,	  M.	  L.,	  C.	  Popp,	  S.	  Petermann,	  S.	  Maier,	  E.	  Kremmer,	  R.	  Lang,	  J.	  Mages	  and	  B.	  Kempkes	  (2009).	  
Differential	   gene	   expression	   patterns	   of	   EBV	   infected	   EBNA-­‐3A	   positive	   and	   negative	   human	   B	  
lymphocytes.	  PLoS	  Pathog	  5(7):	  e1000506.	  
Hickabottom,	  M.,	  G.	   A.	   Parker,	   P.	   Freemont,	   T.	   Crook	   and	  M.	   J.	   Allday	   (2002).	   Two	  nonconsensus	  
sites	   in	   the	   Epstein-­‐Barr	   virus	   oncoprotein	   EBNA3A	   cooperate	   to	   bind	   the	   co-­‐repressor	   carboxyl-­‐
terminal-­‐binding	  protein	  (CtBP).	  J	  Biol	  Chem	  277(49):	  47197-­‐47204.	  
Hislop,	   A.	   D.,	   M.	   Kuo,	   A.	   B.	   Drake-­‐Lee,	   A.	   N.	   Akbar,	   W.	   Bergler,	   N.	   Hammerschmitt,	   N.	   Khan,	   U.	  
Palendira,	   A.	  M.	   Leese,	   J.	  M.	   Timms,	   A.	   I.	   Bell,	   C.	   D.	   Buckley	   and	   A.	   B.	   Rickinson	   (2005).	   Tonsillar	  
homing	   of	   Epstein-­‐Barr	   virus-­‐specific	   CD8+	   T	   cells	   and	   the	   virus-­‐host	   balance.	   J	   Clin	   Invest	  115(9):	  
2546-­‐2555.	  
Hislop,	  A.	  D.,	  G.	  S.	  Taylor,	  D.	  Sauce	  and	  A.	  B.	  Rickinson	  (2007).	  Cellular	  responses	  to	  viral	  infection	  in	  
humans:	  lessons	  from	  Epstein-­‐Barr	  virus.	  Annu	  Rev	  Immunol	  25:	  587-­‐617.	  
Hjertner,	   O.,	   H.	   Hjorth-­‐Hansen,	   M.	   Borset,	   C.	   Seidel,	   A.	   Waage	   and	   A.	   Sundan	   (2001).	   Bone	  
morphogenetic	   protein-­‐4	   inhibits	   proliferation	   and	   induces	   apoptosis	   of	   multiple	   myeloma	   cells.	  
Blood	  97(2):	  516-­‐522.	  
Holien,	   T.,	   T.	   K.	   Vatsveen,	   H.	   Hella,	   C.	   Rampa,	   G.	   Brede,	   L.	   A.	   Groseth,	   M.	   Rekvig,	   M.	   Borset,	   T.	  
Standal,	  A.	  Waage	  and	  A.	  Sundan	  (2012).	  Bone	  morphogenetic	  proteins	  induce	  apoptosis	  in	  multiple	  
myeloma	  cells	  by	  Smad-­‐dependent	  repression	  of	  MYC.	  Leukemia	  26(5):	  1073-­‐1080.	  
Holley-­‐Guthrie,	  E.	  A.,	  E.	  B.	  Quinlivan,	  E.	  C.	  Mar	  and	  S.	  Kenney	   (1990).	  The	  Epstein-­‐Barr	  virus	   (EBV)	  
BMRF1	  promoter	  for	  early	  antigen	  (EA-­‐D)	  is	  regulated	  by	  the	  EBV	  transactivators,	  BRLF1	  and	  BZLF1,	  
in	  a	  cell-­‐specific	  manner.	  J	  Virol	  64(8):	  3753-­‐3759.	  
Horndasch,	  M.,	  E.	  E.	  Raschke,	  G.	  Bommer,	  M.	  Schuhmacher,	  E.	  Dumont,	  C.	  Kuklik-­‐Roos,	  D.	  Eick	  and	  B.	  
Kempkes	  (2002).	  Epstein-­‐Barr	  virus	  antagonizes	  the	  antiproliferative	  activity	  of	  transforming	  growth	  






Huen,	   D.	   S.,	   S.	   A.	   Henderson,	   D.	   Croom-­‐Carter	   and	  M.	   Rowe	   (1995).	   The	   Epstein-­‐Barr	   virus	   latent	  
membrane	  protein-­‐1	  (LMP1)	  mediates	  activation	  of	  NF-­‐kappa	  B	  and	  cell	  surface	  phenotype	  via	  two	  
effector	  regions	  in	  its	  carboxy-­‐terminal	  cytoplasmic	  domain.	  Oncogene	  10(3):	  549-­‐560.	  
Hummel,	   M.,	   S.	   Bentink,	   H.	   Berger,	   W.	   Klapper,	   S.	   Wessendorf,	   T.	   F.	   Barth,	   H.	   W.	   Bernd,	   S.	   B.	  
Cogliatti,	  J.	  Dierlamm,	  A.	  C.	  Feller,	  M.	  L.	  Hansmann,	  E.	  Haralambieva,	  L.	  Harder,	  D.	  Hasenclever,	  M.	  
Kuhn,	   D.	   Lenze,	   P.	   Lichter,	   J.	   I.	   Martin-­‐Subero,	   P.	   Moller,	   H.	   K.	   Muller-­‐Hermelink,	   G.	   Ott,	   R.	   M.	  
Parwaresch,	   C.	   Pott,	   A.	   Rosenwald,	   M.	   Rosolowski,	   C.	   Schwaenen,	   B.	   Sturzenhofecker,	   M.	  
Szczepanowski,	   H.	   Trautmann,	   H.	   H.	   Wacker,	   R.	   Spang,	   M.	   Loeffler,	   L.	   Trumper,	   H.	   Stein	   and	   R.	  
Siebert	   (2006).	   A	   biologic	   definition	   of	   Burkitt's	   lymphoma	   from	   transcriptional	   and	   genomic	  
profiling.	  N	  Engl	  J	  Med	  354(23):	  2419-­‐2430.	  
Humphries,	  D.	  E.,	  B.	  B.	  Bloom,	  A.	  Fine	  and	  R.	  H.	  Goldstein	   (1994).	  Structure	  and	  expression	  of	   the	  
promoter	   for	   the	   human	   type	   II	   transforming	   growth	   factor-­‐beta	   receptor.	   Biochem	   Biophys	   Res	  
Commun	  203(2):	  1020-­‐1027.	  
Huse,	   K.,	   M.	   Bakkebo,	   M.	   P.	   Oksvold,	   L.	   Forfang,	   V.	   I.	   Hilden,	   T.	   Stokke,	   E.	   B.	   Smeland	   and	   J.	   H.	  
Myklebust	   (2011).	   Bone	   morphogenetic	   proteins	   inhibit	   CD40L/IL-­‐21-­‐induced	   Ig	   production	   in	  
human	  B	  cells:	  differential	  effects	  of	  BMP-­‐6	  and	  BMP-­‐7.	  Eur	  J	  Immunol	  41(11):	  3135-­‐3145.	  
Huse,	  K.,	  M.	  Bakkebo,	  S.	  Walchli,	  M.	  P.	  Oksvold,	  V.	  I.	  Hilden,	  L.	  Forfang,	  M.	  L.	  Bredahl,	  K.	  Liestol,	  A.	  A.	  
Alizadeh,	   E.	   B.	   Smeland	   and	   J.	   H.	  Myklebust	   (2012).	   Role	   of	   Smad	   Proteins	   in	   Resistance	   to	   BMP-­‐
Induced	  Growth	  Inhibition	  in	  B-­‐Cell	  Lymphoma.	  PLoS	  One	  7(10):	  e46117.	  
Huse,	  M.,	  T.	  W.	  Muir,	   L.	  Xu,	  Y.	  G.	  Chen,	   J.	  Kuriyan	  and	   J.	  Massague	   (2001).	  The	  TGF	  beta	   receptor	  
activation	  process:	  an	  inhibitor-­‐	  to	  substrate-­‐binding	  switch.	  Mol	  Cell	  8(3):	  671-­‐682.	  
Husson,	   H.,	   E.	   G.	   Carideo,	   D.	   Neuberg,	   J.	   Schultze,	   O.	  Munoz,	   P.	  W.	  Marks,	   J.	  W.	   Donovan,	   A.	   C.	  
Chillemi,	  P.	  O'Connell	  and	  A.	  S.	  Freedman	  (2002).	  Gene	  expression	  profiling	  of	   follicular	   lymphoma	  
and	  normal	  germinal	  center	  B	  cells	  using	  cDNA	  arrays.	  Blood	  99(1):	  282-­‐289.	  
Iavarone,	  A.	  and	  J.	  Massague	  (1997).	  Repression	  of	  the	  CDK	  activator	  Cdc25A	  and	  cell-­‐cycle	  arrest	  by	  
cytokine	  TGF-­‐beta	  in	  cells	  lacking	  the	  CDK	  inhibitor	  p15.	  Nature	  387(6631):	  417-­‐422.	  
Inman,	  G.	  J.	  and	  M.	  J.	  Allday	  (2000a).	  Apoptosis	  induced	  by	  TGF-­‐beta	  1	  in	  Burkitt's	  lymphoma	  cells	  is	  
caspase	  8	  dependent	  but	  is	  death	  receptor	  independent.	  J	  Immunol	  165(5):	  2500-­‐2510.	  
Inman,	  G.	   J.	  and	  M.	   J.	  Allday	   (2000b).	  Resistance	   to	  TGF-­‐beta1	  correlates	  with	  a	   reduction	  of	  TGF-­‐
beta	   type	   II	   receptor	   expression	   in	   Burkitt's	   lymphoma	   and	   Epstein-­‐Barr	   virus-­‐transformed	   B	  
lymphoblastoid	  cell	  lines.	  J	  Gen	  Virol	  81(Pt	  6):	  1567-­‐1578.	  
Inman,	  G.	  J.,	  U.	  K.	  Binne,	  G.	  A.	  Parker,	  P.	  J.	  Farrell	  and	  M.	  J.	  Allday	  (2001).	  Activators	  of	  the	  Epstein-­‐
Barr	  virus	  lytic	  program	  concomitantly	  induce	  apoptosis,	  but	  lytic	  gene	  expression	  protects	  from	  cell	  
death.	  J	  Virol	  75(5):	  2400-­‐2410.	  
Inman,	   G.	   J.	   and	   C.	   S.	   Hill	   (2002).	   Stoichiometry	   of	   active	   smad-­‐transcription	   factor	   complexes	   on	  
DNA.	  J	  Biol	  Chem	  277(52):	  51008-­‐51016.	  
Inman,	   G.	   J.,	   F.	   J.	   Nicolas	   and	   C.	   S.	   Hill	   (2002).	   Nucleocytoplasmic	   shuttling	   of	   Smads	   2,	   3,	   and	   4	  
permits	  sensing	  of	  TGF-­‐beta	  receptor	  activity.	  Mol	  Cell	  10(2):	  283-­‐294.	  
Ishida,	  W.,	  T.	  Hamamoto,	  K.	  Kusanagi,	  K.	  Yagi,	  M.	  Kawabata,	  K.	  Takehara,	  T.	  K.	  Sampath,	  M.	  Kato	  and	  






morphogenetic	   protein-­‐responsive	   element	   in	   the	   mouse	   Smad6	   promoter.	   J	   Biol	   Chem	   275(9):	  
6075-­‐6079.	  
Itoh,	  S.	  and	  P.	  ten	  Dijke	  (2007).	  Negative	  regulation	  of	  TGF-­‐beta	  receptor/Smad	  signal	  transduction.	  
Curr	  Opin	  Cell	  Biol	  19(2):	  176-­‐184.	  
Janssen,	  O.,	   S.	  Gillis	  and	  D.	  Kabelitz	   (1990).	   In	  vitro	   transformation	  by	  Epstein-­‐Barr	  virus	   induces	  a	  
switch	  in	  growth	  factor	  and	  anti-­‐IgM	  responsiveness	  in	  a	  human	  leukemic	  B	  cell	  clone.	  Eur	  J	  Immunol	  
20(1):	  7-­‐14.	  
Janz,	   S.,	   M.	   Potter	   and	   C.	   S.	   Rabkin	   (2003).	   Lymphoma-­‐	   and	   leukemia-­‐associated	   chromosomal	  
translocations	  in	  healthy	  individuals.	  Genes	  Chromosomes	  Cancer	  36(3):	  211-­‐223.	  
Jelinek,	  D.	  F.,	  R.	  C.	  Tschumper,	  G.	  A.	  Stolovitzky,	  S.	   J.	   Iturria,	  Y.	  Tu,	   J.	   Lepre,	  N.	  Shah	  and	  N.	  E.	  Kay	  
(2003).	   Identification	  of	  a	  global	  gene	  expression	  signature	  of	  B-­‐chronic	   lymphocytic	   leukemia.	  Mol	  
Cancer	  Res	  1(5):	  346-­‐361.	  
Jenkins,	  P.	  J.,	  U.	  K.	  Binne	  and	  P.	  J.	  Farrell	  (2000).	  Histone	  acetylation	  and	  reactivation	  of	  Epstein-­‐Barr	  
virus	  from	  latency.	  J	  Virol	  74(2):	  710-­‐720.	  
Jennings,	   R.,	   M.	   Alsarraj,	   K.	   L.	   Wright	   and	   T.	   Munoz-­‐Antonia	   (2001).	   Regulation	   of	   the	   human	  
transforming	   growth	   factor	   beta	   type	   II	   receptor	   gene	   promoter	   by	   novel	   Sp1	   sites.	   Oncogene	  
20(47):	  6899-­‐6909.	  
Ji,	  C.,	  Y.	  Chen,	  T.	  L.	  McCarthy	  and	  M.	  Centrella	  (1999).	  Cloning	  the	  promoter	  for	  transforming	  growth	  
factor-­‐beta	   type	   III	   receptor.	  Basal	   and	   conditional	   expression	   in	   fetal	   rat	  osteoblasts.	   J	  Biol	   Chem	  
274(43):	  30487-­‐30494.	  
Jiang,	   D.	   and	   R.	   C.	   Aguiar	   (2014).	   MicroRNA-­‐155	   controls	   RB	   phosphorylation	   in	   normal	   and	  
malignant	   B	   lymphocytes	   via	   the	   noncanonical	   TGF-­‐beta1/SMAD5	   signaling	  module.	  Blood	  123(1):	  
86-­‐93.	  
Jiang,	   R.,	   X.	   Gu,	   C.	   O.	   Nathan	   and	   L.	   Hutt-­‐Fletcher	   (2008).	   Laser-­‐capture	   microdissection	   of	  
oropharyngeal	  epithelium	   indicates	   restriction	  of	  Epstein-­‐Barr	   virus	   receptor/CD21	  mRNA	   to	   tonsil	  
epithelial	  cells.	  J	  Oral	  Pathol	  Med	  37(10):	  626-­‐633.	  
Jimenez-­‐Ramirez,	  C.,	  A.	  J.	  Brooks,	  L.	  P.	  Forshell,	  K.	  Yakimchuk,	  B.	  Zhao,	  T.	  Z.	  Fulgham	  and	  C.	  E.	  Sample	  
(2006).	   Epstein-­‐Barr	   virus	   EBNA-­‐3C	   is	   targeted	   to	   and	   regulates	   expression	   from	   the	   bidirectional	  
LMP-­‐1/2B	  promoter.	  J	  Virol	  80(22):	  11200-­‐11208.	  
Jonk,	   L.	   J.,	   S.	   Itoh,	   C.	   H.	   Heldin,	   P.	   ten	   Dijke	   and	  W.	   Kruijer	   (1998).	   Identification	   and	   functional	  
characterization	  of	  a	  Smad	  binding	  element	  (SBE)	  in	  the	  JunB	  promoter	  that	  acts	  as	  a	  transforming	  
growth	   factor-­‐beta,	   activin,	   and	   bone	   morphogenetic	   protein-­‐inducible	   enhancer.	   J	   Biol	   Chem	  
273(33):	  21145-­‐21152.	  
Kaiser,	  C.,	  G.	  Laux,	  D.	  Eick,	  N.	  Jochner,	  G.	  W.	  Bornkamm	  and	  B.	  Kempkes	  (1999).	  The	  proto-­‐oncogene	  
c-­‐myc	  is	  a	  direct	  target	  gene	  of	  Epstein-­‐Barr	  virus	  nuclear	  antigen	  2.	  J	  Virol	  73(5):	  4481-­‐4484.	  
Kalla,	  M.	  and	  W.	  Hammerschmidt	  (2012).	  Human	  B	  cells	  on	  their	  route	  to	  latent	  infection-­‐-­‐early	  but	  






Kalla,	  M.,	  A.	  Schmeinck,	  M.	  Bergbauer,	  D.	  Pich	  and	  W.	  Hammerschmidt	  (2010).	  AP-­‐1	  homolog	  BZLF1	  
of	   Epstein-­‐Barr	   virus	   has	   two	   essential	   functions	   dependent	   on	   the	   epigenetic	   state	   of	   the	   viral	  
genome.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  107(2):	  850-­‐855.	  
Kanda,	   T.,	   M.	   Otter	   and	   G.	   M.	   Wahl	   (2001).	   Coupling	   of	   mitotic	   chromosome	   tethering	   and	  
replication	  competence	  in	  epstein-­‐barr	  virus-­‐based	  plasmids.	  Mol	  Cell	  Biol	  21(10):	  3576-­‐3588.	  
Kang,	   Y.,	   C.	   R.	   Chen	   and	   J.	  Massague	   (2003).	   A	   self-­‐enabling	   TGFbeta	   response	   coupled	   to	   stress	  
signaling:	   Smad	  engages	   stress	   response	   factor	  ATF3	   for	   Id1	   repression	   in	  epithelial	   cells.	  Mol	  Cell	  
11(4):	  915-­‐926.	  
Kanzler,	  H.,	  R.	  Kuppers,	  M.	  L.	  Hansmann	  and	  K.	  Rajewsky	  (1996).	  Hodgkin	  and	  Reed-­‐Sternberg	  cells	  in	  
Hodgkin's	   disease	   represent	   the	   outgrowth	   of	   a	   dominant	   tumor	   clone	   derived	   from	   (crippled)	  
germinal	  center	  B	  cells.	  J	  Exp	  Med	  184(4):	  1495-­‐1505.	  
Kaptein,	  J.	  S.,	  C.	  K.	  Lin,	  C.	  L.	  Wang,	  T.	  T.	  Nguyen,	  C.	  I.	  Kalunta,	  E.	  Park,	  F.	  S.	  Chen	  and	  P.	  M.	  Lad	  (1996).	  
Anti-­‐IgM-­‐mediated	   regulation	   of	   c-­‐myc	   and	   its	   possible	   relationship	   to	   apoptosis.	   J	   Biol	   Chem	  
271(31):	  18875-­‐18884.	  
Katagiri,	  T.,	  M.	  Imada,	  T.	  Yanai,	  T.	  Suda,	  N.	  Takahashi	  and	  R.	  Kamijo	  (2002).	  Identification	  of	  a	  BMP-­‐
responsive	  element	  in	  Id1,	  the	  gene	  for	  inhibition	  of	  myogenesis.	  Genes	  Cells	  7(9):	  949-­‐960.	  
Kawabata,	   K.	   C.,	   S.	   Ehata,	   A.	   Komuro,	   K.	   Takeuchi	   and	   K.	   Miyazono	   (2013).	   TGF-­‐beta-­‐induced	  
apoptosis	   of	   B-­‐cell	   lymphoma	   Ramos	   cells	   through	   reduction	   of	   MS4A1/CD20.	  Oncogene	   32(16):	  
2096-­‐2106.	  
Kawamura,	  C.,	  M.	  Kizaki,	  K.	  Yamato,	  H.	  Uchida,	  Y.	  Fukuchi,	  Y.	  Hattori,	  T.	  Koseki,	  T.	  Nishihara	  and	  Y.	  
Ikeda	   (2000).	   Bone	   morphogenetic	   protein-­‐2	   induces	   apoptosis	   in	   human	   myeloma	   cells	   with	  
modulation	  of	  STAT3.	  Blood	  96(6):	  2005-­‐2011.	  
Kaye,	  K.	  M.,	  K.	  M.	  Izumi	  and	  E.	  Kieff	  (1993).	  Epstein-­‐Barr	  virus	  latent	  membrane	  protein	  1	  is	  essential	  
for	  B-­‐lymphocyte	  growth	  transformation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  90(19):	  9150-­‐9154.	  
Kee,	  B.	  L.,	  R.	  R.	  Rivera	  and	  C.	  Murre	  (2001).	  Id3	  inhibits	  B	  lymphocyte	  progenitor	  growth	  and	  survival	  
in	  response	  to	  TGF-­‐beta.	  Nat	  Immunol	  2(3):	  242-­‐247.	  
Kehrl,	   J.	   H.,	   A.	   B.	   Roberts,	   L.	   M.	   Wakefield,	   S.	   Jakowlew,	   M.	   B.	   Sporn	   and	   A.	   S.	   Fauci	   (1986).	  
Transforming	   growth	   factor	   beta	   is	   an	   important	   immunomodulatory	   protein	   for	   human	   B	  
lymphocytes.	  J	  Immunol	  137(12):	  3855-­‐3860.	  
Kehrl,	   J.	   H.,	   A.	   S.	   Taylor,	   G.	   A.	   Delsing,	   A.	   B.	   Roberts,	  M.	   B.	   Sporn	   and	   A.	   S.	   Fauci	   (1989).	   Further	  
studies	  of	   the	  role	  of	   transforming	  growth	  factor-­‐beta	   in	  human	  B	  cell	   function.	  J	   Immunol	  143(6):	  
1868-­‐1874.	  
Kelly,	   G.,	   A.	   Bell	   and	   A.	   Rickinson	   (2002).	   Epstein-­‐Barr	   virus-­‐associated	   Burkitt	   lymphomagenesis	  
selects	  for	  downregulation	  of	  the	  nuclear	  antigen	  EBNA2.	  Nat	  Med	  8(10):	  1098-­‐1104.	  
Kelly,	  G.	  L.,	  A.	  E.	  Milner,	  R.	  J.	  Tierney,	  D.	  S.	  Croom-­‐Carter,	  M.	  Altmann,	  W.	  Hammerschmidt,	  A.	  I.	  Bell	  
and	  A.	  B.	  Rickinson	  (2005).	  Epstein-­‐Barr	  virus	  nuclear	  antigen	  2	  (EBNA2)	  gene	  deletion	  is	  consistently	  
linked	   with	   EBNA3A,	   -­‐3B,	   and	   -­‐3C	   expression	   in	   Burkitt's	   lymphoma	   cells	   and	   with	   increased	  






Kelly,	  G.	  L.,	   J.	  Stylianou,	  J.	  Rasaiyaah,	  W.	  Wei,	  W.	  Thomas,	  D.	  Croom-­‐Carter,	  C.	  Kohler,	  R.	  Spang,	  C.	  
Woodman,	  P.	  Kellam,	  A.	  B.	  Rickinson	  and	  A.	   I.	  Bell	   (2013).	  Different	  Patterns	  of	  Epstein-­‐Barr	  Virus	  
Latency	  in	  Endemic	  Burkitt	  Lymphoma	  (BL)	  Lead	  to	  Distinct	  Variants	  within	  the	  BL-­‐Associated	  Gene	  
Expression	  Signature.	  J	  Virol	  87(5):	  2882-­‐2894.	  
Kempkes,	   B.,	   D.	   Spitkovsky,	   P.	   Jansen-­‐Durr,	   J.	   W.	   Ellwart,	   E.	   Kremmer,	   H.	   J.	   Delecluse,	   C.	  
Rottenberger,	  G.	  W.	  Bornkamm	  and	  W.	  Hammerschmidt	  (1995).	  B-­‐cell	  proliferation	  and	  induction	  of	  
early	  G1-­‐regulating	  proteins	  by	  Epstein-­‐Barr	  virus	  mutants	  conditional	  for	  EBNA2.	  EMBO	  J	  14(1):	  88-­‐
96.	  
Kennedy,	   G.,	   J.	   Komano	   and	   B.	   Sugden	   (2003).	   Epstein-­‐Barr	   virus	   provides	   a	   survival	   factor	   to	  
Burkitt's	  lymphomas.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  100(24):	  14269-­‐14274.	  
Kenney,	  J.	  L.,	  M.	  E.	  Guinness,	  T.	  Curiel	  and	  J.	  Lacy	  (1998).	  Antisense	  to	  the	  epstein-­‐barr	  virus	  (EBV)-­‐
encoded	  latent	  membrane	  protein	  1	  (LMP-­‐1)	  suppresses	  LMP-­‐1	  and	  bcl-­‐2	  expression	  and	  promotes	  
apoptosis	  in	  EBV-­‐immortalized	  B	  cells.	  Blood	  92(5):	  1721-­‐1727.	  
Kenney,	  J.	  L.,	  M.	  E.	  Guinness,	  M.	  Reiss	  and	  J.	  Lacy	  (2001).	  Antisense	  to	  the	  Epstein-­‐Barr	  virus	  (EBV)-­‐
encoded	   latent	   membrane	   protein	   1	   (LMP-­‐1)	   sensitizes	   EBV-­‐immortalized	   B	   cells	   to	   transforming	  
growth	  factor-­‐beta	  and	  chemotherapeutic	  agents.	  Int	  J	  Cancer	  91(1):	  89-­‐98.	  
Kerr,	  J.	  F.,	  A.	  H.	  Wyllie	  and	  A.	  R.	  Currie	  (1972).	  Apoptosis:	  a	  basic	  biological	  phenomenon	  with	  wide-­‐
ranging	  implications	  in	  tissue	  kinetics.	  Br	  J	  Cancer	  26(4):	  239-­‐257.	  
Kersten,	  C.,	  G.	  Dosen,	  J.	  H.	  Myklebust,	  E.	  A.	  Sivertsen,	  M.	  E.	  Hystad,	  E.	  B.	  Smeland	  and	  E.	  Rian	  (2006).	  
BMP-­‐6	   inhibits	   human	   bone	   marrow	   B	   lymphopoiesis-­‐-­‐upregulation	   of	   Id1	   and	   Id3.	   Exp	   Hematol	  
34(1):	  72-­‐81.	  
Kersten,	  C.,	  E.	  A.	  Sivertsen,	  M.	  E.	  Hystad,	  L.	  Forfang,	  E.	  B.	  Smeland	  and	  J.	  H.	  Myklebust	  (2005).	  BMP-­‐6	  
inhibits	   growth	   of	  mature	   human	  B	   cells;	   induction	   of	   Smad	   phosphorylation	   and	   upregulation	   of	  
Id1.	  BMC	  Immunol	  6(1):	  9.	  
Khan,	  G.,	  E.	  M.	  Miyashita,	  B.	  Yang,	  G.	  J.	  Babcock	  and	  D.	  A.	  Thorley-­‐Lawson	  (1996).	  Is	  EBV	  persistence	  
in	  vivo	  a	  model	  for	  B	  cell	  homeostasis?	  Immunity	  5(2):	  173-­‐179.	  
Khan,	  H.,	  C.	  Vale,	  T.	  Bhagat	  and	  A.	  Verma	  (2013).	  Role	  of	  DNA	  methylation	  in	  the	  pathogenesis	  and	  
treatment	  of	  myelodysplastic	  syndromes.	  Semin	  Hematol	  50(1):	  16-­‐37.	  
Kilger,	  E.,	  A.	  Kieser,	  M.	  Baumann	  and	  W.	  Hammerschmidt	  (1998).	  Epstein-­‐Barr	  virus-­‐mediated	  B-­‐cell	  
proliferation	   is	   dependent	   upon	   latent	   membrane	   protein	   1,	   which	   simulates	   an	   activated	   CD40	  
receptor.	  EMBO	  J	  17(6):	  1700-­‐1709.	  
Kim,	  B.	  C.,	  M.	  Mamura,	  K.	  S.	  Choi,	  B.	  Calabretta	  and	  S.	  J.	  Kim	  (2002).	  Transforming	  growth	  factor	  beta	  
1	   induces	  apoptosis	   through	  cleavage	  of	  BAD	   in	  a	  Smad3-­‐dependent	  mechanism	   in	  FaO	  hepatoma	  
cells.	  Mol	  Cell	  Biol	  22(5):	  1369-­‐1378.	  
Kim,	  J.	  H.,	  W.	  S.	  Kim	  and	  C.	  Park	  (2012).	  Epstein-­‐Barr	  virus	  latent	  membrane	  protein-­‐1	  protects	  B-­‐cell	  
lymphoma	   from	   rituximab-­‐induced	   apoptosis	   through	   miR-­‐155-­‐mediated	   Akt	   activation	   and	   up-­‐
regulation	  of	  Mcl-­‐1.	  Leuk	  Lymphoma	  53(8):	  1586-­‐1591.	  
Kim,	  S.	  G.,	  H.	  A.	  Kim,	  H.	  S.	  Jong,	  J.	  H.	  Park,	  N.	  K.	  Kim,	  S.	  H.	  Hong,	  T.	  Y.	  Kim	  and	  Y.	  J.	  Bang	  (2005).	  The	  







Kim,	  W.	  Y.	  and	  N.	  E.	  Sharpless	  (2006).	  The	  regulation	  of	   INK4/ARF	   in	  cancer	  and	  aging.	  Cell	  127(2):	  
265-­‐275.	  
King,	  I.	  L.	  and	  M.	  Mohrs	  (2009).	  IL-­‐4-­‐producing	  CD4+	  T	  cells	  in	  reactive	  lymph	  nodes	  during	  helminth	  
infection	  are	  T	  follicular	  helper	  cells.	  J	  Exp	  Med	  206(5):	  1001-­‐1007.	  
Kirk,	   O.,	   C.	   Pedersen,	   A.	   Cozzi-­‐Lepri,	   F.	   Antunes,	   V.	  Miller,	   J.	  M.	  Gatell,	   C.	   Katlama,	   A.	   Lazzarin,	   P.	  
Skinhoj	  and	  S.	  E.	  Barton	  (2001).	  Non-­‐Hodgkin	  lymphoma	  in	  HIV-­‐infected	  patients	  in	  the	  era	  of	  highly	  
active	  antiretroviral	  therapy.	  Blood	  98(12):	  3406-­‐3412.	  
Kirkbride,	   K.	   C.,	   T.	   A.	   Townsend,	   M.	   W.	   Bruinsma,	   J.	   V.	   Barnett	   and	   G.	   C.	   Blobe	   (2008).	   Bone	  
morphogenetic	  proteins	  signal	  through	  the	  transforming	  growth	  factor-­‐beta	  type	  III	  receptor.	  J	  Biol	  
Chem	  283(12):	  7628-­‐7637.	  
Kirmizis,	   A.,	   S.	  M.	   Bartley,	   A.	   Kuzmichev,	   R.	  Margueron,	   D.	   Reinberg,	   R.	   Green	   and	   P.	   J.	   Farnham	  
(2004).	  Silencing	  of	  human	  polycomb	  target	  genes	  is	  associated	  with	  methylation	  of	  histone	  H3	  Lys	  
27.	  Genes	  Dev	  18(13):	  1592-­‐1605.	  
Kis,	   L.	   L.,	   N.	   Gerasimcik,	   D.	   Salamon,	   E.	   K.	   Persson,	   N.	   Nagy,	   G.	   Klein,	   E.	   Severinson	   and	   E.	   Klein	  
(2011).	  STAT6	  signaling	  pathway	  activated	  by	  the	  cytokines	  IL-­‐4	  and	  IL-­‐13	  induces	  expression	  of	  the	  
Epstein-­‐Barr	   virus-­‐encoded	   protein	   LMP-­‐1	   in	   absence	   of	   EBNA-­‐2:	   implications	   for	   the	   type	   II	   EBV	  
latent	  gene	  expression	  in	  Hodgkin	  lymphoma.	  Blood	  117(1):	  165-­‐174.	  
Kis,	  L.	  L.,	  J.	  Nishikawa,	  M.	  Takahara,	  N.	  Nagy,	  L.	  Matskova,	  K.	  Takada,	  P.	  G.	  Elmberger,	  A.	  Ohlsson,	  G.	  
Klein	  and	  E.	  Klein	   (2005).	   In	  vitro	  EBV-­‐infected	  subline	  of	  KMH2,	  derived	  from	  Hodgkin	   lymphoma,	  
expresses	  only	  EBNA-­‐1,	  while	  CD40	  ligand	  and	  IL-­‐4	  induce	  LMP-­‐1	  but	  not	  EBNA-­‐2.	  Int	  J	  Cancer	  113(6):	  
937-­‐945.	  
Kis,	  L.	  L.,	  D.	  Salamon,	  E.	  K.	  Persson,	  N.	  Nagy,	  F.	  A.	  Scheeren,	  H.	  Spits,	  G.	  Klein	  and	  E.	  Klein	  (2010).	  IL-­‐
21	   imposes	  a	  type	   II	  EBV	  gene	  expression	  on	  type	   III	  and	  type	   I	  B	  cells	  by	  the	  repression	  of	  C-­‐	  and	  
activation	  of	  LMP-­‐1-­‐promoter.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  107(2):	  872-­‐877.	  
Kis,	  L.	  L.,	  M.	  Takahara,	  N.	  Nagy,	  G.	  Klein	  and	  E.	  Klein	  (2006).	  IL-­‐10	  can	  induce	  the	  expression	  of	  EBV-­‐
encoded	   latent	   membrane	   protein-­‐1	   (LMP-­‐1)	   in	   the	   absence	   of	   EBNA-­‐2	   in	   B	   lymphocytes	   and	   in	  
Burkitt	  lymphoma-­‐	  and	  NK	  lymphoma-­‐derived	  cell	  lines.	  Blood	  107(7):	  2928-­‐2935.	  
Klangby,	  U.,	  I.	  Okan,	  K.	  P.	  Magnusson,	  M.	  Wendland,	  P.	  Lind	  and	  K.	  G.	  Wiman	  (1998).	  p16/INK4a	  and	  
p15/INK4b	  gene	  methylation	  and	  absence	  of	  p16/INK4a	  mRNA	  and	  protein	  expression	   in	  Burkitt's	  
lymphoma.	  Blood	  91(5):	  1680-­‐1687.	  
Klein,	  U.	  and	  R.	  Dalla-­‐Favera	  (2008).	  Germinal	  centres:	  role	  in	  B-­‐cell	  physiology	  and	  malignancy.	  Nat	  
Rev	  Immunol	  8(1):	  22-­‐33.	  
Klein,	  U.,	  Y.	  Tu,	  G.	  A.	  Stolovitzky,	  M.	  Mattioli,	  G.	  Cattoretti,	  H.	  Husson,	  A.	  Freedman,	  G.	  Inghirami,	  L.	  
Cro,	   L.	   Baldini,	   A.	   Neri,	   A.	   Califano	   and	   R.	   Dalla-­‐Favera	   (2001).	   Gene	   expression	   profiling	   of	   B	   cell	  
chronic	   lymphocytic	   leukemia	   reveals	  a	  homogeneous	  phenotype	   related	   to	  memory	  B	  cells.	   J	  Exp	  
Med	  194(11):	  1625-­‐1638.	  
Komano,	   J.,	   S.	  Maruo,	   K.	   Kurozumi,	   T.	   Oda	   and	   K.	   Takada	   (1999).	   Oncogenic	   role	   of	   Epstein-­‐Barr	  
virus-­‐encoded	  RNAs	  in	  Burkitt's	  lymphoma	  cell	  line	  Akata.	  J	  Virol	  73(12):	  9827-­‐9831.	  
Konrad,	   L.,	   J.	   A.	   Scheiber,	   E.	   Volck-­‐Badouin,	   M.	   M.	   Keilani,	   L.	   Laible,	   H.	   Brandt,	   A.	   Schmidt,	   G.	  






beta	   RI,	   T	   beta	   RII	   and	   T	   beta	   RIII	   (betaglycan)	   reveal	   new	   variants	   in	   human	  prostatic	   cells.	  BMC	  
Genomics	  8:	  318.	  
Korchynskyi,	   O.	   and	   P.	   ten	   Dijke	   (2002).	   Identification	   and	   functional	   characterization	   of	   distinct	  
critically	   important	  bone	  morphogenetic	  protein-­‐specific	   response	  elements	   in	   the	   Id1	  promoter.	   J	  
Biol	  Chem	  277(7):	  4883-­‐4891.	  
Kouzarides,	  T.	  (2007).	  Chromatin	  modifications	  and	  their	  function.	  Cell	  128(4):	  693-­‐705.	  
Krauer,	  K.	  G.,	  A.	  Burgess,	  M.	  Buck,	  J.	  Flanagan,	  T.	  B.	  Sculley	  and	  B.	  Gabrielli	  (2004).	  The	  EBNA-­‐3	  gene	  
family	  proteins	  disrupt	  the	  G2/M	  checkpoint.	  Oncogene	  23(7):	  1342-­‐1353.	  
Kremer,	  J.	  P.,	  G.	  Reisbach,	  C.	  Nerl	  and	  P.	  Dormer	  (1992).	  B-­‐cell	  chronic	  lymphocytic	  leukaemia	  cells	  
express	  and	  release	  transforming	  growth	  factor-­‐beta.	  Br	  J	  Haematol	  80(4):	  480-­‐487.	  
Kretschmer,	   A.,	   K.	   Moepert,	   S.	   Dames,	   M.	   Sternberger,	   J.	   Kaufmann	   and	   A.	   Klippel	   (2003).	  
Differential	   regulation	  of	  TGF-­‐beta	  signaling	   through	  Smad2,	  Smad3	  and	  Smad4.	  Oncogene	  22(43):	  
6748-­‐6763.	  
Kulwichit,	  W.,	   R.	  H.	   Edwards,	   E.	  M.	  Davenport,	   J.	   F.	   Baskar,	  V.	  Godfrey	   and	  N.	  Raab-­‐Traub	   (1998).	  
Expression	   of	   the	   Epstein-­‐Barr	   virus	   latent	   membrane	   protein	   1	   induces	   B	   cell	   lymphoma	   in	  
transgenic	  mice.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  95(20):	  11963-­‐11968.	  
Kumar,	   A.,	   T.	   Rogers,	   A.	  Maizel	   and	   S.	   Sharma	   (1991).	   Loss	   of	   transforming	   growth	   factor	   beta	   1	  
receptors	  and	   its	  effects	  on	  the	  growth	  of	  EBV-­‐transformed	  human	  B	  cells.	  J	   Immunol	  147(3):	  998-­‐
1006.	  
Kuzmichev,	   A.,	   K.	   Nishioka,	   H.	   Erdjument-­‐Bromage,	   P.	   Tempst	   and	   D.	   Reinberg	   (2002).	   Histone	  
methyltransferase	  activity	  associated	  with	  a	  human	  multiprotein	  complex	  containing	   the	  Enhancer	  
of	  Zeste	  protein.	  Genes	  Dev	  16(22):	  2893-­‐2905.	  
Lagneaux,	   L.,	   A.	   Delforge,	   M.	   Bernier,	   P.	   Stryckmans	   and	   D.	   Bron	   (1998).	   TGF-­‐beta	   activity	   and	  
expression	  of	  its	  receptors	  in	  B-­‐cell	  chronic	  lymphocytic	  leukemia.	  Leuk	  Lymphoma	  31(1-­‐2):	  99-­‐106.	  
Lagneaux,	   L.,	  A.	  Delforge,	  D.	  Bron,	  M.	  Massy,	  M.	  Bernier	   and	  P.	   Stryckmans	   (1997).	  Heterogenous	  
response	   of	   B	   lymphocytes	   to	   transforming	   growth	   factor-­‐beta	   in	   B-­‐cell	   chronic	   lymphocytic	  
leukaemia:	  correlation	  with	  the	  expression	  of	  TGF-­‐beta	  receptors.	  Br	  J	  Haematol	  97(3):	  612-­‐620.	  
Laichalk,	  L.	  L.	  and	  D.	  A.	  Thorley-­‐Lawson	  (2005).	  Terminal	  differentiation	  into	  plasma	  cells	  initiates	  the	  
replicative	  cycle	  of	  Epstein-­‐Barr	  virus	  in	  vivo.	  J	  Virol	  79(2):	  1296-­‐1307.	  
Lambert,	   K.	   E.,	   H.	   Huang,	   K.	   Mythreye	   and	   G.	   C.	   Blobe	   (2011).	   The	   type	   III	   transforming	   growth	  
factor-­‐beta	   receptor	   inhibits	   proliferation,	  migration,	   and	   adhesion	   in	   human	  myeloma	   cells.	  Mol	  
Biol	  Cell	  22(9):	  1463-­‐1472.	  
Landstrom,	  M.	  (2010).	  The	  TAK1-­‐TRAF6	  signalling	  pathway.	  Int	  J	  Biochem	  Cell	  Biol	  42(5):	  585-­‐589.	  
Larsson,	   J.	   and	   S.	   Karlsson	   (2005).	   The	   role	   of	   Smad	   signaling	   in	   hematopoiesis.	  Oncogene	  24(37):	  
5676-­‐5692.	  
Lee,	   J.	  E.,	  H.	  Y.	  Nam,	  S.	  M.	  Shim,	  G.	  R.	  Bae,	  B.	  G.	  Han	  and	   J.	  P.	   Jeon	   (2010).	  Expression	  phenotype	  
changes	   of	   EBV-­‐transformed	   lymphoblastoid	   cell	   lines	   during	   long-­‐term	   subculture	   and	   its	   clinical	  






Lee,	   M.	   A.,	   M.	   E.	   Diamond	   and	   J.	   L.	   Yates	   (1999).	   Genetic	   evidence	   that	   EBNA-­‐1	   is	   needed	   for	  
efficient,	  stable	  latent	  infection	  by	  Epstein-­‐Barr	  virus.	  J	  Virol	  73(4):	  2974-­‐2982.	  
Lee,	  N.	  Y.,	  K.	  C.	  Kirkbride,	  R.	  D.	  Sheu	  and	  G.	  C.	  Blobe	   (2009).	  The	   transforming	  growth	   factor-­‐beta	  
type	   III	   receptor	   mediates	   distinct	   subcellular	   trafficking	   and	   downstream	   signaling	   of	   activin-­‐like	  
kinase	  (ALK)3	  and	  ALK6	  receptors.	  Mol	  Biol	  Cell	  20(20):	  4362-­‐4370.	  
Lei,	   X.,	   Y.	   Zhu,	   T.	   Jones,	   Z.	   Bai,	   Y.	   Huang	   and	   S.	   J.	   Gao	   (2012).	   A	   Kaposi's	   sarcoma-­‐associated	  
herpesvirus	   microRNA	   and	   its	   variants	   target	   the	   transforming	   growth	   factor	   beta	   pathway	   to	  
promote	  cell	  survival.	  J	  Virol	  86(21):	  11698-­‐11711.	  
Lerner,	  M.	  R.,	  N.	  C.	  Andrews,	  G.	  Miller	  and	  J.	  A.	  Steitz	  (1981).	  Two	  small	  RNAs	  encoded	  by	  Epstein-­‐
Barr	   virus	   and	   complexed	  with	  protein	   are	  precipitated	  by	  antibodies	   from	  patients	  with	   systemic	  
lupus	  erythematosus.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  78(2):	  805-­‐809.	  
Lewis,	  K.	  A.,	  P.	  C.	  Gray,	  A.	  L.	  Blount,	  L.	  A.	  MacConell,	  E.	  Wiater,	  L.	  M.	  Bilezikjian	  and	  W.	  Vale	  (2000).	  
Betaglycan	   binds	   inhibin	   and	   can	   mediate	   functional	   antagonism	   of	   activin	   signalling.	   Nature	  
404(6776):	  411-­‐414.	  
Li,	   L.	  C.	  and	  R.	  Dahiya	   (2002).	  MethPrimer:	  designing	  primers	   for	  methylation	  PCRs.	  Bioinformatics	  
18(11):	  1427-­‐1431.	  
Li,	   P.,	   D.	  Nijhawan,	   I.	   Budihardjo,	   S.	  M.	   Srinivasula,	  M.	   Ahmad,	   E.	   S.	   Alnemri	   and	   X.	  Wang	   (1997).	  
Cytochrome	   c	   and	   dATP-­‐dependent	   formation	   of	   Apaf-­‐1/caspase-­‐9	   complex	   initiates	   an	   apoptotic	  
protease	  cascade.	  Cell	  91(4):	  479-­‐489.	  
Li,	  X.,	  V.	  Placencio,	  J.	  M.	  Iturregui,	  C.	  Uwamariya,	  A.	  R.	  Sharif-­‐Afshar,	  T.	  Koyama,	  S.	  W.	  Hayward	  and	  
N.	   A.	   Bhowmick	   (2008).	   Prostate	   tumor	   progression	   is	   mediated	   by	   a	   paracrine	   TGF-­‐beta/Wnt3a	  
signaling	  axis.	  Oncogene	  27(56):	  7118-­‐7130.	  
Lin,	  H.	  Y.,	  X.	  F.	  Wang,	  E.	  Ng-­‐Eaton,	  R.	  A.	  Weinberg	  and	  H.	  F.	  Lodish	  (1992).	  Expression	  cloning	  of	  the	  
TGF-­‐beta	  type	  II	  receptor,	  a	  functional	  transmembrane	  serine/threonine	  kinase.	  Cell	  68(4):	  775-­‐785.	  
Lin,	  J.,	  E.	  Johannsen,	  E.	  Robertson	  and	  E.	  Kieff	  (2002).	  Epstein-­‐Barr	  virus	  nuclear	  antigen	  3C	  putative	  
repression	  domain	  mediates	  coactivation	  of	  the	  LMP1	  promoter	  with	  EBNA-­‐2.	  J	  Virol	  76(1):	  232-­‐242.	  
Lin,	  P.,	  T.	  J.	  Dickason,	  L.	  E.	  Fayad,	  P.	  A.	  Lennon,	  P.	  Hu,	  M.	  Garcia,	  M.	  J.	  Routbort,	  R.	  Miranda,	  X.	  Wang,	  
W.	   Qiao	   and	   L.	   J.	   Medeiros	   (2012).	   Prognostic	   value	   of	   MYC	   rearrangement	   in	   cases	   of	   B-­‐cell	  
lymphoma,	   unclassifiable,	   with	   features	   intermediate	   between	   diffuse	   large	   B-­‐cell	   lymphoma	   and	  
Burkitt	  lymphoma.	  Cancer	  118(6):	  1566-­‐1573.	  
Ling,	   M.	   T.,	   X.	   Wang,	   S.	   W.	   Tsao	   and	   Y.	   C.	   Wong	   (2002).	   Down-­‐regulation	   of	   Id-­‐1	   expression	   is	  
associated	  with	  TGF	  beta	  1-­‐induced	  growth	  arrest	   in	  prostate	  epithelial	  cells.	  Biochim	  Biophys	  Acta	  
1570(3):	  145-­‐152.	  
Liu,	  I.	  M.,	  S.	  H.	  Schilling,	  K.	  A.	  Knouse,	  L.	  Choy,	  R.	  Derynck	  and	  X.	  F.	  Wang	  (2009).	  TGFbeta-­‐stimulated	  
Smad1/5	   phosphorylation	   requires	   the	   ALK5	   L45	   loop	   and	   mediates	   the	   pro-­‐migratory	   TGFbeta	  
switch.	  EMBO	  J	  28(2):	  88-­‐98.	  
Liu,	  M.,	  J.	  L.	  Duke,	  D.	  J.	  Richter,	  C.	  G.	  Vinuesa,	  C.	  C.	  Goodnow,	  S.	  H.	  Kleinstein	  and	  D.	  G.	  Schatz	  (2008).	  







Liu,	  Y.,	  R.	  Sun,	  X.	  Lin,	  D.	  Liang,	  Q.	  Deng	  and	  K.	  Lan	  (2012).	  Kaposi's	  sarcoma-­‐associated	  herpesvirus-­‐
encoded	   microRNA	   miR-­‐K12-­‐11	   attenuates	   transforming	   growth	   factor	   beta	   signaling	   through	  
suppression	  of	  SMAD5.	  J	  Virol	  86(3):	  1372-­‐1381.	  
Lo,	  A.	  K.,	  C.	  W.	  Dawson,	  K.	  W.	  Lo,	  Y.	  Yu	  and	  L.	  S.	  Young	  (2010).	  Upregulation	  of	  Id1	  by	  Epstein-­‐Barr	  
Virus-­‐encoded	   LMP1	   confers	   resistance	   to	   TGFbeta-­‐mediated	   growth	   inhibition.	  Mol	   Cancer	   9(1):	  
155.	  
Locklin,	  R.	  M.,	  B.	  L.	  Riggs,	  K.	  C.	  Hicok,	  H.	  F.	  Horton,	  M.	  C.	  Byrne	  and	  S.	  Khosla	  (2001).	  Assessment	  of	  
gene	  regulation	  by	  bone	  morphogenetic	  protein	  2	  in	  human	  marrow	  stromal	  cells	  using	  gene	  array	  
technology.	  J	  Bone	  Miner	  Res	  16(12):	  2192-­‐2204.	  
Longnecker,	   R.,	   C.	   L.	   Miller,	   X.	   Q.	   Miao,	   A.	   Marchini	   and	   E.	   Kieff	   (1992).	   The	   only	   domain	   which	  
distinguishes	  Epstein-­‐Barr	  virus	  latent	  membrane	  protein	  2A	  (LMP2A)	  from	  LMP2B	  is	  dispensable	  for	  
lymphocyte	   infection	   and	   growth	   transformation	   in	   vitro;	   LMP2A	   is	   therefore	  nonessential.	   J	   Virol	  
66(11):	  6461-­‐6469.	  
Longnecker,	   R.,	   C.	   L.	   Miller,	   X.	   Q.	   Miao,	   B.	   Tomkinson	   and	   E.	   Kieff	   (1993a).	   The	   last	   seven	  
transmembrane	  and	   carboxy-­‐terminal	   cytoplasmic	  domains	  of	   Epstein-­‐Barr	   virus	   latent	  membrane	  
protein	  2	  (LMP2)	  are	  dispensable	  for	  lymphocyte	  infection	  and	  growth	  transformation	  in	  vitro.	  J	  Virol	  
67(4):	  2006-­‐2013.	  
Longnecker,	  R.,	  C.	  L.	  Miller,	  B.	  Tomkinson,	  X.	  Q.	  Miao	  and	  E.	  Kieff	  (1993b).	  Deletion	  of	  DNA	  encoding	  
the	  first	  five	  transmembrane	  domains	  of	  Epstein-­‐Barr	  virus	   latent	  membrane	  proteins	  2A	  and	  2B.	  J	  
Virol	  67(8):	  5068-­‐5074.	  
Longnecker,	  R.	  M.,	  E.	  Kieff	  and	  J.	  I.	  Cohen	  (2013).	  Epstein-­‐Barr	  Virus.	  Fields	  Virology.	  D.	  M.	  Knipe	  and	  
P.	  M.	  Howley,	  Wolters	  Kluwer	  Health/Lippincott	  Williams	  &	  Wilkins.	  2:	  1898-­‐1959.	  
Lopez-­‐Casillas,	  F.,	  S.	  Cheifetz,	  J.	  Doody,	  J.	  L.	  Andres,	  W.	  S.	  Lane	  and	  J.	  Massague	  (1991).	  Structure	  and	  
expression	   of	   the	   membrane	   proteoglycan	   betaglycan,	   a	   component	   of	   the	   TGF-­‐beta	   receptor	  
system.	  Cell	  67(4):	  785-­‐795.	  
Lopez-­‐Casillas,	   F.,	   H.	  M.	   Payne,	   J.	   L.	   Andres	   and	   J.	  Massague	   (1994).	   Betaglycan	   can	   act	   as	   a	   dual	  
modulator	  of	  TGF-­‐beta	  access	  to	  signaling	  receptors:	  mapping	  of	  ligand	  binding	  and	  GAG	  attachment	  
sites.	  J	  Cell	  Biol	  124(4):	  557-­‐568.	  
Lopez-­‐Casillas,	  F.,	  C.	  Riquelme,	  Y.	  Perez-­‐Kato,	  M.	  V.	  Ponce-­‐Castaneda,	  N.	  Osses,	  J.	  Esparza-­‐Lopez,	  G.	  
Gonzalez-­‐Nunez,	   C.	   Cabello-­‐Verrugio,	   V.	  Mendoza,	   V.	   Troncoso	   and	   E.	   Brandan	   (2003).	   Betaglycan	  
expression	  is	  transcriptionally	  up-­‐regulated	  during	  skeletal	  muscle	  differentiation.	  Cloning	  of	  murine	  
betaglycan	   gene	   promoter	   and	   its	   modulation	   by	   MyoD,	   retinoic	   acid,	   and	   transforming	   growth	  
factor-­‐beta.	  J	  Biol	  Chem	  278(1):	  382-­‐390.	  
Lopez-­‐Casillas,	   F.,	   J.	   L.	  Wrana	  and	   J.	  Massague	   (1993).	  Betaglycan	  presents	   ligand	   to	   the	  TGF	  beta	  
signaling	  receptor.	  Cell	  73(7):	  1435-­‐1444.	  
Lopez-­‐Rovira,	  T.,	  E.	  Chalaux,	  J.	  Massague,	  J.	  L.	  Rosa	  and	  F.	  Ventura	  (2002).	  Direct	  binding	  of	  Smad1	  
and	   Smad4	   to	   two	   distinct	   motifs	   mediates	   bone	   morphogenetic	   protein-­‐specific	   transcriptional	  
activation	  of	  Id1	  gene.	  J	  Biol	  Chem	  277(5):	  3176-­‐3185.	  
Lotz,	  M.,	  E.	  Ranheim	  and	  T.	  J.	  Kipps	  (1994).	  Transforming	  growth	  factor	  beta	  as	  endogenous	  growth	  






Love,	   C.,	   Z.	   Sun,	   D.	   Jima,	   G.	   Li,	   J.	   Zhang,	   R.	   Miles,	   K.	   L.	   Richards,	   C.	   H.	   Dunphy,	   W.	   W.	   Choi,	   G.	  
Srivastava,	  P.	  L.	  Lugar,	  D.	  A.	  Rizzieri,	  A.	  S.	  Lagoo,	  L.	  Bernal-­‐Mizrachi,	  K.	  P.	  Mann,	  C.	  R.	  Flowers,	  K.	  N.	  
Naresh,	  A.	  M.	  Evens,	  A.	  Chadburn,	  L.	  I.	  Gordon,	  M.	  B.	  Czader,	  J.	  I.	  Gill,	  E.	  D.	  Hsi,	  A.	  Greenough,	  A.	  B.	  
Moffitt,	   M.	   McKinney,	   A.	   Banerjee,	   V.	   Grubor,	   S.	   Levy,	   D.	   B.	   Dunson	   and	   S.	   S.	   Dave	   (2012).	   The	  
genetic	  landscape	  of	  mutations	  in	  Burkitt	  lymphoma.	  Nat	  Genet	  44(12):	  1321-­‐1325.	  
Luger,	  K.,	  A.	  W.	  Mader,	  R.	  K.	  Richmond,	  D.	  F.	  Sargent	  and	  T.	  J.	  Richmond	  (1997).	  Crystal	  structure	  of	  
the	  nucleosome	  core	  particle	  at	  2.8	  A	  resolution.	  Nature	  389(6648):	  251-­‐260.	  
MacDonald,	  I.,	  H.	  Wang,	  R.	  Grand,	  R.	  J.	  Armitage,	  W.	  C.	  Fanslow,	  C.	  D.	  Gregory	  and	  J.	  Gordon	  (1996).	  
Transforming	   growth	   factor-­‐beta	   1	   cooperates	   with	   anti-­‐immunoglobulin	   for	   the	   induction	   of	  
apoptosis	  in	  group	  I	  (biopsy-­‐like)	  Burkitt	  lymphoma	  cell	  lines.	  Blood	  87(3):	  1147-­‐1154.	  
Machold,	   K.	   P.,	   D.	   A.	   Carson	   and	   M.	   Lotz	   (1993).	   Transforming	   growth	   factor-­‐beta	   (TGF	   beta)	  
inhibition	  of	  Epstein-­‐Barr	  virus	  (EBV)-­‐	  and	  interleukin-­‐4	  (IL-­‐4)-­‐induced	  immunoglobulin	  production	  in	  
human	  B	  lymphocytes.	  J	  Clin	  Immunol	  13(3):	  219-­‐227.	  
Maesako,	  Y.,	  T.	  Uchiyama	  and	  H.	  Ohno	  (2003).	  Comparison	  of	  gene	  expression	  profiles	  of	  lymphoma	  
cell	  lines	  from	  transformed	  follicular	  lymphoma,	  Burkitt's	  lymphoma	  and	  de	  novo	  diffuse	  large	  B-­‐cell	  
lymphoma.	  Cancer	  Sci	  94(9):	  774-­‐781.	  
Maier,	  S.,	  G.	  Staffler,	  A.	  Hartmann,	  J.	  Hock,	  K.	  Henning,	  K.	  Grabusic,	  R.	  Mailhammer,	  R.	  Hoffmann,	  M.	  
Wilmanns,	   R.	   Lang,	   J.	   Mages	   and	   B.	   Kempkes	   (2006).	   Cellular	   target	   genes	   of	   Epstein-­‐Barr	   virus	  
nuclear	  antigen	  2.	  J	  Virol	  80(19):	  9761-­‐9771.	  
Mancao,	   C.,	   M.	   Altmann,	   B.	   Jungnickel	   and	   W.	   Hammerschmidt	   (2005).	   Rescue	   of	   "crippled"	  
germinal	  center	  B	  cells	  from	  apoptosis	  by	  Epstein-­‐Barr	  virus.	  Blood	  106(13):	  4339-­‐4344.	  
Mancao,	  C.	  and	  W.	  Hammerschmidt	   (2007).	  Epstein-­‐Barr	  virus	   latent	  membrane	  protein	  2A	   is	  a	  B-­‐
cell	  receptor	  mimic	  and	  essential	  for	  B-­‐cell	  survival.	  Blood	  110(10):	  3715-­‐3721.	  
Margulis,	   V.,	   T.	   Maity,	   X.	   Y.	   Zhang,	   S.	   J.	   Cooper,	   J.	   A.	   Copland	   and	   C.	   G.	   Wood	   (2008).	   Type	   III	  
transforming	   growth	   factor-­‐beta	   (TGF-­‐beta)	   receptor	   mediates	   apoptosis	   in	   renal	   cell	   carcinoma	  
independent	  of	  the	  canonical	  TGF-­‐beta	  signaling	  pathway.	  Clin	  Cancer	  Res	  14(18):	  5722-­‐5730.	  
Markowitz,	  S.,	  J.	  Wang,	  L.	  Myeroff,	  R.	  Parsons,	  L.	  Sun,	  J.	  Lutterbaugh,	  R.	  S.	  Fan,	  E.	  Zborowska,	  K.	  W.	  
Kinzler,	  B.	  Vogelstein	  and	  et	  al.	  (1995).	  Inactivation	  of	  the	  type	  II	  TGF-­‐beta	  receptor	  in	  colon	  cancer	  
cells	  with	  microsatellite	  instability.	  Science	  268(5215):	  1336-­‐1338.	  
Marshall,	   D.	   and	   C.	   Sample	   (1995).	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   3C	   is	   a	   transcriptional	  
regulator.	  J	  Virol	  69(6):	  3624-­‐3630.	  
Martinez-­‐Valdez,	  H.,	  C.	  Guret,	  O.	  de	  Bouteiller,	   I.	  Fugier,	  J.	  Banchereau	  and	  Y.	  J.	  Liu	  (1996).	  Human	  
germinal	  center	  B	  cells	  express	   the	  apoptosis-­‐inducing	  genes	  Fas,	  c-­‐myc,	  P53,	  and	  Bax	  but	  not	   the	  
survival	  gene	  bcl-­‐2.	  J	  Exp	  Med	  183(3):	  971-­‐977.	  
Maruo,	  S.,	  Y.	  Wu,	  S.	   Ishikawa,	  T.	  Kanda,	  D.	   Iwakiri	  and	  K.	  Takada	  (2006).	  Epstein-­‐Barr	  virus	  nuclear	  
protein	   EBNA3C	   is	   required	   for	   cell	   cycle	   progression	   and	   growth	  maintenance	   of	   lymphoblastoid	  
cells.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  103(51):	  19500-­‐19505.	  
Maruo,	   S.,	   B.	   Zhao,	   E.	   Johannsen,	   E.	   Kieff,	   J.	   Zou	   and	   K.	   Takada	   (2011).	   Epstein-­‐Barr	   virus	   nuclear	  
antigens	   3C	   and	   3A	   maintain	   lymphoblastoid	   cell	   growth	   by	   repressing	   p16INK4A	   and	   p14ARF	  






Massague,	  J.	  (2012).	  TGFbeta	  signalling	  in	  context.	  Nat	  Rev	  Mol	  Cell	  Biol	  13(10):	  616-­‐630.	  
Mathew,	  S.,	  V.	  V.	  Murty,	  S.	  Cheifetz,	  D.	  George,	  J.	  Massague	  and	  R.	  S.	  Chaganti	  (1994).	  Transforming	  
growth	  factor	  receptor	  gene	  TGFBR2	  maps	  to	  human	  chromosome	  band	  3p22.	  Genomics	  20(1):	  114-­‐
115.	  
Maunders,	  M.	  J.,	  L.	  Petti	  and	  M.	  Rowe	  (1994).	  Precipitation	  of	  the	  Epstein-­‐Barr	  virus	  protein	  EBNA	  2	  
by	  an	  EBNA	  3c-­‐specific	  monoclonal	  antibody.	  J	  Gen	  Virol	  75	  (	  Pt	  4):	  769-­‐778.	  
McClellan,	  M.	  J.,	  S.	  Khasnis,	  C.	  D.	  Wood,	  R.	  D.	  Palermo,	  S.	  N.	  Schlick,	  A.	  S.	  Kanhere,	  R.	  G.	  Jenner	  and	  
M.	   J.	  West	   (2012).	  Downregulation	  of	   integrin	   receptor-­‐signaling	  genes	  by	  Epstein-­‐Barr	  virus	  EBNA	  
3C	  via	  promoter-­‐proximal	  and	  -­‐distal	  binding	  elements.	  J	  Virol	  86(9):	  5165-­‐5178.	  
McClellan,	   M.	   J.,	   C.	   D.	   Wood,	   O.	   Ojeniyi,	   T.	   J.	   Cooper,	   A.	   Kanhere,	   A.	   Arvey,	   H.	   M.	   Webb,	   R.	   D.	  
Palermo,	   M.	   L.	   Harth-­‐Hertle,	   B.	   Kempkes,	   R.	   G.	   Jenner	   and	   M.	   J.	   West	   (2013).	   Modulation	   of	  
enhancer	   looping	  and	  differential	   gene	   targeting	  by	  Epstein-­‐Barr	   virus	   transcription	   factors	  directs	  
cellular	  reprogramming.	  PLoS	  Pathog	  9(9):	  e1003636.	  
Molyneux,	  E.	  M.,	  R.	  Rochford,	  B.	  Griffin,	  R.	  Newton,	  G.	  Jackson,	  G.	  Menon,	  C.	  J.	  Harrison,	  T.	   Israels	  
and	  S.	  Bailey	  (2012).	  Burkitt's	  lymphoma.	  Lancet	  379(9822):	  1234-­‐1244.	  
Mori,	  N.,	  M.	  Morishita,	   T.	   Tsukazaki,	  C.	   Z.	  Giam,	  A.	  Kumatori,	   Y.	   Tanaka	  and	  N.	  Yamamoto	   (2001).	  
Human	  T-­‐cell	  leukemia	  virus	  type	  I	  oncoprotein	  Tax	  represses	  Smad-­‐dependent	  transforming	  growth	  
factor	  beta	  signaling	  through	  interaction	  with	  CREB-­‐binding	  protein/p300.	  Blood	  97(7):	  2137-­‐2144.	  
Mori,	   N.,	   M.	   Morishita,	   T.	   Tsukazaki	   and	   N.	   Yamamoto	   (2003).	   Repression	   of	   Smad-­‐dependent	  
transforming	  growth	  factor-­‐beta	  signaling	  by	  Epstein-­‐Barr	  virus	  latent	  membrane	  protein	  1	  through	  
nuclear	  factor-­‐kappaB.	  Int	  J	  Cancer	  105(5):	  661-­‐668.	  
Moustakas,	   A.,	   S.	   Souchelnytskyi	   and	   C.	   H.	   Heldin	   (2001).	   Smad	   regulation	   in	   TGF-­‐beta	   signal	  
transduction.	  J	  Cell	  Sci	  114(Pt	  24):	  4359-­‐4369.	  
Mu,	  Y.,	  S.	  K.	  Gudey	  and	  M.	  Landstrom	  (2012).	  Non-­‐Smad	  signaling	  pathways.	  Cell	  Tissue	  Res	  347(1):	  
11-­‐20.	  
Mueller,	  T.	  D.	  and	  J.	  Nickel	  (2012).	  Promiscuity	  and	  specificity	  in	  BMP	  receptor	  activation.	  FEBS	  Lett	  
586(14):	  1846-­‐1859.	  
Munoz,	   O.,	   F.	   Fend,	   R.	   de	   Beaumont,	   H.	   Husson,	   A.	   Astier	   and	   A.	   S.	   Freedman	   (2004).	   TGFbeta-­‐
mediated	   activation	   of	   Smad1	   in	   B-­‐cell	   non-­‐Hodgkin's	   lymphoma	   and	   effect	   on	   cell	   proliferation.	  
Leukemia	  18(12):	  2015-­‐2025.	  
Murphy,	  K.	  (2011).	  Janeway's	  Immunobiology,	  Garland	  Science.	  
Murray,	  R.	  J.,	  M.	  G.	  Kurilla,	  J.	  M.	  Brooks,	  W.	  A.	  Thomas,	  M.	  Rowe,	  E.	  Kieff	  and	  A.	  B.	  Rickinson	  (1992).	  
Identification	  of	  target	  antigens	  for	  the	  human	  cytotoxic	  T	  cell	  response	  to	  Epstein-­‐Barr	  virus	  (EBV):	  
implications	  for	  the	  immune	  control	  of	  EBV-­‐positive	  malignancies.	  J	  Exp	  Med	  176(1):	  157-­‐168.	  
Nagarajan,	   R.	   P.,	   J.	   Zhang,	   W.	   Li	   and	   Y.	   Chen	   (1999).	   Regulation	   of	   Smad7	   promoter	   by	   direct	  






Nakao,	  A.,	  M.	  Afrakhte,	  A.	  Moren,	  T.	  Nakayama,	  J.	  L.	  Christian,	  R.	  Heuchel,	  S.	  Itoh,	  M.	  Kawabata,	  N.	  E.	  
Heldin,	  C.	  H.	  Heldin	  and	  P.	  ten	  Dijke	  (1997).	  Identification	  of	  Smad7,	  a	  TGFbeta-­‐inducible	  antagonist	  
of	  TGF-­‐beta	  signalling.	  Nature	  389(6651):	  631-­‐635.	  
Neuhierl,	   B.,	   R.	   Feederle,	   W.	   Hammerschmidt	   and	   H.	   J.	   Delecluse	   (2002).	   Glycoprotein	   gp110	   of	  
Epstein-­‐Barr	   virus	   determines	   viral	   tropism	   and	   efficiency	   of	   infection.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A	  
99(23):	  15036-­‐15041.	  
Nikitin,	  P.	  A.,	  C.	  M.	  Yan,	  E.	  Forte,	  A.	  Bocedi,	   J.	  P.	  Tourigny,	  R.	  E.	  White,	  M.	   J.	  Allday,	  A.	  Patel,	   S.	   S.	  
Dave,	  W.	  Kim,	  K.	  Hu,	   J.	  Guo,	  D.	  Tainter,	  E.	  Rusyn	  and	  M.	  A.	   Luftig	   (2010).	  An	  ATM/Chk2-­‐mediated	  
DNA	  damage-­‐responsive	  signaling	  pathway	  suppresses	  Epstein-­‐Barr	  virus	  transformation	  of	  primary	  
human	  B	  cells.	  Cell	  Host	  Microbe	  8(6):	  510-­‐522.	  
Nitsche,	   F.,	   A.	   Bell	   and	   A.	   Rickinson	   (1997).	   Epstein-­‐Barr	   virus	   leader	   protein	   enhances	   EBNA-­‐2-­‐
mediated	   transactivation	   of	   latent	   membrane	   protein	   1	   expression:	   a	   role	   for	   the	  W1W2	   repeat	  
domain.	  J	  Virol	  71(9):	  6619-­‐6628.	  
Noda,	  C.,	  T.	  Murata,	  T.	  Kanda,	  H.	  Yoshiyama,	  A.	  Sugimoto,	  D.	  Kawashima,	  S.	  Saito,	  H.	  Isomura	  and	  T.	  
Tsurumi	  (2011).	  Identification	  and	  characterization	  of	  CCAAT	  enhancer-­‐binding	  protein	  (C/EBP)	  as	  a	  
transcriptional	   activator	   for	   Epstein-­‐Barr	   virus	   oncogene	   latent	  membrane	   protein	   1.	   J	   Biol	   Chem	  
286(49):	  42524-­‐42533.	  
Noer,	   A.,	   L.	   C.	   Lindeman	   and	   P.	   Collas	   (2009).	   Histone	   H3	   modifications	   associated	   with	  
differentiation	  and	  long-­‐term	  culture	  of	  mesenchymal	  adipose	  stem	  cells.	  Stem	  Cells	  Dev	  18(5):	  725-­‐
736.	  
Ohm,	  J.	  E.,	  K.	  M.	  McGarvey,	  X.	  Yu,	  L.	  Cheng,	  K.	  E.	  Schuebel,	  L.	  Cope,	  H.	  P.	  Mohammad,	  W.	  Chen,	  V.	  C.	  
Daniel,	  W.	  Yu,	  D.	  M.	  Berman,	  T.	  Jenuwein,	  K.	  Pruitt,	  S.	  J.	  Sharkis,	  D.	  N.	  Watkins,	  J.	  G.	  Herman	  and	  S.	  
B.	  Baylin	  (2007).	  A	  stem	  cell-­‐like	  chromatin	  pattern	  may	  predispose	  tumor	  suppressor	  genes	  to	  DNA	  
hypermethylation	  and	  heritable	  silencing.	  Nat	  Genet	  39(2):	  237-­‐242.	  
Ohta,	   M.,	   J.	   S.	   Greenberger,	   P.	   Anklesaria,	   A.	   Bassols	   and	   J.	   Massague	   (1987).	   Two	   forms	   of	  
transforming	   growth	   factor-­‐beta	   distinguished	   by	   multipotential	   haematopoietic	   progenitor	   cells.	  
Nature	  329(6139):	  539-­‐541.	  
Osada,	  H.,	  Y.	  Tatematsu,	  A.	  Masuda,	  T.	  Saito,	  M.	  Sugiyama,	  K.	  Yanagisawa	  and	  T.	  Takahashi	  (2001).	  
Heterogeneous	   transforming	   growth	   factor	   (TGF)-­‐beta	   unresponsiveness	   and	   loss	   of	   TGF-­‐beta	  
receptor	   type	   II	   expression	   caused	   by	   histone	   deacetylation	   in	   lung	   cancer	   cell	   lines.	   Cancer	   Res	  
61(22):	  8331-­‐8339.	  
Oyama,	  T.,	  K.	  Ichimura,	  R.	  Suzuki,	  J.	  Suzumiya,	  K.	  Ohshima,	  Y.	  Yatabe,	  T.	  Yokoi,	  M.	  Kojima,	  Y.	  Kamiya,	  
H.	   Taji,	   Y.	   Kagami,	   M.	   Ogura,	   H.	   Saito,	   Y.	   Morishima	   and	   S.	   Nakamura	   (2003).	   Senile	   EBV+	   B-­‐cell	  
lymphoproliferative	  disorders:	  a	  clinicopathologic	  study	  of	  22	  patients.	  Am	  J	  Surg	  Pathol	  27(1):	  16-­‐
26.	  
Oyama,	   T.,	   K.	   Yamamoto,	  N.	   Asano,	   A.	  Oshiro,	   R.	   Suzuki,	   Y.	   Kagami,	   Y.	  Morishima,	   K.	   Takeuchi,	   T.	  
Izumo,	  S.	  Mori,	  K.	  Ohshima,	   J.	  Suzumiya,	  N.	  Nakamura,	  M.	  Abe,	  K.	   Ichimura,	  Y.	  Sato,	  T.	  Yoshino,	  T.	  
Naoe,	  Y.	  Shimoyama,	  Y.	  Kamiya,	  T.	  Kinoshita	  and	  S.	  Nakamura	  (2007).	  Age-­‐related	  EBV-­‐associated	  B-­‐
cell	   lymphoproliferative	   disorders	   constitute	   a	   distinct	   clinicopathologic	   group:	   a	   study	   of	   96	  
patients.	  Clin	  Cancer	  Res	  13(17):	  5124-­‐5132.	  
Park,	   K.,	   S.	   J.	   Kim,	   Y.	   J.	   Bang,	   J.	  G.	   Park,	  N.	   K.	   Kim,	  A.	   B.	   Roberts	   and	  M.	  B.	   Sporn	   (1994).	  Genetic	  






cancer	  cells:	  correlation	  with	  sensitivity	  to	  growth	   inhibition	  by	  TGF-­‐beta.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  
91(19):	  8772-­‐8776.	  
Parker,	  G.	  A.,	   T.	   Crook,	  M.	  Bain,	   E.	  A.	   Sara,	   P.	   J.	   Farrell	   and	  M.	   J.	   Allday	   (1996).	   Epstein-­‐Barr	   virus	  
nuclear	  antigen	  (EBNA)3C	  is	  an	  immortalizing	  oncoprotein	  with	  similar	  properties	  to	  adenovirus	  E1A	  
and	  papillomavirus	  E7.	  Oncogene	  13(12):	  2541-­‐2549.	  
Parker,	  G.	  A.,	  R.	  Touitou	  and	  M.	  J.	  Allday	  (2000).	  Epstein-­‐Barr	  virus	  EBNA3C	  can	  disrupt	  multiple	  cell	  
cycle	  checkpoints	  and	  induce	  nuclear	  division	  divorced	  from	  cytokinesis.	  Oncogene	  19(5):	  700-­‐709.	  
Paschos,	   K.,	   G.	   A.	   Parker,	   E.	   Watanatanasup,	   R.	   E.	   White	   and	  M.	   J.	   Allday	   (2012).	   BIM	   promoter	  
directly	   targeted	   by	   EBNA3C	   in	   polycomb-­‐mediated	   repression	   by	   EBV.	  Nucleic	   Acids	   Res	   40(15):	  
7233-­‐7246.	  
Paschos,	  K.,	  P.	  Smith,	  E.	  Anderton,	  J.	  M.	  Middeldorp,	  R.	  E.	  White	  and	  M.	  J.	  Allday	  (2009).	  Epstein-­‐Barr	  
Virus	   Latency	   in	   B	   Cells	   Leads	   to	   Epigenetic	   Repression	   and	   CpG	   Methylation	   of	   the	   Tumour	  
Suppressor	  Gene	  <italic>Bim</italic>.	  PLoS	  Pathog	  5(6):	  e1000492.	  
Passa,	   O.,	   S.	   Tsalavos,	   N.	   N.	   Belyaev,	   A.	   Petryk,	   A.	   J.	   Potocnik	   and	   D.	   Graf	   (2011).	  
Compartmentalization	   of	   bone	   morphogenetic	   proteins	   and	   their	   antagonists	   in	   lymphoid	  
progenitors	   and	   supporting	   microenvironments	   and	   functional	   implications.	   Immunology	   134(3):	  
349-­‐359.	  
Patil,	  S.,	  G.	  M.	  Wildey,	  T.	  L.	  Brown,	  L.	  Choy,	  R.	  Derynck	  and	  P.	  H.	  Howe	  (2000).	  Smad7	  is	  induced	  by	  
CD40	  and	  protects	  WEHI	  231	  B-­‐lymphocytes	  from	  transforming	  growth	  factor-­‐beta	  -­‐induced	  growth	  
inhibition	  and	  apoptosis.	  J	  Biol	  Chem	  275(49):	  38363-­‐38370.	  
Pattle,	   S.	  B.	   and	  P.	   J.	   Farrell	   (2006).	   The	   role	  of	   Epstein-­‐Barr	   virus	   in	   cancer.	  Expert	  Opin	  Biol	   Ther	  
6(11):	  1193-­‐1205.	  
Pegman,	  P.	  M.,	  S.	  M.	  Smith,	  B.	  N.	  D'Souza,	  S.	  T.	  Loughran,	  S.	  Maier,	  B.	  Kempkes,	  P.	  A.	  Cahill,	  M.	   J.	  
Simmons,	   C.	   Gelinas	   and	   D.	  Walls	   (2006).	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   2	   trans-­‐activates	   the	  
cellular	   antiapoptotic	   bfl-­‐1	   gene	   by	   a	   CBF1/RBPJ	   kappa-­‐dependent	   pathway.	   J	   Virol	   80(16):	   8133-­‐
8144.	  
Pellett,	  P.	  E.	  and	  B.	  Roizman	  (2013).	  Herpesviridae.	  Fields	  Virology.	  D.	  M.	  Knipe	  and	  P.	  M.	  Howley,	  
Wolters	  Kluwer	  Health/Lippincott	  Williams	  &	  Wilkins.	  2:	  1802-­‐1823.	  
Phan,	   R.	   T.	   and	   R.	   Dalla-­‐Favera	   (2004).	   The	   BCL6	   proto-­‐oncogene	   suppresses	   p53	   expression	   in	  
germinal-­‐centre	  B	  cells.	  Nature	  432(7017):	  635-­‐639.	  
Piek,	  E.,	  W.	  J.	  Ju,	  J.	  Heyer,	  D.	  Escalante-­‐Alcalde,	  C.	  L.	  Stewart,	  M.	  Weinstein,	  C.	  Deng,	  R.	  Kucherlapati,	  
E.	  P.	  Bottinger	  and	  A.	  B.	  Roberts	   (2001).	  Functional	  characterization	  of	   transforming	  growth	   factor	  
beta	  signaling	  in	  Smad2-­‐	  and	  Smad3-­‐deficient	  fibroblasts.	  J	  Biol	  Chem	  276(23):	  19945-­‐19953.	  
Pieper,	  K.,	  B.	  Grimbacher	  and	  H.	  Eibel	  (2013).	  B-­‐cell	  biology	  and	  development.	  J	  Allergy	  Clin	  Immunol	  
131(4):	  959-­‐971.	  
Pietersen,	   A.	   M.	   and	   M.	   van	   Lohuizen	   (2008).	   Stem	   cell	   regulation	   by	   polycomb	   repressors:	  
postponing	  commitment.	  Curr	  Opin	  Cell	  Biol	  20(2):	  201-­‐207.	  







Portal,	  D.,	  A.	  Rosendorff	  and	  E.	  Kieff	  (2006).	  Epstein-­‐Barr	  nuclear	  antigen	  leader	  protein	  coactivates	  
transcription	   through	   interaction	   with	   histone	   deacetylase	   4.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A	   103(51):	  
19278-­‐19283.	  
Portal,	  D.,	  B.	  Zhao,	  M.	  A.	  Calderwood,	  T.	  Sommermann,	  E.	  Johannsen	  and	  E.	  Kieff	  (2011).	  EBV	  nuclear	  
antigen	   EBNALP	   dismisses	   transcription	   repressors	   NCoR	   and	   RBPJ	   from	   enhancers	   and	   EBNA2	  
increases	  NCoR-­‐deficient	  RBPJ	  DNA	  binding.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  108(19):	  7808-­‐7813.	  
Portis,	  T.,	  P.	  Dyck	  and	  R.	  Longnecker	   (2003).	  Epstein-­‐Barr	  Virus	   (EBV)	  LMP2A	   induces	  alterations	   in	  
gene	   transcription	   similar	   to	   those	   observed	   in	   Reed-­‐Sternberg	   cells	   of	  Hodgkin	   lymphoma.	  Blood	  
102(12):	  4166-­‐4178.	  
Portis,	  T.	  and	  R.	  Longnecker	  (2004).	  Epstein-­‐Barr	  virus	  (EBV)	  LMP2A	  mediates	  B-­‐lymphocyte	  survival	  
through	  constitutive	  activation	  of	  the	  Ras/PI3K/Akt	  pathway.	  Oncogene	  23(53):	  8619-­‐8628.	  
Price,	   A.	  M.,	   J.	   P.	   Tourigny,	   E.	   Forte,	   R.	   E.	   Salinas,	   S.	   S.	   Dave	   and	  M.	   A.	   Luftig	   (2012).	   Analysis	   of	  
Epstein-­‐Barr	  virus-­‐regulated	  host	  gene	  expression	  changes	  through	  primary	  B-­‐cell	  outgrowth	  reveals	  
delayed	   kinetics	   of	   latent	   membrane	   protein	   1-­‐mediated	   NF-­‐kappaB	   activation.	   J	   Virol	   86(20):	  
11096-­‐11106.	  
Prokova,	   V.,	   G.	   Mosialos	   and	   D.	   Kardassis	   (2002).	   Inhibition	   of	   transforming	   growth	   factor	   beta	  
signaling	   and	   Smad-­‐dependent	   activation	   of	   transcription	   by	   the	   Latent	   Membrane	   Protein	   1	   of	  
Epstein-­‐Barr	  virus.	  J	  Biol	  Chem	  277(11):	  9342-­‐9350.	  
Radkov,	   S.	   A.,	  M.	   Bain,	   P.	   J.	   Farrell,	  M.	  West,	  M.	  Rowe	  and	  M.	   J.	   Allday	   (1997).	   Epstein-­‐Barr	   virus	  
EBNA3C	  represses	  Cp,	  the	  major	  promoter	  for	  EBNA	  expression,	  but	  has	  no	  effect	  on	  the	  promoter	  
of	  the	  cell	  gene	  CD21.	  J	  Virol	  71(11):	  8552-­‐8562.	  
Radkov,	   S.	   A.,	   R.	   Touitou,	   A.	   Brehm,	   M.	   Rowe,	   M.	   West,	   T.	   Kouzarides	   and	   M.	   J.	   Allday	   (1999).	  
Epstein-­‐Barr	   virus	  nuclear	   antigen	  3C	   interacts	  with	  histone	  deacetylase	   to	   repress	   transcription.	   J	  
Virol	  73(7):	  5688-­‐5697.	  
Rahadiani,	  N.,	  T.	  Takakuwa,	  K.	  Tresnasari,	  E.	  Morii	  and	  K.	  Aozasa	  (2008).	  Latent	  membrane	  protein-­‐1	  
of	   Epstein-­‐Barr	   virus	   induces	   the	   expression	   of	   B-­‐cell	   integration	   cluster,	   a	   precursor	   form	   of	  
microRNA-­‐155,	  in	  B	  lymphoma	  cell	  lines.	  Biochem	  Biophys	  Res	  Commun	  377(2):	  579-­‐583.	  
Rai,	   D.,	   S.	  W.	   Kim,	  M.	   R.	  McKeller,	   P.	   L.	   Dahia	   and	   R.	   C.	   Aguiar	   (2010).	   Targeting	   of	   SMAD5	   links	  
microRNA-­‐155	   to	   the	   TGF-­‐beta	   pathway	   and	   lymphomagenesis.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A	   107(7):	  
3111-­‐3116.	  
Rauch,	   T.	   A.	   and	   G.	   P.	   Pfeifer	   (2010).	   DNA	  methylation	   profiling	   using	   the	  methylated-­‐CpG	   island	  
recovery	  assay	  (MIRA).	  Methods	  52(3):	  213-­‐217.	  
Rechsteiner,	  M.	  P.,	  M.	  Bernasconi,	  C.	  Berger	  and	  D.	  Nadal	  (2008).	  Role	  of	  latent	  membrane	  protein	  2	  
isoforms	  in	  Epstein-­‐Barr	  virus	  latency.	  Trends	  Microbiol	  16(11):	  520-­‐527.	  
Remy,	   I.,	   A.	   Montmarquette	   and	   S.	   W.	   Michnick	   (2004).	   PKB/Akt	   modulates	   TGF-­‐beta	   signalling	  
through	  a	  direct	  interaction	  with	  Smad3.	  Nat	  Cell	  Biol	  6(4):	  358-­‐365.	  
Reynisdottir,	   I.,	   K.	   Polyak,	   A.	   Iavarone	   and	   J.	   Massague	   (1995).	   Kip/Cip	   and	   Ink4	   Cdk	   inhibitors	  






Richter,	   J.,	   M.	   Schlesner,	   S.	   Hoffmann,	   M.	   Kreuz,	   E.	   Leich,	   B.	   Burkhardt,	   M.	   Rosolowski,	   O.	  
Ammerpohl,	  R.	  Wagener,	  S.	  H.	  Bernhart,	  D.	  Lenze,	  M.	  Szczepanowski,	  M.	  Paulsen,	  S.	  Lipinski,	  R.	  B.	  
Russell,	  S.	  Adam-­‐Klages,	  G.	  Apic,	  A.	  Claviez,	  D.	  Hasenclever,	  V.	  Hovestadt,	  N.	  Hornig,	  J.	  O.	  Korbel,	  D.	  
Kube,	  D.	  Langenberger,	  C.	  Lawerenz,	  J.	  Lisfeld,	  K.	  Meyer,	  S.	  Picelli,	  J.	  Pischimarov,	  B.	  Radlwimmer,	  T.	  
Rausch,	  M.	  Rohde,	  M.	  Schilhabel,	  R.	  Scholtysik,	  R.	  Spang,	  H.	  Trautmann,	  T.	  Zenz,	  A.	  Borkhardt,	  H.	  G.	  
Drexler,	   P.	   Moller,	   R.	   A.	  MacLeod,	   C.	   Pott,	   S.	   Schreiber,	   L.	   Trumper,	  M.	   Loeffler,	   P.	   F.	   Stadler,	   P.	  
Lichter,	   R.	   Eils,	   R.	   Kuppers,	  M.	   Hummel,	  W.	   Klapper,	   P.	   Rosenstiel,	   A.	   Rosenwald,	   B.	   Brors	   and	   R.	  
Siebert	   (2012).	   Recurrent	  mutation	   of	   the	   ID3	   gene	   in	   Burkitt	   lymphoma	   identified	   by	   integrated	  
genome,	  exome	  and	  transcriptome	  sequencing.	  Nat	  Genet	  44(12):	  1316-­‐1320.	  
Rickinson,	  A.	  B.,	  L.	  S.	  Young	  and	  M.	  Rowe	  (1987).	  Influence	  of	  the	  Epstein-­‐Barr	  virus	  nuclear	  antigen	  
EBNA	  2	  on	  the	  growth	  phenotype	  of	  virus-­‐transformed	  B	  cells.	  J	  Virol	  61(5):	  1310-­‐1317.	  
Ro,	  T.	  B.,	  R.	  U.	  Holt,	  A.	  T.	  Brenne,	  H.	  Hjorth-­‐Hansen,	  A.	  Waage,	  O.	  Hjertner,	  A.	  Sundan	  and	  M.	  Borset	  
(2004).	   Bone	   morphogenetic	   protein-­‐5,	   -­‐6	   and	   -­‐7	   inhibit	   growth	   and	   induce	   apoptosis	   in	   human	  
myeloma	  cells.	  Oncogene	  23(17):	  3024-­‐3032.	  
Robbiani,	   D.	   F.,	   A.	   Bothmer,	   E.	   Callen,	   B.	   Reina-­‐San-­‐Martin,	   Y.	   Dorsett,	   S.	   Difilippantonio,	   D.	   J.	  
Bolland,	  H.	  T.	  Chen,	  A.	  E.	  Corcoran,	  A.	  Nussenzweig	  and	  M.	  C.	  Nussenzweig	  (2008).	  AID	   is	  required	  
for	  the	  chromosomal	  breaks	  in	  c-­‐myc	  that	  lead	  to	  c-­‐myc/IgH	  translocations.	  Cell	  135(6):	  1028-­‐1038.	  
Robertson,	   E.	   S.,	   S.	   Grossman,	   E.	   Johannsen,	   C.	   Miller,	   J.	   Lin,	   B.	   Tomkinson	   and	   E.	   Kieff	   (1995).	  
Epstein-­‐Barr	   virus	   nuclear	   protein	   3C	   modulates	   transcription	   through	   interaction	   with	   the	  
sequence-­‐specific	  DNA-­‐binding	  protein	  J	  kappa.	  J	  Virol	  69(5):	  3108-­‐3116.	  
Robinson,	   J.,	   D.	   Smith	   and	   J.	   Niederman	   (1980).	  Mitotic	   EBNA-­‐positive	   lymphocytes	   in	   peripheral	  
blood	  during	  infectious	  mononucleosis.	  Nature	  287(5780):	  334-­‐335.	  
Ross,	  S.	  and	  C.	  S.	  Hill	  (2008).	  How	  the	  Smads	  regulate	  transcription.	  Int	  J	  Biochem	  Cell	  Biol	  40(3):	  383-­‐
408.	  
Rovedo,	   M.	   and	   R.	   Longnecker	   (2007).	   Epstein-­‐barr	   virus	   latent	   membrane	   protein	   2B	   (LMP2B)	  
modulates	  LMP2A	  activity.	  J	  Virol	  81(1):	  84-­‐94.	  
Rowe,	  M.,	  R.	  Khanna,	  C.	  A.	  Jacob,	  V.	  Argaet,	  A.	  Kelly,	  S.	  Powis,	  M.	  Belich,	  D.	  Croom-­‐Carter,	  S.	  Lee,	  S.	  
R.	  Burrows	  and	  et	  al.	   (1995).	  Restoration	  of	  endogenous	  antigen	  processing	   in	  Burkitt's	   lymphoma	  
cells	   by	   Epstein-­‐Barr	   virus	   latent	   membrane	   protein-­‐1:	   coordinate	   up-­‐regulation	   of	   peptide	  
transporters	  and	  HLA-­‐class	  I	  antigen	  expression.	  Eur	  J	  Immunol	  25(5):	  1374-­‐1384.	  
Rowe,	  M.,	  D.	  T.	  Rowe,	  C.	  D.	  Gregory,	  L.	  S.	  Young,	  P.	  J.	  Farrell,	  H.	  Rupani	  and	  A.	  B.	  Rickinson	  (1987).	  
Differences	   in	   B	   cell	   growth	   phenotype	   reflect	   novel	   patterns	   of	   Epstein-­‐Barr	   virus	   latent	   gene	  
expression	  in	  Burkitt's	  lymphoma	  cells.	  EMBO	  J	  6(9):	  2743-­‐2751.	  
Rowe,	   M.,	   L.	   S.	   Young,	   K.	   Cadwallader,	   L.	   Petti,	   E.	   Kieff	   and	   A.	   B.	   Rickinson	   (1989).	   Distinction	  
between	  Epstein-­‐Barr	  virus	  type	  A	  (EBNA	  2A)	  and	  type	  B	  (EBNA	  2B)	  isolates	  extends	  to	  the	  EBNA	  3	  
family	  of	  nuclear	  proteins.	  J	  Virol	  63(3):	  1031-­‐1039.	  
Ruzinova,	  M.	  B.	  and	  R.	  Benezra	  (2003).	  Id	  proteins	  in	  development,	  cell	  cycle	  and	  cancer.	  Trends	  Cell	  
Biol	  13(8):	  410-­‐418.	  
Saito,	  M.,	  U.	  Novak,	  E.	  Piovan,	  K.	  Basso,	  P.	  Sumazin,	  C.	  Schneider,	  M.	  Crespo,	  Q.	  Shen,	  G.	  Bhagat,	  A.	  
Califano,	  A.	  Chadburn,	  L.	  Pasqualucci	  and	  R.	  Dalla-­‐Favera	  (2009).	  BCL6	  suppression	  of	  BCL2	  via	  Miz1	  






Saltzman,	   A.,	   R.	   Munro,	   G.	   Searfoss,	   C.	   Franks,	  M.	   Jaye	   and	   Y.	   Ivashchenko	   (1998).	   Transforming	  
growth	   factor-­‐beta-­‐mediated	   apoptosis	   in	   the	   Ramos	   B-­‐lymphoma	   cell	   line	   is	   accompanied	   by	  
caspase	  activation	  and	  Bcl-­‐XL	  downregulation.	  Exp	  Cell	  Res	  242(1):	  244-­‐254.	  
Sapkota,	   G.,	   C.	   Alarcon,	   F.	   M.	   Spagnoli,	   A.	   H.	   Brivanlou	   and	   J.	   Massague	   (2007).	   Balancing	   BMP	  
signaling	  through	  integrated	  inputs	  into	  the	  Smad1	  linker.	  Mol	  Cell	  25(3):	  441-­‐454.	  
Saridakis,	  V.,	  Y.	  Sheng,	  F.	  Sarkari,	  M.	  N.	  Holowaty,	  K.	  Shire,	  T.	  Nguyen,	  R.	  G.	  Zhang,	  J.	  Liao,	  W.	  Lee,	  A.	  
M.	   Edwards,	   C.	   H.	   Arrowsmith	   and	   L.	   Frappier	   (2005).	   Structure	   of	   the	   p53	   binding	   domain	   of	  
HAUSP/USP7	   bound	   to	   Epstein-­‐Barr	   nuclear	   antigen	   1	   implications	   for	   EBV-­‐mediated	  
immortalization.	  Mol	  Cell	  18(1):	  25-­‐36.	  
Schiemann,	   W.	   P.,	   D.	   Rotzer,	   W.	   M.	   Pfeifer,	   E.	   Levi,	   K.	   R.	   Rai,	   P.	   Knaus	   and	   M.	   E.	   Kadin	   (2004).	  
Transforming	   growth	   factor-­‐beta	   (TGF-­‐beta)-­‐resistant	   B	   cells	   from	   chronic	   lymphocytic	   leukemia	  
patients	  contain	  recurrent	  mutations	  in	  the	  signal	  sequence	  of	  the	  type	  I	  TGF-­‐beta	  receptor.	  Cancer	  
Detect	  Prev	  28(1):	  57-­‐64.	  
Schlesinger,	  Y.,	  R.	  Straussman,	  I.	  Keshet,	  S.	  Farkash,	  M.	  Hecht,	  J.	  Zimmerman,	  E.	  Eden,	  Z.	  Yakhini,	  E.	  
Ben-­‐Shushan,	   B.	   E.	   Reubinoff,	   Y.	   Bergman,	   I.	   Simon	   and	   H.	   Cedar	   (2007).	   Polycomb-­‐mediated	  
methylation	  on	  Lys27	  of	  histone	  H3	  pre-­‐marks	  genes	  for	  de	  novo	  methylation	  in	  cancer.	  Nat	  Genet	  
39(2):	  232-­‐236.	  
Schmitz,	   R.,	   R.	  M.	   Young,	  M.	   Ceribelli,	   S.	   Jhavar,	  W.	   Xiao,	  M.	   Zhang,	  G.	  Wright,	   A.	   L.	   Shaffer,	  D.	   J.	  
Hodson,	  E.	  Buras,	  X.	  Liu,	  J.	  Powell,	  Y.	  Yang,	  W.	  Xu,	  H.	  Zhao,	  H.	  Kohlhammer,	  A.	  Rosenwald,	  P.	  Kluin,	  H.	  
K.	  Muller-­‐Hermelink,	  G.	  Ott,	   R.	  D.	  Gascoyne,	   J.	  M.	   Connors,	   L.	  M.	   Rimsza,	   E.	   Campo,	   E.	   S.	   Jaffe,	   J.	  
Delabie,	  E.	  B.	  Smeland,	  M.	  D.	  Ogwang,	  S.	  J.	  Reynolds,	  R.	  I.	  Fisher,	  R.	  M.	  Braziel,	  R.	  R.	  Tubbs,	  J.	  R.	  Cook,	  
D.	   D.	   Weisenburger,	   W.	   C.	   Chan,	   S.	   Pittaluga,	   W.	   Wilson,	   T.	   A.	   Waldmann,	   M.	   Rowe,	   S.	   M.	  
Mbulaiteye,	  A.	  B.	  Rickinson	  and	  L.	  M.	  Staudt	  (2012).	  Burkitt	  lymphoma	  pathogenesis	  and	  therapeutic	  
targets	  from	  structural	  and	  functional	  genomics.	  Nature	  490(7418):	  116-­‐120.	  
Schrantz,	  N.,	  D.	  A.	   Blanchard,	  M.	   T.	  Auffredou,	   S.	   Sharma,	  G.	   Leca	   and	  A.	  Vazquez	   (1999).	   Role	  of	  
caspases	  and	  possible	  involvement	  of	  retinoblastoma	  protein	  during	  TGFbeta-­‐mediated	  apoptosis	  of	  
human	  B	  lymphocytes.	  Oncogene	  18(23):	  3511-­‐3519.	  
Seckinger,	  A.,	   T.	  Meissner,	   J.	  Moreaux,	  H.	  Goldschmidt,	  G.	  M.	  Fuhler,	  A.	  Benner,	  M.	  Hundemer,	  T.	  
Reme,	  J.	  D.	  Shaughnessy,	  Jr.,	  B.	  Barlogie,	  U.	  Bertsch,	  J.	  Hillengass,	  A.	  D.	  Ho,	  V.	  Pantesco,	  A.	  Jauch,	  J.	  
De	  Vos,	  J.	  F.	  Rossi,	  T.	  Mohler,	  B.	  Klein	  and	  D.	  Hose	  (2009).	  Bone	  morphogenic	  protein	  6:	  a	  member	  of	  
a	   novel	   class	   of	   prognostic	   factors	   expressed	   by	   normal	   and	   malignant	   plasma	   cells	   inhibiting	  
proliferation	  and	  angiogenesis.	  Oncogene	  28(44):	  3866-­‐3879.	  
Seoane,	   J.,	   C.	   Pouponnot,	   P.	   Staller,	   M.	   Schader,	   M.	   Eilers	   and	   J.	   Massague	   (2001).	   TGFbeta	  
influences	  Myc,	  Miz-­‐1	  and	  Smad	  to	  control	  the	  CDK	  inhibitor	  p15INK4b.	  Nat	  Cell	  Biol	  3(4):	  400-­‐408.	  
Seto,	  E.,	  A.	  Moosmann,	  S.	  Gromminger,	  N.	  Walz,	  A.	  Grundhoff	  and	  W.	  Hammerschmidt	  (2010).	  Micro	  
RNAs	  of	  Epstein-­‐Barr	  virus	  promote	  cell	  cycle	  progression	  and	  prevent	  apoptosis	  of	  primary	  human	  B	  
cells.	  PLoS	  Pathog	  6(8).	  
Shair,	  K.	  H.,	  K.	  M.	  Bendt,	  R.	  H.	  Edwards,	  J.	  N.	  Nielsen,	  D.	  T.	  Moore	  and	  N.	  Raab-­‐Traub	  (2012).	  Epstein-­‐
Barr	   virus-­‐encoded	   latent	   membrane	   protein	   1	   (LMP1)	   and	   LMP2A	   function	   cooperatively	   to	  
promote	  carcinoma	  development	  in	  a	  mouse	  carcinogenesis	  model.	  J	  Virol	  86(9):	  5352-­‐5365.	  
Shair,	  K.	  H.	  and	  N.	  Raab-­‐Traub	   (2012).	   Transcriptome	  changes	   induced	  by	  Epstein-­‐Barr	   virus	   LMP1	  






Shaku,	  F.,	  G.	  Matsuda,	  R.	  Furuya,	  C.	  Kamagata,	  M.	  Igarashi,	  M.	  Tanaka,	  M.	  Kanamori,	  Y.	  Nishiyama,	  
N.	  Yamamoto	  and	  Y.	  Kawaguchi	  (2005).	  Development	  of	  a	  monoclonal	  antibody	  against	  Epstein-­‐Barr	  
virus	   nuclear	   antigen	   leader	   protein	   (EBNA-­‐LP)	   that	   can	  detect	   EBNA-­‐LP	   expressed	   in	   P3HR1	   cells.	  
Microbiol	  Immunol	  49(5):	  477-­‐483.	  
Shannon-­‐Lowe,	  C.,	  E.	  Adland,	  A.	  I.	  Bell,	  H.	  J.	  Delecluse,	  A.	  B.	  Rickinson	  and	  M.	  Rowe	  (2009).	  Features	  
distinguishing	   Epstein-­‐Barr	   virus	   infections	   of	   epithelial	   cells	   and	   B	   cells:	   viral	   genome	   expression,	  
genome	  maintenance,	  and	  genome	  amplification.	  J	  Virol	  83(15):	  7749-­‐7760.	  
Shannon-­‐Lowe,	  C.	  and	  M.	  Rowe	   (2011).	  Epstein-­‐Barr	  virus	   infection	  of	  polarized	  epithelial	   cells	   via	  
the	  basolateral	  surface	  by	  memory	  B	  cell-­‐mediated	  transfer	  infection.	  PLoS	  Pathog	  7(5):	  e1001338.	  
Shariat,	  S.	  F.,	  M.	  W.	  Kattan,	  E.	  Traxel,	  B.	  Andrews,	  K.	  Zhu,	  T.	  M.	  Wheeler	  and	  K.	  M.	  Slawin	   (2004).	  
Association	   of	   pre-­‐	   and	   postoperative	   plasma	   levels	   of	   transforming	   growth	   factor	   beta(1)	   and	  
interleukin	  6	  and	  its	  soluble	  receptor	  with	  prostate	  cancer	  progression.	  Clin	  Cancer	  Res	  10(6):	  1992-­‐
1999.	  
Shi,	  W.,	  C.	  Sun,	  B.	  He,	  W.	  Xiong,	  X.	  Shi,	  D.	  Yao	  and	  X.	  Cao	  (2004).	  GADD34-­‐PP1c	  recruited	  by	  Smad7	  
dephosphorylates	  TGFbeta	  type	  I	  receptor.	  J	  Cell	  Biol	  164(2):	  291-­‐300.	  
Shi,	   Y.	   and	   J.	   Massague	   (2003).	   Mechanisms	   of	   TGF-­‐beta	   signaling	   from	   cell	   membrane	   to	   the	  
nucleus.	  Cell	  113(6):	  685-­‐700.	  
Shibata,	   D.	   and	   L.	   M.	   Weiss	   (1992).	   Epstein-­‐Barr	   virus-­‐associated	   gastric	   adenocarcinoma.	   Am	   J	  
Pathol	  140(4):	  769-­‐774.	  
Shimazu,	  T.,	  K.	  Degenhardt,	  E.	  K.	  A.	  Nur,	  J.	  Zhang,	  T.	  Yoshida,	  Y.	  Zhang,	  R.	  Mathew,	  E.	  White	  and	  M.	  
Inouye	   (2007).	   NBK/BIK	   antagonizes	   MCL-­‐1	   and	   BCL-­‐XL	   and	   activates	   BAK-­‐mediated	   apoptosis	   in	  
response	  to	  protein	  synthesis	  inhibition.	  Genes	  Dev	  21(8):	  929-­‐941.	  
Shimizu,	  N.,	   A.	   Tanabe-­‐Tochikura,	   Y.	   Kuroiwa	   and	   K.	   Takada	   (1994).	   Isolation	   of	   Epstein-­‐Barr	   virus	  
(EBV)-­‐negative	   cell	   clones	   from	   the	   EBV-­‐positive	   Burkitt's	   lymphoma	   (BL)	   line	   Akata:	   malignant	  
phenotypes	  of	  BL	  cells	  are	  dependent	  on	  EBV.	  J	  Virol	  68(9):	  6069-­‐6073.	  
Simon,	   J.	  A.	   and	  R.	  E.	  Kingston	   (2013).	  Occupying	   chromatin:	  Polycomb	  mechanisms	   for	  getting	   to	  
genomic	  targets,	  stopping	  transcriptional	  traffic,	  and	  staying	  put.	  Mol	  Cell	  49(5):	  808-­‐824.	  
Sing,	  G.	  K.,	  J.	  R.	  Keller,	  L.	  R.	  Ellingsworth	  and	  F.	  W.	  Ruscetti	  (1988).	  Transforming	  growth	  factor	  beta	  
selectively	  inhibits	  normal	  and	  leukemic	  human	  bone	  marrow	  cell	  growth	  in	  vitro.	  Blood	  72(5):	  1504-­‐
1511.	  
Skaletsky,	   S.	   R.	   a.	   H.	   J.	   (2000).	   Primer3	   on	   the	   WWW	   for	   general	   users	   and	   for	   biologist	  
programmers.	  Bioinformatics	  Methods	  and	  Protocols:	  Methods	   in	  Molecular	  Biology.	  M.	  S.	  Krawetz	  
S.	  Totowa,	  NJ,	  Humana	  Press:	  365-­‐386.	  
Skalska,	   L.,	   R.	   E.	  White,	  M.	   Franz,	  M.	   Ruhmann	   and	  M.	   J.	   Allday	   (2010).	   Epigenetic	   repression	   of	  
p16(INK4A)	  by	  latent	  Epstein-­‐Barr	  virus	  requires	  the	  interaction	  of	  EBNA3A	  and	  EBNA3C	  with	  CtBP.	  
PLoS	  Pathog	  6(6):	  e1000951.	  
Skalska,	  L.,	  R.	  E.	  White,	  G.	  A.	  Parker,	  A.	   J.	  Sinclair,	  K.	  Paschos	  and	  M.	   J.	  Allday	   (2013).	   Induction	  of	  
p16(INK4a)	  is	  the	  major	  barrier	  to	  proliferation	  when	  Epstein-­‐Barr	  virus	  (EBV)	  transforms	  primary	  B	  






Smeland,	   E.	  B.,	  H.	   K.	  Blomhoff,	  H.	  Holte,	   E.	  Ruud,	  K.	  Beiske,	   S.	   Funderud,	   T.	  Godal	   and	  R.	  Ohlsson	  
(1987).	   Transforming	   growth	   factor	   type	   beta	   (TGF	   beta)	   inhibits	   G1	   to	   S	   transition,	   but	   not	  
activation	  of	  human	  B	  lymphocytes.	  Exp	  Cell	  Res	  171(1):	  213-­‐222.	  
Smith,	  A.	  L.,	  T.	  P.	  Robin	  and	  H.	  L.	  Ford	  (2012).	  Molecular	  pathways:	  targeting	  the	  TGF-­‐beta	  pathway	  
for	  cancer	  therapy.	  Clin	  Cancer	  Res	  18(17):	  4514-­‐4521.	  
Smith,	   O.	   (2012).	   Denis	   Parsons	   Burkitt	   CMG,	  MD,	   DSc,	   FRS,	   FRCS,	   FTCD	   (1911-­‐93)	   Irish	   by	   birth,	  
Trinity	  by	  the	  grace	  of	  God.	  Br	  J	  Haematol	  156(6):	  770-­‐776.	  
Snapper,	   C.	  M.,	   F.	   D.	   Finkelman	   and	  W.	   E.	   Paul	   (1988).	   Regulation	   of	   IgG1	   and	   IgE	   production	   by	  
interleukin	  4.	  Immunol	  Rev	  102:	  51-­‐75.	  
Sorrentino,	  A.,	  N.	  Thakur,	  S.	  Grimsby,	  A.	  Marcusson,	  V.	  von	  Bulow,	  N.	  Schuster,	  S.	  Zhang,	  C.	  H.	  Heldin	  
and	   M.	   Landstrom	   (2008).	   The	   type	   I	   TGF-­‐beta	   receptor	   engages	   TRAF6	   to	   activate	   TAK1	   in	   a	  
receptor	  kinase-­‐independent	  manner.	  Nat	  Cell	  Biol	  10(10):	  1199-­‐1207.	  
Speck,	   P.,	   K.	   A.	   Kline,	   P.	   Cheresh	   and	   R.	   Longnecker	   (1999).	   Epstein-­‐Barr	   virus	   lacking	   latent	  
membrane	   protein	   2	   immortalizes	   B	   cells	   with	   efficiency	   indistinguishable	   from	   that	   of	   wild-­‐type	  
virus.	  J	  Gen	  Virol	  80	  (	  Pt	  8):	  2193-­‐2203.	  
Spender,	  L.	  C.,	  M.	  J.	  Carter,	  D.	  I.	  O'Brien,	  L.	  J.	  Clark,	  J.	  Yu,	  E.	  M.	  Michalak,	  L.	  Happo,	  M.	  S.	  Cragg	  and	  G.	  
J.	   Inman	   (2013).	   Transforming	   growth	   factor-­‐beta	   directly	   induces	   p53-­‐up-­‐regulated	  modulator	   of	  
apoptosis	   (PUMA)	   during	   the	   rapid	   induction	   of	   apoptosis	   in	  myc-­‐driven	   B-­‐cell	   lymphomas.	   J	   Biol	  
Chem	  288(7):	  5198-­‐5209.	  
Spender,	   L.	   C.,	  G.	  H.	  Cornish,	  A.	   Sullivan	  and	  P.	   J.	   Farrell	   (2002).	   Expression	  of	   transcription	   factor	  
AML-­‐2	  (RUNX3,	  CBF(alpha)-­‐3)	  is	  induced	  by	  Epstein-­‐Barr	  virus	  EBNA-­‐2	  and	  correlates	  with	  the	  B-­‐cell	  
activation	  phenotype.	  J	  Virol	  76(10):	  4919-­‐4927.	  
Spender,	  L.	  C.	  and	  G.	  J.	  Inman	  (2009a).	  Targeting	  the	  BCL-­‐2	  family	  in	  malignancies	  of	  germinal	  centre	  
origin.	  Expert	  Opin	  Ther	  Targets	  13(12):	  1459-­‐1472.	  
Spender,	  L.	  C.	  and	  G.	  J.	  Inman	  (2009b).	  TGF-­‐beta	  induces	  growth	  arrest	  in	  Burkitt	  lymphoma	  cells	  via	  
transcriptional	  repression	  of	  E2F-­‐1.	  J	  Biol	  Chem	  284(3):	  1435-­‐1442.	  
Spender,	   L.	   C.	   and	   G.	   J.	   Inman	   (2011).	   Inhibition	   of	   Germinal	   Centre	   Apoptotic	   Programmes	   by	  
Epstein-­‐Barr	  Virus.	  Adv	  Hematol	  2011:	  829525.	  
Spender,	  L.	  C.,	  W.	  Lucchesi,	  G.	  Bodelon,	  A.	  Bilancio,	  C.	  E.	  Karstegl,	  T.	  Asano,	  O.	  Dittrich-­‐Breiholz,	  M.	  
Kracht,	   B.	   Vanhaesebroeck	   and	   P.	   J.	   Farrell	   (2006).	   Cell	   target	   genes	   of	   Epstein-­‐Barr	   virus	  
transcription	  factor	  EBNA-­‐2:	  induction	  of	  the	  p55alpha	  regulatory	  subunit	  of	  PI3-­‐kinase	  and	  its	  role	  
in	  survival	  of	  EREB2.5	  cells.	  J	  Gen	  Virol	  87(Pt	  10):	  2859-­‐2867.	  
Spender,	  L.	  C.,	  D.	  I.	  O'Brien,	  D.	  Simpson,	  D.	  Dutt,	  C.	  D.	  Gregory,	  M.	  J.	  Allday,	  L.	  J.	  Clark	  and	  G.	  J.	  Inman	  
(2009).	  TGF-­‐beta	  induces	  apoptosis	  in	  human	  B	  cells	  by	  transcriptional	  regulation	  of	  BIK	  and	  BCL-­‐XL.	  
Cell	  Death	  Differ	  16(4):	  593-­‐602.	  
Stenvers,	  K.	  L.,	  M.	  L.	  Tursky,	  K.	  W.	  Harder,	  N.	  Kountouri,	  S.	  Amatayakul-­‐Chantler,	  D.	  Grail,	  C.	  Small,	  R.	  
A.	  Weinberg,	  A.	  M.	  Sizeland	  and	  H.	  J.	  Zhu	  (2003).	  Heart	  and	  liver	  defects	  and	  reduced	  transforming	  
growth	   factor	   beta2	   sensitivity	   in	   transforming	   growth	   factor	   beta	   type	   III	   receptor-­‐deficient	  






Strasser,	  A.	  (2005).	  The	  role	  of	  BH3-­‐only	  proteins	  in	  the	  immune	  system.	  Nat	  Rev	  Immunol	  5(3):	  189-­‐
200.	  
Strowig,	  T.,	  F.	  Brilot,	  F.	  Arrey,	  G.	  Bougras,	  D.	  Thomas,	  W.	  A.	  Muller	  and	  C.	  Munz	  (2008).	  Tonsilar	  NK	  
cells	  restrict	  B	  cell	  transformation	  by	  the	  Epstein-­‐Barr	  virus	  via	  IFN-­‐gamma.	  PLoS	  Pathog	  4(2):	  e27.	  
Subramanian,	  C.,	  S.	  Hasan,	  M.	  Rowe,	  M.	  Hottiger,	  R.	  Orre	  and	  E.	  S.	  Robertson	  (2002).	  Epstein-­‐Barr	  
virus	  nuclear	  antigen	  3C	  and	  prothymosin	  alpha	  interact	  with	  the	  p300	  transcriptional	  coactivator	  at	  
the	  CH1	  and	  CH3/HAT	  domains	  and	  cooperate	  in	  regulation	  of	  transcription	  and	  histone	  acetylation.	  
J	  Virol	  76(10):	  4699-­‐4708.	  
Sugai,	  M.,	  H.	  Gonda,	  T.	  Kusunoki,	  T.	  Katakai,	  Y.	  Yokota	  and	  A.	  Shimizu	  (2003).	  Essential	  role	  of	  Id2	  in	  
negative	  regulation	  of	  IgE	  class	  switching.	  Nat	  Immunol	  4(1):	  25-­‐30.	  
Swaminathan,	   S.	   (2008).	   Noncoding	   RNAs	   produced	   by	   oncogenic	   human	   herpesviruses.	   J	   Cell	  
Physiol	  216(2):	  321-­‐326.	  
Swaminathan,	  S.,	  B.	  Tomkinson	  and	  E.	  Kieff	  (1991).	  Recombinant	  Epstein-­‐Barr	  virus	  with	  small	  RNA	  
(EBER)	  genes	  deleted	  transforms	  lymphocytes	  and	  replicates	  in	  vitro.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  88(4):	  
1546-­‐1550.	  
Swanson-­‐Mungerson,	  M.,	  R.	  Bultema	  and	  R.	  Longnecker	   (2010).	  Epstein-­‐Barr	  virus	  LMP2A	   imposes	  
sensitivity	  to	  apoptosis.	  J	  Gen	  Virol	  91(Pt	  9):	  2197-­‐2202.	  
Swanson-­‐Mungerson,	  M.	  A.,	  R.	  G.	  Caldwell,	  R.	  Bultema	  and	  R.	  Longnecker	  (2005).	  Epstein-­‐Barr	  virus	  
LMP2A	   alters	   in	   vivo	   and	   in	   vitro	   models	   of	   B-­‐cell	   anergy,	   but	   not	   deletion,	   in	   response	   to	  
autoantigen.	  J	  Virol	  79(12):	  7355-­‐7362.	  
Swerdlow,	  S.	  H.,	  E.	  Campo,	  N.	  L.	  Harris,	  E.	  S.	  Jaffe,	  S.	  A.	  Pileri,	  H.	  Stein,	  J.	  Thiele	  and	  J.	  W.	  Vardiman	  
(2008).	  WHO	  Classification	  of	  Tumours	  of	  Haematopoietic	  and	  Lymphoid	  Tissues.	  Lyon,	  IARC.	  
Takada,	  K.	  (1984).	  Cross-­‐linking	  of	  cell	  surface	  immunoglobulins	  induces	  Epstein-­‐Barr	  virus	  in	  Burkitt	  
lymphoma	  lines.	  Int	  J	  Cancer	  33(1):	  27-­‐32.	  
Takada,	  K.,	  K.	  Horinouchi,	  Y.	  Ono,	  T.	  Aya,	  T.	  Osato,	  M.	  Takahashi	  and	  S.	  Hayasaka	  (1991).	  An	  Epstein-­‐
Barr	  virus-­‐producer	  line	  Akata:	  establishment	  of	  the	  cell	   line	  and	  analysis	  of	  viral	  DNA.	  Virus	  Genes	  
5(2):	  147-­‐156.	  
Takahashi,	  Y.,	  H.	  Ohta	  and	  T.	  Takemori	  (2001).	  Fas	  is	  required	  for	  clonal	  selection	  in	  germinal	  centers	  
and	  the	  subsequent	  establishment	  of	  the	  memory	  B	  cell	  repertoire.	  Immunity	  14(2):	  181-­‐192.	  
Takanashi,	  M.,	  J.	  Li,	  M.	  Shirakata,	  S.	  Mori	  and	  K.	  Hirai	   (1999).	  Tumorigenicity	  of	  mouse	  BALB/c	  3T3	  
fibroblast	   cells	   which	   express	   Epstein-­‐Barr	   virus-­‐encoded	   LMP1	   and	   show	   normal	   growth	  
phenotypes	   in	   vitro	   is	   correlated	  with	   loss	   of	   transforming	   growth	   factor-­‐beta	   1-­‐mediated	   growth	  
inhibition.	  Arch	  Virol	  144(2):	  241-­‐257.	  
Tan,	   L.	   C.,	   N.	   Gudgeon,	   N.	   E.	   Annels,	   P.	   Hansasuta,	   C.	   A.	   O'Callaghan,	   S.	   Rowland-­‐Jones,	   A.	   J.	  
McMichael,	  A.	  B.	  Rickinson	  and	  M.	  F.	  Callan	  (1999).	  A	  re-­‐evaluation	  of	  the	  frequency	  of	  CD8+	  T	  cells	  
specific	  for	  EBV	  in	  healthy	  virus	  carriers.	  J	  Immunol	  162(3):	  1827-­‐1835.	  
Tarakanova,	   V.	   L.	   and	   W.	   S.	   Wold	   (2003).	   Transforming	   growth	   factor	   beta1	   receptor	   II	   is	  






Thawani,	  J.	  P.,	  A.	  C.	  Wang,	  K.	  D.	  Than,	  C.	  Y.	  Lin,	  F.	  La	  Marca	  and	  P.	  Park	  (2010).	  Bone	  morphogenetic	  
proteins	  and	  cancer:	  review	  of	  the	  literature.	  Neurosurgery	  66(2):	  233-­‐246;	  discussion	  246.	  
Thorley-­‐Lawson,	  D.	  A.	   (2001).	   Epstein-­‐Barr	   virus:	   exploiting	   the	   immune	   system.	  Nat	  Rev	   Immunol	  
1(1):	  75-­‐82.	  
Thorley-­‐Lawson,	   D.	   A.	   and	  M.	   J.	   Allday	   (2008).	   The	   curious	   case	   of	   the	   tumour	   virus:	   50	   years	   of	  
Burkitt's	  lymphoma.	  Nat	  Rev	  Microbiol	  6(12):	  913-­‐924.	  
Thorley-­‐Lawson,	  D.	  A.	  and	  A.	  Gross	   (2004).	  Persistence	  of	   the	  Epstein-­‐Barr	  virus	  and	  the	  origins	  of	  
associated	  lymphomas.	  N	  Engl	  J	  Med	  350(13):	  1328-­‐1337.	  
Thorley-­‐Lawson,	  D.	  A.,	  J.	  B.	  Hawkins,	  S.	  I.	  Tracy	  and	  M.	  Shapiro	  (2013).	  The	  pathogenesis	  of	  Epstein-­‐
Barr	  virus	  persistent	  infection.	  Curr	  Opin	  Virol	  3(3):	  227-­‐232.	  
Thorley-­‐Lawson,	  D.	  A.	  and	  K.	  P.	  Mann	  (1985).	  Early	  events	   in	  Epstein-­‐Barr	  virus	   infection	  provide	  a	  
model	  for	  B	  cell	  activation.	  J	  Exp	  Med	  162(1):	  45-­‐59.	  
Tomkinson,	   B.,	   E.	   Robertson	   and	   E.	   Kieff	   (1993).	   Epstein-­‐Barr	   virus	   nuclear	   proteins	   EBNA-­‐3A	   and	  
EBNA-­‐3C	  are	  essential	  for	  B-­‐lymphocyte	  growth	  transformation.	  J	  Virol	  67(4):	  2014-­‐2025.	  
Touitou,	   R.,	  M.	   Hickabottom,	   G.	   Parker,	   T.	   Crook	   and	  M.	   J.	   Allday	   (2001).	   Physical	   and	   functional	  
interactions	   between	   the	   corepressor	   CtBP	   and	   the	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   EBNA3C.	   J	  
Virol	  75(16):	  7749-­‐7755.	  
Touitou,	  R.,	  J.	  O'Nions,	  J.	  Heaney	  and	  M.	  J.	  Allday	  (2005).	  Epstein-­‐Barr	  virus	  EBNA3	  proteins	  bind	  to	  
the	  C8/alpha7	  subunit	  of	  the	  20S	  proteasome	  and	  are	  degraded	  by	  20S	  proteasomes	  in	  vitro,	  but	  are	  
very	  stable	  in	  latently	  infected	  B	  cells.	  J	  Gen	  Virol	  86(Pt	  5):	  1269-­‐1277.	  
Turley,	   R.	   S.,	   E.	   C.	   Finger,	   N.	   Hempel,	   T.	   How,	   T.	   A.	   Fields	   and	   G.	   C.	   Blobe	   (2007).	   The	   type	   III	  
transforming	   growth	   factor-­‐beta	   receptor	   as	   a	   novel	   tumor	   suppressor	   gene	   in	   prostate	   cancer.	  
Cancer	  Res	  67(3):	  1090-­‐1098.	  
Tuscano,	  J.	  M.,	  K.	  M.	  Druey,	  A.	  Riva,	  J.	  Pena,	  C.	  B.	  Thompson	  and	  J.	  H.	  Kehrl	  (1996).	  Bcl-­‐x	  rather	  than	  
Bcl-­‐2	  mediates	  CD40-­‐dependent	  centrocyte	  survival	  in	  the	  germinal	  center.	  Blood	  88(4):	  1359-­‐1364.	  
Uchida,	   J.,	   T.	   Yasui,	   Y.	   Takaoka-­‐Shichijo,	  M.	  Muraoka,	  W.	  Kulwichit,	  N.	  Raab-­‐Traub	  and	  H.	  Kikutani	  
(1999).	   Mimicry	   of	   CD40	   signals	   by	   Epstein-­‐Barr	   virus	   LMP1	   in	   B	   lymphocyte	   responses.	   Science	  
286(5438):	  300-­‐303.	  
Ueda,	  S.,	  S.	  Uchiyama,	  T.	  Azzi,	  C.	  Gysin,	  C.	  Berger,	  M.	  Bernasconi,	  Y.	  Harabuchi,	  A.	  S.	  Zinkernagel	  and	  
D.	  Nadal	  (2014).	  Oropharyngeal	  group	  a	  streptococcal	  colonization	  disrupts	  latent	  Epstein-­‐Barr	  virus	  
infection.	  J	  Infect	  Dis	  209(2):	  255-­‐264.	  
Urashima,	  M.,	  A.	  Ogata,	  D.	  Chauhan,	  M.	  Hatziyanni,	  M.	  B.	  Vidriales,	  D.	  A.	  Dedera,	  R.	  L.	  Schlossman	  
and	   K.	   C.	   Anderson	   (1996).	   Transforming	   growth	   factor-­‐beta1:	   differential	   effects	   on	   multiple	  
myeloma	  versus	  normal	  B	  cells.	  Blood	  87(5):	  1928-­‐1938.	  
van	   Eijk,	  M.,	   T.	   Defrance,	   A.	   Hennino	   and	   C.	   de	  Groot	   (2001).	   Death-­‐receptor	   contribution	   to	   the	  
germinal-­‐center	  reaction.	  Trends	  Immunol	  22(12):	  677-­‐682.	  
van	  Vlasselaer,	  P.,	  J.	  Punnonen	  and	  J.	  E.	  de	  Vries	  (1992).	  Transforming	  growth	  factor-­‐beta	  directs	  IgA	  






Vereide,	  D.	   T.,	   E.	   Seto,	   Y.	   F.	   Chiu,	  M.	  Hayes,	   T.	   Tagawa,	  A.	  Grundhoff,	  W.	  Hammerschmidt	   and	  B.	  
Sugden	   (2013).	   Epstein-­‐Barr	   virus	  maintains	   lymphomas	   via	   its	  miRNAs.	  Oncogene	  Epub	   ahead	   of	  
print.	  
Victora,	  G.	  D.,	  D.	  Dominguez-­‐Sola,	  A.	  B.	  Holmes,	  S.	  Deroubaix,	  R.	  Dalla-­‐Favera	  and	  M.	  C.	  Nussenzweig	  
(2012).	   Identification	  of	   human	  germinal	   center	   light	   and	  dark	   zone	   cells	   and	   their	   relationship	   to	  
human	  B-­‐cell	  lymphomas.	  Blood	  120(11):	  2240-­‐2248.	  
Victora,	  G.	  D.	  and	  M.	  C.	  Nussenzweig	  (2012).	  Germinal	  centers.	  Annu	  Rev	  Immunol	  30:	  429-­‐457.	  
Vire,	  E.,	  C.	  Brenner,	  R.	  Deplus,	  L.	  Blanchon,	  M.	  Fraga,	  C.	  Didelot,	  L.	  Morey,	  A.	  Van	  Eynde,	  D.	  Bernard,	  
J.	   M.	   Vanderwinden,	   M.	   Bollen,	   M.	   Esteller,	   L.	   Di	   Croce,	   Y.	   de	   Launoit	   and	   F.	   Fuks	   (2006).	   The	  
Polycomb	  group	  protein	  EZH2	  directly	  controls	  DNA	  methylation.	  Nature	  439(7078):	  871-­‐874.	  
Volkmann,	  N.,	  F.	  M.	  Marassi,	  D.	  D.	  Newmeyer	  and	  D.	  Hanein	  (2014).	  The	  rheostat	  in	  the	  membrane:	  
BCL-­‐2	  family	  proteins	  and	  apoptosis.	  Cell	  Death	  Differ	  21(2):	  206-­‐215.	  
Vrazo,	   A.	   C.,	   M.	   Chauchard,	   N.	   Raab-­‐Traub	   and	   R.	   Longnecker	   (2012).	   Epstein-­‐Barr	   virus	   LMP2A	  
reduces	   hyperactivation	   induced	   by	   LMP1	   to	   restore	   normal	   B	   cell	   phenotype	   in	   transgenic	  mice.	  
PLoS	  Pathog	  8(4):	  e1002662.	  
Vrzalikova,	  K.,	  M.	  Vockerodt,	  S.	  Leonard,	  A.	  Bell,	  W.	  Wei,	  A.	  Schrader,	  K.	  L.	  Wright,	  D.	  Kube,	  M.	  Rowe,	  
C.	   B.	  Woodman	   and	  P.	  G.	  Murray	   (2011).	  Down-­‐regulation	  of	   BLIMP1alpha	  by	   the	   EBV	  oncogene,	  
LMP-­‐1,	   disrupts	   the	   plasma	   cell	   differentiation	   program	   and	   prevents	   viral	   replication	   in	   B	   cells:	  
implications	  for	  the	  pathogenesis	  of	  EBV-­‐associated	  B-­‐cell	  lymphomas.	  Blood	  117(22):	  5907-­‐5917.	  
Waltzer,	   L.,	   F.	   Logeat,	   C.	   Brou,	   A.	   Israel,	   A.	   Sergeant	   and	   E.	   Manet	   (1994).	   The	   human	   J	   kappa	  
recombination	  signal	   sequence	  binding	  protein	   (RBP-­‐J	  kappa)	   targets	   the	  Epstein-­‐Barr	  virus	  EBNA2	  
protein	  to	  its	  DNA	  responsive	  elements.	  EMBO	  J	  13(23):	  5633-­‐5638.	  
Waltzer,	  L.,	  M.	  Perricaudet,	  A.	  Sergeant	  and	  E.	  Manet	  (1996).	  Epstein-­‐Barr	  virus	  EBNA3A	  and	  EBNA3C	  
proteins	  both	  repress	  RBP-­‐J	  kappa-­‐EBNA2-­‐activated	  transcription	  by	   inhibiting	  the	  binding	  of	  RBP-­‐J	  
kappa	  to	  DNA.	  J	  Virol	  70(9):	  5909-­‐5915.	  
Wang,	   D.,	   D.	   Liebowitz	   and	   E.	   Kieff	   (1985).	   An	   EBV	  membrane	   protein	   expressed	   in	   immortalized	  
lymphocytes	  transforms	  established	  rodent	  cells.	  Cell	  43(3	  Pt	  2):	  831-­‐840.	  
Wang,	  D.,	  D.	  Liebowitz,	  F.	  Wang,	  C.	  Gregory,	  A.	  Rickinson,	  R.	  Larson,	  T.	  Springer	  and	  E.	  Kieff	  (1988).	  
Epstein-­‐Barr	   virus	   latent	   infection	  membrane	   protein	   alters	   the	   human	   B-­‐lymphocyte	   phenotype:	  
deletion	  of	  the	  amino	  terminus	  abolishes	  activity.	  J	  Virol	  62(11):	  4173-­‐4184.	  
Wang,	  D.,	   J.	   Long,	   F.	  Dai,	  M.	   Liang,	  X.	  H.	   Feng	  and	  X.	   Lin	   (2008).	  BCL6	   represses	  Smad	  signaling	   in	  
transforming	  growth	  factor-­‐beta	  resistance.	  Cancer	  Res	  68(3):	  783-­‐789.	  
Wang,	  F.,	  C.	  Gregory,	  C.	  Sample,	  M.	  Rowe,	  D.	  Liebowitz,	  R.	  Murray,	  A.	  Rickinson	  and	  E.	  Kieff	  (1990a).	  
Epstein-­‐Barr	  virus	   latent	  membrane	  protein	   (LMP1)	  and	  nuclear	  proteins	  2	  and	  3C	  are	  effectors	  of	  
phenotypic	  changes	   in	  B	   lymphocytes:	  EBNA-­‐2	  and	  LMP1	  cooperatively	   induce	  CD23.	   J	  Virol	  64(5):	  
2309-­‐2318.	  
Wang,	  F.,	  S.	  F.	  Tsang,	  M.	  G.	  Kurilla,	  J.	  I.	  Cohen	  and	  E.	  Kieff	  (1990b).	  Epstein-­‐Barr	  virus	  nuclear	  antigen	  






Wang,	  X.	  F.,	  H.	  Y.	  Lin,	  E.	  Ng-­‐Eaton,	  J.	  Downward,	  H.	  F.	  Lodish	  and	  R.	  A.	  Weinberg	  (1991).	  Expression	  
cloning	  and	  characterization	  of	  the	  TGF-­‐beta	  type	  III	  receptor.	  Cell	  67(4):	  797-­‐805.	  
Warner,	  B.	   J.,	  S.	  W.	  Blain,	   J.	  Seoane	  and	   J.	  Massague	   (1999).	  Myc	  downregulation	  by	   transforming	  
growth	  factor	  beta	  required	  for	  activation	  of	  the	  p15(Ink4b)	  G(1)	  arrest	  pathway.	  Mol	  Cell	  Biol	  19(9):	  
5913-­‐5922.	  
Wasil,	  L.	  R.,	  M.	  J.	  Tomaszewski,	  A.	  Hoji	  and	  D.	  T.	  Rowe	  (2013).	  The	  effect	  of	  epstein-­‐barr	  virus	  latent	  
membrane	  protein	  2	  expression	  on	  the	  kinetics	  of	  early	  B	  cell	  infection.	  PLoS	  One	  8(1):	  e54010.	  
Watanabe,	  M.,	  N.	  Masuyama,	  M.	  Fukuda	  and	  E.	  Nishida	  (2000).	  Regulation	  of	  intracellular	  dynamics	  
of	  Smad4	  by	  its	  leucine-­‐rich	  nuclear	  export	  signal.	  EMBO	  Rep	  1(2):	  176-­‐182.	  
White,	  R.	  E.,	  I.	  J.	  Groves,	  E.	  Turro,	  J.	  Yee,	  E.	  Kremmer	  and	  M.	  J.	  Allday	  (2010).	  Extensive	  co-­‐operation	  
between	   the	   Epstein-­‐Barr	   virus	   EBNA3	   proteins	   in	   the	  manipulation	   of	   host	   gene	   expression	   and	  
epigenetic	  chromatin	  modification.	  PLoS	  One	  5(11):	  e13979.	  
White,	  R.	  E.,	  P.	  C.	  Ramer,	  K.	  N.	  Naresh,	  S.	  Meixlsperger,	  L.	  Pinaud,	  C.	  Rooney,	  B.	  Savoldo,	  R.	  Coutinho,	  
C.	  Bodor,	  J.	  Gribben,	  H.	  A.	  Ibrahim,	  M.	  Bower,	  J.	  P.	  Nourse,	  M.	  K.	  Gandhi,	  J.	  Middeldorp,	  F.	  Z.	  Cader,	  
P.	  Murray,	  C.	  Munz	  and	  M.	  J.	  Allday	  (2012).	  EBNA3B-­‐deficient	  EBV	  promotes	  B	  cell	  lymphomagenesis	  
in	  humanized	  mice	  and	  is	  found	  in	  human	  tumors.	  J	  Clin	  Invest	  122(4):	  1487-­‐1502.	  
Wiater,	  E.	  and	  W.	  Vale	   (2003).	   Inhibin	   is	  an	  antagonist	  of	  bone	  morphogenetic	  protein	   signaling.	   J	  
Biol	  Chem	  278(10):	  7934-­‐7941.	  
Widschwendter,	  M.,	  H.	  Fiegl,	  D.	  Egle,	  E.	  Mueller-­‐Holzner,	  G.	  Spizzo,	  C.	  Marth,	  D.	  J.	  Weisenberger,	  M.	  
Campan,	   J.	   Young,	   I.	   Jacobs	   and	   P.	  W.	   Laird	   (2007).	   Epigenetic	   stem	   cell	   signature	   in	   cancer.	  Nat	  
Genet	  39(2):	  157-­‐158.	  
Wildey,	  G.	  M.,	  S.	  Patil	  and	  P.	  H.	  Howe	   (2003).	  Smad3	  potentiates	   transforming	  growth	   factor	  beta	  
(TGFbeta	   )-­‐induced	   apoptosis	   and	   expression	   of	   the	   BH3-­‐only	   protein	   Bim	   in	   WEHI	   231	   B	  
lymphocytes.	  J	  Biol	  Chem	  278(20):	  18069-­‐18077.	  
Woisetschlaeger,	   M.,	   X.	   W.	   Jin,	   C.	   N.	   Yandava,	   L.	   A.	   Furmanski,	   J.	   L.	   Strominger	   and	   S.	   H.	   Speck	  
(1991).	   Role	   for	   the	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   2	   in	   viral	   promoter	   switching	   during	   initial	  
stages	  of	  infection.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  88(9):	  3942-­‐3946.	  
Woisetschlaeger,	   M.,	   J.	   L.	   Strominger	   and	   S.	   H.	   Speck	   (1989).	   Mutually	   exclusive	   use	   of	   viral	  
promoters	  in	  Epstein-­‐Barr	  virus	  latently	  infected	  lymphocytes.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  86(17):	  6498-­‐
6502.	  
Wrana,	   J.	   L.,	   L.	   Attisano,	   J.	   Carcamo,	   A.	   Zentella,	   J.	   Doody,	  M.	   Laiho,	   X.	   F.	  Wang	   and	   J.	  Massague	  
(1992).	  TGF	  beta	   signals	   through	  a	  heteromeric	  protein	  kinase	   receptor	   complex.	  Cell	  71(6):	  1003-­‐
1014.	  
Wrighton,	   K.	   H.,	   X.	   Lin,	   P.	   B.	   Yu	   and	   X.	   H.	   Feng	   (2009).	   Transforming	   Growth	   Factor	   {beta}	   Can	  
Stimulate	   Smad1	   Phosphorylation	   Independently	   of	   Bone	   Morphogenic	   Protein	   Receptors.	   J	   Biol	  
Chem	  284(15):	  9755-­‐9763.	  
Wurstle,	   M.	   L.,	   M.	   A.	   Laussmann	   and	  M.	   Rehm	   (2012).	   The	   central	   role	   of	   initiator	   caspase-­‐9	   in	  
apoptosis	   signal	   transduction	   and	   the	   regulation	  of	   its	   activation	   and	  activity	  on	   the	   apoptosome.	  






Yagi,	   K.,	   D.	   Goto,	   T.	   Hamamoto,	   S.	   Takenoshita,	   M.	   Kato	   and	   K.	   Miyazono	   (1999).	   Alternatively	  
spliced	  variant	  of	  Smad2	  lacking	  exon	  3.	  Comparison	  with	  wild-­‐type	  Smad2	  and	  Smad3.	  J	  Biol	  Chem	  
274(2):	  703-­‐709.	  
Yajima,	  M.,	  K.	  Imadome,	  A.	  Nakagawa,	  S.	  Watanabe,	  K.	  Terashima,	  H.	  Nakamura,	  M.	  Ito,	  N.	  Shimizu,	  
M.	   Honda,	   N.	   Yamamoto	   and	   S.	   Fujiwara	   (2008).	   A	   new	   humanized	  mouse	  model	   of	   Epstein-­‐Barr	  
virus	  infection	  that	  reproduces	  persistent	  infection,	  lymphoproliferative	  disorder,	  and	  cell-­‐mediated	  
and	  humoral	  immune	  responses.	  J	  Infect	  Dis	  198(5):	  673-­‐682.	  
Yamamoto,	   N.,	   T.	   Takizawa,	   Y.	   Iwanaga,	   N.	   Shimizu	   and	   N.	   Yamamoto	   (2000).	   Malignant	  
transformation	  of	  B	   lymphoma	   cell	   line	  BJAB	  by	   Epstein-­‐Barr	   virus-­‐encoded	   small	   RNAs.	  FEBS	   Lett	  
484(2):	  153-­‐158.	  
Yamamura,	  Y.,	  X.	  Hua,	  S.	  Bergelson	  and	  H.	  F.	  Lodish	  (2000).	  Critical	  role	  of	  Smads	  and	  AP-­‐1	  complex	  
in	  transforming	  growth	  factor-­‐beta	  -­‐dependent	  apoptosis.	  J	  Biol	  Chem	  275(46):	  36295-­‐36302.	  
Yamashita,	  M.,	   K.	   Fatyol,	   C.	   Jin,	   X.	  Wang,	   Z.	   Liu	   and	   Y.	   E.	   Zhang	   (2008a).	   TRAF6	  mediates	   Smad-­‐
independent	  activation	  of	  JNK	  and	  p38	  by	  TGF-­‐beta.	  Mol	  Cell	  31(6):	  918-­‐924.	  
Yamashita,	  S.,	  S.	  Takahashi,	  N.	  McDonell,	  N.	  Watanabe,	  T.	  Niwa,	  K.	  Hosoya,	  Y.	  Tsujino,	  T.	  Shirai	  and	  T.	  
Ushijima	   (2008b).	  Methylation	   silencing	   of	   transforming	   growth	   factor-­‐beta	   receptor	   type	   II	   in	   rat	  
prostate	  cancers.	  Cancer	  Res	  68(7):	  2112-­‐2121.	  
Yanagisawa,	  K.,	  H.	  Osada,	  A.	  Masuda,	  M.	  Kondo,	  T.	  Saito,	  Y.	  Yatabe,	  K.	  Takagi,	  T.	  Takahashi	  and	  T.	  
Takahashi	   (1998).	   Induction	   of	   apoptosis	   by	   Smad3	   and	   down-­‐regulation	   of	   Smad3	   expression	   in	  
response	  to	  TGF-­‐beta	  in	  human	  normal	  lung	  epithelial	  cells.	  Oncogene	  17(13):	  1743-­‐1747.	  
Yang,	  X.,	  Z.	  He,	  B.	  Xin	  and	  L.	  Cao	  (2000).	  LMP1	  of	  Epstein-­‐Barr	  virus	  suppresses	  cellular	  senescence	  
associated	  with	  the	  inhibition	  of	  p16INK4a	  expression.	  Oncogene	  19(16):	  2002-­‐2013.	  
Yang,	   Y.	   A.,	   B.	   Tang,	   G.	   Robinson,	   L.	   Hennighausen,	   S.	   G.	   Brodie,	   C.	   X.	   Deng	   and	   L.	  M.	  Wakefield	  
(2002).	  Smad3	   in	  the	  mammary	  epithelium	  has	  a	  nonredundant	  role	   in	  the	   induction	  of	  apoptosis,	  
but	  not	  in	  the	  regulation	  of	  proliferation	  or	  differentiation	  by	  transforming	  growth	  factor-­‐beta.	  Cell	  
Growth	  Differ	  13(3):	  123-­‐130.	  
Yang,	  Z.	  Z.,	  D.	  M.	  Grote,	  S.	  C.	  Ziesmer,	  B.	  Xiu,	  N.	  R.	  Yates,	  F.	  J.	  Secreto,	  L.	  S.	  Hodge,	  T.	  E.	  Witzig,	  A.	  J.	  
Novak	   and	   S.	   M.	   Ansell	   (2013).	   Soluble	   and	   membrane-­‐bound	   TGF-­‐beta-­‐mediated	   regulation	   of	  
intratumoral	   T	   cell	   differentiation	   and	   function	   in	   B-­‐cell	   non-­‐Hodgkin	   lymphoma.	   PLoS	   One	   8(3):	  
e59456.	  
Yee,	   J.,	   R.	   E.	   White,	   E.	   Anderton	   and	   M.	   J.	   Allday	   (2011).	   Latent	   Epstein-­‐Barr	   virus	   can	   inhibit	  
apoptosis	  in	  B	  cells	  by	  blocking	  the	  induction	  of	  NOXA	  expression.	  PLoS	  One	  6(12):	  e28506.	  
Yenamandra,	   S.	   P.,	   R.	   Sompallae,	   G.	   Klein	   and	   E.	   Kashuba	   (2009).	   Comparative	   analysis	   of	   the	  
Epstein-­‐Barr	  virus	  encoded	  nuclear	  proteins	  of	  EBNA-­‐3	  family.	  Comput	  Biol	  Med	  39(11):	  1036-­‐1042.	  
Yin,	   Q.,	   X.	   Wang,	   C.	   Fewell,	   J.	   Cameron,	   H.	   Zhu,	   M.	   Baddoo,	   Z.	   Lin	   and	   E.	   K.	   Flemington	   (2010).	  
MicroRNA	   miR-­‐155	   Inhibits	   Bone	   Morphogenetic	   Protein	   (BMP)	   Signaling	   and	   BMP-­‐Mediated	  
Epstein-­‐Barr	  Virus	  Reactivation.	  J	  Virol	  84(13):	  6318-­‐6327.	  







Young,	  L.	  S.,	  Q.	  Y.	  Yao,	  C.	  M.	  Rooney,	  T.	  B.	  Sculley,	  D.	  J.	  Moss,	  H.	  Rupani,	  G.	  Laux,	  G.	  W.	  Bornkamm	  
and	  A.	  B.	  Rickinson	   (1987).	  New	  type	  B	   isolates	  of	  Epstein-­‐Barr	  virus	   from	  Burkitt's	   lymphoma	  and	  
from	  normal	  individuals	  in	  endemic	  areas.	  J	  Gen	  Virol	  68	  (	  Pt	  11):	  2853-­‐2862.	  
Zawel,	  L.,	  J.	  L.	  Dai,	  P.	  Buckhaults,	  S.	  Zhou,	  K.	  W.	  Kinzler,	  B.	  Vogelstein	  and	  S.	  E.	  Kern	  (1998).	  Human	  
Smad3	  and	  Smad4	  are	  sequence-­‐specific	  transcription	  activators.	  Mol	  Cell	  1(4):	  611-­‐617.	  
Zhang,	  H.	  T.,	  X.	  F.	  Chen,	  M.	  H.	  Wang,	  J.	  C.	  Wang,	  Q.	  Y.	  Qi,	  R.	  M.	  Zhang,	  W.	  Q.	  Xu,	  Q.	  Y.	  Fei,	  F.	  Wang,	  Q.	  
Q.	   Cheng,	   F.	   Chen,	   C.	   S.	   Zhu,	   S.	   H.	   Tao	   and	   Z.	   Luo	   (2004).	   Defective	   expression	   of	   transforming	  
growth	   factor	   beta	   receptor	   type	   II	   is	   associated	  with	   CpG	  methylated	   promoter	   in	   primary	   non-­‐
small	  cell	  lung	  cancer.	  Clin	  Cancer	  Res	  10(7):	  2359-­‐2367.	  
Zhang,	  X.,	  L.	  Ding	  and	  A.	  J.	  Sandford	  (2005).	  Selection	  of	  reference	  genes	  for	  gene	  expression	  studies	  
in	  human	  neutrophils	  by	  real-­‐time	  PCR.	  BMC	  Mol	  Biol	  6:	  4.	  
Zhang,	  Y.,	  C.	  Chang,	  D.	  J.	  Gehling,	  A.	  Hemmati-­‐Brivanlou	  and	  R.	  Derynck	  (2001).	  Regulation	  of	  Smad	  
degradation	  and	  activity	  by	  Smurf2,	  an	  E3	  ubiquitin	  ligase.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  98(3):	  974-­‐979.	  
Zhao,	  B.,	   J.	  C.	  Mar,	  S.	  Maruo,	  S.	   Lee,	  B.	  E.	  Gewurz,	  E.	   Johannsen,	  K.	  Holton,	  R.	  Rubio,	  K.	  Takada,	   J.	  
Quackenbush	   and	   E.	   Kieff	   (2011).	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   3C	   regulated	   genes	   in	  
lymphoblastoid	  cell	  lines.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  108(1):	  337-­‐342.	  
Zhao,	  B.,	  S.	  Maruo,	  A.	  Cooper,	  R.	  C.	  M,	  E.	   Johannsen,	  E.	  Kieff	  and	  E.	  Cahir-­‐McFarland	  (2006).	  RNAs	  
induced	  by	  Epstein-­‐Barr	  virus	  nuclear	  antigen	  2	  in	  lymphoblastoid	  cell	  lines.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  
103(6):	  1900-­‐1905.	  
Zhao,	   B.	   and	   C.	   E.	   Sample	   (2000).	   Epstein-­‐barr	   virus	   nuclear	   antigen	   3C	   activates	   the	   latent	  
membrane	   protein	   1	   promoter	   in	   the	   presence	   of	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   2	   through	  
sequences	  encompassing	  an	  spi-­‐1/Spi-­‐B	  binding	  site.	  J	  Virol	  74(11):	  5151-­‐5160.	  
Zhao,	  H.,	  H.	  Shiina,	  K.	  L.	  Greene,	  L.	  C.	  Li,	  Y.	  Tanaka,	  H.	  Kishi,	  M.	   Igawa,	  C.	   J.	  Kane,	  P.	  Carroll	  and	  R.	  
Dahiya	   (2005).	   CpG	   methylation	   at	   promoter	   site	   -­‐140	   inactivates	   TGFbeta2	   receptor	   gene	   in	  
prostate	  cancer.	  Cancer	  104(1):	  44-­‐52.	  
Zhao,	  S.,	  K.	  Venkatasubbarao,	  S.	  Li	  and	  J.	  W.	  Freeman	  (2003).	  Requirement	  of	  a	  specific	  Sp1	  site	  for	  
histone	   deacetylase-­‐mediated	   repression	   of	   transforming	   growth	   factor	   beta	   Type	   II	   receptor	  
expression	  in	  human	  pancreatic	  cancer	  cells.	  Cancer	  Res	  63(10):	  2624-­‐2630.	  
Zhu,	   H.,	   P.	   Kavsak,	   S.	   Abdollah,	   J.	   L.	   Wrana	   and	   G.	   H.	   Thomsen	   (1999).	   A	   SMAD	   ubiquitin	   ligase	  
targets	  the	  BMP	  pathway	  and	  affects	  embryonic	  pattern	  formation.	  Nature	  400(6745):	  687-­‐693.	  
Zimber-­‐Strobl,	   U.,	   B.	   Kempkes,	   G.	   Marschall,	   R.	   Zeidler,	   C.	   Van	   Kooten,	   J.	   Banchereau,	   G.	   W.	  
Bornkamm	  and	  W.	  Hammerschmidt	   (1996).	   Epstein-­‐Barr	   virus	   latent	  membrane	  protein	   (LMP1)	   is	  
not	   sufficient	   to	  maintain	  proliferation	  of	  B	   cells	  but	  both	   it	   and	  activated	  CD40	  can	  prolong	   their	  
survival.	  EMBO	  J	  15(24):	  7070-­‐7078.	  
Zimber-­‐Strobl,	  U.	  and	  L.	  J.	  Strobl	  (2001).	  EBNA2	  and	  Notch	  signalling	  in	  Epstein-­‐Barr	  virus	  mediated	  
immortalization	  of	  B	  lymphocytes.	  Semin	  Cancer	  Biol	  11(6):	  423-­‐434.	  
Zimber-­‐Strobl,	  U.,	   L.	   J.	   Strobl,	   C.	  Meitinger,	   R.	  Hinrichs,	   T.	   Sakai,	   T.	   Furukawa,	   T.	  Honjo	   and	  G.	  W.	  
Bornkamm	   (1994).	   Epstein-­‐Barr	   virus	   nuclear	   antigen	   2	   exerts	   its	   transactivating	   function	   through	  
interaction	   with	   recombination	   signal	   binding	   protein	   RBP-­‐J	   kappa,	   the	   homologue	   of	   Drosophila	  






zur	   Hausen,	   H.,	   F.	   J.	   O'Neill,	   U.	   K.	   Freese	   and	   E.	   Hecker	   (1978).	   Persisting	   oncogenic	   herpesvirus	  
induced	  by	  the	  tumour	  promotor	  TPA.	  Nature	  272(5651):	  373-­‐375.	  
	  
	  
